0001558370-24-01205110-Q MUSTANG BIO, INC. 20240813202408131601271601281601280 0 0001558370-24-012051 10-Q 72 20240630 20240813 20240813 MUSTANG BIO, INC. 0001680048 2834 473828760 DE 1231 10-Q 34 001-38191 241201232 377 PLANTATION STREET WORCESTER MA 01605 7816524500 377 PLANTATION STREET WORCESTER MA 01605 10-Q 1 tmb-20240630x10q.htm 10-Q http://fasb.org/us-gaap/2024#RelatedPartyMemberhttp://fasb.org/us-gaap/2024#RelatedPartyMember0001680048--12-312024Q2false340980598374869845385845385250000250000796000P1Y7M6DP5YP24MP9MP5YP5DP12MP6MP12MP12M0001680048us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001680048mbio:June2024RegisteredDirectOfferingMember2024-06-192024-06-190001680048mbio:AtMarketOfferingMember2024-01-012024-06-300001680048mbio:AtMarketOfferingMember2023-01-012023-06-300001680048mbio:RegistrationStatements2021S3Member2021-05-242021-05-240001680048mbio:FortressBiotechIncMember2024-01-022024-01-020001680048us-gaap:RetainedEarningsMember2024-06-300001680048us-gaap:AdditionalPaidInCapitalMember2024-06-300001680048us-gaap:RetainedEarningsMember2024-03-310001680048us-gaap:AdditionalPaidInCapitalMember2024-03-3100016800482024-03-310001680048us-gaap:RetainedEarningsMember2023-12-310001680048us-gaap:AdditionalPaidInCapitalMember2023-12-310001680048mbio:CommonStockIssuableMember2023-12-310001680048us-gaap:RetainedEarningsMember2023-06-300001680048us-gaap:AdditionalPaidInCapitalMember2023-06-300001680048us-gaap:RetainedEarningsMember2023-03-310001680048us-gaap:AdditionalPaidInCapitalMember2023-03-3100016800482023-03-310001680048us-gaap:RetainedEarningsMember2022-12-310001680048us-gaap:AdditionalPaidInCapitalMember2022-12-310001680048mbio:CommonStockIssuableMember2022-12-310001680048us-gaap:PreferredClassAMemberus-gaap:PreferredStockMember2024-06-300001680048us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-06-300001680048mbio:CommonUnspecifiedClassMemberus-gaap:CommonStockMember2024-06-300001680048us-gaap:PreferredClassAMemberus-gaap:PreferredStockMember2024-03-310001680048us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-03-310001680048mbio:CommonUnspecifiedClassMemberus-gaap:CommonStockMember2024-03-310001680048us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-12-310001680048mbio:CommonUnspecifiedClassMemberus-gaap:CommonStockMember2023-12-310001680048us-gaap:PreferredClassAMemberus-gaap:PreferredStockMember2023-06-300001680048us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-06-300001680048mbio:CommonUnspecifiedClassMemberus-gaap:CommonStockMember2023-06-300001680048us-gaap:PreferredClassAMemberus-gaap:PreferredStockMember2023-03-310001680048us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-03-310001680048mbio:CommonUnspecifiedClassMemberus-gaap:CommonStockMember2023-03-310001680048us-gaap:PreferredClassAMemberus-gaap:PreferredStockMember2022-12-310001680048us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-12-310001680048mbio:CommonUnspecifiedClassMemberus-gaap:CommonStockMember2022-12-310001680048mbio:June2024RegisteredDirectOfferingMember2024-06-190001680048us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001680048us-gaap:EmployeeStockOptionMember2023-12-310001680048us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001680048us-gaap:EmployeeStockOptionMember2022-06-300001680048us-gaap:EmployeeStockOptionMember2021-06-300001680048us-gaap:EmployeeStockOptionMember2018-06-300001680048us-gaap:EmployeeStockOptionMember2019-12-310001680048us-gaap:EmployeeStockOptionMember2016-12-3100016800482023-06-012023-06-300001680048us-gaap:EmployeeStockOptionMember2022-06-012022-06-300001680048us-gaap:EmployeeStockOptionMember2021-06-012021-06-300001680048us-gaap:EmployeeStockOptionMember2018-06-012018-06-300001680048us-gaap:EmployeeStockOptionMember2016-01-012016-12-310001680048us-gaap:RestrictedStockUnitsRSUMember2023-12-310001680048us-gaap:RestrictedStockMember2023-12-310001680048us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001680048us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001680048us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001680048us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001680048us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001680048us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001680048us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001680048us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001680048us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001680048us-gaap:RestrictedStockMember2024-01-012024-06-300001680048mbio:May2024PublicOfferingMember2024-04-29000168004srt:ScenarioForecastMembermbio:May2024PublicOfferingMember2029-04-292029-04-290001680048mbio:May2024PublicOfferingMember2024-04-292024-04-290001680048mbio:May2024PublicOfferingMember2024-04-122024-04-120001680048mbio:Il13ra2CarAndC134Member2022-11-012022-11-300001680048mbio:Il13ra2CarAndC134Member2020-10-012020-10-310001680048mbio:FortressBiotechIncMemberus-gaap:MajorityOwnedSubsidiaryUnconsolidatedMembermbio:SecondAmendedAndRestatedFoundersAgreementMember2023-01-012023-12-310001680048mbio:RunwayDebtFacilityMember2023-04-112023-04-110001680048us-gaap:LeaseholdImprovementsMember2024-06-300001680048us-gaap:LeaseholdImprovementsMember2023-12-310001680048us-gaap:ConstructionInProgressMember2023-12-310001680048mbio:AssetPurchaseAgreementWithUbrigeneBiosciencesMember2024-01-012024-06-300001680048mbio:FortressBiotechIncMemberus-gaap:MajorityOwnedSubsidiaryUnconsolidatedMembermbio:SecondAmendedAndRestatedFoundersAgreementMember2024-04-012024-06-300001680048mbio:FortressBiotechIncMemberus-gaap:MajorityOwnedSubsidiaryUnconsolidatedMembermbio:SecondAmendedAndRestatedFoundersAgreementMember2024-01-012024-06-300001680048mbio:FortressBiotechIncMemberus-gaap:MajorityOwnedSubsidiaryUnconsolidatedMembermbio:ManagementServicesAgreementMember2024-01-012024-06-300001680048mbio:FortressBiotechIncMemberus-gaap:MajorityOwnedSubsidiaryUnconsolidatedMembermbio:SecondAmendedAndRestatedFoundersAgreementMember2023-04-012023-06-300001680048mbio:FortressBiotechIncMemberus-gaap:MajorityOwnedSubsidiaryUnconsolidatedMembermbio:ManagementServicesAgreementMember2023-04-012023-06-300001680048mbio:FortressBiotechIncMemberus-gaap:MajorityOwnedSubsidiaryUnconsolidatedMembermbio:SecondAmendedAndRestatedFoundersAgreementMember2023-01-012023-06-300001680048us-gaap:RetainedEarningsMember2024-04-012024-06-300001680048us-gaap:RetainedEarningsMember2024-01-012024-06-300001680048us-gaap:RetainedEarningsMember2023-04-012023-06-300001680048us-gaap:RetainedEarningsMember2023-01-012023-06-300001680048mbio:RunwayDebtFacilityMember2023-04-012023-06-300001680048us-gaap:RelatedPartyMember2024-01-012024-06-300001680048us-gaap:NonrelatedPartyMember2024-01-012024-06-300001680048us-gaap:RelatedPartyMember2023-01-012023-06-300001680048us-gaap:NonrelatedPartyMember2023-01-012023-06-300001680048mbio:UbrigeneBiosciencesMember2023-07-282023-07-280001680048us-gaap:RestrictedStockUnitsRSUMember2024-06-300001680048us-gaap:RestrictedStockMember2024-06-300001680048us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-06-300001680048mbio:RunwayDebtFacilityMember2023-01-012023-03-31000168004srt:MinimumMembermbio:RunwayDebtFacilityMember2022-03-042022-03-040001680048mbio:RunwayDebtFacilityMemberus-gaap:BaseRateMember2022-03-042022-03-040001680048mbio:RunwayDebtFacilityMembermbio:LiborLondonInterbankOfferedRateMember2022-03-042022-03-040001680048us-gaap:CommonClassAMember2024-06-300001680048mbio:CommonUnspecifiedClassMember2024-06-300001680048us-gaap:CommonClassAMember2023-12-310001680048mbio:CommonUnspecifiedClassMember2023-12-310001680048us-gaap:EmployeeStockOptionMember2024-06-300001680048mbio:UnregisteredWarrantsMember2024-06-300001680048mbio:PrefundedWarrantsMember2024-06-300001680048mbio:PlacementAgentsWarrantsMember2024-06-300001680048mbio:PrefundedWarrantsMember2024-05-310001680048mbio:PlacementAgentsWarrantsMember2024-05-310001680048mbio:May2024PublicOfferingMember2024-05-310001680048mbio:UnregisteredWarrantsMember2023-10-260001680048mbio:PrefundedWarrantsMember2023-10-260001680048mbio:PlacementAgentsWarrantsMember2023-10-260001680048mbio:PrefundedWarrantsMembermbio:OctoberRegisteredDirectOfferingMember2024-06-300001680048mbio:PrefundedWarrantsMembermbio:MayAndJuneRegisteredDirectOfferingMember2024-06-300001680048mbio:PrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2024-06-190001680048mbio:PrefundedWarrantsMembermbio:June2024RegisteredDirectOfferingMember2024-06-190001680048mbio:WainwrightWarrantsMemberus-gaap:PrivatePlacementMember2024-06-180001680048mbio:UnregisteredWarrantsMember2024-05-310001680048srt:MinimumMembermbio:ExistingWarrantsMembermbio:May2024PublicOfferingMember2024-04-29000168004mbio:PrefundedWarrantsMembermbio:May2024PublicOfferingMember2024-04-290001680048mbio:ExistingWarrantsMembermbio:May2024PublicOfferingMember2024-04-2900016800482022-12-3100016800482023-06-300001680048us-gaap:WarrantMember2024-01-012024-06-300001680048us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001680048us-gaap:RestrictedStockMember2024-01-012024-06-300001680048us-gaap:PreferredClassAMember2024-01-012024-06-300001680048us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001680048us-gaap:WarrantMember2023-01-012023-06-300001680048us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001680048us-gaap:RestrictedStockMember2023-01-012023-06-300001680048us-gaap:PreferredClassAMember2023-01-012023-06-300001680048us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001680048mbio:RunwayDebtFacilityMember2023-01-012023-06-300001680048mbio:CommonStockIssuableMember2023-01-012023-06-300001680048mbio:CommonStockIssuableMember2024-01-012024-06-300001680048us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001680048us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001680048mbio:CommonUnspecifiedClassMemberus-gaap:CommonStockMember2024-04-012024-06-300001680048mbio:CommonUnspecifiedClassMemberus-gaap:CommonStockMember2024-01-012024-06-300001680048mbio:June2024RegisteredDirectOfferingMember2024-06-212024-06-210001680048mbio:RegistrationStatements2024S3Member2024-06-120001680048mbio:RegistrationStatements2021S3Member2021-05-240001680048mbio:UbrigeneBiosciencesMember2023-07-280001680048mbio:St.JudeChildrensResearchHospitalMembermbio:StJudeXscidMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-04-012024-06-300001680048mbio:LeidenUniversityMedicalCentreMembermbio:Rag1ScidMb110Membermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-04-012024-06-300001680048mbio:FredHutchinsonCancerResearchCenterMembermbio:Cd20TechnologyProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-04-012024-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:PscaProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-04-012024-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:Il13r2ProductMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-04-012024-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:Cs1ProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-04-012024-06-300001680048mbio:MayoClinicMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-04-012024-06-300001680048mbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-04-012024-06-300001680048mbio:St.JudeChildrensResearchHospitalMembermbio:StJudeXscidMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-01-012024-06-300001680048mbio:LeidenUniversityMedicalCentreMembermbio:Rag1ScidMb110Membermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-01-012024-06-300001680048mbio:FredHutchinsonCancerResearchCenterMembermbio:Cd20TechnologyProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-01-012024-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:PscaProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-01-012024-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:Il13r2ProductMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-01-012024-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:Cs1ProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-01-012024-06-300001680048mbio:MayoClinicMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-01-012024-06-300001680048mbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-01-012024-06-300001680048mbio:St.JudeChildrensResearchHospitalMembermbio:StJudeXscidMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-04-012023-06-300001680048mbio:LeidenUniversityMedicalCentreMembermbio:Rag1ScidMb110Membermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-04-012023-06-300001680048mbio:FredHutchinsonCancerResearchCenterMembermbio:Cd20TechnologyProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-04-012023-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:PscaProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-04-012023-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:Il13r2ProductMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-04-012023-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:Cs1ProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-04-012023-06-300001680048mbio:MayoClinicMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-04-012023-06-300001680048mbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-04-012023-06-300001680048mbio:St.JudeChildrensResearchHospitalMembermbio:StJudeXscidMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-01-012023-06-300001680048mbio:LeidenUniversityMedicalCentreMembermbio:Rag1ScidMb110Membermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-01-012023-06-300001680048mbio:FredHutchinsonCancerResearchCenterMembermbio:Cd20TechnologyProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-01-012023-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:PscaProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-01-012023-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:Il13r2ProductMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-01-012023-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:Cs1ProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-01-012023-06-300001680048mbio:MayoClinicMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-01-012023-06-300001680048mbio:SponsoredResearchAndClinicalTrialAgreementsMember2023-01-012023-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:Cs1ProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2024-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:PscaProductOrProcessMember2024-06-300001680048mbio:FortressBiotechIncMemberus-gaap:MajorityOwnedSubsidiaryUnconsolidatedMembermbio:ManagementServicesAgreementMember2024-04-012024-06-300001680048mbio:FortressBiotechIncMemberus-gaap:MajorityOwnedSubsidiaryUnconsolidatedMembermbio:ManagementServicesAgreementMember2023-01-012023-06-300001680048mbio:UbrigeneBiosciencesMember2024-05-13001680048mbio:MayoClinicMembermbio:CarTTechnologyProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2022-10-012022-10-310001680048mbio:MayoClinicMembermbio:CarTTechnologyProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2021-06-012021-06-300001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:PscaProductOrProcessMembersrt:MaximumMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2020-10-012020-10-310001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:Cs1ProductOrProcessMembersrt:MaximumMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2020-06-012020-06-300001680048mbio:FredHutchinsonCancerResearchCenterMembermbio:Cd20TechnologyProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2017-07-032017-07-0300016800482023-04-012023-06-3000016800482023-01-012023-06-300001680048mbio:CommonUnspecifiedClassMemberus-gaap:CommonStockMember2023-04-012023-06-300001680048mbio:UbrigeneBiosciencesMember2024-05-132024-05-130001680048mbio:FortressBiotechIncMemberus-gaap:MajorityOwnedSubsidiaryUnconsolidatedMembermbio:SecondAmendedAndRestatedFoundersAgreementMember2024-01-022024-01-020001680048mbio:FortressBiotechIncMemberus-gaap:MajorityOwnedSubsidiaryUnconsolidatedMembermbio:SecondAmendedAndRestatedFoundersAgreementMember2016-07-222016-07-220001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:Il13r2ProductMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2017-02-012017-02-

280001680048mbio:RegistrationStatements2024S3Member2024-06-300001680048mbio:AtMarketOfferingMember2024-05-310001680048mbio:AtMarketOfferingMember2018-07-310001680048mbio:UnregisteredWarrantsMember2023-01-012023-12-310001680048mbio:UnregisteredWarrantsMember2024-05-012024-05-310001680048mbio:PrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2024-06-192024-06-190001680048mbio:PrefundedWarrantsMembermbio:June2024RegisteredDirectOfferingMember2024-06-192024-06-190001680048mbio:PrefundedWarrantsMembermbio:May2024PublicOfferingMember2024-04-292024-04-290001680048mbio:WainwrightWarrantsMemberus-gaap:PrivatePlacementMember2024-06-182024-06-180001680048mbio:SeriesA3WarrantMembermbio:May2024PublicOfferingMember2024-04-290001680048mbio:SeriesA2WarrantMembermbio:May2024PublicOfferingMember2024-04-290001680048mbio:SeriesA1WarrantMembermbio:May2024PublicOfferingMember2024-04-290001680048mbio:AssetPurchaseAgreementWithUbrigeneBiosciencesMember2024-06-270001680048mbio:AssetPurchaseAgreementWithUbrigeneBiosciencesMember2024-06-272024-06-270001680048mbio:LeidenUniversityMedicalCentreMembermbio:Rag1ScidMb110Membermbio:SponsoredResearchAndClinicalTrialAgreementsMember2021-09-082021-09-080001680048mbio:CityOfHopeNationalMedicalCenterCohMembermbio:Il13r2ProductMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2020-10-012020-10-310001680048mbio:CommonUnspecifiedClassMemberus-gaap:CommonStockMember2023-01-012023-06-300001680048us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001680048mbio:FredHutchinsonCancerResearchCenterMembermbio:Cd20TechnologyProductOrProcessMembersrt:MaximumMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2022-01-012022-01-310001680048mbio:FredHutchinsonCancerResearchCenterMembermbio:Cd20TechnologyProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2022-01-012022-01-310001680048mbio:FredHutchinsonCancerResearchCenterMembermbio:Cd20TechnologyProductOrProcessMembermbio:SponsoredResearchAndClinicalTrialAgreementsMember2020-11-012020-11-300001680048202406-300001680048202312-310001680048202404-012024-06-300001680048us-gaap:CommonClassAMember2024-08-090001680048mbio:CommonUnspecifiedClassMember2024-08-0900016800482024-01-012024-06-30xbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharesmbio:itemTable of Contentsâ€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORMÂ 10-Qâ€‹â˜ Â Â Â QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the quarterly period ended JuneÂ 30,Â 2024ORâ˜ Â Â Â Â TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the transition period from Â Â Â Â Â Â Â Â Â Â toCommission File Number 001-38191MUSTANG BIO,Â INC.(Exact name of registrant as specified in its charter)â€‹DelawareÂ Â Â Â 47-3828760(State or other jurisdiction of incorporation or organization)â€‹(I.R.S. Employer Identification No.)â€‹377 Plantation StreetWorcester, MA 01605(Address including zip code of principal executive offices)(781) 652-4500(Registrantâ€™s telephone number, including area code)Securities registered pursuant to SectionÂ 12(b)Â of the Act:â€‹Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, par value $0.0001 per shareMBIONasdaq Capital Marketâ€‹Indicate by check mark whether the registrant: (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. YesÂ Â â˜Â Â Â Â Â NoÂ Â â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files). YesÂ Â â˜Â Â Â Â Â NoÂ Â â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act:â€‹LargeÂ acceleratedÂ filerâ˜AcceleratedÂ filerâ˜Non-accelerated filerâ˜SmallerÂ reportingÂ companyâ˜Â Emerging growth companyÂ Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Â â˜Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesÂ Â Â Â â˜Â Â Â NoÂ Â Â Â â˜â€‹ClassÂ of Common StockÂ Outstanding Shares as of August 9, 2024ClassÂ A Common Stock, $0.0001 par valueÂ 845,385Common Stock, $0.0001 par valueÂ 36,387,236â€‹â€‹â€‹ Table of ContentsMUSTANG BIO, INC.QUARTERLY REPORT ON FORM 10-QTABLE OF CONTENTSâ€‹â€‹â€‹â€‹PART I. FINANCIAL INFORMATION5â€‹â€‹â€‹Item 1.Unaudited Financial Statements5â€‹â€‹â€‹Item 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations25â€‹â€‹â€‹Item 3.Quantitative and Qualitative Disclosures About Market Risks38â€‹â€‹â€‹Item 4.Controls and Procedures39â€‹â€‹PART II. OTHER INFORMATION39â€‹â€‹â€‹Item 1.Legal Proceedings39â€‹â€‹â€‹Item 1ARisk Factors39â€‹â€‹â€‹Item 2.Unregistered Sales of Equity Securities and Use of Proceeds77â€‹â€‹â€‹Item 3.Defaults Upon Senior Securities77â€‹â€‹â€‹Item 4.Mine Safety Disclosures77â€‹â€‹â€‹Item 5.Other Information77â€‹â€‹â€‹Item 6.Exhibits78â€‹â€‹â€‹Signatures80â€‹â€‹â€‹2 Table of Contentsâ€‹SUMMARY OF RISK FACTORSâ€‹Our business is subject to risks of which you should be aware before making an investment decision in our securities. The risks described below are a summary of the principal risks associated with an investment in us and are not the only risks we face. You should carefully consider these risk factors, the risk factors described in Item 1A of this Quarterly Report on Form 10-Q (this â€œForm 10-Qâ€), and the other reports and documents that we have filed with the Securities and Exchange Commission. Â â€‹Risks Related to our Finances and Capital Requirements â€‹â—We have incurred significant losses since our inception and anticipate that we will incur continued losses for the foreseeable future. â—There is substantial doubt regarding our ability to continue as a going concern. We will need to raise additional financing in upcoming periods, which may not be available on acceptable terms to us, or at all. Failure to obtain necessary capital when needed may force us to delay, limit or terminate our potential product candidates. â—We have not generated any revenue from our development stage products, and we do not know when, or if, we will generate any revenue.â—Our short operating history makes it difficult to evaluate our business and prospects. â—Our success is contingent on raising additional capital, and our efforts to do so may fail. Even if successful, our future capital raising activities may dilute our current stockholders, restrict our operations, or cause us to relinquish proprietary rights.â€‹Risks Pertaining to our Business Strategy, Structure and Organizationâ€‹â—Our future growth and success depend on our ability to successfully develop, and, if approved, commercialize our product candidates, which we have yet to do. â—Our future success is highly dependent on the successful development of our chimeric antigen receptor (â€œCARâ€) engineered T cell (â€œCAR Tâ€) technology product candidates. â—Our strategic pivot to our lead product candidate, MB-106, and our disposal of non-core assets, including our facility, may not result in the cost savings we anticipate and could result in total costs and expenses that are greater than expected.â€‹Risks Inherent in Drug Development and Commercializationâ€‹â—Preclinical development is highly speculative and carries a high failure risk. Â â—We may not receive the required regulatory approvals for any of our product candidates on our projected timelines, if at all, which may result in increased costs and delay our ability to generate revenue.â—We may not obtain the desired labeling claims or intended uses for product promotion, or favorable scheduling classifications, to successfully promote our product candidates, if approved.â—If a product candidate demonstrates adverse side effects, we may need to abandon or limit the development of such product candidate. â—Even if a product candidate is approved, it may be subject to various post-marketing requirements, including studies or clinical trials, and increased regulatory scrutiny. â—Our competitors may develop treatments for our productsâ€™ target indications, which could limit our product candidatesâ€™ commercial opportunity and profitability.â—If our product candidates, if approved, are not broadly accepted by the healthcare community, the revenues from any such product will likely be limited. â—Any successful productsâ€™ liability claims related to any of our current or future product candidates may cause us to incur substantial liability and limit the commercialization of any such products.â€‹3 Table of ContentsRisks Related to Reliance on Third Partiesâ€‹â—We rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or complying with applicable regulatory requirements.â—We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and may also do so for commercialization, if and when our product candidates are approved.â—We rely on clinical data and results obtained by third parties, which may prove inaccurate or unreliable.â—We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.â€‹Risks Relating to Legislation and Regulation Affecting the Biopharmaceutical and Other Industriesâ€‹â—We operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations.â—We may be subject to anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.â—We are subject to numerous environmental, health and safety laws and regulations and could become subject to fines or penalties or incur costs that could harm our business.â€‹Risks Pertaining to Intellectual Property and Potential Disputes with Licensors Thereofâ€‹â—If we are unable to obtain and maintain sufficient patent protection for our technology and products, our competitors could develop and commercialize products similar or identical to ours and our ability to successfully commercialize our technology and products could therefore be impaired.â—We depend on our licensors to maintain and enforce the intellectual property rights covering certain of our product candidates.â—We or our licensors may be subject to costly and time-consuming litigation for infringement of third-party intellectual property rights or to enforce our or our licensorsâ€™ intellectual property rights against third-party infringers. â—Any dispute with our licensors may affect our ability to develop or commercialize our product candidates.â€‹Risks Relating to Our Control by Fortress Biotech, Inc. (â€œFortressâ€)â€‹â—Fortress controls a voting majority of our common stock and has the right to receive significant share grants annually, which will result in dilution of our other stockholders and could reduce the value of our common stock. â—We have entered into certain agreements with Fortress and may have received better terms from unaffiliated third parties.â—We share certain directors with Fortress, which could create conflicts of interest between us and Fortress. â€‹4 Table of ContentsPARTÂ I. FINANCIAL INFORMATIONItemÂ 1. Unaudited Financial StatementsMUSTANG BIO,Â INC.Balance Sheets (Unaudited)(in thousands, except share and per share amounts)â€‹â€‹â€‹

â€”â€‹ â€”â€‹Â â€”â€‹Â (16,235)â€‹Â (16,235)Balances at JuneÂ 30,Â 2023Â 250,000â€‹$ â€”Â 845,385â€‹$ â€”Â 7,320,444â€‹$ 1â€‹$ â€”â€‹$ 376,009â€‹$ (362,297)â€‹$ 13,713â€‹â€‹â€‹

million over a period of two years. In October 2022, the SRA was amended to include additional funding of approximately $0.1 million. The research performed pursuant to this agreement supported technology the Company licensed from Mayo Clinic for a novel technology that may be able to transform the administration of CAR T therapies and has the potential to be used as an off-the-shelf therapy. In June 2024, the Company terminated its license agreement and associated SRA with the Mayo Clinic, in exchange for a mutual release of liability and forgiveness by Mayo Clinic of all amounts previously owed by the Company.â€‹NoteÂ 4Â - Related Party AgreementsFounders Agreement and Management Services Agreement with FortressWith respect to the Companyâ€™s Management Services Agreement (the â€œManagement Services Agreementâ€) with Fortress for the three and six months ended JuneÂ 30,Â 2024 and 2023, expenses related to the MSA are recorded 50% in research and development expenses and 50% in general and administrative expenses in the Unaudited Statements of Operations. For the three months ended JuneÂ 30,Â 2024 and 2023, the Company recorded expense of $0.1 million and $0.1 million, respectively, related to the MSA. For the six months ended June 30, 2024 and 2023, the Company recorded expense of $0.3 million and $0.3 million, respectively.Under the terms of the Second Amended and Restated Founders Agreement (the â€œFounders Agreementâ€), which became effective JulyÂ 22, 2016, Fortress will receive a grant of shares of the Companyâ€™s common stock equal to two and one-halfÂ percent (2.5%) of the gross amount of any equity or debt financing. Â For the six months ended JuneÂ 30,Â 2024, the Company issued 575,191 shares to Fortress in connection with the equity financings. For the three months ended JuneÂ 30,Â 2024 and 2023, the Company recorded expense of approximately $163,000 and zero, respectively, in general and administrative expenses related to these shares. For the six months ended JuneÂ 30,Â 2024 and 2023, the Company recorded expense of approximately $163,000 and zero, respectively, in general and administrative expenses related to these shares.Annual Stock Dividendâ€‹Pursuant to the Companyâ€™s Amended and Restated Certificate of Incorporation, as amended (the â€œCertificate of Incorporationâ€), the Company issued 353,086 shares of common stock to Fortress as the Annual Stock Dividend (as such term is defined in the Certificate of Incorporation), representing 2.5% of the fully-diluted outstanding equity of Mustang 14 Table of Contentson January 2, 2024. This was recorded in the Statement of Stockholdersâ€™ Equity at December 31, 2023, as Common stock issuable â€“ Founders Agreement. The Company recorded an expense of approximately $0.5 million in research and development â€“ licenses acquired related to these issuable shares during the year ended December 31, 2023.Payables and Accrued Expenses Related Partyâ€‹In the normal course of business Fortress pays for certain expenses on behalf of the Company. Such expenses are recorded as payables and accrued expensesÂ - related party and are typically reimbursed to Fortress in the normal course of business.â€‹Note 5 â€“ Assets Purchase Agreementsâ€‹Agreements with uBriGeneOn MayÂ 18, 2023, the Company entered into an Asset Purchase Agreement (the â€œOriginal Asset Purchase Agreementâ€) with uBriGene (Boston) Biosciences,Â Inc., a Delaware corporation (â€œuBriGeneâ€), pursuant to which the Company agreed to sell its leasehold interest in its cell processing facility located in Worcester, Massachusetts (the â€œFacilityâ€), and associated assets relating to the manufacturing and production of cell and gene therapies at the Facility to uBriGene (the â€œTransactionâ€). The Company and uBriGene subsequently entered into Amendment No.Â 1 to the Original Asset Purchase Agreement, dated as of JuneÂ 29, 2023 (â€œAmendment No.Â 1â€), and Amendment No.Â 2 to the Original Asset Purchase Agreement, dated as of JulyÂ 28, 2023 (â€œAmendment No.Â 2,â€ and together with the Original Asset Purchase Agreement and Amendment No.Â 1, the â€œPrior Asset Purchase Agreementâ€).Â On JulyÂ 28, 2023, pursuant to the Prior Asset Purchase Agreement, the Company completed the sale of all of its assets that primarily relate to the manufacturing and production of cell and gene therapies at the Facility (such operations, the â€œTransferred Operationsâ€ and such assets, the â€œTransferred Assetsâ€) to uBriGene for upfront consideration of $6 million cash (the â€œBase Amountâ€). The Transferred Assets included all of the Companyâ€™s assets, except for the Companyâ€™s lease and related leasehold improvements of the Facility and contracts that are primarily used in the Transferred Operations. The Company recorded a gain of $1.4Â million in connection with the sale of the Transferred Assets, and recorded approximately $0.3Â million of the base consideration as deferred income, that was to be recognized upon the transfer of the lease.Â Â In connection with the Prior Asset Purchase Agreement, the Company and uBriGene submitted a voluntary joint notice to the U.S. Committee on Foreign Investment in the United States (â€œCFIUSâ€). Following CFIUSâ€™s review and subsequent investigation of the transactions related to the Prior Asset Purchase Agreement, on MayÂ 13, 2024, the Company, together with uBriGene and CFIUS, executed a National Security Agreement (the â€œNSAâ€), pursuant to which the Company and uBriGene agreed to abandon the transactions related to the Prior Asset Purchase Agreement and the agreements entered into in connection therewith. The NSA obligated uBriGene and the Company to terminate agreements between the two parties, including the Manufacturing Services Agreement, Quality Services Agreement, and Subcontracting CDMO Agreement. In addition, uBriGene must sell, or otherwise dispose of, the equipment assets purchased within 180 days after the execution of the NSA.â€‹JuneÂ 2024 Repurchase of AssetsÂ On JuneÂ 27, 2024 (the â€œEffective Dateâ€), the Company entered into an Asset Purchase Agreement (the â€œRepurchase Agreementâ€) with uBriGene, pursuant to which the Company agreed, subject to the terms and conditions set forth therein, to repurchase the Transferred Assets, primarily lab equipment and supplies, (collectively, the â€œRepurchased Assetsâ€). Pursuant to the terms of the Repurchase Agreement, the Company and uBriGene also terminated existing manufacturing and services agreements. Â Â As consideration for the Repurchase Agreement, the Company agreed to pay to uBriGene a total purchase price (the â€œPurchase Priceâ€) of $1.4 million, consisting of (i)Â an upfront payment of $0.1 million due within five (5)Â business days of the Effective Date and a (ii)Â subsequent amount of $1.3 million due on the date that is twelve (12) months after the closing date (the â€œDeferred Amountâ€). In the event that as of the original (or any extended) date on which the Deferred Amount is payable, the Company has, as of the date of the public reporting of its then-most recent quarterly audited or 15 Table of Contentsunaudited financial statements, net assets below $20 million, then the Company may, upon written notice to uBriGene, elect to delay its payment obligation of the Deferred Amount by an additional six (6)Â months, with no limit on the number of such extensions available to the Company. Notwithstanding the foregoing, if the Company has not paid the Deferred Amount in full as of the date that is twelve (12) months after closingÂ of theÂ Repurchase Agreement, any amounts that remain outstanding will accrue interest at a rate of 5% per annum beginning on the date that is twelve (12) months after closing and until the Deferred Amount is paid in full. Additionally, in connection with the termination of the agreements described above under the Repurchase Agreement, the Company agreed to forgive a net receivable from uBriGene of approximately $3.3 million, comprised of outstanding receivables of $6.9 million and payables of $3.6 million, resulting in total purchase consideration in the Repurchase Transactions of approximately $4.7 million. As of June 30, 2024, the $1.4 million Purchase Price was recorded in Accrued Other Expenses (see Note 7). Â â€‹The Company allocated the total purchase consideration of $4.7 million to the Repurchased Assets on a relative fair value basis. The Company used a third-party to perform a valuation of the repurchased equipment, which resulted in a fair value less costs to sell of approximately $2.2 million. The remaining purchase consideration of $2.5 million was allocated to the supplies repurchased. The supplies repurchased with no alternative future use were recognized as research and development expense in an amount of $2.2 million. Â Repurchased supplies with an alternative future use of $0.3 million were also recognized in research and development expense, as the Company does not have plans to resume operations in the facility, and it intends to dispose of the supplies in a single transaction with the equipment. The Company concluded that the disposal group, which includes the repurchased equipment assets and associated supplies, with an aggregate value of approximately $2.2 million met the criteria to be classified as held for sale at the date of acquisition. â€‹NoteÂ 6Â â€“ Property, Plant and Equipment, and Asset ImpairmentAt JuneÂ 30,Â 2024, and DecemberÂ 31,Â 2023, property, plant and equipment consisted of the following:â€‹â€‹â€‹

(the â€œEngagement Letterâ€). Pursuant to the Engagement Letter, we issued to Wainwright (or its designees) warrants to purchase up to 367,800 shares of common stock (the â€œWainwright Warrantsâ€ and, together with the Private Placement Warrants, the â€œ2024 Warrantsâ€). The Wainwright Warrants have substantially the same terms as the Private Placement Warrants, except that the Wainwright Warrants will expire five years from the commencement of the sales of the Offerings and have an exercise price of $0.5125 per share (subject to customary adjustment as set forth in the Wainwright Warrants), representing 125% of the purchase price per share of common stock in the Registered Direct Offering.â€‹At-the-Market OfferingIn July 2018, the Company entered into an At-the-Market Issuance Sales Agreement (the â€œMustang ATMâ€) with B. Riley Securities, Inc. (formerly B. Riley FBR, Inc.), Cantor Fitzgerald & Co., National Securities Corporation (now B. Riley FBR, Inc.), and Oppenheimer & Co. Inc. (each an â€œAgentâ€ and collectively, the â€œAgentsâ€), relating to the sale of shares of common stock pursuant to the 2020 S-3. Under the Mustang ATM, the Company pays the Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock. On December 31, 2020, the Mustang ATM was amended to add H.C. Wainwright & Co., LLC as an Agent. On April 14, 2023, the Mustang ATM was amended to add the limitations imposed by General Instruction I.B.6 to Form S-3 and remove Oppenheimer & Co., Inc. as an Agent. On May 31, 2024, the Company delivered notice to the Agents to terminate the Mustang ATM, which was effective June 5, 2024.On May 31, 2024, the Company entered into an At-the-Market Offering Agreement (the â€œOffering Agreementâ€) with H.C. Wainwright (the â€œManagerâ€) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock through or to the Manager pursuant to the 2024 S-3. Under the Offering Agreement, the Company pays the Manager a commission of 3.0% of the gross proceeds from the sales of any shares of common stock. The Company 19 Table of Contentswill also reimburse the Manager for certain expenses incurred in connection with the Offering Agreement. The Company and the Manager may each terminate the Sales Agreement at any time upon specified prior written notice.â€‹During the six months ended JuneÂ 30,Â 2024 and 2023, no shares of common stock were issued under the Mustang ATM Agreement or the Offering Agreement.â€‹Equity Incentive PlanThe Company has in effect the 2016 Incentive Plan (the â€œIncentive Planâ€). The Incentive Plan was adopted in 2016 by the Companyâ€™s stockholders and the compensation committee of the Companyâ€™s board of directors and is authorized to grant stock-based awards to directors, officers, employees and consultants. The plan initially authorized grants to issue up to 133,333 shares of authorized but unissued common stock, expires 10Â years from adoption, and limits the term of each option to no more than 10Â years from the date of grant. In June 2018, the Companyâ€™s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 200,000 shares, for a total of 333,333 shares. In June 2021, the Companyâ€™s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 200,000 shares, for a total of 533,333 shares. In June 2022, the Companyâ€™s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 200,000 shares, for a total of 733,333 shares.As of JuneÂ 30,Â 2024, 394,393 shares were available for future issuance under the Incentive Plan.Stock OptionsThe following table summarizes stock option activities for the six months ended JuneÂ 30,Â 2024:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

â€‹Â Â Â Â Â â€‹Â Â Â Â â€‹â€‹Â Â Â Â Â WeightedÂ Averageâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Remainingâ€‹â€‹â€‹â€‹â€‹WeightedÂ Averageâ€‹ContractualÂ LifeÂ (inâ€‹â€‹StockÂ Optionsâ€‹ExerciseÂ Priceâ€‹yea
at DecemberÂ 31,Â 2023Â 76,112â€‹$ 85.95Â 3.31Outstanding at JuneÂ 30,Â 2024Â 76,112â€‹$ 85.95Â 2.81Options vested and exercisable at JuneÂ 30,Â 2024Â 47,570â€‹$ 85.95Â 2.81â€‹As of June 30, 2024, the Company had no unrecognized stock-based compensation expense related to options. The Company accounts for forfeited awards as they occur as permitted.â€‹Restricted StockThe following table summarizes restricted stock award activities for the six months ended JuneÂ 30,Â 2024:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

â€‹Â Â Â Â Â â€‹Â Â Â Â Â WeightedÂ Averageâ€‹â€‹â€‹GrantÂ DateÂ Fairâ€‹â€‹NumberÂ ofÂ Sharesâ€‹ValueNonvested at DecemberÂ 31,Â 2023Â 64,706â€‹$ 11.59Vestedâ€‹ (4,595)â€‹â€‹ 54.45Nonvested at JuneÂ 30,Â 2024Â 60,111â€‹$ 8.32â€‹As of JuneÂ 30,Â 2024, the Company had unrecognized stock-based compensation expense related to restricted stock of $0.3 million, which is expected to be recognized over the remaining weighted average vesting period of approximately 1.6 years.20 Table of ContentsRestricted Stock UnitsCertain employees and consultants have been awarded restricted stock units with time-based vesting.Â The following table summarizes restricted stock unitsâ€™ activities for the six months ended JuneÂ 30,Â 2024:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ â€‹Â Â Â Â Â â€‹Â Â Â Â Â WeightedÂ Averageâ€‹â€‹â€‹â€‹GrantÂ DateÂ Fairâ€‹â€‹NumberÂ ofÂ Unitsâ€‹ValueNonvested at DecemberÂ 31,Â 2023Â 95,197â€‹$ 18.78Forfeitedâ€‹ (63,782)â€‹â€‹ 18.19VestedÂ (17,199)â€‹Â 22.41Nonvested at JuneÂ 30,Â 2024Â 14,216â€‹$ 17.02â€‹As of JuneÂ 30,Â 2024, the Company had unrecognized stock-based compensation expense related to restricted stock units of approximately $57,000, which is expected to be recognized over the remaining weighted average vesting period of approximately 1.9 years. The following table summarizes stock-based compensation expense for the three and six months ended JuneÂ 30,Â 2024 and 2023 (in thousands):â€‹ForÂ the three months ended JuneÂ 30,Â â€‹ForÂ the six months ended JuneÂ 30,Â â€‹

â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â General and administrativeâ€‹ $ 51â€‹$ 153â€‹$ 98â€‹$ 262â€‹Research and development â€‹Â (670)â€‹Â (108)â€‹Â (640)â€‹Â 18â€‹Total stock-based compensation expenseâ€‹ $ (619)â€‹$ 45â€‹$ (542)â€‹$ 280â€‹â€‹On April 12, 2024, the Company reduced its workforce by approximately 81 percent, which resulted in the forfeiture of a significant number of outstanding restricted stock units and the reversal of previously incurred stock-based compensation expense.â€‹Employee Stock Purchase Planâ€‹Eligible employees can purchase the Companyâ€™s common stock at the end of a predetermined offering period at 85% of the lower of the fair market value at the beginning or end of the offering period. Â The Employee Stock Purchase Plan (â€œESPPâ€) is compensatory and results in stock-based compensation expense. The ESPP was initially authorized in 2019 to sell up to 26,667 shares of authorized but unissued common stock. In June 2021, the Companyâ€™s stockholders approved an amendment to the ESPP to increase the number of authorized shares issuable by 40,000 shares. In addition, in June 2023, the Companyâ€™s stockholders approved an amendment to the ESPP to increase the number of authorized shares issuable thereunder by 400,000 for a total of 466,667 shares.â€‹As of JuneÂ 30,Â 2024, 128,352 shares have been purchased and 338,315 shares are available for future sale under the Companyâ€™s ESPP.21 Table of ContentsWarrantsA summary of warrant activities for the six months ended JuneÂ 30,Â 2024, is presented below:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

â€‹Â Â Â Â Â â€‹Â Â Â Â â€‹â€‹Â Â Â Â Â WeightedÂ Averageâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Remainingâ€‹â€‹â€‹â€‹â€‹WeightedÂ Averageâ€‹ContractualÂ LifeÂ (inâ€‹â€‹Warrantsâ€‹ExerciseÂ Priceâ€‹years)Ou
as of DecemberÂ 31,Â 2023Â 4,481,868â€‹$ 1.34Â 5.34ExercisedÂ (20,490,874)â€‹Â â€”Â Â â€”GrantedÂ 76,966,010â€‹Â 0.19Â 2.74Outstanding as of JuneÂ 30,Â 2024Â 60,957,004â€‹$ 0.29Â 2.98â€‹Upon the cashless exercise of warrants, the Company will issue new shares of common stock. In connection with the Companyâ€™s Registered Direct Offering on October 26, 2023, the Company issued pre-funded warrants to purchase up toÂ 1,668,236Â shares of common stock, and in a concurrent private placement, the Company issued unregistered warrants to purchase up toÂ 2,588,236Â shares of common stock, and the resale of the underlying shares of common stock were subsequently registered in April 2024 on Form S-1 (File No. 333-275997). In connection with these offerings, H.C. Wainwright received Placement Agent Warrants to purchase up toÂ 155,294Â shares of common stock. In connection with the Public Offering the Company completed in May 2024, the 2,588,236 unregistered warrants were repriced from the original exercise price of $1.58 to $0.237.â€‹In connection with the May 2024 Offering, the Company issued pre-funded warrants to purchase up toÂ 15,717,638Â shares of common stock and issued three series of warrants to purchase up toÂ 50,632,914Â shares of common stock. In connection with these offerings, H.C. Wainwright received Placement Agent Warrants to purchase up toÂ 1,012,658Â shares of common stock.â€‹In connection with the Registered Direct Offering, the Company issued pre-funded warrants to purchase up toÂ 3,105,000Â shares of common stock, and in the concurrent Private Placement, the Company issued unregistered warrants to purchase up toÂ 6,130,000Â shares of common stock, the resale of the underlying shares of common stock were subsequently registered in July 2024 on Form S-1 (File No. 333-280927). In connection with these offerings, H.C. Wainwright received Placement Agent Warrants to purchase up toÂ 367,800Â shares of common stock.â€‹During the six months ended June 30, 2024, all of the 1,668,236 pre-funded warrants issued in the October Registered Direct Offering were exercised at an exercise price of $0.001, and all of the 18,822,638 pre-funded warrants issued in the May 2024 Offering and the June Registered Direct Offering were exercised at an exercise price of $0.0001.â€‹NoteÂ 10Â â€” Net Loss per ShareNet loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period less unvested restricted stock. Since dividends are declared, paid and set aside among the holders of shares of common stock and ClassÂ A common shares pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect of shares of common stock to be issued upon the exercise of warrants or outstanding ClassÂ A preferred shares, as their inclusion would be anti-dilutive. The two-class method is an earnings allocation formula that treats participating securities as having rights that would otherwise have been available to common stockholders. In addition, as our non-pre-funded warrants are participating securities, we are required to calculate diluted earnings per share under the if-converted method and utilize the most dilutive result. In periods where there is a net loss, no allocation of undistributed net loss to non-pre-funded warrants is performed as the holders of our non-pre-funded warrants are not contractually obligated to participate in our losses.â€‹22 Table of ContentsThe table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ForÂ the six months ended JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023WarrantsÂ 60,957,004â€‹ 70,102OptionsÂ 76,112Â 76,112ClassÂ A Preferred SharesÂ 250,000Â 250,000Unvested restricted stock awardsÂ 60,111Â 34,016Unvested restricted stock unitsÂ 14,216Â 129,476TotalÂ 61,357,443Â 559,706â€‹â€‹â€‹NoteÂ 11Â â€” Income TaxesThe Company incurred net operating losses and recorded a full valuation allowance against net deferred tax assets for all periods presented. Accordingly, the Company has not recorded a provision for federal or state income taxes.â€‹The Company is subject to US federal and state income taxes. Income tax expense is the total of the currentÂ year income tax due or refundable and the change in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in theÂ years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of Management, it is more likely than not that some portion, or all, of the deferred tax asset will not be realized.â€‹Note 12 â€” Commitments and ContingenciesIndemnificationIn accordance with its Certificate of Incorporation, amended and restated bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Companyâ€™s request in such capacity. The Company has director and officer insurance to address such claims. The Company also provides indemnification of contractual counterparties in certain situations, including without limitation to clinical sites, service providers and licensors.LeasesThe Company leases office space under an agreement classified as operating leases that expires in October 2026. On June 28, 2024, the Company terminated the lease of its Mercantile Center Facility for a termination fee of $40,000. The Companyâ€™s lease liabilities result from the lease of its Plantation Street Facility, which expires in 2026. Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Certain of the Companyâ€™s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right of use assets as the Company is not reasonably certain to exercise the options. The Company does not act as a lessor or have any leases classified as financing leases. At JuneÂ 30,Â 2024, the Company identified triggering events that required an impairment of the asset group consisting of the right-of-use asset and associated leasehold improvements. The assessment concluded that impairment existed as of June 30, 2024, and the impairment loss was allocated to the leasehold improvements and right-of-use assets based on the relative carrying amounts of the assets (see Note 6). As of June 30, 2024, the Company had operating lease liabilities of $1.1 million and right of use assets of $0.1Â million, which were included in the Unaudited Balance Sheet. At DecemberÂ 31,Â 2023, the Company had operating lease liabilities of $2.5Â million and right of use assets of $1.6Â million, which were included in the Unaudited Balance Sheet.23 Table of ContentsThe following summarizes quantitative information about the Companyâ€™s operating leases:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

oncolytic virus (MB-108) in order to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors. The Phase 1 clinical trial sponsored by COH for MB-101 (ClinicalTrials.gov Identifier: NCT02208362) has completed the treatment phase and patients continue to be assessed for long-term safety. A Phase 1 clinical trial sponsored by the University of Alabama at Birmingham (â€œUABâ€) for MB-108 (ClinicalTrials.gov Identifier: NCT03657576) began during the third quarter of 2019. In October 2023, we announced that the FDA accepted our IND application for the combination of MB-101 and MB-108 â€“ which is referred to as MB-109 â€“ for the treatment of patients with IL13RÎ±2+ relapsed or refractory glioblastoma (â€œGBMâ€) and high-grade astrocytoma. â€‹On May 18, 2023, we announced a series of changes resulting from a review of our portfolio of product candidates to determine the future strategy of our programs and the proper allocation of our resources. Following this review, we determined to discontinue development of our MB-102 (CD123), MB-103 (HER2), MB-104 (CS1) and MB-105 (PSCA) programs, all of which were CAR T therapies being developed in partnership with City of Hope.â€‹MB-106 (CD20-targeted CAR T cell therapy for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia)â€‹In the first quarter of 2024, we completed a successful End-of-Phase 1 meeting with the FDA regarding a potential pivotal Phase 2 single-arm clinical trial for the treatment of WM. Per the discussions, the FDA agreed with the proposed overall design of the pivotal trial for WM at the recommended dose of 1 x 107 CAR-T cells/kg and requested only minimal modifications to the study protocol. No additional nonclinical studies are expected prior to Phase 2 or a Biologics License Application (â€œBLAâ€) filing. Due to limited resources, and as a result of the reduction in work force described below, we do not expect to initiate our pivotal Phase 2 single-arm clinical trial of MB-106 for the treatment of WM trial in 2024. Subject to available funds, we intend to rely on third party service providers to conduct study and manufacturing services to advance our priority potential product candidates.Â Also in the first quarter of 2024, we completed enrollment of the indolent lymphoma arm in our multicenter Phase 1 trial. The tenth and final patient enrolled on that arm was a patient with follicular lymphoma (FL) who achieved a complete response following treatment with 1 x 107 CAR-T cells/kg. As a result, the overall complete response rate for FL in the Phase 1 portion of this trial was sustained at 100% (N=6), with no occurrence of CRS above grade 1 and no ICANS of any grade, despite not using prophylactic tocilizumab or dexamethasone.Â In March 2024, we announced plans to collaborate with Fred Hutch for a proof-of-concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 in autoimmune diseases.Â In March 2024, we were granted the Regenerative Medicine Advanced Therapy (â€œRMATâ€) designation by the FDA for the treatment of relapsed or refractory CD20 positive WM and FL, based on potential improvement in response as seen in clinical data to date. Drugs eligible for RMAT designation are those intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and that present preliminary clinical evidence indicating the drug has the potential to address unmet medical needs for such disease or condition. RMAT designation provides regenerative medicine advanced therapy products with the same benefits to expedite the development and review of a marketing application that are available to drugs that receive Breakthrough Therapy Designation. These advantages include timely advice and interactive communications with FDA, as well as proactive and collaborative involvement by senior FDA managers and experienced review and regulatory health project management staff. A product designated as an RMAT also may be eligible for other FDA-expedited programs, such as Priority Review. The FDA also may conduct a rolling review of products in its expedited programs, reviewing portions of a marketing application before the complete application is submitted.â€‹In June 2024, we announced that updated data for MB-106 in the Phase 1/2 Fred Hutch investigator-sponsored trial showed a favorable safety and efficacy profile in 10 patients with WM. There was an overall response rate (â€œORRâ€) of 90% with durable responses observed, including three complete responses (â€œCRâ€), two very good partial responses (â€œVGPRâ€), and four partial responses (â€œPRâ€). One of the patients who achieved a CR remained in remission for 31 months, with an 26 Table of Contentsimmunoglobulin M (IgM) level that decreased rapidly to the normal range after treatment with MB-106 and remained normal since. Patients had a median of nine prior lines of therapy, and only one patient started additional anti-WM treatment after being treated with MB-106. From a safety perspective, CRS occurred in nine patients: five patients with grade 1 and four patients with grade 2. One patient experienced grade 1 ICANS. No grade 3 or 4 CRS or grade 2, 3 or 4 ICANS was observed, despite dose escalation.â€‹In May 2024, we informed the clinical sites participating in the Mustang-sponsored Phase 1/2 study in non-Hodgkin lymphoma and chronic lymphocytic leukemia, MB106-CD20-001, that we had decided to close the trial. In June 2024, we similarly informed the clinical sites participating in the Mustang-sponsored Long-term Follow-up Study in Patients Previously Treated with Mustang Bio, Inc. CAR-T Cell Investigational Products, MB100-OBS-001, that we had decided to close that trial. As a result, further clinical development of MB-106 is currently focused solely on autoimmune diseases unless funding and resources become available to restart the program for hematologic malignancies. Planning for the aforementioned Phase 1 investigator-sponsored clinical trial in autoimmune diseases is in progress, with initiation of the trial planned for the fourth quarter of 2024 and proof-of-concept anticipated in 2025.â€‹MB-109 (Combination of MB-101 CAR T Therapy with MB-108 Oncolytic Virus Therapy for Malignant Brain Tumors)In OctoberÂ 2023, we received a safe-to-proceed â€œapprovalâ€ from the FDA for our MB-109 IND application allowing us to initiate a Phase 1, open-label, non-randomized, multicenter study of MB-109 in patients with IL13RÎ±2+ recurrent GBM and high-grade astrocytoma. In this Phase 1 clinical study, we intend to evaluate the combination of CAR-T cells (MB-101) and the herpes simplex virus type 1 oncolytic virus (MB-108) in patients with IL13RÎ±2+ high-grade gliomas. The design of this study involves first a lead-in cohort, wherein patients are treated with MB-101 alone without prior MB-108 administration. After successful confirmation of the safety profile of MB-101 alone, the study will then investigate increasing doses of intratumorally administered MB-108 followed by dual intratumoral (ICT) and intraventricular (ICV) administration of MB-101. Due to limited resources, we do not currently expect to initiate this study until such time, if any, that additional resources become available to us.â€‹Terminated Product Candidates (Gene Therapies and in vivo CAR-T)Â We previously developed several gene therapy product candidates, which included MB-117 and MB-217 (based on technologies licensed from St. Jude Childrenâ€™s Research Hospital (â€œSt. Judeâ€)) and MB-110 (based on technologies licensed from Leiden University Medical Centre (â€œLUMCâ€)). In April 2024, we entered into a termination and release agreement with St. Jude, pursuant to which we agreed to terminate the license agreement underpinning the MB-117 and MB-217 product candidates in exchange for a mutual release of liability and forgiveness by St. Jude of all amounts previously owing to them. Also in April 2024, we delivered a termination notice to LUMC pursuant to which we terminated the license agreement underpinning the MB-110 product candidate; we are currently in discussions with LUMC regarding the terms that will govern such termination.Â In June 2024, we also agreed with Mayo Foundation for Medical Education and Research (â€œMayo Clinicâ€) to terminate the license agreement underpinning our (now former) preclinicalÂ in vivoÂ CAR-T program, together with a related sponsored research agreement, in exchange for a mutual release of liability and forgiveness by Mayo Clinic of all amounts previously owed to them.Â To date, we have not received approval for the sale of any of our product candidates in any market and, therefore, have not generated any product sales from our product candidates. In addition, we have incurred substantial operating losses since our inception, and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. â€‹Recent Developmentsâ€‹April 2024 Reduction in Work ForceÂ On April 10, 2024, our board of directors approved a reduction of our workforce by approximately 81% of our employee base in order to reduce costs and preserve capital due to the fundraising environment and continued uncertainty regarding the CFIUS review of the sale of the Facility and the Transaction with uBriGene (Boston) Biosciences, Inc., a Delaware corporation (â€œuBriGeneâ€). The workforce reduction took place primarily in April 2024 and was completed in the second 27 Table of Contentsquarter of 2024. As a result of these actions, we incurred personnel-related restructuring charges of approximately $0.2 million in connection with one-time employee termination cash expenditures, which were incurred in the second quarter of 2024. â€‹Sale of Manufacturing Facility â€“ Overview of Transactionâ€‹On May 18, 2023, we entered into an Asset Purchase Agreement (the â€œOriginal Asset Purchase Agreementâ€) with uBriGene, pursuant to which we agreed to sell our leasehold interest in our cell processing facility located in Worcester, Massachusetts (the â€œFacilityâ€), and associated assets relating to the manufacturing and production of cell and gene therapies at the Facility to uBriGene (the â€œTransactionâ€). We and uBriGene subsequently entered into Amendment No. 1, dated as of June 29, 2023, and Amendment No. 2, dated as of July 28, 2023, to the Original Asset Purchase Agreement (the Original Asset Purchase Agreement, as so amended, the â€œPrior Asset Purchase Agreementâ€).Â â€‹On July 28, 2023 (the â€œClosing Dateâ€), pursuant to the Prior Asset Purchase Agreement, we completed the sale of all of our assets that primarily relate to the manufacturing and production of cell and gene therapies at the Facility (such operations, the â€œTransferred Operationsâ€ and such assets, the â€œTransferred Assetsâ€) to uBriGene for upfront consideration of $6 million cash (the â€œBase Amountâ€). The Transferred Assets that were transferred to uBriGene on the Closing Date include, but are not limited to: (i) our leases of equipment and other personal property and all other property, equipment, machinery, tools, supplies, inventory, fixtures and all other personal property primarily related to the Transferred Operations, (ii) the data, information, methods, quality management systems, and intellectual property primarily used for the purposes of the Transferred Operations, (iii) the records and filings, including customer and vendor lists, production data, standard operating procedures and business records relating to, used in or arising under the Transferred Operations and (iv) all transferrable business license, permits and approvals necessary to operate the Transferred Operations. Certain Transferred Assets, including our lease of the Facility and contracts that are primarily used in the Transferred Operations (the â€œTransferred Contractsâ€) did not transfer to uBriGene on the Closing Date.Â Voluntary Notice to U.S. Committee on Foreign Investment in the United Statesâ€‹uBriGene is an indirect, wholly owned subsidiary of UBrigene (Jiangsu) Biosciences Co., Ltd., a Chinese contract development and manufacturing organization. Under the Prior Asset Purchase Agreement, we and uBriGene agreed to use our reasonable best efforts to obtain clearance for the Transaction from the U.S. Committee on Foreign Investment in the United States (â€œCFIUSâ€), although obtaining such clearance was not a condition to closing the Transaction. In accordance with the Prior Asset Purchase Agreement, we and uBriGene previously submitted a voluntary joint notice to CFIUS on August 10, 2023.Â Following an initial 45-day review period and subsequent 45-day investigation period, on November 13, 2023, CFIUS requested that we and uBriGene withdraw and re-file our joint voluntary notice to allow more time for review and discussion regarding the nature and extent of national security risk posed by the Transaction. Upon CFIUSâ€™s request, we and uBriGene submitted a request to withdraw and re-file our joint voluntary notice to CFIUS, and on November 13, 2023, CFIUS granted this request, accepted the joint voluntary notice and commenced a new 45-day review period on November 14, 2023. CFIUSâ€™s 45-day review ended on December 28, 2023. Since CFIUS had not concluded its review by December 28, 2023, the proceeding transitioned to a subsequent 45-day investigation period, which ended on February 12, 2024.Â Following the 45-day review period and subsequent 45-day investigation period described above, on February 12, 2024, we and uBriGene requested permission to withdraw and re-file our joint voluntary notice to allow more time for review and discussion regarding the nature and extent of national security risk posed by the Transaction. Upon our joint request to withdraw and re-file their joint voluntary notice to CFIUS, on February 12, 2024, CFIUS granted this request, accepted the joint voluntary notice and commenced a new 45-day review period on February 13, 2024. CFIUSâ€™s new 45-day review ended on March 28, 2024. Because CFIUS had not yet concluded its action, the proceeding transitioned to a second 45-day phase as CFIUS further investigated the Transaction. On March 28, 2024, CFIUS advised us that its investigation would be completed no later than May 13, 2024.Â On May 13, 2024, together with uBriGene and CFIUS, we executed a National Security Agreement (the â€œNSAâ€), pursuant to which we and uBriGene agreed to abandon the Transaction and all other transactions contemplated by the Asset 28 Table of ContentsPurchase Agreement and the agreements entered into in connection therewith. The execution of the NSA was the result of CFIUSâ€™ determination that such transactions posed a risk to the national security of the United States. We disagree with this position but did not feel a meaningful likelihood existed that the Transaction would be consummated in light of CFIUSâ€™ objections. The NSA imposes certain conditions on us and uBriGene and its affiliates. Most significantly, we agreed (i) not to effect the Transaction with uBriGene or any of its affiliates; and (ii) to appoint a point of contact representative with whom CFIUS and uBriGeneâ€™s designated contact person may interact as needed. The NSA also obligates uBriGene to sell, or otherwise dispose of, the equipment assets purchased within 180 days after the execution of the NSA, with uBriGene able to eliminate some of its obligations under the NSA if it is able to sell the equipment assets purchased back to us within 45 days after the execution of the NSA (an â€œExpedited Divestmentâ€).â€‹June 2024 Repurchase of AssetsÂ On June 27, 2024 (the â€œEffective Dateâ€), we entered into an Asset Purchase Agreement (the â€œAsset Purchase Agreementâ€) with uBriGene, pursuant to which we agreed, subject to the terms and conditions set forth therein, to repurchase (the â€œRepurchase Transactionâ€) the assets, properties and rights previously transferred by the Company to uBriGene under the Prior Asset Purchase Agreement, excluding any inventory transferred under the Purchase Agreement that has been consumed or transferred to a third party by uBriGene since the closing of the Prior Asset Purchase Agreement (collectively, the â€œRepurchased Assetsâ€). For the avoidance of doubt, â€œRepurchased Assetsâ€ also includes all Mustang Assets (as such term is defined in the NSA) that were previously sold, transferred, conveyed, assigned, delivered, or contributed by us or our affiliates to uBriGene or its affiliates, to the extent such assets have not been consumed or transferred to a third party by uBriGene since the closing of the Prior Asset Purchase Agreement. The Repurchased Assets do not include inventory acquired by uBriGene after the closing of the Prior Asset Purchase Agreement. We further agreed to assume all obligations, liabilities and commitments previously transferred by us to uBriGene under the Prior Asset Purchase Agreement. The Repurchase Transaction was intended to constitute an Expedited Divestment by uBriGene pursuant to the NSA with CFIUS.Â As consideration for the Repurchase Transaction, we agreed to pay to uBriGene a total purchase price (the â€œPurchase Priceâ€) of $1,395,138, consisting of (i) an upfront payment of $100,000 due within five (5) business days of the Effective Date and a (ii) subsequent amount of $1,295,138 due on the date that is twelve (12) months after the Closing (the â€œDeferred Amountâ€). In the event that as of the original (or any extended) date on which the Deferred Amount is payable we have, as of the date of the public reporting of our then-most recent quarterly audited or unaudited financial statements, net assets below $20 million, then we may, upon written notice to uBriGene, elect to delay our payment obligation of the Deferred Amount by an additional six (6) months, with no limit on the number of such extensions available to us. Notwithstanding the foregoing, if we have not paid the Deferred Amount in full as of the date that is 12 (twelve) months after closing of the Repurchase Transaction, any amounts that remain outstanding will accrue interest at a rate of 5% per annum beginning on the date that is 12 (twelve) months after closing and until the Deferred Amount is paid in full.Â The Asset Purchase Agreement contains customary representations and warranties from both us and uBriGene with respect to each party. Additionally, we agreed to provide a purchase price allocation schedule to uBriGene within sixty (60) days of the Effective Date.Â Pursuant to the terms of the Asset Purchase Agreement, we and uBriGene terminated the following agreements between us that were entered into in connection with the Asset Purchase Agreement: (i) the Manufacturing Services Agreement, dated July 28, 2023, and work orders entered into under such agreement, (ii) the Quality Services Agreement, dated July 28, 2023, (iii) the Subcontracting CDMO Agreement, dated July 28, 2023, and work orders entered into under such agreement, (iv) the Quality Services Agreement, dated July 28, 2023, and (v) the Transition Services Agreement.â€‹Notification of Non-Compliance with Nasdaq Continued Listing RequirementsÂ On March 13, 2024, we received a deficiency letter (the â€œLetterâ€) from the Listing Qualifications Department (the â€œStaffâ€) of The Nasdaq Stock Market LLC (â€œNasdaqâ€) notifying us that we were not in compliance with the minimum stockholdersâ€™ equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholdersâ€™ equity of at least $2,500,000 (the â€œStockholdersâ€™ Equity Requirementâ€). As of December 31, 2023, we reported stockholdersâ€™ equity 29 Table of Contentsof $123,000, and as of June 30, 2024, we reported negative stockholdersâ€™ equity of $ ($8.3) million. The Letter further noted that as of its date, we did not have a market value of listed securities of $35 million, or net income from continued operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years, the alternative quantitative standards for continued listing on the Nasdaq Capital Market.Â The Letter had no immediate effect on our continued listing on the Nasdaq Capital Market, subject to our compliance with the other continued listing requirements. In accordance with Nasdaq rules, we were provided 45 calendar days, or until April 29, 2024, to submit a plan to regain compliance (the â€œCompliance Planâ€). We submitted our Compliance Plan on April 29, 2024, and the Staff granted our request for an extension of 180 calendar days through September 9, 2024, to regain compliance with the Stockholdersâ€™ Equity Requirement.Â On May 16, 2024, we received a notice (the â€œSecond Letterâ€) from the Staff of Nasdaq indicating that the bid price of our common stock had closed below $1.00 per share for 31 consecutive business days and, as a result, we were not in compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Second Letter from Nasdaq had no immediate effect on the listing of our common stock on Nasdaq. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), we were afforded a 180-calendar day grace period, or until November 12, 2024, to regain compliance with the bid price requirement. Compliance can be achieved by evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days (but generally not more than 20 consecutive business days) during the 180-calendar day grace period.Â If we do not regain compliance with the bid price requirement by November 12, 2024, we may be eligible for an additional 180-calendar day compliance period so long as we satisfy the criteria for initial listing on Nasdaq and the continued listing requirement for market value of publicly held shares and we provide written notice to Nasdaq of our intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. In the event we are not eligible for the second grace period, Nasdaq staff will provide written notice that our common

stock is subject to delisting; however, we may request a hearing before the Nasdaq Hearings Panel (the â€œPanelâ€), which request, if timely made, would stay any further suspension or delisting action by the Staff pending the conclusion of the hearing process and expiration of any extension that may be granted by the Panel. There can be no assurance that we would be successful in our efforts to maintain the listing of our common stock on the Nasdaq Capital Market.Â Financing Activitiesâ€‹May 2024 Public Offering On April 29, 2024, we commenced a best efforts public offering with an institutional investor (the â€œInvestorâ€) (the â€œMay 2024 Offeringâ€) of an aggregate of (i) 1,160,000 shares of common stock, (ii) pre-funded warrants (the â€œMay 2024 Pre-Funded Warrantsâ€) to purchase up to an aggregate of 15,717,638 shares of common stock (the â€œMay 2024 Pre-Funded Warrant Sharesâ€), (iii) Series A-1 warrants (the â€œSeries A-1 Warrantsâ€) to purchase up to an aggregate of 16,877,638 shares of common stock (the â€œSeries A-1 Warrant Sharesâ€), (iv) Series A-2 warrants (the â€œSeries A-2 Warrantsâ€) to purchase up to an aggregate of 16,877,638 shares of common stock (the â€œSeries A-2 Warrant Sharesâ€), and (v) Series A-3 warrants (the â€œSeries A-3 Warrants,â€ and together with the Series A-1 Warrants and Series A-2 Warrants, the â€œWarrantsâ€) to purchase up to an aggregate of 16,877,638 shares of common stock (the â€œSeries A-3 Warrant Sharesâ€). Each share of common stock or May 2024 Pre-Funded Warrant was sold together with one Series A-1 Warrant to purchase one share of common stock, one Series A-2 Warrant to purchase one share of common stock, and one Series A-3 Warrant to purchase one share of common stock. The public offering price for each share of common stock and accompanying Warrants was $0.237, and the public offering price for each May 2024 Pre-Funded Warrant and accompanying Warrants was $0.2369. The May 2024 Pre-Funded Warrants have an exercise price of $0.0001 per share, were exercisable immediately and will expire when exercised in full. Each Warrant has an exercise price of $0.237 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Warrants (the â€œWarrant Stockholder Approvalâ€), which was obtained on June 27, 2024. The Series A-1 Warrant will expire on the five-year anniversary of the Warrant Stockholder Approval. The Series A-2 Warrant will expire on the twenty-four-month anniversary of the Warrant Stockholder Approval. The Series A-3 Warrant will expire on the nine-month anniversary of the Warrant Stockholder Approval. â€‹30 Table of ContentsThe net proceeds of the May 2024 Offering, after deducting the fees and expenses of the Placement Agent (as defined below), described in more detail below, and other offering expenses payable by us, but excluding the net proceeds, if any, from the exercise of the Warrants, was approximately $3.2 million. The May 2024 Offering closed on May 2, 2024.Â In connection with the May 2024 Offering, we also entered into a warrant amendment agreement (the â€œWarrant Amendment Agreementâ€) with the Investor. Under the Warrant Amendment Agreement, we agreed to amend certain existing warrants to purchase up to 2,588,236 shares of common stock that were previously issued in October 2023 to the Investor, with an exercise price of $1.58 per share (the â€œExisting Warrantsâ€), in consideration for their purchase of the securities in the May 2024 Offering, as follows: (i) lower the exercise price of the Existing Warrants to $0.237 per share, (ii) provide that the Existing Warrants, as amended, will not be exercisable until the receipt of Warrant Stockholder ApprovalÂ for the exercisability of the Warrants in the May 2024 Offering, and (iii) extend the original expiration date of the Existing Warrants by five years following the receipt of such Warrant Stockholder Approval. The Warrant Amendment Agreement became effective on May 2, 2024.â€‹June 2024 Registered Direct Offering and Concurrent Private Placement of Warrants (the â€œJune 2024 Offeringâ€)â€‹On June 19, 2024, we entered into a Securities Purchase Agreement (the â€œJune 2024 SPAâ€) with an institutional accredited investor, pursuant to which we agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of Nasdaq (the â€œRegistered Direct Offeringâ€), (i) 3,025,000 shares of common stock, at a price per Share of $0.41 and (ii) pre-funded warrants (the â€œPre-Funded Warrantsâ€) to purchase up to 3,105,000 shares of our common stock, at a price per Pre-Funded Warrant equal to $0.4099, the price per share of common stock, less $0.0001.Â The Pre-Funded Warrants were sold, in lieu of shares of common stock,Â to the investor, whose purchase of shares of common stock in the Registered Direct Offering would otherwise result in the investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the investorâ€™s option upon issuance, 9.99%) of our outstanding common stock immediately following the completion of the Registered Direct Offering. The Pre-Funded Warrants have an exercise price of $0.0001 per share, became exercisable upon issuance and remain exercisable until exercised in full.Â The Registered Direct Offering closed on June 21, 2024. We intend to use the net proceeds of approximately $2.1 million from the Registered Direct Offering for general corporate purposes and working capital requirements.Â In a concurrent private placement, pursuant to the terms of the June 2024 SPA, we also agreed to issue and sell to the investor unregistered warrants (the â€œPrivate Placement Warrantsâ€) to purchase up to 6,130,000 shares of common stock, at an offering price of $0.41 per Private Placement Warrant to purchase one share of common stock (the â€œPrivate Placementâ€ and, together with the Registered Direct Offering, the â€œOfferingsâ€) (which offering price was included in the purchase price per share of common stock or Pre-Funded Warrant). The Private Placement Warrants have an exercise price of $0.41 per share (subject to customary adjustments as set forth in the Private Placement Warrants), were exercisable upon issuance and will expire five years from the date of issuance. The Private Placement Warrants contain customary anti-dilution adjustments to the exercise price, including for share splits, share dividends, rights offering and pro rata distributions. The Private Placement Warrants were subsequently registered in July 2024 on Form S-1 (File No. 333-280927).Â H.C. Wainwright & Co., LLC (â€œWainwrightâ€) acted as the exclusive placement agent in connection with the Offerings under an Engagement Letter, dated as of June 18, 2024, between us and Wainwright (the â€œEngagement Letterâ€). Pursuant to the Engagement Letter, we issued to Wainwright (or its designees) warrants to purchase up to 367,800 shares of common stock (the â€œWainwright Warrantsâ€ and, together with the Private Placement Warrants, the â€œ2024 Warrantsâ€). The Wainwright Warrants have substantially the same terms as the Private Placement Warrants, except that the Wainwright Warrants will expire five years from the commencement of the sales of the Offerings and have an exercise price of $0.5125 per share (subject to customary adjustment as set forth in the Wainwright Warrants), representing 125% of the purchase price per share of common stock in the Registered Direct Offering.â€‹â€‹â€‹31 Table of ContentsMay 2024 At the Market Offering AgreementÂ On May 31, 2024, we entered into an At the Market Offering Agreement (the â€œATM Agreementâ€) with Wainwright (the â€œManagerâ€) under which we may offer and sell, from time to time at our sole discretion, shares of our common stock (the â€œATM Sharesâ€), through or to the Manager. The offer and sale, if any, of ATM Shares by us under the Offering Agreement will be made pursuant to our registration statement on Form S-3 (File No. 333-279891) (the â€œRegistration Statementâ€) under the Securities Act, and the related prospectus included therein, filed with the SEC on May 31, 2024, and declared effective on June 12, 2024.Â Under the ATM Agreement, the Manager may sell ATM Shares by any method permitted by law deemed to be an â€œat the market offeringâ€ as defined inÂ Rule 415(a)(4) under theÂ Securities Act. The Manager will use commercially reasonable efforts to sell the ATM Shares from time to time, based upon instructions from us (including any price, time or size limits or other customary parameters or conditions we may impose). We will pay the Manager a commission of 3.0% of the gross proceeds from the sales of ATM Shares sold through the Manager under the ATM Agreement and have provided the Manager with customary indemnification and contribution rights. We will also reimburse the Manager for certain expenses incurred in connection with the ATM Agreement. The Company and the Manager may each terminate the ATM Agreement at any time upon specified prior written notice.Â The offering of ATM Shares pursuant to the ATM Agreement will terminate upon the earlier of (i) the sale of all ATM Shares subject to the ATM Agreement or (ii) the termination of the ATM Agreement in accordance with its terms.â€‹During the six months ended June 30, 2024, no shares of common stock were issued under the ATM Agreement.â€‹The amount of securities we are able to sell pursuant to the registration statements on Form S-3 is limited. See â€œRisk Factorsâ€ and â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations â€“ Liquidity and Capital Resources.â€Termination of 2018 At Market Issuance Sales AgreementÂ On May 31, 2024, we delivered notice to B. Riley Securities, Inc. (formerly B. Riley FBR, Inc.), Cantor Fitzgerald & Co., and the Manager (collectively, the â€œAgentsâ€) to terminate our At Market Issuance Sales Agreement, dated July 27, 2018, as amended on July 20, 2020, December 31, 2020, and April 14, 2023 (collectively, the â€œ2018 Sales Agreementâ€), with the Agents. Termination of the 2018 Sales Agreement was effective June 5, 2024, pursuant to Section 13(b) of the 2018 Sales Agreement.Â Pursuant to the terms of the 2018 Sales Agreement, we were previously able to issue and sell, from time to time through or to the Agents, shares of our common stock, having an aggregate offering price of up to $100,000,000, subject to the limitations of Instruction I.B.6 of Form S-3. As a result of the termination of the 2018 Sales Agreement, we will not issue or sell any additional shares of our common stock under the 2018 Sales Agreement.Â â€‹Critical Accounting Policies and Use of Estimatesâ€‹Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. Applying these principles requires our judgment in determining the appropriateness of acceptable accounting principles and methods of application in diverse and complex economic activities. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of expenses, assets and liabilities, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. â€‹For a discussion of our critical accounting estimates, see the MD&A in the 2023 Form 10-K. There were no material changes in our critical accounting estimates or accounting policies from December 31, 2023.â€‹32 Table of ContentsAccounting Pronouncements â€‹During the six months ended JuneÂ 30,Â 2024, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2023 Form 10-K that are expected to materially affect the Companyâ€™s present or future financial statements.â€‹Smaller Reporting Company Statusâ€‹We are a â€œsmaller reporting company,â€ within the meaning of federal securities laws, meaning that the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Reports on Form 10-K, have reduced disclosure obligations regarding executive compensation and certain other matters, and smaller reporting companies are permitted to delay adoption of certain recent accounting pronouncements discussed in Note 2 to our financial statements in this Form 10-Q.â€‹Controlled Company StatusWe are a majority-controlled subsidiary of Fortress. As a â€œControlled Companyâ€ we rely on the exemption provided by Nasdaq Listing RuleÂ 5615(c)(2), which permits us to maintain less than a majority of independent directors on our board.Results of Operationsâ€‹Comparison of the Three Months Ended JuneÂ 30,Â 2024 and 2023â€‹â€‹â€‹

approximately $0.6 million forgiveness of payables to St. Jude as a result of the mutual termination of the license agreement and $0.3 million forgiveness of payables to the Mayo Clinic as a result of the termination of the license agreement, $1.4 million for facility and deprecation expenses, which includes approximately $0.4 million of costs reimbursed through the subcontracting agreement with uBriGene, and $1.2 million for consulting expenses, offset by approximately $4.0 million increase in other expenses, of which approximately $3.2 million of expenses incurred related to the June 2024 Repurchase of Assets from uBriGene. â€‹â€‹35 Table of ContentsThe following table provides a breakout of the components of research and development expenses for the six months ended JuneÂ 30,Â 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ForÂ the six months ended JuneÂ 30,Â ($ in thousands)â€‹2024â€‹2023R&D program related expenses (1)Â Â Â Â â€‹Â Â Â Â Â Â â€‹Â Â MB-102â€‹$ (2)â€‹$ 110MB-106â€‹â€‹ 1,567â€‹â€‹ 2,126MB-107/207 (2)â€‹â€‹ (562)â€‹â€‹ (472)MB-109â€‹â€‹ 403â€‹â€‹ 675MB-110â€‹â€‹ 241â€‹â€‹ 224Mayo in situ CAR Tâ€‹â€‹ (294)â€‹â€‹ 582All others (3)â€‹â€‹ 8â€‹â€‹ 494Total R&D development expenseâ€‹â€‹ 1,361â€‹â€‹ 3,739R&D personnel related expenses (4)â€‹â€‹ (1,138)â€‹â€‹ 9,715R&D facility and depreciation expenseâ€‹â€‹ 659â€‹â€‹ 2,065R&D consulting expensesâ€‹â€‹ 758â€‹â€‹ 1,930R&D lab suppliesâ€‹â€‹ 183â€‹â€‹ 5,109R&D other expense (5)â€‹â€‹ 6,341â€‹â€‹ 2,278Total research and development expenseâ€‹$ 8,164â€‹$ 24,836â€‹(1) Includes sponsored research, license and clinical trial related costs.(2) Credit for the six months ended June 30, 2024, reflects the forgiveness of outstanding payables and accrued expenses due to the mutual termination of the license agreement and related data transfer agreement with St. Jude. (3) Includes costs for long-term follow up and programs that were terminated.(4) Credit for the six months ended June 30, 2024, reflects the reversal of 2023 accrued bonus that will not be paid due to the reduction in the workforce in April 2024.(5) Includes approximately $3.2 million of expenses incurred related to the June 2024 Repurchase of Assets from uBriGene.â€‹Asset Impairmentâ€‹For the six months ended June 30, 2024, we incurred impairment charges of $2.6 million attributable to our assessment of the recoverability of the asset group consisting of leasehold improvements and associated right-of-use asset. No impairment was recorded in the six months ended June 30, 2023.â€‹General and Administrative Expensesâ€‹General and administrative expenses consist primarily of salaries and related expenses, including stock-based compensation, for executives and other administrative personnel, recruitment expenses, professional fees and other corporate expenses, including investor relations, legal activities including patent fees, and facilities-related expenses.â€‹For the six months ended JuneÂ 30,Â 2024, and 2023, general and administrative expenses were $3.0 million and $5.4 million, respectively. The decrease of approximately $2.4 million is primarily attributed to a $1.0 million decrease in personnel costs, $1.0 million decrease in legal and patent protection expenses, $0.2 million decrease in consulting expenses, $0.1 million decrease in professional services. and a $0.3 million decrease across various other general and administrative expenses, offset by $0.2 million increase in the equity fee to Fortress, in connection with the financings.â€‹36 Table of ContentsOther Income or Expenseâ€‹For the six months ended JuneÂ 30,Â 2024, and 2023, other income (expense) was $0.4 million and $(2.7) million, respectively. The increase of approximately $3.1 million in income is primarily attributed to a $4.1 million decrease in interest expense, related to the repayment of the Term Loan, partially offset by a $0.5 million decrease in other income and a $0.5 million decrease in interest income.â€‹Liquidity and Capital Resourcesâ€‹We have incurred substantial operating losses and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of JuneÂ 30,Â 2024, we had an accumulated deficit of $394.4 million.We have funded our operations to date primarily through the sale of equity. For example, on May 2, 2024, we completed the May 2024 Offering and on June 21, 2024, we completed the June 2024 Offering (together the â€œOfferingsâ€) described in â€œFinancing Activitiesâ€ above. The net proceeds of the Offerings, after deducting the fees and expenses of the placement agent and other offering expenses payable by us, but excluding the net proceeds from the exercise of the Warrants, were approximately $5.3 million. We intend to use the net proceeds from the Offering for working capital and general corporate purposes.â€‹As of JuneÂ 30,Â 2024, the Company had cash and cash equivalents of $4.3 million. On April 10, 2024, our Board approved a reduction in our workforce of approximately 81%, in order to reduce costs and preserve capital due to the fundraising environment and continued uncertainty regarding the CFIUS review of the sale of the Facility and the Transaction with uBriGene. The reduction occurred primarily in April 2024 and was completed in the second quarter. Additionally in April 2024, we terminated our license agreements with St. Jude and Leiden University Medical Centre. The mutual termination of the St. Jude license and associated Data Transfer Agreement included the forgiveness of outstanding amounts owed by us. In June 2024, we terminated our license agreement with the Mayo Clinic, which included the forgiveness of the outstanding amounts owed by us of approximately $0.3 million. In June 2024, we also terminated the sublease of the Mercantile Center Facility. Based on our current operating plan, reflecting these changes described above, we currently expect that such cash and cash equivalents, together with the approximately $5.3 million net proceeds received in the Offerings described above, will be sufficient to fund our operations into the fourth quarter of 2024. We will continue to seek additional funding through corporate partnerships and capital markets fundraising. See â€œRisk Factorsâ€”Risks Related to Our Finances and Capital Requirements.â€â€‹The continuation of our business as a going concern is dependent upon raising additional capital and eventually attaining and maintaining profitable operations. As of JuneÂ 30,Â 2024, there is substantial doubt about our ability to continue as a going concern for the next 12 months from the date of issuance of these unaudited financial statements. The financial statements included in this Form 10-Q do not include any adjustments that might be necessary should operations discontinue. â€‹In addition, the amount of proceeds we may be able to raise pursuant to our existing shelf registration statements on Form S-3 may be limited. As of the filing of this Form 10-Q, we are subject to General Instruction I.B.6 to Form S-3 known as the â€œbaby shelf rules.â€ Under these instructions, the amount of funds we can raise through primary offerings of securities in any 12-month period using our registration statements on Form S-3 is limited to one-third of the aggregate market value of the shares of our common stock held by our non-affiliates. Therefore, we will be limited in the amount of proceeds we are able to raise by selling securities using our Form S-3 until such time as our public float exceeds $75 million.â€‹Contractual Obligationsâ€‹We enter into contracts in the normal course of business with licensors, CROs, contract manufacturing organizations (CMOs) and other third parties for the procurement of various products and services, including without limitation biopharmaceutical development, biologic assay development, commercialization, clinical and preclinical development, clinical trials management, pharmacovigilance and manufacturing and supply. These contracts typically do not contain minimum purchase commitments and are generally terminable by us upon written notice. Payments due upon termination or cancelation/delay consist of payments for services provided or expenses incurred, including non-cancelable obligations 37 Table of Contentsof our service providers, up to the date of cancellation; in certain cases, our contractual arrangements with CROs and CMOs include cancelation and/or delay fees and penalties. â€‹During the three and six months ended JuneÂ 30,Â 2024, there were no material changes in our contractual obligations and commitments, as described in our 2023 Form 10-K. See above for recent terminations of our agreements with St. Jude and LUMC in April 2024 and the Mayo Clinic in June 2024.â€‹Cash Flows for the Six Months Ended June 30, 2024 and 2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ForÂ the six months ended JuneÂ 30,Â ($ in thousands)â€‹2024â€‹2023Statement of cash flows data:Â Â Â Â â€‹Â Â Â Â Â Â â€‹Â Â Total cash (used in) provided by:Â â€‹Â Â Â Â â€‹Â Â Operating activitiesâ€‹$ (7,656)â€‹$ (30,200)Investing activitiesâ€‹Â â€”â€‹Â (34)Financing activitiesâ€‹Â 5,315â€‹Â (30,287)Net change in cash, cash equivalents and restricted cashâ€‹$ (2,341)â€‹$ (60,521)â€‹Operating Activitiesâ€‹Net cash used in operating activities was $7.7 million for the six months ended June 30, 2024, compared to $30.2 million for the six months ended June 30, 2023.â€‹Net cash used in operating activities for the six months ended June 30, 2024, was primarily due to approximately $13.4 million in net loss, partially offset by $5.7 million of non-cash items, primarily related to the $2.6 million asset impairment charge, and a $3.1 million change in operating assets and liabilities.â€‹Net cash used in operating activities for the six months ended June 30, 2023, was primarily due to approximately $32.9 million in net loss and $1.8 million change in operating assets and liabilities, partially offset by $0.3 million of non-cash stock compensation expenses, $1.3 million of depreciation, $2.8 million due to the loss on extinguishment of debt,Â and $0.1 million from other operating activities.â€‹Investing Activitiesâ€‹During the six months ended June 30, 2024, no cash was used in or provided by investing activities. Net cash used in investing activities was $34,000 for the six months endedÂ June 30, 2023, primarily for the purchases of fixed assets.â€‹Financing Activitiesâ€‹Net cash provided by financing activities was $5.3 during the six months ended June 30, 2024, primarily reflecting the proceeds from the May 2024 Offering and the June 2024 Offering.â€‹Net cash used in financing activities was $30.3 million during the six months endedÂ June 30, 2023, driven by the repayment of the Term Loan, partially offset by $0.1 million raised from the issuance of common shares in connection with the ESPP.â€‹â€‹Item 3. Quantitative and Qualitative Disclosures About Market Risksâ€‹We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.â€‹38 Table of ContentsItem 4. Controls and Proceduresâ€‹Evaluation of Disclosure Controls and ProceduresUnder the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness, as of JuneÂ 30,Â 2024, of the design and operation of our disclosure controls and procedures, as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.Changes in Internal Control over Financial ReportingNo change in internal control over financial reporting occurred during the most recent quarter with respect to our operations, which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.â€‹PART II. OTHER INFORMATIONâ€‹Item 1. Legal Proceedingsâ€‹None.â€‹Item 1A. Risk Factorsâ€‹Investing in our common stock or any other type of equity or debt securities we may offer (together, our â€œSecuritiesâ€) involves a high degree of risk. The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Form 10-Q and those we may make from time to time. You should carefully consider the risks described below, in addition to the other information contained in this Form 10-Q, including our consolidated financial statements and the related notes and â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ before making an investment decision. Our business, financial condition or results of operations could be harmed by any of these risks. The risks and uncertainties described below are not the only ones we face. Additional risks not presently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business operations. Some of the statements in the following risk factors constitute forward-looking statements. Please see the section titled â€œSpecial Note Regarding Forward-Looking Statements.â€â€‹Risks Related to Our Finances and Capital Requirementsâ€‹We have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. We do not have any products that are approved for commercial sale and therefore do not expect to generate any revenues from product sales in the foreseeable future, if ever.We have a limited operating history. We have focused primarily on organizing, acquiring and developing and securing our proprietary technology and identifying and obtaining preclinical data for various product candidates, with the goal of supporting regulatory approval for these product candidates. We have incurred losses since our inception in MarchÂ 2015. Our net losses were $13.4 million and $32.9 million for the six months ended JuneÂ 30,Â 2024 and 2023, respectively, and we had an accumulated deficit of $394.4 million as of JuneÂ 30,Â 2024. We expect to continue to incur significant operating losses for the foreseeable future. We also do not anticipate that we will achieve profitability for a period of time after generating material revenues, if ever. If we are unable to generate revenues, we will not become profitable and may be unable to continue operations without continued funding.39 Table of ContentsBecause of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the timing or amount of increased expenses or when or if, we will be able to achieve profitability. Our net losses may fluctuate significantly from quarter to quarter andÂ year toÂ year. We anticipate that our expenses will increase substantially if:â—one or more of our product candidates receive regulatory approval and are approved for commercial sale, due to our need to establish the necessary commercial infrastructure to launch and commercialize this product candidate without substantial delays, including hiring sales and marketing personnel and contracting with third parties for manufacturing, testing, warehousing, distribution, cash collection and related commercial activities;â—we are required by the FDA or foreign regulatory authorities to perform studies in addition to those currently expected;â—there are any delays in completing our clinical trials or the development of any of our product candidates;â—we execute other collaborative, licensing or similar arrangements that require us to make payments to collaborators or licensors;â—there are variations in the level of expenses related to our future development programs;â—there are any product liability or intellectual property infringement lawsuits in which we may become involved; andâ—there are any regulatory developments affecting product candidates of our competitors.Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from our development stage products, and we do not know when, or if, we will generate any revenue. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to:â—obtain regulatory approval for one or more of our product candidates, or any future product candidate that we may license or acquire;â—manufacture or have manufactured commercial quantities of one or more of our product candidates or any future product candidate, if approved, at acceptable cost levels;Â andâ—develop a commercial organization and the supporting infrastructure required to successfully market and sell one or more of our product candidates or any future product candidate, if approved.Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our Company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations. A decline in the value of our Company could also cause you to lose all or part of your investment in our Securities.There is substantial doubt regarding our ability to continue as a going concern. We will need to raise additional funding (which may not be available on acceptable terms to us, or at all) and/or delay, limit or terminate our product development efforts or other operations. If we are unable to raise capital, we could be required to seek bankruptcy protection or other alternatives that would likely result in our securityholders losing some or all of their investment in us.â€‹We are currently advancing our programs in hematologic cancers and solid tumors through clinical development. Developing and commercializing CAR T products is expensive, and we do not expect to generate meaningful product revenues in the foreseeable future until we obtain marketing approval for products in the United States and following any potential commercial launch. â€‹40 Table of ContentsAs of JuneÂ 30,Â 2024, our cash and cash equivalents were $4.3 million. Based on our current business plan, there is substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that our financial statements for the year ended JuneÂ 30,Â 2024, are issued. Our fundraising efforts to raise additional funding may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our potential products following marketing approval if and when obtained. In addition, we cannot guarantee that financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. Potential indebtedness, if incurred, would result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. â€‹In addition, in order to address our current funding constraints, we may be required to further revise our business plan and strategy, which may result in us (i) further curtailing, delaying or discontinuing one or more of our research or development programs or the commercialization of any product candidates, (ii) selling certain of our assets and/or (iii) may result in our being unable to expand our operations or otherwise capitalize on our business opportunities. Such actions may become necessary whether or not we are able to raise additional capital. As a result, our business, financial condition, and results of operations could be materially affected. Furthermore, if we are unable to raise capital, we could be required to seek bankruptcy protection or other alternatives that would likely result in our securityholders losing some or all of their investment in us.â€‹Our short operating history makes it difficult to evaluate our business and prospects.We have been conducting operations only since our incorporation in MarchÂ 2015. Our operations to date have been limited. We have not yet demonstrated an ability to successfully complete clinical trials, obtain regulatory approvals, manufacture a clinical scale or commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions about our future performance may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products.In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to expand our capabilities to support commercial activities. We may not be successful in adding such capabilities.We expect our financial condition and operating results to continue to fluctuate significantly

from quarter to quarter andÂ year toÂ year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any past quarterly period as an indication of future operating performance.We will require substantial additional funding which may not be available to us on acceptable terms, or at all. If we fail to raise the necessary additional capital, we may be unable to complete the development and commercialization of our product candidates or continue our development programs.Our operations have consumed substantial amounts of cash since inception. We will need to significantly increase our spending to advance the preclinical and clinical development of our product candidates and launch and commercialize any product candidates for which we may receive regulatory approval, including building our own commercial organizations to address certain markets. We will require substantial additional capital for the further development and, if approved, commercialization of our product candidates, as well as to fund our other operating expenses and capital expenditures. As of JuneÂ 30,Â 2024, we had $4.6 million in cash and restricted cash and have not generated positive cash flows from operations. We cannot provide any assurance that we will be able to raise funds to complete the development of our product 41 Table of Contentscandidates. Additionally, if we are unable to secure additional funding, it is likely that we will need to delay or terminate the development of certain product candidates; any such delay or termination, or the announcement of any such delay or termination, may impact our potential growth and have a material adverse effect on the value of our Securities.In order to carry out our business plan and implement our strategy, we will need to obtain substantial additional financing and may choose to raise additional funds through strategic collaborations, licensing arrangements, public or private equity or debt financing, bank lines of credit, asset sales, government grants, or other arrangements. We cannot be certain that additional funding will be available on acceptable terms, or at all. Additional funding may be more difficult to obtain, or may be more expensive, as a result of recent increases in inflation and interest rates in the U.S. economy generally. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or, if approved, commercialization of one or more of our product candidates. We may also seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available. Any of these events could significantly harm our business, financial condition and prospects.Our future funding requirements will depend on many factors, including, but not limited to:â—the scope, timing, design and conduct of, and results from, preclinical studies and clinical trials for our product candidates;â€‹â—the potential for delays in our efforts to seek regulatory approval for our product candidates, and any costs associated with such delays;â€‹â—the costs of establishing a commercial organization to sell, market and distribute our product candidates;â€‹â—the rate of progress and costs of our efforts to prepare for the submission of a New Drug Application (â€œNDAâ€) or Biologics License Application (â€œBLAâ€) for any product candidates that we may in-license or acquire in the future, and the potential that we may need to conduct additional clinical trials to support applications for regulatory approval;â€‹â—the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights associated with our product candidates, including any such costs we may be required to expend if our licensors are unwilling or unable to do so;â€‹â—the cost and timing of securing sufficient supplies of our product candidates from our contract manufacturers for clinical trials and in preparation for commercialization;â€‹â—the effect of competing technological and market developments;â€‹â—the terms and timing of any collaborative, licensing, co-promotion or other arrangements that we may establish;â€‹â—if one or more of our product candidates are approved, the potential that we may be required to file a lawsuit to defend our patent rights or regulatory exclusivities from challenges by companies seeking to market generic versions of one or more of our product candidates; â€‹â—the success of the commercialization of one or more of our product candidates, if approved;â€‹â—the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; andâ€‹â—macroeconomic factors such as inflationary pressures, rising interest rates, liquidity constraints, failures and instability in U.S. and international financial banking systems, supply disruptions due to political unrest, conflict and war or other factors, and pandemics.â€‹Under current SEC regulations, if at the time we file our Annual Report on Form 10-K our public float is less than $75 million, and for so long as our public float remains less than $75 million, the amount we can raise through primary public 42 Table of Contentsofferings of securities in any twelve-month period using shelf registration statements is limited to an aggregate of one-third of our public float, which is referred to as the â€œbaby shelf rules.â€ SEC regulations permit us to use the highest closing sales price of our common stock (or the average of the last bid and last ask prices of our common stock) on any day within 60 days of sales under the registration statement to calculate our public float. As of the date of the 2023 Form 10-K, our public float was less than $75 million. As a result, for sales following the date of the 2023 Form 10-K, and until we again have a public float with a value in excess of $75 million, if ever, we only have the capacity to sell shares up to one-third of our public float under shelf registration statements in any twelve-month period. If our public float decreases, the amount of securities we may sell under our Form S-3 shelf registration statements will also decrease.Our inability to raise capital when needed would harm our business, financial condition and results of operations, and could cause our stock value to decline or require that we wind down our operations altogether.Raising additional capital, including through lending arrangements, may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights.Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, grants and license and development agreements in connection with any collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing, including through lending arrangements, and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.We will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.As a public company, we incur significant legal, accounting and other expenses under the Sarbanes-Oxley Act of 2002, (the â€œSarbanes-Oxley Actâ€), as well as rulesÂ subsequently implemented by the SEC, and the rulesÂ of the Nasdaq Stock Exchange. These rulesÂ impose various requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and appropriate corporate governance practices. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rulesÂ and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rulesÂ and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our Board, our Board committees or as executive officers.The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. As a result, we are required to periodically perform an evaluation of our internal controls over financial reporting to allow management to report on the effectiveness of those controls, as required by SectionÂ 404 of the Sarbanes-Oxley Act. These efforts to comply with SectionÂ 404 and related regulations have required, and continue to require, the commitment of significant financial and managerial resources. While we anticipate maintaining the integrity of our internal controls over financial reporting and all other aspects of SectionÂ 404, we cannot be certain that a material weakness will not be identified when we test the effectiveness of our control systems in the future. If a material weakness is identified, we could be subject to sanctions or investigations by the SEC or other regulatory 43 Table of Contentsauthorities, which would require additional financial and management resources, costly litigation or a loss of public confidence in our internal controls, which could have an adverse effect on the market price of our stock.We are a "smaller reporting company," and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.We are a smaller reporting company, and we will remain a smaller reporting company until the fiscalÂ year following the determination that our voting and non-voting common shares held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscalÂ year and our voting and non-voting common shares held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Smaller reporting companies are able to provide simplified executive compensation disclosure, are exempt from the auditor attestation requirements of SectionÂ 404, and have certain other reduced disclosure obligations, including, among other things, being required to provide only twoÂ years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors.We have elected to take advantage of certain of the reduced reporting obligations available to us. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile.Our ability to use our pre-change NOLs and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation.We may, from time to time, carry net operating loss carryforwards (â€œNOLsâ€) as deferred tax assets on our balance sheet. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an â€œownership changeâ€ (generally defined as a greater than 50-percentage- point cumulative change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporationâ€™s ability to use its pre-change NOLs and other pre-change tax attributes to offset its post-change taxable income or taxes may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership, some of which changes are outside our control. As a result, our ability to use our pre-change NOLs and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation.Risks Related to Our Business Strategy, Structure, and Organizationâ€‹We currently have no products for sale. We are heavily dependent on the success of our product candidates, and we cannot give any assurances that any of our product candidates will receive regulatory approval or be successfully commercialized.To date, we have invested a significant portion of our efforts and financial resources in the acquisition and development of our product candidates. We have not demonstrated our ability to perform the functions necessary for the successful acquisition, development or commercialization of the technologies we are seeking to develop. As an early stage company, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. Our future success is substantially dependent on our ability to successfully develop, obtain regulatory approval for, and then commercialize such product candidates. Most of our product candidates are currently in early stage clinical trials. Our business depends entirely on the successful development and commercialization of our product candidates, which may never occur. We currently have no drug products for sale, currently generate no revenues from sales of any drug products and may never be able to develop or commercialize a marketable product.The successful development, and any commercialization, of our technologies and any product candidates that may occur would require us to successfully perform a variety of functions, including:â—developing our technology platform;44 Table of Contentsâ—identifying, developing, formulating, manufacturing and, if approved, commercializing product candidates;â—entering into successful licensing and other arrangements with product development partners;â—participating in regulatory approval processes, including ultimately gaining approval to market a drug product, which may not occur;â—obtaining sufficient quantities of our product candidates from our third-party manufacturers to meet clinical trial needs and, if approved, to meet commercial demand at launch and thereafter;â—establishing and maintaining agreements with wholesalers, distributors and group purchasing organizations on commercially reasonable terms;â—conducting sales and marketing activities including hiring, training, deploying and supporting our sales force and creating market demand for our product candidates through our own marketing and sales activities, and any other arrangements to promote our product candidates that we may establish; â—maintaining patent protection and regulatory exclusivity for our product candidates; andâ€‹â—raising additional required capital on acceptable terms.â€‹Our operations have historically been limited to organizing the Company, acquiring, developing and securing our proprietary technology and identifying and obtaining preclinical data or clinical data for various product candidates. These operations provide a limited basis for you to assess our ability to continue to develop our technology, identify product candidates, develop and commercialize any product candidates we are able to identify and enter into successful collaborative arrangements with other companies, as well as for you to assess the advisability of investing in our securities. Each of these requirements will require substantial time, effort and financial resources.Each of our product candidates will require additional clinical development, management of clinical and manufacturing activities, regulatory approval in the jurisdictions in which we plan to market the product, obtaining manufacturing supply, building a commercial organization, and significant marketing efforts before we generate any revenues from product sales, which may not occur. We are not permitted to market or promote any of our product candidates in the U.S. or any other jurisdiction before we receive regulatory approval from the FDA or comparable foreign regulatory authority, respectively, and we may never receive such regulatory approval for any of our product candidates.Our approach to the development of our product candidates is unproven, and we do not know whether we will be able to develop any products of commercial value.Our product candidates are emerging technologies and, consequently, it is conceivable that such technologies may ultimately fail to develop into commercially viable therapies to treat human patients with cancer or other diseases. One of the reasons for the lack of commercial viability could be our inability to obtain regulatory approval for such technologies.CAR T is a new approach to cancer treatment that presents significant challenges.We have concentrated much of our research and development efforts on CAR T technology, and our future success is highly dependent on the successful development of T cell immunotherapies in general and our CAR T technology and product candidates in particular. Because CAR T is a relatively new approach to cancer immunotherapy and cancer treatment generally, developing and commercializing our product candidates subjects us to a number of challenges, including, but not necessarily limited to:â—obtaining regulatory approval from the FDA and other regulatory authorities that may have very limited experience with the commercial development of genetically modified T cell therapies for cancer;45 Table of Contentsâ—developing and deploying consistent and reliable processes for engineering a patientâ€™s T cells ex vivo and infusing the engineered T cells back into the patient;â—conditioning patients with chemotherapy in conjunction with delivering each of our products, which may increase the risk of adverse side effects of our product candidates;â—educating medical personnel regarding the potential side effect profile of each of our product candidates;â—developing processes for the safe administration of these product candidates, including long-term follow-up for all patients who receive our product candidates;â—sourcing clinical and, if approved, commercial supplies for the materials used to manufacture and process our product candidates;â—developing a manufacturing process and distribution network with a cost of goods that allows for an attractive return on investment;â—establishing sales and marketing capabilities after obtaining any regulatory approval to gain market acceptance, and obtaining adequate coverage, reimbursement and pricing by third-party payors and government authorities; andâ—developing therapies for types of cancers beyond those addressed by our current product candidates.We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay the pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately and/or effectively evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.Risks Inherent in Drug Development and Commercializationâ€‹Delays in the commencement or conduct of our clinical trials could result in increased costs and delay our ability to pursue regulatory approval.ClinicalÂ trials are expensive and can take many years to complete, and the outcome is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or will be completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage and our future clinical trials may not be successful. The commencement or conduct of clinical trials can be delayed for a variety of reasons, including, but not necessarily limited to, delays in:â—commencing a clinical trial, as a result of regulatory authority action;â—identifying, recruiting and training suitable clinical investigators;â—reaching and preserving agreements on acceptable terms with prospective clinical research organizations (â€œCROsâ€) and trial sites, the terms of which can be subject to extensive negotiation, may be subject to modification from time to time and may vary significantly among different CROs and trial sites;â—obtaining

sufficient quantities of a product candidate for use in clinical trials;46 Table of Contentsâ—obtaining Institutional Review Board (â€œIRBâ€) or ethics committee approval to conduct a clinical trial at a prospective site;â—developing and validating companion diagnostics on a timely basis, if required;â—adding new clinical sites once a trial has begun;â—change in the principal investigator or other key staff overseeing the clinical trial at a given site;â—identifying, recruiting and enrolling patients to participate in a clinical trial; orâ—retaining (or replacing) patients who have initiated a clinical trial but who may withdraw due to adverse events from the therapy, insufficient efficacy, fatigue with the clinical trial process, personal issues, or other reasons.Any delays in the commencement of our clinical trials will delay our ability to pursue regulatory approval for product candidates. In addition, many of the factors that cause, or lead to, a delay in the commencement of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate.Suspensions or delays in the completion of clinical testing could result in increased costs and delay or prevent our ability to complete development of that product candidate or generate product revenues, if approved.Once a clinical trial has begun, patient recruitment and enrollment may be slower than we anticipate due to the nature of the clinical trial plan, the proximity of patients to clinical sites, the eligibility criteria for participation in the study or other factors. Clinical trials may also be delayed as a result of ambiguous or negative interim results or difficulties in obtaining sufficient quantities of product manufactured in accordance with regulatory requirements and on a timely basis. Further, a clinical trial may be modified, suspended or terminated by us, an IRB, an ethics committee or a data safety monitoring committee overseeing the clinical trial, any clinical trial site with respect to that site, or the FDA or other regulatory authorities, due to a number of factors, including, but not necessarily limited to:â—failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;â—inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;â—stopping rulesÂ contained in the protocol;â—unforeseen safety issues or any determination that the clinical trial presents unacceptable health risks; andâ—lack of adequate funding to continue the clinical trial.Changes in regulatory requirements and guidance also may occur, and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit clinical trial protocols to IRBs for re-examination, which may in turn impact the costs and timing of, and the likelihood of successfully completing, a clinical trial. If we experience delays in the completion of, or if we must suspend or terminate, any clinical trial of any product candidate, our ability to obtain regulatory approval for that product candidate will be delayed, and the commercial prospects, if any, for the product candidate may suffer as a result. In addition, many of these factors may also ultimately lead to the denial of regulatory approval of a product candidate.Product candidates that we advance into clinical trials may not receive regulatory approval.Pharmaceutical development has inherent risks. We will be required to demonstrate through well-controlled clinical trials that product candidates are effective with a favorable benefit-risk profile for use in their target indications before seeking regulatory approvals for their commercial sale. Success in early clinical trials does not mean that later clinical trials will be successful, as product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through initial clinical testing. Also, we may need to conduct additional clinical trials that are not 47 Table of Contentscurrently anticipated. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. As a result, product candidates that we advance into clinical trials may not receive regulatory approval.In addition, even if our product candidates were to obtain approval, regulatory authorities may approve any such product candidates or any future product candidate for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. The regulatory authority may also require the label to contain warnings, contraindications, or precautions that limit the commercialization of the product. Any of these scenarios could impact the commercial prospects for one or more of our current or future product candidates.Any product candidates we advance into clinical development are subject to extensive regulation, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize product candidates.The research and clinical development, testing, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of any product candidate, including our product candidates, is subject to extensive regulation by the FDA in the United States and by comparable health authorities in foreign markets. In the United States, we are not permitted to market a product candidate until such product candidateâ€™s BLA or NDA is approved by the FDA. The process of obtaining approval is uncertain, expensive, often spanning manyÂ years, and can vary substantially based upon the type, complexity and novelty of the products involved. In addition to significant and expensive clinical testing requirements, our ability to obtain marketing approval for product candidates depends on obtaining the final results of required non-clinical testing, including characterization of the manufactured components of our product candidates and validation of our manufacturing processes. The FDA may determine that our product manufacturing processes, testing procedures or equipment and facilities are inadequate to support approval. Approval policies or regulations may change, and the FDA has substantial discretion in the pharmaceutical approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in the clinical development of product candidates, regulatory approval is never guaranteed.The FDA and other regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including, but not limited to:â—the FDA or comparable foreign regulatory authorities may disagree with the trial design or implementation of our clinical trials, including proper use of clinical trial methods and methods of data analysis;â—an inability to establish sufficient data and information to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for an indication;â—the FDA may not accept clinical data from trials conducted by individual investigators or in countries where the standard of care is potentially different from that of the United States;â—the results of clinical trials may not meet the level of statistical significance required by the FDA for approval;â—the FDA may disagree with the interpretation of data from preclinical studies or clinical trials;â—the FDA may determine that our manufacturing processes or facilities or those of third-party manufacturers with which we or our respective collaborators currently contract for clinical supplies and plan to contract for commercial supplies do not satisfactorily comply with cGMPs; orâ—the approval policies or interpretation of regulations of the FDA may significantly change in a manner rendering the clinical data insufficient for approval or the product characteristics or benefit-risk profile unfavorable for approval.48 Table of ContentsWith respect to foreign markets, approval procedures vary among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, rapid drug and biological development during the COVID-19 pandemic has raised questions about the safety and efficacy of certain marketed pharmaceuticals and may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new pharmaceuticals based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us from commercializing our product candidates.Regulatory approval for our product candidates by the FDA, or any similar regulatory authorities outside the United States, is limited to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.Any regulatory approval is limited to the indications for use and related treatment of those specific diseases and indications set forth in the approval for which a product is deemed to be safe and effective by the FDA, or other similar regulatory authorities outside the United States. In addition to the regulatory approval required for new drug products, new formulations or indications for an approved product also require regulatory approval. If we are not able to obtain regulatory approval for any desired future indications for our products, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.While physicians may choose to prescribe drugs for uses that are not described in the productâ€™s labeling and for uses that differ from those tested in clinical studies and approved by the regulatory authorities (â€œoff-label usesâ€), our ability to promote the products is limited to those indications that are specifically approved by the FDA, or similar regulatory authorities outside the United States. Such off-label uses are common across medical specialties and may constitute an appropriate treatment forÂ someÂ patients in certain circumstances. Regulatory authorities in the U.S. generally do not regulate practice of medicine or the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the promotion of off-label use. If our promotional activities fail to comply with these regulations or guidelines, we may be subject to compliance or enforcement actions, including Warning Letters, by these authorities. In addition, our failure to follow FDA laws, regulationsÂ and guidelines relating to promotion and advertising may cause the FDA toÂ suspend or withdrawÂ an approved product from the market, request a recall or institute fines or penalties, or could result in disgorgement of money, operating restrictions, corrective advertising, injunctions or criminal prosecution, any of which could harm our business.If any of our product candidates are approved and we or our contract manufacturer(s)Â fail to produce the product, or components of the product, in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the commercialization of our product candidates, if approved, or be unable to meet market demand, and may lose potential revenues.The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls, and the use of specialized processing equipment. We may enter into development and supply agreements with contract manufacturers for the completion of pre-commercialization manufacturing development activities and, if approved, the manufacture of commercial supplies for one or more of our product candidates. Any termination or disruption of our relationships with our contract manufacturers may materially harm our business and financial condition and frustrate any commercialization efforts for each respective product candidate.All of our contract manufacturers must comply with strictly enforced federal, state and foreign regulations, includingÂ cGMP requirements enforced by the FDA through its establishment inspection program. We are required by law to establish adequate oversight and control over raw materials, components and finished products furnished by our third-party suppliers and contract manufacturers, but we have little control over their compliance with these regulations. Any failure to comply with applicable regulations may result in fines and civil penalties, suspension of production, restrictions on imports and exports, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval, and would limit the availability of our product and customer confidence in our product. Any manufacturing defect or error discovered after products have been produced and distributed could result in even more significant 49 Table of Contentsconsequences, including costly recalls, re-stocking costs, damage to our reputation and potential for product liability claims.If the contract manufacturers upon whom we may rely to manufacture one or more of our product candidates, and any future product candidate we may in-license, fails to deliver the required commercial quantities on a timely basis at commercially reasonable prices, we would likely be unable to meet demand for our approved product and we would lose potential revenues.If serious adverse or unacceptable side effects are identified during the development of one or more of our product candidates or any future product candidate, we may need to abandon or limit the development of some of our product candidates.If one or more of our product candidates or any future product candidate are associated with undesirable side effects or adverse events in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In our industry, many compounds that initially showed promise in early stage testing have later been found to cause serious adverse events that prevented further development of the compound. In the event that our clinical trials reveal a high or unacceptable severity and prevalence of adverse events, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development or deny approval of one or more of our product candidates or any future product candidate for any or all targeted indications. The FDA could also issue a letter requesting additional data or information prior to making a final decision regarding whether or not to approve a product candidate. The number of requests for additional data or information issued by the FDA in recentÂ years has increased and has resulted in substantial delays in the approval of several new drugs. Adverse events or undesirable side effects caused by one or more of our product candidates or any future product candidate could also result in the inclusion of unfavorable information in our product labeling or in denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, which would, in turn, prevent us from commercializing and generating market acceptance and revenues from the sale of that product candidate. Adverse events or side effects could affect patient recruitment or the ability of enrolled patients to complete the trial and could result in potential product liability claims.Additionally, if one or more of our product candidates or any future product candidate receives marketing approval and we or others later identify undesirable side effects caused by this product, a number of potentially significant negative consequences could result, including:â—regulatory authorities may require the addition of unfavorable labeling statements, including specific warnings, black box warnings, adverse reactions, precautions, and/or contraindications;â—regulatory authorities may suspend or withdraw their approval of the product, and/or require it to be removed from the market;â—we may be required to recall a product, be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;Â orâ—our reputation may suffer.Any of these events could prevent us from achieving or maintaining market acceptance of any of our product candidates or any future product candidate or could substantially increase our commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues, or any revenues, from their sale.Even if one or more of our product candidates receives regulatory approval, it and any other products we may market will remain subject to substantial regulatory scrutiny.If one or more of our product candidates that we may license or acquire is approved, the approved product candidate will be subject to ongoing requirements and review by the FDA and other regulatory authorities. These requirements include 50 Table of Contentslabeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping of the drug, and requirements regarding our presentations to and interactions with health care professionals.The FDA, or other regulatory authorities, may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. The FDA and other applicable regulatory authorities closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and other applicable regulatory authorities impose stringent restrictions on manufacturersâ€™ communications regarding off-label use and if we do not market any approved product for only their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food Drug and Cosmetics Act (â€œFDCAâ€) relating to the promotion of prescription drugs may lead to investigations, civil claims, and/or criminal charges alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:â—restrictions on such products, operations, manufacturers or manufacturing processes;â—restrictions on the labeling or marketing of a product;â—restrictions on product distribution or use;â—requirements to conduct post-marketing studies or clinical trials;â—warning letters, untitled letters, Form 483s, import alerts, and/or inspection observations;â—withdrawal of the products from the market;â—refusal to approve pending applications or supplements to approved applications that we submit;â—recall of products;â—fines, restitution or disgorgement of profits;â—suspension or withdrawal of marketing or regulatory approvals;â—suspension of any ongoing clinical trials;â—refusal to permit the import or export of our products;â—product seizure; orâ—injunctions, consent decrees, and/or the imposition of civil or criminal penalties.The FDAâ€™s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates, or negatively affect those products for which we may have already received regulatory approval, if any. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to the various actions listed above, including losing any marketing approval that we may have obtained.51 Table of ContentsWe will need to obtain FDA approval of any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business.A pharmaceutical product cannot be marketed in the U.S. or other countries until we have completed a rigorous and extensive regulatory review process, including approval of a brand name. Any brand names we intend to use for our product candidates will require approval from the FDA regardless of whether we have secured a formal trademark registration from the USPTO. The FDA typically conducts a review of proposed product brand names, including an evaluation of the potential for confusion with other product names. The FDA may also object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternative brand name, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.Public concern regarding the safety of drug products could delay or limit our ability to obtain regulatory approval,Â result in the

inclusion of unfavorable information in our labeling or require us to undertake other activities that may entail additional costs.In light of widely publicized events concerning the safety risk of certain drug products, the FDA,Â members of the U.S. Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and the establishment of risk management programs. The Food and Drug Administration Amendments Act of 2007 (â€œFDAAAâ€), grants significant expanded authority to the FDA, much of which is aimed at improving the safety of drug products before and after approval. In particular, the new law authorizes the FDA to, among other things, require post-approval studies and clinical trials, mandate changes to drug labeling to reflect new safety information and require risk evaluation and mitigation strategies for certain drugs, including certain currently approved drugs. It also significantly expands the federal governmentâ€™s clinical trial registry and results databank, which we expect will result in significantly increased government oversight of clinical trials. Under the FDAAA, companies that violate these and other provisions of the new law are subject to substantial civil monetary penalties, among other regulatory, civil and criminal penalties. The increased attention to drug safety issues may result in a more cautious approach by the FDA in its review of data from our clinical trials. Data from clinical trials may receive greater scrutiny, particularly with respect to safety, which may make the FDA or other regulatory authorities more likely to require additional preclinical studies or clinical trials. If the FDA requires us to conduct additional preclinical studies or clinical trials prior to approving any of our product candidates, our ability to obtain approval of this product candidate will be delayed. If the FDA requires us to provide additional clinical or preclinical data following the approval of any of our product candidates, the indications for which this product candidate is approved may be limited or there may be specific warnings or limitations on dosing, and our efforts to commercialize our product candidates may be otherwise adversely impacted.If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.We may not be able to initiate or continue clinical trials for one or more of our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Some of our competitors have ongoing clinical trials for product candidates that treat the same indications that we are targeting for our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitorsâ€™ product candidates. Available therapies for the indications we are pursuing can also affect enrollment in our clinical trials. Patient enrollment is affected by other factors including, but not necessarily limited to:â—the severity of the disease under investigation;â—the eligibility criteria for the study in question;52 Table of Contentsâ—the perceived risks and benefits of the product candidate under study;â—the efforts to facilitate timely enrollment in clinical trials;â—the patient referral practices of physicians;â—the number of clinical trials sponsored by other companies for the same patient population;â—the ability to monitor patients adequately during and after treatment; andâ—the proximity and availability of clinical trial sites for prospective patients.Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates or future product candidates, which would cause the value of our Company to decline and limit our ability to obtain additional financing.If our competitors develop treatments for any of our product candidatesâ€™ target indications and those competitor products are approved more quickly, marketed more successfully or demonstrated to be more effective, the commercial opportunity for our product candidate will be reduced or eliminated.The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and, if approved, marketing of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. There can be no assurance that developments by others will not render one or more of our product candidates obsolete or noncompetitive. Furthermore, new developments, including the development of other drug technologies and methods of preventing the incidence of disease, occur in the pharmaceutical industry at a rapid pace. These developments may render one or more of our product candidates obsolete or noncompetitive.Competitors may seek to develop alternative formulations that do not directly infringe on our in-licensed patent rights. The commercial opportunity for one or more of our product candidates could be significantly harmed if competitors are able to develop alternative formulations outside the scope of our in-licensed patents. Compared to us, many of our potential competitors have substantially greater:â—capital resources;â—development resources, including personnel and technology;â—clinical trial experience;â—regulatory experience;â—expertise in prosecution of intellectual property rights;Â andâ—manufacturing, distribution and sales and marketing experience.As a result of these factors, our competitors may obtain regulatory approval of their products more rapidly than we are able to or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize one or more of our product candidates. Our competitors may also develop drugs that are more effective, safe, useful and less costly than ours and may be more successful than us in manufacturing and marketing their products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. We will also face competition from these third parties in establishing clinical trial sites, in patient registration for clinical trials, and in identifying and in-licensing new product candidates.53 Table of ContentsFurther, generic therapies are typically sold at lower prices than branded therapies and are generally preferred by hospital formularies and managed care providers of health services. We anticipate that, if approved, our product candidates will face increasing competition in the form of generic versions of branded products of competitors, including those that have lost or will lose their patent exclusivity. In the future, we may face additional competition from a generic form of our own candidates when the patents covering them begin to expire, or earlier if the patents are successfully challenged. If we are unable to demonstrate to physicians and payers that the key differentiating features of our product candidates translate to overall clinical benefit or lower cost of care, we may not be able to compete with generic alternatives.If any of our product candidates are successfully developed but, if approved, do not achieve broad market acceptance among physicians, patients, healthcare payors and the medical community, the revenues that any such product candidates generate from sales will be limited.Even if our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors and the medical community. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally would also be necessary for commercial success. The degree of market acceptance of any approved products would depend on a number of factors, including, but not necessarily limited to:â—the efficacy and safety as demonstrated in clinical trials;â—the timing of market introduction of such approved product as well as competitive products;â—the clinical indications for which the product is approved;â—acceptance by physicians, major operators of cancer clinics and patients of the product as a safe and effective treatment;â—the safety of such product candidates seen in a broader patient group, (i.e., based on actual use);â—the availability, cost and potential advantages of alternative treatments, including less expensive generic drugs;â—the availability of adequate reimbursement and pricing by third-party payors and government authorities;â—changes in regulatory requirements by government authorities for our product candidates;â—the relative convenience and ease of administration of the product candidate for clinical practices;â—the product labeling or product insert required by the FDA or regulatory authority in other countries, including any contradictions, warnings, drug interactions, or other precautions;â—changes in the standard of care for the targeted indications for our product candidate or future product candidates, which could reduce the marketing impact of any labeling or marketing claims that we could make following FDA approval;â—the approval, availability, market acceptance and reimbursement for a companion diagnostic, if any;â—the prevalence and severity of adverse side effects;Â andâ—the effectiveness of our sales and marketing efforts.If any product candidate that we develop does not provide a treatment regimen that is as beneficial as, or is not perceived as being as beneficial as, the current standard of care or otherwise does not provide patient benefit, that product candidate, if approved for commercial sale by the FDA or other regulatory authorities, likely will not achieve market acceptance. Our ability to effectively promote and sell any approved products will also depend on pricing and cost-effectiveness, including our ability to produce a product at a competitive price and our ability to obtain sufficient third-party coverage or 54 Table of Contentsreimbursement. If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, patients and third-party payors, our ability to generate revenues from that product would be substantially reduced. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources, may be constrained by FDA rulesÂ and policies on product promotion, and may never be successful.Reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably.There is significant uncertainty related to the third-party coverage and reimbursement of newly approved drugs. Such third-party payors include government health programs such as Medicare, managed care providers, private health insurers and other organizations. We intend to seek approval to market our product candidates in the U.S., the European Union (â€œEUâ€) and other selected foreign jurisdictions. Market acceptance and sales of our product candidates in both domestic and international markets will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for any of our product candidates and may be affected by existing and future health care reform measures. Government and other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for new drugs and, as a result, they may not cover or provide adequate payment for our product candidates, if approved. These payors may conclude that our product candidates are less safe, less effective or less cost-effective than existing or future introduced products, and third-party payors may not approve our product candidates, if approved, for coverage and reimbursement or may cease providing coverage and reimbursement for these product candidates.Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.In some foreign countries, particularly in the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. To obtain reimbursement or pricing approval in some countries, we may be required to conduct additional clinical trials that compare the cost-effectiveness of our product candidates to other available therapies. If reimbursement of our product candidates, if approved, is unavailable or limited in scope or amount in a particular country, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability of our products in such a country.If we are unable to establish sales, marketing and distribution capabilities or to enter into agreements with third parties to market and sell our product candidates, we may be unsuccessful in commercializing our product candidates, if they are approved.We currently do not have a marketing or sales organization for the marketing, sales and distribution of pharmaceutical products. In order to commercialize any approved product candidate, we would need to build marketing, sales, distribution, managerial and other non-technical capabilities or arrange for third parties to perform these services, and we may be unsuccessful in doing so. In the event of successful development and regulatory approval of any of our current or future product candidates, we expect to build a targeted specialist sales force to market or co-promote the product. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.55 Table of ContentsFactors that may inhibit our efforts to commercialize our product candidates, if approved, on our own include, but are not necessarily limited to:â—our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;â—the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;â—the lack of complementary or other products to be offered by sales personnel, which may put us at a competitive disadvantage from the perspective of sales efficiency relative to companies with more extensive product lines; andâ—unforeseen costs and expenses associated with creating our own sales and marketing organization.We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for one or more of our product candidates or a future product candidate, if approved, we may license or acquire and may have to limit their commercialization.The use of one or more of our product candidates and any future product candidate we may license or acquire in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. For example, we may be sued if any product candidate we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, and, if approved, during marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Product liability claims might be brought against us by consumers, health care providers or others using, administering or selling our products. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:â—withdrawal of clinical trial participants;â—suspension or termination of clinical trial sites or entire trial programs;â—decreased demand for any product candidates or products that we may develop;â—initiation of investigations by regulators;â—impairment of our business reputation;â—costs of related litigation;â—substantial monetary awards to patients or other claimants;â—loss of revenues;â—reduced resources of our management to pursue our business strategy; andâ—the inability to commercialize our product candidate or future product candidates, if approved.We will obtain limited product liability insurance coverage for any and all of our upcoming clinical trials. However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. When needed we intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for one or more of our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. On occasion, large judgments have been 56 Table of Contentsawarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.Product candidates, even if successfully developed and commercialized, may be effective only in combating certain specific types of cancer, and the market for drugs designed to combat such cancer type(s)Â may be small and unprofitable.There are many different types of cancer, and a treatment that is effective against one type of cancer may not be effective against another. CAR T or other technologies we pursue may only be effective in combating specific types of cancer but not others. Even if one or more of our product candidates, if approved, proves to be an effective treatment against a given type of cancer, the number of patients suffering from such cancer may be small, in which case potential sales from a therapy designed to combat such cancer would be limited.Negative public opinion and increased regulatory scrutiny of the therapies that underpin many of our product candidates may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.Public perception may be influenced by claims that one or more of the therapies underpinning our product candidates is unsafe, and such therapy may not gain the acceptance of the public or the medical community. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity, could lead to increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for those product candidates that do obtain approval and/or a decrease in demand for any such product candidates. Concern about environmental spread of our products, whether real or anticipated, may also hinder the commercialization of our products.Risks Related to Reliance on Third Partiesâ€‹We rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or complying with applicable regulatory requirements.We rely on our licensors to conduct some of our preclinical studies and some of our clinical trials for our product candidates and for future product candidates, and we rely on third-party CROs and site management organizations to conduct most of the remainder of our preclinical studies and all the rest of our clinical trials. We expect to continue to rely on third parties, such as our licensors, CROs, site management organizations, clinical data management organizations, medical institutions and clinical investigators, to conduct some of our preclinical studies and all of our clinical trials. The agreements with these third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that could delay our product development activities.Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and

protocols for the trial and for ensuring that our preclinical studies are conducted in accordance with good laboratory practices (â€œGLPsâ€) as appropriate. Moreover, the FDA requires us to comply with standards, commonly referred to as good clinical practices (â€œGCPsâ€) for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our 57 Table of Contentsclinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register certain clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.The third parties with whom we have contracted to help perform our preclinical studies and/or clinical trials may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates, if approved.If any of our relationships with these third-party CROs or site management organizations terminates, we may not be able to enter into arrangements with alternative CROs or site management organizations or to do so on commercially reasonable terms. Switching or adding additional CROs or site management organizations involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO or site management organization commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. We are currently reliant on COH, Fred Hutch, and UAB for a substantial portion of our research and development efforts and the early clinical testing of our product candidates.A substantial portion of our research and development has been and will continue to be conducted by COH, Fred Hutch, and UAB, pursuant to a sponsored research agreement and/or clinical trial agreements with each of those parties. As a result, our future success is heavily dependent on the results of research and development efforts of Dr.Â Stephen Forman and his team at COH, of Drs.Â Brian Till and Mazyar Shadman and their team at Fred Hutch, and of Dr.Â James M. Markert and his team at UAB. We have limited control over the nature or timing of their research and limited visibility into their day-to-day activities, and as a result can provide little assurance that their efforts will be successful.We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and may also do so for commercialization, if and when our product candidates are approved.Â This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or any future product candidate or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.Â Due to limited resources, and in light of our reduction in work force in April 2024, we may increase our reliance on third-party manufacturers or third-party collaborators for the manufacture of commercial supply of one or more product candidates for which our collaborators or we obtain marketing approval. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including, but not necessarily limited to:Â Â·reliance on the third party for regulatory compliance and quality assurance, while still being required by law to establish adequate oversight and control over products furnished by that third party;Â Â·the possible breach of the manufacturing agreement by the third party;Â Â·manufacturing delays if our third-party manufacturers are unable to obtain raw materials due to supply chain disruptions, give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreement between us;Â Â·the possible misappropriation of our proprietary information, including our trade secrets and know-how; andÂ 58 Table of ContentsÂ·the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.Â We rely on our third-party manufacturers to produce or purchase from third-party suppliers the materials and equipment necessary to produce our product candidates for our preclinical and clinical trials. Forces beyond our control could disrupt the global supply chain and impact our or our third-party manufacturersâ€™ ability to obtain raw materials or other products necessary to manufacture our product candidates. There are a limited number of suppliers for raw materials and equipment that we use (or that are used on our behalf) to manufacture our product candidates, and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials and equipment necessary to produce our product candidates for our preclinical and clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials or equipment by our third-party manufacturers. Any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing preclinical or clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our preclinical or clinical trials, product testing and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these raw materials or equipment after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.Â The facilities used by contract manufacturers to potentially manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit an New Drug Application (NDA) or BLA to the FDA. We are required by law to establish adequate oversight and control over raw materials, components and finished products furnished by our contract manufacturers, but we do not control the day-to-day manufacturing operations of, and are dependent on, the contract manufacturers for compliance with current Good Manufacturing Practices (â€œcGMPâ€) regulations for manufacture of our product candidates. Third-party manufacturers may not be able to comply with the cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, restrictions on imports and exports, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.Â One or more of the product candidates that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. We may incur added costs and delays in identifying and qualifying any replacement manufacturers.Â Future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that may receive marketing approval on a timely and competitive basis. We also expect to rely on third parties to distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, if approved, producing additional losses and depriving us of potential product revenue.We rely on third parties to conduct all aspects of our LV vector production and these third parties may not perform satisfactorily.We do not independently conduct our LV vector production and we currently rely, and expect to continue to rely, on third parties with respect to the manufacture of these items.Our reliance on these third parties for manufacturing LV vector reduces our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For products that we develop and, if approved, commercialize, we will remain responsible for ensuring that each of our IND-enabling studies and clinical studies is conducted in accordance with the study plan and protocols, and that our LV vectors are manufactured in accordance with GMP as applied in the relevant jurisdictions.59 Table of ContentsIf these third parties do not successfully carry out their contractual duties, meet expected deadlines, conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, or manufacture our LV vectors in accordance with GMP, we will not be able to complete, or may be delayed in completing, the preclinical and clinical studies and manufacturing process validation activities required to support future IND, market authorization application and BLA submissions and approval of our product candidates, or to support commercialization of our products, if approved. Many of our agreements with these third parties contain termination provisions that allow these third parties to terminate their relationships with us at any time. If we need to enter into alternative arrangements, our product development and commercialization activities could be delayed.We may be forced to enter into an agreement with a different manufacturer, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills required to manufacture LV vector for our drug product candidates may be unique or proprietary to the original manufacturer, and we may have difficulty or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. Any of these events could lead to clinical study delays or failure to obtain marketing approval or impact our ability to successfully commercialize our product candidates or any future product candidates, if approved. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production.We rely on clinical data and results obtained by third parties that could ultimately prove to be inaccurate or unreliable.As part of our strategy to mitigate development risk, we seek to develop product candidates with well-studied mechanisms of action, and we utilize biomarkers to assess potential clinical efficacy early in the development process. This strategy necessarily relies upon clinical data and other results obtained by third parties that may ultimately prove to be inaccurate or unreliable. Further, such clinical data and results may be based on products or product candidates that are significantly different from our product candidates or any future product candidate. If the third-party data and results we rely upon prove to be inaccurate, unreliable or not applicable to our product candidates or future product candidate, we could make inaccurate assumptions and conclusions about our product candidates and our research and development efforts could be compromised.We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.A third party may hold intellectual property, including patent rights that are important or necessary to the development and commercialization of our products. It may be necessary for us to use the patented or proprietary technology of third parties, who may or may not be interested in granting such a license, to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.Collaborative relationships with third parties could cause us to expend significant resources and incur substantial business risk with no assurance of financial return.Establishing strategic collaborations is difficult and time-consuming. Our discussions with potential collaborators may not lead to the establishment of collaborations on favorable terms, if at all. Potential collaborators may reject collaborations based upon their assessment of our financial, regulatory or intellectual property position. In addition, there has been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we successfully establish new collaborations, these relationships may never result in the successful development or commercialization of product candidates or the generation of sales revenue. To the extent that we enter into collaborative arrangements, the related product revenues are likely to be lower than if we directly marketed and sold products. Such collaborators may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for any future product candidate.â€‹60 Table of ContentsRisks Relating to Legislation and Regulation Affecting the Biopharmaceutical and Other Industriesâ€‹We are subject to new legislation, regulatory proposals and managed care initiatives that may increase our costs of compliance and adversely affect our ability to market our products, obtain collaborators and raise capital.In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could prevent or delay marketing approval of our product candidate, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the â€œPPACAâ€ or collectively, the â€œACAâ€), substantially regulates the way healthcare is financed by both governmental and private insurers in the United States. Among other things, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain â€œbranded prescription drugsâ€ to specified federal government programs; implemented a new methodology under which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded the eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation (â€œCMMIâ€) at the CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.Since its enactment, there have been executive, judicial, and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. Drug pricing continues to be a subject of debate at the executive and legislative levels of U.S. government. The American Rescue Plan Act of 2021 signed into law by President Biden on March 14, 2021, includes a provision that eliminated the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. With the elimination of the rebate cap, manufacturers may be required to compensate states in an amount greater than what the state Medicaid programs pay for the drug. Additionally, the Inflation Reduction Act of 2022 contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated â€œmaximum fair priceâ€ for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction Act of 2022. The Inflation Reduction Act of 2022 could have the effect of reducing the prices we can charge and reimbursement we receive for our product candidates, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial condition, results of operations, and growth prospects. The effect of Inflation Reduction Act of 2022 on our business and the pharmaceutical industry in general is not yet known.At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.We expect that additional federal, state, and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.These and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any current or future product candidates. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates, if approved. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and 61 Table of Contentspromotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals of any current or future product candidates, if any, may be. In addition, increased Congressional scrutiny of the FDAâ€™s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business or the business of our partners.The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, ability to accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recentÂ years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business or the business of our

partners. The U.S. government has shut down several times in the past, and certain regulatory agencies, such as the FDA, have had to furlough nonessential FDA employees and stop routine activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. If the timing of FDAâ€™s review and approval of new products is delayed, the timing of our or our partnersâ€™ development process may be delayed, which could result in delayed milestone revenues and materially harm our operations or business.Our current and future relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.Healthcare providers, physicians and third-party payors in the U.S. and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which we sell, market and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by the federal and state governments and by governments in foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not necessarily limited to:â—The federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either (1) the referral of an individual to a person for, furnishing any item or service for which payment is available under a federal health care program, or (2) the purchase, lease, order or recommendation thereof of any good, facility, service or item for which payment is available under a federal healthcare program;â—The False Claims Act and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment from the federal government or making or using, or causing to be made or used, a false record or statement material to a false or fraudulent claim;Â·The federal Health Insurance Portability and Accountability Act of 1996 (â€œHIPAAâ€) which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program, obtaining money or 62 Table of Contentsproperty of the health care benefit program through false representations or knowingly and willingly falsifying, concealing or covering up a material fact, making false statements or using or making any false or fraudulent document in connection with the delivery of, or payment for, health care benefits or services;Â·HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (â€œHITECHâ€), and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;Â·The provision under the Affordable Care Act (â€œACAâ€) commonly referred to as the Sunshine Act, which requires applicable manufacturers of covered drugs, devices, biologics and medical supplies to track and annually report to CMS payments and other transfers of value provided to physicians and teaching hospitals and certain ownership and investment interests held by physicians or their immediate family members in applicable manufacturers and group purchasing organizations; applicable manufacturers are also required to report such information regarding payments and transfers of value provided, as well as ownership and investment interests held, to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives;Â·The Foreign Corrupt Practices Act (â€œFCPAâ€) generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA; and Â·State law equivalents of each of the above federal laws, such as the Anti-Kickback Statute and False Claims Act, and state laws concerning security and privacy of health care information, which may differ in substance and application from state-to-state thereby complicating compliance efforts.Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could have a material adverse effect on our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including our collaborators, is found not to be in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business.If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. Although we believe that the safety procedures for handling and disposing of these materials comply with the standards prescribed by these laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, 63 Table of Contentsand any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.Although we maintain workersâ€™ compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.Risks Related to Intellectual Property and Potential Disputes Thereofâ€‹If we are unable to obtain and maintain sufficient patent protection for our technology and products, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.Our success depends, in large part, on our ability to obtain patent protection for product candidates and their formulations and uses. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our partners will be successful in obtaining patents or what the scope of an issued patent may ultimately be. These risks and uncertainties include, but are not necessarily limited to, the following:â—patent applications may not result in any patents being issued, or the scope of issued patents may not extend to competitive product candidates and their formulations and uses developed or produced by others;â—our competitors, many of which have substantially greater resources than us or our partners, and many of which have made significant investments in competing technologies, may seek, or may already have obtained, patents that may limit or interfere with our abilities to make, use, and sell potential product candidates, file new patent applications, or may affect any pending patent applications that we may have;â—there may be significant pressure on the U.S. government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful as a matter of public policy regarding worldwide health concerns; andâ—countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.In addition, patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or otherwise may not provide any competitive advantage. Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of these proceedings could be substantial, and it is possible that our efforts to establish priority of invention would be unsuccessful, resulting in a material adverse effect on our U.S. patent positions. An adverse determination in any such submission, patent office trial, proceeding or litigation could reduce the scope of, render unenforceable, or invalidate, our patent rights, allow third parties to commercialize our technologies or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Third parties are often responsible for maintaining patent protection for our product candidates, at our and their expense. If that party fails to appropriately prosecute and maintain patent protection for a product candidate, our abilities to develop and commercialize products may be adversely affected, and we may not be able to prevent competitors from making, using and selling competing products. Such a failure to properly protect intellectual property rights relating to any of our product candidates could have a material adverse effect on our 64 Table of Contentsfinancial condition and results of operations. In addition, U.S. patent laws may change, which could prevent or limit us from filing patent applications or patent claims to protect products and/or technologies or limit the exclusivity periods that are available to patent holders, as well as affect the validity, enforceability, or scope of issued patents.We and our licensors also rely on trade secrets and proprietary know-how to protect product candidates. Although we have taken steps to protect our and their trade secrets and unpatented know-how, including entering into confidentiality and non-use agreements with third parties, and proprietary information and invention assignment agreements with employees, consultants and advisers, third parties may still come upon this same or similar information independently. Despite these efforts, any of these parties may also breach the agreements and may unintentionally or willfully disclose our or our licensorsâ€™ proprietary information, including our trade secrets, and we may not be able to identify such breaches or obtain adequate remedies. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, if any of our or our licensorsâ€™ trade secrets were to be lawfully obtained or independently developed by a competitor, we and our licensors would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our or our licensorsâ€™ trade secrets were to be disclosed to or independently developed by a competitor, our competitive positions would be harmed.The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify any patentable aspects of our research and development output and methodology, and, even if we do, an opportunity to obtain patent protection may have passed. Given the uncertain and time-consuming process of filing patent applications and prosecuting them, it is possible that our product(s)Â or process(es) originally covered by the scope of the patent application may have changed or been modified, leaving our product(s)Â or process(es) without patent protection. If our licensors or we fail to obtain or maintain patent protection or trade secret protection forÂ one or more product candidates or any future product candidate we may license or acquire, third parties may be able to leverage our proprietary information and products without risk of infringement, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and achieve profitability. Moreover, should we enter into other collaborations we may be required to consult with or cede control to collaborators regarding the prosecution, maintenance and enforcement of licensed patents. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recentÂ years been the subject of much litigation. In addition, no consistent policy regarding the breadth of claims allowed in pharmaceutical or biotechnology patents has emerged to date in the U.S. The patent situation outside the U.S. is even more uncertain. The laws of foreign countries may not protect our rights to the same extent as the laws of the U.S., and we may fail to seek or obtain patent protection in all major markets. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18Â months after a first filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in patents or pending patent applications that we own or licensed, or that we or our licensors were the first to file for patent protection of such inventions. In the event that a third party has also filed a U.S.Â patent application relating to our product candidates or a similar invention, depending upon the priority dates claimed by the competing parties, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention in the U.S. We might also become involved in derivation proceedings in an event that a third party misappropriates one or more of our inventions and files their own patent application directed to such one or more inventions. The costs of these proceedings could be substantial, and it is possible that our efforts to establish priority of invention (or that a third party derived an invention from us) would be unsuccessful, resulting in a material adverse effect on our U.S.Â patent position. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents or narrow the scope of our patent protection. For example, the federal courts of the U.S. have taken an increasingly dim view of the 65 Table of Contentspatent eligibility of certain subject matter, such as naturally occurring nucleic acid sequences, amino acid sequences and certain methods of utilizing the same, which include their detection in a biological sample and diagnostic conclusions arising from their detection. Such subject matter, which had long been a staple of the biotechnology and biopharmaceutical industry to protect their discoveries, is now considered, with few exceptions, ineligible in the first instance for protection under the patent laws of the U.S. Accordingly, we cannot predict the breadth of claims that may be allowed and remain enforceable in our patents or in those licensed from a third party.Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.We also may rely on the regulatory period of market exclusivity for any of our biologic product candidates that are successfully developed and approved for commercialization. Although this period in the United States is generally 12Â years from the date of marketing approval (depending on the nature of the specific product), there is a risk that the U.S. Congress could amend laws to significantly shorten this exclusivity period. Once any regulatory period of exclusivity expires, depending on the status of our patent coverage and the nature of the product, we may not be able to prevent others from marketing products that are biosimilar to or interchangeable with our products, which would materially adversely affect our business.We depend on our licensors to maintain and enforce the intellectual property covering certain of our product candidates. We have limited, if any, control over the resources that our licensors can or will devote to securing, maintaining, and enforcing patents protecting our product candidates.We depend on our licensors to protect the proprietary rights coveringÂ our product candidates and we have limited, if any, control over the amount or timing of resources that they devote on our behalf, or the priority they place on, maintaining patent rights and prosecuting patent applications to our advantage. Moreover, we have limited, if any, control over the strategies and arguments employed in the maintenance of patent rights and the prosecution of patent applications to our advantage. Our licensors might become involved in disputes with one of their other licensees, and we or a portion of our licensed patent rights might become embroiled in such disputes.Our licensors, depending on the patent or application, are responsible for maintaining issued patents and prosecuting patent applications. We cannot be sure that they will perform as required. Should they decide they no longer want to maintain any of the patents licensed to us, they are required to afford us the opportunity to do so at our expense. If our licensors do not perform, and if we do not assume the maintenance of the licensed patents in sufficient time to make required payments or filings with the appropriate governmental agencies, we risk losing the benefit of all or some of those patent rights. Moreover, and possibly unbeknownst to us, our licensors may experience serious difficulties related to their overall business or financial stability, and they may be unwilling or unable to continue to expend the financial resources required to maintain and prosecute these patents and patent applications. While

we intend to take actions reasonably necessary to enforce our patent rights, we depend, in part, on our licensors to protect a substantial portion of our proprietary rights and to inform us of the status of those protections and efforts thereto.Our licensors may also be notified of alleged infringement and be sued for infringement of third-party patents or other proprietary rights. We may have limited, if any, control or involvement over the defense of these claims, and our licensors could be subject to injunctions and temporary or permanent exclusionary orders in the U.S. or other countries. Our licensors are not obligated to defend or assist in our defense against third-party claims of infringement. We have limited, if any, control over the amount or timing of resources, if any, that our licensors devote on our behalf or the priority they place on defense of such third-party claims of infringement.Because of the uncertainty inherent in any patent or other litigation involving proprietary rights, we or our licensors may not be successful in defending claims of intellectual property infringement alleged by third parties, which could have a material adverse effect on our results of operations. Regardless of the outcome of any litigation, defending the litigation may be expensive, time-consuming and distracting to management.66 Table of ContentsProtecting our proprietary rights is difficult and costly, and we may be unable to ensure their protection.The degree of future protection for our proprietary rights is uncertain, because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage, in addition to being costly and time consuming to undertake. For example:â—our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents;â—our licensors might not have been the first to file patent applications for these inventions;â—others may independently develop similar or alternative technologies or duplicate our product candidates or any future product candidate technologies;â—it is possible that none of the pending patent applications licensed to us will result in issued patents;â—the scope of our issued patents may not extend to competitive products developed or produced by others;â—the issued patents covering our product candidates or any future product candidate may not provide a basis for market exclusivity for active products, may not provide us with any competitive advantages, or may be challenged by third parties;â—we may not develop additional proprietary technologies that are patentable;Â orâ—intellectual property rights of others may have an adverse effect on our business.We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful, and an unfavorable outcome in any litigation would harm our business.Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file one or more actions for patent infringement, which can be expensive and time consuming. Any claims we assert against accused infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents; or provoke those parties to petition the USPTO to institute inter partes review against the asserted patents, which may lead to a finding that all or some of the claims of the patent are invalid. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patentâ€™s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question or as a matter of public policy. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, rendered unenforceable, or interpreted narrowly. Furthermore, adverse results on U.S. patents may affect related patents in our global portfolio.If we or our licensors are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.Our success also depends on our ability, and the abilities of any of our respective current or future collaborators, to develop, manufacture, market and sell product candidates without infringing the proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing products, some of which may be directed at claims that overlap with the subject matter of our or our licensorsâ€™ intellectual property. Because patent applications can take manyÂ years to issue, there may be currently pending applications, unknown to us, which may later result in issued patents that our product candidates or proprietary technologies may infringe. Similarly, there may be issued patents relevant to our product candidates of which we or our licensors are not aware. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18Â months after a first filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or such licensors were the first to make the inventions claimed in patents or pending patent applications that we own or licensed, or that we and our licensors were the first to file for patent protection of such inventions. In the event that a third party has also filed a U.S. patent application 67 Table of Contentsrelating to our product candidates or a similar invention, depending upon the priority dates claimed by the competing parties, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention in the U.S. The costs of these proceedings could be substantial, and it is possible that our efforts to establish priority of invention would be unsuccessful, resulting in a material adverse effect on our U.S. patent position. As a result, the issuance, scope, validity, enforceability and commercial value of our or any of our licensorsâ€™ patent rights are highly uncertain.There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that we or any of our licensors, suppliers or collaborators infringe the third partyâ€™s intellectual property rights, we may have to, among other things:â—obtain additional licenses, which may not be available on commercially reasonable terms, if at all;â—abandon an infringing product candidate or redesign products or processes to avoid infringement, which may demand substantial funds, time and resources and which may result in inferior or less desirable processes and/or products;â—pay substantial damages, including the possibility of treble damages and attorneysâ€™ fees, if a court decides that the product or proprietary technology at issue infringes on or violates the third partyâ€™s rights;â—pay substantial royalties, fees and/or grant cross-licenses to our product candidates; and/orâ—defend litigation or administrative proceedings which may be costly regardless of outcome, and which could result in a substantial diversion of financial and management resources.Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.If we fail to comply with our obligations under our intellectual property licenses and third party funding arrangements, we could lose rights that are important to our business.We are currently a party to license agreements with COH, Fred Hutch, Nationwide and Mayo Clinic. In the future, we may become party to licenses that are important for product development and commercialization. If we fail to comply with our obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market any product or utilize any technology that is covered by these agreements or may face other penalties under the agreements. Such an occurrence could materially and adversely affect the value of a product candidate being developed under any such agreement or could restrict our drug discovery activities. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology.68 Table of ContentsWe may be subject to claims that our employees and/or consultants have wrongfully used or disclosed to us alleged trade secrets of their former employers or other clients.As is common in the biopharmaceutical industry, we rely on employees and consultants to assist in the development of product candidates, many of whom were previously employed at, or may have previously been or are currently providing consulting services to, other biopharmaceutical companies, including our competitors or potential competitors. We may become subject to claims related to whether these individuals have inadvertently or otherwise used, disclosed or misappropriated trade secrets or other proprietary information of their former employers or their former or current clients. Litigation may be necessary to defend against these claims. Even if we are successful in defending these claims, litigation could result in substantial costs and be a distraction to management and/or the employees or consultants that are implicated.If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.In addition to seeking patent protection for our product candidates or any future product candidate, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position, particularly where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We limit disclosure of such trade secrets where possible but we also seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who do have access to them, such as our employees, our licensors, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and may unintentionally or willfully disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.We in-license intellectual property pertaining to certain product candidates from third parties. As such, any dispute with the licensors or the non-performance of such license agreements may adversely affect our ability to develop and commercialize the applicable product candidates.The types of disputes which may arise between us and the third parties from whom we license intellectual property include, but are not limited to:â—the scope of rights granted under such license agreements and other interpretation-related issues;â—the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to such license agreements;â—the scope and interpretation of the representations and warranties made to us by our licensors, including those pertaining to the licensorsâ€™ right title and interest in the licensed technology and the licensorsâ€™ right to grant the licenses contemplated by such agreements;â—the sublicensing of patent and other rights under our license agreements and/or collaborative development relationships, and the rights and obligations associated with such sublicensing, including whether or not a given transaction constitutes a sublicense under such license agreement;â—the diligence and development obligations under license agreements (which may include specific diligence milestones) and what activities or achievements satisfy those diligence obligations;69 Table of Contentsâ—whether or not the milestones associated with certain milestone payment obligations have been achieved or satisfied;â—the applicability or scope of indemnification claims or obligations under such license agreements;â—the permissibility and advisability of, and strategy regarding, the pursuit of potential third-party infringers of the intellectual property that is the subject of such license agreements;â—the calculation of royalty, sublicense revenue and other payment obligations under such license agreements;â—the extent to which license rights, if any, are retained by licensors under such license agreements;â—whether or not a material breach has occurred under such license agreements and the extent to which such breach, if deemed to have occurred, is or can be cured within applicable cure periods, if any;â—disputes regarding patent filing and prosecution decisions, as well as payment obligations regarding past and ongoing patent expenses;â—intellectual property rights resulting from the joint creation or use of intellectual property (including improvements made to licensed intellectual property) by our and our partnersâ€™ licensors and us and our partners; andâ—the priority of invention of patented technology.In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations or may conflict in such a way that puts us in breach of one or more agreements, which would make us susceptible to lengthy and expensive disputes with one or more of such third-party licensing partners. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreements, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.Risks Relating to Our Control by Fortressâ€‹Fortress controls a voting majority of our common stock.Pursuant to the terms of the ClassÂ A Preferred Stock held by Fortress, Fortress is entitled to cast, for each share of ClassÂ A Preferred held by Fortress, the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A)Â the shares of outstanding common stock and (B)Â the whole shares of common stock into which the shares of outstanding ClassÂ A common shares and the ClassÂ A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding ClassÂ A Preferred Stock. Accordingly, Fortress is able to control or significantly influence all matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combination transactions. The interests of Fortress may not always coincide with the interests of other stockholders, and Fortress may take actions that advance its own interests and are contrary to the desires of our other stockholders. Moreover, this concentration of voting power may delay, prevent or deter a change in control of us even when such a change may be in the best interests of all stockholders, could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our Company or our assets, and might affect the prevailing market price of our common stock.70 Table of ContentsFortress has the right to receive a significant grant of shares of our common stock annually which will result in the dilution of your holdings of common stock upon each grant, which could reduce their value.Under the terms of the Second Amended and Restated Founders Agreement (the â€œFounders Agreementâ€), which became effective JulyÂ 22, 2016, Fortress will receive a grant of shares of our common stock equal to two and one-halfÂ percent (2.5%) of the gross amount of any equity or debt financing. Additionally, the ClassÂ A Preferred Stock, as a class, will receive an annual dividend on JanuaryÂ 1st, payable in shares of common stock in an amount equal to two and one-halfÂ percent (2.5%) of our fully-diluted outstanding capital stock as of the business day immediately prior to JanuaryÂ 1st of suchÂ year. Fortress currently owns all outstanding shares of ClassÂ A Preferred Stock. These share issuances to Fortress and any other holder of ClassÂ A Preferred Stock will dilute your holdings in our common stock and, if the value of our Company has not grown proportionately over the priorÂ year, would result in a reduction in the value of your shares. The Founders Agreement has a term of 15Â years and renews automatically for subsequent one-year periods unless terminated by Fortress or upon a Change in Control (as defined in the Founders Agreement).We might have received better terms from unaffiliated third parties than the terms we receive in our agreements with Fortress.The agreements we have entered into with Fortress include a Management Services Agreement and the Founders Agreement. While we believe the terms of these agreements are reasonable, they might not reflect terms that would have resulted from armâ€™s-length negotiations between unaffiliated third parties. The terms of the agreements relate to, among other things, payment of a royalty on product sales and the provision of employment and transition services. We might have received better terms from third parties because, among other things, third parties might have competed with each other to win our business.The dual roles of our directors who also serve in similar roles with Fortress could create a conflict of interest and will require careful monitoring by our independent directors.We share some directors with Fortress which could create conflicts of interest between the two companies in the future. While we believe that the Founders Agreement and the Management Services Agreement were negotiated by independent parties on both sides on armâ€™s length terms, and the fiduciary duties of both parties were thereby satisfied, in the future situations may arise under the operation of both agreements that may create a conflict of interest.Â We will have to be diligent to ensure that any such situation is resolved by independent parties. In particular, under the Management Services Agreement, Fortress and its affiliates are free to pursue opportunities which could potentially be of interest to us, and they are not required to notify us prior to pursuing such opportunities. Any conflict of interest or pursuit by Fortress of such a corporate opportunity could expose us to claims by our investors and/or creditors and could harm our results of operations.General Risks and Risks Associated with Ownership of our Common Stockâ€‹Our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or third partiesâ€™ cybersecurity.We are increasingly dependent upon information technology systems, infrastructure, and data to operate our business. In the ordinary course of business, we collect, store, and transmit confidential information, including, but not limited to, information related to our intellectual property and proprietary business information, personal information, and other confidential information. It is critical that we maintain such confidential information in a manner that preserves its confidentiality and integrity. Furthermore, we have outsourced elements of our operations to third party vendors, who each have access to our confidential information, which increases our

disclosure risk.â€‹Despite the implementation of our internal security and business continuity measures and our information technology infrastructure, our internal computer systems and those of current and future third parties on which we rely may fail and are vulnerable to damage from computer viruses and unauthorized access. Our information technology and other internal infrastructure systems, including corporate firewalls, servers, data center facilities, lab equipment, and connection to the internet, face the risk of breakdown or other damage or interruption from service interruptions, system malfunctions, natural disasters, terrorism, war, and telecommunication and electrical failures, as well as security breaches from 71 Table of Contentsinadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), each of which could compromise our system infrastructure or lead to the loss, destruction, alteration, disclosure, or dissemination of, or damage or unauthorized access to, our data or data that is processed or maintained on our behalf, or other assets.â€‹If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, and could result in financial, legal, business, and reputational harm to us. â€‹In addition, the loss or corruption of, or other damage to, clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our drug candidates or any future drug candidates and to conduct clinical trials, and similar events relating to their systems and operations could also have a material adverse effect on our business and lead to regulatory agency actions. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. Sophisticated cyber attackers (including foreign adversaries engaged in industrial espionage) are skilled at adapting to existing security technology and developing new methods of gaining access to organizationsâ€™ sensitive business data, which could result in the loss of proprietary information, including trade secrets. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations, or hostile foreign governments or agencies.â€‹Any security breach or other event leading to the loss or damage to, or unauthorized access, use, alteration, disclosure, or dissemination of, personal information, including personal information regarding clinical trial subjects, contractors, directors, or employees, our intellectual property, proprietary business information, or other confidential or proprietary information, could directly harm our reputation, enable competitors to compete with us more effectively, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. Each of the foregoing could result in significant legal and financial exposure and reputational damage that could adversely affect our business. Notifications and follow-up actions related to a security incident could impact our reputation or cause us to incur substantial costs, including legal and remediation costs, in connection with these measures and otherwise in connection with any actual or suspected security breach. We expect to incur significant costs in an effort to detect and prevent security incidents and otherwise implement our internal security and business continuity measures, and actual, potential, or anticipated attacks may cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants.â€‹The costs related to significant security breaches or disruptions could be material, and our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach of, our systems or third-party systems where information important to our business operations or commercial development is stored or processed. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention. Furthermore, if the information technology systems of our third-party vendors and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.â€‹â€‹72 Table of ContentsOur business could be adversely affected by the effects of health pandemics or epidemics, which could cause significant disruptions in our operations.â€‹Health pandemics or epidemics, such as the COVID-19 pandemic, have in the past and could again in the future result in quarantines, stay-at-home orders, remote work policies or other similar events that may disrupt businesses, delay our research and development programs and timelines, negatively impact productivity and increase risks associated with cybersecurity, the future magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations. More specifically, these types of events may negatively impact personnel at third-party manufacturing facilities or the availability or cost of materials, which could disrupt our supply chain. In addition, impact on the operations of the FDA or other regulatory authorities could negatively affect our planned approval processes. Finally, economic conditions and business activity may be negatively impacted and may not recover as quickly as anticipated. The effects of epidemics and pandemic are highly uncertain and subject to change. If we are not able to respond to and manage the impact of such events effectively, our business, operating results, financial condition and cash flows could be adversely affected.â€‹Our growth is subject to economic and geopolitical conditions.Our business is affected by global and local economic and geopolitical conditions as well as the state of the financial markets, inflation, recession, financial liquidity, currency volatility, growth, and policy initiatives. There can be no assurance that global economic conditions and financial markets will not worsen and that we will not experience any adverse effects that may be material to our consolidated cash flows, results of operations, financial position or our ability to access capital, such as the adverse effects resulting from a prolonged shutdown in government operations both in the United States and internationally. Geopolitical changes, including war or other conflicts (including the conflicts between Russia and Ukraine and Israel and Hamas), some of which may be disruptive, could interfere with our supply chain, our customers and all of our activities in a particular location.We may not be able to manage our business effectively if we are unable to attract and retain key personnel.We may not be able to attract or retain qualified management and commercial, scientific and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.Our employees, consultants, or third-party partners may engage in misconduct or other improper activities, including but not necessarily limited to noncompliance with regulatory standards and requirements or internal procedures, policies or agreements to which such employees, consultants and partners are subject, any of which could have a material adverse effect on our business.We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, consultants, or third-party partners could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with cGMPs, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately, comply with internal procedures, policies or agreements to which such employees, consultants or partners are subject, or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee, consultant, or third-party misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation, as well as civil and criminal liability. The precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other civil and/or criminal sanctions.73 Table of ContentsWe receive a large amount of proprietary information from potential or existing licensors of intellectual property and potential acquisition target companies, all pursuant to confidentiality agreements. The confidentiality and proprietary invention assignment agreements that we have in place with each of our employees and consultants prohibit the unauthorized disclosure of such information, but such employees or consultants may nonetheless disclose such information through negligence or willful misconduct. Any such unauthorized disclosures could subject us to monetary damages and/or injunctive or equitable relief. The notes, analyses and memoranda that we have generated based on such information are also valuable to our businesses, and the unauthorized disclosure or misappropriation of such materials by our employees and consultants could significantly harm our strategic initiativesÂ â€“ especially if such disclosures are made to our competitors.We rely on information technology, and any internet or internal computer system failures, inadequacies, interruptions or compromises of our systems or the security of confidential information could damage our reputation and harm our business.Although a significant portion of our business is conducted using traditional methods of contact and communications such as face-to-face meetings, our business is increasingly dependent on critical, complex and interdependent information technology systems, including internet-based systems, to support business processes as well as internal and external communications. We could experience system failures and degradations in the future. We cannot assure you that we will be able to prevent an extended and/or material system failure if any of the following or similar events occurs:â—human error;â—subsystem, component, or software failure;â—a power or telecommunications failure;â—hacker attacks, cyber-attacks, software viruses, security breaches, unauthorized access or intentional acts of vandalism; orâ—terrorist acts or war.If any of the foregoing events were to occur, our business operations could be disrupted in ways that would require the incurrence of substantial expenditures to remedy. Any system failure, accident or security breach that causes interruptions in our operations could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed clinical trials forÂ one or more of our product conducts could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data and applications, or inappropriate/unauthorized disclosure of confidential or proprietary information (including trade secrets), we could incur liability and our business and financial condition could be harmed.The occurrence of a catastrophic disaster could damage our facilities beyond insurance limits, or we could lose key data which could cause us to curtail or cease operations.We are vulnerable to damage and/or loss of vital data from natural disasters, such as earthquakes, tornadoes, power loss, fire, health epidemics and pandemics, floods and similar events, as well as from accidental loss or destruction. If any disaster were to occur, our ability to operate our businesses could be seriously impaired. We have property, liability and business interruption insurance that may not be adequate to cover losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business, financial condition and prospects. Any of the aforementioned circumstances, including without limitation the resurgence of COVID-19 virus, may also impede our employeesâ€™ and consultantsâ€™ abilities to provide services in-person and/or in a timely manner; hinder our ability to raise funds to finance our operations on favorable terms or at all; and trigger effectiveness of â€œforce majeureâ€ clauses under agreements with respect to which we receive goods and services, or under which we are obligated to achieve developmental milestones on certain timeframes. Disputes with third parties over 74 Table of Contentsthe applicability of such â€œforce majeureâ€ clauses, or the enforceability of developmental milestones and related extension mechanisms in light of such business interruptions, may arise and may become expensive and time-consuming.The market price for our common stock has been volatile and may continue to fluctuate or may decline significantly in the future.â€‹An active, liquid and orderly market for our common stock may not be sustained, which could depress the trading price of our common stock or cause it to continue to be highly volatile or subject to wide fluctuations. Some of the factors that could negatively affect our share price or result in fluctuations in the price or trading volume of our common stock include, among other things:Â Â Â·the commencement, enrollment, or results of our current and future preclinical studies and clinical trials, and the results of trials of our competitors or those of other companies in our market sector;Â Â Â·regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;Â Â Â·manufacturing, supply or distribution delays or shortages;Â Â Â·our ability to identify and successfully acquire orÂ in-licenseÂ new product candidates on acceptable terms;Â Â Â·FDA, state or international regulatory actions, including actions on regulatory applications any of our product candidates;Â Â Â·legislative or regulatory changes;Â Â Â·judicial pronouncements interpreting laws and regulations;Â Â Â·changes in government programs;Â Â Â·announcements of new products, services or technologies, commercial relationships, acquisitions or other events by us or our competitors;Â Â Â·market conditions in the pharmaceutical and biotechnology sectors;Â Â Â·fluctuations in stock market prices and trading volumes of similar companies;Â Â Â·changes in accounting principles;Â Â Â·litigation or public concern about the safety of our product candidates or similar product candidates;Â Â Â·sales of large blocks of our common stock, including sales by our executive officers, directors and significant shareholders; andÂ Â Â·our ability to obtain additional financing to advance our development operations;Â These broad market and industry factors may decrease the market price of our common stock, regardless of our actual operating performance. The stock market in general has from time to time experienced extreme price and volume fluctuations. In addition, in the past, following periods of volatility in the overall market and decreases in the market price of a companyâ€™s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our managementâ€™s attention and resources.â€‹â€‹75 Table of ContentsWe may become involved in securities class action litigation that could divert managementâ€™s attention and harm our business.â€‹The stock markets have from time to time experienced significant price and volume fluctuations that have affected the market prices for the common stock of biotechnology and pharmaceutical companies. These broad market fluctuations may cause the market price of our stock to decline. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant stock price volatility in recentÂ years. We may become involved in this type of litigation in the future. Litigation often is expensive and diverts managementâ€™s attention and resources, which could adversely affect our business. â€‹If we are unable to maintain compliance with all applicable continued listing requirements and standards of Nasdaq, our common stock may be delisted from Nasdaq. â€‹Our common stock is listed on the Nasdaq Capital Market under the symbol â€œMBIO.â€ The Nasdaq Capital Market requires that listed companies satisfy continued listing standards to maintain their listing. On March 13, 2024, we received a deficiency letter (the â€œLetterâ€) from the Listing Qualifications Department (the â€œStaffâ€) of Nasdaq notifying us that we were not in compliance with the minimum stockholdersâ€™ equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholdersâ€™ equity of at least $2,500,000 (the â€œStockholdersâ€™ Equity Requirementâ€). Our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, reported stockholdersâ€™ equity of $123,000. The Letter further noted that as of its date, we did not have a market value of listed securities of $35 million, or net income from continued operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years, the alternative quantitative standards for continued listing on the Nasdaq Capital Market. â€‹The Letter had no immediate effect on our continued listing on the Nasdaq Capital Market, subject to our compliance with the other continued listing requirements. In accordance with Nasdaq rules, we were provided 45 calendar days, or until AprilÂ 29, 2024, to submit a plan to regain compliance (the â€œCompliance Planâ€). We submitted our Compliance Plan on April 29, 2024, and the Staff granted our request for an extension of 180 calendar days through September 9, 2024, to regain compliance with the Stockholdersâ€™ Equity Requirement.â€‹On May 16, 2024, we received a notice (the â€œSecond Letterâ€) from the Staff of Nasdaq indicating that the bid price of our common stock had closed below $1.00 per share for 31 consecutive business days and, as a result, we were not in compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Second Letter from Nasdaq had no immediate effect on the listing of our common stock on Nasdaq. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), we were afforded a 180-calendar day grace period, or until November 12, 2024, to regain compliance with the bid price requirement. Compliance can be achieved by evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days (but generally not more than 20 consecutive business days) during the 180-calendar day grace period.â€‹If we do not regain compliance with the bid price requirement by November 12, 2024, we may be eligible for an additional 180-calendar day compliance period so long as we satisfy the criteria for initial listing on Nasdaq and the continued listing requirement for market value of publicly held shares and we provide written notice to Nasdaq of our intention to cure the deficiency during the second compliance period by

effecting a reverse stock split, if necessary. In the event we are not eligible for the second grace period, Nasdaq staff will provide written notice that our common stock is subject to delisting; however, we may request a hearing before the Nasdaq Hearings Panel (the â€œPanelâ€), which request, if timely made, would stay any further suspension or delisting action by the Staff pending the conclusion of the hearing process and expiration of any extension that may be granted by the Panel. Although we intend to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on the Nasdaq Capital Market, there can be no assurance that we would be successful in our efforts to maintain the listing of our common stock on the Nasdaq Capital Market.â€‹If we are delisted from Nasdaq, there can be no assurance that our common stock will be eligible for trading on another stock exchange or quotation on an over-the-counter market. If we are not able to obtain a listing on another stock exchange or quotation service for our common stock, it may be extremely difficult or impossible for stockholders to sell 76 Table of Contentstheir shares. Additionally, if we are delisted from Nasdaq, but obtain a substitute listing or quotation service for our common stock, it will likely be on a market with less liquidity and our common stock may therefore experience potentially more price volatility than it has historically experienced on Nasdaq. Stockholders may not be able to sell their shares of common stock on any such substitute market in the quantities, at the times, or at the prices that could potentially be available on a more liquid trading market. As a result of these factors, if our common stock is delisted from Nasdaq, the value and liquidity of our common stock would likely be adversely affected. A delisting of our common stock from Nasdaq could also adversely affect our ability to obtain financing for our operations and/or result in a loss of confidence by investors, employees and/or business partners. â€‹â€‹Item 2. Unregistered Sales of Equity Securities and Use of Proceedsâ€‹Pursuant to our Amended and Restated Certificate of Incorporation, as amended (the â€œCertificate of Incorporationâ€), we issued 353,086 shares of our common stock to Fortress as the Annual Stock Dividend (as such term is defined in the Certificate of Incorporation), representing 2.5% of our fully-diluted outstanding equity on January 2, 2024. â€‹The issuance of the above securities was deemed to be exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving any public offering. â€‹On June 19, 2024, we entered into a Securities Purchase Agreement (the â€œJune 2024 SPAâ€) with an institutional accredited investor, for a private placement offering of warrants to purchase 6,130,000 shares of our Common Stock. Pursuant to the June 2024 SPA, we agreed to issue and sell the warrants at an offering price of $0.41 per warrant to purchase one share of our Common Stock. The warrants have an exercise price of $0.41 per share (subject to adjustment as set forth in the warrants), were exercisable beginning on the date on which stockholder approval was received, which was obtained on June 27, 2024, and will expire five (5) years from the date on which the warrants become exercisable. The warrants contain standard anti-dilution adjustments to the exercise price including for share splits, share dividend, rights offerings and pro rata distributions. This private placement closed on June 21, 2024, concurrently with an offering to the same institutional accredited investor that was registered under the Securities Act. The gross proceeds to us from the private placement, before deducting placement agent fees and other estimated offering expenses payable by us, were approximately $2.5 million. H.C. WainwrightÂ & Co., LLC (â€œWainwrightâ€) acted as the exclusive placement agent in connection with the private placement under an engagement, between us and Wainwright. Pursuant to the Engagement Letter, Wainwright was paid a cash fee equal to 7.0% of the gross proceeds received by us in the Offerings, a management fee equal to 1.0% of the gross proceeds of the Offering, $25,000 for non-accountable expenses, $50,000 for fees and expenses of legal counsel and other out-of-pocket expenses, and a clearing fee of $15,950. In addition, under the terms of the Engagement Letter, we issued to Wainwright (or its designees) warrants to purchase up to 367,800 shares of our Common Stock (the â€œPA Warrantsâ€). The PA Warrants have substantially the same terms as the Warrants, except that the PA Warrants will expire five (5)Â years from the commencement of the sales of the Offerings and have an exercise price of $0.5125 per share (subject to customary adjustment as set forth in the PA Warrants). The June 2024 Warrants were offered and sold in reliance on the exemption from registration provided by SectionÂ 4(a)(2)Â of the Securities Act. The investor also represented that it qualified as an â€œaccredited investorâ€ within the meaning of RuleÂ 501 of Regulation D.â€‹Item 3. Defaults Upon Senior Securitiesâ€‹None.â€‹Item 4. Mine Safety Disclosuresâ€‹None.â€‹Item 5. Other Informationâ€‹During the three months ended June 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K under the Securities Act).77 Table of ContentsItem 6. Exhibitsâ€‹The exhibits listed on the Exhibit Index are either filed or furnished with this report or incorporated herein by reference.â€‹EXHIBIT INDEXâ€‹Exhibit No.Â Â Â Â Â Â Descriptionâ€‹â€‹â€‹4.1â€‹Form of Pre-Funded Warrant (May 2024) (incorporated by reference to Exhibit 4.1 to the Registrantâ€™s Current Report on Form 8-K filed on May 2, 2024 (File No. 001-38191)).â€‹â€‹â€‹4.2â€‹Form of Series A-1, A-2, and A-3 Warrant (May 2024) (incorporated by reference to Exhibit 4.2 to the Registrantâ€™s Current Report on Form 8-K filed on May 2, 2024 (File No. 001-38191)).â€‹â€‹â€‹4.3â€‹Form of Placement Agent Warrant (May 2024) (incorporated by reference to Exhibit 4.3 to the Registrantâ€™s Current Report on Form 8-K filed on May 2, 2024 (File No. 001-38191)).â€‹â€‹â€‹4.4â€‹Form of Pre-funded Warrant (June 2024) (incorporated by reference to Exhibit 4.1 to the Registrantâ€™s Current Report on Form 8-K filed on June 21, 2024 (File No. 001-38191)).â€‹â€‹â€‹4.5â€‹Form of Warrant (June 2024) (incorporated by reference to Exhibit 4.2 to the Registrantâ€™s Current Report on Form 8-K filed on June 21, 2024 (File No. 001-38191)).â€‹â€‹â€‹4.6â€‹Form of Wainwright Warrant (June 2024) (incorporated by reference to Exhibit 4.3 to the Registrantâ€™s Current Report on Form 8-K filed on June 21, 2024 (File No. 001-38191)).â€‹â€‹â€‹10.1â€‹Form of Securities Purchase Agreement, dated April 29, 2024, by and between the Company and the purchaser party thereto (incorporated by reference to Exhibit 10.1 of the Registrantâ€™s Current Report on Form 8-K filed on May 2, 2024 (File No. 001-38191)).â€‹â€‹â€‹10.2â€‹Warrant Amendment Agreement, dated April 29, 2024, by and between the Company and purchaser party thereto (incorporated by reference to Exhibit 10.2 of the Registrantâ€™s Current Report on Form 8-K filed on May 2, 2024 (File No. 001-38191)).â€‹â€‹â€‹10.3â€‹Form of Securities Purchase Agreement, dated June 19, 2024, by and between the Company and the purchaser party thereto (incorporated by reference to Exhibit 10.1 of the Registrantâ€™s Current Report on Form 8-K filed on June 21, 2024 (File No. 001-38191)).â€‹â€‹â€‹31.1â€‹Certification of President and Chief Executive Officer (Principal Executive Officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).â€‹â€‹â€‹31.2â€‹Certification of Interim Chief Financial Officer (Principal Financial Officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).â€‹â€‹â€‹32.1â€‹Certification of President and Chief Executive Officer (Principal Executive Officer), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).â€‹â€‹â€‹32.2â€‹Certification of Interim Chief Financial Officer (Principal Financial Officer), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).â€‹â€‹â€‹78 Table of Contents101â€‹The following financial information from the Companyâ€™s Quarterly Report on Form 10-Q for the period ended June 30, 2024, formatted as Inline Extensible Business Reporting Language (iXBRL): (i) the Balance Sheets, (ii) the Unaudited Statements of Operations, (iii) the Unaudited Statement of Stockholdersâ€™ Equity, (iv) the Unaudited Statements of Cash Flows, and (v) Notes to the Unaudited Financial Statements (filed herewith).â€‹â€‹â€‹104â€‹Cover Page Interactive Data File (formatted as Inline XBRL and contained in exhibit 101)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹79 Table of ContentsSignaturesâ€‹Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.â€‹â€‹â€‹â€‹Â MUSTANG BIO, INC.Â Â Â August 13, 2024By:/s/ Manuel Litchman, M.D.Â Â Manuel Litchman, M.D., President andÂ Â Chief Executive OfficerÂ Â (Principal Executive Officer)Â Â Â Â By:/s/ James MurphyÂ Â James MurphyÂ Â Interim Chief Financial OfficerÂ Â (Principal Financial Officer)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Clinical Trial and Sponsored Research Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Property, Plant and Equipment, and Asset Impairment (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Organization, Description of Business and Liquidity and Capital Resources (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details) link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Related Party Agreements (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Assets Purchase Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Property, Plant and Equipment, and Asset Impairment (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Notes Payable (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Stockholders Equity (Registration Statements and At-the-Market Offering) (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Stockholders' Equity - May 2024 Public Offering (Details) link:presentationLink link:calculationLink link:definitionLink 99940903 - Disclosure - Stockholders' Equity - June 2024 Registered Direct Offering (Details) link:presentationLink link:calculationLink link:definitionLink 99940904 - Disclosure - Stockholders Equity (Equity Incentive Plans and Employee Stock Purchase Plan) (Details) link:presentationLink link:calculationLink link:definitionLink 99940905 - Disclosure - Stockholders Equity (Stock Option Activities) (Details) link:presentationLink link:calculationLink link:definitionLink 99940906 - Disclosure - Stockholders Equity (Restricted Stock or Restricted Units Awards) (Details) link:presentationLink link:calculationLink link:definitionLink 99940907 - Disclosure - Stockholders Equity (Stock-based Compensation Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 99940908 - Disclosure - Stockholders' Equity (Warrants Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Net Loss per Share (Potentially Dilutive Securities) (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Commitments and Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99941203 - Disclosure - Commitments and Contingencies (Cash Flows) (Details) link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Assets Purchase Agreements link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 tmb-20240630_cal.xml EX-101.CAL EX-101.DEF 8 tmb-20240630_def.xml EX-101.DEF EX-101.LAB 9 tmb-20240630_lab.xml EX-101.LAB Document and Entity Information Document Information [Table] Class of Stock [Axis] Class of Stock [Domain] Common Class A [Member] Class A common shares Class A Common Shares Classification of common stock representing ownership interest in a corporation. Common Shares [Member] Common shares Common Shares Document Information [Line Items] Document Type Document Quarterly Report Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Balance Sheets (Unaudited) Statement [Table] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current Assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Other Receivables Other receivables Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Asset, Held-for-Sale, Not Part of Disposal Group, Current Property, plant and equipment, held for sale Assets, Current Total current assets Property, Plant and Equipment, Net Property, plant and equipment, net Property, plant and equipment, net Restricted Cash, Noncurrent Restricted cash Other Assets, Noncurrent Other assets Operating Lease, Right-of-Use Asset Operating lease right-of-use asset, net Assets Total Assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current Liabilities: Accounts Payable and Accrued Liabilities, Current Total accounts payable and accrued expenses Accounts payable and accrued expenses Other Liabilities, Current Payables and accrued expenses - related party Other Liability, Current, Related Party [Extensible Enumeration] Operating Lease, Liability, Current Operating lease liabilities - short-term Liabilities, Current Total current liabilities Deferred Income, Noncurrent Deferred income Operating Lease, Liability, Noncurrent Operating lease liabilities - long-term Liabilities Total Liabilities Commitments and Contingencies. Commitments and Contingencies (Note 12) Equity, Attributable to Parent [Abstract] Stockholders' Equity Preferred Stock, Value, Issued Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of June 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Common stock ($0.0001 par value), 200,000,000 shares authorized as of June 30, 2024 and December 31, 2023, respectively Common Stock, Value, Subscriptions Common stock issuable, zero and 419,089 shares as of June 30, 2024 and December 31, 2023, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Equity, Attributable to Parent Balances Balances Total Stockholders' Equity Liabilities and Equity Total Liabilities and Stockholders' Equity Preferred Stock, Par or Stated Value Per Share Preferred stock par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares Subscribed but Unissued Common stock, shares issuable Statements of Operations (Unaudited) Operating Expenses [Abstract] Operating expenses: Research and Development Expense (Excluding Acquired in Process Cost) Research and development Research and development expense Asset Impairment Charges Asset impairment Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Research and development for licenses acquired Research and development - licenses acquired Gain (Loss) on Disposition of Property Plant Equipment Gain on the sale of property and equipment Gain on sale of property and equipment General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense) The amount of grant income, such as from governmental agencies in reimbursement of covered expenses, recognized during the period. Grant income Other income Interest Income, Other Interest income Interest Expense, Debt Interest expense Total Interest Expense Interest expense Nonoperating Income (Expense) Total other income (expense) Net Loss Net loss Earnings Per Share, Basic Net loss per common share outstanding, basic Earnings Per Share, Diluted Net loss per common share outstanding, diluted Weighted Average Number of Shares Outstanding, Basic Weighted average number of common shares outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Weighted average number of common shares outstanding, diluted Statements of Stockholders' Equity (Unaudited) Preferred Class A [Member] Class A Preferred Shares Equity Components [Axis] Equity Component [Domain] Preferred Stock [Member] Preferred Stock Common Stock [Member] Common Shares Common Stock Issuable [Member] Common Stock Issuable Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit Shares, Outstanding Balances (in shares) Balances (in shares) The Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. Stock Issued During Period Value Issued For Founders Agreement Issuance of common shares - Founders Agreement Stock Issued During Period, Shares, Issued for Services Shares issued for services (in shares) Issuance of common shares - Founders Agreement (in shares) Value of stock issued at the public offering. Stock Issued During Period Value, at the Public Offering Issuance of common shares, net of offering costs - Public Offerings Number of shares issued at the public offering. Stock Issued During Period Shares , at the Public Offering Issuance of common shares, net of offering costs - Public Offerings (in shares) Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common shares under ESPP Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common shares under ESPP (in shares) Number of shares purchased under ESPP Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Stock-based compensation expenses Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Stock-based compensation expenses (in shares) The value of shares issued on exercise of warrants. Share Issued During Period, Value, On Exercise Of Warrants Exercise of warrants The number of shares issued on exercise of warrants. Share Issued During Period, Shares, On Exercise Of Warrants Exercise of warrants (in shares) The amount of additions (reductions) to additional paid-in capital during the period attributable to reverse stock splits. Additions (Reductions) To Additional Paid In Capital, Reverse Stock Splits Reverse Split (15:1) adjustment Value of shares adjusted due to fractional shares being issued. Fraction share adjustment Fraction share adjustment Number of shares adjusted due to fractional shares being issued. Fraction share adjustment (in shares) Fractional share adjustment (in shares) Statements of Cash Flows (Unaudited) Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] Related Party [Member] Related Party Nonrelated Party [Member] Non related party Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: It Represents issuance of common stock for equity fee on public offering. Issuance of Common Shares Equity Fee on Public Offering Issuance of common shares - Equity fee on public offerings to Fortress Biotech Share-Based Payment Arrangement, Noncash Expense Total stock-based compensation expense Stock-based compensation expenses Depreciation Depreciation expense Amortization of Debt Discount (Premium) Amortization of debt discount Operating Lease, Right-of-Use Asset, Periodic Reduction Amortization of operating lease right-of-use assets Gain (Loss) on Disposition of Assets Loss on disposal of property and equipment Gain (Loss) on Extinguishment of Debt Loss on extinguishment of debt Loss on Extinguishment Amount of gain (loss) on modification of lease before expiration of lease term. Gain on lease modification Gain on lease modification Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Other Receivables Other receivables The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid excluding those attributable to related parties. Increase (Decrease) In Accounts Payable And Accrued Expenses Excluding Amounts Due To Related Parties Accounts payable and accrued expenses Increase (Decrease) in Due to Related Parties Payable and accrued expenses - related party Amount of Increase Decrease In Lease Liabilities. Increase Decrease In Lease Liabilities Lease liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows from Investing Activities: Proceeds from Sale of Property, Plant, and Equipment Proceeds from the sale of property and equipment Payments to Acquire Property, Plant, and Equipment Purchase of fixed assets Net Cash Provided by (Used in) Investing Activities Net cash from investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows from Financing Activities: Repayments of Debt Payment of debt Proceeds from Issuance of Common Stock Proceeds from issuance of common shares - public offerings Payments of Stock Issuance Costs Offering costs for the issuance of common shares - public offerings Proceeds from Warrant Exercises Proceeds from exercise of warrants Proceeds from Stock Plans Proceeds from issuance of common shares under ESPP Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash, end of the period Cash, cash equivalents and restricted cash, beginning of the period Total cash, cash equivalents and restricted cash Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of noncash activities: Stock Issued Issuance of common shares - Founders Agreement and Equity fee to Fortress Value of assets transferred from PP&E to held for sale. Transfer of assets classified as held for sale Noncash or Part Noncash Acquisition, Value of Assets Acquired [Abstract] Supplemental disclosure of noncash activities related to the uBriGene Repurchase Transaction (see Note 5): Noncash or Part Noncash Acquisition, Fixed Assets Acquired Fair value of assets received The amount of supplies received, expensed to research and development, that an Entity acquires in a noncash (or part noncash) acquisition. Noncash or Part Noncash Acquisition, Supplies Received Expensed to Research and Development Fair value of supplies received expensed to research and development The amount of accounts receivable written off in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period n cash receipts or cash payments in the period. Noncash or Part Noncash Acquisition, Accounts Receivable Written Off Accounts receivable written off The amount of accounts payable written off in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period n cash receipts or cash payments in the period. Noncash or Part Noncash Acquisition, Accounts Payable Written Off Accounts payable written off The amount of net purchase consideration of assets recorded to accrued other in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period n cash receipts or cash payments in the period. Noncash or Part Noncash Acquisition, Purchase Consideration Accrued Net purchase consideration of assets recorded to accrued other Organization, Description of Business and Liquidity and Capital Resources Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization, Description of Business and Liquidity and Capital Resources Significant Accounting Policies Significant Accounting Policies [Text Block] Significant Accounting Policies Clinical Trial and Sponsored Research Agreements Collaborative Arrangement Disclosure [Text Block] Clinical Trial and Sponsored Research Agreements Related Party Agreements Related Party Transactions Disclosure [Text Block] Related Party Agreements Assets Purchase Agreements Asset Acquisition [Text Block] Assets Purchase Agreements Property, Plant and Equipment, and Asset Impairment Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment, and Asset Impairment Accounts Payable and Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts Payable and Accrued Expenses Notes Payable Debt Disclosure [Text Block] Notes Payable Stockholders' Equity Equity [Text Block] Stockholders' Equity Net Loss per Share Earnings Per Share [Text Block] Net Loss per Share Income Taxes Income Tax Disclosure [Text Block] Income Taxes Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents and Restricted Cash Disclosure of company's police regarding assets held for sale. Assets Held for Sale [Policy Text Block] Assets Held for Sale Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets Disclosure of material changes to the company's significant accounting policies previously disclosed. Significant Accounting Policies [Policy Text Block] Significant Accounting Policies New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Standards Restrictions on Cash and Cash Equivalents [Table Text Block] Reconciliation of Cash, Cash Equivalents, and Restricted Cash Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Information pertaining to collaborative agreements involving sponsored research and clinical trials of pharmaceutical products or processes. Sponsored Research and Clinical Trial Agreements [Member] Sponsored research and clinical trial agreements Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] License, Clinical Trial and Sponsored Research Agreements Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Schedule of Clinical Trial and Sponsored Research Agreements Property, Plant and Equipment [Table Text Block] Schedule of Property, Plant and Equipment Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of Accounts Payable and Accrued Expenses Tabular disclosure of information pertaining to interest expense. Schedule of Interest Expense [Table Text Block] Schedule of components in interest expense Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Restricted Stock [Member] Unvested restricted stock awards Restricted stock award Restricted Stock Units (RSUs) [Member] Unvested restricted stock units Restricted stock units Share-Based Compensation

Arrangement by Share-Based Payment Award [Line Items] Stockholders' Equity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Option Activities Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Schedules of Restricted Stock and Restricted Stock Unit Activity Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Schedule of Stock-Based Compensation Expense Summary of warrant activities [Table Text Block] Summary of warrant activities [Table Text Block] Summary of Warrant Activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Potentially Dilutive Securities Lease, Cost [Table Text Block] Schedule of information about operating leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Maturities of operating leases excluding short term leases Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Number of positions eliminated period percent Stock Issued During Period, Shares, New Issues Issuance of common shares (in shares) Number of common stock agreed to issue and sell Shares Issued, Price Per Share Price per common stock Shares issued, price per share Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued Class of Warrant or Right, Exercise Price of Warrants or Rights Warrant exercise price (in dollars per share) Exercise price of warrant Warrants and Rights Outstanding, Term Warrants expiration term Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group, Held-for-Sale, Not Discontinued Operations [Member] Assets held for sale, not discontinued operations Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current Property, plant and equipment, held for sale Product and Service [Axis] Product and Service [Domain] Information pertaining to City of hope, a pharmaceutical product or process. City of Hope [Member] Information pertaining to Il13r2, a pharmaceutical product. IL13Ra2 (MB-101) [Member] Information pertaining to CS1, a pharmaceutical product or process. CS1 (MB-104) [Member] Information pertaining to PSCA, a pharmaceutical product or process. PSCA (MB-105) [Member] Represents information pertaining to CD20 Technology License. CD20 (MB-106) [Member] Information pertaining to St Jude - XSCID, a pharmaceutical product or process. ST. Jude - XSCID [Member] RAG1 SCID (MB-110) [Member] RAG1 SCID (MB-110) [Member] Counterparty Name [Axis] Counterparty Name [Domain] Information pertaining to City Of Hope National Medical Center ("COH"), a counterparty in agreement(s) with the entity. City of Hope National Medical Center ("COH") [Member] City of Hope National Medical Center Information pertaining to Fred Hutchinson Cancer Research Center, a counterparty in agreement(s) with the entity. Fred Hutchinson Cancer Center [Member] Fred Hutchinson Cancer Center St. Jude Children's Research Hospital [Member] St. Jude Children's Research Hospital [Member] St. Jude Children's Research Hospital Mayo Clinic [Member] Mayo Clinic [Member] Mayo Clinic Leiden University Medical Centre [Member] Leiden University Medical Centre [Member] Leiden University Medical Center Amount of net expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Research and Development Expense, Net (Excluding Acquired in Process Cost) Research and development for sponsored research and clinical trial agreements Information pertaining to IL13Ra2 CAR C134, a pharmaceutical product. IL13Ra2 CAR and (C134) [Member] Car T Technology Product or Process [Member] Car T Technology [Member] Maximum [Member] Maximum The amount of milestones payable under the arrangement. Milestones Payable Under The Arrangement Milestones payable The amount of additional milestones payable under the arrangement. Additional Milestones Payable Under Arrangement Additional milestone payments The amount of contribution to be paid toward patient costs. Contribution Toward Patient Costs Contribution toward patient costs The amount of contribution to be paid per patient under the arrangement. Research Arrangement, Contribution Per Patient Contribution per patient The term of the research arrangement. Research Arrangement Term Agreement term The amount of annual maintenance fee payable under the arrangement. Annual Maintenance Fee Payable Annual maintenance fee payable Represents total payments for reimbursable expenses over the lifetime of the agreement. Reimbursement Of Fees, Total Payments Total reimbursement payments made Related Party Transaction [Table] Majority-Owned Subsidiary, Nonconsolidated [Member] Parent Company Management Services Agreement [Member]. Management Services Agreement [Member] Management Services Agreement (MSA) Second Amended and Restated Founders Agreement [Member]. Second Amended and Restated Founders Agreement [Member] Founders Agreement Fortress Biotech, Inc [Member] Fortress Biotech, Inc Related Party Transaction [Line Items] Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses Percentage of Annual Fees Expenses Related to Management Services Agreement recorded in research and development expenses Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses Represents the percentage of diluted outstanding equity paid as equity fee or used to calculate stock issuance to maintain parity. Diluted Outstanding Equity, Percentage Percentage of fully diluted equity Operating Costs and Expenses Expenses from related party transaction Asset Acquisition [Table] Ubrigene Biosciences [Member]. Ubrigene Biosciences [Member] uBriGene Asset Acquisition [Axis] Asset Acquisition [Domain] Represents information pertaining to Asset Purchase Agreement with uBriGene (Boston) Biosciences, Inc. Asset Purchase Agreement with Ubrigene Biosciences [Member] June 2024 Repurchase of Assets Asset Acquisition [Line Items] The amount of sale of property, plant and equipment considered deferred income. Sale of Property, Plant and Equipment, Deferred Income Sale consideration considered deferred income Payments to Acquire Productive Assets Purchase price Amount of upfront consideration recognized as part of consideration transferred in asset acquisition. Asset Acquisition, Consideration Transferred, Upfront Payment Upfront payment Represents the due period for upfront payment from Effective Date in an asset acquisition. Asset Acquisition, Consideration Transferred, Upfront Payment, Due Period from Effective Date Upfront payment, due period from Effective Date Amount of subsequent consideration recognized as part of consideration transferred in asset acquisition. Asset Acquisition, Consideration Transferred, Subsequent Payment Subsequent payment Represents the due period for deferred payment from Effective Date in an asset acquisition. Asset Acquisition, Consideration Transferred, Deferred Payment, Due Period from Closing Date Subsequent amount, due period from closing date Amount of net assets below this threshold, then the Company may, upon written notice to uBriGene, elect to delay its payment obligation of the Deferred Amount by an additional six (6) months, with no limit on the number of such extensions available to the Company. Net Assets Threshold to Delay Consideration Payment Obligation Amount of net assets below this threshold, the Company may elect to delay payment obligation by additional six months Represents the extension term for delay in payment of deferred payment. Asset Acquisition, Consideration Transferred, Deferred Payment, Extension Term Extension term for deferred payment Represents percentage of interest accrual on outstanding liability of deferred payment in asset acquisition transaction. Asset Acquisition, Consideration Transferred, Deferred Payment, Interest Rate on Outstanding Liability Interest rate on outstanding Deferred Amount Represents the period starts accruing interest for deferred payment from Effective Date in an asset acquisition. Asset Acquisition, Deferred Payment Accrue Interest, Period from Closing Date Rate of interest accrual on Deferred Amount not paid in full after 12 months Amount of net receivables to forgive under Asset Purchase Agreement. Asset Acquisition, Net Receivables, Forgiveness Amount of net receivables to forgive under Asset Purchase Agreement Amount of receivables recognized at acquisition date in asset acquisition. Asset Acquisition, Receivables Outstanding receivables Amount of payables recognized at acquisition date in asset acquisition. Asset Acquisition, Payable Outstanding payables Asset Acquisition, Consideration Transferred Total purchase consideration Amount of fair value less costs to sell provided from valuation services in asset acquisition. Asset Acquisition, Net Realizable Value, Amount Fair value provided from valuation services less costs to sell Amount of purchase consideration allocated to the supplies repurchased in asset acquisition. Asset Acquisition, Purchase Consideration Allocated to Supplies Repurchased Purchase consideration allocated to the supplies repurchased Amount of the supplies repurchased with no alternative future use were recognized as research and development expense. Asset Acquisition, Supplies Repurchased, No Alternative Future Use, Recognized as Research and Development Expense Supplies repurchased with no alternate future use recognized as research and development expense Amount of the supplies repurchased with alternative future use were recognized as research and development expense. Asset Acquisition, Supplies Repurchased, Alternative Future Use, Recognized as Research and Development Expense Supplies repurchased with alternate future use recognized as research and development expense Represents the number of parties obligated to terminate agreements. Number of Parties Obligated To Terminate Agreements Number of parties obligated to terminate agreements The term of the equipment assets purchased. Equipment Assets Purchased Term Equipment assets purchased term Property, Plant and Equipment [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Leasehold Improvements [Member] Leasehold improvements Construction in Progress [Member] Construction in process Property, Plant and Equipment [Line Items] Property and Equipment Property, Plant and Equipment, Useful Life Estimated useful life Property, Plant and Equipment, Gross Total property, plant and equipment Amount of impairment loss. Accumulated Impairment Loss, Property Plant and Equipment Less: impairment loss Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation Impairment of Leasehold Impairment of leasehold improvements Operating Lease, Impairment Loss Impairment on the right-of-use asset Accounts Payable, Current Accounts payable Carrying value as of the balance sheet date of obligations incurred and payable for research and development. Research and Development Current Accrued research and development Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued compensation. Accrued Compensation Current Accrued compensation Other Accounts Payable and Accrued Liabilities Other Amount of accrued consideration in asset acquisition, classified as current. Asset Acquisition, Accrued Consideration, Current Accrued consideration for the uBriGene Asset Purchase Agreement Debt Instrument [Axis] Debt Instrument, Name [Domain] Information pertaining to the long-term debt facility with Runway Growth Capital LLC. Runway Debt Facility Variable Rate [Axis] Variable Rate [Domain] Base Rate [Member] Base Rate Interest rate at which a bank borrows funds from other banks in the London interbank market. LIBOR London Interbank Offered Rate [Member] Three month LIBOR Repayments of Long-Term Lines of Credit Payoff amount of debt facility Debt Instrument, Basis Spread on Variable Rate Variable interest rate floor (as a percent) Debt Instrument, Interest Rate During Period Interest rate during period Interest Expense, Other Interest expense Amount of debt discount amortization included in interest expense. Interest Expense, Amortization Of Debt Discount Amortization of Debt Discount Other Nonoperating Expense Other Sale of Stock [Axis] Sale of Stock [Domain] Information pertaining to issuances of stock offered on an At The Market basis. At the Market Offering [Member] At the Market Offering Registration Statements [Member] Registration Statements [Member] Registration Statements Registration Statements, 2021 S-3 [Member] Registration Statements, 2021 S-3 [Member] 2021 S-3 Registration Statements, 2024 S-3 [Member] Registration Statements, 2024 S-3 [Member] 2024 S-3 Sale of Stock aggregate offering price permitted by agreement. Sale of Stock aggregate offering price permitted by agreement Sale of Stock aggregate offering price Common Stock Shares Available For Future Issuance Value Common Stock Shares Available For Future Issuance Value Shares available for future issuance Percentage of commission rate on gross sale of common stock. Commission Rate Percentage Agent commission (as a percent) Stockholders' Equity. Represents information pertaining to May 2024 public offering. May 2024 Public Offering [Member] May 2024 Public Offering Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents the information pertaining to existing warrants. Existing Warrants [Member] Existing Warrants Represents the information pertaining to series A-3 warrants. Series A3 Warrant [Member] Series A-3 Warrant Represents the information pertaining to series A-2 warrants. Series A2 Warrant [Member] Series A-2 Warrant Represents the information pertaining to series A-1 warrants. Series A1 Warrant [Member] Series A-1 Warrant Represents the information pertaining to prefunded warrants. Prefunded Warrants [Member] Prefunded Warrants Scenario [Axis] Scenario [Domain] Forecast [Member] Class of Stock [Line Items] Stockholders' Equity Sale of Stock, Number of Shares Issued in Transaction Number of common stock agreed to issue and sell Sale of Stock, Price Per Share Price per share Number of warrant or right may be converted. Class of Warrant Converted Number of warrant to converted Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of common stock, each warrant get converted Denotes the price per warrant. Class of Warrant or Right, Warrant Price Price per warrant Sale of Stock, Consideration Received on Transaction Net proceeds of offering Represents the member information pertaining to June 2024 registered direct offering. June 2024 Registered Direct Offering [Member] June 2024 Registered Direct Offering Private Placement [Member] Private Placement Represents information pertaining to private placement warrants. Private Placement Warrants [Member] Private Placement Warrants Represents information pertaining to wainwright warrants. Wainwright Warrants [Member] Represents the amount per share to be reduced from offering price for calculating the offering price of warrants. Offering Price of Warrants Calculation, Amount Per Share to be Reduced from Offering Price Amount per share to be reduced from offering price Exercise price of warrants expressed as percentage of purchase price of common stock. Class of Warrant or Right, Exercise Price, Purchase Price of Common Stock, Percentage Purchase Price of Common Stock, Percentage Cash received on stock transaction after deduction of issuance costs, for general corporate purposes and working capital requirements. Sale of Stock, Consideration Received on Transaction, for Specific Purposes Proceeds for general corporate purposes and working capital requirements Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Additional shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Shares available for grant Employee stock purchase plan, predetermined offering period, lower fair market value percentage. Employee Stock Purchase Plan, Predetermined Offering Period, Lower Fair Market Value Percentage Predetermined offering period, lower fair market value percentage Common Stock, Capital Shares Reserved for Future Issuance Shares available for future sale Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Options rollforward Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Options, Outstanding, Number, Ending Balance Stock Options, Outstanding, Number, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Options vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price, Ending Weighted Average Exercise Price, Beginning Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price, options vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Options vested and exercisable (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized share-based compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Restricted stock and RSU rollforward Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Nonvested, Number, Ending Balance Nonvested, Number, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Nonvested, Ending Balance Nonvested, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Weighted average vesting period (in years) Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] General and Administrative Expense [Member] General and administrative Research and Development Expense [Member] Research and development Class of Warrant or Right [Table] Represents the information pertaining to unregistered warrants. Unregistered Warrants [Member] Unregistered Warrants Represents the information pertaining to placement agents warrants. Placement Agents Warrants [Member] Placement Agents Warrants Represents the information about October registered direct offering. October Registered Direct Offering [Member] October Registered Direct Offering Represents the information about May and June registered direct offering. May And June Registered Direct Offering [Member] May and June Registered Direct Offering Class of Warrant or Right [Line Items] Stockholders' Equity Class of Warrant or Right, Outstanding Warrants outstanding, ending Warrants outstanding, beginning The number of warrants or rights exercised during the period. Class Of Warrant Or Right, Warrants Exercised During The Period Warrants

exercised The number of warrants or rights granted during the period. Class Of Warrant Or Right Warrants Granted During The Period Warrants granted Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants that were granted during the period. Class Of Warrant Or Right, Weighted Average Exercise Price, Grants During The Period Warrant exercise price, grants during the period (in dollars per share) Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants that were exercised during the period. Class Of Warrant Or Right Weighted Average Exercise Price Exercised During The Period Warrant exercise price, exercised during the period (in dollars per share) The weighted average remaining contractual life for warrants outstanding. Class Of Warrant Or Right Weighted Average Remaining Contractual Life Warrants outstanding, remaining contractual life The weighted average remaining contractual life for warrants granted during the period. Class Of Warrant Or Right Weighted Average Remaining Contractual Life, Grants In Period Warrants granted, remaining contractual life Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member] Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive securities Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Commitments and Contingencies Gain (Loss) on Termination of Lease Termination fee Operating Lease, Liability Operating lease liability Operating lease liabilities Lease, Cost [Abstract] Lease cost Operating Lease, Cost Operating lease cost Amount of variable lease cost, net, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. Variable Lease, Cost, Net Variable lease cost Lease, Cost Total Operating Lease, Payments Operating cash flows from operating leases Amount of gain (loss) on modification of lease before expiration of lease term. Gain (Loss) on Modification of Lease Gain on lease modification Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term - operating leases Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate - operating leases Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Year ended December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Year ended December 31, 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Year ended December 31, 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Year ended December 31, 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Year ended December 31, 2028 Lessee, Operating Lease, Liability, to be Paid, after Year Five Thereafter Lessee, Operating Lease, Liability, to be Paid Total Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less present value discount EX-101.PRE 10 tmb-20240630_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Aug. 09, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Jun. 30, 2024 Â Document Transition Report false Â Securities Act File Number 001-38191 Â Entity Registrant Name MUSTANG BIO,Â INC. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 47-3828760 Â Entity Address, Address Line One 377 Plantation Street Â Entity Address, City or Town Worcester Â Entity Address, State or Province MA Â Entity Address, Postal Zip Code 01605 Â City Area Code 781 Â Local Phone Number 652-4500 Â Title of 12(b) Security Common Stock, par value $0.0001 per share Â Trading Symbol MBIO Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Central Index Key 0001680048 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Amendment Flag false Â Class A common shares Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding Â 845,385 Common shares Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding Â 36,387,236 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance Sheets (Unaudited) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Current Assets: Â Â Cash and cash equivalents $ 4,268 $ 6,234 Other receivables 728 3,879 Prepaid expenses and other current assets 114 1,233 Property, plant and equipment, held for sale 2,209 0 Total current assets 7,319 11,346 Property, plant and equipment, net 472 3,247 Restricted cash 375 750 Other assets 250 833 Operating lease right-of-use asset, net 103 1,566 Total Assets 8,519 17,742 Current Liabilities: Â Â Accounts payable and accrued expenses 13,190 14,017 Payables and accrued expenses - related party $ 2,304 $ 834 Other Liability, Current, Related Party [Extensible Enumeration] Related Party [Member] Related Party [Member] Operating lease liabilities - short-term $ 429 $ 520 Total current liabilities 15,923 15,371 Deferred income 270 270 Operating lease liabilities - long-term 656 1,978 Total Liabilities 16,849 17,619 Commitments and Contingencies (Note 12) Stockholders' Equity Â Â Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 0 0 Common stock issuable, zero and 419,089 shares as of June 30, 2024 and December 31, 2023, respectively 0 591 Additional paid-in capital 386,028 380,502 Accumulated deficit (394,361) (380,971) Total Stockholders' Equity (8,330) 123 Total Liabilities and Stockholders' Equity 8,519 17,742 Class A common shares Â Â Stockholders' Equity Â Â Common stock ($0.0001 par value), 200,000,000 shares authorized as of June 30, 2024 and December 31, 2023, respectively 0 0 Common shares Â Â Stockholders' Equity Â Â Common stock ($0.0001 par value), 200,000,000 shares authorized as of June 30, 2024 and December 31, 2023, respectively $ 3 $ 1 X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 15 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4 + Details Name: us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMonetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2 + Details Name: us-gaap_CommonStockSharesSubscriptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section

50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates status and type of related party for liability classified as other and current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionAmount due from parties in nontrade transactions, classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed

earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance Sheets (Unaudited) (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Preferred stock par value (in dollars per share) $ 0.0001 $ 0.0001 Preferred stock, shares authorized 2,000,000 2,000,000 Preferred stock, shares issued 250,000 250,000 Preferred stock, shares outstanding 250,000 250,000 Common stock par value (in dollars per share) $ 0.0001 $ 0.0001 Common stock, shares authorized 200,000,000 200,000,000 Common stock, shares issuable 0 419,089 Class A common shares Â Â Common stock, shares issued 845,385 845,385 Common stock, shares outstanding 845,385 845,385 Common shares Â Â Common stock, shares issued 34,098,059 8,374,869 Common stock, shares outstanding 34,098,059 8,374,869 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesSubscribedButUnissued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Statements of Operations (Unaudited) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Operating expenses: Â Â Â Â Research and development $ 4,360 $ 10,836 $ 8,164 $ 24,836 Asset impairment 2,649 0 2,649 0 General and administrative 1,531 3,055 2,958 5,376 Total operating expenses 8,540 13,891 13,771 30,212 Loss from operations (8,540) (13,891) (13,771) (30,212) Other income (expense) Â Â Â Â Other income 314 429 314 780 Interest income 29 159 70 612 Interest expense (2) (2,932) (3) (4,108) Total other income (expense) 341 (2,344) 381 (2,716) Net Loss $ (8,199) $ (16,235) $ (13,390) $ (32,928) Net loss per common share outstanding, basic $ (0.35) $ (2.00) $ (0.78) $ (4.06) Net loss per common share outstanding, diluted $ (0.35) $ (2.00) $ (0.78) $ (4.06) Weighted average number of common shares outstanding, basic 23,123,178 8,127,473 17,090,705 8,110,661 Weighted average number of common shares outstanding, diluted 23,123,178 8,127,473 17,090,705 8,110,661 X - DefinitionThe amount of grant income, such as from governmental agencies in reimbursement of covered expenses, recognized during the period. + ReferencesNo definition available. + Details Name: mbio_GrantIncome Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -

Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income earned from interest bearing assets classified as other. + ReferencesNo definition available. + Details Name: us-gaap_InterestIncomeOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands Class A Preferred Shares Preferred Stock Class A Common Shares Common Shares Common Shares Common Shares Common Stock Issuable Additional Paid-in Capital Accumulated Deficit Total Balances at Dec. 31, 2022 Â Â $ 11 $ 1,109 $ 374,522 $ (329,369) $ 46,273 Balances (in shares) at Dec. 31, 2022 250,000 845,385 7,100,111 Â Â Â Â Issuance of common shares - Founders Agreement Â Â Â (1,109) 1,109 Â Â Issuance of common shares - Founders Agreement (in shares) Â Â 187,134 Â Â Â Â Issuance of common shares under ESPP Â Â Â Â 88 Â 88 Issuance of common shares under ESPP (in shares) Â Â 12,642 Â Â Â Â Stock-based compensation expenses Â Â Â Â 280 Â 280 Stock-based compensation expenses (in shares) Â Â 22,097 Â Â Â Â Exercise of warrants (in shares) Â Â 93 Â Â Â Â Reverse Split (15:1) adjustment Â Â $ (10) Â 10 Â Â Fractional share adjustment (in shares) Â Â (1,633) Â Â Â Â Net Income (Loss) Â Â Â Â Â (32,928) (32,928) Balances at Jun. 30, 2023 Â Â $ 1 Â 376,009 (362,297) 13,713 Balances (in shares) at Jun. 30, 2023 250,000 845,385 7,320,444 Â Â Â Â Balances at Mar. 31, 2023 Â Â $ 1 Â 375,876 (346,062) 29,815 Balances (in shares) at Mar. 31, 2023 250,000 845,385 7,293,242 Â Â Â Â Issuance of common shares under ESPP Â Â Â Â 88 Â 88 Issuance of common shares under ESPP (in shares) Â Â 12,642 Â Â Â Â Stock-based compensation expenses Â Â Â Â 45 Â 45 Stock-based compensation expenses (in shares) Â Â 16,193 Â Â Â Â Fractional share adjustment (in shares) Â Â (1,633) Â Â Â Â Net Income (Loss) Â Â Â Â Â (16,235) (16,235) Balances at Jun. 30, 2023 Â Â $ 1 Â 376,009 (362,297) 13,713 Balances (in shares) at Jun. 30, 2023 250,000 845,385 7,320,444 Â Â Â Â Balances at Dec. 31, 2023 Â Â $ 1 591 380,502 (380,971) 123 Balances (in shares) at Dec. 31, 2023 250,000 845,385 8,374,869 Â Â Â Â Issuance of common shares - Founders Agreement Â Â Â (477) 640 Â 163 Issuance of common shares - Founders Agreement (in shares) Â Â 928,277 Â Â Â Â Issuance of common shares, net of offering costs - Public Offerings Â Â Â $ (114) 5,379 Â 5,265 Issuance of common shares, net of offering costs - Public Offerings (in shares) Â Â 4,251,003 Â Â Â Â Issuance of common shares under ESPP Â Â Â Â 48 Â $ 48 Issuance of common shares under ESPP (in shares) Â Â 47,463 Â Â Â 128,352 Stock-based compensation expenses Â Â Â Â (542) Â $ (542) Stock-based compensation expenses (in shares) Â Â 5,573 Â Â Â Â Exercise of warrants Â Â $ 2 Â 1 Â 3 Exercise of warrants (in shares) Â Â 20,490,874 Â Â Â Â Net Income (Loss) Â Â Â Â Â (13,390) (13,390) Balances at Jun. 30, 2024 Â Â $ 3 Â 386,028 (394,361) (8,330) Balances (in shares) at Jun. 30, 2024 250,000 845,385 34,098,059 Â Â Â Â Balances at Mar. 31, 2024 Â Â $ 1 Â 381,218 (386,162) (4,943) Balances (in shares) at Mar. 31, 2024 250,000 845,385 9,545,541 Â Â Â Â Issuance of common shares - Founders Agreement Â Â Â 163 Â 163 Issuance of common shares - Founders Agreement (in shares) Â Â 575,191 Â Â Â Â Issuance of common shares, net of offering costs - Public Offerings Â Â Â Â 5,265 Â 5,265 Issuance of common shares, net of offering costs - Public Offerings (in shares) Â Â 4,185,000 Â Â Â Â Issuance of common shares under ESPP (in shares) Â Â 5,689 Â Â Â Â Stock-based compensation expenses Â Â Â Â (619) Â (619) Exercise of warrants Â Â $ 2 Â 1 Â 3 Exercise of warrants (in shares) Â Â 19,786,638 Â Â Â Â Net Income (Loss) Â Â Â Â Â (8,199) (8,199) Balances at Jun. 30, 2024 Â Â $ 3 Â $ 386,028 $ (394,361) $ (8,330) Balances (in shares) at Jun. 30, 2024 250,000 845,385 34,098,059 Â Â Â Â X - DefinitionThe amount of additions (reductions) to additional paid-in capital during the period attributable to reverse stock splits. + ReferencesNo definition available. + Details Name: mbio_AdditionsReductionsToAdditionalPaidInCapitalReverseStockSplits Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares adjusted due to fractional shares being issued. + ReferencesNo definition available. + Details Name: mbio_FractionShareAdjustmentInShares Namespace Prefix: mbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares issued on exercise of warrants. + ReferencesNo definition available. + Details Name: mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants Namespace Prefix: mbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe value of shares issued on exercise of warrants. + ReferencesNo definition available. + Details Name: mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued at the public offering. + ReferencesNo definition available. + Details Name: mbio_StockIssuedDuringPeriodSharesAtPublicOffering Namespace Prefix: mbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued at the public offering. + ReferencesNo definition available. + Details Name: mbio_StockIssuedDuringPeriodValueAtPublicOffering Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash Flows from Operating Activities: Â Â Net loss $ (13,390) $ (32,928) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Issuance of common shares - Equity fee on public offerings to Fortress Biotech 163 0 Stock-based compensation expenses (542) 280 Depreciation expense 569 1,291 Amortization of debt discount 0 118 Amortization of operating lease right-of-use assets 128 204 Loss on disposal of property and equipment 29 0 Asset impairment 2,649 0 Loss on extinguishment of debt 0 2,796 Gain on lease modification (314) (220) Changes in operating assets and liabilities: Â Â Prepaid expenses and other assets 672 325 Accounts payable and accrued expenses 981 (2,022) Payable and accrued expenses - related party 1,470 5 Lease liabilities (238) (85) Net cash used in operating activities (7,656) (30,200) Cash Flows from Investing Activities: Â Â Purchase of fixed assets 0 (34) Net cash from investing activities 0 (34) Cash Flows from Financing Activities: Â Â Payment of debt 0 (30,375) Proceeds from issuance of common shares - public offerings 5,944 0 Offering costs for the issuance of common shares - public offerings (680) 0 Proceeds from exercise of warrants 3 0 Proceeds from issuance of common shares under ESPP 48 88 Net cash provided by financing activities 5,315 (30,287) Net change in cash, cash equivalents and restricted cash (2,341) (60,521) Cash, cash equivalents and restricted cash, beginning of the period 6,984 76,656 Cash, cash equivalents and restricted cash, end of the period 4,643 16,135 Supplemental disclosure of cash flow information: Â Â Cash paid for interest 0 1,340 Supplemental disclosure of noncash activities: Â Â Issuance of common shares - Founders Agreement and Equity fee to Fortress 591 1,109 Transfer of assets classified as held for sale 0 4,348 Related Party Â Â Changes in operating assets and liabilities: Â Â Other receivables 0 36 Non related party Â Â Changes in operating assets and liabilities: Â Â Other receivables $ 167 $ 0 X - DefinitionAmount of gain (loss) on modification of lease before expiration of lease term. + ReferencesNo definition available. + Details Name: mbio_GainOnLeaseModification Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid excluding those attributable to related parties. + ReferencesNo definition available. + Details Name: mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of Increase Decrease In Lease Liabilities. + ReferencesNo definition available. + Details Name: mbio_IncreaseDecreaseInLeaseLiabilities Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIt Represents issuance of common stock for equity fee on public offering. + ReferencesNo definition available. + Details Name: mbio_IssuanceOfCommonSharesEquityFeeOnPublicOffering Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of assets transferred from PP&E to held for sale. + ReferencesNo definition available. + Details Name: mbio_TransferOfAssetsClassifiedAsHeldForSale Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDueToRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in receivables classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards

Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of stock issued in noncash financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_StockIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Statements of Cash Flows - Non-Cash Activities (Unaudited) (Parenthetical) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Supplemental disclosure of noncash activities related to the uBriGene Repurchase Transaction (see Note 5): Â Â Fair value of assets received $ 2,209 $ 0 Fair value of supplies received expensed to research and development 2,509 0 Accounts receivable written off (6,967) 0 Accounts payable written off 3,644 0 Net purchase consideration of assets recorded to accrued other $ (1,395) $ 0 X - DefinitionThe amount of accounts payable written off in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period n cash receipts or cash payments in the period. + ReferencesNo definition available. + Details Name: mbio_NoncashOrPartNoncashAcquisitionAccountsPayableWrittenOff Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of accounts receivable written off in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period n cash receipts or cash payments in the period. + ReferencesNo definition available. + Details Name: mbio_NoncashOrPartNoncashAcquisitionAccountsReceivableWrittenOff Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net purchase consideration of assets recorded to accrued other in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period n cash receipts or cash payments in the period. + ReferencesNo definition available. + Details Name: mbio_NoncashOrPartNoncashAcquisitionPurchaseConsiderationAccrued Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of supplies received, expensed to research and development, that an Entity acquires in a noncash (or part noncash) acquisition. + ReferencesNo definition available. + Details Name: mbio_NoncashOrPartNoncashAcquisitionSuppliesReceivedExpensedToResearchAndDevelopment

Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization, Description of Business and Liquidity and Capital Resources 6 Months Ended Jun. 30, 2024 Organization, Description of Business and Liquidity and Capital Resources Â Organization, Description of Business and Liquidity and Capital Resources NoteÂ 1Â - Organization, Description of Business and Liquidity and Capital ResourcesMustang Bio,Â Inc. (the â€œCompanyâ€ or â€œMustangâ€) was incorporated in Delaware on MarchÂ 13, 2015. Mustang is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers and solid tumors. The Company may acquire rights to these technologies by licensing the rights or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.The Company is a majority-controlled subsidiary of Fortress Biotech,Â Inc. (â€œFortressâ€ or â€œParentâ€).Liquidity and Capital ResourcesThe Company has incurred substantial operating losses and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of JuneÂ 30,Â 2024, the Company had an accumulated deficit of $394.4 million.The Company has funded its operations to date primarily through the sale of equity and via debt raises. The Company expects to continue to use the proceeds from its previous financing transactions and asset sale primarily for working capital and general corporate purposes. The Company will require substantial additional financings through equity and debt offerings, collaborations and licensing arrangements or other sources to fully develop, prepare regulatory filings, obtain regulatory approvals and commercialize its existing product candidates. The continuation of our business as a going concern is dependent upon raising additional capital and eventually attaining and maintaining profitable operations.â€‹In accordance with Accounting Standards Codification (â€œASCâ€) 205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these unaudited consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of managementâ€™s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Companyâ€™s ability to continue as a going concern. The mitigating effect of managementâ€™s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entityâ€™s ability to continue as a going concern within one year after the date that these unaudited financial statements are issued. In performing its evaluation, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipt of potential funding from future equity or debt issuances cannot be considered probable at this time because these plans are not entirely within the Companyâ€™s control nor have been approved by the Board of Directors as of the date of these financial statements.The Company's expectation to generate operating losses and negative operating cash flows in the future, and the need for additional funding to support its planned operations raise substantial doubt regarding the Companyâ€™s ability to continue as a going concern for a period of one year after the date that these unaudited financial statements are issued. The Company made strategic decisions, including a significant reduction in the workforce by approximately 81% in April 2024, and also in April 2024, terminated certain license agreements with St. Jude and Leiden University Medical Centre, and with Mayo Clinic in June 2024, to preserve capital and prioritize the allocation of resources. The Company continues to pursue additional cash resources through public or private equity or debt financings. The Company has concluded that substantial doubt exists about the Companyâ€™s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these unaudited financial statements.â€‹The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary if the Company is unable to continue as a going concern. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Significant Accounting Policies Â Significant Accounting Policies NoteÂ 2Â - Significant Accounting PoliciesBasis of PresentationThe accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œGAAPâ€) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the interim unaudited financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. They do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company's audited financial statements and notes thereto for the year ended December 31, 2023, which were included in the Companyâ€™s Annual Report on Form 10-K and filed with the Securities and Exchange Commission (â€œSECâ€) on March 11, 2024 (the â€œ2023 Form 10-Kâ€). The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.Use of EstimatesThe Companyâ€™s unaudited financial statements include certain amounts that are based on managementâ€™s best estimates and judgments. The Companyâ€™s significant estimates include, but are not limited to, assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Due to the uncertainty inherent in such estimates, actual results could differ from those estimates.Cash, Cash Equivalents and Restricted Cashâ€‹The Company records cash held in an escrow account as a security deposit for the manufacturing facility in Worcester, Massachusetts, as restricted cash. â€‹The following table provides a reconciliation of cash, cash equivalents, and restricted cash from the Unaudited Balance Sheets to the Unaudited Statements of Cash Flows for the six months ended JuneÂ 30,Â 2024, and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â ($ in thousands)2024â€‹2023Cash and cash equivalents$ 4,268â€‹$ 15,385Restricted cash 375â€‹ 750Total cash, cash equivalents and restricted cash$ 4,643â€‹$ 16,135â€‹Assets Held for Saleâ€‹Assets held for sale represent assets that have met the criteria of â€œheld for saleâ€ accounting, as specified by Accounting Standards Codification (â€œASCâ€) 360, â€œLong-lived Assets.â€ As of June 30, 2024, there were $2.2 million of lab and cell processing equipment, furniture and fixtures and computer equipment that are recorded as assets held for sale. The effect of suspending depreciation on the assets held for sale is immaterial to the results of operations. The assets held for sale are part of the repurchase of assets from uBriGene (see Note 6). â€‹â€‹Impairment of Long-Lived Assetsâ€‹The Company reviews long-lived assets, including tangible assets and other intangible assets with definitive lives, for impairment whenever events or changes in circumstances indicate that the assetâ€™s carrying amount may not be recoverable. The Company conducts its long-lived asset impairment analyses in accordance with ASC 360-10, "Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires the Company to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset group is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals.Â â€‹Significant Accounting PoliciesThere have been no material changes to the Companyâ€™s significant accounting policies previously disclosed in the 2023 Form 10-K. Recently Issued Accounting StandardsAs of JuneÂ 30,Â 2024, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2023 Form 10-K that affect the Companyâ€™s present or future results of operations, overall financial condition, liquidity, or disclosures upon adoption. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Clinical Trial and Sponsored Research Agreements 6 Months Ended Jun. 30, 2024 Clinical Trial and Sponsored Research Agreements Â Clinical Trial and Sponsored Research Agreements NoteÂ 3Â - Clinical Trial and Sponsored Research AgreementsResearch and Development ExpensesÂ - Sponsored Research and Clinical Trial AgreementsFor the three and six months ended JuneÂ 30,Â 2024 and 2023, the Company recorded the following expenses in research and development for sponsored research and clinical trial agreements in the Unaudited Statements of Operations pursuant to the terms of these agreements:â€‹â€‹â€‹â€‹â€‹â€‹â€‹

release of liability and forgiveness by Mayo Clinic of all amounts previously owed by the Company. X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ResearchAndDevelopmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Agreements 6 Months Ended Jun. 30, 2024 Related Party Agreements Â Related Party Agreements NoteÂ 4Â - Related Party AgreementsFounders Agreement and Management Services Agreement with FortressWith respect to the Companyâ€™s Management Services Agreement (the â€œManagement Services Agreementâ€) with Fortress for the three and six months ended JuneÂ 30,Â 2024 and 2023, expenses related to the MSA are recorded 50% in research and development expenses and 50% in general and administrative expenses in the Unaudited Statements of Operations. For the three months ended JuneÂ 30,Â 2024 and 2023, the Company recorded expense of $0.1 million and $0.1 million, respectively, related to the MSA. For the six months ended June 30, 2024 and 2023, the Company recorded expense of $0.3 million and $0.3 million, respectively.Under the terms of the Second Amended and Restated Founders Agreement (the â€œFounders Agreementâ€), which became effective JulyÂ 22, 2016, Fortress will receive a grant of shares of the Companyâ€™s common stock equal to two and one-halfÂ percent (2.5%) of the gross amount of any equity or debt financing. Â For the six months ended JuneÂ 30,Â 2024, the Company issued 575,191 shares to Fortress in connection with the equity financings. For the three months ended JuneÂ 30,Â 2024 and 2023, the Company recorded expense of approximately $163,000 and zero, respectively, in general and administrative expenses related to these shares. For the six months ended JuneÂ 30,Â 2024 and 2023, the Company recorded expense of approximately $163,000 and zero, respectively, in general and administrative expenses related to these shares.Annual Stock Dividendâ€‹Pursuant to the Companyâ€™s Amended and Restated Certificate of Incorporation, as amended (the â€œCertificate of Incorporationâ€), the Company issued 353,086 shares of common stock to Fortress as the Annual Stock Dividend (as such term is defined in the Certificate of Incorporation), representing 2.5% of the fully-diluted outstanding equity of Mustang on January 2, 2024. This was recorded in the Statement of Stockholdersâ€™ Equity at December 31, 2023, as Common stock issuable â€“ Founders Agreement. The Company recorded an expense of approximately $0.5 million in research and development â€“ licenses acquired related to these issuable shares during the year ended December 31, 2023.Payables and Accrued Expenses Related Partyâ€‹In the normal course of business Fortress pays for certain expenses on behalf of the Company. Such expenses are recorded as payables and accrued expensesÂ - related party and are typically reimbursed to Fortress in the normal course of business. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Assets Purchase Agreements 6 Months Ended Jun. 30, 2024 Assets Purchase Agreements Â Assets Purchase Agreements Note 5 â€“ Assets Purchase Agreementsâ€‹Agreements with uBriGeneOn MayÂ 18, 2023, the Company entered into an Asset Purchase Agreement (the â€œOriginal Asset Purchase Agreementâ€) with uBriGene (Boston) Biosciences,Â Inc., a Delaware corporation (â€œuBriGeneâ€), pursuant to which the Company agreed to sell its leasehold interest in its cell processing facility located in Worcester, Massachusetts (the â€œFacilityâ€), and associated assets relating to the manufacturing and production of cell and gene therapies at the Facility to uBriGene (the â€œTransactionâ€). The Company and uBriGene subsequently entered into Amendment No.Â 1 to the Original Asset Purchase Agreement, dated as of JuneÂ 29, 2023 (â€œAmendment No.Â 1â€), and Amendment No.Â 2 to the Original Asset Purchase Agreement, dated as of JulyÂ 28, 2023 (â€œAmendment No.Â 2,â€ and together with the Original Asset Purchase Agreement and Amendment No.Â 1, the â€œPrior Asset Purchase Agreementâ€).Â On JulyÂ 28, 2023, pursuant to the Prior Asset Purchase Agreement, the Company completed the sale of all of its assets that primarily relate to the manufacturing and production of cell and gene therapies at the Facility (such operations, the â€œTransferred Operationsâ€ and such assets, the â€œTransferred Assetsâ€) to uBriGene for upfront consideration of $6 million cash (the â€œBase Amountâ€). The Transferred Assets included all of the Companyâ€™s assets, except for the Companyâ€™s lease and related leasehold improvements of the Facility and contracts that are primarily used in the Transferred Operations. The Company recorded a gain of $1.4Â million in connection with the sale of the Transferred Assets, and recorded approximately $0.3Â million of the base consideration as deferred income, that was to be recognized upon the transfer of the lease.Â Â In connection with the Prior Asset Purchase Agreement, the Company and uBriGene submitted a voluntary joint notice to the U.S. Committee on Foreign Investment in the United States (â€œCFIUSâ€). Following CFIUSâ€™s review and subsequent investigation of the transactions related to the Prior Asset Purchase Agreement, on MayÂ 13, 2024, the Company, together with uBriGene and CFIUS, executed a National Security Agreement (the â€œNSAâ€), pursuant to which the Company and uBriGene agreed to abandon the transactions related to the Prior Asset Purchase Agreement and the agreements entered into in connection therewith. The NSA obligated uBriGene and the Company to terminate agreements between the two parties, including the Manufacturing Services Agreement, Quality Services Agreement, and Subcontracting CDMO Agreement. In addition, uBriGene must sell, or otherwise dispose of, the equipment assets purchased within 180 days after the execution of the NSA.â€‹JuneÂ 2024 Repurchase of AssetsÂ On JuneÂ 27, 2024 (the â€œEffective Dateâ€), the Company entered into an Asset Purchase Agreement (the â€œRepurchase Agreementâ€) with uBriGene, pursuant to which the Company agreed, subject to the terms and conditions set forth therein, to repurchase the Transferred Assets, primarily lab equipment and supplies, (collectively, the â€œRepurchased Assetsâ€). Pursuant to the terms of the Repurchase Agreement, the Company and uBriGene also terminated existing manufacturing and services agreements. Â Â As consideration for the Repurchase Agreement, the Company agreed to pay to uBriGene a total purchase price (the â€œPurchase Priceâ€) of $1.4 million, consisting of (i)Â an upfront payment of $0.1 million due within five (5)Â business days of the Effective Date and a (ii)Â subsequent amount of $1.3 million due on the date that is twelve (12) months after the closing date (the â€œDeferred Amountâ€). In the event that as of the original (or any extended) date on which the Deferred Amount is payable, the Company has, as of the date of the public reporting of its then-most recent quarterly audited or unaudited financial statements, net assets below $20 million, then the Company may, upon written notice to uBriGene, elect to delay its payment obligation of the Deferred Amount by an additional six (6)Â months, with no limit on the number of such extensions available to the Company. Notwithstanding the foregoing, if the Company has not paid the Deferred Amount in full as of the date that is twelve (12) months after closingÂ of theÂ Repurchase Agreement, any amounts that remain outstanding will accrue interest at a rate of 5% per annum beginning on the date that is twelve (12) months after closing and until the Deferred Amount is paid in full. Additionally, in connection with the termination of the agreements described above under the Repurchase Agreement, the Company agreed to forgive a net receivable from uBriGene of approximately $3.3 million, comprised of outstanding receivables of $6.9 million and payables of $3.6 million, resulting in total purchase consideration in the Repurchase Transactions of approximately $4.7 million. As of June 30, 2024, the $1.4 million Purchase Price was recorded in Accrued Other Expenses (see Note 7). Â â€‹The Company allocated the total purchase consideration of $4.7 million to the Repurchased Assets on a relative fair value basis. The Company used a third-party to perform a valuation of the repurchased equipment, which resulted in a fair value less costs to sell of approximately $2.2 million. The remaining purchase consideration of $2.5 million was allocated to the supplies repurchased. The supplies repurchased with no alternative future use were recognized as research and development expense in an amount of $2.2 million. Â Repurchased supplies with an alternative future use of $0.3 million were also recognized in research and development expense, as the Company does not have plans to resume operations in the facility, and it intends to dispose of the supplies in a single transaction with the equipment. The Company concluded that the disposal group, which includes the repurchased equipment assets and associated supplies, with an aggregate value of approximately $2.2 million met the criteria to be classified as held for sale at the date of acquisition. â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_AssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property, Plant and Equipment, and Asset Impairment 6 Months Ended Jun. 30, 2024 Property, Plant and Equipment, and Asset Impairment Â Property, Plant and Equipment, and Asset Impairment NoteÂ 6Â â€“ Property, Plant and Equipment, and Asset ImpairmentAt JuneÂ 30,Â 2024, and DecemberÂ 31,Â 2023, property, plant and equipment consisted of the following:â€‹â€‹â€‹

thousands)Â Â Â Â 2024Â Â Â Â 2023â€‹2024Â Â Â Â 2023Interest expenseâ€‹$ â€”â€‹$ 133â€‹$ â€”â€‹$ 1,188Amortization of Debt Discountâ€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 118Loss on Extinguishmentâ€‹â€‹ â€”â€‹â€‹ 2,795â€‹â€‹ â€”â€‹â€‹ 2,794Otherâ€‹â€‹ 2â€‹â€‹ 4â€‹â€‹ 3â€‹â€‹ 8Total Interest Expenseâ€‹$ 2â€‹$ 2,932â€‹$ 3â€‹$ 4,108â€‹The Term Loan accrued interest at a variable annual rate equal toÂ 8.75% plus the greater of (i)Â 0.50% and (ii) the three month LIBOR Rate for U.S. dollar deposits; provided that the Applicable Rate would not be less thanÂ 9.25%. On December 7, 2022, the Company entered into the First Amendment (the â€œFirst Amendmentâ€) to the Loan Agreement by and between the Company and Runway. The First Amendment amended certain definitions and other provisions of the Loan Agreement to replace LIBOR-based benchmark rates applicable to loans outstanding under the Loan Agreement with SOFR-based rates, subject to adjustments as specified in the First Amendment. The Applicable Rate at March 31, 2023 wasÂ 13.77%. For the three and six months ended JuneÂ 30,Â 2023, the Company made interest payments of $0.3 million and $1.3 million, respectively, recorded in interest expense in the Unaudited Statements of Operations.â€‹Amortization of the debt discount associated with the Term Loan was approximately $0.1 million for the three and six months ended JuneÂ 30,Â 2023, and was recorded in interest expense in the Unaudited Statements of Operations.In addition, the Term Loan was secured by a lien on substantially all of the Companyâ€™s assets other than certain intellectual property assets and certain other excluded collateral, and it contained a minimum liquidity covenant and other covenants that included among other items: (i) limits on indebtedness, and (ii) repurchase of stock from employees, officers and directors. Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity 6 Months Ended Jun. 30, 2024 Stockholders' Equity Â Stockholders' Equity NoteÂ 9Â - Stockholdersâ€™ EquityRegistration StatementsOn April 23, 2021, the Company filed a shelf registration statement on Form S-3 (File No. 333-255476) (the â€œ2021 S-3â€), which was declared effective on May 24, 2021. Under the 2021 S-3, the Company was able to sell up to a total of $200.0 million of its securities. The 2021 S-3 expired on May 24, 2024. The Company sold approximately $4.4 million of securities under the 2021 S-3.On May 31, 2024, the Company filed a shelf registration statement on Form S-3 (File No. 333-279891) (the â€œ2024 S-3â€), which was declared effective on June 12, 2024. Under the 2024 S-3, the Company may sell up to a total of $40.0 million of its securities. As of June 30, 2024, approximately $37.5 million of the 2024 S-3 remains available for sales of securities. The 2024 S-3 expires on June 12, 2027.As of the filing of this Form 10-Q, the Company is subject to the General Instruction I.B.6 to Form S-3, known as the â€œbaby shelf rules,â€ which limit the number of securities it can sell under its registration statements on Form S-3.May 2024 Public Offeringâ€‹On April 29, 2024, the Company commenced a best efforts public offering with an institutional investor (the â€œInvestorâ€) (the â€œMay 2024 Offeringâ€) of an aggregate of (i) 1,160,000 shares of common stock, (ii) pre-funded warrants (the â€œMay 2024 Pre-Funded Warrantsâ€) to purchase up to an aggregate of 15,717,638 shares of common stock (the â€œMay 2024 Pre-Funded Warrant Sharesâ€), (iii) Series A-1 warrants (the â€œSeries A-1 Warrantsâ€) to purchase up to an aggregate of 16,877,638 shares of common stock (the â€œSeries A-1 Warrant Sharesâ€), (iv) Series A-2 warrants (the â€œSeries A-2 Warrantsâ€) to purchase up to an aggregate of 16,877,638 shares of common stock (the â€œSeries A-2 Warrant Sharesâ€), and (v) Series A-3 warrants (the â€œSeries A-3 Warrants,â€ and together with the Series A-1 Warrants and Series A-2 Warrants, the â€œWarrantsâ€) to purchase up to an aggregate of 16,877,638 shares of common stock (the â€œSeries A-3 Warrant Sharesâ€). Each share of common stock or May 2024 Pre-Funded Warrant was sold together with one Series A-1 Warrant to purchase one share of common stock, one Series A-2 Warrant to purchase one share of common stock, and one Series A-3 Warrant to purchase one share of common stock. The public offering price for each share of common stock and accompanying Warrants was $0.237, and the public offering price for each May 2024 Pre-Funded Warrant and accompanying Warrants was $0.2369. The May 2024 Pre-Funded Warrants have an exercise price of $0.0001 per share, were exercisable immediately and will expire when exercised in full. Each Warrant has an exercise price of $0.237 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Warrants (the â€œWarrant Stockholder Approvalâ€). The Series A-1 Warrant will expire on the five-year anniversary of the Warrant Stockholder Approval. The Series A-2 Warrant will expire on the twenty-four-month anniversary of the Warrant Stockholder Approval. The Series A-3 Warrant will expire on the nine-month anniversary of the Warrant Stockholder Approval. The Warrants contain customary anti-dilution adjustments to the exercise price, including for share splits, share dividends, rights offering and pro rata distributions.â€‹The net proceeds of the May 2024 Offering, after deducting the fees and expenses of the Placement Agent (as defined below), described in more detail below, and other offering expenses payable by us, but excluding the net proceeds, if any, from the exercise of the Warrants, was approximately $3.2 million. The May 2024 Offering closed on May 2, 2024.Â In connection with the May 2024 Offering, the Company also entered into a warrant amendment agreement (the â€œWarrant Amendment Agreementâ€) with the Investor. Under the Warrant Amendment Agreement, the Company agreed to amend certain existing warrants to purchase up to 2,588,236 shares of common stock that were previously issued in October 2023 to the Investor, with an exercise price of $1.58 per share (the â€œExisting Warrantsâ€), in consideration for their purchase of the securities in the May 2024 Offering, as follows: (i) lower the exercise price of the Existing Warrants to $0.237 per share, (ii) provide that the Existing Warrants, as amended, will not be exercisable until the receipt of Warrant Stockholder ApprovalÂ for the exercisability of the Warrants in the May 2024 Offering, and (iii) extend the original expiration date of the Existing Warrants by five years following the receipt of such Warrant Stockholder Approval. The Warrant Amendment Agreement became effective on May 2, 2024. â€‹June 2024 Registered Direct Offering and Concurrent Private Placement of Warrants (the â€œJune 2024 Offeringâ€)â€‹On June 19, 2024, the Company entered into a Securities Purchase Agreement (the â€œPurchase Agreementâ€) with an institutional investor (the â€œJune 2024 Investorâ€), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of Nasdaq (the â€œRegistered Direct Offeringâ€), (i) 3,025,000 shares of common stock, at a price per Share of $0.41 and (ii) pre-funded warrants (the â€œPre-Funded Warrantsâ€) to purchase up to 3,105,000 shares of our common stock, at a price per Pre-Funded Warrant equal to $0.4099, the price per share of common stock, less $0.0001.Â The Pre-Funded Warrants were sold, in lieu of shares of common stockÂ to the June 2024 Investor. The Pre-Funded Warrants have an exercise price of $0.0001 per share, became exercisable upon issuance and remain exercisable until exercised in full.Â The Registered Direct Offering closed on June 21, 2024. The Company intends to use the net proceeds of approximately $2.1 million from the Registered Direct Offering for general corporate purposes and working capital requirements.Â In a concurrent private placement, pursuant to the terms of the Purchase Agreement, the Company also agreed to issue and sell to the June 2024 Investor unregistered warrants (the â€œPrivate Placement Warrantsâ€) to purchase up to 6,130,000 shares of common stock, at an offering price of $0.41 per Private Placement Warrant to purchase one share of common stock (the â€œPrivate Placementâ€ and, together with the Registered Direct Offering, the â€œOfferingsâ€) (which offering price was included in the purchase price per share of common stock or Pre-Funded Warrant). The Private Placement Warrants have an exercise price of $0.41 per share (subject to customary adjustments as set forth in the Private Placement Warrants), were exercisable upon issuance and will expire five years from the date of issuance. The Private Placement Warrants contain customary anti-dilution adjustments to the exercise price, including for share splits, share dividends, rights offering and pro rata distributions. The Private Placement Warrants were subsequently registered in July 2024 on Form S-1 (File No. 333-280927).Â H.C. Wainwright & Co., LLC (â€œWainwrightâ€ and together with the June 2024 Investor, the â€œSelling Stockholdersâ€) acted as the exclusive placement agent in connection with the Offerings under an Engagement Letter, dated as of June 18, 2024, between us and Wainwright (the â€œEngagement Letterâ€). Pursuant to the Engagement Letter, we issued to Wainwright (or its designees) warrants to purchase up to 367,800 shares of common stock (the â€œWainwright Warrantsâ€ and, together with the Private Placement Warrants, the â€œ2024 Warrantsâ€). The Wainwright Warrants have substantially the same terms as the Private Placement Warrants, except that the Wainwright Warrants will expire five years from the commencement of the sales of the Offerings and have an exercise price of $0.5125 per share (subject to customary adjustment as set forth in the Wainwright Warrants), representing 125% of the purchase price per share of common stock in the Registered Direct Offering.â€‹At-the-Market OfferingIn July 2018, the Company entered into an At-the-Market Issuance Sales Agreement (the â€œMustang ATMâ€) with B. Riley Securities, Inc. (formerly B. Riley FBR, Inc.), Cantor Fitzgerald & Co., National Securities Corporation (now B. Riley FBR, Inc.), and Oppenheimer & Co. Inc. (each an â€œAgentâ€ and collectively, the â€œAgentsâ€), relating to the sale of shares of common stock pursuant to the 2020 S-3. Under the Mustang ATM, the Company pays the Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock. On December 31, 2020, the Mustang ATM was amended to add H.C. Wainwright & Co., LLC as an Agent. On April 14, 2023, the Mustang ATM was amended to add the limitations imposed by General Instruction I.B.6 to Form S-3 and remove Oppenheimer & Co., Inc. as an Agent. On May 31, 2024, the Company delivered notice to the Agents to terminate the Mustang ATM, which was effective June 5, 2024.On May 31, 2024, the Company entered into an At-the-Market Offering Agreement (the â€œOffering Agreementâ€) with H.C. Wainwright (the â€œManagerâ€) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock through or to the Manager pursuant to the 2024 S-3. Under the Offering Agreement, the Company pays the Manager a commission of 3.0% of the gross proceeds from the sales of any shares of common stock. The Company will also reimburse the Manager for certain expenses incurred in connection with the Offering Agreement. The Company and the Manager may each terminate the Sales Agreement at any time upon specified prior written notice.â€‹During the six months ended JuneÂ 30,Â 2024 and 2023, no shares of common stock were issued under the Mustang ATM Agreement or the Offering Agreement.â€‹Equity Incentive PlanThe Company has in effect the 2016 Incentive Plan (the â€œIncentive Planâ€). The Incentive Plan was adopted in 2016 by the Companyâ€™s stockholders and the compensation committee of the Companyâ€™s board of directors and is authorized to grant stock-based awards to directors, officers, employees and consultants. The plan initially authorized grants to issue up to 133,333 shares of authorized but unissued common stock, expires 10Â years from adoption, and limits the term of each option to no more than 10Â years from the date of grant. In June 2018, the Companyâ€™s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 200,000 shares, for a total of 333,333 shares. In June 2021, the Companyâ€™s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 200,000 shares, for a total of 533,333 shares. In June 2022, the Companyâ€™s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 200,000 shares, for a total of 733,333 shares.As of JuneÂ 30,Â 2024, 394,393 shares were available for future issuance under the Incentive Plan.Stock OptionsThe following table summarizes stock option activities for the six months ended JuneÂ 30,Â 2024:â€‹â€‹â€‹

Company reduced its workforce by approximately 81 percent, which resulted in the forfeiture of a significant number of outstanding restricted stock units and the reversal of previously incurred stock-based compensation expense.â€‹Employee Stock Purchase Planâ€‹Eligible employees can purchase the Companyâ€™s common stock at the end of a predetermined offering period at 85% of the lower of the fair market value at the beginning or end of the offering period. Â The Employee Stock Purchase Plan (â€œESPPâ€) is compensatory and results in stock-based compensation expense. The ESPP was initially authorized in 2019 to sell up to 26,667 shares of authorized but unissued common stock. In June 2021, the Companyâ€™s stockholders approved an amendment to the ESPP to increase the number of authorized shares issuable by 40,000 shares. In addition, in June 2023, the Companyâ€™s stockholders approved an amendment to the ESPP to increase the number of authorized shares issuable thereunder by 400,000 for a total of 466,667 shares.â€‹As of JuneÂ 30,Â 2024, 128,352 shares have been purchased and 338,315 shares are available for future sale under the Companyâ€™s ESPP.WarrantsA summary of warrant activities for the six months ended JuneÂ 30,Â 2024, is presented below:â€‹â€‹â€‹

Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (8,199) $ (16,235) $ (13,390) $ (32,928) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Significant Accounting Policies Â Basis of Presentation Basis of PresentationThe accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œGAAPâ€) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the interim unaudited financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. They do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company's audited financial statements and notes thereto for the year ended December 31, 2023, which were included in the Companyâ€™s Annual Report on Form 10-K and filed with the Securities and Exchange Commission (â€œSECâ€) on March 11, 2024 (the â€œ2023 Form 10-Kâ€). The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. Use of Estimates Use of EstimatesThe Companyâ€™s unaudited financial statements include certain amounts that are based on managementâ€™s best estimates and judgments. The Companyâ€™s significant estimates include, but are not limited to, assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Due to the uncertainty inherent in such estimates, actual results could differ from those estimates. Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents and Restricted Cashâ€‹The Company records cash held in an escrow account as a security deposit for the manufacturing facility in Worcester, Massachusetts, as restricted cash. â€‹The following table provides a reconciliation of cash, cash equivalents, and restricted cash from the Unaudited Balance Sheets to the Unaudited Statements of Cash Flows for the six months ended JuneÂ 30,Â 2024, and 2023:â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â ($ in thousands)2024â€‹2023Cash and cash equivalents$ 4,268â€‹$ 15,385Restricted cash 375â€‹ 750Total cash, cash equivalents and restricted cash$ 4,643â€‹$ 16,135 Assets Held for Sale Assets Held for Saleâ€‹Assets held for sale represent assets that have met the criteria of â€œheld for saleâ€ accounting, as specified by Accounting Standards Codification (â€œASCâ€) 360, â€œLong-lived Assets.â€ As of June 30, 2024, there were $2.2 million of lab and cell processing equipment, furniture and fixtures and computer equipment that are recorded as assets held for sale. The effect of suspending depreciation on the assets held for sale is immaterial to the results of operations. The assets held for sale are part of the repurchase of assets from uBriGene (see Note 6). Impairment of Long-Lived Assets Impairment of Long-Lived Assetsâ€‹The Company reviews long-lived assets, including tangible assets and other intangible assets with definitive lives, for impairment whenever events or changes in circumstances indicate that the assetâ€™s carrying amount may not be recoverable. The Company conducts its long-lived asset impairment analyses in accordance with ASC 360-10, "Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires the Company to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset group is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals.Â Significant Accounting Policies Significant Accounting PoliciesThere have been no material changes to the Companyâ€™s significant accounting policies previously disclosed in the 2023 Form 10-K. Recently Issued Accounting Standards Recently Issued Accounting StandardsAs of JuneÂ 30,Â 2024, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2023 Form 10-K that affect the Companyâ€™s present or future results of operations, overall financial condition, liquidity, or disclosures upon adoption. X - DefinitionDisclosure of company's police regarding assets held for sale. + ReferencesNo definition available. + Details Name: mbio_AssetsHeldForSalePolicyTextBlock Namespace Prefix: mbio_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of material changes to the company's significant accounting policies previously disclosed. + ReferencesNo definition available. + Details Name: mbio_SignificantAccountingPoliciesPolicyTextBlock Namespace Prefix: mbio_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Accounting Policies (Tables) 6 Months Ended Jun. 30, 2024 Significant Accounting Policies Â Reconciliation of Cash, Cash Equivalents, and Restricted Cash â€‹The following table provides a reconciliation of cash, cash equivalents, and restricted cash from the Unaudited Balance Sheets to the Unaudited Statements of Cash Flows for the six months ended JuneÂ 30,Â 2024, and 2023:â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â ($ in thousands)2024â€‹2023Cash and cash equivalents$ 4,268â€‹$ 15,385Restricted cash 375â€‹ 750Total cash, cash equivalents and restricted cash$ 4,643â€‹$ 16,135 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cash and cash equivalents restricted as to withdrawal or usage. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 8 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Clinical Trial and Sponsored Research Agreements (Tables) 6 Months Ended Jun. 30, 2024 Sponsored research and clinical trial agreements Â License, Clinical Trial and Sponsored Research Agreements Â Schedule of Clinical Trial and Sponsored Research Agreements â€‹â€‹â€‹â€‹â€‹â€‹

Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss per Share (Tables) 6 Months Ended Jun. 30, 2024 Net Loss per Share Â Schedule of Potentially Dilutive Securities â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ForÂ the six months ended JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â Â 2023WarrantsÂ 60,957,004â€‹ 70,102OptionsÂ 76,112Â 76,112ClassÂ A Preferred SharesÂ 250,000Â 250,000Unvested restricted stock awardsÂ 60,111Â 34,016Unvested restricted stock unitsÂ 14,216Â 129,476TotalÂ 61,357,443Â 559,706â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Tables) 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Â Schedule of information about operating leases â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â For the Six Months Ended Â Â Â Â â€‹â€‹â€‹JuneÂ 30,Â â€‹â€‹JuneÂ 30,Â â€‹($ in thousands)Â Â Â Â 2024Â Â Â Â Â 2023Â Â Â Â Lease costâ€‹Â Â Â Â â€‹Â Â Â Â â€‹Operating lease costÂ $ 78Â $ 395â€‹Variable lease costâ€‹ (25)â€‹â€‹ 380â€‹TotalÂ $ 53Â $ 775â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â ForÂ the Six Months Ended Â â€‹â€‹â€‹JuneÂ 30,Â â€‹â€‹â€‹JuneÂ 30,Â â€‹($ in thousands)Â Â Â Â 2024Â Â Â Â Â 2023Â Operating cash flows from operating leasesÂ $ 281â€‹Â $ 132â€‹Gain on lease modificationâ€‹ 314â€‹â€‹ 220â€‹Weighted-average remaining lease term â€“ operating leasesâ€‹â€‹ 2.3â€‹â€‹â€‹ 4.9â€‹Weighted-average discount rate â€“ operating leasesâ€‹â€‹ 9.0%â€‹â€‹ 9.1% Schedule of Maturities of operating leases excluding short term leases â€‹â€‹â€‹â€‹â€‹($ in thousands)Â Â Â Â â€‹â€‹Year ended DecemberÂ 31,Â 2024â€‹ 588Year ended DecemberÂ 31,Â 2025â€‹â€‹ 774Year ended DecemberÂ 31,Â 2026â€‹Â 703Year ended DecemberÂ 31,Â 2027â€‹Â 269Year ended DecemberÂ 31,Â 2028â€‹Â 274Thereafterâ€‹â€‹ 303Totalâ€‹Â 2,911Less present value discountâ€‹â€‹ (1,826)Operating lease liabilitiesâ€‹ 1,085â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization, Description of Business and Liquidity and Capital Resources (Details) - USD ($) $ / shares in Units, $ in Thousands Apr. 12, 2024 Jun. 30, 2024 Dec. 31, 2023 Accumulated deficit Â $ (394,361) $ (380,971) Number of positions eliminated period percent 81.00% Â Â Warrant exercise price (in dollars per share) Â $ 0.29 $ 1.34 X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s). + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Accounting Policies (Cash, Cash Equivalents, and Restricted Cash) (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2023 Dec. 31, 2022 Cash and cash equivalents $ 4,268 $ 6,234 $ 15,385 Â Restricted cash 375 750 750 Â Total cash, cash equivalents and restricted cash 4,643 $ 6,984 $ 16,135 $ 76,656 Assets held for sale, not discontinued operations Â Â Â Â Property, plant and equipment, held for sale $ 2,200 Â Â Â X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details) - Sponsored research and clinical trial agreements - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Research and development for sponsored research and clinical trial agreements $ 268 $ 1,634 $ 235 $ 3,375 Mayo Clinic Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Research and development for sponsored research and clinical trial agreements (275) 275 (275) 551 IL13Ra2 (MB-101) [Member] | City of Hope National Medical Center Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Research and development for sponsored research and clinical trial agreements 111 326 391 636 CS1 (MB-104) [Member] | City of Hope National Medical Center Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Research and development for sponsored research and clinical trial agreements 0 139 0 188 PSCA (MB-105) [Member] | City of Hope National Medical Center Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Research and development for sponsored research and clinical trial agreements 0 22 0 44 CD20 (MB-106) [Member] | Fred Hutchinson Cancer Center Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Research and development for sponsored research and clinical trial agreements 312 544 312 1,098 ST. Jude - XSCID [Member] | St. Jude Children's Research Hospital Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Research and development for sponsored research and clinical trial agreements 0 216 (434) 634 RAG1 SCID (MB-110) [Member] | Leiden University Medical Center Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Research and development for sponsored research and clinical trial agreements $ 121 $ 112 $ 241 $ 224 X - DefinitionAmount of net expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesNo definition available. + Details Name: mbio_ResearchAndDevelopmentExpenseNetExcludingAcquiredInProcessCost Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mbio_MayoClinicMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mbio_Il13r2ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mbio_CityOfHopeNationalMedicalCenterCohMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mbio_Cs1ProductOrProcessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mbio_PscaProductOrProcessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mbio_Cd20TechnologyProductOrProcessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mbio_FredHutchinsonCancerResearchCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mbio_StJudeXscidMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mbio_St.JudeChildrensResearchHospitalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:

srt_ProductOrServiceAxis=mbio_Rag1ScidMb110Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended Sep. 08, 2021 Jul. 03, 2017 Nov. 30, 2022 Oct. 31, 2022 Jan. 31, 2022 Jun. 30, 2021 Nov. 30, 2020 Oct. 31, 2020 Jun. 30, 2020 Feb. 28, 2017 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development expense Â Â Â Â Â Â Â Â Â $ 4,360 $ 10,836 $ 8,164 $ 24,836 PSCA (MB-105) [Member] | City of Hope National Medical Center Â Â Â Â Â Â Â Â Â Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Â Â Â Â Â Â Â Â Â Total reimbursement payments made Â Â Â Â Â Â Â Â Â Â Â 500 Â 500 Â IL13Ra2 CAR and (C134) [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development expense Â Â $ 600 Â Â Â Â $ 300 Â Â Â Â Â Â Sponsored research and clinical trial agreements | IL13Ra2 (MB-101) [Member] | City of Hope National Medical Center Â Â Â Â Â Â Â Â Â Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Â Â Â Â Â Â Â Â Â Contribution toward patient costs Â Â Â Â Â Â Â Â Â Â Â $ 100 Â Â Â Â Contribution per patient Â Â Â Â Â Â Â 100 Â Â Â Â Â Â Annual maintenance fee payable Â Â Â Â Â Â Â 200 Â Â Â Â Â Â Sponsored research and clinical trial agreements | CS1 (MB-104) [Member] | City of Hope National Medical Center Â Â Â Â Â Â Â Â Â Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Â Â Â Â Â Â Â Â Â Total reimbursement payments made Â Â Â Â Â Â Â Â Â Â Â $ 2,200 Â $ 2,200 Â Sponsored research and clinical trial agreements | CS1 (MB-104) [Member] | City of Hope National Medical Center | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Â Â Â Â Â Â Â Â Â Milestones payable Â Â Â Â Â Â Â $ 2,400 Â Â Â Â Â Sponsored research and clinical trial agreements | PSCA (MB-105) [Member] | City of Hope National Medical Center | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Â Â Â Â Â Â Â Â Â Milestones payable Â Â Â Â Â Â Â $ 2,300 Â Â Â Â Â Â Sponsored research and clinical trial agreements | CD20 (MB-106) [Member] | Fred Hutchinson Cancer Center Â Â Â Â Â Â Â Â Â Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Â Â Â Â Â Â Â Â Â Milestones payable Â $ 5,300 Â Â Â Â Â Â Â Â Â Â Â Â Â Additional milestone payments Â Â Â Â Â $ 2,200 Â $ 1,800 Â Â Â Â Â Â Â Â Â Contribution toward patient costs Â Â Â Â Â Â $ 800 Â Â Â Â Â Â Â Sponsored research and clinical trial agreements | CD20 (MB-106) [Member] | Fred Hutchinson Cancer Center | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Â Â Â Â Â Â Â Â Â Additional milestone payments Â Â Â Â $ 9,300 Â Â Â Â Â Â Â Â Sponsored research and clinical trial agreements | RAG1 SCID (MB-110) [Member] | Leiden University Medical Center Â Â Â Â Â Â Â Â Â Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Â Â Â Â Â Â Â Â Â Agreement term 5 years Â Â Â Â Â Â Â Â Â Â Â Â Â Annual maintenance fee payable $ 500 Â Â Â Â Â Â Â Â Â Â Â Sponsored research and clinical trial agreements | Car T Technology [Member] | Mayo Clinic Â Â Â Â Â Â Â Â Â Â Â Â Â License, Clinical Trial and Sponsored Research Agreements Â Â Â Â Â Â Â Â Â Â Â Â Â Milestones payable Â Â Â Â $ 100 Â $ 2,100 Â Â Â Â Â Â Â Â Â Agreement term Â Â Â Â Â 2 years Â Â Â Â Â Â Â Â Â X - DefinitionThe amount of additional milestones payable under the arrangement. + ReferencesNo definition available. + Details Name: mbio_AdditionalMilestonesPayableUnderArrangement Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of annual maintenance fee payable under the arrangement. + ReferencesNo definition available. + Details Name: mbio_AnnualMaintenanceFeePayable Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of contribution to be paid toward patient costs. + ReferencesNo definition available. + Details Name: mbio_ContributionTowardPatientCosts Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of milestones payable under the arrangement. + ReferencesNo definition available. + Details Name: mbio_MilestonesPayableUnderArrangement Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents total payments for reimbursable expenses over the lifetime of the agreement. + ReferencesNo definition available. + Details Name: mbio_ReimbursementOfFeesTotalPayments Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of contribution to be paid per patient under the arrangement. + ReferencesNo definition available. + Details Name: mbio_ResearchArrangementContributionPerPatient Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe term of the research arrangement. + ReferencesNo definition available. + Details Name: mbio_ResearchArrangementTerm Namespace Prefix: mbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=mbio_PscaProductOrProcessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mbio_CityOfHopeNationalMedicalCenterCohMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mbio_Il13ra2CarAndC134Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mbio_Il13r2ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mbio_Cs1ProductOrProcessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mbio_Cd20TechnologyProductOrProcessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mbio_FredHutchinsonCancerResearchCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mbio_Rag1ScidMb110Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mbio_CarTTechnologyProductOrProcessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mbio_MayoClinicMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Agreements (Narrative) (Details) - Fortress Biotech, Inc - USD ($) 3 Months Ended 6 Months Ended 12 Months Ended Jan. 02, 2024 Jul. 22, 2016 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Related Party Transaction [Line Items] Â Â Â Â Â Â Â Shares issued for services (in shares) 353,086 Â Â Â Â Â Â Parent Company | Management Services Agreement (MSA) Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses Â Â 50.00% Â Â 50.00% Â Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses Â Â 50.00% Â Â 50.00% Â Expenses from related party transaction Â Â $ 100,000 $ 100,000 $ 300,000 $ 300,000 Â Parent Company | Founders Agreement Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Shares issued for services (in shares) Â Â Â Â 575,191 Â Â Percentage of fully diluted equity 2.50% 2.50% Â Â Â Â Â Expenses from related party transaction Â Â $ 163,000 $ 0 $ 163,000 $ 0 Â Research and development for licenses acquired Â Â Â Â Â Â $ 500,000 X - DefinitionRepresents the percentage of diluted outstanding equity paid as equity fee or used to calculate stock issuance to maintain parity. + ReferencesNo definition available. + Details Name: mbio_DilutedOutstandingEquityPercentage Namespace Prefix: mbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses + ReferencesNo definition available. + Details Name: mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses Namespace Prefix: mbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of annual fees expense related to Management Services Agreement recorded in research and development expenses + ReferencesNo definition available. + Details Name: mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses Namespace Prefix: mbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingCostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=mbio_FortressBiotechIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityOwnedSubsidiaryUnconsolidatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mbio_ManagementServicesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=mbio_SecondAmendedAndRestatedFoundersAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Assets Purchase Agreements (Details) $ in Thousands 6 Months Ended Jun. 27, 2024 USD ($) May 13, 2024 item Jul. 28, 2023 USD ($) Jun. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Asset Acquisition [Line Items] Â Â Â Â Â Property, plant and equipment, held for sale Â Â Â $ 2,209 $ 0 June 2024 Repurchase of Assets Â Â Â Â Â Asset Acquisition [Line Items] Â Â Â Â Â Purchase price $ 1,400 Â Â $ 1,400 Â Upfront payment $ 100 Â Â Â Â Upfront payment, due period from Effective Date 5 days Â Â Â Â Subsequent payment $ 1,300 Â Â Â Â Subsequent amount, due period from closing date 12 months Â Â Â Â Amount of net assets below this threshold, the Company may elect to delay payment obligation by additional six months $ 20,000 Â Â Â Â Extension term for deferred payment 6 months Â Â Â Â Interest rate on outstanding Deferred Amount 5.00% Â Â Â Â Rate of interest accrual on Deferred Amount not paid in full after 12 months 12 months Â Â Â Â Amount of net receivables to forgive under Asset Purchase Agreement $ 3,300 Â Â Â Â Outstanding receivables 6,900 Â Â Â Â Outstanding payables 3,600 Â Â Â Â Total purchase consideration 4,700 Â Â Â Â Fair value provided from valuation services less costs to sell 2,200 Â Â Â Â Purchase consideration allocated to the supplies repurchased 2,500 Â Â Â Â Supplies repurchased with no alternate future use recognized as research and development expense 2,200 Â Â Â Â Supplies repurchased with alternate future use recognized as research and development expense 300 Â Â Â Â Property, plant and equipment, held for sale $ 2,200 Â Â Â Â uBriGene Â Â Â Â Â Asset Acquisition [Line Items] Â Â Â Â Â Proceeds from the sale of property and equipment Â Â $ 6,000 Â Â Gain on sale of property and equipment Â Â 1,400 Â Â Sale consideration considered deferred income Â Â $ 300 Â Â Number of parties obligated to terminate agreements | item Â 2 Â Â Â Equipment assets purchased term Â 180 days Â Â Â X - DefinitionRepresents the due period for deferred payment from Effective Date in an asset acquisition. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionConsiderationTransferredDeferredPaymentDuePeriodFromClosingDate Namespace Prefix: mbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the extension term for delay in payment of deferred payment. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionConsiderationTransferredDeferredPaymentExtensionTerm Namespace Prefix: mbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents percentage of interest accrual on outstanding liability of deferred payment in asset acquisition transaction. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionConsiderationTransferredDeferredPaymentInterestRateOnOutstandingLiability Namespace Prefix: mbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of subsequent consideration recognized as part of consideration transferred in asset acquisition. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionConsiderationTransferredSubsequentPayment Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of upfront consideration recognized as part of consideration transferred in asset acquisition. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionConsiderationTransferredUpfrontPayment Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the due period for upfront payment from Effective Date in an asset acquisition. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionConsiderationTransferredUpfrontPaymentDuePeriodFromEffectiveDate Namespace Prefix: mbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the period starts accruing interest for deferred payment from Effective Date in an asset acquisition. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionDeferredPaymentAccrueInterestPeriodFromClosingDate Namespace Prefix: mbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of fair value less costs to sell provided from valuation services in asset acquisition. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionNetRealizableValueAmount Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of net receivables to forgive under Asset Purchase Agreement. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionNetReceivablesForgiveness Namespace Prefix: mbio_ Data Type:

xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of payables recognized at acquisition date in asset acquisition. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionPayable Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of purchase consideration allocated to the supplies repurchased in asset acquisition. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionPurchaseConsiderationAllocatedToSuppliesRepurchased Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of receivables recognized at acquisition date in asset acquisition. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionReceivables Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of the supplies repurchased with alternative future use were recognized as research and development expense. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionSuppliesRepurchasedAlternativeFutureUseRecognizedAsResearchAndDevelopmentExpense Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of the supplies repurchased with no alternative future use were recognized as research and development expense. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionSuppliesRepurchasedNoAlternativeFutureUseRecognizedAsResearchAndDevelopmentExpense Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe term of the equipment assets purchased. + ReferencesNo definition available. + Details Name: mbio_EquipmentAssetsPurchasedTerm Namespace Prefix: mbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of net assets below this threshold, then the Company may, upon written notice to uBriGene, elect to delay its payment obligation of the Deferred Amount by an additional six (6) months, with no limit on the number of such extensions available to the Company. + ReferencesNo definition available. + Details Name: mbio_NetAssetsThresholdToDelayConsiderationPaymentObligation Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the number of parties obligated to terminate agreements. + ReferencesNo definition available. + Details Name: mbio_NumberOfPartiesObligatedToTerminateAgreements Namespace Prefix: mbio_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionThe amount of sale of property, plant and equipment considered deferred income. + ReferencesNo definition available. + Details Name: mbio_SaleOfPropertyPlantAndEquipmentDeferredIncome Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 15 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4 + Details Name: us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_AssetAcquisitionAxis=mbio_AssetPurchaseAgreementWithUbrigeneBiosciencesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mbio_UbrigeneBiosciencesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property, Plant and Equipment, and Asset Impairment (Schedule of Property, Plant and Equipment) (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Property and Equipment Â Â Total property, plant and equipment $ 7,694 $ 7,723 Less: impairment loss (2,177) Â Less: accumulated depreciation (5,045) (4,476) Property, plant and equipment, net $ 472 $ 3,247 Leasehold improvements Â Â Property and Equipment Â Â Estimated useful life 9 years 9 years Total property, plant and equipment $ 7,694 $ 7,694 Construction in process Â Â Property and Equipment Â Â Total property, plant and equipment Â $ 29 X - DefinitionAmount of impairment loss. + ReferencesNo definition available. + Details Name: mbio_AccumulatedImpairmentLossPropertyPlantAndEquipment Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property, Plant and Equipment, and Asset Impairment (Narrative) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Property, Plant and Equipment, and Asset Impairment Â Â Â Â Depreciation expense $ 300 $ 600 $ 569 $ 1,291 Asset impairment 2,649 $ 0 $ 2,649 $ 0 Impairment of leasehold improvements 2,200 Â Â Â Impairment on the right-of-use asset $ 400 Â Â Â X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_ImpairmentOfLeasehold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of loss from impairment of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6 + Details Name: us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Accounts Payable and Accrued Expenses Â Â Accounts payable $ 8,934 $ 6,322 Accrued research and development 1,606 4,118 Accrued compensation 778 2,838 Other 1,872 739 Total accounts payable and accrued expenses 13,190 $ 14,017 Accrued consideration for the uBriGene Asset Purchase Agreement $ 1,400 Â X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for accrued compensation. + ReferencesNo definition available. + Details Name: mbio_AccruedCompensationCurrent Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accrued consideration in asset acquisition, classified as current. + ReferencesNo definition available. + Details Name: mbio_AssetAcquisitionAccruedConsiderationCurrent Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for research and development. + ReferencesNo definition available. + Details Name: mbio_ResearchAndDevelopmentCurrent Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_OtherAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Notes Payable (Narrative) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Apr. 11, 2023 Mar. 04, 2022 Jun. 30, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Interest expense Â Â $ 2 $ 2,932 Â $ 3 $ 4,108 Amortization of debt discount Â Â Â Â Â $ 0 118 Runway Debt Facility Â Â Â Â Â Â Â Payoff amount of debt facility $ 30,400 Â Â Â Â Â Â Â Interest rate during period Â Â Â Â 13.77% Â Â Interest expense Â Â Â $ 300 Â Â 1,300 Amortization of debt discount Â Â Â Â Â Â $ 100 Runway Debt Facility | Minimum [Member] Â Â Â Â Â Â Â Â Variable interest rate floor (as a percent) Â 9.25% Â Â Â Â Â Runway Debt Facility | Base Rate Â Â Â Â Â Â Â Variable interest rate floor (as a percent) Â 8.75% Â Â Â Â Â Runway Debt Facility | Three month LIBOR Â Â Â Â Â Â Â Variable interest rate floor (as a percent) Â 0.50% Â Â Â Â Â Â X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_BaseRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=mbio_LiborLondonInterbankOfferedRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Notes Payable - Interest Expense (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Notes Payable Â Â Â Â Interest expense Â $ 133 Â $ 1,188 Amortization of Debt Discount Â Â Â 118 Loss on Extinguishment Â 2,795 $ 0 2,796 Other $ 2 4 3 8 Total Interest Expense $ 2 $ 2,932 $ 3 $ 4,108 X - DefinitionAmount of debt discount amortization included in interest expense. + ReferencesNo definition available. + Details Name: mbio_InterestExpenseAmortizationOfDebtDiscount Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as other. + ReferencesNo definition available. + Details Name: us-gaap_InterestExpenseOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders Equity (Registration Statements and At-the-Market Offering) (Details) - USD ($) $ in Millions 6 Months Ended May 24, 2021 Jun. 30, 2024 Jun. 30, 2023 Jun. 12, 2024 May 31, 2024 Jul. 31, 2018 At the Market Offering Â Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Issuance of common shares (in shares) Â 0 0 Â Â Â Agent commission (as a percent) Â Â Â Â 3.00% 3.00% 2021 S-3 Â Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Sale of Stock aggregate offering price $ 200.0 Â Â Â Â Â Issuance of common shares (in shares) 4,400,000 Â Â Â Â Â 2024 S-3 Â Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Sale of Stock aggregate offering price Â Â Â $ 40.0 Â Â Shares available for future issuance Â $ 37.5 Â Â Â Â X - DefinitionPercentage of commission rate on gross sale of common stock. + ReferencesNo definition available. + Details Name: mbio_CommissionRatePercentage Namespace Prefix: mbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionCommon Stock Shares Available For Future Issuance Value + ReferencesNo definition available. + Details Name: mbio_CommonStockSharesAvailableForFutureIssuanceValue Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSale of Stock aggregate offering price permitted by agreement. + ReferencesNo definition available. + Details Name: mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -

SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=mbio_AtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=mbio_RegistrationStatements2021S3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=mbio_RegistrationStatements2024S3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity - May 2024 Public Offering (Details) - USD ($) $ / shares in Units, $ in Millions Apr. 29, 2029 Apr. 29, 2024 Jun. 30, 2024 May 31, 2024 Dec. 31, 2023 Oct. 26, 2023 Stockholders' Equity Â Â Â Â Â Â Exercise price of warrant Â Â $ 0.29 Â $ 1.34 Â Prefunded Warrants Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Warrants issued Â Â 3,105,000 15,717,638 Â 1,668,236 May 2024 Public Offering Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Price per share Â $ 0.2369 Â Â Â Â Warrants issued Â Â Â 50,632,914 Â Â Net proceeds of offering Â $ 3.2 Â Â Â Â May 2024 Public Offering | Forecast [Member] Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Number of common stock agreed to issue and sell 1,160,000 Â Â Â Â Â May 2024 Public Offering | Existing Warrants Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Warrants issued Â 2,588,236 Â Â Â Â Exercise price of warrant Â $ 1.58 Â Â Â Â Warrants expiration term Â 5 years Â Â Â Â May 2024 Public Offering | Existing Warrants | Minimum Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Exercise price of warrant Â $ 0.237 Â Â Â Â May 2024 Public Offering | Series A-3 Warrant Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Warrants issued Â 16,877,638 Â Â Â Â Number of warrant to converted Â 1 Â Â Â Â Number of common stock, each warrant get converted Â 1 Â Â Â Â Warrants expiration term Â 9 months Â Â Â Â May 2024 Public Offering | Series A-2 Warrant Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Warrants issued Â 16,877,638 Â Â Â Â Number of warrant to converted Â 1 Â Â Â Â Number of common stock, each warrant get converted Â 1 Â Â Â Â Warrants expiration term Â 24 months Â Â Â Â May 2024 Public Offering | Series A-1 Warrant Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Warrants issued Â 16,877,638 Â Â Â Â Number of warrant to converted Â 1 Â Â Â Â Number of common stock, each warrant get converted Â 1 Â Â Â Â Warrants expiration term Â 5 years Â Â Â Â May 2024 Public Offering | Prefunded Warrants Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Warrants issued Â 15,717,638 Â Â Â Â Price per warrant Â $ 0.237 Â Â Â Â Exercise price of warrant Â $ 0.0001 Â Â Â Â X - DefinitionNumber of warrant or right may be converted. + ReferencesNo definition available. + Details Name: mbio_ClassOfWarrantConverted Namespace Prefix: mbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDenotes the price per warrant. + ReferencesNo definition available. + Details Name: mbio_ClassOfWarrantOrRightWarrantPrice Namespace Prefix: mbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mbio_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=mbio_May2024PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mbio_ExistingWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mbio_SeriesA3WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mbio_SeriesA2WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mbio_SeriesA1WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity - June 2024 Registered Direct Offering (Details) - USD ($) $ / shares in Units, $ in Millions Jun. 21, 2024 Jun. 19, 2024 Jun. 18, 2024 Jun. 30, 2024 May 31, 2024 Dec. 31, 2023 Oct. 26, 2023 Class of Stock [Line Items] Â Â Â Â Â Â Â Exercise price of warrant Â Â Â $ 0.29 Â $ 1.34 Â Prefunded Warrants Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Warrants issued Â Â Â 3,105,000 15,717,638 Â 1,668,236 June 2024 Registered Direct Offering Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Issuance of common shares (in shares) Â 3,025,000 Â Â Â Â Â Price per common stock Â $ 0.41 Â Â Â Â Â Â Proceeds for general corporate purposes and working capital requirements $ 2.1 Â Â Â Â Â Â June 2024 Registered Direct Offering | Prefunded Warrants Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Warrants issued Â 3,105,000 Â Â Â Â Â Price per warrant Â $ 0.4099 Â Â Â Â Â Amount per share to be reduced from offering price Â 0.0001 Â Â Â Â Â Exercise price of warrant Â $ 0.0001 Â Â Â Â Â Private Placement | Private Placement Warrants Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Warrants issued Â 6,130,000 Â Â Â Â Â Price per warrant Â $ 0.41 Â Â Â Â Â Exercise price of warrant Â $ 0.41 Â Â Â Â Â Number of common stock, each warrant get converted Â 1 Â Â Â Â Â Warrants expiration term Â 5 years Â Â Â Â Â Private Placement | Wainwright Warrants [Member] Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Warrants issued Â 367,800 Â Â Â Â Purchase Price of Common Stock, Percentage Â Â 125.00% Â Â Â Â Exercise price of warrant Â Â $ 0.5125 Â Â Â Â Warrants expiration term Â Â 5 years Â Â Â Â X - DefinitionExercise price of warrants expressed as percentage of purchase price of common stock. + ReferencesNo definition available. + Details Name: mbio_ClassOfWarrantOrRightExercisePricePurchasePriceOfCommonStockPercentage Namespace Prefix: mbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDenotes the price per warrant. + ReferencesNo definition available. + Details Name: mbio_ClassOfWarrantOrRightWarrantPrice Namespace Prefix: mbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionRepresents the amount per share to be reduced from offering price for calculating the offering price of warrants. + ReferencesNo definition available. + Details Name: mbio_OfferingPriceOfWarrantsCalculationAmountPerShareToBeReducedFromOfferingPrice Namespace Prefix: mbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs, for general corporate purposes and working capital requirements. + ReferencesNo definition available. + Details Name: mbio_SaleOfStockConsiderationReceivedOnTransactionForSpecificPurposes Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18:

http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mbio_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=mbio_June2024RegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mbio_PrivatePlacementWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mbio_WainwrightWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders Equity (Equity Incentive Plans and Employee Stock Purchase Plan) (Details) - shares 1 Months Ended 6 Months Ended 12 Months Ended Jun. 30, 2023 Jun. 30, 2022 Jun. 30, 2021 Jun. 30, 2018 Jun. 30, 2024 Dec. 31, 2016 Dec. 31, 2019 Stockholders' Equity Â Â Â Â Â Â Â Shares authorized Â Â Â Â Â Â 26,667 Additional shares authorized 400,000 Â 40,000 Â Â Â Â Shares available for grant 466,667 Â Â Â Â Â Â Â Predetermined offering period, lower fair market value percentage Â Â Â Â 85.00% Â Â Number of shares purchased under ESPP Â Â Â Â 128,352 Â Â Shares available for future sale Â Â Â Â 338,315 Â Â Employee Stock Option Â Â Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Â Â Shares authorized Â Â Â Â Â 133,333 Â Expiration period Â Â Â Â Â 10 years Â Additional shares authorized Â 200,000 200,000 200,000 Â Â Â Shares available for grant Â 733,333 533,333 333,333 Â Â Â Shares available for future sale Â Â Â Â Â 394,393 Â Â X - DefinitionEmployee stock purchase plan, predetermined offering period, lower fair market value percentage. + ReferencesNo definition available. + Details Name: mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage Namespace Prefix: mbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders Equity (Stock Option Activities) (Details) - Employee Stock Option - USD ($) 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Options rollforward Â Â Stock Options, Outstanding, Number, Beginning Balance 76,112 Â Options, Outstanding, Number, Ending Balance 76,112 76,112 Options vested and exercisable 47,570 Â Weighted Average Exercise Price Â Â Weighted Average Exercise Price, Beginning $ 85.95 Â Weighted Average Exercise Price, Ending 85.95 $ 85.95 Weighted Average Exercise Price, options vested and exercisable $ 85.95 Â Weighted Average Remaining Contractual Life, Options outstanding (in years) 2 years 9 months 21 days 3 years 3 months 21 days Weighted Average Remaining Contractual Life, Options vested and exercisable (in years) 2 years 9 months 21 days Â Unrecognized share-based compensation $ 0 Â X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and

currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders Equity (Restricted Stock or Restricted Units Awards) (Details) - USD ($) 6 Months Ended Apr. 12, 2024 Jun. 30, 2024 Weighted Average Grant Date Fair Value Â Â Number of positions eliminated period percent 81.00% Â Restricted stock award Â Â Restricted stock and RSU rollforward Â Â Nonvested, Number, Beginning Balance Â 64,706 Vested Â (4,595) Nonvested, Number, Ending Balance Â 60,111 Weighted Average Grant Date Fair Value Â Â Nonvested, Beginning Balance Â $ 11.59 Vested Â 54.45 Nonvested, Ending Balance Â $ 8.32 Unrecognized share-based compensation Â $ 300,000 Weighted average vesting period (in years) Â 1 year 7 months 6 days Restricted stock units Â Â Restricted stock and RSU rollforward Â Â Nonvested, Number, Beginning Balance Â 95,197 Forfeited Â (63,782) Vested Â (17,199) Nonvested, Number, Ending Balance Â 14,216 Weighted Average Grant Date Fair Value Â Â Nonvested, Beginning Balance Â $ 18.78 Forfeited Â 18.19 Vested Â 22.41 Nonvested, Ending Balance Â $ 17.02 Unrecognized share-based compensation Â $ 57,000 Weighted average vesting period (in years) Â 1 year 10 months 24 days X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s). + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders Equity (Stock-based Compensation Expense) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Total stock-based compensation expense $ (619) $ 45 $ (542) $ 280 General and administrative Â Â Â Â Total stock-based compensation expense 51 153 98 262 Research and development Â Â Â Â Total stock-based compensation expense $ (670) $ (108) $ (640) $ 18 X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Warrants Activity) (Details) - $ / shares 1 Months Ended 6 Months Ended 12 Months Ended May 31, 2024 Jun. 30, 2024 Dec. 31, 2023 Apr. 29, 2024 Oct. 26, 2023 Stockholders' Equity Â Â Â Â Â Warrants outstanding, beginning Â 4,481,868 Â Â Â Warrants exercised Â (20,490,874) Â Â Â Â Warrants granted Â 76,966,010 Â Â Â Warrants outstanding, ending Â 60,957,004 4,481,868 Â Â Warrant exercise price (in dollars per share) Â $ 0.29 $ 1.34 Â Â Warrant exercise price, grants during the period (in dollars per share) Â $ 0.19 Â Â Â Warrants outstanding, remaining contractual life Â 2 years 11 months 23 days 5 years 4 months 2 days Â Â Warrants granted, remaining contractual life Â 2 years 8 months 26 days Â Â Â May 2024 Public Offering Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Warrants issued 50,632,914 Â Â Â Â Prefunded Warrants Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Warrants issued 15,717,638 3,105,000 Â Â 1,668,236 Prefunded Warrants | May 2024 Public Offering Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Warrant exercise price (in dollars per share) Â Â Â $ 0.0001 Â Warrants issued Â Â Â 15,717,638 Â Prefunded Warrants | October Registered Direct Offering Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Warrant exercise price (in dollars per share) Â $ 0.001 Â Â Â Warrants issued Â 1,668,236 Â Â Â Prefunded Warrants | May and June Registered Direct Offering Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Warrant exercise price (in dollars per share) Â $ 0.0001 Â Â Â Warrants issued Â 18,822,638 Â Â Â Unregistered Warrants Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Warrants outstanding, ending 2,588,236 Â Â Â Â Â Warrant exercise price (in dollars per share) $ 1.58 Â Â Â Â Warrant exercise price, exercised during the period (in dollars per share) $ 0.237 Â Â Â Â Warrants issued Â 6,130,000 Â Â 2,588,236 Placement Agents Warrants Â Â Â Â Â Stockholders' Equity Â Â Â Â Â Warrants issued 1,012,658 367,800 Â Â 155,294 X - DefinitionThe number of warrants or rights exercised during the period. + ReferencesNo definition available. + Details Name: mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod Namespace Prefix: mbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants or rights granted during the period. + ReferencesNo definition available. + Details Name: mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod Namespace Prefix: mbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants that were exercised during the period. + ReferencesNo definition available. + Details Name: mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisedDuringPeriod Namespace Prefix: mbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants that were granted during the period. + ReferencesNo definition available. + Details Name: mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod Namespace Prefix: mbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average remaining contractual life for warrants outstanding. + ReferencesNo definition available. + Details Name: mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife Namespace Prefix: mbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average remaining contractual life for warrants granted during the period. + ReferencesNo definition available. + Details Name: mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod Namespace Prefix: mbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=mbio_May2024PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mbio_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=mbio_OctoberRegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_SubsidiarySaleOfStockAxis=mbio_MayAndJuneRegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mbio_UnregisteredWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mbio_PlacementAgentsWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss per Share (Potentially Dilutive Securities) (Details) - shares 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Potentially dilutive securities 61,357,443 559,706 Warrants Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Potentially dilutive securities 60,957,004 70,102 Employee Stock Option Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Potentially dilutive securities 76,112 76,112 Class A Preferred Shares Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Potentially dilutive securities 250,000 250,000 Unvested restricted stock awards Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Potentially dilutive securities 60,111 34,016 Unvested restricted stock units Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Potentially dilutive securities 14,216 129,476 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Narrative) (Details) - USD ($) Jun. 28, 2024 Jun. 30, 2024 Dec. 31, 2023 Commitments and Contingencies Â Â Â Termination fee $ 40,000 Â Â Operating lease liability Â $ 1,085,000 $ 2,500,000 Operating lease right-of-use asset, net Â $ 103,000 $ 1,566,000 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on termination of lease before expiration of lease term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1 + Details Name: us-gaap_GainLossOnTerminationOfLease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Schedule of Operating Leases) (Details) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Lease cost Â Â Operating lease cost $ 78 $ 395 Variable lease cost (25) 380 Total $ 53 $ 775 X - DefinitionAmount of variable lease cost, net, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesNo definition available. + Details Name: mbio_VariableLeaseCostNet Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeaseCostAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Cash Flows) (Details) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Commitments and Contingencies Â Â Operating cash flows from operating leases $ 281 $ 132 Gain on lease modification $ 314 $ 220 Weighted-average remaining lease term - operating leases 2 years 3 months 18 days 4 years 10 months 24 days Weighted-average discount rate - operating leases 9.00% 9.10% X - DefinitionAmount of gain (loss) on modification of lease before expiration of lease term. + ReferencesNo definition available. + Details Name: mbio_GainLossOnModificationOfLease Namespace Prefix: mbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Maturities of Operating Leases) (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Commitments and Contingencies Â Â Year ended December 31, 2024 $ 588 Â Year ended December 31, 2025 774 Â Year ended December 31, 2026 703 Â Year ended December 31, 2027 269 Â Year ended December 31, 2028 274 Â Thereafter 303 Â Total 2,911 Â Less present value discount (1,826) Â Operating lease liabilities $ 1,085 $ 2,500 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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}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

7V_3)WK^;]RFI#(9IH(.\K3(M@I"_. ,/*'A^S\]>?O M.W^FB+*/?!,791Z07]R50:R)'G M/,-% <"B]=9]=6&R_C<,MVP<%^%:8!#FLR-=K3LZ+Q-\'!^9-)'LV^PGL+2YLO%TNWI8? (X/8"'OLM14SZBMC!;D84,#DA_^L"/Z7U M=$2PNM+UY_;4I&$R A+"[2&J?(#WD+3V\? EE@&3H+0R+BMD"D05I_;NW)KYBQ%V'KHHNZ/I MC7/#+F ;=R 3('I]Z0YOPWC^-=S/K,7\P=SWUQI@^M[@V3O!L_<- >?9&>0[2 MB)V;;/LGV/9KMFNW1AJEV' 8GDO7P(D#RJ&1 P*PS.CQ[:3BCTC%9F\"B%-$ MJD<)W/N8(6,^HNS:%HA(AP32VAH.&5S2:L_V'CL;A=ZBX#^.@DPZW1 (8324 M>8J/"PN7#L)0AE> <55L"RNF)8WO^7#)8GE[BF-@?L-!L*3=R+/:Q;0#@ MD(T@5[!UE23*U/0VMH@&1U8'4;461]JK]OHK2))I2ND^)8DV@"A2KE(TH%M" ME'L)A(%&[D['(M5JD<:X?!X- #2UB*_35P M?GG@ >"V/63[P^5:5/GE#BLY!MODZJ7.[D@XY25(382<1S4$ZF59,+EU";R! MZA'9@+QH-(EX#FY #EA!0/:O.NE\F"@U3?@540"U<5 (\O85)%FC-S4Q:+$1H< M++;.Q4YJ>40WEJPN.D#4]C0.[?A#C9;"1!1&!:$1]+L4G#M- 5;>BCO,#TC4Q M59 4@H'4>$ZR(6B]UUX+0HU(L %$B*I(# M.9NTE@]A*1 &@Q!]C;[U9JP::@[$!->>+IJ0T)+<&\UW- YM:N'*HL8A!1A)- M8X"%J7%NY (5 Q4GHZZ4@4C#RXBE!5'BEI-]G&3_ML89[[L6A%_V.B 6! M%:%8_J7D*L.)/(8(':@X)\6O(_.P;%8'BH(,HZ 6M X+QEZ*RL@B0QN2OG[$ M'T!D(A_5^'62HU:;>R34.>_1K"-A2/=0S! [=^(%.PG1^*W>7R/^VQ" M::. =@YIJ/=J(J.*D^7N8!'7B35WC0W?:O.^'HPV_J_AOUOY6>A? MF&$)=\E:V&0<%32$22AR(*8DWTUB7I'&1V*-C!_V*+5'(1QM$Z8K(1JHD0*J M678O!OQM .T@5T>LILD\4HSN4/,*% O62V&C*G@O05+IW,YYGNW6O93-K@?KO+ZC/J >FUFN M?[PK$2!$[R)[:7,3:7&C"S^L2#F^":-2M09*U7%3:%6F^L- &%.?2BSO[0M05 MIPC@I.G+VD;M0 YILO9 ?=EWVPOMSV/*.>[6$]>$"4:C3Y[?!#E85/1/>"U[M:EC"@D-AZVNK^1]? ^F*@$.H'"1/=4T+[FWUC XTXW>=X+L6^"W;9,S!PVV+? M? W_#SFL(J$<<[S;TC;VENCOP"U10]\R!M!B$);;\"I7P07$%5I#=XK=A4Y>*P[5#12'E8PLADQ:B*Y+ MLRFH;CNA9&#Y/=> $\:8*PC97H7R)=ZD4 !='$.Z_FQN+4:]O /=ZS4Z 63, M"<%8V*'1H MH9Z!*\2FTXWN+6OP([E(FBJSL2.T@J/^/'6]Z2,\>M"A!_8 GIQS.C=,"83" M*G_6W#TX?BGRXR&U 9+7Y24,O7P? Y)^YD7W?8?9/$%"CCXQ#N[1#X)V.-WL&$4-DAK(? H45#1AZHQ %1I'S5.R'R:(1?,@RGD)E!JLW1!53 MU! (#&:A]46?"#)$AE H2R">'E@/12*,>S'D2R!Z(J(WR",#LXA;P1T>>OC1E MMR'DM@*SX""]33)!(&FW@\A$- RA4(:1BC>W4QK?)15$T *_V*JNS+G75GM ^SS4=M]-691ONEDIU4F4 M5P?3,M6=G\(\DRAJ'>)9#EB%3)- DL*""NE'6);$201[APXC AE"$8OA7E5N1 MQ[_*L+NABI(6O,2[<@#) >_*9D(]U4(W!T7C*[[+$G'0)P/8.*T2A)+J*D:6 M4%%_12ZQY(U%VXE)M?M_N-A_&D=7/_=_S_195U8_QK@&.2R MKR;TD9JSYAVH1R]Y _+(0585*/C[> WU9ISV9K>U4. <@7;W>4M6H/Z:X<\$^ M5"7F-CKFA!SD^F\\LU_7J:4_88FHOIP!8?+<[N9UN1R9Z]L*M><0N$7E* MU&I=]6A- YM9T[@S3JBO9(2,O6ZD6(37U7T.Q2:5O&5FHE>T4'I*5FQ-3^D@H\X3YY M,UY=\,"U_DA'>K2C_)40P&M,=6^#..\]_Z$.@_)24/W@YR"I\(YJJ@UGR&)G M$VONS QC<5U[NF0_RRGZX_.)-5U.+WIK3R?V9-I>HFV+,P?LVC5MT?:]QUGA M5YM@3_>R%^7KDQ5= +FPMFAFK:BLMFE.? AJ<<15W(GEN>V/'5N.W^8+TF;ZY]<3N>(M;ZA:RUE^D.W9\SUWJ) /:?_-*=P'I M=F.T Z7**_#WW+#;J9D/W*EOO%LNC#?>K+%N")^@96H@1RSB]SP1&94*C=?- MG<:9SEUG8;R;38QG;K/&CU0#G+2,AJ7SF6NX[!,&R<]X.)UXYD-OX?2$UO1= MO2$?S?%^'_8?,)Z+_#/89$@U3- OJ%W0\&E+G3#H:^"7^Q*SV MY\Y^P. R>SZPE6++C-KG001CLV?/) %>]ZG%)@')BL.38'DXWH,)/ MF;I^'P;%- N%%T;I@OF]=RF@=]\A&=\KWHR=$(U?(NQYQY&J>,.Y+SZQ^Y-$' M*$/?@.M?:'$A)AR[NBT;Z_'IVWP#' S?M7O\]7'+ WZP!O?44!)Z,LNQPZ4 M\.X+_Z4"+I,#,SB*ZZ]"HFDT7Z-T>U_&G2Z7\XLQW15-A@:3Z!ZST@UEC/C= MKU!\.J*3Z=3REI-1&])F^G5?1WB<>9S\?J,\9)(7JZ@L*.076PQ'&: [=8"F M9RW=\5U^,VE#+/&LV71LAR?E?>KNY% <)WK=<9WK\0FE:@_/PR#7SW^29IZ^U M_CN\4MU].NZ4"V?I?4NG/'[S[RM.Q$?W%LR8,#YE'\TT9.O)6T?](CC"O MH\K6S_A]=Y=)6S*Y65A0-)#7GV:G_^TI':UIN[\3E\"F/?0#'E?&[ZKL>+ZA M7X_!2J=*2_D3*_6G]0_47,O? 96F&RU^W>1_D&_P-@H2O8:ICSZ=G+)>_&"/? ME"*C7VE9B;(4.WJYY0%8.PZ YVLA2OT&%ZA_MN?EOP!02P,$% @ +(- M65.&ULI5;O M;]LV$/U7"!7H)]F69,?YT<1 TFY8AW4+FG;]3$MGFRA%JB1E)_OK]XZR%*>+ MTV$#@DBB[]Z]>W='\G)GW5>_.(0KBOM;&7R6;$)J+R<27&ZJE']N&#'Y965?+ M@$^WGOC&D:RB4ZTG19;-)[54)EE- _L>ML_-$E*T/MMX[@T&M M3/>4]WL=#AS.LB,.Q=ZAB+R[0)'E.QGDXM+9G7!L#31^B:E&;Y!3AHMR%QQ^ M5? +B]]1]]^L]Z(A)^XVTM'E) "7?YV4>XR;#J,X@C$7'ZP)&R]^,A553_TG MX#.0*GI2-\6+@+^V9BRF62J*K)B]@# <=DIQ&O.G_2K+#F#V/P<-QX1M9TE6" M[O?DMI0L7K_*Y]F;%QC.!H:SE]#_)<,?8-A (L_$ZU=G19Z_$?_CNZ7_)Q

M27E1VKII U5B^2 JM565,FMA>E,LA@V)7>QO&,DM.8RK,&V]!(I=L7^- 8MX M7F#R?9 F@E2MXP?[(Z*RE= $R-
9LR3,6[(-3);^BT\NO8W&G3$D="S*5%TRQ MHE+C6:6BD0H$#*S!3GK8"(G0782-
U14YSXQZ*H_<&#UZOM42#*Z_(]TX.W*8 M'\$;!?[\2*U&I05/%X5!+)_&*&%G1V7$J"ELD%$7! (^4>V)P,8&I/JM54AB
M+-XI'=5^QK:RU%NO>-^*$6FUXM?C:04KEAS'MT!M&ZQ'MWMRI?+$YCOIG#0! MKNY)?7HQT-$K,^S =)JR7@)?
+#00):C71!E:J1441/)?HF**0*&ANYY47' M[><[KXZ)!4&WXPQA0B!&*-
Q6*BV7FEB40Y'VS3$6[V%458JIQ"QMZZ"X&4&" MT:KE#>Q1+2[),6HI)B(:](6-
$:4ND5O@#NZ*/"CP6&0.XF*)GO387CCN40BK MU5\4;6KK@^C%YH'!<1.SZ
;*BQU4B*9=K\FAKU+D=2@\^@"A%4_<\FD#@ODQ M"51DSC7CT???#]J/U.->1HK!X?
1MP>5!V*56:QDZO1[%!7<3T9@0H4Z\BV73 M-UUWQ8HN^0:QOSU '1##AH=6C+"#0@?-
T_4*/=+@#8,KI;H)Z<9V$*@9_Q?G[AE1%I>W:/J\4"EJ"B.0XK'86_)QR+_FXHOO=CS+#T_
M.4VS;#98G69IGA7BCX83].)TGN9YT3_ZR;\=)O^NVUR*DPPHV?#\?&RO%A*5 MKF+D/,_%=)9F^?
P%\]8H\,QG:0&SO#A/9Z=S\7J: MS?LDGCM:)P>WG9K<.M[I^!1K3>@N/L/J<&V\[FY+C^;=G?.#=&L%;32MX)J-
M3T^2;J/I/X)MXMUI:0-N8O%U@ZLO.3; [RN+'MQ_<(#A,KWX&U!+ P04 M" L@ U9/3/W_/<# !R"0 &0 'AL+W=O;,F>%
<=KIQ_C54B 3;VM@PRRJBYB;/0U%AK4+?-6CY9NE\ MK8BW?
I6'QJ,JHU)M\M%@<)772MML/HUGSWX^=2T9;?'90VCK6OG=/1JWF67# M['#P2:\JDH-\/FW4"E^0OC3/GG?Y$:74-
=J@G06/RUEV-[RYGXA\%/A#XR9T MUB">+)Q[EGP^"5S@3XB]LDNQPG$'1!G+U7ID9U-JF M?
[7=QZ&C<#UX0V&T5QA%WLE09/E1D9I/O=N %VE&DT5T-6HS.6WE45[(\ZUF M/9H_VL+5")_5%L,T)T:4\
[S8:]\G[=$;VE?PY"Q5 7ZV)9:G^CDS.=(9'>C< MCRX"_M;:/HP'/1@-1I,+>..C>^.(-_Z?[B7MR7EM*8B;T*@"9QEG?
$"_QFS^ M_MWP:G![@=ODR&UR"?V'W"YK_^X(83B$]^^N1\/A+731X'.%\.#J1MD=:%NT MWF,)EDN;9I=#ZC#K%
(!K*.N_<:[MM8X%+X!++)FN 5X&4NRO3DZ2.-F/K@_&MZ?>!NXOB[^XYH$ MCSO +;>Z@((A-,F1V%
[&38RA)=BA\AT$*%L4>MQ*6ENJA<%H*&I4RJ[$VMEX MB931:J&-)BT\/OY8")3'&*R5U=]84D(DEI8MM3[1*1P[\+5%?
C(6)_)ZT5*D MQ=$H]9)MI+L%T@;1)GUM^8TU.QL#5(N?A?)^)WFB:M=:YL)QP*T.,7?>HI<\ MUQ*.T&#LMY&5M,UT?
9I_24-HL^-Z;Y2]VBA?_H>0U*A"*W)M$&2TW.KW6FR,
MA>1ATY$#U31F)PN^CH'9/Z9.L9#W#;+95+JH^,AQ0G!,&N=Y9IV4QWD1?I
M<=8H5"1ED<&IV$H"O3MFGZN.E(KDQ;8DI MEV-,XL.6C/-&:&-
VE6W!QXL=$SC7!S85VM[!G&NTE6NF^Z0LSW"QP+$:_HH2;78FE'ID%8@>I,;1.Q3:/\/#Y;BVC""LCOO?/->"\,P=K
M]*LX[0,7!6=P&HG'T^,'Q5V:H]_%T]?(D_(K;GA@<,FJ@_Y/'S+P:<*G#;DF M3M6%(Y[1<5GQ1Q%Z$>#[I>,&O=^(@>-
GUOQO4$L#!!0 ("R #5GP+2MR MYP8 ($3 9 >&PO=V]R:W-
H965TKK3YS19$3CQ496VO!H5SS>OQV*8%5=*.=$,U9G)M*NGP M:I9CVQB2F5>JRG$21;-Q)54]N+
[T8Q_,]:5N7:EJ^F"$;:M*FL<;*O7J:A / MU@,_JV7A>&!\?=G()=V1^]1\,'@;]U8R55%ME:Z%H?QJ\"9^?3-E>2_PBZ*5
MW7H6[,E"Z]_XY6UV-8@8$)64.K8@\7=/MU26; @P/G3UI=$K85@:UOC!N^JU 4[5')0[
M9S"KH.>N;W55*0>6G16RSL2MKIVJEU2GBNSEV&$)%ARGG;F;8"YYQMQ,O(.! MPHKOZXRR7?
TQH/7XDC6^F^2HP1_;>B0FT5 D43(]8F_2^SOQ]B9?R]]@;OJT M.2Z9U[:1*5T-4!.6S#T-KK_])IY%%T?
3GNPTV/6OQSL<7/_UHY$G(AOOYDG M<7PACIH7;Q'!JE:Y2J6OG[=<0JDVF:Q30I:Z0B@HWI)Q08BSB%D48;KS,4
M$M:1"-X\^'&0RL3BL92KL*3:6T0N#9%'-!2N((;8R/I1%-(>R.I%J9;^T0JG M/1B=8Y9,L)TI@]+7>$/O$AAVZ%&"[KV_&-
%IVAH#;PF+V7;Q7TBSH;5DJ< . MIE:%*HG1/
II2'"0P9*0;ANAY_3LPL++SRT[V0:#:,HVHE.GQ+!>JGD@JTP]T",74/D1E>'
MZW\HL7JPCNKEC7F]OL]%I,*6T\'9.TZ0CI9,BUH[GX<0$NQMNBYL'H;M4C3R ML:LR537:!K$<3J'V,$6-]V M"05/GJJ-
#F%(,6(LM((=W80BYL0AB]P*SB/\+<0O#N0*>4_>QP51O;;&O<0O M"OVT+?L*V-"['0#?CWC#9I&6_;>6N W:G311MN-
26EW+1?G8EPPJ@1Z0*,KZ MUK#&MEN>F:9@ !7(IB606,NMQP0GMHIA-]F[4/3)/A)O7,CG]5ZXF\^HO-H%
M;01NN23#NEVO\X72Y0.W8HZY5,;76,>0=U\LC6X;CK55UE=:-^N9>J7S5SU3 MGD
\::0+%Y%'6>@R8]OH!*&'!S98P=I0T7H=+(]I"P<]8,FNT/-]3WDQQK$E M7VKTQ15S6I8Z#86L-\$^@+*)^(X?UA_IT'Y#
[ACBQ+GG)#+FT7?YBKNFW>') MBA<69>^WT]E+A.8IS+N[5[;?OG:RD1M(/(IQOBM+OPL^DYTL%VWDUNU@1:CS
M_3+X5$NT<>;E!@7%&\H='Q)](GU'*57<*B>QASOY^Z-0-+GX:O^X*?B5
M[]3#SDGX684^:_[GQ(N3P)5N+0BW+WV>^>B%+1;%A6/'<^N\WXNG%SX19W/\ M3,Y/>[E?P"X:'6V+
[=MZD9R^/!B9GYXB;/3KT[SWT?[_T/_ MAMM4VD+DR%4;]O:#,\L)SB-Q;_-$Q).D?
_NGWSGKCOE*9YN3W$9A$D\/L,)H MLB'_5W\1I>P5-AB#>S6:&E_.-Z'GXTM_!SA N&\\&4V>)6DZ.G]^V4Q9?^(4
MAJ\&?WJ]\U$D_O'$:/S$Z#OI6M/W)-V: _-#;"SK\ZPMM'&OO/?K23[/\V[K M^\L7M(.#9-@7^])(\+59[_93K?
B=CJ?'Q,]+)RSL^DQA=E&,)H<$SS;Q'=V M?DQPOA'$TFC&. OE?"8^J'\L&.J^5QB>QS%Z$S9J?S=&*H038Y\9!
[3&PWDR M>WG0K+8WGZW:&4;SGJ&G;MOCK<\B%9FE__ACPSTH?"'I1_OO2V_"9Y6->/@X M]4Z:):YFP)-
#-1J=G0["EK=^<;KQ'UD6VCE=^<>")*XT+(#Y7..TT+WP OU7 MM^L_ %!+ P04 " L@ U9O@T+WH4" #"!P &0
'AL+W=OC?&F90%(9('^-/R^ETD@:X MN]ZR7]K<=2[W1,*,%[]IIO*)<^Z@#):D+M0-WWR%-I^!X4MY(>T7;9K8P2P"_!?
C/ >$+@* %!*]5"%M ^%J%00NPJ>,F M=UNXA"@21X)OD##1FLTL;/4M6M>+,O-.;I70NU3C5+P@3V@MT0*$?7,L!910
MF19O#)8?SP ![KG+O$_6WB4_\@X;>:G:' _81\UP][SC-[/3SH2^?_U.=O
M5M\K1M"]@L#R!6]Y!7V7W="%_72FMXUE15*8.+IY21!K<.*/'[RA^Z6OTN]) MEKPGV?
R=R/;N).SN)#S$'O_00^**I;P$=/R=2WG2=P\-Q=!2F)&PCD_/O=$H MPNO= O=$>4,_&.R')7UA03!R]\/F/6&!/_+/N[
F7;S3E$H0*SL-)$IYS53S M,CMO-W N;)]]YI]ZXYG7XT_T@&KFR3_Z9KI=$[&B3*("EEK*/?NL>Z9H)D9C M*%
[9EGC/E6ZP=IGK(0O"!.C])>=J:QB!;FS'?P%02P,$% @ +(-61#" M[$!$ @ B@8 !D !X;"]W;W)K&ULG95=;YLP
M%$#_BL6D/;6!0#ZV#)"2;M-2J5.4=MNS@R]@U=C,-DG[[V<;PK(IH5)>P#;W
M'I]KQ"4^"/FL2@"-7BK&5>*56M<+WU=9"156(U$#-T]R(2NLS506OJHE8.*2
M*N:'03#S*TRYE\9N;2/36#2:40X;B51355B^KH")0^*-O>/"EA:EM@M^&M>X M@$?0/^J--#._IQ!:
5=4<"0A3[SE>+&:VW@7\)/"09V,D:UD)\2SG:Q)X@56 M"!ADVA*PN>WA#ABS(*/QNV-Z_98V\71\I']UM9M:=EC!G6"_*-
%EXGWP$($< M-TQOQ>$;=/5,+2\33+DK.K2QT47O'+]TYG"08SOFLL(MG7>[D;/\C#5.8RD.2-IH0[,#5ZK+-G*4VY?
RJ*5Y2DV>3M?F> E()"0QH;Q M2RDQ+\ M-WR$HN &A4$X&>!%?;F1XT47>.?*O$&[5[3FA.XI:3 [5W4+G9R'VN]FH6J<
M0>*9#T.!W(.7OG\WG@6?!I0GO?)DB)YN&P9H'.RFM^-3;;0DHM;_'W*K.PS, M,5,P(#;MQ::#G.^"WUXA-
PQ]2V[6R\VN.K4GD.8KPA??](<*9.&ZH$*9:+AN6T6_VC?:9=M?_H:W7?H!RX)RA1CD)C48SQH@ M04JF**]K:U\D#@ET-
[I/G^XF3V^-_=/MA?#LKE#:G8WVWI=OIU.7[47!W<24
M0N/)UMB">_RTNZDKK>!YV%2HZ6(V.YH67.K1^6FX=V7/3TWEE=3BRC)7%06W
M]Q="F=NST7S4W+B6N[VG&]/STY+OQ%KXS^65Q:]IDI++0F@GC696;,]&J_G; MB_F,-H05_Y+BUG6N&1UE8\R?].-C?
C::D45"B-])_"X7&8#7?BTJ@_9.[W9Z.3$+$[;*,E-I+_6.71DE,RD<>]E<
MO3J=>NBC7=.LEGT192^>D'W$/AGM]XY]T+G('^Z?PLYD[*(Q]F(Q*/#72D_8 M,AU^&>0MO^_P?2>.
@_Z!5(*O74ES\39"#GBA+T1H_,??Y@? MS=X-F'N0S#T8DGY^P9UTS&S9%98+8!GOV<[MH87E2MW3$U&2--
XZO+02M_AA4KZV6F M!&Z0RFNQJU3GRXR_9<[P3@XVG/_,WR8,RX8QS> M >C92]I0V]Q=W-@^"
<"S.=R@[LCVM]WX0!$"FQ M;+"4YU_ 6N'^F-WN9;9/!S$:\==T (4M*&EX'$^,_I+I6.Q"DE#IEW&A/P;CCH4 ;
(Z6NQ).Y#=>.-><,LB%M_#N\4& M(%[. X4NFP#=8DOCE[Q)P5HS 75^_,ZQE=85E%Z+TE@$0J?<^7OTF538F^SN MY
@]3="'U$*Z4-.;5%Y_N$R9C-N?N(5)\VCBP8,$(IM;M6T*$7>^3&/45+W)6 .L6A=C#\ M#X3@_"Z#>X*[:Z6&8O%
(]62@#ARF.G X2."?7;#P@_.R('[L*P'_G83@P<K2#L+P*Y->N"W4P0H2]KP05)WH(0HC^]010 MRFU-%
(8N&DF2_#"F[K8*M!H1FP5RR>5V"P1NK2D@S"#H:<<0#H\2#H\&473) MW7[,Z"_[

)J\X2J=_QJ*4*_I]/2\#Z'_*]F!'&;+=UW44'E!484?:,%>J-B4 M:)P_HT/6O4[2!.?IN.^*W_DZ"7+V*],96#-/\$.QHNC
MD[3\!9L?CI[Y*FHX-E5]/1>+X\',BB MXY1%QX-(7T6V^85 2HY?PXR^?!F4TC]Y](E.1Z@?[IN'CAZ"BV+7U)!@8//0
MXQ_#UGA4#;!W[&5Z@Q; *'..>7JI__9O3NM4*MSNN#3!J]JX#F1T@-75'LL$*_FB7MP4PDA 5 ->X
M\X&G8J$3X.@X/+@*3M(T"A 587?#!+$AZQ/!,,G)@AC=4A6J4[RW%XK:>H60 ML1C=?-OWE!6:,!Z[A'I+
()CJPLJ?,W3GC[,F)08']&/*/EB5IR0^^"F&HA%UTRKMN/R.9Z)XG0.\U# MZO\>/0M-N@P)&?29E6!KB.,
M077K*B+V$EA2\Y1Q:\-0'UN1T,M2I[2)((46*D8/&B]JB'),RA#NOSY[UU!T M=^K>1;,>S_U(7TK;UW-
DXJCK?,O>2X=RRU5O(":=G:_GA\TH40 M#S29 E6EBI&I@]+8O./T,B+6V:IHQ%>:VE(*$O7=52"=5B5F]IYE'9/2C)OP
M(+X*?JVI:XQT71Q08>\&&+"#.VA1(3CURX'1@HPH$8P>??J-ZL1=)D0>D14& M?')29V#H.UL-
,QD2@9>EY1+@<8/<\R9QSYM![OF.]X"# ONYY[E7K>&]0>=] MFC8L$7N3^37!#PU'W?=JC>B2.
PM%B!=3SWMG/]PJ![TYWS6OE6>#7KT&G.U M]E#WT;F*LKJGX/>^4!X4V^_7;]'U;%< 9VMQ^_"EI-
&&QJ^BH=^JS,/0B2#8 M1J>,.I_>]XR_ZVXA]@!]H6WZ,>BOZ:"WNH]9R%ZT,.U,2@PNZ>D8M 3^Q(_[
M,0EJ)U],^26]],I-20O[HS_M?%XH!*B /J*$&5/[^*4AW4T?:E;Q\T2[/'[E M^00F >V!C+?8.IL<'XZ8C1].X@]ORO"Q8F.\-
T6XW N>"TL+\)Q>S34_2$'Z M?'7^'U!+ P04 " L@ U9.@)G.M," "M!@ &0 'AL+W=OX!?
#C=Y;@XMD*>6KV_S()D'D!"%':AP#L=,:[Y%S1V1EO&TY@]:E ^ZO M=^R//G8;RY)HO)?\-\M,,0F& 628DYJ;N=Q\QVT\?
<=')==^A$UC.X@#H+4V MLMR"K8*2B68F[]L\[&&T1> > N(O>[&D5?YC1B2CI7<@'+6ELTM?*@>;<4Q
MX3[*PBA[RRS.I NV$BQGE @#=Y3*6A@F5C"3G%&&&BZ?R9*COAJ'QGISF)!N MF:<-<_P%\P">I#"%A@>18?
8W/K0J6ZGQ3NHT/DGXLQ;7D$0=B*.X=X(O:4-/ M/%_R?Z$?B[@A[!TG=.]GI"M"<1+8!Z)1K3%(+\ZZ@^CVA-Q>*
[=WBCV=(Y6" M,LZ(+V>9PSW11<>/\/!6LS7A*(SN !$9S%$;Q:C!S!L<"^:TNXNS81PEM_!< M(.22V\?KDF-
<-4"EY)IEMCJ(?9>'JJA7Y4; 0U7J4Y4WR)4LP5@/+X+4&7/G M4*)H @+5](:C#RX7QABL'24NQ3
HQ6GK4CE335[A[*I/'25![9NL*V;1H== M)2/8A?BO0Y,6&>RUI9-7WGFULR1-*@_4.E?P!02P,$% @ +(-67C8=0!] P
W0H !D M !X;"]W;W)K&ULQ59M<^(V$/XK&NIGIRP=L[7I?GGVT$CM< M2?59YP"&O):%T",O-Z:Z\GV=YE R?
2K/AE+E7)#(IJX>M* %)$+\N2J;<;*.1JY(7>1C'EB]Q8A3\>5FP!,S"? MJB>%DM]$R7@)0G,IB(+YR)N$5S<]:^\,?
N.PTCMK8BMYD?*S%>ZSD1=80%! M:FPAJ^OD!1V$ (X\LZIM>DM(Z[ZTWTGUSM6,L+TY#(XG>>F7SD#3R2P9PM
M"S.5JSM8U^, IK+0[DE6M6T?,Z9+;62Y=D:YY*)^L][
M3N10WC+#QD,E5T19:XQF%ZY4YXW@N+";,C,*OW+T,^,$%3QE!7E6')],9&16 M2:&E@HQ,00-3:4XF"P6
6V$TZ3RSEP+TV= WF-X&\=-UJILZ%3V0JD\>I3"Y M)C^*#+*_^OL(N\%.-]AOZ-& ORS%!8F"+J$!C8_$BQHN(AG0 _P-/
M\;1 E[QW4_<5$O\+A?2:0GK'-P*OGFQ9)'S?Z26X]E.3P8TB*[)__W&6X:8 M'/"'M9"R/BM@SPK!3@?7Z=_::O[Z-
Y:=#X0+M)5+C=SI,W=8["/:627U\BUX^0.>83Y!74?\;#_4,834]/+N/>-6U]#,.PI8MHOZV[;-OU
MHZU=,@M))SS;"R*D;5!A=/G]MH-!LWZ:)9-W):+MF@^9QO&V'^QIN%N:-.=X M-
1)F$AQR]8[=TZ26QJT.0K;N7H[08_9A=W@ MS3NI*VZPC\[)'[/D_I9TZ#OH"-M[VXFCN!VA'VV1/P#/0)!/ O_QE;;-_4TO
MGY/IY.>0.#BMTFB[=<()%-"X;4?I%L0C>Y/KZXMTHC;@#OW8:VM1^9V6O=XV M_[.T!&^D#X3V!SM2V-TE!
[]&O1TIZD;[&ULK55M;],P$/XKIS"A3HJ6 M-,G:K;25NC$$"%"U\?+932Z-A6,'VUG9O^?LM%D'7?>%+[']CWWW!/?>;I1
M^J>I$"W\KH4TLZ"RMIE$DJ193$\2BJ M&9?!?.K7EGH^5:T57.)2@VGKFNF'*Q1J,PN&P6[AEJ\KZQ:B^;1A:[Q#^ZU9
M:K*B'J7@-4K#E02-Y2Q8#"=7F3OO#WSGN#%
[8_;?,X=7JZ$\5_8=&='%#%OC57UUIGLFLMN9+^W.NPY7,3/."1;A\3S[@)Y
MEF^99?.I5AO0[C2AN8E/U7L3.2[=3[FSFG8Y^=GY4M/_U?8AA*5@T@*3!=S\
M:GE#PMO0FPMCZ')\J!O&M5N%P5>V$FA.IY$E!@XGRK?1KKIHR3/11O!925L9 MN)$%%D_](V+>TT]V]*^2HX ?
6WD&:1Q"$B?9$;RTER/U>.G_D^.0"EV0[' 0 M5V<3T[<9P$5DD%]C\'\]:OA*'YS)
(6L3R$[ACZ_H[HM6H&@2CB:SB'BQZ$7 M%DAP[7O!'F+.=8KU) ._7(:0M/';?JXN(L+N:*:-A8+1]%6"*42U!RX7$_@
M]:N+)$[?_/?QQEA.-4PQOQDL6_&8R!/Z@Q/@DCBIUA!G<]K[?^(EPH#V'I#I MO74GP[Z1PB>D)E$I40"O28=
[=#D;N.Q/C(%M9]3Y&\:8_=F(GCO2MUH8C$2]H.DG X'I\>W'>$ M.U26YVW="O\/"J2+GW/FTWT1_CR,L_-
X0=9F(U'IWN7$#Z(4A\7H,3R,;) MGI6&238^5(/17H>M4:_].V+H)K?2=LVV7^V?JD77H1^/=^_<9Z;77!H06))K M?
#8^#T!W;T=G6-7X?KU2EKJ_GU;TW*)V!VB_5,KN#!>@?\#G?P!02P,$% M @ +(-66I:A_VO @ Y08 !D
!X;"]W;W)K&ULK55M3]LP$/XK5D (I(B\T@9H(U%@VB:A5<"VSVYR;2(2.[.=%O[]SLY+ M,UKZ8=N7V'?
V\]QSY_@\V7#Q(C, 15[+@LFIE2E573F.3#(HJ3SG%3!<67)1 M4H6F6#FR$D!3 RH+QW?
=D5/2G%GQQ/CF(I[P6A4Y@[D@LBY+*MYF4/#-U/*L
MSO&8KS*E'4X\J>@*GD!]K^8"+:=G2?,2F,PY(P*64^O&NYJ%>K_9\".'C1S, MBM"/?+-9VCSN=!\"2^D^9)-
L_?"M4A22\7+%HP*RIPU M(WUMZS 1!\!_!;@&]U-(*/RCBH:3P3?$*%W(YN>F%0-&L7E3!_*DQ*XFB-. MQ3=)PFNF))G3-
[HH@%"6$G2*&E)R_XIG+T&2TV>])L\FCL*8&NDD+?^LX?<_ MX!^1!\Y4)LD]2R']$^^@UEZPWPF>^0<)O];LG
2N37S7#P_P!7T! L,7_$L! M]N7=T(;[:?5=NI(536!JX661(-9@Q2='WLB]/B Z[$6'A]CC)[R;:8UB^9+\ M=0*'0YP<1;X;7)/_-
>*Y@3FWSG$'"90+$"3PML[38Y(SHC)>2TQ#GO4+^K3U M)^@]?=Y5FW>W<$PB^S((!_;
(#GQ_"#2UT<="19*9@J6PQ@958;M1.](]>^2. M=KRA[7G1#FG"2UUQ:EK.>\AX'.WX?
#L*MMYO*L.*G'IG>T1$8W^7,;CLY\]< MT0+;W+NRZ.QHJPZZ"[VMC1?8WJ4[=(2VZXUW(J&F?3^N,V@])8B5:;"2& U-
M%^J]?0^_:5K7=GOS #Q0LJ>CR\L(IJFVAB*5Z:1+;C"MFBF&;Y# M(/0&7%]RKCI#!^A?MO@W4$L#!!0 ("R
#5F<%G*NN ('(' 9 M>&PO=V]R:W-H965TGKJO2'$JJ#D4%'%?F0I94XU0N7%5)H)D%E84;>-Z16U+&G61D
M=5.9C$2M"\9A*HFJRY+*IPD48CEV?.=9<A;L?P(;3Y# MPY>*0MDO63:V4>B0M%9:E"T8(R@9;T:Z:O>A!XB]-
P!!"PALW(TC&^4EU309 M2;$DTE@CFQ%LJA:-P3%NBG*G):XRQ.GDB]"@R)0^T5D!9/_>#.I@Y&KD-A9N
MVO),&I[@#9XC@,2>$&TA2_L M$@TM7_B>1#?EU\"CS7!S-TY515,8.WCX%SS,)^Q(7C37KS:O,]FU
MDA^<]31^&&Y?'_AQ3,Y+(37[16U+P6I=PDR32Z9247.]<0_Z+/^J]_V8?!9*
M$71ZM=*,+VJFVVRMB:].TQ$[;/2CG31]],6]>HQLJ M%XPK4L D3(]_3PE+I:P*SXG,%"MIZ)=F7,^5<]>),
<]QQM$>0P41J"X=\U MG$&>:R2TX]L*M-?HU(+MYS7Z2^,\.C-F$LYX_B5+5'KN[3MU M.P'_J$J;#!V+N([K=> -
&W^'!F]XE[\I$_#L%,\Q(6>\P."6S(3'B1"LG $& MG"+C)6FONV!+,WVR8"(A?[Y%2/)&02'_VK=!M7YOOWY-
LD,Y9Q,X[B&+)(AK MZ(V>/J&!\[S#.Z_QSNM"'UW5W")\2LS!D@_SVCD=^YG*0.ZSN!OS8PIDRG.D M;U;.B-*1L>)P]C=
((HT>/M]PS.A!$4$4BLKLAA1U3("."8(G"LV)'I*G3R+7 M&3[_X?]?##]1_\DU",PWCP:Z!)WL]%X\6N49[H? O:I83MYF4R
'6;DCW3Y MVWX"89!+(A<@F&\0E,"'[Y$.EI&)EHJUCBKR "11C$&1(S78/21A8E+J- MV&\D\NW8)T-
[2&\+;YW378*N'='&QFN0VEN$(%";:8)E!\L++3]T]F)U<,!O M..!W

C8W"25LAU H;6JA4)BMZB:(M66*.3L>(2GDE<4;V?QYQ[OM_N>71?D]NK[W;Y]OH9@^,_YNG5U BGW*S-2S!
MHIA)I).N[JV8\FEK0/UA:Q1'K8$;;*+Z$A,R$Y/4("=PC3W+W&3^]8*#('3Z MFQ%UHM8H\%KOZ$;'1Z[0V'LC8V/204#C?
FOL^>V7ON>V7[J10?&&Z,JI[:D@WW,FZZ]. BQ7@@XN%13))3-4L=9X9ZY;R_P)R9P%9'=RC M:H?4!
[5;/CS+BZ@5!6T"47OH$5__K/$3@P<*_9#RW&\EDF.[6KQ..I@0M@P(>P,707D/2_7[=Z^/C/PK-)VEF"VGY,/ME8H?U
ME+8+?&0/W8Y H\[F<]AY&-TK#*2]%:\;Z)&,H*WO=OJ+&;\RX%]VT-TXZ/YT MTM^C\@R$PM),H)CG? FH6JN9X+=-
E2M32E.&3>88H*P9CYIW4H$)&++(5$I4 M5L"JY=.1C*G$)@_-+ ;.E,SP^7\TP7PR._:@_!+[%HW#=GZ)
[##2WQ=3R+92 M3#"TPLC=S3$H0)N$=$!#Q&LUW:YK>[0K U'/5)?[FV6UW>D[YB89?BAG<,411T[Q&]545\
[U@/%Y^:J M;\R5XH5Y3($E(/0"?#_E7*T'6D%S^3OZ!U!+ P04 " L@ U9$Q_)JZX" M #Z!0 &0
'AL+W=O7Q$#3;MB&=0N:=GU6;"86*EN>)#?MWX^R$R\#TF#8BR5*Y.&A MZ,/)1NDG4R):>*ED;:9>:6US$00F+
['BYE0U6-/-2NF*6S+U.C"-1EYT094,
M(L;2H.*B]K))=S;7V42U5HH:YQI,6U5S!+GWSG\%+@Q>WMPE2R5>G+&EV+J,4<(M)>;6(7!:GO$:I71 1./7%M,;4KK

_?T._5-7.]6RY :OE7P4A2VGWID'!:YX M*^V=VGS&;3TCAYV\"4A=5T*RC.9M^I[]^4,="@AD7) M-<+[>[Z4:#Y,
DL)G%N0;\%F/5CT!E@*MZJVI8&/=8'%W_$!$1O813MVL^@H MX-
>V/H68^1"Q*#F"%P_5QAU>_,_5'BJRQT@.8SB57)B&YSCU2 8&]3-ZVH.H[C:[30'W"KD\[3]8^:'+((?
C1.H@7'JAV&T6ZXEIT9=P9QDBEI3EJYA!J(1(Q0VK _U,QI+
M]W1IM<6]K03S#Q(_(+8S._62A[LZ;%"O>ZFCH%L.JIE/W4EF:%=VVI.&,VCG0_4K17[0U7()AW&>_ M 5!+ P04 " L@
U9$G8-VXT# #A"@ &0 'AL+W=OED M$:5(CZ3B[-_W2#JR$]E:4'1?)+[\V4:JK[H",.2QYD+/@\J8]448 MZKR"FNJ!7(/
G5*JFAJY*EE%_MY&,Q#R+K$'#(C46@^'N :^#< J$;_VPQ M@]:D5=P?/Z'_XLZ.9UE2#=>2?V&%J>9!%I "2MIP\TEN?
H/M>9R#N>3:?014<4DJU"XOSVAIR7'ZBABYF2&Z*L-*+9 M@3NJTT;GF+"7-SF".R8WB%1I\K,HH'BN'Z*/K:/)DZ-
722_@[XT8D#0Z)TF4 M#'OPTO;@J<-+O^?@A\[KX8:'X6SN7.@US6$>8')H4 \0+-Z]BI)+;8[:^?-Y
MJ+SP"9ED^$FGHU;N,U7,4G]?["76:3(ZZRRF6=2.[Z6A'(%'J34Q&?VP\/[_ M8?^>\.]BFU-=D1+KO2:EDG6'H!B.)
(M;S!,2ITD[^Q5?$H+<]I&O9<%*EGNZ M[Q32>-CQ%4&37?"_N'H,Q4_T 8VO %\0^T;MKMZ JIUT'%]V/7P)G@S2HT$:
M#J;'S19,Y[(1AB ^O-[>=!"1MP=68_*VIYZ,VGHR>G4]N:&F4"OP-5!%PW/X .=1+4,@)_SCL$6*497VB
MW8R<3(9]"N.=8)3V"4YVQ!E/^P2SG2":OJ\ .ZL28]PM+&C0%Y16X7P:QUCT MM";NR4&./5#>
[%&N$];X/$O&9YTJR+'6,>XYL)>4YU'61N@0Z<*]MJ,&M7+- ME2;.MN] VM6V?
WOOVY:=N&_^;JA:,;'1GQ)5H\$$>:1\0^4G1JY=$[.4!ELB M-ZRP!P5E!7"_E-(\3:R!MJM=? -02P,$% @ +(-66,=T"O% @
50< M !D !X;"]W;W)K&ULK55M3]LP$/XKIPQ-($'S
M2FE9&PD:3=NT%P1C?':3:V/AV,%V6MBOG^V$KF5M!=+ZH?;9]SRY>WP^CY9" MWJL24<-
CQ;@:>Z76];GOJ[S$BJB>J)&;G9F0%='&E'-?U1))X4 5\Z,@Z/L5 MH=Q+1V[M2J8CT6A&.5Y)4$U5$?
ETB4PLQU[H/2]JM/6N#Z_)G]H\O=Y#(E"B>"W=%"EV-OX$&!,](P?2V6 MG[#+Y]3RY8(I]P_+SC?P(&^4%E4'-
A%4E+>QT6 .$R0Y U &BUP+B#A"_ M%I!T ">UWZ;B=,B()NE(BB5(ZVW8[,2)Z= F?GTAYP33G\3
M>PC'D*'*):W=B8@97#;*N"L%A!?PE3XTM*#ZR5D34E--&%RC$HW,4<%AAII0 MIH[@!&YO,C@\.
((#\$&51)IMRN&64ZV.S:*9_RQ%HPR1&OG:I&&#\?,NY,LV MY&A'R!>U[$$8'4,41,D6^&0__$O#>Q '.^'9?
GB&N8&'#AYOPGVC_>H HM4! M1(XOV95-GC=5PXC&PM8KS:G>)LE>$ML;SE5-_?7;2#E>I1SO3?E[4TU1V@*KA:*V
MV!0@HZ:ZG0HU2BK\6[(U(2K@$?C3Y4(=22Y@B'YDX5@C$BE56NO75'V\3;2__62FK)!ALG$0U? ME-
&_3F$O3E[4D+_6P^R#\XW(.36%P7!F8$'O[-0#V3;QUM"B=FUM*K1IDFY: MFGY$*N.G=D.M/]^MI-F0&C&)KX0.SGG^-
YS+\D=;;AX MDAF 0L\Y97+L9$H55ZXKDPQR+"]Y 4P_67*18Z6W8N7*0@!.+2FGKN]YL9MC MPIS)R-
Y;B,F(EXH2!@N!9)GG6+S< .6;L=-W7F_O+&J9 J1'28?RJ-9WF2$/<7K^J?[:YZUP>L80IIS])JK*Q,W10"DM<4G7+ M-
U^@SB@FGTOZB38WU')244O&\)NL(8$^H(>
[&3H_NT!GB#!TG_%2:HH#_F>'QZ@3[OI,T@TO6_IP0'Z[/C3#]'GQY_N[])=7:FF7'Y3
M+M_JA6_HV3H8ZQ.S@#\%.>1K)15;*?.^6$]"/QZ.W/6V>VU0[?A+FC6!O6C M8!CMHN:=H9L7WI4L<)C1[_1)
(@U.)/W[_JQ]ZG#F* Q)N@T9JL5C36'[*@$ MHJTD@L%>"M,V9A!Y>V8<@9EW!ON?5H2-%6&G%?=
<86I=Z+7:Q/:.^+M782O' M, Z#/;/"=NM\'.ZW3AO4C_O!?NNT48,XCN(&M6-$U!@1=1IQ+27HE#.@*=)?
M5"2U!SWN(ID0DW;[I2>Z"_N0*;K];!/U'G$<=7LG+LE&*S4XK-3R2V4Z>X
MJ5/<6:>%,"50+SU44/,=,CUJ>K;0\XCJ[=;O4(GB5O/X>DS::];.$/[5^E.* MS4\D5EGO;HT"9M#[CL6*,
(DH++6\=SG0A1;5\%1M%"_L=/#(E9XU[#+3\R8(M]#/EYRKUXT9.)H)=O(;4$L#!!0 ("R #5G"T+D\A@4
%&PO=V]R:W-H965TV#S,_(:=6?_- MP(Y67'S)9HQ)]#6)T^RL-Y-R?FH863!CB9\=\SE+U9E'+A)?JEWQ9&1SP?RP
M<$IB@YBF8R1^E/;&H^+8C1B/^$+&4*+YPL6\]59#_=>#MQ&3S.9 M'S#&H[G_Q*9,WL]OA-HS*DH8)2S-
(IXBP1[/>N?XE))^[E!8_!:Q5;:QC?*A M/'#^)=^Y"L]Z9GY%+&:!S!&^^EHRE\5Q3E+7\7<)[54Q<\?-[1?ZIV+P:C / M?
L9<'O\>A7)VUAOT4,@>_44L;_GJDI4#*BXPX'%6?*)5:6OV4+#()$]*9W4% M292NO_VO92(V'!1'[T!*!])VL%]QL$H'Z[T1[-
+!?F^$?NE0#-U8C[U(G.=+ M?SP2?(5$;JUH^4:1_<);Y2M*\XDRE4*=C92?'+OJ0!3X,;H3D?KTTQ!-YSS- MN&
ANF49\T4P0^=/@C$U/62&#C2GDWX4JZVC#;C8] Y>O.7Z M,NIX1^A^ZJ&##X?H XI2=#?CBTQY9"-#JN'G@S""I,?
(,C\B8A);-8KO.LH4/+#/K8GTILS4C<1UJ%L?:A<>T^SN1^PL]X\GX5B MR7KC'W_ COFSK@J0,
\21H%@C7K95;WL+OJX\>,/V5+]YB#UYX6R'7_E MNAJNPSM%^/SO;CDFSF!D+#=+LVV#'I7&>IW M9FCB/_-R-
NO&U^F\ZQR%A'F0, H$:U3 J2K@[$]3',AZ0<(\2!@%@C7J=5+5 MZ^3[:LHZ?'_C9WY$3EI:X&X;;=EX[P'1;:-^'^LU95!E:-
"9H:MK;-WZ!!U, M+HZPB0_1GQ.6/##Q%_H'N9%\1OP17:HN OWJY_?A*B$3%A;I<55.F- EI3/B
MKA,;$N9!PB@0K%&V856VX?Z$: A9+TB8!PFC0+!&O;!9MT7F]Y6B,OZF.F", M6U*D,;*(T](BG=&P1:(:(\=R]&*$-
YI'W)DE=XI+*;)!I*@[W*YS&Y3F@=(H M%*U9.%(7CNQ/D,I84%6#I'F@- I%:U:M;I%Q9T>W!U&RME3";$O2M@FVAFU)
M>I-#=9S!X!5!JIM2W-V5WDS=\U*1^C"*U!EOY[D-2?- :12*UJQQ0BT.8:E.:!TB@4K5FUNL'&G?W@'H1HN-
UE8=*6HFVCOMU^'OT>$M4887/X MROT1J=M:TMW63N^.T>=%R- 1^F/J7GF;DC25Y3EW%L6A8.E/63W-+WDVCZ0?
MZU+3'7/720Y*\T!I%(K6K%[=;A.\/VDBH+TV*,T#I5$H6K-J=:]-.KO";R]- M9?RN>R2-"<'M!TD:HR.[_3J-
:JPVW[DUDU2WMN2-UO;\%XP*12KNEK#9N%NZ M9E'(4G2?1DLFLKR5>[MSZPZX_P&?0L,2J-
0M&;IZIZ;V'M4)=!^&Y3F@=(H M%*U9M;K?)MUOI[^]*O6W7\Z3]@-NG5'[7LC3&!&[_8!;9T3:LF1L+)1*F'@J
M5JAE*."+5*Z7JE1'JU5PY\7:K];Q"WSJ8LUQ#Y_2]1JW&K]>5)LSI@?,I$;J/./G,N7G3Q M99P_"]0 M2P,$% @ +(-66SY
!3R"P J;H !D !X;"]W;W)K&ULO=UM;]I8&L;QKV*QHU5'FA9L"$FS2:04/S]636?WQ6I?.'"2 MH ',V$[22O/AUR8&X^"
<0.:OO&F ^/X=.ZXO^9@;<_:8I']D=T+DRH_Y;)&= M=^[R?'G:[6;C.S&/LT_)4BR*W]PDZ3S.BZ?
I;3=;IB*>K(KFLZ[6ZPV[\WBZ MZ%ROM"].%O& MM^)*Y+\OOZ;%L^Y&F4SG8I%-
DX62BIOSSJ5Z&@UZ9<%JB7]/Q6.V]5@I-^4Z M2?XHGSB3\TZO7",Q$^.\).+BQX,8B=FLE(KU^+-
".YLQR\+MQVO=7&U\L3'7 M<29&R>P_TTE^=]XYZ2@3<1/?S_)OR:,MJ@TZ*KUQ,LM6_RJ/U;*]CC*^S_)D M7A47:S"?
+IY^QC^J/\16@3IXH4"K"K1]"_I50?]YP=$+!8.J8+#O"$=5P=&^ M!
<.J8+AOP7%5<+QOP4E5<+)OP>>JX/.^!6IOO>=Z>Y=L=O;.WGYI7ZCKW:WN MO;_5]0Y7]][CZGJ7JWOO?
_L>O#A<]SN.+LS1Y5-)R^<(K'ZR. MN55]<91,%V4\7.5I\=MI49=?C(H7IN-XIGQ/I\6_\6*B7"V319:D8J)\$YF(
MT_&=2W"AV$5'*Q[:E2^296P._*A_".$WC,A6*Q[K(MX^FL>/6C\ON5KGSXY5?E%V6Z4+[?)?=9 65GW;S8S')EN^-
JD_2G3=)>V"15 M"9)%?I[9["-MO8^^:%+P2BP_*;V3WQ2M
MIZDMZS.2E[OWLZ*\7Y:KQVU_3GEYF#Q\4OJ]U>A:2[DA+X_&>5&NOEANOK+R M\4):;KVV[8O-
RK?]Z>S]M[W74N[LO^UMY>[^*]]6[LG+37']2=%.7MSO_OZC M#UK*@_W+^VT'T=\;/7KSZ(U#L+^)R?[*Z[_@^=-
Q<4HD?GN>:Z_F9)HMX[$X[Q0G?)E('T3GXI__4(>]?[4=^R2FDYA!8B:)621FDYA# M8BZ)>23FDUA
8B&)11#62*S!)K$&,OVB<38V$0_%1'!9)I(B?BS+*&L+)JEX
M:#"1F$YB!HF9)&:1F$UB#HFY).:1F/^$#5=8>67EX6+0'Q;G7@_;@;.[D-H[MZ0^;2X6[2YVHPT%SH6AW(6VP334._:/-
H7\D/?2_7HTNE0_!EX]J[^A7Y;^! MF%^+]'_*7TICZA;&Y?69XAPF$)/5&1MN6"=+A#1VA_4$[>V%)&"AZ8(B>DD9I"8
M26(6B=DDYI"82V(>B?DD%I!82&(1A#5RZ?,FESZ_WXSL,YE8)*:3F$%B)HE9 M)&:3F$-
B+HEY).:36$!B(8E%$-9(++6WB:RR_PM^VTM.'II-J*97VO8[!,/G
M)Z\&.J2):A:JV:CFM/QQ^__N"XZI(=J/JH%J!:B6D1IS5C9ZI)4I;%2G^ZD MVP$S7I\8Y4\G1G6;Y%_*>E;W]$:XW2B+
(NSKG)>.$ZR M%Y(*;=-&-1W5#%0S4S]FOA:*\WJNFH M9J":B6H6JMFHYE3:=OIHN^F#MG*CFH]J :J%J!916C-
]ZH9N5=I]^9:+YJ,K MM;I@/F NF*.-X*BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1936S+VZ+5P] M?
L<+YFC#.*KIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:4U$ZQN2%?E'>EO
M^F2+W#PXJ="N=%0S4,U$-0O5;%1S4,U%-0_5_$IK?+!_9Y8XT946,V MDZ5N*5>E_9_O/2?S(\=TT>U
-5"5(LHK1DY6ATYTE;1M\P?_I;M\/:<0,K7 M^N",0]O:4JCFHUJ :B&J1936C)RZ)5Z3M\2_Y0U(
M7>M5$\AA8P)IEHQ]GX_OIH6Y4$9EAWTJ:4>5K]O!289VUZ.:@6HFJEFH9J.: M@VHNJGFHYJ-:@&HAJD64UDR\N@U?

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

W1*Y60TC3S+M/DJMOJ=+)T4:F2W3A$8EI+"[1[^CSDX;?@Z]_,]U>H4<,Y>[#7+_='E3\L$)R3O'^QZ^+_GHIY.OC:13
M&=G)>>X1WETJ"2="(O*BZKH@#1F-M83L*7$M5GA*AH9Z# C"GXDQ^O47JV/^ MT>0,2)A7P#HY+'OU6CVCBZ
MU3BZVG&\21B7]#O.GVQLKIY#$XEF5$S9.I5-@ZK%G3NHD# /$N9#P@)(6.@> MN,#
<\TG1HKW3PK*.V*1=V:2MM=7FMQYSH%$N9!PGQ(6)"R%A M4?_@AK"..A(+?UL M1UI-LP^S;[?K3R$/-*P/2@M
:2$H+8*BUT_9K7Z[K]W;_] @B9 M@P]*"T!I(2@M@J+5G;==K;?TR_5'"N"G)2<$)=G+.O37W?COQT;;@2[=@](\
M4)H/2@M :2$H+8*BU>VX?2M@Z5\+O+<0@KXN*&G[A= \F/N!O@H I06@M!"4 M%D'1"J^U=C91)(0O\@TU N4+
(\5KZ.IJM6GG)M^JLG?=LZX#J^%ZF&WRR3=M M;/'%#J%[S!5S5RPXX*D!%;GK>U[D%IA0)QZ8M2L>
M#]A2YH3"%4=B6128/YY#SM9#I^,\+5R3>2;U@AL/%G@.-R#O%E=(4'2;L:7 M="H&KE2!:#IW4CD]+YWZSS@-
T"6C,A,HI5.86O!).SYJP;M*@%H%_TF%<[^5 M\/.2'J/ >X=\SP\M\8Q>#@]LZ?R?]_2?O6^)$=1'(C!\P4N.A*VX)3RTP_6'
M[50L\ 2&COIR"> K<.*W;SJ1]\&F[#[)DGV2I7LBVZI!6-<@;&./Z]<0RM?0
M5H96AM>6H22+#)F^6U9Q)U"';;6I[CX=IA:'G7Z_]KBE6K=6K=NJVEG!N"2_ ML+F"V
PE,)8H(6+"EE3:)&RE>ZV$^R1+]DF6EF3=;:WM4D>UU%&KU%^8$$BI MG#Y(0N=+
(C+5/%@U;N5YK<91(Q._=]+=.:=1XVAYVQ:IE2:R*]*K%>FU*O)- M9L!M O0:X?C;X8QZC7#"G92:%CLO9]JT>*;"_3J??
FL^MTSBO-$/V!+L_S5! MB\5)L&.4-(UVZ9Z:_VUD_[YR. M.I;U1#7&91_[A[[LJB\QGQ,J4 XSY2+4PK-F92-79FF*GF
M'K@V4/LSIN[>:J(=U'\7XM]02P,$% @ +(-62CTGB%Q! Y!X !D M !X;"]W;W)K&ULM9EK;^(X%(;_BI4=[;;2EERY MM
M(;7/96:G:JFAV/[O!!*M)S-@&IO]^'"=-$Q0"K,[V0TD^;S*=O*E.;DF2.QS3+,WQ](RO8SPS8^"EYHLI9%@3F?;G!"
M%D1^VSQS=6?6E"7-2"XHRQ$GJYEQ;]]%ME<(=(U_*-F+QC4JAO+*V%MQ\W4Y M,ZRB1R0EL2P06'WLR"-
)TX*D^O&]@AIUFX6P>?U!#_7@U6!>L2"/+/V7+N5Z M9DP,M"0KO$WE"]O_2:H!#0M>S%*A_Z-
]5="X1&!6PG<0X%W1.!5 N]=HZV'IX?NVD?5T:G&TT$EMR<]@7!KU[F:YQWAW4ND3(0.3-31KX=>3C%/ MWXD-
CLG,4!.Q('Q'C/FOO]@CZX^N^$+"?$A8 D+(6$1$*QE$Z^VB:?I[AF3 MTV_5[-1E$@_2)) P'Q(60,)"2%@$!&N99%B;9-
@[EWP58HOSF""V0C'+,K5D MB356[: K^G%YW>6:7NREKBEA0PTKTK_=W)J:NZ853M8((#L40L(B(%@KOJ,Z
MOJ/^M2)1N8>.+!4Z ;["*A-!&\)C]: SLKW 2R,+"?,A80$D+"QAMTU[#BRW
M[=#H1*56?,=U?,>]\2V2,;2XZ4J)'GJ5EP82$N9#P@)(6 @)BX!@+6-,:F-, M0%;_":1)(&$^)"R A(60L @(UC+);6V2V]
[98X%3O?)KLR"<))PDZO>J*BI_ M4Z -IS'ILDW)'37F,L]N^U V0L 2%D+"(B!8RPVV];F=8?T_V6#% M;>9GGF<5?P>>Z._
I:8 I06@M!"4%D'1VL9H['/9I](,[UB:T2^]= D!I?F@ MM "4%H+2(BA:VR#.IT$@'7VP?T"U-
4%I0T9H9EG>PF(:@+490M+8I/G4!^6/]IU?'KA^8LKSWR?,$YH+E)*50EJ#
ML4I*>7FD6MY(MM$G>J],2I;IRS7!:N$J*JCG*\;DQTW10'VP/?\)4$L#!!0 M ("R #5DF=AYA5 @ "1B 9 >&PO=V]R:W-
H965TB MDQ38CY]D*Z9IRR=6^]ZTLN/SD Y?2.1C6CE[R(NOY4PIS1[G:5:>]V9:+][V M^V4\4_.H/,D7*JM^Y&SUW%4Q
M..6?U6;O+\:_W@S^EYSZE[MI%(5ZQH15?_=JPN5IC6IZL>W!MK;M%D7;A_T<7JS5=OYB8JU46>?DFF>G;> M&_?85-
U&RU1_RA_^4,T;6G4PSM-R]2]][:%[K]%B\+'4^;XJK'LR3;/U_]-C\ M(K8*W.! @=<4>,<6^$V!?VQ!T!0$NP7^@8)!4S
XMH5A4S \MF#4%(Q6@[7^ M[:Z&)HQT-#DK\@=6U*^N:/7!:GQ7U=6()%D=Q6M=5#]-JCH]N=9Y_'66IU-5
ME+\Q_FV9Z._L#;N,OC/\0)VM;Q)DYA]O+U519+=L9>ATE&2EJ^J%WV^#MG+
M%Z_8"]9GY2PJ5,F2C'W.$EV^KIZLCB^3-*T"5Y[U==77NL5^W/3K_;I?WH%^ MO5L4)\P[?
5WWXK2E_.+X\J"E/*3+_UIF)\QW#I9SNKS^[?GNP6I!5XK<&P2XFT2XJUX?H>$M(WGFA*T4^HSZMMR$<7JO%>=
M,DM5W*O>Y-=?W*'S>]OH(FAL:1,(&$21#,"HF_"8E/T2?\415Q4BJV*))8 ML?
R6/41%$66Z+2DDJFM2D+!P#1NO8/5%_'[BG-2GG_OM!"!;%/LMNB=^8+'^Y,YD-DFQP)$TB8!,&L
MD7<=XYB@[4H4S<[EF=TR0Q\ M4)HMBCQ6:EK6?B G9A,TJG,8&@/J;D_?3KR=$P&T30ZE"2A-HFAV$(Q.=$D1
M=7!:R?YC(B]4')6:_7.IYC>J^+EAT5U07(Z;S M];2$1=F4E2I-6W,4[*^QJ_[M&8 +NBN=(P*UEU":@-(DBF9'Q!A,EW1?
U$6) M/R:EK@\I_TWC.Y]GH'(32N-0FH#2)(IFA\@83G>(N2A!12>4%D)I'$H34)I$
MT>RP&+GJTG;UF#4QU*HVM.U+F#<86YJXB0!4F4)I DJ3*)H= :--75*X=?O0 MG&9U#L.XY7/GP7@W"5
O"J4)*$VB:'82C!MU:3FZ.1FHQT521*M->EH5\]8@ M0#7I,QT;L.\J*MJF/"&T'QQ*$U":1-'L[5?&GGJT/>TR-
ZV>NTRR9+YLC0[= M4.<]6E#)"J5Q*$U :1)%L^-D1*SG0F:I'E3"0FDAE,:A- &E213-#HN1M1XM M:SM-
46A6Y\2L::ZW\Q'>:&>2 FV50VD"2I,HFIT%XUP]>H\G<1VZK@Y4R=Z] M\9^N1*WY@,I8*"V$TCB4)J
TB:+9*3(RU@LPEQ^D7KR TD(HC4-I DJ3*)H= M%J-E/5K+'B%):$+GG SV/?]P/-K?P1="V^50FH#2)
(IF9\!858_>.&H^O6FF M'O4G-G&>W:M"'X@$U*]Z+=LK=[, E:90FH#2)(IF9\%(4X^6INV?Y+UF*HIG MFWC<*?
U,/J!>U=OWJGOY@!I5*$U :1)%L_-AC*I'&]4N'HU&=4X!W;%35J55 MSUI%&K0C'$H34)I$T>QT&,OJT3+SF
6,1RY@H.H52@NA- ZE"2A-HFCV%QV- MCO4=R +&A\I6*"V$TCB4)J TB:+983&RU:=WO1ZQ@*$)G7/B'KN @;;+H30!
MI4D4S,].4*$-=JA8A8P=".= M\^$_GP^H'872!)0F430['\:.^J10Z[2 H5&=4T!WK)HU'U[!0'O"H30!I4D4
MS8Z'\:'^#V]3W:Q@7&H%0_,[9P:Z3Q5*XU":@-(DBF:GR!A5'[-/U8=Z5"@M MA-(XE":@-(FBV6$QRM7_Z7VJ-
*%S3EI\ZH$5#%2K0FD"2I,HFIT!HU5]VE[^ MP H&*E<;&CE#A4I4*$U :1)%L[-@)*I/2U30"@9J4AL:F0^H'H72!)0F433[
M;F%&CP9'?M?_B!4,C>J:@FKX^XS M!Y6E4%H(I7$H34!I$D6S4V2$:H"Y(VD U:A06@BE<2A-0&D21;/#8HQK0!O7
M(]8O-*%S3EIT:NM-X$)HNQQ*$U":1-'L#&S=PI26E^;>4\3N=9K1.05KVK.[MUZ&MKPYF* MJNE$_8+JY[=YKI\>U#?
9W_QAB,G_4$L#!!0 ("R #5FO#]P2; <)]+ M 9 >&PO=V]R:W-H965T@X ?;C1\FR9=HR(P'OOL22K/.0 MBEZ0.N>E=;W-
^/=\Q9@@3TF]E1#K=_U^'JY80O.K;,U2^%L<=-[;[X+;*,(*,_X M.V+;_&B;%)?RD&7?BYT/\YN>4?
2(Q2P4!8+*CT=VR^*X(,E^_*B@O4.;1>#Q M]I[NE1F,5Y^9=LJW.- M'@DWNTH[Z5#!9U=\VQ+>'&VI!4;I2#*:'D+
MH[30[KW@\MM(QHG9O_T+<'YM(/)-?R1^;E!'+L ;D,UM&N6"< MS8D3<:DX\FFQ8#Q*E^2UPP2-XOR-
#/AR[Y#7K]Z05Z1/\A7E+"=12KZDDBC[,P5L?! LR?]I4L4.-FB&%8/ZNWQ-0W;3 MDZ-
VSO@CZ\U^_LD<&;\U:00)]Q^/Y81LT3]O MT;RR!VJ+ :A%12:#@TP&6IG>F33J74]W7G3P:)RLMHZL^D# '"7.1, \)
M\Y&P 13]#8\Z&V(G ^'2.$A80X2YB)A'A+F(V$!"*8(;W00WD@[T.V'-Q+E M^8;-F\2F!705&Q+F(&'N#C8\FI-
LTQ@:AGR9Z?9P['YGAD3]03?63O@H96 M1Z.)98\.C2JW?WRX_6/M[6^3W35I0DOMJ@DDS$'"7"3,0\)\)"P P10%3@X*
MG"!GO@E2>$B8@X2Y2)B'A/E(6 ""*<*;'H0WU0Y]'^2$1]-=#AAF29*E^W+5 MZVB_^:9)@EIL5PE.SV<=PSJ?
=1QDHRX2YB%A/A(6@&"*NDRC+J<:+Z2018%A MS?A!7<4 UUCSU(*Z*JJBJ>G\P#S1$[1-%TKSH#0?2@M0-
%541S5Z\P5192%C M\YPL,DZ6+&6>E5504YT.ZCH0\C;,?&_EDE[+ MU8RJ:=,\4HYU=2*
<6WT'NTZ:4)H+I7E0F@^E!2B:*L.Z>F]J:[2MT@;R+VE7 M1=.WU7GX@Y;WH3072O.@-!]*"U
T59]UD=^TD4F%"2WT0VD.E.9":1Z4YD-I M
8JF*K#V#TR]@="BKJ8G=%;=H%W]RH$VZT)I'I3F0VD!BJ8*JC8(3&T9^"B=
MT!B6>D9G2>UH8S63,*;34T5!B_Y0F@>E^5!:@**IBJHK_Z:^]/\^R3:I*"55
M5CN(R,@#DVG"?!/*1[8%SQ(YA58/>C(M(WS M/!3:K NE>5":#Z4%*)HJJ-
J!L%YR(%KDH7I&9TF9;1PM:)LNE.9!:3Z4%J!H MJIYJ*\'26PF=,@(]J[.NK%:ZPB[QQZ[QQR[RQZ[R_S\L *NV "S]0O^_-
LF# M'*2.%G<4CV!O":/A:B\QLF1"?IT^,BXNS(U09Z"B*:OX3M4&+?=#:1Z4YD-I M 8JFJJTN]ULMR_WL:1UQ6OX84S">-
&H*6O=_H6-#\LPH;\IW'6@_7"C-@])\ M*"U T52IU4:]:(1<%;H^$JC=,N+'^<>*ASDVT=6C(#-OZ>#^@10F@.EN5":
M!Z7Y4%J HJFRK-T$:X0L=5A0VP!*:D?!>L%1V/!P165F>K?/3&]W MF<3]+I.XDXFKG'[ILM$7U<,
[2PWJ)E2TZ7$>BJ1;KT#Q7%K3Z#Z7Y4%J HJGO.JBK_W;+ZG^+M%2/ MZBHL*,UYX3(O)[DNM!\>E.9#:0&*MI-
:_^A%0L6KJSY2OHS2G,1L(?'&U5@^ MI_#=VZ!V.R);E^\6>LB$R))R<\7HG/'B!/G](LO$?J=X7='AG5RS_P!02P,$ M% @
+(-66+0)S0C!0 =R< !D !X;"]W;W)K&ULK9IK;]LV%(;_"J$!6PMTT9N+*A+,5<'+*MGN\9P5$E2A/=,@Q'3W&<:D-@-P*
[KV#4 M"$9]!>-&,.[;!J<1.)<"YPW!I!%,^E9IV@BF5>_6W5'UI8LY7LX9/2)6EA:T MX^MUWM\;RF) MOQ?
9#;*-3\@R+%M2H<_]Y99$[O:7FQ*YUUMN3F6]T3_Z2-89:KE+UD)N5M$= MB3SL+Y\I>M)NGQ:[XMD]GI9?
FL=%YO":,I)3RN'H-M_C-5EH8KS)"3L0;?GS M3Z9C_"9S!R3,A81YD# ?$A9 PD(@6,=QH]9Q(Q5]^5"]11$N^(ZR^(?

TA7:O M1 RU&R3,A81YD# ?$A9 PL(:-JY@Y:?G86DYCC.9ZP>)C\:MC\9*']U%45Q^ M+.*D&9C?
L=3XJA(CH_QK:U&;11ET]%G>B-D-Z4&&]"%A 20L!()US.*T9G%Z MO70.XEL./R8$B3D2VC*<<9E5G.MN1/@ICT^
MLNVI;5Z^M"!CAD"PCJ],XY23,Y3.NDBR_;DOO]REF30E9ZB?0&DN*,T#I?F@ MM "4%D+1NMX[RP>;("FN!@-
E/4B:"TKS0&D^*"T I850M*[UK)/UK/^?ZU(S M!OL.DN:"TCQ0F@]*"QI:YV//+O^Z@W((%;7KJ%.ZWE3F9I?
>\SYFN/J1M)YJ M2AT%FJT'I;F@- ^4YH/2@G=ZTC30"\%,]GMB"%61KLE.&7I3G:(?FEI5XP;[M39(NEF1JW9[EO)[E?-
!6!*"T$(K6-<0IU6ZJ<^W#TJ=JV& [7"?1)Y(7LRLI M-Y:4\R3E;$DY'[05 2@MA*)U[7!*IIO_(9O^3IY C1QL"M#<.RC-
Z7YYO6/ M$?9L9,\N[!J 1@VA:+7!]+/5/"EAVVIE5X[6M,AXO>BD/=NN'KNKUDQ=G+\W M;[UZ#=@)4R])^XK9-
LYRE)"-0!HW$W'#6+W*JS[@=%^M&7JDG-.TVMT1+.:$ M90%Q?4,I?STH [1K[9;_ E!+ P04 " L@ U9ZI?YS:X# !_#@ &0
M 'AL+W=O;)'B&XT:3 *W@ ^5C< M<=5R&Y2Y %811Q6$Z=:_]J[O=T@!GQ+X&-:#TC+67!V)-N_)5,'4\S@@QB
MJ2&P^EO#'+),(RD>WVM0IYE3![:?=^A_&/%*S (+F+/L&TED.G5&#DI@BS#)A?
M&F'NLY*"Z%9'D=K!CDA%;_^+DVHA40A*\$!'5 \-:
M7AU@G',K9D;6#98XFG"V05R/5FCZP7ACHI4:0O4R/DBNWA(5)Z,'R>*GE&4) M<(%NOY=$;M&9Z41?"V/TM3::2
+B$SJ[8E)IIXNT&U>9&P+@ Y&7Z#'AQMT M]NNGB2L5/3V)&]=49A65X!4J _2%49DJ&C2!I"-^;H_W PN JWQIS
EVYLP" M*^+GDEZBGG>. B_H=Q&RA]] K,)]$]ZST.DU:]4S>+U7\"J+!>(LTQMX@WF7 M2[,*I-\-
HH^%*U'@&*:.VO<"^!JY?"#P([T-MO]/9MZ%'[PQ+G MZ&LIA<0T(71UCOXI\P7P2M:=L4AF]2>&S4 ?
5!0WWP%NIH#4)"@A1W!,_ 8R+P M(NLD._@?C?XP''HOR%IG/7$YAHVFH76G?3.GOU)SO0:N;C-T6RD"=,=)]PH,
M/W+7?1#8@?91HWUD7<\CVEM;KLN&"GO46MM1>#D.7ZRME<&)^L:-OO'/Z:MV M6Y>X"MCO'U$W/N+! 6W?
V]_4WL\19^_>B?6,QY;+3NS$]?);*8K_/N'WH!-4 M?23.U87/52I8X@S]39;*A-UQQ/8'*3HC%&T!<]&=E=AG#ZI0-
$9YE5T$/DKP M5G0F*':H7@W5LT(=NA3L70H^WJ7N3^68878B[S+,"G7JE[5/J'QK_A(]4@XQ
M6U'RGS)!I)C#A:X)$A2S7!5* FN7.BVH< >MC?/R_K)/_5YI;BO%SX&O3.4C M%,^2RBK;;WJ;ZNK:U!3N?
GA5FGW!7!W@ F6P5*'>Y5#=Q+RJ=JJ&9(4I&!9, MJO+#/*:J0@2N!ZCW2\;DKJ$G:&K.Z =02P,$% @ +(-60=;E7#Z!
M#QL !D !X;"]W;W)K&ULM9E=;Z,X%(;_BL6N M5AVI#=@AD'232$V[W9V19E6U:N?:!2=!!3MC.\ET?
_W:0/E8P!.Z="XF0#AO MSGO,L1_J^9'Q%[$E1((?24S%PMI*N;NT;1%L28+%B.T(5=^L&4^P5*=\8XL=
M)SA,@Y+81H[CV0F.J+6$,>B'SD=SQ%Y"@JQT!;
M>6;L19]\#A>6HS,B,0FDEL#JXT"N21QK)97']US4*GY3!U:/W]1O4_/*S#,6 MY)K%WZ)0;A?6U (A6>-
]+._9\2^2&YIHO8#%(OT?'/-['0L$>R%9D@>K#)*(M9I_X1UZ(2@!T.P)0'H#^$X F'0'C/&"
<<R2VW=8(F7<\Z.@.N[E9H^2&N3 M1BLW$=7#^""Y^C92<7+Y(%GPLF5Q2+@ ?WS?1_(5G-T3(7D42!*"]'O .*A<
M>Z21%.#JB'DH/H&S&R)Q%*NC"_#X< /.?OTTMZ5*3?^ '>1I7&=IH(XT//"5 M4;E5*="0A/5X6UDJ?*$W7RMD%+S:\1&
Z!P@![EM^9C#O^SI"(R=MO!:.N.B MS.-4;]RA]RU]G%3MK@Z$J_8 ?W),)5!#1L MCCAXPO&>M.2YRG3==EW=Y)=B
MAP.RL%07"\(/Q%K^]@OTG-_;3 \D5BN!6Y3 -:DO_]XGSX0#M@8[)B+=PP*0 M.%+/--:%V1$>L?
0C(%2V52*3GZ7R>G8Z+)W1%#K5?W!N'ZI^C1F]T^^D\#LQ M^JTTC$B;".N&:3-FU.D[Q .)U2Q[A67/^)0W+=,0W#\\
LYBO>1T%< ;L@ # MB=4*X!<%\,W/.*,'50,2GH/L<3\'*[*)*(WH!JQPC&G0VN1&U;X%R,0FE3[Q M7-
_QBM:H.9L6SJ9&9T^IK;;^ZS(O=9WU%1R\Q/AL0H MV=?6K#DD#H2PW19TRK7;^:!5)1<>R-Y0:O4R5!
&GCJ^)W6;6:ZW^4QM6AE< M"$>36F?'F0-[YY^I0;=B8.*.W(ZF@R7R0"-.5(?EY^UFUNKM:=P8 MD^EHC#HJP365-
/J;B 0R=UE M:E[%W3C%GPY_);% ,[(4\PG.YQ,]?GK@%EZ'4 MZD4H*0>:,>>] &>6[5V$)@;-
)G#F=_1WR4'0#$*WC*])U+6J#$H\L(D\%][8 MGW;,P:AD'F2$"<.R: [L:R!7JQF /IQUK.NHI!5T,JV<3J-FS=[>8,,;=!'L
M>$5);(@]$$\B@9%FJ'4ZF4HP0>=##XG31YFN=[FF^P#IR-_VC&X)?P@,_P8 M)P]S;&\+;A-)E0?8U7LEX" S-
1@FCT'A)5>K&4!HY':\\:&239"937HQM5FK MMR>O^5SY(Z=K0B^Y YG_9O)NJ#;K]K;G-Z!ZXGYQV.7MV5;15\S5 M)"E
3-8JU!GYJGEXMON2G4BV2S&ULM59K;YLP%/TK%JNF5EK+FZ19@M2$["55JIIV^^S"34 %
M3&V3M/]^MB&,$!IU6_HELC'2=A3%D MF%V0 G+Q9$EHAKF8TI7."@HX4J LU2W#\/0,)[GFC]7:#?7'I.1IDL,-1:S,
M,DQ?II"2S40SM>W";;**N5S0_7&!5[?E_<4#'3&Y8HR2!G"5$NS)'
M\X&,5P$_$]BPUAA))0^$/,K)]VBB&3(A2"'DD@&+OS7,($TED4CCJ>;4FBTE ML#W>LG]1VH66!\Q@1M)?2<3CB3;44
1+7*;\EFR^0:W'E7PA29GZ19LZUM!0 M6#).LAHL,LB2O/K'SW4=6@#!TP^P:H#5!3BO .P:8+]U!Z<&.&_=P:T!2KI>
M:5>%"S#'_IB2#:(R6K#)@:J^0HMZ);GTR8)3\301..XO. D?8Y)&0!F:/Y4) M?T&G:O%+)V>G*$3E.3H+B8E
MPWG$QCH7Z0=2##P[CO0-X792EJ8VUK?:<8=F,46_$YK_#=$8Y3Q%K. M"-
O.@,H9?:=>\7J*5UY;;__<,R_'^KI=ROT@Q]T-"7IX7,?:#9KO!UE#HXG9 M4>XTRIV#RK]"#E1H%ZY&.!+O8,(XQ?)^ZU-
[D$O>^B-6X! FFKC6&= U:/[' M#Z9G?.XSV#')@F.2S8]$MG,@;G,@[CM9L>)U6^YPS8X1]T-
,U^XX<3_FBD)B&L3)B!&OQC2_$%YOW"3W(]+:PXT2]U4!D0%>J&UL MM9SA;YLX&,;_%2MWNMNDK@$3"-
FUD=IBZV[2M&K3;I\I<1(T IDA[2K='W] M*,1 W- ^^]($POM[C1^P\5/CBX=$?D_70F3DYR:*T\O1.LNV[\?C-%B+C9^>
M)UL1Y[\L$[GQLWQ3KL;I5@I_409MHC$U#&>\\<-X-+\H]]W*^46RRZ(P%K>2 MI+O-
QI>/UR)*'BY'YNAIQ^=PM/YQ=9?B2\B^[J]E?G6N*8LPHV(TS") MB13+R]&5^9Y;;A%0'O%O*!
[2@^^D.)6[)/E>;/RSN!P918E$)(*L0/CYQ[VX M$5%4D/)R_*B@HSIG$7CX_8G.RY//3^;.3\5-$GT+%]GZ
M_A;5"=D%+TBBM/Q+'O;'3NT1"79IEFRJX+P$FS#>?_H_JXHX"#"/!= J@+8" MJ',DP*H"K'; Y$C I J8M(MT+,"N NQ3
YPJP"GK?E]994U[?N;/+V3R0&1Q M=$XKOI1RE=%Y!8=Q<65]R63^:YC'9?,O61)\7R?10LCT3\)^[,+LD;SYYDOI
MQUE*K@KA\UUOR1M/9'X8I6_)._([&9-T[4N17HRSO! %:AQ4":_W">F1A";Y MF,39.B4L7HA%3_R-/MYY+MY[)C_5
,9Y[=552)^J\)IJB1_]1V*99X0:=-)W M/OKH#[OXG%C&T7!/'^Z)X/PIN]43SO3A5UMY3NCL:':N#_\49'FXTY==J4JK
MOAJMDF<-N!K[+K$]9=)/*1KC]^G6#\3E*&]M4R'OQ6C^QV^F8_S5IP\2YB%A M#
GC()BBZZ36=:*CS^OV)._;TLR/%V&\.B-W8A7&YA=PHJ^ M]GX^F;BFZ[@7X_M#]9!)&1+&03!%/;M6SSY-/?
%3R"!,>YO=:RUCJ&!V1[!W MU)C,#'DUKO:8O:"!%^=FGG98V5+MI1SO'F-E3PVC?:]T#>YM1ABP=!\$4
M6=Q:%O<46>J&CVQE& CR)HS)(HDB7Z9D*^3^6?AMGTY:_%"=]C#WH/J-2Q4[F-Q#)UJ+0*4P6 Z33)AXJ
MW:Q'.K,M'3(C0\(X"*9(;!K-$-5X0>,H16&<%/(&^7A.^D&V\R,2A4O1.RC5 MIA@JYS,%IN11%!>8:9+-?
JQ)+;+P'_N&R]XS++MB36K4,1*#GB-'T531#WP) M<] 3S&#!M?C!@NL+^R2X6XOD'-<;63 &I7$43=6<-
II3;3463DIA1)#;W5T4 M!N33$VKQ0&D>E,:@-(ZBJ?(V M/H]YHM$3INFN?]AI=LT8VW L.C-;3ZDW^ER#58.:.U
:1]%4U1I_Q]0;/+=2 M+'>%&TZ>].L5#NKP0&D>E,:@-(ZBJ>(V3I#I8%IWZ-J8]-:>.Y;9;W.Z1EFG8AM%V\?
2%&BP(U##J.UW'<:GEU">A MUG7C!IEZ.ZC;3I+_R*"'5J@?!*5Y4!J#TCB*INK>F$SF#-.$0CTC*,V#TAB4
MQE$T]=_WC;]$3_*77N[RZOE#=8?2/"B-5;2I8F3FW8.I]@\HS#587Z@Y!:0Q*XRB:>@4T[A#%N$,4Z@Y!:1Z4QJ
TCJ*I\C;N M$#W)'7I%1PN=%5313-KJS5J=F0?-RJ TCJ*IBC;.$3UQ:I"FHX7:1K0[,Z@] MN*M$@SI"4!I'T531&D>
(ZB<''1W&^O&"?-C%8FAG"W6.H#0/2F-0&D?1U,N@ M<8[H%-/90B<;06D>E,:@-(ZBJ?
(V9A7]Q7.7]/S!NKLGC1P]:%8&I7$4356T ML:'H29.=M)TMU(&J:$IGZ[J4=D:.'C0O@](XBJ:^T="X2Y;>7?H:RZ8WU?U_
M3<\9_%8#U$6"TAB4QE$T5=_&:[),2#=J00TG*,V#TAB4QE$T5=[&E++TIM30 MF=D5[K#-
I+;;':#,+AK[5I,CFD9W4D0T+0,2N,])]'NAE0]&O?(>L8]BO)";$1^ M UZM1*&+]ID6:@U!:1Z4QJ TCJ*I&C?6D(6QABRH-
02E>5 :@](XBJ;*VUA# MUDG6D+9)=;M#?\.D3O>QIWN@Y4S=;F,)]76@--YWLK9-9Y-66SD^6&=C(^2J
M7!$E)4&RB[/]DAOUWGK5E:MRK9%Q<_A^R9:/OER%<4HBL&UL MS5A-;^,V$/TKA HLMD ;B?J,4]M XJ38+7:
[QAK;/10],-+8)B*1*DG9R;\O M*2N29)CQEHLGN090Z#E+F9Q8:Z7R&]N6\1HR(J]X M#DQ_L^0B(TI?BI4M
M[B#EVXF%K=<;7^EJKSK.R0H6H+
[E/J=)FH]L:XME,"2%*GZRKZ3/%=$["5HG.X$MTIP#Q/\$PE>E>"5C>XJ*]NZ)XI,QX)O MD3#1<<2F[*;-T-
96:,"R7TMU3GJ>F?6BF?N)0H!X$6:R(O9]S!4Q1DJ8O MZ)ZFA2$:+2 N!%44Y,_H_3TH0E-
]^A5)DR/'MM+%&$@[KAY\MWNP>^+!(?K, MF5I+], 22-KYMFZB[L1][>3.[07\HV!7R'-^0:

[C^AWUS/Y_NM=3CE<3ZY5X MW@F\6\U@>GB.TT)WC):"9VC&L[Q0I%0T7Z('(AAE*XGF]33^_J2!T4<% MF?
RGB^5=%7YW%>8E<"-S$L/$TK]R"6(#UO3=3SAT?NNB:""P%F%^39C?AS[= M5UU-G*R)Z^I]!QB4@.9]M9F&V LBW]
<#W.SW=1P8!*/(">NP5L5!77'06_%W M(@1AJK.TWLQSQS(06*O)L&XRO @=AT,2-A!8B["H)BP:6L?1L8Z=41 YCG^@
MX^/ R,&.VRWCZ[K@Z]Z"'[(\Y2^@IZMX_(2^Y&:*767VPIP[HH' 6AV/ZHY'
M%Z'IT9"$#036(@P[C4UPAE9UA=A2:XBQ>Z#I'X:U*]XS-KBWXEE*M*VY17/M M"T$(/=7%::O2"W7NI(9":S?N-
HV[%Z'NJHRA2!L(K4U:X]9PK[=YD[Z](^&Z
M@:/_#@7^P[AVS8UAPOV.Z1O;@%1ZH)H0)6ALCK)\AY,M$4EWT;V09P]M(+0V M 8W_PL%E*'U0-S<46INTQL_A7O?
S)J6''08%8WPH].,PSW?P"9>-&T.%^QW5 M:9T7C';;[W[$LRO+D/F@!F\HM#9IC<7#O8;H33(?'>D7^^Z> M?
JO&.L+V\ID(%;ELDJBF!=,[=8:]=UZ(79;KH$.[M^915FY[6E@ M=ENVST2L*),HA:6&=*XB7938+:YV%XKGY>
[GD2O%L_*X!I* , 'Z^R77-%47 MY@'U^G#Z'U!+ P04 " L@ U95 M+GXD" R" &0
'AL+W=O.0H_D:VUDV8AQ!B43]9,^-1SV!(/X!4'8",+7"J)&$+U6$#>"V)&I4W$<
M,FIHFBBY)DS89?]WBCL9:@SZ526)3.XCD83*A9D*H5A8@DB M9Z#)Q0^J%+4KN3A/B,7[R\3W^ 4K)&?-
\/=U,.%+PSW;2WZ M)+R^(F$0QAWRZ2OD4?"B/#LMSR!'^<#)HT.YC]Q:>&$++W1^T?_ ZX)3V\7= M=G:'CW5%+#-
O'A68DK>VSW9-%; M8X5J#>:*"#!=&$X:GXMAV($A.J;0$38PUT'XFI/\ 4$L#!!0 (M "R #5E#%;K-E (.(& 9
>&PO=V]R:W-H965TFF;5]UJFF[SPY<@E6PF6V2[M_O; A- M$XKV85_ 9]][?N^PCW@CY)/* 31Y+@NN)DZN=77INBK-
H:3J3%3 <64I9$DU MAG+EJDH"S2RH+%S?\R*WI(P[26SG;F42BUH7C,.M)*HN2RK_3*$0FXES[FPG
M[M@JUV;"3>**KF .^J&ZE1BY'4O&2N"*"4XD+"?.U?GE+#+Y-N&1P4;MC(EQ MLA#BR03?LHGC&4%00*H- \77&F90%
(8(9?QN.9UN2P/<'6_9OUCOZ&5!%V M#CL Y.D'^"W WP>,W@ $+2"P1AMEUM8UU32)I=@0:;*1S0QL;2P:W3!NON)<
M2UQEB-/)3)0ET_A9M"*49V0FN&9\!3QEH,CQ'$]-5A= Q)+\K$!2LTA^ !9.
MG9#C:]"4%3@Z)0_S:W)\=$*."./D/A>U0CH5NQI%FJW:GY' ^T!\SQ_UZ)G].SP8D!-T!0\L7_ & MGZT=2872?;5IL*-
^K+G1EZJB*4P"Q'A;7 MD(0[.Y_ZX9ZZPYS@PNM7%W7JHD%U]T+3HD]/=%"),-B3VB"JM0<]WX" !"" &0 'AL+W=O_KK
1.=4_.0>!.(16G!J=JYNNY M IH[)U[Y41 ,?4Z9\)*Q6[M6R5@N3,4$7"NB%YQ3]3R%2JXF7NBM%V[8K#1V MP4_&
($E!!5DQB)0_"PAA:JR0$CC5X/IM2&MX^9XC7[IM*.6!ZHAE=4]RTTY M\4X\DD-
!%Y6YD:LOT.@96+Q,5MK]DE5M.T+C;*&-Y(TS,N!,U%_ZU.1APR$: MO.(0-0[1KL/P%8>X<8B=T)J9DW5!#4W&2JZ(LM:
(9@25'+.#!Z+T82*G*12&"9F(#(&FARF5)?D$H]:'Y'#"S"453@Z)G>W%^3P MX(@<$";(CU(N-#KKL6^0D@7VLR;\M X?
O1)^2*XP8*G))Y%#ONWOHY163[36 M,XWV GY;B!Z)@P\D"J)^!Y_T[>[Q'CIQF][8X<7_DMZN=-5P_6XX^Z3/])QF
M,/'PS6I02_"2]^_"8?"Q2^M_ MM2WF^5]_>A)]_GH*C52C)[API[ATBA)">R MW:D 'V!G&FKLH<.VA6B91"?
AV%]NJGMI$\91:[-%>M"2'NPE_1G+'L'BXH@1 M+G-6L(S:>M-%@2I,84^%>:7A"N MZ#](@RW$#4ML\J"L >X74IKUQ
9H_S8DOP%02P,$% @ +(-6?DF.D0) M P D@L !D !X;"]W;W)K&ULK99M;YLP%(7_ MBL6JJ976\A8(Z1*D-
=&T3:U6]673/CIP$ZR"G=DFZ?[];$-H&BB:T+X$&WR. MSW,)<*<[QI]$!B#17MBV2# HL+M@&J+JR8KS
4DWYVA8;#C@U MHB*W/<<)[0(3:L53<^Z6QU-6RIQ0N.5(E$6!^9\KR-EN9KG6_L0=66=2G[#C
MZ0:OX1[DX^:6JYG=N*2D "H(HXC#:F9]O(U MG5F.3@0Y%);8'78PASR7#NI'+]K4ZO94PL/QWOWSP9>P2RQ@#G+?
Y)49C,K MLE **USF\H[MOD -%&B_A.7"_*)=O=:Q4%(*R8I:K!(4A%9'_%P7XD#@CMX0 M>+7 ^U>!7PM\
UHE,U@++'$\Y6R'N%ZMW/3 U,:H%0VA^C;>2ZZN$J63\9P5
M!9'JODB!,$W1G%%)Z!IH0D"@TQLL2TZD'K,5^KX!CO5E= VJ=.(,G2Y 8I*K MT3EZO%^@TY,S=(((10\9*X4R%%-
;JIAZ,SNI(UU5D;PW(GTKZ07RG0_(<[Q1 MAWS>+U] HN2ND?NOY;8J3E,AKZF09_S\
(17JHJOL1MUV^K&\%!NP5N=^0^WWN\2_ ' %-(46JJ% L@>\+VW5?KBJWT+CI
MU\7IW',@S:GA&0WF"+I[*+3C@&8]'1SR].P[D"1J>8"A/V,43 MM'D<_XBG=\>!/&'#$P[E&7?QA"T>+YP<\?
3N.)!GW/",A_)$73SC-D_K_]:[MXT">J.&)>GD>,E"=PDH"[TH?M=+[K7]7K__]),F_:0_/9,X[PH^:9=]XKI'
MR7N]!R9WG9>/M-.;_1J$0,:92K3%>0DH)2)A)96=WU>GA73N1OJE\(JI?].A M4 >=A]L+]=)-
Y+J;0#G!2Y*;9J,3RFU]7EPG"HZ9VJN\P'&:5556^Z!ATMWJ
M#>9K0H4*LE(RYV*L2L>K!K":2+8Q/=222=61F6&FFF;@>H&ZOF),[B>Z+6O: M\/@O4$L#!!0 ("R #5D\AW'350, -05 -
>&PO5-BKE0 [_7F#Q[M^YX._##^['N6;E2D=._7'S\,R_4]0?/WL\^G9VU'BZO=^T7!KCT R=IYP#2 MJY:^4&:#8O3Q8?
3[R#']JC:U67ZNB:SC.>;6<[CI*&M/F&#.R4'I[,D&(>ZV
M#BS#WBI@Y*$[9<.V6\.@[L5A/RO$NB4CWQHT/\FI]TCXP!\1SL:2@5=&2.P M[5O#L%\2I:@4-WIB%AOC"\BKQ_?
+4BN<2K(,VQU_[6!N.LBXD"F539C07YF& M?4XSD"/9= 9W590!@$H5N1ZDC$P+08R&E4<]T+03ROD=O$-
^9UORS4M[E.1Y@Y-!N]E31C"S-?9(T C#W$ MV4E9\N57SJ8BIS;Y@P,.^V3EY\T*R9YT-
&B5B390Z7N/5"HVV;3\E:2\IPNU M:J=%AFMNGZ#F?[O/4RJH)'Q3M.[]8][E-RN.NN\EV;Q5=@4[-=8'@V,7V3D% MD?
$IB#R)GNR=@LCD!$1VW^VM^1J1X?&+C(ZSVD%]7-LX$VZ="!NK!R?O@?\+ M3O)\'=0;SQE73-2S&4M3*EX<##6]
(F/])^L6OUZ?THS,N;IOP(&_'O^D*9OG M2;/J%C:B7K4>_X#TPK@Y]NM83*1T0=-1/973L1EZ>J"CUA9CO; X_U,^/30?
BV':>DZDA_KT4!_KY4)&YH/%;;Q#]O&!5P'H'XKOC0$^Y?:((JHIIPYY@'$D2#(%>=/=H'".[
M$\/'71_L*8FB)'$C@+D51!&&P-.((Y@"T(A462^!W>^CX+5]U2P_C_N\!E0 M2P,$% @ +(-69>*NQS $P(L !?
3T\$MP>:4#M M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3 MY?
YVX$G1H2)8%II%R=.B':5_'9.7+0$!;) #P 'AL+W=O7VZW.I$^WVEROM;YF=U6I[&2P,>K.1
MN9CIO*F$#_,)+KG+!VGA:-OQ+\::03A3O KX8X8O?BH\-E]P$ MD D"F=!"KOQQ?1_+](9=U,+L^SSB!I I IF^)N3*Z?
QZI\M"&/L+.__1!) 9 M IF])N24VQW[6NK;GDB>() G;P1YS!9:'0>0[Q'(][20%V;+E7QH-QRQF;"Y MD;5?
\S*2/CK9_-5#7VT$06[%.$\/L8F\C$MYJ5O!"*8%4$T9ULC]O=HR(>* MAM@T9];Z&7S9F'S'K7B!$%-
-1.P:R'A@ZG;W1VQ9\H.W?S2R]K\[8B$F)IN(MV#:/ P5"R>\Y'+KEA$;3P-
4_OPLQ,=U$Q+Y90/KXQ!A"87J)R/WR3'N0E(5L MF%4B8JTL8+_?M+4,;D+(=[CI1
U3243LDKG*=278%;_KS,D19HZ(6!U37572 M[2WL!\!4M^X0ZIDX(LP<$;$ZX.YG-S
(A&E_[A/9F;1YJ6W3N;HQ)HZ86!QS M926,!] ;+[Q]SXSA$,CG4W.,R2,FE@>:*/P3AYAHL4)L$!PS"3$Q@\3$!D$S
MFFXT,8/$Q 9!?=S%Q)P2$SL%]7$7$]-+3*V7T,=L>.47ME/E8XJ)B173)^9> M2,PY,;%S?
C9T+R)FG)BZ6,&TR(;A\Q+,.0FQ<]#JM#-F$DP[R9MJ)PTQ,>TD MQ-K!Y_-0.PGZE.Q-
M=.))J:=A%@[+Q72;+C@D!J%F)AV$FKMO%A/L^%,N! 3 MTTY"K!U7:$J9\2.)Y68;/?3/,0AFQA="2
MK5,+99B%,F(+X9AAZI%A%LJH:R$4,[10AEDHHZZ%4,PLQ,0LE+46&AT^9BG$ M1BI1+.
0%MJAULJ7AOG%_N5:FOG'X9NF+*?0=J&^:5XZ)0A&. M14&#YE36V/+U7UB?
K)'G+VG7EFUWR)MMGR?'_>Z0%\VFE/XAA+SNN7' M/AW*+X/#9S>\YTU*I9F\ML,ZE443CKOKZ1PN!
[DY3VXFSV^+9GA^DR;4#E((MTQI!!D%6/\@AR.L'10B*]8-F$#2K'W0+0;?U@^X@Z*Y^T#T$W=0J"W
MHMY*H+>BWDJ@MXX^M@GT5M1;"?16U%L)]%;46PGT5M1;"?16U%L)]%;46PGT M5M1;"?0VU-L(]#;4VPCT-
M3;"/2VT68)@=Z&>AN!WH9Z&X'>AGH;@=Z&>AN! MWH9Z&X'>AGH;@=Z.>CN!WHYZ.X'>CGH[@=Z.>CN!WC[:
[";0VU%O)]#;46\G MT-M1;R?0VU%O)]#;46\GT#NBWI% [XAZ1P*](^H="?2.J'GLO. ?XD^#Q"U!+ P04 " L@ U9
M(5VG)LT! D($P %M#;VYT96YT7U1Y<&5S72YX;6S-VLENPC 4!=!? M0=E6Q'@('01LVFY;%OT!-WE 1!);MJ'P]W7"
(+6BJ(A*O1LB8OO=%ULZFV3T MMK7D>YNZ:OPX681@'QCS^8)J[5-CJ8DC,^-J'>)?-V=6YTL])R8&@R'+31.H M"?
W0UD@FHR>:Z545>L^;>-N7IADGCBJ?]!YW$]NL<:*MKE/MPHNNXRRVJ9@/VXI\>K[$ MB1[-
;%;F5)A\5<.=.$71*&NTEW1F_/)(>XP[7[YU?E=F7.!<>;4&>OC
MB3FZ/.YP).WJOHV%R(7R_",>$V/IJY^/VM,NJ/AE=MS>#^.6W7EXUEVNW^.O M9WRL?V$? J0/"=*' NDC ^EC"-
+'+4@?=R!]W(/TP0&UL4$L! A0#% @ +(-67&2E-GM *P(M !$ (!KP &1O8U!R;W!S+V-O&UL4$L! A0#% M @ +(
-69E&PO=V]R:W-H965T&UL4$L! A0#% M @ +(-6<7F(H*)!@ ;QX !@ ("!A0X 'AL+W=O&PO=V]R:W-H965T&UL4$L!

A0#% @ +(-6?UNX;@P"0 QQ@ !@ M ("!"S4 'AL+W=OFL3(S,* "R(@ &0 M @(&+1P >&PO=V]R:W-H965T&UL4$L! A0#% @ +(-6;@ZF/1G" &A@ M !D ("!:E< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +(-61^=LL33!0 S@X !D M ("!!6@ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ +(-63TS]_SW P <@D !D ("!O84 'AL+W=O M&PO=V]R:W-H965TA0(,(' 9 " @0F1 M !X;"]W;W)K&UL4$L! A0#% @ +(-61#" M[$!$ @ B@8 !D ("!Q9, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +(-67C8=0!] P W0H !D M ("!UZ('AL+W=O&PO M=V]R:W-H965TI !X;"]W;W)K&UL4$L! A0#% @ +(-69P6&PO=V]R:W-H965T&UL4$L! A0#% M @ +(-61)V#=N- P X0H !D ("!.;@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +(-6<+0N3R& M!0 5R@ !D ("!3,('AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +(-6?GB$-2R!P DCH !D M ("!J]D 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ +(-63#)%R#N @ U @ !D ("!;^@ M 'AL+W=O&PO=V]R:W-H965T,')P, #H, 9 M " @:_P !X;"]W;W)K&UL4$L! A0#% @ M+(-62CTGB%Q! Y!X !D ("!#?0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +(-6;])FI(4 P ;@L !D M ("!4Q&@$ >&PO=V]R:W-H M965T&UL4$L! M A0#% @ +(-650+2Y^) @ ,@@ !D ("!228! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +(- M6?DF.D0) P D@L !D ("!^2X! 'AL+W=O&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M" L@ U9(5VG)LT! D($P @ &5/0$ 6T-O;G1E;G1? @5'EP97-=+GAM;%!+!08 /@ ^ .D0 "3/P$! end XML 67 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}}if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 225 274 1 false 66 0 false 5 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - Balance Sheets (Unaudited) Sheet http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited Balance Sheets (Unaudited) Statements 2 false false R3.htm 995200105 - Statement - Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - Statements of Operations (Unaudited) Sheet http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited Statements of Operations (Unaudited) Statements 4 false false R5.htm 995200300 - Statement - Statements of Stockholders' Equity (Unaudited) Sheet http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 995200400 - Statement - Statements of Cash Flows (Unaudited) Sheet http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995200405 - Statement - Statements of Cash Flows - Non-Cash Activities (Unaudited) (Parenthetical) Sheet http://www.mustangbio.com/role/StatementStatementsOfCashFlowsNonCashActivitiesUnauditedParenthetical Statements of Cash Flows - Non-Cash Activities (Unaudited) (Parenthetical) Statements 7 false false R8.htm 995210101 - Disclosure - Organization, Description of Business and Liquidity and Capital Resources Sheet http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResources Organization, Description of Business and Liquidity and Capital Resources Notes 8 false false R9.htm 995210201 - Disclosure - Significant Accounting Policies Sheet http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 995210301 - Disclosure - Clinical Trial and Sponsored Research Agreements Sheet http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreements Clinical Trial and Sponsored Research Agreements Notes 10 false false R11.htm 995210401 - Disclosure - Related Party Agreements Sheet http://www.mustangbio.com/role/DisclosureRelatedPartyAgreements Related Party Agreements Notes 11 false false R12.htm 995210501 - Disclosure - Assets Purchase Agreements Sheet http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreements Assets Purchase Agreements Notes 12 false false R13.htm 995210601 - Disclosure - Property, Plant and Equipment, and Asset Impairment Sheet http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairment Property, Plant and

Equipment, and Asset Impairment Notes 13 false false R14.htm 995210701 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses Notes 14 false false R15.htm 995210801 - Disclosure - Notes Payable Notes http://www.mustangbio.com/role/DisclosureNotesPayable Notes Payable Notes 15 false false R16.htm 995210901 - Disclosure - Stockholders' Equity Sheet http://www.mustangbio.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 995211001 - Disclosure - Net Loss per Share Sheet http://www.mustangbio.com/role/DisclosureNetLossPerShare Net Loss per Share Notes 17 false false R18.htm 995211101 - Disclosure - Income Taxes Sheet http://www.mustangbio.com/role/DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 995211201 - Disclosure - Commitments and Contingencies Sheet http://www.mustangbio.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 20 false false R21.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 21 false false R22.htm 99920202 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies 22 false false R23.htm 99930203 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies 23 false false R24.htm 99930303 - Disclosure - Clinical Trial and Sponsored Research Agreements (Tables) Sheet http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsTables Clinical Trial and Sponsored Research Agreements (Tables) Tables http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreements 24 false false R25.htm 99930603 - Disclosure - Property, Plant and Equipment, and Asset Impairment (Tables) Sheet http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentTables Property, Plant and Equipment, and Asset Impairment (Tables) Tables http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairment 25 false false R26.htm 99930703 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables Accounts Payable and Accrued Expenses (Tables) Tables http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpenses 26 false false R27.htm 99930803 - Disclosure - Notes Payable (Tables) Notes http://www.mustangbio.com/role/DisclosureNotesPayableTables Notes Payable (Tables) Tables http://www.mustangbio.com/role/DisclosureNotesPayable 27 false false R28.htm 99930903 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.mustangbio.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.mustangbio.com/role/DisclosureStockholdersEquity 28 false false R29.htm 99931003 - Disclosure - Net Loss per Share (Tables) Sheet http://www.mustangbio.com/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://www.mustangbio.com/role/DisclosureNetLossPerShare 29 false false R30.htm 99931203 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.mustangbio.com/role/DisclosureCommitmentsAndContingencies 30 false false R31.htm 99940101 - Disclosure - Organization, Description of Business and Liquidity and Capital Resources (Details) Sheet http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDeta Organization, Description of Business and Liquidity and Capital Resources (Details) Details http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResources 31 false false R32.htm 99940201 - Disclosure - Significant Accounting Policies (Cash, Cash Equivalents, and Restricted Cash) (Details) Sheet http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDet Significant Accounting Policies (Cash, Cash Equivalents, and Restricted Cash) (Details) Details http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables 32 false false R33.htm 99940301 - Disclosure - Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details) Sheet http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndCli Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details) Details http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsTables 33 false false R34.htm 99940302 - Disclosure - Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details) Sheet http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRese Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details) Details http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsTables 34 false false R35.htm 99940401 - Disclosure - Related Party Agreements (Narrative) (Details) Sheet http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails Related Party Agreements (Narrative) (Details) Details http://www.mustangbio.com/role/DisclosureRelatedPartyAgreements 35 false false R36.htm 99940501 - Disclosure - Assets Purchase Agreements (Details) Sheet http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails Assets Purchase Agreements (Details) Details http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreements 36 false false R37.htm 99940601 - Disclosure - Property, Plant and Equipment, and Asset Impairment (Schedule of Property, Plant and Equipment) (Details) Sheet http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentScheduleOfPropertyPlan Property, Plant and Equipment, and Asset Impairment (Schedule of Property, Plant and Equipment) (Details) Details http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentTables 37 false false R38.htm 99940602 - Disclosure - Property, Plant and Equipment, and Asset Impairment (Narrative) (Details) Sheet http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentNarrativeDetails Property, Plant and Equipment, and Asset Impairment (Narrative) (Details) Details http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentTables 38 false false R39.htm 99940701 - Disclosure - Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details) Sheet

http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAcc
Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details) Details
http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables 39 false false R40.htm
99940801 - Disclosure - Notes Payable (Narrative) (Details) Notes
http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails Notes Payable (Narrative) (Details) Details
http://www.mustangbio.com/role/DisclosureNotesPayableTables 40 false false R41.htm 99940802 - Disclosure -
Notes Payable - Interest Expense (Details) Notes
http://www.mustangbio.com/role/DisclosureNotesPayableInterestExpenseDetails Notes Payable - Interest Expense
(Details) Details 41 false false R42.htm 99940901 - Disclosure - Stockholders Equity (Registration Statements and
At-the-Market Offering) (Details) Sheet
http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails
Stockholders Equity (Registration Statements and At-the-Market Offering) (Details) Details 42 false false R43.htm
99940902 - Disclosure - Stockholders' Equity - May 2024 Public Offering (Details) Sheet
http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails Stockholders' Equity -
May 2024 Public Offering (Details) Details 43 false false R44.htm 99940903 - Disclosure - Stockholders' Equity -
June 2024 Registered Direct Offering (Details) Sheet
http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails
Stockholders' Equity - June 2024 Registered Direct Offering (Details) Details 44 false false R45.htm 99940904 -
Disclosure - Stockholders Equity (Equity Incentive Plans and Employee Stock Purchase Plan) (Details) Sheet
http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlanI
Stockholders Equity (Equity Incentive Plans and Employee Stock Purchase Plan) (Details) Details 45 false false
R46.htm 99940905 - Disclosure - Stockholders Equity (Stock Option Activities) (Details) Sheet
http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails Stockholders Equity
(Stock Option Activities) (Details) Details 46 false false R47.htm 99940906 - Disclosure - Stockholders Equity
(Restricted Stock or Restricted Units Awards) (Details) Sheet
http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails
Stockholders Equity (Restricted Stock or Restricted Units Awards) (Details) Details 47 false false R48.htm 99940907
- Disclosure - Stockholders Equity (Stock-based Compensation Expense) (Details) Sheet
http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails
Stockholders Equity (Stock-based Compensation Expense) (Details) Details 48 false false R49.htm 99940908 -
Disclosure - Stockholders' Equity (Warrants Activity) (Details) Sheet
http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails Stockholders' Equity
(Warrants Activity) (Details) Details http://www.mustangbio.com/role/DisclosureStockholdersEquityTables 49 false
false R50.htm 99941001 - Disclosure - Net Loss per Share (Potentially Dilutive Securities) (Details) Sheet
http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails Net Loss per Share
(Potentially Dilutive Securities) (Details) Details http://www.mustangbio.com/role/DisclosureNetLossPerShareTables
50 false false R51.htm 99941201 - Disclosure - Commitments and Contingencies (Narrative) (Details) Sheet
http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails Commitments and
Contingencies (Narrative) (Details) Details
http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables 51 false false R52.htm 99941202
- Disclosure - Commitments and Contingencies (Schedule of Operating Leases) (Details) Sheet
http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails
Commitments and Contingencies (Schedule of Operating Leases) (Details) Details
http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables 52 false false R53.htm 99941203
- Disclosure - Commitments and Contingencies (Cash Flows) (Details) Sheet
http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails Commitments and
Contingencies (Cash Flows) (Details) Details
http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables 53 false false R54.htm 99941204
- Disclosure - Commitments and Contingencies (Maturities of Operating Leases) (Details) Sheet
http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails
Commitments and Contingencies (Maturities of Operating Leases) (Details) Details
http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables 54 false false All Reports Book All
Reports tmb-20240630.xsd tmb-20240630_cal.xml tmb-20240630_def.xml tmb-20240630_lab.xml tmb-
20240630_pre.xml tmb-20240630x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024
http://xbrl.sec.gov/ecd/2024 true true JSON 73 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2",
"instance": { "tmb-20240630x10q.htm": { "nsprefix": "mbio", "nsuri": "http://www.mustangbio.com/20240630", "dts":
{ "schema": { "local": ["tmb-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
"https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-
2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
"https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
"https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["tmb-20240630_cal.xml"] },
"definitionLink": { "local": ["tmb-20240630_def.xml"] }, "labelLink": { "local": ["tmb-20240630_lab.xml"] },
"presentationLink": { "local": ["tmb-20240630_pre.xml"] }, "inline": { "local": ["tmb-20240630x10q.htm"] } },
"keyStandard": 202, "keyCustom": 72, "axisStandard": 18, "axisCustom": 0, "memberStandard": 23,
"memberCustom": 39, "hidden": { "total": 26, "http://fasb.org/us-gaap/2024": 16, "http://xbrl.sec.gov/dei/2024": 5,
"http://www.mustangbio.com/20240630": 5 }, "contextCount": 225, "entityCount": 1, "segmentCount": 66,
"elementCount": 533, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 518,
"http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role":
"http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document
- Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true",

"groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited", "longName": "995200100 - Statement - Balance Sheets (Unaudited)", "shortName": "Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:OtherReceivables", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "unique": true } }, "R3": { "role": "http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical", "longName": "995200105 - Statement - Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_nTcBH7jjxE6On55m_EkkoQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_nTcBH7jjxE6On55m_EkkoQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited", "longName": "995200200 - Statement - Statements of Operations (Unaudited)", "shortName": "Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_SAHZJorsx0OldWRyvoxm4w", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_SAHZJorsx0OldWRyvoxm4w", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "unique": true } }, "R5": { "role": "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited", "longName": "995200300 - Statement - Statements of Stockholders' Equity (Unaudited)", "shortName": "Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__vFIx0RjIEijkI1d4-q9Fg", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__vFIx0RjIEijkI1d4-q9Fg", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited", "longName": "995200400 - Statement - Statements of Cash Flows (Unaudited)", "shortName": "Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "mbio:IssuanceOfCommonSharesEquityFeeOnPublicOffering", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "unique": true } }, "R7": { "role": "http://www.mustangbio.com/role/StatementStatementsOfCashFlowsNonCashActivitiesUnauditedParenthetical", "longName": "995200405 - Statement - Statements of Cash Flows - Non-Cash Activities (Unaudited) (Parenthetical)", "shortName": "Statements of Cash Flows - Non-Cash Activities (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R8": { "role":

"http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResources", "longName": "995210101 - Disclosure - Organization, Description of Business and Liquidity and Capital Resources", "shortName": "Organization, Description of Business and Liquidity and Capital Resources", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreements", "longName": "995210301 - Disclosure - Clinical Trial and Sponsored Research Agreements", "shortName": "Clinical Trial and Sponsored Research Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreements", "longName": "995210401 - Disclosure - Related Party Agreements", "shortName": "Related Party Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreements", "longName": "995210501 - Disclosure - Assets Purchase Agreements", "shortName": "Assets Purchase Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairment", "longName": "995210601 - Disclosure - Property, Plant and Equipment, and Asset Impairment", "shortName": "Property, Plant and Equipment, and Asset Impairment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpenses", "longName": "995210701 - Disclosure - Accounts Payable and Accrued Expenses", "shortName": "Accounts Payable and Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.mustangbio.com/role/DisclosureNotesPayable", "longName": "995210801 - Disclosure - Notes Payable", "shortName": "Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:DebtDisclosureTextBlock",

"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquity", "longName": "995210901 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.mustangbio.com/role/DisclosureNetLossPerShare", "longName": "995211001 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.mustangbio.com/role/DisclosureIncomeTaxes", "longName": "995211101 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211201 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_SAHZJorsx0OldWRyvoxm4w", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_SAHZJorsx0OldWRyvoxm4w", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_SAHZJorsx0OldWRyvoxm4w", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables", "longName": "99930203 - Disclosure - Significant Accounting Policies (Tables)", "shortName": "Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-

gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsTables", "longName": "99930303 - Disclosure - Clinical Trial and Sponsored Research Agreements (Tables)", "shortName": "Clinical Trial and Sponsored Research Agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_KB86wlImV0yse57vaDA "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_KB86wlImV0yse57vaDA "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentTables", "longName": "99930603 - Disclosure - Property, Plant and Equipment, and Asset Impairment (Tables)", "shortName": "Property, Plant and Equipment, and Asset Impairment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables", "longName": "99930703 - Disclosure - Accounts Payable and Accrued Expenses (Tables)", "shortName": "Accounts Payable and Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.mustangbio.com/role/DisclosureNotesPayableTables", "longName": "99930803 - Disclosure - Notes Payable (Tables)", "shortName": "Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "mbio:ScheduleOfInterestExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "mbio:ScheduleOfInterestExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables", "longName": "99930903 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.mustangbio.com/role/DisclosureNetLossPerShareTables", "longName": "99931003 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables", "longName": "99931203 -

Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDet "longName": "99940101 - Disclosure - Organization, Description of Business and Liquidity and Capital Resources (Details)", "shortName": "Organization, Description of Business and Liquidity and Capital Resources (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDe "longName": "99940201 - Disclosure - Significant Accounting Policies (Cash, Cash Equivalents, and Restricted Cash) (Details)", "shortName": "Significant Accounting Policies (Cash, Cash Equivalents, and Restricted Cash) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_vZqHc9CnFkqjolEJrvxH5Q", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "unique": true } }, "R33": { "role": "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC "longName": "99940301 - Disclosure - Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details)", "shortName": "Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_wtE-Fnc9TUK41WakQ6qYcw", "name": "mbio:ResearchAndDevelopmentExpenseNetExcludingAcquiredInProcessCost", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_wtE-Fnc9TUK41WakQ6qYcw", "name": "mbio:ResearchAndDevelopmentExpenseNetExcludingAcquiredInProcessCost", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes "longName": "99940302 - Disclosure - Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)", "shortName": "Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_SAHZJorsx0OldWRyvoxm4w", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_11_1_2022_To_11_30_2022_srt_ProductOrServiceAxis_mbio_Il13ra2CarAndC134Member_QWX0dBqZlUmWd "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "unique": true } }, "R35": { "role": "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "longName": "99940401 - Disclosure - Related Party Agreements (Narrative) (Details)", "shortName": "Related Party Agreements (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "Duration_1_2_2024_To_1_2_2024_srt_CounterpartyNameAxis_mbio_FortressBiotechIncMember_Ncjw_oCdrUmnATu_E "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_2_2024_To_1_2_2024_srt_CounterpartyNameAxis_mbio_FortressBiotechIncMember_Ncjw_oCdrUmnATu_E "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1,

"baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails", "longName": "99940501 - Disclosure - Assets Purchase Agreements (Details)", "shortName": "Assets Purchase Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_27_2024_To_6_27_2024_us-gaap_AssetAcquisitionAxis_mbio_AssetPurchaseAgreementWithUbrigeneBiosciencesMember_l9MRMdOn4E6-BAWTdUmAWw", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "unique": true } }, "R37": { "role": "http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentScheduleOfPropertyPla "longName": "99940601 - Disclosure - Property, Plant and Equipment, and Asset Impairment (Schedule of Property, Plant and Equipment) (Details)", "shortName": "Property, Plant and Equipment, and Asset Impairment (Schedule of Property, Plant and Equipment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentNarrativeDetails", "longName": "99940602 - Disclosure - Property, Plant and Equipment, and Asset Impairment (Narrative) (Details)", "shortName": "Property, Plant and Equipment, and Asset Impairment (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_SAHZJorsx0OldWRyvoxm4w", "name": "us-gaap:Depreciation", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_SAHZJorsx0OldWRyvoxm4w", "name": "us-gaap:Depreciation", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAc "longName": "99940701 - Disclosure - Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details)", "shortName": "Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails", "longName": "99940801 - Disclosure - Notes Payable (Narrative) (Details)", "shortName": "Notes Payable (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_SAHZJorsx0OldWRyvoxm4w", "name": "us-gaap:InterestExpenseDebt", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_11_2023_To_4_11_2023_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_wmfb5grHc0aa7zTwuMX9tQ", "name": "us-gaap:RepaymentsOfLongTermLinesOfCredit", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "unique": true } }, "R41": { "role": "http://www.mustangbio.com/role/DisclosureNotesPayableInterestExpenseDetails", "longName": "99940802 - Disclosure - Notes Payable - Interest Expense (Details)", "shortName": "Notes Payable - Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_4_1_2023_To_6_30_2023_IFIcIasW6UyWxAhA2zzsKQ", "name": "us-gaap:InterestExpenseOther", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "mbio:ScheduleOfInterestExpenseTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2023_To_6_30_2023_IFIcIasW6UyWxAhA2zzsKQ", "name": "us-gaap:InterestExpenseOther", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "mbio:ScheduleOfInterestExpenseTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div",

"div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails", "longName": "99940901 - Disclosure - Stockholders Equity (Registration Statements and At-the-Market Offering) (Details)", "shortName": "Stockholders Equity (Registration Statements and At-the-Market Offering) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_O5sbcrTErkyc8XL5OmcVBw", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:StockIssuedDuringPeriodSharesNewIssues", "p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_O5sbcrTErkyc8XL5OmcVBw", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:StockIssuedDuringPeriodSharesNewIssues", "p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails", "longName": "99940902 - Disclosure - Stockholders' Equity - May 2024 Public Offering (Details)", "shortName": "Stockholders' Equity - May 2024 Public Offering (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "Unit_Divide_USD_shares_nTcBH7jjxE6On55m_EkkoQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "mbio:SummaryOfWarrantActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_4_29_2024_us-gaap_SubsidiarySaleOfStockAxis_mbio_May2024PublicOfferingMember_IZTovqj9DkCv7pZx7Qav_A", "name": "us-gaap:SaleOfStockPricePerShare", "unitRef": "Unit_Divide_USD_shares_nTcBH7jjxE6On55m_EkkoQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "unique": true } }, "R44": { "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails", "longName": "99940903 - Disclosure - Stockholders' Equity - June 2024 Registered Direct Offering (Details)", "shortName": "Stockholders' Equity - June 2024 Registered Direct Offering (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "Unit_Divide_USD_shares_nTcBH7jjxE6On55m_EkkoQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "mbio:SummaryOfWarrantActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_19_2024_To_6_19_2024_us-gaap_SubsidiarySaleOfStockAxis_mbio_June2024RegisteredDirectOfferingMember_LW-Ca15nT0Gddna93fyoXQ", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "unique": true } }, "R45": { "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlan", "longName": "99940904 - Disclosure - Stockholders Equity (Equity Incentive Plans and Employee Stock Purchase Plan) (Details)", "shortName": "Stockholders Equity (Equity Incentive Plans and Employee Stock Purchase Plan) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_12_31_2019_u-1Ki6w-YkGKolYaJ2m0LQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2019_u-1Ki6w-YkGKolYaJ2m0LQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "longName": "99940905 - Disclosure - Stockholders Equity (Stock Option Activities) (Details)", "shortName": "Stockholders Equity (Stock Option Activities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_B9uw4CEn20GDHReKXgTP3Q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Om1w30jxi0uvEjPmN1RW1A", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "unique": true } }, "R47": { "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails", "longName": "99940906 - Disclosure - Stockholders Equity (Restricted Stock or Restricted Units Awards) (Details)", "shortName": "Stockholders Equity (Restricted Stock or Restricted Units Awards) (Details)", "isDefault": "false",

"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration_4_12_2024_To_4_12_2024_l3l5ECrDmEqFrrJu5MWMKw", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "unitRef": "Unit_Standard_pure_zU6LJO8yb0-5dj9xi5mjoQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_bxbEtqd3hECA0NqXs4Mm9Q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonve "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "unique": true } }, "R48": { "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "longName": "99940907 - Disclosure - Stockholders Equity (Stock-based Compensation Expense) (Details)", "shortName": "Stockholders Equity (Stock-based Compensation Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_SAHZJorsx0OldWRyvoxm4w", "name": "us-gaap:ShareBasedCompensation", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_SAHZJorsx0OldWRyvoxm4w", "name": "us-gaap:ShareBasedCompensation", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails", "longName": "99940908 - Disclosure - Stockholders' Equity (Warrants Activity) (Details)", "shortName": "Stockholders' Equity (Warrants Activity) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_12_31_2023_lpNswIT6ZUWC-xHwuUH8Yg", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "mbio:SummaryOfWarrantActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "mbio:ClassOfWarrantOrRightWarrantsExercisedDuringPeriod", "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "mbio:SummaryOfWarrantActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "unique": true } }, "R50": { "role": "http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails", "longName": "99941001 - Disclosure - Net Loss per Share (Potentially Dilutive Securities) (Details)", "shortName": "Net Loss per Share (Potentially Dilutive Securities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_gHha1v_htUaR9XeAnwkTxQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "longName": "99941201 - Disclosure - Commitments and Contingencies (Narrative) (Details)", "shortName": "Commitments and Contingencies (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_6_28_2024_To_6_28_2024_cdlj7ZyG4E6k5jcdtMqgDA", "name": "us-gaap:GainLossOnTerminationOfLease", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_6_28_2024_To_6_28_2024_cdlj7ZyG4E6k5jcdtMqgDA", "name": "us-gaap:GainLossOnTerminationOfLease", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails", "longName": "99941202 - Disclosure - Commitments and Contingencies (Schedule of Operating Leases) (Details)", "shortName": "Commitments and Contingencies (Schedule of Operating Leases) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation",

"div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails", "longName": "99941203 - Disclosure - Commitments and Contingencies (Cash Flows) (Details)", "shortName": "Commitments and Contingencies (Cash Flows) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_xIDHj_e6XEiUpJSUT7HyYQ", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails", "longName": "99941204 - Disclosure - Commitments and Contingencies (Maturities of Operating Leases) (Details)", "shortName": "Commitments and Contingencies (Maturities of Operating Leases) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_f8WjJd0OY0GorQSBSbWcjg", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_36yIAaaOJEyduBroD9MWVA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240630x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAc "http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current", "totalLabel": "Total accounts payable and accrued expenses", "verboseLabel": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r46", "r47"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpenses"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r45", "r47", "r51", "r679"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAc], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r45", "r538"] }, "mbio_AccruedCompensationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AccruedCompensationCurrent", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAc], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued compensation.", "label": "Accrued Compensation Current", "terseLabel": "Accrued compensation" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentScheduleOfPropertyPla], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r27", "r119", "r384"] }, "mbio_AccumulatedImpairmentLossPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AccumulatedImpairmentLossPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentScheduleOfPropertyPla

], "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss.", "label": "Accumulated Impairment Loss, Property Plant and Equipment", "negatedLabel": "Less: impairment loss" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r590"] }, "mbio_AdditionalMilestonesPayableUnderArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AdditionalMilestonesPayableUnderArrangement", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes], "lang": { "en-us": { "role": { "documentation": "The amount of additional milestones payable under the arrangement.", "label": "Additional Milestones Payable Under Arrangement", "terseLabel": "Additional milestone payments" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r56"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "verboseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r418", "r655", "r656", "r657", "r659", "r686", "r739"] }, "mbio_AdditionsReductionsToAdditionalPaidInCapitalReverseStockSplits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AdditionsReductionsToAdditionalPaidInCapitalReverseStockSplits", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "The amount of additions (reductions) to additional paid-in capital during the period attributable to reverse stock splits.", "label": "Additions (Reductions) To Additional Paid In Capital, Reverse Stock Splits", "terseLabel": "Reverse Split (15:1) adjustment" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r603"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r603"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r603"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r603"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r636"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r562", "r572", "r582", "r614"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r565", "r575", "r585", "r617"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r637"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r603"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r610"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [

"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r566", "r576", "r586", "r610", "r618", "r622", "r630"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r628"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails", "http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "verboseLabel": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r6", "r64", "r242", "r692"] }, "mbio_AnnualMaintenanceFeePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AnnualMaintenanceFeePayable", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes], "lang": { "en-us": { "role": { "documentation": "The amount of annual maintenance fee payable under the arrangement.", "label": "Annual Maintenance Fee Payable", "terseLabel": "Annual maintenance fee payable" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r172"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r21"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r21"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsTables", "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r319"] }, "us-gaap_AssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Assets Purchase Agreements" } } }, "auth_ref": [] }, "mbio_AssetAcquisitionAccruedConsiderationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionAccruedConsiderationCurrent", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAc], "lang": { "en-us": { "role": { "documentation": "Amount of accrued consideration in asset acquisition, classified as current.", "label": "Asset Acquisition, Accrued Consideration, Current", "terseLabel": "Accrued consideration for the uBriGene Asset Purchase Agreement" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": ["r188", "r189", "r190", "r191", "r193", "r681"] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": {

"label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Total purchase consideration", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": ["r530", "r682", "r683", "r684"] }, "mbio_AssetAcquisitionConsiderationTransferredDeferredPaymentDuePeriodFromClosingDate": { "xbrltype": "durationItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionConsiderationTransferredDeferredPaymentDuePeriodFromClosingDate", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the due period for deferred payment from Effective Date in an asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Deferred Payment, Due Period from Closing Date", "terseLabel": "Subsequent amount, due period from closing date" } } }, "auth_ref": [] }, "mbio_AssetAcquisitionConsiderationTransferredDeferredPaymentExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionConsiderationTransferredDeferredPaymentExtensionTerm", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the extension term for delay in payment of deferred payment.", "label": "Asset Acquisition, Consideration Transferred, Deferred Payment, Extension Term", "terseLabel": "Extension term for deferred payment" } } }, "auth_ref": [] }, "mbio_AssetAcquisitionConsiderationTransferredDeferredPaymentInterestRateOnOutstandingLiability": { "xbrltype": "percentItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionConsiderationTransferredDeferredPaymentInterestRateOnOutstandingLiability", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents percentage of interest accrual on outstanding liability of deferred payment in asset acquisition transaction.", "label": "Asset Acquisition, Consideration Transferred, Deferred Payment, Interest Rate on Outstanding Liability", "terseLabel": "Interest rate on outstanding Deferred Amount" } } }, "auth_ref": [] }, "mbio_AssetAcquisitionConsiderationTransferredSubsequentPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionConsiderationTransferredSubsequentPayment", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of subsequent consideration recognized as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Subsequent Payment", "terseLabel": "Subsequent payment" } } }, "auth_ref": [] }, "mbio_AssetAcquisitionConsiderationTransferredUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionConsiderationTransferredUpfrontPayment", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of upfront consideration recognized as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Upfront Payment", "terseLabel": "Upfront payment" } } }, "auth_ref": [] }, "mbio_AssetAcquisitionConsiderationTransferredUpfrontPaymentDuePeriodFromEffectiveDate": { "xbrltype": "durationItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionConsiderationTransferredUpfrontPaymentDuePeriodFromEffectiveDate", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the due period for upfront payment from Effective Date in an asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Upfront Payment, Due Period from Effective Date", "terseLabel": "Upfront payment, due period from Effective Date" } } }, "auth_ref": [] }, "mbio_AssetAcquisitionDeferredPaymentAccrueInterestPeriodFromClosingDate": { "xbrltype": "durationItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionDeferredPaymentAccrueInterestPeriodFromClosingDate", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the period starts accruing interest for deferred payment from Effective Date in an asset acquisition.", "label": "Asset Acquisition, Deferred Payment Accrue Interest, Period from Closing Date", "terseLabel": "Rate of interest accrual on Deferred Amount not paid in full after 12 months" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": ["r188", "r189", "r190", "r191", "r193", "r681"] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionLineItems", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r681"] }, "mbio_AssetAcquisitionNetRealizableValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionNetRealizableValueAmount", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of fair value less costs to sell provided from valuation services in asset acquisition.", "label": "Asset Acquisition, Net Realizable Value, Amount", "terseLabel": "Fair value provided from valuation services less costs to sell" } } }, "auth_ref": [] }, "mbio_AssetAcquisitionNetReceivablesForgiveness": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionNetReceivablesForgiveness", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of net receivables to forgive under Asset Purchase Agreement.", "label": "Asset Acquisition, Net Receivables, Forgiveness", "terseLabel": "Amount of net receivables to forgive under Asset Purchase Agreement" } } }, "auth_ref": [] }, "mbio_AssetAcquisitionPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionPayable", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of payables recognized at acquisition date in asset acquisition.", "label": "Asset Acquisition, Payable", "terseLabel": "Outstanding payables" } } }, "auth_ref": [] }, "mbio_AssetAcquisitionPurchaseConsiderationAllocatedToSuppliesRepurchased": { "xbrltype": "monetaryItemType",

"nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionPurchaseConsiderationAllocatedToSuppliesRepurchased", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of purchase consideration allocated to the supplies repurchased in asset acquisition.", "label": "Asset Acquisition, Purchase Consideration Allocated to Supplies Repurchased", "terseLabel": "Purchase consideration allocated to the supplies repurchased" } } }, "auth_ref": [] }, "mbio_AssetAcquisitionReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionReceivables", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of receivables recognized at acquisition date in asset acquisition.", "label": "Asset Acquisition, Receivables", "terseLabel": "Outstanding receivables" } } }, "auth_ref": [] }, "mbio_AssetAcquisitionSuppliesRepurchasedAlternativeFutureUseRecognizedAsResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionSuppliesRepurchasedAlternativeFutureUseRecognizedAsResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of the supplies repurchased with alternative future use were recognized as research and development expense.", "label": "Asset Acquisition, Supplies Repurchased, Alternative Future Use, Recognized as Research and Development Expense", "terseLabel": "Supplies repurchased with alternate future use recognized as research and development expense" } } }, "auth_ref": [] }, "mbio_AssetAcquisitionSuppliesRepurchasedNoAlternativeFutureUseRecognizedAsResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetAcquisitionSuppliesRepurchasedNoAlternativeFutureUseRecognizedAsResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of the supplies repurchased with no alternative future use were recognized as research and development expense.", "label": "Asset Acquisition, Supplies Repurchased, No Alternative Future Use, Recognized as Research and Development Expense", "terseLabel": "Supplies repurchased with no alternate future use recognized as research and development expense" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTable", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": ["r681"] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreements"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Text Block]", "terseLabel": "Assets Purchase Agreements", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": ["r681"] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentNarrativeDetails", "http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited", "http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Asset Impairment Charges", "terseLabel": "Asset impairment", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r6", "r25"] }, "mbio_AssetPurchaseAgreementWithUbrigeneBiosciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetPurchaseAgreementWithUbrigeneBiosciencesMember", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Asset Purchase Agreement with uBriGene (Boston) Biosciences, Inc.", "label": "Asset Purchase Agreement with Ubrigene Biosciences [Member]", "terseLabel": "June 2024 Repurchase of Assets" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r91", "r98", "r121", "r141", "r176", "r180", "r181", "r182", "r185", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r320", "r322", "r338", "r376", "r453", "r515", "r516", "r538", "r553", "r675", "r676", "r698"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r115", "r126", "r141", "r185", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r320", "r322", "r338", "r538", "r675", "r676", "r698"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current Assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails", "http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Asset, Held-for-Sale, Not Part of Disposal Group, Current", "terseLabel": "Property, plant and equipment, held for sale", "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer." } } }, "auth_ref": ["r75", "r538"] }, "mbio_AssetsHeldForSalePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AssetsHeldForSalePolicyTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": {

"documentation": "Disclosure of company's police regarding assets held for sale.", "label": "Assets Held for Sale [Policy Text Block]", "terseLabel": "Assets Held for Sale" } } }, "auth_ref": [] }, "mbio_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "AtMarketOfferingMember", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to issuances of stock offered on an At The Market basis.", "label": "At the Market Offering [Member]", "terseLabel": "At the Market Offering" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r625"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r626"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r621"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r621"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r621"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r621"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r621"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r621"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlan "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r624"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r623"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r622"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r622"] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": ["http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Base Rate [Member]", "terseLabel": "Base Rate", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "mbio_CarTTechnologyProductOrProcessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "CarTTechnologyProductOrProcessMember", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes], "lang": { "en-us": { "role": { "documentation": "Car T Technology Product or Process [Member]", "label": "Car T Technology [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [

"http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDe
"http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Cash
and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash
equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial
institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also
includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so
near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r16",
"r117", "r508"] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [
"http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": {
"label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel":
"Cash, Cash Equivalents and Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting
policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating
balances against short-term borrowing arrangements, contracts entered into with others, or company statements of
intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not
generally included in legally restricted deposits." } } }, "auth_ref": ["r17", "r90"] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDe
"http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash
equivalents and restricted cash, end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash,
beginning of the period", "totalLabel": "Total cash, cash equivalents and restricted cash", "documentation": "Amount
of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for
disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits
with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash
equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to
known amounts of cash and so near their maturity that they present insignificant risk of changes in value because
of changes in interest rates." } } }, "auth_ref": ["r16", "r69", "r137"] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeF
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateE
"crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"],
"lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents,
Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash, cash equivalents
and restricted cash", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and
cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but
is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with
general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly
liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they
present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r69"]
}, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [
"http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "verboseLabel":
"Supplemental disclosure of noncash activities:" } } }, "auth_ref": [] },
"mbio_Cd20TechnologyProductOrProcessMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "Cd20TechnologyProductOrProcessMember", "presentation":
[
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to CD20 Technology License.",
"label": "CD20 (MB-106) [Member]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer
Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r601"] },
"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair
Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in
Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r598"] },
"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year
Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
"terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding
and Unvested" } } }, "auth_ref": ["r596"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label":
"City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "mbio_CityOfHopeMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "CityOfHopeMember",
"presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
], "lang": { "en-us": { "role": { "documentation": "Information pertaining to City of hope, a pharmaceutical product

or process.", "label": "City of Hope [Member]" } } }, "auth_ref": [] },
"mbio_CityOfHopeNationalMedicalCenterCohMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "CityOfHopeNationalMedicalCenterCohMember",
"presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
], "lang": { "en-us": { "role": { "documentation": "Information pertaining to City Of Hope National Medical Center
(\"COH\"), a counterparty in agreement(s) with the entity.", "label": "City of Hope National Medical Center (\"COH\")
[Member]", "terseLabel": "City of Hope National Medical Center" } } }, "auth_ref": [] }, "us-
gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ClassOfStockDomain", "presentation": [
"http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation",
"http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited",
"http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical",
"http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": {
"role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the
holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock,
nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r111", "r122", "r123", "r124", "r141",
"r166", "r167", "r169", "r171", "r178", "r179", "r185", "r211", "r213", "r214", "r215", "r218", "r219", "r248", "r249",
"r252", "r255", "r262", "r338", "r409", "r410", "r411", "r412", "r418", "r419", "r420", "r421", "r422", "r423", "r424",
"r425", "r426", "r427", "r428", "r429", "r440", "r462", "r484", "r497", "r498", "r499", "r500", "r501", "r640", "r650",
"r660"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ClassOfStockLineItems", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us":
{ "role": { "label": "Class of Stock [Line Items]", "verboseLabel": "Stockholders' Equity", "documentation": "Line
items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r122", "r123",
"r124", "r178", "r248", "r249", "r250", "r252", "r255", "r260", "r262", "r409", "r410", "r411", "r412", "r523", "r640",
"r650"] }, "mbio_ClassOfWarrantConverted": { "xbrltype": "sharesItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "ClassOfWarrantConverted", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us":
{ "role": { "documentation": "Number of warrant or right may be converted.", "label": "Class of Warrant Converted",
"terseLabel": "Number of warrant to converted" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis",
"presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": {
"role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right
issued." } } }, "auth_ref": ["r36"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": {
"role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or
right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase
securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often
included in a new debt issue to entice investors by a higher return potential. The main difference between warrants
and call options is that warrants are issued and guaranteed by the company, whereas options are exchange
instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the
lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
"presentation": [
"http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDet
"http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": {
"role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant exercise
price (in dollars per share)", "verboseLabel": "Exercise price of warrant", "documentation": "Exercise price per share
or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r263"] },
"mbio_ClassOfWarrantOrRightExercisePricePurchasePriceOfCommonStockPercentage": { "xbrltype":
"percentItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname":
"ClassOfWarrantOrRightExercisePricePurchasePriceOfCommonStockPercentage", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails"], "lang":
{ "en-us": { "role": { "documentation": "Exercise price of warrants expressed as percentage of purchase price of
common stock.", "label": "Class of Warrant or Right, Exercise Price, Purchase Price of Common Stock, Percentage",
"terseLabel": "Purchase Price of Common Stock, Percentage" } } }, "auth_ref": [] }, "us-
gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ClassOfWarrantOrRightLineItems", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": {
"role": { "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Stockholders' Equity", "documentation":
"Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [

"http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of common stock, each warrant get converted", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDet "http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r263"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Warrants outstanding, ending", "periodStartLabel": "Warrants outstanding, beginning", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r36"] }, "mbio_ClassOfWarrantOrRightWarrantPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ClassOfWarrantOrRightWarrantPrice", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Denotes the price per warrant.", "label": "Class of Warrant or Right, Warrant Price", "terseLabel": "Price per warrant" } } }, "auth_ref": [] }, "mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ClassOfWarrantOrRightWarrantsExercisedDuringPeriod", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights exercised during the period.", "label": "Class Of Warrant Or Right, Warrants Exercised During The Period", "negatedLabel": "Warrants exercised" } } }, "auth_ref": [] }, "mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ClassOfWarrantOrRightWarrantsGrantedDuringPeriod", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights granted during the period.", "label": "Class Of Warrant Or Right Warrants Granted During The Period", "terseLabel": "Warrants granted" } } }, "auth_ref": [] }, "mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisedDuringPeriod": { "xbrltype": "perShareItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceExercisedDuringPeriod", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants that were exercised during the period.", "label": "Class Of Warrant Or Right Weighted Average Exercise Price Exercised During The Period", "terseLabel": "Warrant exercise price, exercised during the period (in dollars per share)" } } }, "auth_ref": [] }, "mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod": { "xbrltype": "perShareItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants that were granted during the period.", "label": "Class Of Warrant Or Right, Weighted Average Exercise Price, Grants During The Period", "terseLabel": "Warrant exercise price, grants during the period (in dollars per share)" } } }, "auth_ref": [] }, "mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLife", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "The weighted average remaining contractual life for warrants outstanding.", "label": "Class Of Warrant Or Right Weighted Average Remaining Contractual Life", "terseLabel": "Warrants outstanding, remaining contractual life" } } }, "auth_ref": [] }, "mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "The weighted average remaining contractual life for warrants granted during the period.", "label": "Class Of Warrant Or Right Weighted Average Remaining Contractual Life, Grants In Period", "terseLabel": "Warrants granted, remaining contractual life" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r602"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" }

```
} }, "auth_ref": [ "r602" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CollaborativeArrangementDisclosureTextBlock", "presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreements" ], "lang": { "en-us": {
"role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "verboseLabel": "Clinical Trial and Sponsored
Research Agreements", "documentation": "The entire disclosure for collaborative arrangements in which the entity
is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and
obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement
classification and amounts attributable to transactions arising from the collaborative arrangement between
participants." } } }, "auth_ref": [ "r101", "r103", "r110" ] }, "us-
gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsTables" ], "lang": { "en-
us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
"terseLabel": "License, Clinical Trial and Sponsored Research Agreements", "documentation": "Line items represent
financial concepts included in a table. These concepts are used to disclose reportable information associated with
domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r319" ] },
"mbio_CommissionRatePercentage": { "xbrltype": "percentItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "CommissionRatePercentage", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails"
], "lang": { "en-us": { "role": { "documentation": "Percentage of commission rate on gross sale of common stock.",
"label": "Commission Rate Percentage", "terseLabel": "Agent commission (as a percent)" } } }, "auth_ref": [] }, "us-
gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
"http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label":
"Commitments and Contingencies.", "verboseLabel": "Commitments and Contingencies (Note 12)",
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered
into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms
thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a
company's resources due to future performance under contract terms, and (b) possible losses or likely gains from
uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do
occur or fail to occur." } } }, "auth_ref": [ "r52", "r94", "r378", "r439" ] }, "us-
gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us":
{ "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-
gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation":
[ "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": {
"label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and
Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [
"r80", "r203", "r204", "r503", "r667", "r672" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": [
"http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation",
"http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited",
"http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical",
"http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": {
"role": { "label": "Common Class A [Member]", "terseLabel": "Class A common shares", "verboseLabel": "Class A
Common Shares", "documentation": "Classification of common stock representing ownership interest in a
corporation." } } }, "auth_ref": [ "r739" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlan
], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel":
"Shares available for future sale", "documentation": "Aggregate number of common shares reserved for future
issuance." } } }, "auth_ref": [ "r55" ] }, "mbio_CommonStockIssuableMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.mustangbio.com/20240630", "localname": "CommonStockIssuableMember", "presentation": [
"http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": {
"role": { "label": "Common Stock Issuable [Member]", "verboseLabel": "Common Stock Issuable" } } }, "auth_ref": []
}, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockMember", "presentation": [
"http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": {
"role": { "label": "Common Stock [Member]", "verboseLabel": "Common Shares", "documentation": "Stock that is
subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r544", "r545", "r546", "r548", "r549", "r550",
"r551", "r655", "r656", "r659", "r686", "r738", "r739" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": {
"label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value (in dollars per
share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r55" ] },
"us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockSharesAuthorized", "presentation": [
"http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": {
"label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation":
"The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } },
"auth_ref": [ "r55", "r440" ] }, "mbio_CommonStockSharesAvailableForFutureIssuanceValue": { "xbrltype":
```

"monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "CommonStockSharesAvailableForFutureIssuanceValue", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Common Stock Shares Available For Future Issuance Value", "label": "Common Stock Shares Available For Future Issuance Value", "terseLabel": "Shares available for future issuance" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r55"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r9", "r55", "r440", "r459", "r739", "r740"] }, "us-gaap_CommonStockSharesSubscribedButUnissued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesSubscribedButUnissued", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Subscribed but Unissued", "terseLabel": "Common stock, shares issuable", "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds." } } }, "auth_ref": ["r55"] }, "us-gaap_CommonStockSharesSubscriptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesSubscriptions", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Subscriptions", "terseLabel": "Common stock issuable, zero and 419,089 shares as of June 30, 2024 and December 31, 2023, respectively", "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds." } } }, "auth_ref": ["r30", "r55"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock ($0.0001 par value), 200,000,000 shares authorized as of June 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r55", "r380", "r538"] }, "mbio_CommonUnspecifiedClassMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "CommonUnspecifiedClassMember", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation", "http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited", "http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical", "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Shares [Member]", "terseLabel": "Common shares", "verboseLabel": "Common Shares" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r607"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r606"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r608"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r605"] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentScheduleOfPropertyPla], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "verboseLabel": "Construction in process", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "mbio_ContributionTowardPatientCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ContributionTowardPatientCosts", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes], "lang": { "en-us": { "role": { "documentation": "The amount of contribution to be paid toward patient costs.",

"label": "Contribution Toward Patient Costs", "terseLabel": "Contribution toward patient costs" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails",
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
"http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r145", "r146", "r224", "r250", "r366", "r370", "r375", "r509", "r511"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "mbio_Cs1ProductOrProcessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "Cs1ProductOrProcessMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
], "lang": { "en-us": { "role": { "documentation": "Information pertaining to CS1, a pharmaceutical product or process.", "label": "CS1 (MB-104) [Member]" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Notes Payable" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [
"http://www.mustangbio.com/role/DisclosureNotesPayable"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Notes Payable", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r81", "r139", "r196", "r197", "r198", "r199", "r200", "r209", "r210", "r220", "r226", "r227", "r228", "r229", "r230", "r231", "r236", "r243", "r244", "r245", "r345"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [
"http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r14", "r46", "r47", "r92", "r93", "r147", "r221", "r222", "r223", "r224", "r225", "r227", "r232", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r518", "r519", "r520", "r521", "r522", "r536", "r651", "r668", "r669", "r670", "r691", "r693"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [
"http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable interest rate floor (as a percent)", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [
"http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Interest rate during period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": ["r49", "r239", "r691"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [
"http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r14", "r147", "r221", "r222", "r223", "r224", "r225", "r227", "r232", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r518", "r519", "r520", "r521", "r522", "r536", "r651", "r668", "r669", "r670", "r691", "r693"] }, "us-gaap_DeferredIncomeNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeNoncurrent", "crdr": "credit", "presentation": [
"http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Deferred Income, Noncurrent", "verboseLabel": "Deferred income", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": ["r643"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [
"http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentNarrativeDetails",
"http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Depreciation", "verboseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r6", "r26"] }, "mbio_DilutedOutstandingEquityPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "DilutedOutstandingEquityPercentage", "presentation": [
"http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of diluted outstanding equity paid as equity fee or used to calculate stock issuance to maintain parity.", "label": "Diluted Outstanding Equity, Percentage", "terseLabel": "Percentage of fully diluted equity" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype":

"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": ["r8", "r37"] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": ["http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDe], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r113"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": ["http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDe], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "presentation": ["http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDe], "lang": { "en-us": { "role": { "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]", "terseLabel": "Assets held for sale, not discontinued operations", "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": ["r3", "r12", "r113"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDe], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "terseLabel": "Property, plant and equipment, held for sale", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r2", "r43", "r44", "r76", "r78"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r557"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r589"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered

Year" } } }, "auth_ref": ["r600"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss per Share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share outstanding, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r132", "r153", "r154", "r155", "r156", "r157", "r158", "r164", "r166", "r169", "r170", "r171", "r175", "r315", "r318", "r332", "r333", "r373", "r388", "r512"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share outstanding, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r132", "r153", "r154", "r155", "r156", "r157", "r158", "r166", "r169", "r170", "r171", "r175", "r315", "r318", "r332", "r333", "r373", "r388", "r512"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureNetLossPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r163", "r172", "r173", "r174"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized share-based compensation", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r297"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlan "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlan], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan, predetermined offering period, lower fair market value percentage.", "label": "Employee Stock Purchase Plan, Predetermined Offering Period, Lower Fair Market Value Percentage", "terseLabel": "Predetermined offering period, lower fair market value percentage" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r555"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",

"localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r555"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r555"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [
"http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r639"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r555"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r555"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r555"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r555"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r594"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r635"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r635"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r635"] }, "mbio_EquipmentAssetsPurchasedTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "EquipmentAssetsPurchasedTerm", "presentation": [
"http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "The term of the equipment assets purchased.", "label": "Equipment Assets Purchased Term", "terseLabel": "Equipment assets purchased term" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r9", "r112", "r129", "r130", "r131", "r148", "r149", "r150", "r152", "r157", "r159", "r161", "r177", "r186", "r187", "r194", "r264", "r306", "r307", "r312", "r313", "r314", "r316", "r317", "r318", "r324",

"r325", "r326", "r327", "r328", "r329", "r331", "r339", "r340", "r341", "r342", "r343", "r344", "r346", "r347", "r359", "r387", "r400", "r401", "r402", "r418", "r484"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r604"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r562", "r572", "r582", "r614"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r559", "r569", "r579", "r611"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r610"] }, "mbio_ExistingWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ExistingWarrantsMember", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to existing warrants.", "label": "Existing Warrants [Member]", "terseLabel": "Existing Warrants" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r566", "r576", "r586", "r618"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r566", "r576", "r586", "r618"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r566", "r576", "r586", "r618"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r566", "r576", "r586", "r618"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r566", "r576", "r586", "r618"] }, "mbio_FortressBiotechIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "FortressBiotechIncMember", "presentation": ["http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Fortress Biotech, Inc [Member]", "terseLabel": "Fortress Biotech, Inc" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r599"] }, "mbio_FractionShareAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "FractionShareAdjustment", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Value of shares adjusted due to fractional shares being issued.", "label": "Fraction share adjustment", "negatedLabel": "Fraction share adjustment" } } }, "auth_ref": [] }, "mbio_FractionShareAdjustmentInShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "FractionShareAdjustmentInShares", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Number of shares adjusted due to fractional shares being issued.", "label": "Fraction share adjustment (in shares)", "negatedLabel": "Fractional share adjustment (in shares)" } } }, "auth_ref": [] }, "mbio_FredHutchinsonCancerResearchCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "FredHutchinsonCancerResearchCenterMember", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Fred Hutchinson Cancer Research Center, a counterparty in agreement(s) with the entity.", "label": "Fred Hutchinson Cancer Center [Member]", "terseLabel": "Fred Hutchinson Cancer Center" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Loss on disposal of property and equipment", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant

and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } },
"auth_ref": ["r648"] }, "mbio_GainLossOnModificationOfLease": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "GainLossOnModificationOfLease", "crdr": "credit",
"presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails"],
"lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on modification of lease before expiration of
lease term.", "label": "Gain (Loss) on Modification of Lease", "terseLabel": "Gain on lease modification" } } },
"auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit",
"presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails",
"http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": {
"label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Gain on the sale of property and
equipment", "terseLabel": "Gain on sale of property and equipment", "documentation": "Amount of gain (loss) on
sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } },
"auth_ref": ["r6"] }, "us-gaap_GainLossOnTerminationOfLease": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GainLossOnTerminationOfLease", "crdr": "credit", "presentation": [
"http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": {
"role": { "label": "Gain (Loss) on Termination of Lease", "terseLabel": "Termination fee", "documentation": "Amount
of gain (loss) on termination of lease before expiration of lease term." } } }, "auth_ref": ["r348"] },
"mbio_GainOnLeaseModification": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "GainOnLeaseModification", "crdr": "credit", "presentation": [
"http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"documentation": "Amount of gain (loss) on modification of lease before expiration of lease term.", "label": "Gain on
lease modification", "negatedLabel": "Gain on lease modification" } } }, "auth_ref": [] }, "us-
gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [
"http://www.mustangbio.com/role/DisclosureNotesPayableInterestExpenseDetails",
"http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt",
"negatedTerseLabel": "Loss on Extinguishment", "documentation": "Difference between the fair value of payments
made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r6", "r28", "r29"
] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": {
"label": "General and Administrative Expense", "verboseLabel": "General and administrative", "documentation": "The
aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the
reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product
or product line." } } }, "auth_ref": ["r62", "r464"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GeneralAndAdministrativeExpenseMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"], "lang":
{ "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and
administrative", "documentation": "Primary financial statement caption encompassing general and administrative
expense." } } }, "auth_ref": ["r62"] }, "mbio_GrantIncome": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "GrantIncome", "crdr": "credit", "presentation": [
"http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": {
"documentation": "The amount of grant income, such as from governmental agencies in reimbursement of covered
expenses, recognized during the period.", "label": "Grant income", "terseLabel": "Other income" } } }, "auth_ref": []
}, "mbio_Il13r2ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630",
"localname": "Il13r2ProductMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Il13r2, a pharmaceutical product.",
"label": "IL13Ra2 (MB-101) [Member]" } } }, "auth_ref": [] }, "mbio_Il13ra2CarAndC134Member": { "xbrltype":
"domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "Il13ra2CarAndC134Member",
"presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
], "lang": { "en-us": { "role": { "documentation": "Information pertaining to IL13Ra2 CAR C134, a pharmaceutical
product.", "label": "IL13Ra2 CAR and (C134) [Member]" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLeasehold": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLeasehold",
"crdr": "debit", "presentation": [
"http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentNarrativeDetails"],
"lang": { "en-us": { "role": { "label": "Impairment of Leasehold", "terseLabel": "Impairment of leasehold
improvements", "documentation": "The adjustment to reduce the value of existing agreements that specify the
lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by
the leased property are reduced." } } }, "auth_ref": ["r6", "r25"] }, "us-
gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
"presentation": ["http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-
us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel":
"Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and
measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets
to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": ["r0", "r79"] }, "us-
gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Statements of Operations
(Unaudited)" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"], "lang":
{ "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by

location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r195", "r201", "r202", "r335", "r336", "r337", "r397", "r399", "r469", "r506", "r531", "r709"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r201", "r202", "r335", "r336", "r337", "r397", "r399", "r469", "r506", "r531", "r709"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r142", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r308", "r309", "r310", "r311", "r414", "r529"] }, "mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid excluding those attributable to related parties.", "label": "Increase (Decrease) In Accounts Payable And Accrued Expenses Excluding Amounts Due To Related Parties", "terseLabel": "Accounts payable and accrued expenses" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDueToRelatedParties", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Due to Related Parties", "verboseLabel": "Payable and accrued expenses - related party", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence." } } }, "auth_ref": ["r5"] }, "mbio_IncreaseDecreaseInLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "IncreaseDecreaseInLeaseLiabilities", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Amount of Increase Decrease In Lease Liabilities.", "label": "Increase Decrease In Lease Liabilities", "negatedLabel": "Lease liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Receivables", "negatedLabel": "Other receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r5"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r566", "r576", "r586", "r610", "r618", "r622", "r630"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r628"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r558", "r634"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r558", "r634"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r558", "r634"] }, "mbio_InterestExpenseAmortizationOfDebtDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "InterestExpenseAmortizationOfDebtDiscount", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureNotesPayableInterestExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of debt discount amortization included in interest expense.", "label": "Interest Expense,

Amortization Of Debt Discount", "verboseLabel": "Amortization of Debt Discount" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureNotesPayableInterestExpenseDetails", "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails", "http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "negatedLabel": "Interest expense", "totalLabel": "Total Interest Expense", "verboseLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r64", "r240", "r246", "r521", "r522"] }, "us-gaap_InterestExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseOther", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureNotesPayableInterestExpenseDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Other", "terseLabel": "Interest expense", "documentation": "Amount of interest expense classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeOther", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Interest Income, Other", "terseLabel": "Interest income", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "verboseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r133", "r135", "r136"] }, "mbio_IssuanceOfCommonSharesEquityFeeOnPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "IssuanceOfCommonSharesEquityFeeOnPublicOffering", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "It Represents issuance of common stock for equity fee on public offering.", "label": "Issuance of Common Shares Equity Fee on Public Offering", "terseLabel": "Issuance of common shares - Equity fee on public offerings to Fortress Biotech" } } }, "auth_ref": [] }, "mbio_June2024RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "June2024RegisteredDirectOfferingMember", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to June 2024 registered direct offering.", "label": "June 2024 Registered Direct Offering [Member]", "terseLabel": "June 2024 Registered Direct Offering" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lease, Cost", "totalLabel": "Total", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r352", "r537"] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "verboseLabel": "Lease cost" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of information about operating leases", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r695"] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentScheduleOfPropertyPla], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r77", "r358"] }, "mbio_LeidenUniversityMedicalCentreMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "LeidenUniversityMedicalCentreMember", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC], "lang": { "en-us": { "role": { "documentation": "Leiden University Medical Centre [Member]", "label": "Leiden University Medical Centre [Member]", "terseLabel": "Leiden University Medical Center" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of operating leases excluding short term leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r696"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r357"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "verboseLabel": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r357"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Year ended December 31, 2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r357"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "verboseLabel": "Year ended December 31, 2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r357"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "Year ended December 31, 2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r357"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "Year ended December 31, 2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r357"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Year ended December 31, 2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r696"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less present value discount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r357"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r14", "r46", "r47", "r48", "r50", "r51", "r52", "r53", "r141", "r185", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r321", "r322", "r323", "r338", "r438", "r513", "r553", "r675", "r698", "r699"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r60", "r95", "r382", "r538", "r652", "r666", "r690"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r48", "r116", "r141", "r185", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r321", "r322", "r323", "r338", "r538", "r675", "r698", "r699"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "LiabilitiesCurrentAbstract", "presentation": [
"http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label":
"Liabilities, Current [Abstract]", "verboseLabel": "Current Liabilities:" } } }, "auth_ref": [] },
"mbio_LiborLondonInterbankOfferedRateMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "LiborLondonInterbankOfferedRateMember", "presentation":
["http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"], "lang": { "en-us": { "role": {
"documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
"label": "LIBOR London Interbank Offered Rate [Member]", "terseLabel": "Three month LIBOR" } } }, "auth_ref": []
}, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "LocalPhoneNumber", "presentation": [
"http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label":
"Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-
gaap_MajorityOwnedSubsidiaryUnconsolidatedMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "MajorityOwnedSubsidiaryUnconsolidatedMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role":
{ "label": "Majority-Owned Subsidiary, Nonconsolidated [Member]", "terseLabel": "Parent Company",
"documentation": "Nonconsolidated entity in which financial interest is held through direct or indirect ownership of
more than 50 percent of voting interest but entity is not controlled or broker-dealer has control of entity but control
is likely to be temporary." } } }, "auth_ref": ["r39"] }, "mbio_ManagementServicesAgreementMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname":
"ManagementServicesAgreementMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role":
{ "documentation": "Management Services Agreement [Member].", "label": "Management Services Agreement
[Member]", "terseLabel": "Management Services Agreement (MSA)" } } }, "auth_ref": [] }, "srt_MaximumMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation":
[
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r205",
"r206", "r207", "r208", "r267", "r298", "r334", "r371", "r396", "r398", "r405", "r430", "r431", "r492", "r493", "r494",
"r495", "r496", "r504", "r505", "r517", "r523", "r525", "r532", "r533", "r534", "r535", "r540", "r677", "r700", "r701",
"r702", "r703", "r704", "r705"] }, "mbio_May2024PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "May2024PublicOfferingMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": {
"role": { "documentation": "Represents information pertaining to May 2024 public offering.", "label": "May 2024
Public Offering [Member]", "terseLabel": "May 2024 Public Offering" } } }, "auth_ref": [] },
"mbio_MayAndJuneRegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "MayAndJuneRegisteredDirectOfferingMember",
"presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang":
{ "en-us": { "role": { "documentation": "Represents the information about May and June registered direct offering.",
"label": "May And June Registered Direct Offering [Member]", "terseLabel": "May and June Registered Direct
Offering" } } }, "auth_ref": [] }, "mbio_MayoClinicMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "MayoClinicMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
], "lang": { "en-us": { "role": { "documentation": "Mayo Clinic [Member]", "label": "Mayo Clinic [Member]",
"terseLabel": "Mayo Clinic" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel":
"Measure:" } } }, "auth_ref": ["r602"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel":
"Name" } } }, "auth_ref": ["r602"] }, "mbio_MilestonesPayableUnderArrangement": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname":
"MilestonesPayableUnderArrangement", "crdr": "credit", "presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
], "lang": { "en-us": { "role": { "documentation": "The amount of milestones payable under the arrangement.",
"label": "Milestones Payable Under The Arrangement", "terseLabel": "Milestones payable" } } }, "auth_ref": [] },
"srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"MinimumMember", "presentation": ["http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
"http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDet
"http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us":
{ "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": ["r205", "r206", "r207", "r208",
"r267", "r298", "r334", "r371", "r396", "r398", "r405", "r430", "r431", "r492", "r493", "r494", "r495", "r496", "r504",
"r505", "r517", "r523", "r525", "r532", "r533", "r534", "r540", "r677", "r700", "r701", "r702", "r703", "r704", "r705"]
}, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MnpiDiscTimedForCompValFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed
for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [
"r621"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of
Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [
"r629"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers,
Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r603"] },

"mbio_NetAssetsThresholdToDelayConsiderationPaymentObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "NetAssetsThresholdToDelayConsiderationPaymentObligation", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of net assets below this threshold, then the Company may, upon written notice to uBriGene, elect to delay its payment obligation of the Deferred Amount by an additional six (6) months, with no limit on the number of such extensions available to the Company.", "label": "Net Assets Threshold to Delay Consideration Payment Obligation", "terseLabel": "Amount of net assets below this threshold, the Company may elect to delay payment obligation by additional six months" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r134"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash Flows from Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash from investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r134"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash Flows from Investing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r69", "r70", "r71"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash Flows from Operating Activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited", "http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited", "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net Loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r61", "r71", "r96", "r114", "r127", "r128", "r131", "r141", "r151", "r153", "r154", "r155", "r156", "r157", "r160", "r161", "r168", "r185", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r315", "r318", "r333", "r338", "r386", "r461", "r482", "r483", "r552", "r675"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r602"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r566", "r576", "r586", "r610", "r618"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r593"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r592"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",

"localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r610"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r629"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r629"] }, "mbio_NoncashOrPartNoncashAcquisitionAccountsPayableWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "NoncashOrPartNoncashAcquisitionAccountsPayableWrittenOff", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsNonCashActivitiesUnauditedParenthetical"], "lang": { "en-us": { "role": { "documentation": "The amount of accounts payable written off in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period n cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Accounts Payable Written Off", "terseLabel": "Accounts payable written off" } } }, "auth_ref": [] }, "mbio_NoncashOrPartNoncashAcquisitionAccountsReceivableWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "NoncashOrPartNoncashAcquisitionAccountsReceivableWrittenOff", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsNonCashActivitiesUnauditedParenthetical"], "lang": { "en-us": { "role": { "documentation": "The amount of accounts receivable written off in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period n cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Accounts Receivable Written Off", "negatedLabel": "Accounts receivable written off" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsNonCashActivitiesUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Fair value of assets received", "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r18", "r19", "r20"] }, "mbio_NoncashOrPartNoncashAcquisitionPurchaseConsiderationAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "NoncashOrPartNoncashAcquisitionPurchaseConsiderationAccrued", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsNonCashActivitiesUnauditedParenthetical"], "lang": { "en-us": { "role": { "documentation": "The amount of net purchase consideration of assets recorded to accrued other in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period n cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Purchase Consideration Accrued", "negatedLabel": "Net purchase consideration of assets recorded to accrued other" } } }, "auth_ref": [] }, "mbio_NoncashOrPartNoncashAcquisitionSuppliesReceivedExpensedToResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "NoncashOrPartNoncashAcquisitionSuppliesReceivedExpensedToResearchAndDevelopment", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsNonCashActivitiesUnauditedParenthetical"], "lang": { "en-us": { "role": { "documentation": "The amount of supplies received, expensed to research and development, that an Entity acquires in a noncash (or part noncash) acquisition.", "label": "Noncash or Part Noncash Acquisition, Supplies Received Expensed to Research and Development", "terseLabel": "Fair value of supplies received expensed to research and development" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredAbstract", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsNonCashActivitiesUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired [Abstract]", "verboseLabel": "Supplemental disclosure of noncash activities related to the uBriGene Repurchase Transaction (see Note 5):" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r63"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense)" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrelatedPartyMember", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "terseLabel": "Non related party", "documentation": "Party not related to reporting entity." } } }, "auth_ref": ["r653", "r654"] }, "mbio_NumberOfPartiesObligatedToTerminateAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "NumberOfPartiesObligatedToTerminateAgreements", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": {

"documentation": "Represents the number of parties obligated to terminate agreements.", "label": "Number of Parties Obligated To Terminate Agreements", "terseLabel": "Number of parties obligated to terminate agreements" } } }, "auth_ref": [] }, "mbio_OctoberRegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "OctoberRegisteredDirectOfferingMember", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information about October registered direct offering.", "label": "October Registered Direct Offering [Member]", "terseLabel": "October Registered Direct Offering" } } }, "auth_ref": [] }, "mbio_OfferingPriceOfWarrantsCalculationAmountPerShareToBeReducedFromOfferingPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "OfferingPriceOfWarrantsCalculationAmountPerShareToBeReducedFromOfferingPrice", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the amount per share to be reduced from offering price for calculating the offering price of warrants.", "label": "Offering Price of Warrants Calculation, Amount Per Share to be Reduced from Offering Price", "terseLabel": "Amount per share to be reduced from offering price" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses", "terseLabel": "Expenses from related party transaction", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r97", "r514", "r661", "r662", "r663", "r664", "r665"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r353", "r537"] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Impairment Loss", "terseLabel": "Impairment on the right-of-use asset", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": ["r694"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails", "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability", "verboseLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r350"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities - short-term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r350"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities - long-term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r350"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "verboseLabel": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r351", "r354"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r349"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit",

"presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "verboseLabel": "Amortization of operating lease right-of-use assets", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r648"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Weighted-average discount rate - operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r356", "r537"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Weighted-average remaining lease term - operating leases", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r355", "r537"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Description of Business and Liquidity and Capital Resources" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResources"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization, Description of Business and Liquidity and Capital Resources", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r42", "r89", "r406", "r407"] }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccountsPayableAndAccruedLiabilities", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAc
], "lang": { "en-us": { "role": { "label": "Other Accounts Payable and Accrued Liabilities", "terseLabel": "Other", "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "verboseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r120"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Payables and accrued expenses - related party", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r47", "r538"] }, "us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Other Liability, Current, Related Party [Extensible Enumeration]", "documentation": "Indicates status and type of related party for liability classified as other and current." } } }, "auth_ref": ["r697"] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingExpense", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureNotesPayableInterestExpenseDetails"], "lang": { "en-us": { "role": { "label": "Other Nonoperating Expense", "terseLabel": "Other", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": ["r65"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r602"] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivables", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Other Receivables", "verboseLabel": "Other receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": ["r125", "r448", "r516", "r707"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r564", "r574", "r584", "r616"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r567", "r577", "r587", "r619"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r567", "r577", "r587", "r619"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r591"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Expenses" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "negatedLabel": "Offering costs for the issuance of common shares - public offerings", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r15"] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Productive Assets", "terseLabel": "Purchase price", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": ["r99", "r682", "r683", "r684"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of fixed assets", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r67"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r601"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r601"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r593"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r610"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r603"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r592"] }, "mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrat { "xbrltype": "percentItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExp "presentation": ["http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses", "label": "Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses", "terseLabel": "Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses" } } }, "auth_ref": [] }, "mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopm { "xbrltype": "percentItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentEx "presentation": ["http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses", "label": "Percentage of Annual Fees Expenses Related to Management Services Agreement recorded in research and development expenses", "terseLabel": "Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses" } } }, "auth_ref": [] }, "mbio_PlacementAgentsWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "PlacementAgentsWarrantsMember", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to placement agents warrants.", "label": "Placement Agents Warrants [Member]", "terseLabel": "Placement Agents Warrants" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r594"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r638"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r593"] }, "us-gaap_PreferredClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredClassAMember", "presentation": ["http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Preferred Class A [Member]", "terseLabel": "Class A Preferred Shares", "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified

within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer." } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [
"http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r544", "r545", "r548", "r549", "r550", "r551", "r738", "r739"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r54", "r248"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r54", "r440"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [
"http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r54", "r248"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [
"http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r54", "r440", "r459", "r739", "r740"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of June 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r54", "r379", "r538"] }, "mbio_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "PrefundedWarrantsMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to prefunded warrants.", "label": "Prefunded Warrants [Member]", "terseLabel": "Prefunded Warrants" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r645"] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails"], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "terseLabel": "Private Placement", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "mbio_PrivatePlacementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "PrivatePlacementWarrantsMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to private placement warrants.", "label": "Private Placement Warrants [Member]", "terseLabel": "Private Placement Warrants" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Proceeds from issuance of common shares - public offerings", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r4"] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": [
"http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails",
"http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentNarrativeDetails",

"http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from the sale of property and equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": ["r66"] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuance of common shares under ESPP", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": ["r4"] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of warrants", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r646"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r183", "r372", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r507", "r524", "r539", "r540", "r541", "r542", "r543", "r673", "r674", "r678", "r708", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r183", "r372", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r507", "r524", "r539", "r540", "r541", "r542", "r543", "r673", "r674", "r678", "r708", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737"] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, and Asset Impairment" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentScheduleOfPropertyPla], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r7", "r358"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairment"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "Property, Plant and Equipment, and Asset Impairment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r74", "r105", "r108", "r109"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentScheduleOfPropertyPla], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property, plant and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r77", "r118", "r385"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentScheduleOfPropertyPla], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r358"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentScheduleOfPropertyPla "http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r7", "r358", "r374", "r385", "r538"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentTables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Schedule of Property, Plant and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r7"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [

"http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentScheduleOfPropertyPla
], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-
lived, physical assets that are used in the normal conduct of business to produce goods and services and not
intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and
equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and
software." } } }, "auth_ref": ["r77", "r358"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife",
"presentation": [
"http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentScheduleOfPropertyPla
], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful
life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not
intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one
year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and
equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] },
"mbio_PscaProductOrProcessMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "PscaProductOrProcessMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
], "lang": { "en-us": { "role": { "documentation": "Information pertaining to PSCA, a pharmaceutical product or
process.", "label": "PSCA (MB-105) [Member]" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure
[Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r591"] }, "ecd_PvpTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs
Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r591"] },
"mbio_Rag1ScidMb110Member": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630",
"localname": "Rag1ScidMb110Member", "presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
], "lang": { "en-us": { "role": { "documentation": "RAG1 SCID (MB-110) [Member]", "label": "RAG1 SCID (MB-110)
[Member]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "RangeAxis", "presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
"http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
"http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDet
"http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us":
{ "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r205", "r206", "r207", "r208", "r265", "r267",
"r293", "r294", "r295", "r298", "r334", "r368", "r369", "r371", "r396", "r398", "r405", "r430", "r431", "r492", "r493",
"r494", "r495", "r496", "r504", "r505", "r517", "r523", "r525", "r532", "r533", "r534", "r535", "r540", "r546", "r671",
"r677", "r688", "r701", "r702", "r703", "r704", "r705"] }, "srt_RangeMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
"http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
"http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDet
"http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us":
{ "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r205", "r206", "r207", "r208", "r265",
"r267", "r293", "r294", "r295", "r298", "r334", "r368", "r369", "r371", "r396", "r398", "r405", "r430", "r431", "r492",
"r493", "r494", "r495", "r496", "r504", "r505", "r517", "r523", "r525", "r532", "r533", "r534", "r535", "r540", "r546",
"r671", "r677", "r688", "r701", "r702", "r703", "r704", "r705"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded
Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
} } }, "auth_ref": ["r559", "r569", "r579", "r611"] }, "mbio_RegistrationStatements2021S3Member": { "xbrltype":
"domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname":
"RegistrationStatements2021S3Member", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails"
], "lang": { "en-us": { "role": { "documentation": "Registration Statements, 2021 S-3 [Member]", "label":
"Registration Statements, 2021 S-3 [Member]", "terseLabel": "2021 S-3" } } }, "auth_ref": [] },
"mbio_RegistrationStatements2024S3Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "RegistrationStatements2024S3Member", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails"
], "lang": { "en-us": { "role": { "documentation": "Registration Statements, 2024 S-3 [Member]", "label":
"Registration Statements, 2024 S-3 [Member]", "terseLabel": "2024 S-3" } } }, "auth_ref": [] },
"mbio_RegistrationStatementsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "RegistrationStatementsMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails"
], "lang": { "en-us": { "role": { "documentation": "Registration Statements [Member]", "label": "Registration
Statements [Member]", "terseLabel": "Registration Statements" } } }, "auth_ref": [] },
"mbio_ReimbursementOfFeesTotalPayments": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "ReimbursementOfFeesTotalPayments", "crdr": "credit",
"presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
], "lang": { "en-us": { "role": { "documentation": "Represents total payments for reimbursable expenses over the
lifetime of the agreement.", "label": "Reimbursement Of Fees, Total Payments", "terseLabel": "Total reimbursement
payments made" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
"http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r184", "r266", "r363", "r364", "r377", "r383", "r433", "r434", "r435", "r436", "r437", "r458", "r460", "r491"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [
"http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"label": "Related Party [Member]", "terseLabel": "Related Party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r143", "r144", "r363", "r364", "r365", "r366", "r377", "r383", "r433", "r434", "r435", "r436", "r437", "r458", "r460", "r491"] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r184", "r465", "r466", "r469"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Agreements" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
"http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r184", "r266", "r363", "r364", "r377", "r383", "r433", "r434", "r435", "r436", "r437", "r458", "r460", "r491", "r697"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://www.mustangbio.com/role/DisclosureRelatedPartyAgreements"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Agreements", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r360", "r361", "r362", "r364", "r367", "r415", "r416", "r417", "r467", "r468", "r469", "r488", "r490"] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [
"http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"label": "Repayments of Debt", "negatedLabel": "Payment of debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r647"] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "presentation": [
"http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Repayments of Long-Term Lines of Credit", "terseLabel": "Payoff amount of debt facility", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": ["r68"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails",
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
"http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r145", "r146", "r224", "r250", "r366", "r370", "r375", "r510", "r511"] }, "us-gaap_ResearchAndDevelopmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentAbstract", "lang": { "en-us": { "role": {
"label": "Clinical Trial and Sponsored Research Agreements" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
"http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": {
"label": "Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff", "terseLabel": "Research and development for licenses acquired", "verboseLabel": "Research and development - licenses acquired", "documentation": "Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both." } } }, "auth_ref": ["r192", "r506", "r680"] }, "mbio_ResearchAndDevelopmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ResearchAndDevelopmentCurrent", "crdr": "credit", "presentation": [
"http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAc
], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research and development.", "label": "Research and Development Current", "terseLabel": "Accrued research and development" } } }, "auth_ref": [] }, "us-

gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes "http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development", "verboseLabel": "Research and development expense", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r680"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "mbio_ResearchAndDevelopmentExpenseNetExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ResearchAndDevelopmentExpenseNetExcludingAcquiredInProcessCost", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC], "lang": { "en-us": { "role": { "documentation": "Amount of net expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.", "label": "Research and Development Expense, Net (Excluding Acquired in Process Cost)", "terseLabel": "Research and development for sponsored research and clinical trial agreements" } } }, "auth_ref": [] }, "mbio_ResearchArrangementContributionPerPatient": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ResearchArrangementContributionPerPatient", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes], "lang": { "en-us": { "role": { "documentation": "The amount of contribution to be paid per patient under the arrangement.", "label": "Research Arrangement, Contribution Per Patient", "terseLabel": "Contribution per patient" } } }, "auth_ref": [] }, "mbio_ResearchArrangementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ResearchArrangementTerm", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes], "lang": { "en-us": { "role": { "documentation": "The term of the research arrangement.", "label": "Research Arrangement Term", "terseLabel": "Agreement term" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r560", "r570", "r580", "r612"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r561", "r571", "r581", "r613"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r568", "r578", "r588", "r620"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDe "http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "verboseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r100", "r644", "r649"] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": ["http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted stock awards", "verboseLabel": "Restricted stock award", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": ["r21"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Unvested restricted stock units", "verboseLabel": "Restricted stock units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": ["http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDet "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period

Percent", "terseLabel": "Number of positions eliminated period percent", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDet "http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r57", "r86", "r381", "r403", "r404", "r413", "r441", "r538"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "verboseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r112", "r148", "r149", "r150", "r152", "r157", "r159", "r161", "r186", "r187", "r194", "r306", "r307", "r312", "r313", "r314", "r316", "r317", "r318", "r324", "r326", "r327", "r329", "r331", "r346", "r347", "r400", "r402", "r418", "r739"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r629"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r629"] }, "mbio_RunwayDebtFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "RunwayDebtFacilityMember", "presentation": ["http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the long-term debt facility with Runway Growth Capital LLC.", "label": "Runway Debt Facility" } } }, "auth_ref": [] }, "mbio_SaleOfPropertyPlantAndEquipmentDeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "SaleOfPropertyPlantAndEquipmentDeferredIncome", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails", "http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of sale of property, plant and equipment considered deferred income.", "label": "Sale of Property, Plant and Equipment, Deferred Income", "terseLabel": "Sale consideration considered deferred income" } } }, "auth_ref": [] }, "mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "SaleOfStockAggregateOfferingPricePermittedByAgreement", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Sale of Stock aggregate offering price permitted by agreement.", "label": "Sale of Stock aggregate offering price permitted by agreement", "terseLabel": "Sale of Stock aggregate offering price" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds of offering", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "mbio_SaleOfStockConsiderationReceivedOnTransactionForSpecificPurposes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "SaleOfStockConsiderationReceivedOnTransactionForSpecificPurposes", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs, for general corporate purposes and working capital requirements.", "label": "Sale of Stock, Consideration Received on Transaction, for Specific Purposes", "terseLabel": "Proceeds for general corporate purposes and working capital requirements" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of common stock agreed to issue and sell", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "auth_ref": ["r268", "r658"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain",

"presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r162", "r268", "r641", "r658"] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Expenses", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r21"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potentially Dilutive Securities", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r21"] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsTables"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r319"] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsTables"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "terseLabel": "Schedule of Clinical Trial and Sponsored Research Agreements", "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r685"] }, "mbio_ScheduleOfInterestExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ScheduleOfInterestExpenseTableTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureNotesPayableTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to interest expense.", "label": "Schedule of Interest Expense [Table Text Block]", "terseLabel": "Schedule of components in interest expense" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.mustangbio.com/role/DisclosurePropertyPlantAndEquipmentAndAssetImpairmentScheduleOfPropertyPla], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r7", "r358"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r40", "r41", "r465", "r466", "r469"] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "verboseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": ["r13", "r90", "r706"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlan "http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label":

"Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activities", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r10", "r11", "r87"] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedules of Restricted Stock and Restricted Stock Unit Activity", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity.", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r30", "r31", "r32", "r33", "r34", "r35", "r82", "r84", "r85", "r86", "r122", "r123", "r124", "r178", "r248", "r249", "r250", "r252", "r255", "r260", "r262", "r409", "r410", "r411", "r412", "r523", "r640", "r650"] }, "mbio_SecondAmendedAndRestatedFoundersAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "SecondAmendedAndRestatedFoundersAgreementMember", "presentation": ["http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Second Amended and Restated Founders Agreement [Member].", "label": "Second Amended and Restated Founders Agreement [Member]", "terseLabel": "Founders Agreement" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r554"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r556"] }, "mbio_SeriesA1WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "SeriesA1WarrantMember", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to series A-1 warrants.", "label": "Series A1 Warrant [Member]", "terseLabel": "Series A-1 Warrant" } } }, "auth_ref": [] }, "mbio_SeriesA2WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "SeriesA2WarrantMember", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to series A-2 warrants.", "label": "Series A2 Warrant [Member]", "terseLabel": "Series A-2 Warrant" } } }, "auth_ref": [] }, "mbio_SeriesA3WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "SeriesA3WarrantMember", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to series A-3 warrants.", "label": "Series A3 Warrant [Member]", "terseLabel": "Series A-3 Warrant" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Total stock-based compensation expense", "verboseLabel": "Stock-based compensation expenses", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Weighted average vesting period (in years)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r526"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfei
{ "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedIn
"presentation": [

"http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails"],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r287"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfei
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitures
"presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails"],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r287"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonve
{ "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedI
"presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails"],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested, Number, Ending Balance", "periodStartLabel": "Nonvested, Number, Beginning Balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r282", "r283"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonve
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedI
"presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails"],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted stock and RSU rollforward", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonve
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedW
"presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails"],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested, Ending Balance", "periodStartLabel": "Nonvested, Beginning Balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r282", "r283"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonve
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedW
"presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails"],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested
{ "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPe
"presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails"],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r286"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPe
"presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails"],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r286"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlan
"http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails",
"http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails",

"http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Stockholders' Equity", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlan], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional shares authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlan], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r528"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlan], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r37"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options vested and exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r276"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercis { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePri "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, options vested and exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r276"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options, Outstanding, Number, Ending Balance", "periodStartLabel": "Stock Options, Outstanding, Number, Beginning Balance", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r274", "r275"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options rollforward", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExerc { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePr "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Ending", "periodStartLabel": "Weighted Average Exercise Price, Beginning", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r274", "r275"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExerc { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePr
"presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlan "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockOrRestrictedUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296"] }, "mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ShareIssuedDuringPeriodSharesOnExerciseOfWarrants", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "The number of shares issued on exercise of warrants.", "label": "Share Issued During Period, Shares, On Exercise Of Warrants", "terseLabel": "Exercise of warrants (in shares)" } } }, "auth_ref": [] }, "mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "ShareIssuedDuringPeriodValueOnExerciseOfWarrants", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "The value of shares issued on exercise of warrants.", "label": "Share Issued During Period, Value, On Exercise Of Warrants", "terseLabel": "Exercise of warrants" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlan], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Expiration period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r527"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemain { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingC "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r37"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemai { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingC "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life, Options outstanding (in years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r88"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDet "http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Price per common stock", "verboseLabel": "Shares issued, price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balances (in shares)", "periodStartLabel": "Balances (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "mbio_SignificantAccountingPoliciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "SignificantAccountingPoliciesPolicyTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of material changes to the company's significant accounting policies previously disclosed.", "label": "Significant Accounting Policies [Policy Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r72", "r138"

```
] }, "mbio_SponsoredResearchAndClinicalTrialAgreementsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "SponsoredResearchAndClinicalTrialAgreementsMember",
"presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsTables" ], "lang": { "en-
us": { "role": { "documentation": "Information pertaining to collaborative agreements involving sponsored research
and clinical trials of pharmaceutical products or processes.", "label": "Sponsored Research and Clinical Trial
Agreements [Member]", "terseLabel": "Sponsored research and clinical trial agreements" } } }, "auth_ref": [] },
"mbio_St.JudeChildrensResearchHospitalMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.mustangbio.com/20240630", "localname": "St.JudeChildrensResearchHospitalMember", "presentation":
[
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
], "lang": { "en-us": { "role": { "documentation": "St. Jude Children's Research Hospital [Member]", "label": "St. Jude
Children's Research Hospital [Member]", "terseLabel": "St. Jude Children's Research Hospital" } } }, "auth_ref": [] },
"mbio_StJudeXscidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630",
"localname": "StJudeXscidMember", "presentation": [
"http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC
], "lang": { "en-us": { "role": { "documentation": "Information pertaining to St Jude - XSCID, a pharmaceutical
product or process.", "label": "ST. Jude - XSCID [Member]" } } }, "auth_ref": [] }, "us-
gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementClassOfStockAxis", "presentation": [
"http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation",
"http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited",
"http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical",
"http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": {
"role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the
entity." } } }, "auth_ref": [ "r111", "r122", "r123", "r124", "r141", "r166", "r167", "r169", "r171", "r178", "r179",
"r185", "r211", "r213", "r214", "r215", "r218", "r219", "r248", "r249", "r252", "r255", "r262", "r338", "r409", "r410",
"r411", "r412", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r440",
"r462", "r484", "r497", "r498", "r499", "r500", "r501", "r640", "r650", "r660" ] }, "us-
gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": {
"role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } },
"auth_ref": [ "r9", "r55", "r58", "r59", "r112", "r129", "r130", "r131", "r148", "r149", "r150", "r152", "r157", "r159",
"r161", "r177", "r186", "r187", "r194", "r264", "r306", "r307", "r312", "r313", "r314", "r316", "r317", "r318", "r324",
"r325", "r326", "r327", "r328", "r329", "r331", "r339", "r340", "r341", "r342", "r343", "r344", "r346", "r347", "r359",
"r387", "r400", "r401", "r402", "r418", "r484" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
"http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDet
"http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDe
"http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
"http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited",
"http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical",
"http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited",
"http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": {
"role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a
table. These concepts are used to disclose reportable information associated with domain members defined in one
or many axes to the table." } } }, "auth_ref": [ "r148", "r149", "r150", "r177", "r347", "r372", "r408", "r429", "r432",
"r433", "r434", "r435", "r436", "r437", "r440", "r443", "r444", "r445", "r446", "r447", "r449", "r450", "r451", "r452",
"r454", "r455", "r456", "r457", "r458", "r460", "r463", "r464", "r470", "r471", "r472", "r473", "r474", "r475", "r476",
"r477", "r478", "r479", "r480", "r481", "r484", "r547" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": {
"en-us": { "role": { "label": "Statements of Cash Flows (Unaudited)" } } }, "auth_ref": [] }, "us-
gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Balance
Sheets (Unaudited)" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract",
"lang": { "en-us": { "role": { "label": "Statements of Stockholders' Equity (Unaudited)" } } }, "auth_ref": [] },
"srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"StatementScenarioAxis", "presentation": [
"http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails" ], "lang": { "en-us":
{ "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r162", "r268", "r641", "r642", "r658" ] }, "us-
gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementTable", "presentation": [ "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
"http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDet
"http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDe
"http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
"http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited",
"http://www.mustangbio.com/role/StatementBalanceSheetsUnauditedParenthetical",
"http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited",
"http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": {
"role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of
comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders'
equity." } } }, "auth_ref": [ "r148", "r149", "r150", "r177", "r184", "r347", "r372", "r408", "r429", "r432", "r433",
"r434", "r435", "r436", "r437", "r440", "r443", "r444", "r445", "r446", "r447", "r449", "r450", "r451", "r452", "r454",
```

"r455", "r456", "r457", "r458", "r460", "r463", "r464", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r484", "r547"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r563", "r573", "r583", "r615"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssued1", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Stock Issued", "verboseLabel": "Issuance of common shares - Founders Agreement and Equity fee to Fortress", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": ["r18", "r19", "r20"] }, "mbio_StockIssuedDuringPeriodSharesAtPublicOffering": { "xbrltype": "sharesItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "StockIssuedDuringPeriodSharesAtPublicOffering", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Number of shares issued at the public offering.", "label": "Stock Issued During Period Shares , at the Public Offering", "terseLabel": "Issuance of common shares, net of offering costs - Public Offerings (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansAndEmployeeStockPurchasePlan "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common shares under ESPP (in shares)", "verboseLabel": "Number of shares purchased under ESPP", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r9", "r54", "r55", "r86"] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Shares issued for services (in shares)", "verboseLabel": "Issuance of common shares - Founders Agreement (in shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDet "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common shares (in shares)", "verboseLabel": "Number of common stock agreed to issue and sell", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r9", "r54", "r55", "r86", "r409", "r484", "r498"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "verboseLabel": "Stock-based compensation expenses (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r9", "r54", "r55", "r86"] }, "mbio_StockIssuedDuringPeriodValueAtPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "StockIssuedDuringPeriodValueAtPublicOffering", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Value of stock issued at the public offering.", "label": "Stock Issued During Period Value, at the Public Offering", "terseLabel": "Issuance of common shares, net of offering costs - Public Offerings" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common shares under ESPP", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r9", "r54", "r55", "r86"] }, "mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "StockIssuedDuringPeriodValueIssuedForFoundersAgreement", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "The Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period Value Issued For Founders Agreement", "terseLabel": "Issuance of common shares - Founders Agreement" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [

"http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "verboseLabel": "Stock-based compensation expenses", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r38", "r54", "r55", "r86"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited", "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "totalLabel": "Total Stockholders' Equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r55", "r58", "r59", "r73", "r442", "r459", "r485", "r486", "r538", "r553", "r652", "r666", "r690", "r739"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.mustangbio.com/role/StatementBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "verboseLabel": "Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r83", "r140", "r247", "r249", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r261", "r264", "r330", "r487", "r489", "r502"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityRegistrationStatementsAndAtMarketOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "mbio_SummaryOfWarrantActivitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "SummaryOfWarrantActivitiesTableTextBlock", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "documentation": "Summary of warrant activities [Table Text Block]", "label": "Summary of warrant activities [Table Text Block]", "terseLabel": "Summary of Warrant Activities" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r609"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r601"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r608"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r628"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r630"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "mbio_TransferOfAssetsClassifiedAsHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "TransferOfAssetsClassifiedAsHeldForSale", "crdr": "credit", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Value of assets transferred from PP&E to held for sale.", "label": "Transfer of assets classified as held for sale" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r631"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r632"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r632"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r630"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",

"localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r630"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r633"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r631"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredRes "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndC "http://www.mustangbio.com/role/DisclosureClinicalTrialAndSponsoredResearchAgreementsTables", "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r319"] }, "mbio_UbrigeneBiosciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "UbrigeneBiosciencesMember", "presentation": ["http://www.mustangbio.com/role/DisclosureAssetsPurchaseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Ubrigene Biosciences [Member].", "label": "Ubrigene Biosciences [Member]", "terseLabel": "uBriGene" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r627"] }, "mbio_UnregisteredWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "UnregisteredWarrantsMember", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to unregistered warrants.", "label": "Unregistered Warrants [Member]", "terseLabel": "Unregistered Warrants" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r22", "r23", "r24", "r102", "r104", "r106", "r107"] }, "mbio_VariableLeaseCostNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "VariableLeaseCostNet", "crdr": "debit", "presentation": ["http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, net, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost, Net", "terseLabel": "Variable lease cost" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": ["http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": ["http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r597"] }, "mbio_WainwrightWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.mustangbio.com/20240630", "localname": "WainwrightWarrantsMember", "presentation": ["http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to wainwright warrants.", "label": "Wainwright Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r544", "r545", "r548", "r549", "r550", "r551"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails", "http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDet "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityJune2024RegisteredDirectOfferingDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityMay2024PublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants expiration term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r687", "r688", "r689"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-

us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r165", "r171"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.mustangbio.com/role/StatementStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r164", "r171"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r595"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275",

"SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "15", "Paragraph": "10", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481410/810-10-15-10" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":

"S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482309/360-10-15-4" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r80": { "role": "http://fasb.org/us-

gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r188": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r189": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r190": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r191": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r192": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r193": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r194": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r195": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r196": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r197": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r198": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r199": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r200": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r201": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r202": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r203": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r204": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r205": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r206": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r207": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r208": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r209": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r210": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r211": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r212": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r213": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB",

"URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r299": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification",
"Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r300": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r301": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r302": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r303": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r304": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r305": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r306": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r307": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r308": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r309": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r310": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r311": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r312": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r313": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r314": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r315": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r316": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r317": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r318": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, r344": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1" }, r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards

Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards

Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards

Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii",

"Sentence": "C", "Clause": "1", "Subclause": "i" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",

"Section": "408", "Subsection": "b", "Paragraph": "1" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r640": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r642": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting

Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r689": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r715": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 74 0001558370-24-012051-

xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-012051-xbrl.zip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

N=T"K(UKBL_EXO^.'2EX;L4^VX MT]OO]+O] ZU_.C@Z'?2TT4-0[H%J-H59!4UH_WW*_AG3]C2*T":G'P2>M6:.
M,S_M=-[?W_?>]_<0?J75N[W.7P_WS\8,6'H;VL31;0.T-%K^E/ O[Y&A.]P\ MH>H?8VP& O8[B[:$)=A?
[:!8FWW5[O7;^[V]#S)I>2I*R&\%8-@727!Z)RF?I) M JO0_@H2PT3$Q> 9OMIT##!TVSDW#.3:#AVK1LB$!@2$-
<_^N_['A6^ZR70Z MMR=/@#@8&E09]ML5<'1H$GF@ZVB[6IN,,*)NXWR.3*:9/6$JS!DC]/,Y(<"Y ML^8ZQ)PL.J9-
7!,,I\)*)0RT)D6JM99/'1GIG_K8!$PUP\ NF%Q_S(%- %FJ MEEFTA*W6HD:UEGI$#@@:O;,=@*DS^TV6
"XCM5HR^/39IG./U;1'> (P706V-)=0A=";+>T=P->9PW^I M@1H6.+&Q9"6V*OW& 4'[&H M^-;QEPN(HN-R:%;))"ZQ[-
:Q)H]"T6$SNE/RQ%093G_0&(%A$E&75F?[*,R- MQJ=RH!B5]U ?0Y/O@-
'Q_]E!QM\S9%)5"9L+G,^4G9'LJO7B$3ABJ(2B;B?+ M2=@ALU INH\24CL]\(X75(@\61)2:9,(GR4W0VI:7XD>"ESG-
"U$I'*BRQ M):E,6%Z5A*UHUXY.D0&6SW072*_4)-8+(%5T\<7#6>E.+BC=*&IS0%1U49;L MG=D+M*QZ:O-M^PE5YH).
M7% A0LLNCB3!*=I!1]CW2@XC[M)B,=TE#@4I]#1S=# $7[%YD5FT1X0;2*/M)X8MF>-IA_EUM2FOFT9:P_5-S6_NQW-
:E; U- MM:7TFK-<'X'C+6GN$1%-52MEZMQTR-0UH:2"O2S1ZHG["!DP% UH%^H'1SZR MV K**YR6[+
<06^RI]NO,QT^V6&D?LZNW)C0B9ZUIC:'/3_HFA0\.FX72: M:XPHWDR#?
&@CIE%TY7U+UQ9LYAW:+,MXY13N(C=5X%-RE1OD*24 9R[":XI& M;H%-;6&R%(B)!6U('&:9-^!;1L1\>JTF45X
J:*)AX_(1M&8.YUD87D%ZZ.NWQB+(IW$DI&@-*./1@<-(7.+)29$>TBHMGT%G/2]4/2
M.\P'&3O,3+C&I=>\PYQPTU#T<%+LWJ%0R1' $+&D&\SRJ:Z]__%+@G]0!<[MK^")(K^>3H$AZA*;5J*.L
DX3&\:Z[]!ZC07GS\(VSY:!)3G!HT'TXX_R M0 M<#2IQ\LBD5LY\VU#
(G_NAT4*.DI)FA)YSP"L:'RXW"7P#FOS9_;#J7>TK2>@ M-[W2+O!=P *9$66Q397D==H=(2Z[18G&%U["!<^Y\9[EWP
PM$?NV(3&D YD MF.)/6LOE%!'%?*!")F%EK%=F#T4W5CD4?M,MA<8":6Y942IP8N$FTU\ N:)I M3%=@CH$!T^@-
%]D%4C/Q*KI!>FXA[,#_Z=[$PQ:^[$9#=E)PA($%74O ;V:] M72"]F!%\3SA4S!-2+QL((TW?0<\K9A?\I!*;^&YSI)C;5)V;
<3!08G^X\J%" M'KE/]+%B1+.U"F&+%4"7*]59M=<3==1,H*@3ML: LPIF3F.QF6B<<6+WCE@A?T
M!/CY'7:C9_RQT1I;:K(C;=IL@>>IMO$8-T&VR^6JVV0G*F^(P"TJWJ:4'8\B MUZ-(CRVKM:+(#AOUN*F,"0)RQ1N7-04?
NO'FUP*OD!2CH524YC3M)26NH>IZ1GZ,#$W)#K9=P+$+& M3>0E[(2?E#2'HJ.)P$XWT-9MH\019/8.X/JZD;[ZO%
M%/20DOS$"9?"O VS2BQ-*.5&H,QZN\!\,2,H.F^,%D[,50_PL'/[HIDBK4H4 M.KMVYZAY_.?%+W^6H\;8DD%A$9"0]
<3".\&W/'*9++JZKU -P_E3Q^R4X/4' MP 847WB35F77/$
*OPKW@ZWCE>IA[H3GO$X.NOUN3VMK2PW8.:^E$MI2"RU0 M0_O"&OKJ'0 +Z?)5T^V)ME2'%_A-
^^*KM'5'PP0]K*3,QK\Q5HV!I1+FR[U. M=F6$4>UTSCI>7-=0[G-AEUX];&1"$>Z8L0? T?3#9V,&)F[J-EONV>4P/KL$
MPK]J7#R?-!8->',(5TQ;:J9]"71C!X]3!=0[W^1XJ6?X8OGT:BJ]G/06BP]F
MIE>*]I7CP\'A:DQ=RYW^,HQ)O;94#'(]XW_R@_#0I;C+[L-23&4?1124LN7L M5HEZ366DWIF M:MDRLL@LFCO".
(I'&$$CFM^*%U-X[6A!0]&80JI*O;'%1E]RJ,)K''.!27K1 M6;VC1PG>4E[1F(8SWPT?A;8TA5$'
Q0^N9Q,7D;IYK!7!*C,PG$M]"7?^YK" M8&J%AI&8'^LVO)S-.UTB81;!Z"M=/VJA$Q6>,I<!^4 MQK/)O9<5I<3W0"2?
19"LO(VT58!0T9P<[GGABT8S[L$0%-]&4@MA4C1Y]!=US,UZA5C'T'.<>^9>LJ MCGYTN@-1FP1+^L\@F_@JEBT5?
E(D+Z*&\5-*N2=@T:F?^O)P>D-YU44D/\J7LL..D64#1=7HN:+1-T3Y,;CF[[B9"&RAZ&74><#?(
M+17=A,3LN)L(3:#H/=>RV,ZG#L <('PK.Z1$9$6-U:LS>7[3_I)M!^DKL47+ M:?][]L^8:O']_U!+ P04 " L@ U9]O)GM((Z
!;Z , % '1M8BTR M,#(T,#8S,%]D968N>&UL[7UM<^.XL>[W4W7_@^Z<#]E3%>_8,[O)SE8VI^2W
M7>=Z+%_;D\VY7U(T"4G,4H0"DI[1_OH+@'KA"P ")$BT/*Q49F6I ?33W6@
MC0;PE__^LHHF+X@D(8Y_>G/V[>F;"8I]'(3QXJ'-?__U?_W'7_[W MRB8/(Y3)>3)[Q>>_'D(R(DC*+).0F#!9I,SDZ_
M_?.WI]^>34Y._LJK./<26@3'$U[7NV_/=C]<;&O#\8^3']Z>O7_[[O3==Y-W M/W[_YQ^_/YOU)65H3\
[,.'#V_YKSO2&F4S$Z&"?B_+O_['9)+KA. (/:#YA#?[M8[I9HY_>).%J';%*^7=+@N8_O4E7SR=,L:=_>G_*)/2?
EUNSV_UW&@=7<1JF MFYMXCLF*Z^?-A%7_Z>&FQ-
,J8UPLGD/\K8]7;QG)6[W:WEK@^S&E9LV:./]%UEBOU&H5Q_Y#,IL_IMC_ M;8FC@#J[JW]G5-
M=U*!=1WASYVLJ:E"&]Q?AHD?X20CZ(*2,2T_MD="+:*=[7.,XP00%#RA!'O&7TP5!.3M/WG.$$H,NW:41NRCKYM
>C+PNNSS/ MR,*+P]^YY[M$B4_"-?LXFY]G21BC)*&"O TI]0N-O3SA;<.4R^B(L49\5%R MB5(OC%I!M-
:T92V&BYA.-7R/#@^^CS,Z/L2+>QR%?H@2UE78_YE*7KR(V1+E MC+*4DM"G'8?]UD$D]MIVUG_K/U'-
E8KO23L(JF>&G$GO@IKZ;/X+7B,#MN\\ M0F@O>D'#"-02CW9E_(B+Y]34%]A53*Z-=O%,TT2.E>ZIXYN26?>5OI,8Y5V
M$=P3:B%49O>1ET^TJ=M:;R?=G)6;U=H+"9^,T.56D$5H-I<6ZH"I)T;L2NL.
MIRBY]S9LD+=AM>KZ^I[W/*!%2(T9'@,B3([T>]VHWUC3K_]X:N M:&/6JYB+8%9V1:O%&Y07V+E9]J-
5*;1NO&^I\&]F? H_]2EK81IV6AZ8MM"_ M3]M-M',^R.&+3W%(_23W J_6*$ZXI[WZPCYV&:O:MM0W MWE_9N,E&D-
S8-E8A2BNW/*] Z2U.DGM$'I<>G0O1:0'U&UX4;2[#*&,>Y!'Y M&>G:65LU4T!*%P\[L-N/U?
91LO*^11F=EK'_\%CW6[KJF+_=TK_]'%+AGL14 MK/@S(F\:A28*7T>$[.MC#9YL_Z#2/?OAY.SLY!V/V_]GM2V!SMK8B!
<'M$.S M110EQ*OIES"YQ"LOI$Y\[F51FA@8LW9=90FUL#X&,-EM1LR]Y)F+,DM.%IZW
MYMLT;Q%MCWW#JDPXSYQ?A()5W=IJ5>3JH+1OK[Y0NTI".J>]BK,5RJ=ZMW0V M8&)-
>VV';VU@^_VZHML,MK.EFAU7-;KR'FM5QO=T:7E"?B9_H9"\&B^P*:R\P30TD MI%,.WMWBW[9M,+ZZ=MLB L3H
K;]L/TV3%D#A^*30OE)[LXF'[F$$T-NK;IC M)?T;13V\:Z?]Y5I&$5HFWPR,NLG%9\ED5 MJ'5"*48Q:0GILMXE O@
M@.I'#:XG3WBBYA83.M7ZZ8U%RTA(6K *^M?!(N@?!VX?Z1+;(R$6V+Z4KF8/ M2LJA$&V;_10G:^3S-
!JAF2MIQX6*/]P>Q?18X+O1WY>5<(%X@,7=]Z*?GRB"_'$_D^M,K]-Q>4RT"K M:.?
A04,WV)2IX8<+.8KB<*''O=N^M7,*>?:EH#L(*&KF(*'IG?.\.:$]5W\6\EPE:&NU:AEA<6.#F:60 M.V:$(JX&G^5?L.0J1-
8LJX,-'Y))OHA,.!.6$0X$YP&MJWD=58ZD4W[MLD+@ M1J6[+ D:5(%;L#/H"D',_VZ!8,2WTTG-$ZU[-
I^RW:L%YU,QF1'22H=U*;4# ME 4NV/;Z'8Z]PS>%F6;RL10XKN WK$4JF1;U=)T*-:D.=^)N\,F1!$YQ4M0"
MQN##UCW!0>:G,_*(R$OHRX8M$9G0>\L(AX7#Q+UE()$.4U):%3 Q=9=AJ$&T M6*/Y08<=,;^[84?)I]-
AYB/RV%X)ZWLW\3I+60=6C#0RY8I87 M,()L;^VLH0&LR\O@PX.<^>((H6;:>1@7_3MCJ_\7-ERI>XN$6AG"E=##P*J.
MV\KH3?#:C=*JA8\U.7$2FA6R7@K,JE@>?,;TP&9PDFG2_C?QRK;XZY#<"I<4 ME5_E''=?
LA$@X6M##J;*;"U7SF7V7'JA7E";H/O+='(5WQ5*A=^EJ5RUK)P MB\ND\\V!YM[;\'458_S ?1RP)'1I_*G/IN3>O:?
&N@X,,LO _:,^^$A2P5H: M/WK"Z-0S%$\1%F,)YYO2^4*YV]"O0&KW9E4X%I+27=0)M4#;ZZJMM(&;N!J\ M%YK *'91,?
M..]A-[.,5VN^![N[N4?0H10FI-364@8-;V7V494RQV^M4>@K! M!AP-WJ&4$(H]J)%UIYU)>OKY?-,PN]4H*34PS;*0Y-
$8>] H:2X/N_$(,Y5A M8_X&[X1:@(J=41.(VRZYG<^J^EZ!1&Y4%2*'4-0=1V\M9W\5)I$B5K4YO(F7
MF"S9,JQUS_LD"OB UVF2GNLT4DU+J1TC4QIR@)*/73VC%HE7MS8^N#F+6"W M:.,2-
MV&_N(T#&IGG:^^^%$6H.":::H-%,[+4R^\XN_)(',:+_8GI\XVX E4@ ML;\6Y6')?ML$H[?&X:FIF*$$+0<2![$,;
9J^!!CGU(H)0YIH'?JFR[1=!KJ1G?\71B0I-$P8[M.:ARP6%%B\,F:E19/!QT$+#F=%@HWDZOL6TD(Y]N)KIX4_+9:LLXE?
(7LWGR$_I&BG$P6&8D9V>TR@F/DVG M61 (?.GXH%>PE0@L':HSTQ VY6W8$W9:8'8#D3X(MXG=2TS2)T16;%G5E-
8M MHE6DP4FH(:!LR!844NLCM9C,W2!RK,7%\(G<8K;+:7A2=IUV"/;,!7\-I/P2 MAKQ7R
M(#49=Q$EF7/&5CSIKXF^5B_8N52JR[;I5VK4[:ND:V^-W\(ZK EC. MT.L&S&D7_SME/HP7BCY=H)#:8H7&'0[E6%:B:
<)B;]P2"Q K6AS/!2U=RL2B97M8#0,2RU =<(M:!9-&6Y9'%3V\,;=8W9DF4+ MF0205_WD?9EF*9T1BF]K4A,W9!2+R$$
URUI6LR'HWSI M.N/U5&DQPVYQPO&^Y$$#U0TX11KYGEB5RB4:I=E7J)H1V3-RF2BQLM7A;YHI MLUG:FZNSY]2
;W&\2/5"2R)2J?)EQ @*HU;3*P-TYZI-T@;Z_ PN.&+F2[: MOYQ9MQN N_=F?;H23L*F_3\QM7PO3$X/!"O[2)"Z:S26,\)?
]EY2[!1=B0 MH^$W!F402ON".JR[#<_FM_AOG[>:D8=PL52E'$KIY<%950DHB)6=25'"#+6]
M#J2CAOK+$C)NA@^+RMD7/#$A8]MMDFZ8K''B13\3G*TYH_PE\(;1J*&4/*NU
MN1PL&:B3>IO*M9&#Q31?;25A0\Z&3_YM@E+*!-:!X#8EF+W_K#?O$Y'*$WPE MQ @JH^U"(FU85H\PJ*6-M;A8?
BT72'3I:,B4F8'S^F:?8X129;A6I*\5?I= MF*)4HQB:585"S;V=3"J9N+"TM4%SHRKL[9*@!&Q5#/$O;RO2N*5_6GEI

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|:Z.@G(5GYK"PGTU$D3G@ ;AHTD\@B,|= MWP?>Y]>JT2NSG1!OU3YV]JF8XEQVSX9<#;<@N0GC&U"$JYR%R:H38C4\7H! M_10'.&ZU)!O$L;^WMU\-XD#?F^ /3M#N?D(^.?EIYZ.3XJN3[6?U!G1<.A&>MO#8:$@CE8%7Y=K1_M*VE>Q4>,FI6D|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|I:+V$9M@_S"YF7$W!%YW?5_F MY@97*2I#GJD+[=6RTA;$1S+M#&]\F:_$S9=9[0S#K;J.2@\$95%JQB9A=171M+JY6KSKYE_93O4>6*A[AC/ZM6Z#7$&;77NZ=_;>NHXZWO(&^"M>V2<_.Y\1Y MEB(+U$1X3\C5KMXJ_SL>IW/SO4V%OB]6:UGY/5X,*7M:48=D-HL31=[6BA#M]6YU?:\DKR_B29Y77):NW7+X2*-1GLSFX<10'4U&V=BM"^TK MJ@F;EXY.ZJD]]8GO1Y9%F*LR:+QPRC\87NM(EFHB,:P-+QUD'^J+*,OY%J\=8%?%F;56K'3U+L-E2\D&S&J5EWT..K6==8U MA-FUE_L53[*=[]FCC"$Q9$&#W4AR,8M,TK?*SU?Q),^\P.\Y=KHY)+=WF/)M MXF#_H)W?Q2+)="(QN^@(8-

&@A7QJ,$KF@A|9Y+2;GR1YK:5P;4X!L^";24\!N:,ZCY/JCLMW9Z<_7V\7 MZ:1DE$;S"MFFM?14TEO,Z@:L]
[O>_L0]$Y^IMZN2)#XV!:M&)G-1H161&$&X M@9UQWUUO7PN)E]?;W$BH6"FEI9):MQBNJ;UI5:_=HB'Y+?
7V9VVU^7S%/;3; M_' 0FD4%QYER?#>17O7+MRPHOXWB_L0=(Y^IN?MY:M2B$EINXE1!&&-)_G<*
M30/R&VCN:T+Q\JH[:K 4EI<7.#2H55;,**A6OH68Y+?3W5_WJ:KS]?<":VK M6*-.I"QHD-5$<07;-G?+@O(;:>*
[/VBKVF8I;L4<,E:F$W@ M)_:^N>*^&A(OK[?%8;2F"T:D0%:HK$;F,JM2[28MR>^HMS]K>^7GZ^UY>=F8
*M))=%4ZBDM&B.K2]SC^(MPO([ZNU/VA3ZF7J;;0Q'Y*_N]Z^%A(OK[>3Y5'32?08;9(ZC\.P+S4J54(^U59Z2%RYS0*
M&//M;J6<:Z6'P57"@2NE>K@?<5L=]?TK?K0>YI$DWO&;6WAMJAHK"%W:5:X M(W^MZX-A1#:X7IEL][14-*
]KO#E>KP$J3O=EM^??9Z9US5:UW%\'<8_J/EK<[MPYHG8LZ"3?(Z3692V3HL=(;-
A/8:,0UU_P2:Z,_!HC7Z.V\7XBAW[WDD=@?)RRI[F.T)!I30IUEIEI<),O >%C M^C+I..K=J\A(5F0TSCK:!
(8&0DTRN7E_&5@/,R"K2%UD%:GHNU=Q77IA'RBIP055"X1:@[R10,M0ORM$86@U5> MD(I=)DQ!
*<>|&,5_2"_2$!)$)**ZR.C#H02Q[!_'+R\B=W3#DCEYY4)VW0]EB*
M)JL)R7Z!TYDXE::60:AS|:,:SJ'8(]W[SB@EEZ\EDIUH3"N9C^I$) MA^G(+!AD,!8U/3I"* OA0!J%P'O-*
\UTVAPL:^E.06B7Y60XRD75W/QNFKV& M .IT!%"?A !!"['W5"B(22-?(HLC_NQH1HXX1D PB$3>$NX#]C#0ZW7)7M#*
*MS1*TYER+I:/YR$*YFQ*O(,"SB$]"P*'Q?+:KEI#]N!-:_H UF>YG9UG9";=) M8)='XDRO+U7A+CU?@P!W-ZK99-F>9$GM*
*MD6R.(_/Y]%&^M4CDBU,,>HCY8\OI+V-_V>?MFC+=WC%ZC,9@IPN&1KF_97YOV)3,*IUZU>O[;$C^.F S4*
*MH0E41+FXK"FZ?WW<'.YC)M%L%&8-)]/P;2<]*3?&9JX3W.K')V'FI(E_3=2\ MG(D\EYP96EQ-4U?*
1(0G#LQAJ/73RJ<#:@[<@9ZY^*^O%Y4P-AF:-;!=P FBV MVI/>Q.EV@[L?
^#;DS/50_*5|>>2,W1_RM08UJKRE6(_GN/(1R'9OFW==$TY M<]6KXS^.F-/DC!W6RHJ2I1;DK)#6)E5@QD+!C?
*3>@)RY*FI>OC/\7')F67TL M)NEZ.<8G.\8L]=@L.Z00V#C'+!\.7;*6NULO>(\MOF*&1^%DI%L9P(#JX>N'3L-CF5[!B3X*
*M""A75]-\5%8B?&&UC):S9FE>J@160EPK['KUE?="[*Q(O^T$3@FL,U,!<#"SOOW;LYH697BC^[H;0Z'.>M5DO;PRS*
M]?:#9=K;TWL-">H]>RNL?N+_T7:,$$+/OPV-_[6*MHJ3"#Z@"#^I9:-,3*
*M*I>N!DXT(!K\/DJ='W_]P13;!^1+PFF@Z9G<9W7LFD'O&<1 M5-'9(U\;AI(BV>#H&3-KM>>5X)X9"R(PV-.!P5X &!2]*
XSU!Y51PWS23&G\ M+&V:>2=<:I<@=LBY9*#HD^FW+;L.:P\:F>#*?]PWF&*Q7[5-&1'LBMF YIS*
*M18);5LJI%&,".@E,Y",E*89=Q[;;'5).S'JJH+7EQ*@*;.SX!VSQ3+[V-Q\ M[GEF1F MDJ0_!DZ,!FS]R1!%GKC^;M-*
S[(YZ[>PU7OZDX: 'S"D:SJH,M)WE1X:.;4++ M2BB&#:513I<.+,(Z5-&XY"I^M&D"W0(2?IN56.W^LN>CNJ,O MP
K_F@:2HJ)^@RST ;]\-#,2B0 DJ[3V5N'"2E!U(F]JJH $467<4D9-SV26#T)[14AL.#(4.6<-C6-N$66^%V*
O3OES,YQ(G2'=X_5S+KG9D MJ3ALM68"9RS #&G-;G@:.&O_1I;]\CNEW[+L2<,5EJZ2S^GHR2&V];L+C1L*
MBUDFF\@6G0UKT4REN"^QKJ_-.^@+_RIF1O+@G9<0E2PE$W*U]7U[B]5QY1& M"/P;HZBMV".A;RI#J$-D6%J2*
G4)KK'0RA7G%7-1J)!:L=SN1Y/29@'-L)_ M;.Z^(?".R7^I[,\K^ZV_G4,8$;IY/G]=9_>OQN\[^$IP= M()U]O9-*
3+]UJG#JT@8(6DP>FKNC#=9)EQ0WFZ>R4:TV@$N8(%2/.1];CDL89EALSG/984&838:]:+RJ+.ZURT)5'A@F^@C+
MAHU^PF]2= ?%30B]^&UN!['0S*CCL9S7N/JN6*T%XVV\X%=\5>HL<7 .\D1 M=)0<-9&9)V?TWARV*|>H=KJ@S?*
4)K6J\D:V8]?QC8$WA0(7MWF#R,N<]B_@ MXE5^S9W-W]ALJ^/D^J;L6DG1% M>DL R_W2;T]1U,I:.=J,!P:,55BUP''6-
*Y!7)[_RD)!;S;A/R3LX/P!.][&B MTC?,HJ'+^*@WECKU,F&S5C46%Y9 M^> I[2?I^<,I[E96.)QCT$WVMZ^G*U:\B0JZ-*
842)JOL-O.753$,9V3D%ZE) M,M47YW$J#T/&+2ZKR^,O3?4V5O=
(F91WL6NT($T5\C''\,YTF3:Y4H&8/LRS@R2ON:OLBSQ5&^&!,BH23/5=MB?<'6!T7R=E?V.CQ[V?7]P.4G\7YR M1,
<[XS29I+O0&6ALA FNK@W(Y2>76UL:5MNWX5]OWG,JNV(K19S,1X4YVVY*
*MDYT8XVE@US9PYC&#+UR@N>LM[7.ZUBD(V66U&BGS2BAN:B3=<6*B>2N];02L5>R-:E3FP*
MX4:AO!FTZQ:'':VW4)FS/;MVH;7DJ2G4?MF MD!I]$U+;0-$7)O[NW!)T%)ZENT5Q+)+
FM)Z8L@+8>5FPX3/T>FKRL[HN1#Y MYN#S"_$K9KELMG,M92XT!JEEB-4[K?CJ9DW':Z1WSQF:W-ZY?>IIA5=6GD=_
MV4C@OML!>3:H76[7R '773%\)K1,RXOS2K>:SK8WPR3EY._2KM6 M6!E=-2JTRURDS=86\YEQL][T74J^-SFRWH]+B]
(M[.L%$QJZ MJL^PZ[UGB=GCJ&&7JP*=-M-*:CYFN&A@]>0%Z;-U-/<(=$Z9$K@:9E=$X4OE99)@3?;XA4,)DUNAD*
*MS4Y:C[3'9T7K5-S1^5NK!DBL]?T#RNM#]SEX]56KIA*I Q<@N8;>#UWE![Q>N1H/:M35 3P,ZXZHV;]T..*
*<_MZ1HL_U>KXY*H][M/871*).WQPM6T&16D(18(E87OK?,_%ROYYNC\GFO)]2+DM+,8DR!YFU+G3_F*
MRT8BL.F^+^KU!!B=;Z[=UY.0K!N(;45HC$(F[I+62<]:$Y#DI:4Q9P!%!E; O')?W4XUIB-S_=+8 M>-
<=J]@8VB46[FPZG3Y64I)1$NI2:4:O%OC@XV-(-R!^J'[<>.RK.#.@%H% MBIS3DV"JV$#U(5)BA&(AM*
*CU!3I&#L=Q6TJQYJV*CXT9\]*4+XF4V[Y)^66D M3)?*
MZJI+Y5@AV6UVY\QL&&TXMRI,KHZ4P,N4=Q2%?!O:=D2Y_WQ,K(XJC7@] M1S:2R(G@LIW5W
ZL:7N1HI+GQO<3(G]KZ7<%3$MC/MYC>@3N^ M>N32P]/A0I_A[IS-65?Z3?#P.0A;<-V%NZAP:P]*
Q!CE>3C:$2&BA,C.4W7 MPZW6S4+C]0F?$Q9/SI#2F[E^^ PI[=[^07UXI:G-2O<-I;QLK2I](;D:%[5P M.N-
*D^>!:]N]=:>K"*TWA,Z4T>ZZ5_OC%I;&%$QNI>CG+:XWLK*VT'^-D/G#K M&H2+2_^S>17J&PQ['':Z7%*
[5A/^0=&29'BBJ;B%)U:$%@2J.L8>WZY+B3 MJFG(#M)Q9@.:&@@F\LR|&TT_BOC M.K+R%%V1@-
HT%:#&AR;T>,KOE+0%:K$HK1IDLE1=T>-'6 X7_J=+(WQJWGKH*%V/94];OSL,!Y>$D MFE=ED#6FL
R\K,R.M(=FTAB=Q,-52P?R;DEMC6LR>$4PP,@F6:Q/X>AV*WY M6:?2_F*<^_RJW?GU:_-K3J48D_9_OR2C1M+]LEUO<*
*,AR3Q6LT6[I@U;MZ9B MK\ZH1Y;KSJ%?FT.3%O69"G4U*XGU?B_^R#NSU;Q!+1^C6NK6(DI7Y]-G%^W.*
MK0'EUA)8&1ZI+LE=.LWH2/G)4=Z9:K5QHV.GBLU;XZY#4MTQ?35,7P2D"YL/
MI74IUA0+-4&DQHWZTJ!,]7NV#D9.\>W:'V=+)B9"B46S$A+39S\2BJ3L4Q< M"%XYH'L6+*B<>?*
*6R'%|U"S9.+9S\I*JK0J-3J?=B\[HQR-Z:N7//@MWY\EMD MP?I*1AL/))TBVU&S::1KM3P9O#M7[UFP.P]?C(=O-*
*O&];OC9<;D^CP-!H-, MK%.;=Y>WQKE7#]K=LV#?E5_+0LV7(0T<|&%6D*A9(V$^E"|^"W0JF+P+20B+*+=2*M.?*
WW+-B=+T_ARYO/@NEA>T!IU5154(#- M]-DP; W[M^:/6AW
*MSX)]5W[]M"Q8J#&51_EI[I%LM&M"68]P8IJZ'IJ\9\'N'!JH+)AJUV9*K=+I*
*MD]J$&U:5EI[FF5N+*%V=3[]%NSFN/5SLF#)^7)9;[8*(U*I5@H]<]$/C<5; MXZ[OF@4+(*8O M):-5/OPF0T)0*
+S9ABIFS2")RI=L?.R=@Y?AW.U\F"S8) MK9+9YDA-FSVRZ<+CK!V]-:EZSX)=C3.O?AG15|V"K?]SK+
(2R|&)DDB6DPDQ MU(A' J=)[EFP.U^>@2]O/@L6SU3&O-+,K809!TA(6?'0([RUG/4]"W;GX??S M\(UFP91ZN<:5%A;/-
*Q;M,A-/2,ER_=8,X*L'[>Y9L,_*KY^6!5/FO!*;*(\I MOE F$["DMT>D=FLJ]NJ,^KVS8-^20S\Y"U:8SPJC\FC1%D!-*
RFE<<5"9+6[- M<;TZG]ZS8+?&K9^3!5NEDW(O&H[&R5DUG(3S22HAZ+?&7=\X"Q8T3%\$I-0D
*MGIM.*JG\I+#LM"237%*3\D&FFFPV6SK>D].G;Y MZ%A \/BQ>ZX,TS:15!.*84-IE-*
,/+>,Z5)%BDJOXT2;B;PM(^&568K7[B]OA M^I$2&!LF7L^%#N7M_:J"+F%)H"HR?NQT?5$".O"^\U?-
VD@,OY,#A@O7\|S"XL4[<='MC)M MS+VCYFB]]PCI]8;=Z3[;2(8H
M4;:Z31GJC'82YS$EM6LG45^%)X=69[ELM1R55YKM:CGVF(ID(W>>O//DJSQ) M82/F-)ZDSN^[^)J2W-.4Y-4#9?
C!.EXVMS7^5)+17.T2_+PXE&:PMZX%2(K MUHP--8P%%V[<8]'KZ+K"!/U]_DI?0WN:N_/TE2/)_$
*MNHJ@&'#DJAP*MS(\-S56CJHU.$:XM<#'U07%!9)<=SFQ9OZ3;0KR[#9%1,11 M%"J"Y<3F[R]^8*7$+[/9*BF$R-*
DP'HN4IORXS]R:Z7_L!(<%J8B(1+]/W," M"Q\VO=@1_UPZ)^6
U>:$57L9'\7IQT>K<'&U]X[X<=#.MY+2C1LU#WFHZ0+*LR:-B&--F1^X:F&;J@6U,HX;_I@Y\YB"#H&*
*<3KF)'WDFA>5V[__O.DZ91$.342^#9HM4%N90W[V<#% M]-?"[5E*K47L"Z3ZN&A]D<;;+-<3(E\RF70]8;#-)R%0?*
SRYQ)5SJX92CC7) M52:2JUE">F5OP&[3L^@#>H. S=|WOS6@ =%S]7?H41C]L>@9&IUTWQ8MM(2:/GA+CZ-.<+J\I'?
*TXAQZ>]-AX_1N)V0 J M?!(YJ,.A8MD>0U)7FAWXX$_-]]U M&:]7)WRY77[G/-,3]KI4^]%?7'K%*G5*B=4%KAQQE*
*MZG"5@GVSJWM\DI?BE+1#ZYHTNZEN49'J)+)'MD(CQU6R;3O M*WK"BE)1;"^=8T6/QL,IVN=91DP.A+ 07:Q"_(R-*
*@F6:7#4*EZ_&>-& .$6? M=[=%>.>$V%-AYT=WVP"; LC^]"O#T8[1)^BF*^<"&VYR@ MS8M0'L>XT*,8V'#VL_-*

*AEXXDGGS4*GWT/3FSGX.#ZPXFPJ)K*' V@ MJ@+)U?L'T'A=[JY;'';D=[!<+'K"J"!9?&B6;&>7O2K9J=PLMEZFUAF2)<^+M_G63XW2^)+2Y$!4[$=J[30, ;3C <8A#<7>B+9%W=(A?5]](DY1B0NG0ML@- MNP:58&1IHN0;8>FQQ)-#]H8!?I1F%T6V^^+3J/TU8AZY M'=V5V]$W ;H-%'UAXN_.;8P,N5B9'G35[(0>]"5-GT$X<@(7QCP5S_1Z>N:M(='3Y?/9XH=OEL<-])HQ1G_]_-)8W+*R%6AP*?)C%+)Z9V&LLI6 AO%> V] M1\GT963Q?DQL5[Q^-";V7CS29\>C-6B$.6$R(2K(A+BJ* +M()>9YNR+-;ET^4G<\OC7?1T?V\1BW+&C'I9FC M6 HV3W?2!?B7JF-*(V#!32ZTK=BCY[=#NP>C"X MB'AJ\&\Q\:K!OVUZ!O\U)D8W92DV?W^9>|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

*; FQ.M-OE[L M$G6^6]DWB:I0;PCQ4PNXG(.',(;\Z?V!A_-YFN)#*U:I;Q!_UP/?4 ^XA7A=#^R)M(HCUVM0XM*IWA((12X#:H,:*U3,H O9$17"".FC6X^5&#@O]+ZT/HK>N#^P- MRM8*86:&O'R2;1*9.FES4.,SDV8ETPK5>GIO^ K92D*CB80(D>Z>1^[^*G.5-&1?:B \U)6CC#XR^4^MF6!C(N36+LF(HE*^YM(EB_*;N"UZ;JL4*KO,\B1-EX^._5';- M!>H^15;%91G?#N3_4U1T2.U8S.D4W>9F^1A+)BNQ9&1A9JMT_+4 &A.)$%45 M6:/>PC9L$T+[N@;SI]'1/3QN-HV%OD-%E;.6_26UY'A0E<.S1:I75JW7W+6V M@?D]1X)ZU]\2'6'6GA;U1[YA#_AP08GH M,/DTX'3@;\7?/.'/G6_50-:IVE.F6SO1G:V9S5%DK.ND2'INE_N%7MPLQ%]U MRI$%%0Y.:/DO?XY8Y:H.UA'$HS)%Q)1=1W-JHN^5*5)N(22@[=WH*^1"(?6 MA;S+-Z>B_[HT%C"'QTT(#E:_/6]60DXZ:?.51U&PA_HRGJ)>DY21Z/%@S$O/ M_/?B:"\:R(2HC@S]:>")(R/]49O/+\ADK=,L=DI%JCI[;99)W]<#C]5]\/A"-&Q3':N&3__B(AGPC-QH!$2B+#<5!D@106MHW*8$EF:C@W8",O(X=AA(&'B7)ATAGZCOM>2[XF&H_- M5+I"CZ/8Z\=7KF@>>0KYA5%]UW.WX3UZ!D@ME2&;;?))MD4V"V'%,2P_R> =O2'<$SD_B2DPB3E0'4C_^0#/F*"LZB$NR__M':'BLTN2+[QXOACRI-!FY32Z;\=[L9@^@=.2WBFF*4TP\,HA"Z"4R%4^M"CG MDUW!6I?#G T65Q=)UZP9CO?EX4%65U$6E,8.67X">$-))T5C66&'6)9:,I@= M+AWAEW(BO(L(+QIQO(K)_E#/_"F+L2=G9FCH)='>3A]*'? /6\[^TP. VP ML_G']WEVG*8U6K ?A%4]WOQ#R ZN">XVG9I0@JY)0M%>'^Y618OX"_6,L$U8 M#M*XULC N?/U+A=[!.R#"1$+L#]H/&+O87]*__U)%TF_J)WYMU';((:]<=H M5O@AMSUZ$H_'[\RM5.".Q!TNL&PB1GH]R&!E/1"7CW@E'=-$H_!VDF&Q:0/; ML79XSX[[JPD]05!JY'+*?_8,WD+\5X7GR][?C_8>;8>O[R?]&R<\XWK/6[! M9S "PPLA2U-L&P$2]@AAIN%6P5!7!$1J:D7DL''DAN_2P$;>/N:#CAOV\=N MT*'NJ/[N6)8,8[ZJPZ&C^I'^4)/X"_\8^9MFZ >_@3U2W#TH4[P'Y5,XT!OY MA]>@]=_/8)8=HF*:^KRSPRP=9ACOI$JAUD2A'Q><)683#KZ)_LXL'U6D;V,0 M!$= J.AY2 !)0@R"EA\!!R/%Q*+ZZ+<$6IW0D1\L#?$5>H>YEI$(6AI2QJN? M6$.ASI S0>^?:\/VZ%:6L1M>+'@HZ:4H?R9"(:9#+A@)HRC!8>VXMC0<<1L^*D5:W2 MXV?%;JO;RLVRN2%N^60_7%(8K9H9D&@*'"|-Y-&R(WNA]OV.>7B*ZXTEDCP*"9@.A0MJ*NA2'^1D.=(L6$(@43" M9ZD7)MCXW/0#]]GG#(I8.'ALN", O"]<*?"VS2'1!Y;Y[),2YU,Q)P='P@_D M)TSS-9$5__B",0^?L)WGHLOUE]#E-1CLM5"';_"Y"X?-CJ%AKBZT214;YF;2 M?\AE@1.7Q5 E;3BA3LV+-):/V2D?"F#=HGS@ BL?]I.\GG7F M"8*-B>9]](VOH$N&ZQUY\SC$)6'"L10=6M:&0QJ-\@204GE.KN@!F1@5$GHB MA#F$N=3!YXL(M]...EZ#0=^V]_M9X^D*/,<_Y^2||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

.M;8N3@J.O)TK1'FB:FI0!L;)FY0V7I!&@81S1 MAF\-*501$R#;#B^5'U5(K.5-P|9:;HAL./074I%X>3% *N80Z,JCOVWKK && M5R=T#S#'-9Q*,OKA#8%FX 5]X(3!E.(1:#^J&[MI5XZFIM2+HB|R>6AV"* MY- |+VKM?OP#T%N#OJ?80:N8C$ MN/65/ YJ;?&ZY_88 Q>3:Y@%P'^31JACI/3=Z!TR4Y!RQ]$)I/'_|K,3R7A] MG9<@H([P"-USV$U"@L@AVVE%--?MKC._'W\ (&THCW5"-X>H>VKBS]YO-=L_H M0LPP5>:&O3;*5 CDIW#Z2902(8KDMH8[OHW8L)#]C;A<-W2$'VRT61;$ 0Y% MEU1G$X@< ,E5;3|W04+3O38!AQ.Q^) ,"QGG8(XKB&$]M1-:QV^3W+3ESB,& M-OOQ0YZG"I=3?,./GR($KJZ%Z&$<<$=DQ3]+-I3OIOK)IGI.QS%F+|&<,ITA MD=J1ZFX*<,? PN%OGGRH%GU+F+AC/)QBKR"! [CZ>W)XILS5^<%#,4;?W!4C M--V-!VX#-W2!K2:|=6*[Z>!K*>([!"^9MU6X2)LCA6I! M>4?INCFW0[]UDZ^XYRKN,#|=YG[2%Z-N(K3 MO|YZ/\4:Y>A?S0\A11"NH: Z/I@2*+*:/X60HXB0YP2@6Z:>.&SB+|O _31 MPUB,F_Y6!X]A]N(M"-.CIR_[>K& .V0O"=EUYNT8;I$EO U (Q!BA/;A[F[J M.3 5P[&(*3(60II[8186P>;.=M'=" (%EHW^A*^(WIK=M(M?2WRBQM3YV+!]+ M,AW4Z^J.[#NRWQKXD@QMBB#I;FIW,\6>"$6@@\#V=C-CZV+'$K#|*T()&ZTN MQ#:QO+4D/(O9"U+Y6]".VA#K/K9)&|*8XIWNCH[-9W_/Q4"Q?8/ZRYD9=QB? MTZ8XP5#]N3D6TC<-(",KU]N,B8^@K%SK802!:H_PB1 7EBX2_:,?G@=G>1O: ML&NY9UJXV]-490)55_J[N$>6\5T:WV'\!AC'/5BM'TE95UK$%WPLTMZ=2 M=H(=Z^T]QB9E>23\@07] [JX>;YO^[A;J[=NP*-Y:V-)AK!N_]Y AKKD1Z+WQ M[QL[G_|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|UQN3>:^,<>>$E[>DRIXM[YGR M3YD"N/'Z0U-B;9T-L5\UC]OZ_G=^"R%7/#91L-C TW M@KS>58^$F($'9T@35^6/@.5?"H*Z]+;E>=4)=HOF6R.O_@[0W6"N[N ||Z8$ M'3XTLBTKX%;H]'? (N:K>#5OO%NG<*_^#!*AG#^.2M?#8,+^>8K]SPV=<_^"> M/'!3C=C(]?TH,#2A? [>):P=L6&>]U\U]U.)W6%Z89AZ8G4-35E!L',#8WO(W,_H26X--"SH!\A|M=WKK107 MZ!;>%60O(-S<'K7NX24!&@QCZ&L>;6+O1YON1YO>>;3)SZ^17)]B.)(5@1P9 MB.P@W!>C|B L]F$L&H$QD@WW!W[BS7NB&J\W<^E<.5Y.YN+%7#E=J9?BS5RE M++)R V0R)VQK232<0WSU&"#AP9GSA&5,7;":#LW5"& M7.Z&C<0>TMN? -7["8Y<-9O#XO,E0#\1FG,1F?,1Z@!@*9W,RGPSPE7L;2T*C M&2]GB$2N\M,G? 3GYL$/F#6$30,5'TAHC"&U+9%F2BM&7RN"^^0Y,?W"$-SK7 M<7^I.?'79D$NZ.6_>19_N<6O#,="NAAI<;C$A_1]G>_FG;!;Y'W2D!JPK<|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|7;0$[@!R%5LYV&MY:U*IJA89FV*I--,,)'!!;0;.Z6\'?C#6H ME)6VI)'/VE@@X >00Y[W\V8QRU?A90X7ZV97DW0\'IICKEI6HN95=5XU*]O M$4V;%_TU&PU]1HXO1.-VSE2T:]WO6*.]F[3;\ST[1?$66?0]Z_F#W?XX_N2G M;33|(S*U'Y.,4GC.||3V+T3VL;:7L-6;B-C.)=L_A22?,.I?K]V\-T&N5QO2 M5\^/DDVFNA4|.W+/?T-17.W;+N@0A'3Z<+/_*OKX,E2)-_F_=FB1 MSSNKKV(U;Z.%OR#[K*0Z!.% T:D@!$(8$1*&($^H23@1 HX ; I)8P V)06 M1J!/@!%'9$1\Q/CS\? ?N:WG6S7SA56?%(3/M^2# =|OTB#<-44?_OV /ORN M"IZ6&O0?!O,KQJGL3E0P^/'Y_I\)$(13",)3RF4AKTB*,5&B&0 MOAD(I!,K?H^M.RXF? R;T_#A@MP|\/1^IV>M,:/!5.?.GO"&[JO/&$<.;V=_RPKJMX[K=K<)U.K6#WIDWOGPE?*^@# ;P: 3P] MM\Z'W9?T-5Z*WW9-!G.BNVO"*$6_1+>>K$3]I3SF^ARK%,IN&MS+?][H;B"# M_53*F?F?N@XG;1:_"%TOE'31D06^FQ?M_?\B8HA$2PW>AF2C:WR+E M8TTY^@_W0_-8+RA=|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|*@@5<:WC*^7#%*?7L7C(& M PT&H8+35@1^1H/7/:6M=W(HEQL9H]*R*95GT>VD>.1.T-><@1_Y#K;BB%[X MBHRNB*Z2B7D,65/(#_^(78KC'D3<(P)=+F4UA20!B?HG]4J>U;D6:7,G6EMS MRKM*#','>J:0)5-JP-F.M@Q8WH3D^KSOS:+[G*-R0?@]; - (I/.GUKGY M(A"LLPM>MZ;]"HQV>WC9]V"GUXZ!("XT),CC)]JEN:7[+J.?W8=4KK:Q^Y?4 M/D&&R^[2?H8&+(0&V?*CFZPO4<7TKK#|\T@2|NL@S:5I\7F\UZ%]<9'(K>1%K#J6P(D-P;D]RT'>'K"FS.RU\Y7G]NIU/1V%=/D_UQUJXUY]TM@/(MF6YFX43C;"/L$6% .C30ZBO<.EUYLM"?:?6H:VBGMMU+\'P'AA%JK-"MM.&5N2S6K MI>):;G80 7Y3$G=_1<\)B1KR6/_IV'W_T'"$,HZBBU%]N"TZ MWN8%;<#Y6WHW,"E<\J5WWM?M5,6%*)^"6H73R7:QO2SSAH5I.K(8*KUU6T"1 M71]U##[A_2[W)=%WN&10G_['U62?4F*:S!$&G3K4+E"U?A I<5Q/ M=OQK:E,4R'E;;J;_(%@&RKASR_$@3W$,L.L[;V8D*$;Y5.;UW16HG*E0[1DW M-

[]&39B;U[:RA;C:DC;8(E>_"WHW='UV+?=0T,0=0,BE(21U5$H#@IRKQ.T3 M$-
)"H69NLV[VM&ZGE1O9SL1HZ#&$A(X7@1Z_+]#YO:R#%]*|>[$@7>QM^:\.,@)58:H,:4.*Z!QOS:2 M>*^U)4 1@"*
(@=^#F'*W?09&UW40]?J*27'=$;! MX*/#F%U"0>UU(@$X<+R5YN"73S:X&IR[T62$0[>>Z(-QKB12+D_";7NC\?JR*
MN@CWEU2 MGT/7,2CL>M:2'W:^OH;84_HV"& S>9.'P.=/7XB9^OXQ*6Y#&3])F4=)#R<*
MQQ/+68:A>H82=3897<^2M'GXN^*X+Y=U+'TU MZB_']A7WZ-:!?040P$M#?*
PKE[QKV%0FVM)SGBAHWPOG,O__Y_B%67EVILA(? M8;EST5%*

Q)V1*U6*PYLFD2A"%PFF:U__1TN]PH?.$DZV45L;%JB4[3Z7I1 MJ].^J/M*2W&ZT5Q?*
#KG@W2%70W0<806/VJHDR7,.FJF*W%L7[66_'=+Z9&3X MTH'>V>A05X3!)INO+K7E;#[7\@:F=/7@X3O\!,/PH4+E-*
Q]$364SJ^@U_WG\ M[$'HGG2STEQ$5L+6$:B,?I)B'=!2_N+/YO0F(L1-ZAK$D&/25^4AJX58@Q)?*
E!QKFLGIHKMO<,UF[#?63'7=J]V M=#9B_9A31HR_6?%-9?=%#'[<_1()2#PZKTB*,5&<#(8\9B*Z/6;"]]E*^/J5 MHF] 5*
)$):XDGI;Z"I"MXEBRZ,[?!Y;8@3F0I629^&(R,.PV5[5KY-KAC2*7 M;PM8W"HR#E>@?*
X&2#Z"^5QI43'_IQ9^I[X+BZ]PFR[/P4NS08DB>856(U9?\ MC/JF/[0:I6A8YE5OKG=+^/J.,H]09H*
/F*U6K16K9AV5RLTN>Z4[Z]\E@E<= MF,(2'_>XYK94;.C55;Z09^]F6_V*;)_:50:;"EF8V9C$HZWZT*B6F"7$!%>Y M,?*
KJT]>S?)YD>G2%5UH-H3-VVK4Y%FVH=]OIW]U2IVBSNT;7Z0>"(!PC@*
MI1WQ%,K?]1WQO+F3Y:=HF;3W36.3<0[O8F\:A=AYBM*6X^DTI[&19->J^S)B M9SSC?V;KL7$2"FQW8A+&L -*
W/EC'.M]<%AZQ7X:5[)IJ9,9KXO"]S.(B[$^+T.#<@%'1CH:![C^2>&*P_&T=Z!3F_M"B)I,H=[OD;D--^7N_I(Y$KT>B9@.*
(@! \4',>"OQH!/['$<4?%%:V78;+V0 MY12B@O%F;569V$&D^-<9/?["==0_2\^/./.S+[]7[_>^D@9_WYBHUEZ,>#/R*
MRM2IJLCQL+U J9;ESZU*D-=R^8FP8I&* EEGOF/X(\S0CS!QJ /"QX2/_=)+E(-QJ/&(4_DB3O\FF_?[CT-C#M\$K*
M=JE2(P:8PPUR6VDU[YJP76\?5-W3W@:_VS*]N>']MT3R\$);=+\JR;TYS'C7VI=] GGL%"G MZW#772APL=E9MD:M;+*
QPEUAW,#^T*UJ0(OO38OOJGW]>3R]8VNQ:2LRC<[: M$H>.BABTF8J^VV0C+8ZZD-U:X_N?*
LH4B)TZ2L[X7S_O6N:YLKKSK-&NUIN98U+L.CEE"UV8?O4: @>4@0.ZXW MD!WR>?ITU<&](.=M_WM_N^JQC:D?*
OY_]"D5JA(93.W4Z-7<', 6[HTMEXX^3&M M#?1.4>HK,)UE0VR)V_QC-/D(H^]=:P(T\UXT\Z[B8D>V^+^EF1RI#"2+<*
^_M"<]XK[B0-MR C323C#03?B1@]-9B7:PD^8:O1V54(:VGJJ1Z8%MRPU>Q72(MD=Y[12)D^_=U^1P=Q1-
54Y$YT3%#2KFO%#B_T]\0V<*UAH\] '&#AB%13KTR MT[H\/MBJ(W[;F(?.!QT['PS^B)')S >%TOLZ?(<)LVPB$ MIK:?)*
[(+A4E&*_F94-K>G;JS$Y(@>31@B"3.06T8\8EBSZO\W[M7 R7 9+K_V.[UZ\2!*
().*U2G%4;V7Q,=P=%2>KZ=182V,VPH8H]PD]E,,X MN?:HT-*
=NIHZS5L[D0J5X!WE1[/QHDX6%D");_D17TH>G_SRRDY4^6J0:7\]Q MW35KRI\"6]; 2=J#ETU.+!$(]IE(PGT* MV7+,Q?*
XQS?\KJZOO_PM_/']/TA71B3!DOG_X"QY$+]DC" S_ZWB&XY<,0_%7 M5>N[)1*O)AW__+_7<_^!:9!DZ9;S[1FX7BUJOL,*-*
,:PF0)-'$74('$:OO>; MJ ?BQMTODF*>L.<-[;<7[,-B"8*?,.)?F5>_1]1(D-(0U] K@NTA$]*5]?=M*
M_[7GSV*\>_G0&_/%L^QO*/(4E?,;X9_[A>&AI2-. MQ*DWBH2] F0Q,W\79?P.>,/24FLH"$1H2 5=@1:!I,?0$*
M*44A*1JC98K^Z1NA>[8EH(6^G5-%.$?H9K 1JRMD'@CAE]Z.;%J2OUEYWE9K*
M3MLHGI51IN&WPY&)9ZXA73=PVQAHACUA?)+AMETC$-#D,ZOR2)J,%]Z65SNE M58N8+-*
:&W0Y'$F]'#C6KT9OC^)JKPCETB&F!H,VC9R;>[FQ*0LZNSLKP6Z0MPJK<#N=7+Q(:(V*N6X2L&_/^OJL*
MD1]7\>B9B<7WN56)E;ML73,:!$8LYUNH78E&)A9/E=VM[C06"WZYQ=!1?E;+ MTU8T,KGX<$] S*
JVY\.#NC%N%WT4;E S@4@N"9KA<(ZWG8&6TX;]-3_G@KPY M$\CDR*H[8:&<-*
Y7@8K=:UR;.H+:M!P*5')D7BF])W=90CF28M>I8_6T/:@MT MKK46G-=8755#!:=E J!='6*3%4*'#!R&(=':6;W+5[F-*
ZY4(TYIVVM'0A$PQ_6PCCQ094ZNRRZK1EPV6G@71T(10;5D9*
M;I$M,^#):FVL=^IZM5Z*)Y"0]DV+%$LHM4%@=6@13G=D*^-I/(&D6+E])[O, MKYTE7,V5NHJ9I[I9-7SL 1EHS299Q_?*
K,-]FEA7'6%=B4.+ M*VY#]@>F6RD9L#>+AB;613;7FMT39BHG-DFN(TT(TRW'0Q/K8AR?7:#5>9.'*
MO/X\Z&ENEW;CH@"'U[M7;1=Y=OS+Z]M3.0.[UWAR"F4=L[DL^6(?6_1]ZSG#W:.=_S)3_[YJQC'?DQR*
M^^,YSQ/;OQ#9F;#/G9#@Z!.%O7=B^LK3??5|*WSF5+>"9VQW_#<417B^[78S*
M417UA[N(O1&-7_P\5)RXENY[RHEW#[\.$")?R&#[L0G\X]@@^>[1-6#$V1B! M(8 1:6 $_(0#3J2"$P";TL((8*Q3P0?*
TB7RWU!-P D#3O3$"(0 CTL (^ DP M(A6,>"(!(]+!" 38B%0P(MS1,8 3:> $<)N.RH@O)J9_&'8]WZKI+ZSZI")W*
MWB7_:0*H9.G1AW_$ ^_FR-+Q7DV%RQ6H?\P!Z%@.;O4$&^N9+RYHR@9(QPU*
M=S.**2ORH;Z!;+TLRSA3\QE*R*/*DNNN@:2]&5)2IT-HM^N//-;R:'I*
MYF]BD9^H=DS^3$CS"R:@OXL)"!+S]XHQ(2JCN18U3Z\88$\,=>UB@ $Q^',T M(*_;0S@N&KP;F;MM,;ALA3Q*
@S\3@]_S\BY=BKE/N#=G&65M1V4#[K>C,?#2 M:SM>BZ\X\^C2R[F C[Y+]+G*
PM_OX?.S$@)I/9"+;ZMP03PX\5T.>7]7F!X5=N[Z M2/6L5TVENFQI7+$<=PTW=7G0V:RLM8$'?]#M>*=%K"GG?*
^@0M]NBP^_%ZW3;1FL+[\ZFETDP5L?OM<"78P_>H&7JR M[R?0UJ/D_:=563_*DK\U9<5>*RLFE MEJ2RZ Y+?#-*
;LG$6W6[?Z^U<+'U=9 M&;XS:1FU*<23Q4$X4VM8M^FHGCQJW@0_TA@)M/6/-IO7IZX?)([?C+8B!TWK*
MNIPO+02%"(J;U>Z?(\J;49IT=;5;4BDW[VSG^)0-M96).CDB M)'XB93VW'%]$6<^-2,=RA-]-*
I;XU;7UC6QO:J.CUESD:WE3EEK!J5$7>2HNV M]IGB-"MTIP.X6'00K^8IM:P;:2N"/GQ'<6!.#%TJ&'&'ZT[CP>=-*
!3AB)2V_Z&AN'BY3.71)=7EE3YUB?VUKRX77LH/> MJ-/G H&(8A?H(XD?:I4-]/V:CXZ/>3-*
;^DZ$KRWRL54<2Q;=^6\K,%=NZH-I MO>7"W0$R,GA;)"MXU/2.W DP@OX%5/C8,8X[7'<*#]1O*F[R:87W:JU@,6OZ*
M$)PKCY6BW@C4U8 -%9XYK<6^3[$'*0EW]^]_''GY8]O>9)8K'E_W)GRN53.[M6], ^(;C(MD?Q%&#@JBRBC0Y0-*
U51=SXF[!]Q9;.Q/XRB7 M*^XXY2YK'RNY\.)2 ,MG"9SLE9$U9?8G5=R'Q_^ M$7]%EMIP7,>O<4#*
M3ISPJXYDS+3Z,++5<>R$(6B03O)G@9);U>HX& +4^BPY*5]7:Y@FVO9:'U7Y M0;XU;@R,7 X;ML,91G$2XA&C0-*
K)]:6=_/5\2;R5J*$'(:[CIYQ<&MU.&SU) MWWI3@.9G":B\=,#8P_?!))31FA/QM3#G5;G.+[Q-7FW3;8':W]>.G[" YBX1*
M()4*<>XDE4NO-ST <-K8RV< 8+2HVTU\GMMR2KE9Q;*TX9I"=,MB5)2#/=+, M"8.H]X@ O\AAN;1*G#0HD[[EI@*
!SA*G^0P"X!.HX9M,2>&7CB517I;IJ&4V M1 F1@"*.A4"@+26-*G$:0,XZ5MO>B#@M#&=ST!*
&UZ.M]LRM]2**WP+!1"4 M74B1$Q!%<3#X$450X 5<7;)+^,R:Y;J9J6,9SZ$".2661*MOJP.^/47N %INB+E7(@T+^.Q/P'*
M:#+(9DE]-LLY%/E,893/*3+27HI"M5NQ^"[;Z,V1RIS)K=JA(O\ZH@(T&62P MI#^#Y:2:?-*
YPR.:]H6M&1OF=",>]6>7KS%2YU 5? M][CN-/1,.4."RF6!^29[/Z)*A36-'3^ L-Y6;XO3G_O?FK"F@&DI.L*^ M6F%-7\,%*
*W7=]C:].:*DU'C_6CFW_N,^7O;1%[3]1#'WDK<(%[\.-EM7 M?D0 VJK?3C&K,5&M;T5'-+W=0>^!L]T-8[*HL93S?*
%&K]=KM?M6?K%@!0:+4 M20PYU44U]ZK@=[GL-!Z_W$2MZB?T.\!@/-\H5C#-0)8]?:83_8W2CO2;?/B. MH^">A)L[B)-*
UL^IWR=-O?R$?K>E5I<;+3L:WZP6R/5"9DMH$-MOYI3V^S[E M/!5G=Z"K^NW4F7Y"P=5>AQH-#6' *Y-"L3L[[WP3*
M/RF'8NMXT?IZE7/19@W8H&LLB&Z;1)I\\90>I MZU#%ZT^2>-GD[W.;090&-._X6;@?UU]"ZIGA=VW_LLK$^\ #\;"-*
M9Z,KZ1"0.:#SI_WU7G[Y-J_EE#)N]KOL06450V.4S;J!VX MKQNK89EG(\V/\BU.V-+J+K4>=/M.PWIONA?*
6Y]1^H$QX0^-A#BZN,<$LU#31 ML]N1VD+FL#Y>>@V_>5=ON^J4R.AF5:/WNX. &>]#S&_3\OD ,Y3T=_F63T8I;*
M+0J#EM^&U66I!@^TGC"0@TB9XY *AB=3V8%]_EK\Y#85.NV=OV\JK^0KYIF0*
M+7<+U>8$YRMU@IXC_7H7GT4:'85*Z!/>C';[Z@S:?]^F?3Y+R..W['.WW1VT MVXC=X7)CB?#H?J?E56)G.XJ*
H(\4DKRM_MX,]!5FJ43/G/STS$")!#Z+]#DG$&HSZ*)4>SV7&O9SFGJ2M.7OLW9,#:+T&1W"1W&*
M'+P8]EAHDK:LG8NAR6?2>.X%33Z5XP/@Y)SAL,_"25D-*-Q>3>M\T5&Y]QZN/_+V(H3]D4-(]S%NG/143*6[[G1*
M!C9_V-F(KJJE G_RLBJ[GN*?)L[.W $_H,P_[SG$^Z/0CMY=:7*2AS8B;7% M%E"U1B\6:(YLF01@"IVE1<.:H)]GH%*
([G.B8(=7:,;$U:V<5,0*CH0/OFR)'?X=AO$D1 '[[#3P<.Y4 U MW-T=[Q\%**_U]/X\0/GE4_J3 F5N#)5X5F!-/J=.>VM"-*
;A*/\8%\CQ >59R M? (HWR%(!)3H$WRHIR(RGO+7#B22YG2I5X4*'\W >&D0#GC%R-*9J4^3*Y8*
M.!L4>XW1!*NBMU]ESL5YD/++ MN14G1GX#*]R@2827^!"<+KX!3 M"1).;NY@*

22<@-.LJQ*ZJY4YD$URK3('LDG2)7,@523E,@=21:[.);_T#F00 M9[PKQF5IJ+ MR$J8>[S8888*:P9:;WWLQ GX" [&;9[5G=UK?B)6^.8WC.&[SAZH_Q[C>!G+Z M;59=,"@[@!5MHG)S:%+J"8& ,!^GE5PK;?;AK02)OD:=^.@4>T2B_W_F7 MZXTGFIS]CI5[Q]4OYUF<$U=SO8V7V\RV&K\4=6.UEF=,*QLCQX=9*-=*FR_@ MZCO4B7"5#F&5>L2IY,T5 %;O+BWEW!?8W"VL_FY6QCEA=0VQ:&W-DBM-[(OE M)@,AB-IL1\#Q8<[*M=+F" [#Z#G4B6$6H1YB!'RGX$XG1((OEUK-8SGY%T+T# MZY=S.,
[JKWH\U89MRM0&LBM@Z,C+NM78(_LXQ>5:B?,5A_4=\NP]5@1^),E# M[<.!QWHHP/Y? 3PR1(#43.SK>2$ITA==KP(G^CZ OB)-L6A/__DWUP@=(G^U: M],/WWES)B))D&>$,-Z'\94S+"Z<2E:R&JU7#9||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|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

***M(L+3K4T%+I;[(XTRE%S#FX4CD^#;7P\77R@"_]5[M=X\>GN24$M9P4)=
M6@6\FBM)0:B%]GP9#TV\WQI3LEE'FT.X26WZY3J".C,\>G^24*751&U5U[6
M0^TN;\RSVT!W9@*=))3KCP:#4J'4AIOXJH_-.@4G)P?AR 2A5FZSY(NA#L/H MR.MVR_YV;'6C9R8FRIFSE8 H"X-
7N@@R[&ELBR]'(Q.$*OB]1F]KBTMN20K- M<>"I*+1IAR.3A.JLRX'8J&)%3I4"F24Z900-
+2]]@%#%F2Q(FPI2XM#)&&E8 M94K<%N.A=(*FHXF\[?)S0FNNU/%(6YI-IQB.,$]:2KP1F .EW)OD M
I<-1R;6U(8;6!7>=ON:W]ZL?9MC&B,L>GN"IN-5J3%3Y7F%-V#25G W:.3] MZ.U)FA90),)R80QW-
ZBMNE:I;>#1ZY,TW>BF3V"#>D<3F0DQTG*\,[/BIR9H MVIU79TR!JBQALEW3D+'GLKP0+S]!4U\--
RIM:S;6C%&EMZ4]>X@4@ZAM96*N M U->TGD<-D.A*I@PD@];J+WKKYSP4@G%RERH M*ZT!UZSUB%6G/-CH3A!5-
B6%D%-Z08>4,6T9[@3EX:3N\(U=$=3;H5*Y.A]H MSG)%X=]:E-OB;.E%@]-T(L=B64'XSR'0QN^PFG=.:(QLVAH@E[ZT
B1?$,S M7-.VZXMVE>VL S8:FJ37?*X0KDK+E: MMRUC*W/51 KS> I)J6V+2"M@-
QV)@]IN;MR5E/6HO7MN@@^=:5E;Y'N(R&\L M!1ER,,R4^9BV41C^Y{&B.>J-39X185'=DEDTW
S3AO*+&T;F4P:A;K\Z46 M^N##B;OU:GTY'IK@KK[!M_Z,Z.9Y935N>&/&*QK+./R66!AKM;YI2L
MMEHMQNRDAL5#$_Z582NT++BE(2?F.OX*R9+T@(VWXTD^2(QOUH))M\8WFY:R
M\09=:W>TYPR*/UK'%0%"8$5]*QR;],4-?MSFQFFOQW0:?MA]NDBQ=%VU7 M^?;\R^NM.1GNI.>
]C;8AKJ$X)&.^1)\@79EZK\-14!PWBC_9Q_=@^%_1[MUS MGM^Z?QJRV]4?J0)15E<'GF^%SYSJ5O<
'C^&XHB;]\FCB)J4! 2X2_;NE+>/',?5XA?_#Q4G+B6[GO*FX5>+(:+?#[F\=]P:2_3QK1!GRY
M#%\^NJ48\.5B^O)NM2+@RV7X\M$-SH OE^'+1]=-_[X NP_X\ODKNP%?+J4O M[]=V KYV41X,NE]/[[UYX!O@"
[#_CR^0ON 5^ O@"^?/[:><"7R_% M!W'^5/(%X%@Z^?+11?>_+Y?:OZ# 'TLA7P".I9,ON]IHP)>T\657K WXDC:^ M
!Q+)U]@$+=,)5]IVI=Z +VGC"\"QM/(%!N=B*>3+KDX<\.5$?$G=Q2C7V-#A MAGM<2)8>??CW TH^_"9]:/1
[[A+WJHD*:.G.+_?ZJ%@.1EOKF2ZZCI3#_]Y M[F8X4U;DS]W% S0.:-SQ2?)1^OO16U9\1HD21'I^;RY\QL11P_>4%'VE1
N-MWBF:+G10><\E5>!>G:\EB=\A23[*STZ'H@& 3AM)/LI33H?CBR!+RXPX#("7GN L@721)M5OW42I)
M.@QVJDEXTVKXYV!-/^&GW7L=&:Q[EG<8IV_J<]HQM$T_]=S4#P W=H7?/A M>7PSXTYUV-U_6HXR51Q'D7=_QA<3
._G+,)%/*$W+ERO-UZ[VX.!:)U%M+ G M.G'G[U6+%A D$.GYA)Q=6YO\>;0+L*/DY-O9 M"QS;_S^]X3F]9!S#/:,2%Z-
>LY2PAN6;WK48YW3C!Y6XMOJ:)>/(^''BK-CK MP0\&OR4I ?AQ+/S8I7;>CF1<5_SQ6O"#>(*I6Y(2@!^GL3+P37FI9=?
UHRO2 M@)R<(MA\.W*2$VW5$W4@)J<(.]^.F.25J2JIP.J<))A\.V+"+7W5VQPCRCP1 M)6WFA)Z._T?
DJ0HTVEJY24KZJ(IA:\2O4Q>D11CHCC[=B'(CW8AV%%UYXK(
M8BLA+F'B]VF*'"FH'66[,B8HA%2&E:$@JYTVE.)%8CH)FV4@!]#./W??W^F_O>C!OS/*YK7=V''V M:SUR1?
#USR.)QZ[!R+4C5R0/'"K<*J8K$H93'']{1HXG363'B[#!UE5:,N"K@.IX58\[NY KEF8KMC^$NW*)2(45,R;JM;=_MO.G:H?
V8JOMMV9&,&>W@(J+V298G"]!FP%LTU"[,3FO,R/IVXR^TGL$I7:6Y M+JV-
G%V,C!D2[LGH1XS"'VF2.>&N[.S*>8WVC+K/71E^H6#C1="+[^8%C-R4 M65%L5KB-[&<=*_4!WWV)J
+PKZ"7*_2HG8$N[6Z^,U$0)%)><:AR+*^ M6L]G@U(00Q?Q\!T!D'59R**OR^LZG@N.WH_#=3S(.@@WKV
K!H3GK(D]YJS' M7J4LK$H(7$4T?EN84>Z@QIX61[UHS?8_V?O/9L3Y[*UX>_/KZ!ZSJEWILKT* OZ
MS'25$"*#2")]40DEA!(H(.#7OY*PW6X+IVZ"!/NNNKMM][;86N%.:Z^]0E02 M6K<>P4?;6;6^U5A6];R[6_+
(AB3L>>_,#L_"+I1*NN-P:[N!EQT#Q64A M A\$_O83+4 /.(0 +I^E[,[!*!#M[)T =#7*)'[9[K@IR][@F:)$B,X5DBU
MIX.:1@D#_@ATT9)7Z#[O/@XCZ]*%0.ES@8Q5QPWJ0V+&C>G\MA;X M7*TP/7.0Z2SV33V
2C,RSOHAQ_V$H]2[=UV6U-7!?R3N\3'5 M$N6\!?_8A61?#E[//MOHC?'FV M!D!63Y1.
<@NR>L@/2=.MR,DO/KYJ!O\D]T.U.Z,Z;OA39EW62H5V66>[XM>O M0:)/>(T20KVN5/RY*^J"M"X0_D3 @X **1"E]%-
;4>2(P.$_NUYTA=_U MYX8FYMC'G[L936U*3Z3_-KH&G>.:'R2[W5B[FC,D P"]4AZ6SUKSI%%)#T MQE]FG"'7 .A-
VI'TQ!D)Z6C7*4I%59Z,$Q2P!P2''R#HO6-RIC0P]2&Q-/9".7$B0P9@Z=1! M7B#DJ>^><>
(,B'0)>>)M05+$.P'F(U;SS52(#KR>CM RU.5HI5D9M:!'!\H' MD?DL?/L)P]@94R$ J*2^.
<:)$R;2!2HIN'+*8@[%FS[Y+U!!E:&%>+4QS?G3 M6<6;$7Q3E7LAJ$29$_@#2AYK6
A0Y7SI%#>**FGL:@'\\6OE8=RLD&>C<<*-M9FM\PMS!:,F $T30-,$T#3AKL7_?J .-$T 31- TX3[%7_0-"$%9S"0C_#'31,8
M JOF/5,'20YS>C3C8 O')(3R ?L MW03^]&I9ZB-"H'E"M@*:]RVKH'D"D-7,R"HHX;^^_W:[U\\?^&!Q2/Y-%^Q(
M;'[7(61]MFY2'*NM.VNV&.01MQ=Z8-%5-%8 WM?Y+IUO 25 #?^MRRJHX;\E
MBW:B6^%36R&DAB)2O=SNZS2Q7LMX8[;M8%$<(+HA?M<*W4(1?TRA_#PDCQ3= M&*]DRXUYF).WT=?
RK9;HG]!7S48%_FD-4Z8*[.^VGOZ$P8-LE,MG/)GO@J"5 MC6+WD_(S6[7L=UNZ?D+0RD9E.@ M4'@.+GJ_=-
$;_UF*#BWTBS/+D4M>6>X(M \DJ5*!J=[D)NT9MZFH?#&^Y,4?#*JDL,KX MY/?,=XXJ-
Y*UF#6&@/;\CROVHC*PU!\"8Q #U@1>BB0R7;J6="P#%@#4.V; HPYUT5 M*@'F"]WECN-
+'#]Y%UY>C*+MJ$Q7GAD!MYO)1&_0ZDN;;2^&%SR$%X JH"X; MU&7?
N:R"NNS;M8#7OPH_E27CB9%>I7:FHPO:OF6+IDS/RE1DR:+;;QA8,E"/
M#>JQ[UE603WV+5FRDW;I_GOK4S.UG=_&)90SR^8R7Y1ES$'B46_]IN?7<=B39R1]^_P>\VN92Z MY=IWK22W#
(IOE'?,[]!N??GR[WO Q3?2"B_9R6Y85!\LUP<\!N XF?JDN\! M%-^L6P9* I3D,W7-]Z D;]8] R4!2O*9NNA[4)(WZZ:!D@
E^4Q=[STHR9MU MORE6D@0UTMU\H"]\@F;)$B,X5DBFIZ3#*L?6=5Z?#R%BSK'5.I9'-U;PQW67
M'=FK6Z)MRBW;==\KJ81IG>DOBF0+V@F[KJ>6FT75Z_%P^*+8MY\P^H 6(=!4 MX+
(7V.G3O^O68P/PN5B]]J=QH[$GZ%G1+PXY3<*G075&-ILC*L8-\C.XD;ER M['8$+]?P+?
F@$RCT4R[/*ERH@GE9T'5F1'>>Q^('ZH^J'YV>\+((:'1'%KV6SPG! M
.$:965!U]6_:+5YJ*;R/3>B3\C@(T54DKN;8M)N1T+YT8B0G?%N ?DJ#R-\ M5$.%0P^AJ!Q)T3F53J;W4#\AA9=,;
[BR[OXQCOW/2<>37YL,8*AO2NQ9G 5Q M4*0)GMVJ,3["V.6+.4;KMLK?YAG1QQ;5EBYI5:MD1ZS9"EN#G$U2X9?
7VM38,GBL.A-@1>P9'^7 MNG)3PI &2W;^VO1*3UI7Z=6TH=,,.=*(.:$)Z[^9@O)@[9IM)I*73$M?3RF
MS%&C*U84)SZ:1?TM4.P!*A8>(+QXQN-9>NNBKF742' |>|XNND<<^VSX.9L@ M]O4>I8N0?++C'G9R)-
Z]G\ABN+HUUK4R4<[C=',FS]@8Q/#CU5\ N\Z:ZG7O MV/68]'53V)4QASR3ND-<7VBNKCN/N6
W13N7MOM_T58$L6DL6'7T(L?K+W^'0&\EV;A>M2N1R7M
MS)QI#^KDWIZZ$#1H^EW+R4E3L'[MR>$W#V5WK_@WM)W/4W9O9278[K_DF>'I<]YGLCJ MTUFW)]^]&)H2V?
EH_'7/R+/5A,ON]4O4/6S&"IIFY__"?]X>I!HR((3H<;B M%6/0Z%,?H1."_O=T5N--
^B/8D_8_JS[Y8M/QG__OY=Y_)1'G1=NPG1]/Z/7B MI18'&B$QD*ER?N[(@IX7E/!S?PA&(.S<)V L?G\.EO]X!L"
("CD8^H[B_YM[M\75$C00I36&;?T&P1]S,&[+B_7C\M:>?Q:#W_$/;C8]1/QS9$#QM(T=/_^VY
M,5\|>_4#@:\3D5R$WSZ^& 9_)_$S<>H5**._^/(?(;=P(K3\QY"EW]89*T)%
MXS>#__BC;S^'$2)%4X_H'''SCJ4>/8BI\1E1_)_4Q"IZ&!@E%^P_^VMQ@2'6J MN5*=?4P+KG?H[R?$A*]NZ-F%=B-
BOS0_<1R._+_Z&7I7Q=$_MV_=L^S\U*^QNSCB_KD=$V+SSI,B M*LT1A.25.4+P&%G_^;D$HSP)R45\+A'A/^/?
#OH@/#D$3GD]8&O3MLB8R^4< MXX6MW8P<@BC_]?>5C:I='N%*0HA\LR2RVQ#,GLJC_P^7H(@8)KR^J0R4-Y
M6J^5]=6&;/M4N!2!7B^=-1;%B>/T^CJ+<3KJPBNY;D1/18C72W5YE!_7.9YD M=@C2F@D6U>S4*!Y-
;G6"+;N8XSIK/5]E%K;K^?4Z'80K$SOE*N.R9S:TD$3. MJ-=>#8*N/(Y6PHF'KO?+7FN!%$B=6/A$@\T71;@7?
7SR_8=NFQ;@4FW'">'1 ML6!/*H&CJ-%.$^]?9@:*3.PPD_'QIMJKS]IK%HF7HJ^7PM*B'2C>/_(:Z@Z
MHO,MN0_'[Y\@%25LK+%ESQENUVEBI5Z]62I1/1Y+D@HSK:+!S6P/VM$SJ.9(_MW'QA!>%*
[/5*GPT*NPU*8%!U[6^H/3G=;@K1,Q.OS_3UC<#U2Q6(("M>2ZBN MIFLD>F8Q(5.C?FV&%=0M9#81WRGL,*B_5,.52?
*;GJ'K(N,+*Z(D3RIT68CVFN24 MNYQAZ'[HY*'FP4-:&-;G<#46<2C)UQ'<$1U!',K1&.Q#OV'V.*JGA&3#Q^7K1+*JHLUI
MPK*.B)O]8EZH4N'*A/QS\QK6];TN @G(RLXSTK3>R0?AR@13Z^M)S^=JW0(W MV+=KBP*F+X)>],PD3JU@=
JW^273+$^KB"'.IAX6[3/)U"91I]G:C!;TL=9; M##>TH%F3Z./AQ.?/?%%QE/)&Y:H*[DSU1G_$R-'G)SDU:E9,CG3,***

*(H=8&VG7-M5B6WU^E%KY\0E7S%FHN*I8RA=3"H,\&6,Q8{E2>3-)6A+34KS#1;1X+.=-ZW-MA_!$I<*5"9HJ\%(8,OT5SP@A%G7]U-_[07ARL0{S=5!=3JO%@6&('8E"6G/*

*MER,L>F923@>8'@0KK\"835H51R2W:/:C9R9I*OO&;F!T(IJ6U8X{FA"K1A-O*

M37P^7&H@_$6PYBJ8ZI>F!=M<(QBX4%-=FK),BXQ*],*5"9IV4*?L-M08-5@]GYE-'#*

DO@J}$^DS0UUQUZPNEEC6F6YD2%V\."RD4?GZ3INFXP':%< M&W#(PF_O\H;.M9OQT@1-VX1)5/HZJD.RTAR8-3-

CN"85O3[\>JG=Z,T\RD : M.FMJ0:@%K.8T5LER>\,)PW?@\F:#4@IWL0I>7VW/-'EMK;3N^L5U'*Q/[G"(+G-*

;:4@B]DY%1H/@I-MVBM$GY{D5!N:-'J-,=;399':\7I74EMFO#3II#-(WFE1$P,B]!:9<'^HXWF.# M:&EBJX$$.

[VYGV\QZV))?<#5)\7>]'2!%.#3;U0Q0-]HR/,#++EO519J**W-M2C*U.U2K\WK%Y{B\A=8;!K92*B&G8"A)?]7:R.-*

JG6DSFKMF\{RGAUH>+TWP-M?^8V(!L-L+;>5,<:K3]?M..6T,G7FO,:&V!KBY@O;GJL%*U7G0M-YYAD+#4-M?*

5H;6FJ]6('6!:38,)?[R9HX#.Y)(E"_-1EV-R^O-[<8H:EVO2&(AQEBB=UZ-M1%&;-^62P>PFJ(P[[=TVC8VE"PZ+M-I,?

*5^@#FN33A@ER<4R-MQM6Y?,N1RA5I55B.8D8\&^PXB/D<_#FL7:,(25*_]X^N+EB2Z*E3S&2:*(-M@7B(-*

*/P>F7D1XGX,RR0#7Y{S]*F/3X,/Y\-/5C63'PPL>1'C>/%\.WRF8MC!-MTU'RZ?*

M\%,W_<8AC!2$1/HP?/9Y0XP]^6BK,7=OP/?D2<://W-O!GS\]OX@&-MGOF6#/#E.GSY:.0WX,O5].7="FC-E^OPY:,!ZH

*OU^'+1^/@-5^-W0=|>5TZ-M#_B2-KY\5"\.^'(UN__N(#3-EVO9_?>'*0*^-+L/^/+2[N/-[J>0+T!?TLF7*

M0UT_X$O:^()T+T4\-7@&.#+ZQI_P)>T\>70=-#P)6U\-3B63KX<^BT-OJ2-

M+P3(NT@E7P".I9,O$(A;H(OA_81@"]IXPO-L;3R!0+W8BGDRZ'W!.#+F?CR

MU6%+'Z4EWV63F!ONFR/:1O3#_WY#B&]_2)]"2!$)ZMKCFI+U)1_L7U,Q79R*

MWD+.#1>.+.?:X8%FV,L29;>F/'"%'NFN-G0.Z-Q)2?)1-OSY6S-\ADA/GTN'-MSY@{6O@Y-=G8R-&+1I\I6&[^J/I>2JK*

*M*ZOI8G?(4D^RM!.AZ(!@$X;23[*-M5$Z'W*0-MQ-Y#RH%H742TT.]P8BYMID4+"!*

((_7Q"3K)GOC)R$KN_&%$T,S>O69D2ILSB-M3.$[?-XPT:D#B*+HF[XA>+*4*0&Y&{3)6I#CY>"O_P^$.;

*(6YOBKV;$'MS;Y-MYXF0Y9"M?#MG@5/[_^7C%.X9V1B_G*6I82*!Q!FQ3BG&S_(FZHI.C%^-MG#E--COX4<1N24H-?*

IP./W"'SG'/T11EA4EM?)2$@S!$L./$KQ<6W#$Q6/S$/C-YB%_J3@9HLTY-MXLT7?_L7"A(/BGU)#N0[@G^)(KG_:-

OPM:R(XA1I4#.MS2O+RO__<:%7_#-M3[-DP9%X-SX,\FIM(<,:?N%Q0K\XD2DKT(?;WK=_A%RN59A4=Y%.8C-M6>-]-*

*Z*PBIZEB>;H4K'^5.L$E\%45O-?5[QG*,7KZ#:LCF7G>3O']2:MLV5-M;87?NL>?*

$3_^\1&;SG:@T]N6P[%ELU#'^MOZG@^W+<)9@A-1_Y,?A:,SZGAO1)V1PB+BAX(0KH&]/

M@X0YNEPK=6=%54<.]2BG(J[M@(>CR9J(SCT$$+I?_[]._%_GC38?UG)S-YE-MV:$/28;0ZW],)!Z';B-9!ZY('F#DM"5-*

&1&X.B]Q'#LGIOV95>G-&RHT8N2W-MGP4,?T-+^/F,&'YQE,JD$<,SA5NG,V+%B_LXP(BEVXCAP(B=Q(B9<\U^-$"<*

MY:Y"\Z%HCX>R$]DRNK,8^J49:NKTHK(==CE9)2?!>6V9L:>ZV+!DM;AF>SGI-M3?;+\7H2V3(X/)&1#T@1?4

*PY(QGLHOK9A;-&7F?9[)#_YH[-2]N4.918E>G-M!(%M,#O)+SEVN=@>CZA;0*X\^A7@>I$/?*

*=C),W*AS\BU6T&61F*L">7752]H-M=/3]OM"+D-O_]A,&B'5=Q"IDR^3>?+.F)EWP'/I,IDZTKM5"I#7.DN*

M,=M&_ET#_:O#553'6+<>$T@>C?74&_D,.1AT]/4&+ZG&0E_4BM1YC?5@QQ5-M5=*J029:J-MT*X)FR1(C.%9(M*("*

(9Y/@7_*"'+EFE"]QFT/TQ>2Q<-MI[RK!ZY@@#6V6"#CINNY-VHL8U2#V_C2*C2+D-MMY](\;$-?*

W3/E[KJ[8\$/DY)MT0Y9RLA.Z(P3^X05_Y&=(JQPRZW5P6LDO_M!O]N8XS4GZCXKY-

_^FNK4_A5(]TNHT)3M>7\;M'L3//6KHZAU,\"G,/;J-M,4=7EW&

8F<>2/1''#Y]TDO9=X3H43S&/QZKAC9^\"B4GIMDR/';O%1><,Q8-M&

(V%^LY5YS7]+W)@HF='1QI9"M\^Y&DWY(TM'5)C&'-EV#M9CA=U?4=<"[<-M-03+/9(I8UO#Y;AG[!5N-*

U!51Q=T7)}3(?FB3!D8>2".ILD-[;SMP4ZW,<<)-M6"KRWCASBEPR)P,OYW'/[:I=+UA3Z]O2HOY'A>(-Y[+L?*

SLZ'\KWJ=?Y':-ML[XDWUCM_6AJH%6EU"UHLS4@L*V>_=YE]FUIS-ZAF6PTER@-VY]7BMYQL]9B$)063U-MR*

^LWBVTHXDIE)^'Y(F:$)DKV7)C'N;D;?1UU$/R[A!++GBQGOYTFI/?M0,Y-MN'HGD]03)2M=3D{N)0(YR&1ODY-?*

Y0,YN'JGC-03)2M=-!(7B(M(-R-#(%-MSITI$/]9B@YS](NSW)$L;G4KP9US=&9)D>L!R648Z56CRRT:4D^4K+1ON

*7ER&"J-M"63'9N-D-G[G:^<#%-M_76OTU;V\T)%9%%H;&S4^3-?^(*IABYNE,V-'2N)S"Y(I5G]KM&Q(?5$26,W*

MAUNUX&F6@VMT$T@]4;+2:>!V\R<^;63A#A40RF308(AUJ1-RTIST6U1D9,D/-MC&SF>@X\O8-@"'H-Y

1IZ;M>Y#EE(4GLH]=[:N<,.@:-C@'7[AAP,5D%E?]9-MX12HX+\#5#EODO-%4054XF>#4U>OJ$^\VJ>;)

*();\F.'FVBG/YY(%Y]BJ&;@-*6NS-MA#S;4H"\YT;&N3@"\[.6$R@7J/7\-MHUK/>S!);]9T-JT!)NDSQ8?*

WH"1O%AFF6$D2U#CYU.B3ED6_,41:71+-X:2I-MM71!-!C>JKB%OO7G]=-=V;M;HFW+=MUWYL?S?*

F]9KLZP,N,W$$(*"D[SJXXW\;[J/AKHOV?[@Z-MLB([SF-1!O5'51G/SWA9F%$RIYJ[F)

=SI0QD^=W\M@C>G_1OC"F!NM[;D2?-MD,%'JC%$K]6R*$[CH.9\Y;7RP7S4I,>#JGR[2>"0P^AJ'PPT?XVJWL34GC)-M+

*(DKZ^X?X]C_G$@R'O,E;@K"GJ,/P)[}43+%30E#FNS9H4+P+XQ9LL10\Q8H-M7&7S=8BM54H,L_9Z+>]O&O%^PI*M-*

*K*RV!5=&S*K[>%$W,];JTELR:+9,AC^-M@!:.]4@YD3:FN*+\:I8,O[[6IL"2Q4'1FP(O8,G^+@/FIH0A#9;L_#7SO%KH*

*M69Q--B$6KIE0O;IK]SIG/IK-"J3C^Y.MP\G40.T&2K^+56.#%E7*DP\H-CU@-M&';&TUEZZX:N9=-(<#I[SE&Z1QC[;/*

YFQCV]9Z&BY!\LN,>=G(DVMU8+C+Z-M0G-UW7E,!+LIW;FTW?^+QO\=DI_/)W

*M./1&IMU262'>JFHHD+FN(*V9F;_",^JT-/1FWDQ%D2Q69F<2)+L;EZ#\R1!V-MXI-*

*$E&^'$L@#4B2/9!C%J8/2%*2)QZMV_/2%DZ^D5-M_JB&OV3+8>ES+B>R^G1F[C_*

*P^7HI83GRNA9@8\X7!ZJ^5BO+\HX*ER+0-MZZ7S&;R:#"N[H=YD:OQJ,YG9,!]$2XG72WFLWLXO'6/!["8D"@V\8J]-!CR:*

*MW.JN6"7(Q=:%N=VLWMJ*7F]!C;*5B9TRSH#NS\EIFQE4%U*Q)G2CKI8C%6RNH*LYUNE+9YSO^4N*5>&F"5-O]*

*M7,)+0;D.#1K5-=Y2]N726N6Q)*F&D@4SL]X-"NE9:DJS_A#=5X)P)99@ZEB!-M9E!-#!AB->,T/.?*

F8RAZ9N+U@ZX@4>AZ-61\'1U3%EJI5\U>N++X>B6F+S>;-M.;58ZGE!89L58S(83:@H&3FQT76[K_96G2K,L3UH+$+-

MD!.HHW"B9VVUHMU-MM=3H[Z"U[:@WGBS6*RBG28Y14Y(OCI!+1]B.5B8X51ZO9RW4$]H,L;.7*

*MO15:MJP@6@DG-MHI=(AY?Y7O,M7>=%,QM8+?@^.EB9WRCMIO#L=-MS'R((*AH:8)3D[W$J#2Q='5-*

;196%0&'>3YZ:I)3U6I>M)=%V(&TG3VAB)YC-M!DI$J22G\&)7:BW71D=O$FO(\I1:)7"C#20YU5!)JI\O[PS.KQ3T27?

1D4:H-M&EKLQ.>7ZZY8J:T$FUNC%Q2'Y=J^Y9WF-Z-MX%Z)D)0[WW&]?>5%B>JQ)*?K'8T\6Q$X0K-MDYQ"0J/@!(K?

*9\8RZ@B^&M1X.5Z:.^'S7EF?Z$"X.(;8PZ))Z&[8T*MHIDE0_-MU2AN@ZE.03XM5Q>KD3;BU?CUDX8"YLO]CB]6.*

*<*MCV%$FKB>&$UK2FPUV/;H-M1IEM"]P@/U&40F\P8T?Q7*?7*TNKY9;/>_Z,0;;3^L;3^052BE8FWJE((I*,*

*MUO(=:##0I3Q-*R[C10,9$_M$:L6UUMB@&C.F>DU)KX3:R$0KDS0=C8@MJ\Z9*

M,K,SFS1D"-71IA,O37R^6H$D;,B+:*C1&C_JT]!@C\2:&#$.H6@L5I$W/)-MA59_.C"H<&6"IIKSKB>(#

<80I4$N6E[KHK$+>X3&]WO-;$T6)!];I=O5NS-MIKLA"M%#DS1=EEO3ODM;LHZ,[%V[2-F2RJG1T@1-*

*4<1@.*D^XR#9H]CF>(3/-M\%'TU"1-.:.Z[3>;/1=:UTOC!23(XKP=E;$EMBH&39HNM$8J9Q;*Y,A?-[=3*

*M):Y<>;TRO\>KQD*8U2%6F-=0S]Y1-A,],_%.0;$X1BLA-'(TL1G-RY-A/[^/-MGIF@Z0QJ+P(-7D]"B:Z/1O9H-*

RY4>^')$T7]U&J/A8\QJ.[/!1-NB-MI8G/;S>)T<#8*6LFCXC]]8"NLT@WVFF2IBZ\K.PU6:W-*

*:>OZ3!Z@C9X[B",@"0KT0S_5*G,VHPL<%7HIK2J,3-3'-MK/Y7HC)SZ[C6YU!FO9@IU<9(K^&"4(-:.WZ#*

*[#8%H.E+O;,IESQ4\2GW,-ML'QE^PD<*LL]>0()E?Z8'U5:/BH=F&^E$J8/:&@ZF19-"+,/:Y,,,]N#DM_I&YR*

EE'=9AHK"Z:>(D:O-MH(WN[)NMEFU!LCR0]^7Y3O#AWM/Q\+6S7B)#KQL+L65,]E?+?J4!^>%:.,D'

MN#&;4#B[6T#L?FBO=]BH@\R#:&GBS69#L22LO44IM&T$.1^A?(VNQD]-\,%O-MPT6A-

*ALI^F#+,V:KA=K#5;PTL5=C#O/JO-4?,>.5MMIH4[)45S45BY9\Q@:*2-8CK$N\=/3?*,[H0.0-&U.(AN->J-.JV5*

*MI]!A;6*WL*^(&+*4:8C86%@9;>W'|"3>0I*_:UCT==(G/6Z,,97Y>E!@^I%.-M(D?X:Z'DJ!.T'$??+6<\UV(U=-*

*+]Y#D+S]I+XD\(WYRJ,W%8GDZ:\=Z!JO-GDR4#=2)*Y&ZV*.JM."LL=N:^0]OH^'X6%?\P=-M6=#S04B$_UO9;GR?*

*^\.1#<'3-O*K9S[&P^(/?EHJS%W;\#WYU8M>)-YX6/CY-MX-R_PW=Y_O.L]RN-$1=BQ$<390$C+J<1[Q;'-D9-%C+@0(SX:*

(P8-M-8SU?3'BHT'-@!$7TXCWZW\!(RYGK-\=]008<3%C_?Y\,,(8*SOBQ$?S3\'-MC :<5^,^&@@.6#$A1CQT3QUP-@-3??

%B(_FSP-&7.P<$=5K T9,N#HC #2EAA$0N!A* R,. M]?* $:=B1.H&PGSZK;_9NN*RW3S.2P/1-J(?
O<;0GS[0X(40HHD&NI<+/H0P7+S1Q7P4G)ST:D:92;CW**[X$&'Z7S7DEW M *I>G08?
I;4"5+W^!)HTRLU'R9_W0(./\BX!]MZK9'R4?PA0%9,"<=:09DX+4,G/ED_[LOT?8PG?LW8S@JR/LT/:.@RNX90+2_RC]V)]*
M/XP=F465J9O:>*3A03VHPU]=1U9DQY&EP[=Q/W_@EIQ'?/#OR*V)S\M3S6&N M+A">\P@/^AU.#$_,EO
40&AD%@2LF=DTGJJN8.8232-,:]9F1*7[&!%X3M\ MWK#)7X?,1-$W?4/P9"E3(G"{B)'Z&,#+F63_'X@"I%Y?R
0)WN/NP8%,_GFR M.Q3N];G-P]GX/TI_"(R,6$S4W) F;9O>5FQF2G# #+;!1DGQH S M9S>F& .*6*;E &#
7V;L99CWV0JQI18#\.\0F6DY !APPJ!JAN6@[KI^-"D(M2,))(J89E@1:6&F>8 !!.$GL-,."4)853=2 ;3A-
1#3#@L"L?]^.N^$/MX3N&+S\LAWQ$_ LZ_/\1.7+_T;;A.UD51Q"C).V<;VE>7U;^ M^XT+O^ 'GF!)@B/Q;GRPXM7:0H
W_,+CA'YQ(E-6H ^WO6^Y>)SB}O"+E,NS M2C2,$X7Y2+1XW\VK@K"'*N;)9JBF<48-J\17%M16*59:#'5>DS1F/+L--
?,PUW27';<|)9;U M"A6:)/+;SP*&/Z %_'PF";\X(F7#).'IQ]73F:3BQ7T28)+29))P8)).8)+,
MN68_FA/.A,5"TQP/3B2P3OZG4MU!_66>TI5Z')2R_+E;4\UJFU3IPQWBU MID ^XDBM%J)8DT5T6(+#TQ+Y $/0
PS#9SPO75P5,V&D0E]1B;(]_M2;3HH MZW3-9+H\5)W.MI'/#./??@)(NC@D%5+N-)W.7X[F4 %(^@HD'863%[4*_Q3
M3L CIHP;,V]1M444:IKRE*2#-:E7J/-B"F\ZE0DBH2&86(LB6]6;OD[U(DPI MA)@2>CM% "N7AI64W^.="E:
(*]U8WARL/*WZU=XH*MJK6X^))H_HTNVU)D-K M.C"8)CTHPKUN,"/@WGG1!>ZX[2U4Q#?ZKC""R!+27[J5^.
()_O83);$'/+KO M!?AR\49-]X OAX9+J<*7#P'EG^E"E+[L"9HE2XS@6"&9G@Y/9<+5@WT5-9GF M-*";+&^K;?
7$CDI(OO Q1S"E*>.+O5(HU3FD@-L%8N@VE]7H%(1@(:8@Q0>4 M2/HL_P*@A.[@X.(YQ2!2IPMIA3(!
(=$/_(S4E28GY#L^+5JBG+.5D '1 M(3)WB._G\KF*)(LA@7*4ZL@QKM]J1NE)\^6RH[0GO_"[?K?.ZSO"Y^^\5\ MNJ:2I?
#M0X9V0\;8TB&/YO#SBNT,9&>CB;)[+,\3VEBK9* M-!52+E+UF*VQA60IY/4>\WKLTH
>^QF[(JJ!KQ>J\/)WJB_%"C(2(=VS.+$7!8+/I1L$#JGWO&; <&.SLS2%^@1K=[Y^"_!W>/.!E;4#A%5 M7.;U
6VM)K2QUTILY(U&^0AO93L!%/C3+(-,HL#9YS0!7_3",Z0NT([_7**(
MILT@)40QDWU*WKY*C6U(CAETN_>0+7*AXB9Z7IR4ZRGOJ'"S#1321X5,-%< B'=RQ,M 2P5P)7SV*V'&7!GV
M3I;C15W?$1>"*W<-P3IV-]QF\1V+.1*I"X,YX907#7WI43QYN!M&'@CL6'$0 MT-C,=E1('Q4RT6T!6*L;*-
U/'Q4R4=8/9/\&ZLO31X5,U)Z#V]\/?,[X OA- ME_/8_2\Y8=5IP>$8UE1M%*KU/8,(0H\SNO\M%
("W>4M5Y^FC0@HKTH'%OVN!U]6O5&:[H [9I2E]]TF@)G_V5+EA-826107T_+X:]#PGZO M!JHI,:M5%)>)BJG?
M9+I+Z*.WS_#U\^FCQCKF3+C3F4D[?1U]'$/I:D\Z=W M_*E2Y5-?Z-\5/\]>')V^5TY?S33(^[NM2NF3W[C?
%3_/7O>&T&%>VRJ_*%^#H<01Z@ M(@FJ4[)1*9V^5P85UK?%S[-76*?OE:]=F0U$.&.5PNE[95!AG,T[Y@]\N%^A
MV@N&)'FK<;!N,-,IP"@:)G[A_M-I#ANY/AZX?V3MP(.N4R?/G)-$#(4S Z^<1]CE,NY "H;Z 8]=P-DC,GP^DO
MD^S+X89<.3=8A?*8^R>,_X#_E1.DI>]Z61DNFS[= T62M\7/RT^0/?'EV.V*
M8E:G3X&BQ9N#B*P.GP#%A^GD2PJ+"#/$ES1"!!C;^8>B^'\IF)68RNO/SX]6 M>RJQ"OQP=!];^2B-QZ["[:BL/J8%OB%-
&_;A0G% MPQ /X]]^PLG$4C!P\2^NCS*)'Z"B[^9$$;T#K@2%)0627XB&@H$0O(R5Z8 (H$,64E-J!":"9*P-[0G?!.$S^ M/,?
EUKW?-8,JLGOD.J@BR[@,WU R*J@BNU,NJ<)U!%EF7NI;"*["NW)J!N M[,W U!/IXD(QZOGT4#_\X%B56'Z[',FDB?
0G8?6Y&[?'?OK@(?AP\#+!P)- M5HJ=[E($6 50*@:L0M9E&)2* 1G.O Q?/_QW7Z5B0(9!)1BH! ,R#"K!TB;#
MZ:\$Z\A>SK#=3,S%.WM#1-N19"=_6/P#7FUSKFUH4NX?4/Q?RF4-E'9]^1+K
MNOP^ZXW6W8IR=B$HOLNZ5[[=:>G8C4)0?'RZ5U'., 3A]PQ!=Y2@B!5#2?M*KJ=N$ M!335%NX*L'#BJ6B?UNCM=-
DN2>NQRK"S8*NUU5W)HX)8H\G/:'0FZ]{>[1I< M$@S!$L-G"UZNX5OR0>I1Z.'P1<2M##<4_AHMGC3^)*_[9B7<[T"
AD @V?[< MD%. !%_M.'WZC'+*Y5GE2RGD3RNZCJS(CO.8/4[]4?KX\S->9I"7S*GF+B9D MAS-ES.3YG3SVB-[7,\B?
1S@>IHSXGAO1)^3ND;3QA3!"URKIS_2QFE\L?0(G MN_40IU >^?83P:&'4$Z.-
"TXE9ZFNZ0Q(8G7K7&\MCY_'M_^YT02\F:!Y+5) M 9KII\7VO5&#>4,"DB;;=RA[^@O#EZR;TKP%"E?
9?!UB:Y42PZR]7LO[@[JI MKUB] MLM2'/?&7,TM)I)^2&%8) .6;W0.2]@^-:P,]G]5)>1GLUJW<\8_3: MFGP-J_=&
OBU20&L7EJLWAMUOSN%F+S)^4:4P^8 BT .&86<\]:6[0.);]N^- M"N)KZ_3E[=^;YVS4?!L8MN70N_QHQSD2-
B=&Q*=@LV6 MZXS9VZV[^\:\LZI0,;9%?:$!ET8T]ZH*+^V(E_#IW^C'/W:I ^?>9TZOA% MW[4%Z?(Z]69Y_+5)D6$_X2\:
MS>L^,2$K;,7:->CX+!/UVT9)X@&"BL#J7SJ2E\[PU>41ZLWF!]/X.D]{(Y%LJ*\1;50T%,M<5I#4S\U5X]O4I
>^"T9O)/\&L/EB*.+3D M9#W0.+Y0-8W;.96B=#X">4"*Y+'L'P!+5VA)<6U=O 8LO='/XMJDR({CM)FM
M:V*1MBKZ>FD;3,/9;&OXF9T=I3HTA9FZ:^ORD%"[R+Q9H.SXUC+**831!Q). M]GC\763BM,)_>T+(T_-K_2?
5^C3;>"$Z8F@D9.>E[$3_P\@OR4EB4_3UC\B9 MU<3/PM$5]JV]O>EO/X<+.2>
(8F@F!6L7:F;.LKTHW3*;/V#EM/#9JB,8N97@ M>#E;R7D+V95#M1#\T*F7I9RB68(E:M',@B?
#ZWX/Q>F4+_N1A;@:%\#&P,; MQL#&P,:RL[%_2]KFYW_"/YZ>)!JRX$3.[^+QXYX=V>AC'T\!$/2_ISOQO&F\
M$>R7J_IHO LO-AW_^?]>[OV7,YX7;<-V?CQYW"]>:G'P<)'8^5;E_-R1!3TO M*.'G_A",0-BY3_Y]\?MS:X4?
STX[&GL3T'<4_]_4-6O!^/O_;TL]A1?_ZA[<81PA^.; B>MI&CI__VW)@OGKWZ@<#?B4@PPF\?
M7PR#OY/XF3CURJE"7QPCA-S"B5S\?PQ9^FW9M")7WOCM[/KXH]#SBOSIR*>B MHQ-#Z#
<]BZGP&5']G=3'*)A:'13BLPF/8(0LSM$BCV("S&-(0>*+&"GPI 1C M$H&A! &CWP[D.,VK)$Y\[[G1X=;;W&!
(=;JY4IU]K#>J=^CO+UXAY%SXDFY4 MD/'D_-H*+;B+BF$'+E]$(>RT;_#!AM\]W/[:8RQTX2YS\3;CL]{[L3ONR=__
M%6VZ_OO\4]/"XXCMN^&AW#WCQJ(Q"IJR^T@17F[N=T,2G<72A(O\O%@,];H@%?
CB')GS"H**BBA"S-.C8HS7Z]4VZM^1^('G*XA_*8Q6G5Z/$WQ2')E;ZG1ULK<[2"S7"L/
MNAM"@2I!N!)_O7(4]#9XWQ%Y?> M*9H*#*Y-4CS*0Z]7&G5X(1J[8,(-!A6D MC3D(U_!Z/)9<29-0R1N-
^I*>;Y;VS&;DL_0R6IG8I\?,.GESN&ES@NY2$D.M MEK;EABL3^UQ12]FHKX*.+N_(57X]5@4**S,TO[27$PN;M4LJ
M7TBNA%2I-R/:/86AZTLG/PAZZ$I7^6)R);JL882WJ]!0E9%=FM.K6
TNM!>]/1N*\Q%.#;R^5:FX(P):+^AQG0@*=78:+CW"*EQGEA)>
M7T\8?]L9.R+.2&+T6D=XM>"QUGA2D4A&VY='(M%MCRTGI.L19FUUN-U25[,* MA B]Q98N]^NP%&
[@"+=P1NS@5MNEH,&\76K2@;[&C5#WCG"KT;/GQ5Z[UN*T M\8C=-:M693D+E>\(MUJ[.C+5.-73D:*N6#/']7I[E4>.
<&M6T@=68[(2('JQ MPBM]O2@VY7#I$1:HU2U4:LHRRNS8MMC&_'%KLNWQR!$6;&K+MC@;2Q3CU[;0 M&L.
(59<,EQYA0:';M^0FB10X$&CK [C SVFM8 ZA)].M44^_+:SU<
M>H2N:U*0J;HZ=AC9K*B]BM_:E3OA7H^(MJ1Z_5YIM^49%BDU-]7B@&+4<.D1 M%C3J;1+O]MP!-]AU_(ZYS
H'T1+$R#,]!<%E"K@4VY=*+4HEK607;T7+4V@ M,"5J*+1>D1O.K_*C7]\JZI00(OL1;HUPTN;[T[VBLUU)XUED"$&M$-
J/<,OI M8//ROM[RF %!K!J^ML,[R5[WMM/Q"M'K>6D$IW.9_6C 45+4WLU8#(M.5I=#@?
<3M868ZB^4G=2^-0CC+59CAU0,+UE=HPYUQO!1I?&X5Z/,':(EXC5
MUFL&W%IFVI,=Q>/.)EZ:V*NE;_I(7EF6&%K+"\.)!Z]LB8J6)O;:KV 2.6]/ M
DXHLE1^/]ZT##2DZQ&-7;KTNDK.Z@J#C,8]956%H4-BTN)A3+>AV2=5/)# M?
[MKU=5H:6(#8VY4JC3[ZR*'A&H[W$G[-MV-GYK8 $835M[L=-;0F-JM*@V\ M#T/S4!".:
($_W5.U$6+M.1/9U/R:KPR)52]:FMA T%?80FFR63'TH,0T-K2X M+/?BI8D-X-
NRJ2+^3(3,57OE,J'&CD(+@Q_1K>)TS$)?'%0J#M5 M*EJ:V$"?%BUSO%VT(&$/YYN+2=6$M5ZT-+$!V-UJ1HM""] .MS
R#P4S(PB] ML2/XVJRI$,_/,2QT12EI5*ZROE[I14L3&V@*AH1O=B+$C4MY?-XW&L(PU%C\ ME]L:7\0]AX
.EZ^B;1C"RI5_/'WQ\D@014P>HR51W$ \Q!N>'/TX/"/XGOWT M@T-L)O[);R&
<%_>WCVN2$3+/>=K8XP?"AQ/'YQJ2$.]V5'X1"7GQ<#M\H!*> M8Y].)D_?YZ.KZQ^':%<0$NG#*-/C@2?
^X*>EPMRU#=^3SQQ=>COS ?[\Z>M% MD/ O;_J1{P0)&)$"1L#?B2)@1!H8@7S'@4]D@1/$=Q(P(@V,_B4%D:$V(0#
M3IR.$U_LHO>^TWJY5RY\X97/ZAY>]I7_-B\X/#!%/_SO-_S;']{#Q;^CUVUW M7OC+J[2*[1SN-[U%>+#4MCDS7+-
P<[(ER=*QOHM'\D-3HS"%U*3^Y\TI2K M2.(E/|%')/EG(C/\61F0/U4&&/N.D)E6!@1"L-,U&KMC,;ANP^03B 'ZUS!W
MV7J:KTG#KPR0G.+89HY=R5%39$O-46+HYH6.G.S^.)$B'/#PRM0X6[%!TW_J>2FW+D^X3#F=)TK+U1> M^GX0[?

3\^I_3(?]5E>7L(R&PER,A,'Y;+]>6O$Q,&(U;-0;3A??C?[>@BZF M9#S+G@]_<3:?
*K+A\K\9*HXJE^'ZDB\09AK.DX/A(25'N^Z%DP+-SCASR2-0,*
M.6<]&OWHI]'78G24]%U9RFE6SGX^1PHOSY&9/$.F%:7NG@K7.'N^+JTXU@/G-MRG2YQFDUA=
*(!=.1:I]RSD2'EQ^"ZZ_K1H+*HM$Z,F]KF#DW&<_GN=7,ES?9D<0$.T]EPX$\7E[OVB3J'_CY#*
*M.),'ZZ@[]8\G3625Q^;2L1H>=+ BRZS5C160?=2_(VY^I]L<+<=!$>6(?ALE MD*I/%>E>M-*
WPR$T<:Y8$CMMWIZU7/7-?6%O_^OB]EQU;"L^()U9483.I\A+, MHAQ=8PUADR?
I62L(=TH\O/A>B@'77LDBTWYE-.WD9? MRZ<+PM^(TYBI$\39O8NTW7=E/(0?XU4I4D;ZA2Z^%S^4>^-ZB?))2??
U(=I< MM+F% ?5X,G(L< PY8R ?Z/.MZ7/:[J^SYI+\F6HG;@1@M-^KK+L4Y^<;P&B$G=XS@%1B5/Y"R]5Z@B40,&R
M,97,XH09]-P]I,^4.FX'?"%V#HACXRA U.'NM!%$'4YEXC_0QL5\OY.UFLDR MK(GI56NS)29$I(VA882"H MD.%#2
JID,)@1-;\C-?QU"=0>ZG'K%(.M;C\],1=1S8UWSR"=!JR-MEB<]3C M!JOJ9$CFE1V,4'PQ\CL^#J"N 2*
!!#/2+NS\R>X4)9M4B]MAE5N;!<:HY7F MU'BF%^)"Y '!R4S'S(0V7CL[O_(5#5EPY5PL"7E;R?OA-X+KRAXH;DCG62N%
MKPPB)B>,F#Q7I+8BQ>Q'K\HJG"M3D5^5&/F$* \@F+MC9VGFW;#T#6Z.A#G M)7-*
;WO6B_L)1,L>1A&T05@&J#L(Q%_=03J#J\](85\K5KL#EU:H8F.6FT.G&
*MJAY=QD#8345LHE*5*)M4TMR5[0I&Y,BLG,B5\7:YD-,Y>>UKJZAT X1OP%D-*
MA&^RX_14!>DEEW6T617I2AN1F9T!NG7%AS ;1 M@(30UT'.>(-T]SH!D %$<5W:C2/?),'@@,I+<*
E09QF.OZ&)_69J%5Y!IKF5Y# M"%?09\J6[3H7J3--UIW\Q1L"5D2?HZON8N(0$^),B# HY1(,"2*J_EO6.4 M&VFS')ZDF-*
*^T^7 M?@3M],G8*3>*W)9;6[)<1/O-?9D(H@&1($$&8 ((K63% M[?DPZ/H1,+P9=\4Q;S^N;%=-*
+|>SV33[$/E+14A1'3Q]$ 6B>Q&6B+"1[/ M(37&M"5-";<6O0.(N8 #6C9B+MDM-8[|)$0JR%KQO7C[A?X=*
*2)H@^42;^$ MHO$55YS28FA" M+.>@GVC&#U@WUND$] 4%LIXE*ERM+^A%="3-*
!^IG@P+NA(UCNX=/=TN[EOU!;S7W^E8YM.2_^ MK2V;<]GA\SVCA
ON4F%VC0E,S_BN%3#!"=$UQHC^+XAX#TDMV&5F;A')G"FU?.U\GQ!E5;PTV]IC:YM:[."E2G
MQLH2]2>I5Y^"FM<(T\I/(7(AUHN,SP;%[J)24(.:&B%,YJM8/G3.6M%!6+P: O MEGH.+4%YE@PJ[@#A-
*^O0Q2I<)/GTOM3F/I'BCD-5IT4*U*R254(8$+K6@"6G M.UKX4^J4@:^O',T:M(,Q$TC:Z*
*C3Z{OBQ.Z/AFJ$&U&0Z\3YJ&F*<5%BW-;. M#7VF742E^$9-$$7'ER4P)N<6SJ$WECR2+H0\YUR^!**
*JZ6KWH*J4)5$'17V, MZ;O,5C3\B-J4&2\L^_+0?@&]VE&?J4+84YU6^HI.%'RZ4BPO)[.H#4K*]S-PA+ 3A(=7@IXUFP9\. -*
QVAU:)<'PD>87&TOV^K38U2ZUX,!G%M#H2\ M.W4K2P&D[CL.ST$G0$ I"\=$D%N4;F?
F[0/:Y]P3MUDM:2O5%_3U=ACBZ;:) M&C 5;C&^-7O R/>FAH& SMUHZAT'9LZ>0_0Y30W'WPGJUF4=RA-'=B$6ZT1W9
M:J2IH>]PPWE"<972RVH;$"\Y]P%I;CN2[.0/O_\#7FUSKFUH4NX?4/S?G5'I MS3C,%!Y78+3K?'(X=^LVBR MMSZ89PR
)!T)OO<-)!>-|'P"2;K2G$V@T=3"%&K\]ZFX4W6K1A(0D>KD/2T M,A*A"1_9D;V<*+B+G._*TJO"YO!=-*
J=UK^Y+N0\0>%U%/N]%U%V#U'FC-Z%B MTJ%>=AU[HTFR5-IQH8+6K>6?"#PY$T[:+D"M/VXEW+7VG[>"-!IM'W$"?
+$K;4&C-;F,9[#*_B,[T7: M'B750 \(E.WF+.G3>A UNLUK];1EV3R_W\G>$H0I;E-R4Y@0X98,?*
*S'R%;G*H8=N#G%LXF>Q5(04;2M+IVZ !5RQ M]-T87>.0D=XP2]:RX]XJ=.P*NZAOOCNT*7'M:X[\B@A+M7B*
MQ.::]:EF=N3N?EGL1? 0A6#?;7"?\@/Q\TUQ?.+5GD^\X)H87!QE]9KX5CR: M-ZZ/GL-2OUT?)7K8#
)4'PO0"C({3CGO[DH&P08\0H 6#D#7P25Q>AR3+VGY MFY?$3=.NT])B.V4$PJ35(:NQ"[P7J?LY/)1[/["
V,YM7K.!"V(@N=F47'!! M?(4+XHIF"98(+HC!_1RX(8">'4!!!?$9[@@/H2-H_MA29Y[X.P /+",G!UN M)0K:EU>/5S?/(]$3
XAWE!(T!]4E1 BE^FAE#$?^+."1(KB]!:I\&X>IC @B;9IA]QU%X(3=^)?^7-#$\-_4<(/L%1P%YM.MSZ%KWSM\VC6O(_W
M%;82ZFO]45U9A8Z5=>#9HGX$SARN9/3QZ;;/K3M2E^;@_=3=!=$.0Y\$?RAB MR3L9<&@'VIV-
*PW[6^K2]F3/Z!XH]*Y9%J;7-BTP^WU7'+EL@M@,UVMRYA@.E M*!S"/GHB(;MS_I+8;!)VRD(ZT_*
MUOM^7ZJ/6W4!9P:ES/=Y MH@/QFG/$:\8'560>M?,88O78&@C -4&H0 MIDE-F.83^LSX^SP]X LJ5%T,Q]I49WW4C?
7Y#B(TG[U<"O)/BHB\4%QZ' MX"8YQ$KU/7-0]L=F^P42]%(O11NXAK_ONJASE4A"R3WUB0W;8DDIRRMO?CI
M>"%8JAR-H(O.R0^'T[\]K5-:'@MS\V%/D7.D5W/T40O/#]'_PX.RZF\8+WM M[@D93]B,7-_H?^:7:O6?M2KZ:\J2?*
O_!BY7=D%RV]'J&)K,5#3_B0OA%K,5] MP9,919%%[ST/6O[_V?O.YL25;='O]U>HYI[S[NPJXR,AXNQ34T7..=G^0@FI M
8&0A_+!O_[UZI:$",9A&QM[=&[=V1@4NE>O' N;4&@VUKC)EU>1?AI)Z8L6D#Q MV&:.L3?
*1\%F2OWJ;^8@,,B]696Z8$<+WJ1 -T,:D5D8GH \,YV\<*PT&3'Q@ M)"%E#AOC(1>&#'/"9Q6l;JY+W=A#;Y*
);8IKNU=,W$\^A\^>TH\,@R_'QS,U MM[4B>5,+C89I'G/+.*F5N4DF+E@8'#"+/XU9! D2YYA%>(BT4-_H1$R#C2T>
*M8X-I*C\-*:FK819B<=*2!IE1/E=II.L-P\P7C,($F 56K>*QDZ.^OXQ_Z-E> MFR_5L1#^\D"[^H8].(^*
]&E!61XS#$FS1PKZ% 9Y%F_^]4YG?S)!X^,W_G)6 M>18JE^&C.V_6.#&8E26V<<\6-/527=&*
W%V/3I7)M1>)>I2=IR+A1+WPB"I MUL2[]9!/D$S6FUCD5)7/NZ#1=;FE A;RT2SD.DC8"$G60@_7#TLBV(RH^;G*
*MRYFFY,K&:E.,?I)[[0+T?1^J5QGU<1<6*S$O%!Y;*=CA(5@38R+W7#\J32P*
*MT3_3QOYT>RUP<7W/"/OG'.KY<,!GGW+@H?F>N!YDDWR RM:Q=5U!T*9$4!A) M-*
*D5%,VV#EKV2Z9:*MF9DE6H/6#0'4SK^U*CS!QS75Y S R6#R_2&CQSWA;U6:_3Z"#6P/+^:&O_9%0[!?,@_' $#._)S*
*M/9%8T!%GY*XMS/NZ(0/=]0ITUZ\=)PMJJ /,_9;FUU>-:>I6>:N!*]Q%B\AKI MY&HRJ8F!B-*
*PA.,*0S&)MF3%"C*7ABPP+WQ.T(?LB:M\[>C'_&&_'9>NKO=$7 M2.),#;U8KV2C/E_DV) 2U>Y7:2E7?4@-*
*([1'6/*X_C$PP/XL2@SZP+^7W_$9 M2GQ@\?^-B^M03N:ZXE*TDPM=60,E$JC^MF]F&WFL-(]$@ !I0]M>VPK^%*
M(O(/R3NRL:J%R,:V84.9V3#-JUJ25\#><>@%HT_.UCAY0K*DU0>!$J__9;_ MT%E;?]HQ!PZ /V++%_<>7&S/7\^%1@"*
(S<@B4^UD] MV'Z2:7@D;/.";# K0;&1SWMM(!')*_1^#3*_XEE>KWX-\?A .U44; M1E,P+.>/E+BT,?[!*
(O+R!IQ40&SD6^-T'(TW>^'53-ZP.2&+VG)UUBW9Z_4P MDJ!MQ,-GXVB!2?
LGD&P0TWZ'V>;O0ZV%67A0R+5RCVPC75\NA,XDHA<(M;[S MR/-SNL,GV^[[ZH0)QCJUPZE"P:"-CE236N0&,I&
*K7"2*R>A%5(T'0S[P.C^ MPA9&$"#_2NH*":,]P_TZ#A&W'1K..238/8)A-2UE-V MJQD-9'0:PJ#?&D:25(^)7E*/"9C -*
V("02S]?16@#Z+_WJ >9M& J^4R=636 M!&UM>T)T/\':D8?B>\I4<08ZGE2!.@TNC9DRT(JUHO&@5_ESS+2/KOJ^(O.*
M57L)=W(IK>T1VH#266,\/L&)LM&'1B6VZL7GB^6BN!FTM)4BI(91UAG\$3L[M63APJ?
P)U!JX5"ZL4;R29IN/X=FZ$0HG>X6"$)NV5L-0<3P!FOUS_"J>0J$+ MVXMI$X&I](U,I&RMNE8YWZY-@-"_J0<$YLY[
M.9;XZ$Q90O3,]O-,8"X+B08)HFC8^*-F39$1.$C^+),K<)!<3!UI.D28\=-@ MBA+;"495SRB14B4<2?
*3LPK@M3]@)'"1_&+4&#I(+ M;Q:OI-F"^/JJK &FGVY(?^U.$6@HV@*O< N#Y%7-PDL1#/RU2MK8*
*M3PQ!871\G,X45*SVV*I@2S+4GXQE55!%&5]A6H)%RE=,?"+ON=?W [DDF[HB M;_%;T-^O6Y,BJR@TI04[KSZ T_P8?*
*CP^D9=R:$E>_?XO_L=]KJ@@P0 F-W56 MXHT$A/"%14S3CESN[T+/*6=\#I>\\EYV)I^J\P MEI& VOA/9V,1{C8>O=!)':*
*FOSN7_PK,U #I\+_=1N8DIA+<5('M*WL#/IVO M, ,A7EO,&C(@; CY.V@JO 15]T%]"H("D0;#>*
(P;B9%D9(C"8VD8X2+B,:D; M1X=Q"8W";#PJ\ +_@[[U?:!V5/G0_B9;5KR>+O/FVJ]3C=5+S#I4N.&-M K*
MU3.WE^'Z)Q=PMKZP3O@ZMD=['O/.>\R[XV/>HPL)JM-+/L(X_ZKW.1FPU)?R M1XHTL&>N84P$57XDJD86F:
(AZ_:1&Z=M$W-UTQ14!V\<3"LJ[$LEZM:!WTJ8)XO(IN858RC,V;0+0A\1D_U8*2 M8^#*
<^"$+))'+B*"VIEB\3Z:P)D9$BD(/X&"97""?H6-$V-T360(,"01(S. M)NDL-D78XL!:P00(#YJ5&O00"9$PEKW0#/.6 3760*
ZS$/#!TG1VA@AHTRF3 MQIJKA<2I2IZ&'S_:,ECE0M@4P>L%#M7X[<29]U:-I'S)+@",RIMK>+W3V7= M&_*
*$.X);_0^^8<98EW$>*AM/YH.3O_&?JF4+BK)ED QO933;"NW6A1[M:]S; =X7Q]\CNX+-[S3&F8\,2 \Q%]/?<]*
[$R_BI(G!=E/WX_RW4N:"2^[ARG ME'G8AN&<'>8*A"HUG9CL&!.QP#$1)42H?! IC;EB!3Z3!S F?KL\QHP 8_O1
MW4#>@-+XOYA"$%$DQ[9E$]M3(G2L8O+ !(PLT&,;FACF9CSMTS!%0JVZHC M!GC602,0NS?DL;OM2$"*
*[V,JU%S9MFR AO":96+3_NNCD\/]1PJ,:H/ MU 7#&&;5S*8>6^CQ>:4;N:\7Y615J:Q_.:3D=OCF"R#,4_!'SZ8O82?1$M@*
*MK"#-@$OKCO^(H![6EP!:,,@,O"K&$3@$#Z W)9PTHEVK ;56LH /8&0QAH!Y M_('\>_*A;9-*
(\!"2)K\70%F0ENH%6LF:;KC<$./6N^0:E$A(8HDO9K1((M8*T9<[A#=!B"*QD-*

(F(=^0T1)VP'+)%NT0/&00"5W4<7!"R_LA]?%C#P5$\3@1".'JH'"HH)DE)". M,.YB/FCK^"9 /++1'?
*C\&.#3"@0+ED\5$&"*6/-P_M{Q0Q\Q?*C!Z1=Y;S?6 M/H&OE(@\T R)M+]?8\6+<:+>*
%B7Z9L8_24BOF@7'4<%274RG](=9J.A"'O# M%,AY9^AY[\L?!&6#1.RLIXC@,?R#B(\5(P@]?W-
*W{0VJ'^<*N[P,&$RP0B, MGP+/%AS&M4>(DF9C L,495L$B04*^3TV=@(U8>_X'1K6Q;=82V6(2XV\DK!4*
M\K)#KZ_HV:A/N(#)WF321AD(!J,_ P0 (T9>6#"0KX9/6-7P"X0YHB; ?D2= M\%O/%C@^R94@T"8CXA$?F/4$"BC(&!^-*
^8'RL"" 58^518(?&$4*JPS3D MA=-HB?8PIEYM=[?H^?T,IOA1QY G3,-DR, $_""\YP4^;4T"77U[XUNGAQ"F M'R%.*
[XZ(%[(=TQZ#>,?W T_ :C668?"(IU# AX$>8%Z&$I3%O0K8-\Q46X.J M=@.L3E/Q$OTH/&; V\?\Y/["&X(K,.<:$;
{EHI>S22)E1LAYHXR9^_YQO1!9 MGSO#&T)L/\//+.<&SD?U+^"&KM"!#<47 ^&S /W61\M88E%2?@FQPD, PZW7
M'M2;:/=9],.L$0L34$CA540<>K2[C\8;4;%!&\-K(1(6;['OLU-)!4&)QT*
*M.5B24G+T(X@+_UNF1Z@',UB/L9+CI$8!]3G2"2+NF()K:A-MS+G0T3KP*1"E M0W;&G)CGW\X0:&%TL+"< 9M#*
<%0^TT5/ !/<#Z\V #>= SA%:X{YBZ\W!(KD0(@:KF_FC0R2K@JH1-;(X;TO >[!LB2\"PM "PXP, I-V-\- MV-*
>8^HA:N&=E8XRV14?.DI6 @8$7C-6DI:=,T$I,?OQ/'DU;^#5!.88M.8:CC@=AZ MBJD=?H_QPEF QRZIM0.JG3-
;R:2:,>Z9#U@:\.S!ZB8RJ*)GHV MC>%ZIO8QTJ4+8H5AS#"!1/Q&#*9K[U;/#M3M$=XN<&3\SA70Q@&/WMF.^Z\#*
MHQ_(CDH:0E!/JE[_5/$YHFO\,@4))E@.S_+?-W6,?C]SEGTSM%Y"ZI]FGUV/ M,78J]>09_KB3H(ZE3^(-A^INB26@+\T
MQPX3Q#\I,D48<+$[7%0#H0$.;&PD&B8Y;=?@IPA[F,N!47_/=78V3.V$GS^*)8&T$23XB=(N73=5-BG[$+'F
*M;KBBA'@.G;D,?J'I)/Y3?Z^PH,6-3J##_?/TO7ZN0P0=!$!&H B+D*6 >8\|*
MWG,LR>!MH';K>8/>XSM^X'\Q)Z$O.2,>8>,)/AD?LON)&VPR,HHG6"()UEI
M&,&7#)/A9'@8BT1BTB@<'8^$Y'&J1YQ/)#BL)^S]TA6'U MU=O6.[%\"O(\#J_,YN\+0F>8-
7(=2>JG^/ZLJ)13P_#!^O"52AD]R(A-E7OR M_6PX91\S_)W:PE<>/7.T3 WLN5:?L)V^D!R-[I+]Z>-D2++5]Z_D&K-IO,:F
MHW.[=K)L)M$Q-BFAOSQVQ-M+JO=2>M*#ZG*6$KE[MKK^1KKYT=7QIL3>=CM
M1RNL;3_V,)/H9$+]U##J77GAA)C.SJ#9N66;F@(.,/,XS:69KM;&"W!:[(7O M"G?\-KJ/;">L]J5IN5-
:/Z8N"=R]B/TKP$TV!GS7GV'UF7'. M/7V8Y)?(BS?HQ?)Q;,.))X+C6!213AS?.VS"%AE^KJ[LE%TP__$U),>,@"A%
*MD$OP(B"%5*KIA4# :G*7NUNDK%)#'H2;Z]*156JQNT';/+X":V^A%KDB!?4: M6)AQ++RR3<-*
U<'LG=.>YU1'30:)M4"F9VXA3"!-BVB!>02[)@PF.!> "D3BQ M/W??[&7/D*HBOB#E"WQ-6X/=78,-M"8P2MQ[AL $3E-!*
MUA.>._"S$L-"QP8[50!VOM4;YWTOP@&L]"G@GX>5^A08UPYR-T\\E35 S7% M-*
*FA2DT_CV2D:7F8&=+WT7N7"820HU)T*0,#$8RO6+IF#6L\F=3B SYR81Q\' MUB[$UB"CY.:,WY0QIYJM2*!=8=N#T*
QFG#-;I28@(1IKS]}YWGL'/D[-L3,- M!.%I!QK$*TAQ,8NA"UXIAN<@X2[,NP>TAF"@[+HXGG GIU2LMD&Z$'%ZXC6Z
MM%.A,),5)SQR2"-D7K>+^OBI"]DT_<';3FX7S'03 QF.+C&R1T"PYMUK=R34 M).5Z4KQG^G5AZG9V';-N MX,2
0P9''@6W\U:,K#_ZMN3%OB%)6C/1(UQ#DL \+J:GJ0,Q>6-M]UQ$-@A(7 MDZ694F0BD>K*
UP+2!JZHDEQ9T\;LQ8/##5I(UI58,==#T6[$ M-$KW,Q:M+T3OSQ4$G^4$/W[#3FX8^)?Q;8A@R&[7Y/?
W=QV_HC[DZES:KF>& MNH%,&@TA0[!T:APUH:V=I5OZJHQJ:R&9#;B,_-$&UZ4#4YI2G'X$W4\X2<- M()QG6I!N4<-*
$+XA3&U,^J'P'"*$W> <'KG8S!2QOLXA1)MH(%W7-4<6PR+MF& MODE,8N%Y;-6)\|
*<5QHLOV+B4(OU!\9*PIBK8FW)8X^2!S0): H1A4@$?/>A M2"B6X!O: ?O&5='}&+&+8>U*P=)4I6@G?[[MR(^(>AJ?*
D2?#>1593 MWK@A,JKN/IF:#2L"5?+7E0?"-#=L :)081(SJINHE_N!_J"(K@1 # %RY2 M'_I^S,'75\ ).!S'="S#?:OS-(*
([NXR5XNR%#PX62 M^W<('OV+!FW6&"[/!DL<;R]YL7NI,#(UQ;;01P1)V%LV^EPU-O>[AB[T-<_*
*M;>7#WT9BP<%CNU96?,9<''?DL%[&!DR M?FH1*2L$ ^X(W"*H9.G[-:^#H(#76"N!+TL+F;>"+)&*
[CG)ORX(5)]8U3[NHF M4UP:O,^V-]D'^+F^ R?TP/T!Q-\#Y\XVV?GY+^K6U6R,:Y+YE]WQ2ED9P3
@JM^'^8$G^MQ5NHEM01JV1%98 M=6I9?I(-A>0PL/]^!VY"<<2EVB631GDE2'}6QPU[\,B_VQ2X(>KAV513&;4*
M_'PYTY1#FLK-,VP MK6@(SUFZ_$H^RX_2IU^1@-YVF64QMW'*,[%:*[J(J_3Q()@FHHE/0==+$ M5[0!GDL4V?*
_"=^4)RK'4GC#0N-FTUZAGTN(@+,WB4TC%)[9!+,('ML$GV 8! M#5W:>'A/&DK,I9A>[8T>V(+<",
<:M8AMC%J8AL"HB-UP_+-&A=M%_JAX\^#O MZ\C6?+^JJPNE#9%9 2F2KEA$BI37C
*X^LJ=J2I2'NQ273MW%V49.K\IZM%%, M\:TKS93%<*0;8V!G)#\&]G8]R2Y^;C8F__O,1*>]Q9Y'&&;N36?*
*>^N@R7#LS>,U[?20+0BP#V+9P%TZ0Z6#E<>9F53 MUS#D"G@!>F:O?#6UDZ^*F67?O9(@V:R[]I^*
MF;8)S0OAY1(0GNCF'3J]Z4Y1J&PR\@)2M@U(,_=JJ$^4B="WG7P(+-8W>@3(MWAV]MNO@0-(9,3++!6@H_=-
*$B(%22B8&W8%?"O<]I?$B0OU+L>U_E#_^4MW\ MBS?"X()&&$$CC/=MA'&V0/WB2?REA2[(!HB*AN%*S\88-)@J*#!4?*
*WE*24_) MO26[C41++\TIJ4V47\?*\,;U4%O_KQXH\5_&RVSL<.]':JCZM[9,5XZONK7M4*
*M^[*2T=IDE)WF2P6UOV<=S)F02<_%7Q)T,6 \A#AL$/_PH M:3 N09Y$SUO?G2$NZA9.FWOM8J!-*
*(^C"S]0)*MH:BAP5:*U-.Y33,G+H78T5 M?L(9?=T;0453,"X@6L/K=;EV-#;?E:#TD2,^4]OHML;='8J[YHD W0-HK8F]*
M4;J'#^CH\)TW^1O:N_P\8EA2F+WP=VM"&\X!9I"(?@.2K4SVU-P?-9$((
MT/51D#'R@/5),S"_NII[2XS3\F_<3S57\QE^IE[M:KP6I>G/16U^]D M.BRC?DF?F<^I[L;TO.MQHL*X&\>B=)F[8UF>**
[OV]SIQ=N3-;(NY+2>>M=[M8;_1P>WIMGT7UL4P1'VX9VBJ!A75BUU=\5-XR'%YUX&TDT@;G)=
*(+]Z3_[0/5FN>'S+C..HR9*EKO=]7QGQEP85N7!&<& MG^'ND_;\/7/?,\CI^'2HI^84';AN4OQ^KXOV"1_,#4.DF:+X6@-*
*X_L((6'D40\ M-A1B26D8$Y)B5!*$,8LBA^WU>H;=MFM[%AP_=&#G%H*T3NX9G1HZ9WZ[Y1 MF3\6&G-*
[LA(GY41H61>@Y=[1.HVE4IOHL9Z:DU6T:D--#0*I.7>4<^]69?+ MA]B,F)XO^I%E#DT,3HB<[*2WQ)?*
%R2)4RLRWY55S'!)GTF,]=:J3WF/6M!"? M'=GLLBK?CZ1MI79WY^^DYUVY2M;U:+4M]GO+T)W(€QXZO+"-]THHV*
*M)MV<_-# 2B<_:O3*D^%A/T1\97XQ*JY3=XWP7$;C3A=)TSG/M8:)XRNY:%]+*
M6O7'AUQXHD0GV70ULFRDALGC^]RL4E.;@S,N5RLBP=C$'5_:7EOS:*Y[7^\-LCU^L]'4.[&QADN/L&2Q*
*M3&:3HRCJL0M9'G7#6BQM9B9PZ1&:-,188Q0MY:R<+/")2+>:VYI#7C-9D\!B*94+@/;C]<1Q_I6\H['2:L*5X*
;=?]PEX37JN)_7E,7O3+ MVFNRX;4X(K/"GIC822)3'KSV+G,'IC(61<]=5W^OJ^+I;AJ[0"CMIP\FBV/5 MP-0 =QS(WJ2
7__,"'9#M=VMCAIC'Z\A@5PP@H<>5KA(=G\SA8)1NP0PHG? M5M)V%HI+?KLUD31^$K(IHSDF4XQ3_$[$[\)DDF?*
^+GK&ZU'_/0GFI":\44I M(F_O6:$SZPYBU;3=&%S*!OH@1^[7:T="GL(G;B/QH&+_R;#$Y[52N.7#P;E<
MW[EPMY&@5\\UG@M[FPP.Y@H/!C,R/CB7ZSN7@)%=Z;D$C.PZ#R9@9-=Y+@$C
MN])S"1C9=1Y,P,BN\UP"1G;EYQ(PLNL\&,S(@C;PU]!M]&6NY$\#0N)EJ5 ? M4[/^C%_W\X'T#T#B-5B-
*OK7!;CA^&XY_;EN8A/ZN#1'SFD$CGKL8Z7.QT7?J ML/F]4[XMG5"<#$ZP'Q3%W5<>OC+R/HG@7&.6*A M%'#\[Q%->*
(PF_%9&PX4_N[W?.S.;=^P"?7$9%2#)YR$)'R!)@"0!)PF0Y)HX MR655U0] DK0;]7"_MNE#)F:V2LKX?
*OTM5CF__O_]-1J)_A[]"O.,;B?N9C+5ON>?GLL&^P6 :KSPY M.X]>A;IV,-G4*DN$Q34.# MMGP-HX.,E2SZ'E-2.-X(.[\|*
[=URD+CJ>']6M=B6HPSTCIB%W+YLQ>.!PQ M-OS]HIF.M.A@'@Y:W+[_<)$KRQL)&%G R-Z-D?
*%^1L9_,T86ZNC2M*R7'MG. MH-6KJ_'8,,^EKH21Q0>]4(V+S]GY8A2*U4PUT=O,)_A<8C]^\^%8P,@"1A8P*
MLAY6:.>VU)\-E2GO]R+?+,+)2O&=TD\9]?F[' MA4=>'26SRQ+TEDMB1I8,-+ D06,[!6,[%MK9/(J)R?G\F,V5ZFS:513!U-*
V M<2V,K)?2V7QN]I#H9:92)QR-9$M6> V:5CHF2[G>LG!GSW)HV9L^=+#Z6-C36?2DN[MX;\OI^H']!^PP8 - M?*
*JK7]H/9H&*UEG*K<3=B%_/8I"GWU7R.?_V$[LOPPNV(J]=2Q?R"S7\0>SP==:W6_.IK!]C':6+=P]*
MH.18R.Q.^^7N!)_&1SAD_S#2#MC9'\'._@3M3&[76[':VLSE.NM! MG4^EQ4R]?2UQ]L%V(:%YO],:+
]>Z%$^AWF+0!YX&CM5()$C(_4X)N?05>9A3 M7;0M<2IC3%:9C"*R' ZX#$A)I,-LT%V;1!'#.*(G^QULIQ_^W?*
\M5%/#./A:>>Z"CHF %P0L,6");W/0?GF6J$:M,;=H9IL]6;#X M422*^I/1M;#$7#GY4(K)
*([FPF(U%E6,'":.KY5NM,CN_EHKEQ_5JLR@)H7DNHU2'MB(95J@$ M6F(RT!(#EABPQ*MT%']YEI@J-*
&8YN5O:]I8Q@466\4J_QC5JC M5S!-N5L8\)U"%@BR<6]89-!-NZWRL:EK^A8MTS9EA"3F54&:2&B2!?-^!A*
*0^[O#OX*_$P^=[0DLVM'&$KVHB=BG(GP9O7D@8RLQ_:*
MXU)_ULW)U6FTC,P"NA\%F>"'7S8^'TGV%D]6A;#V>9LFLM$&]WR(F7F8JD69F?) M'[\C_'$@ZZ^ GP7\|

[.OPL^OVOGXE=K84#&36C$&,72R6CY%\Y7$Y2%R+4J8J-M-2@EV1Z^^DA0#O4C4M84)UP$Y-^(X]I+"CL]Q M5J>3*$YS#1TMV'F96X6U:\D]:^6:JOK0$=A>I[E,F%PJ1#^44L,DF3H6ON", MBX#J ^87,+^W^5^_$/,S)O%X;1O)%UF4BF]FP](P_5"]EI0%,Y&ARH_&?5L-M95.9/,YKL>$4F!]TNPVRS +F%S"_ZTN_4+,;Y9=V^5Y4U5ZG;M&^R&Y:FOC-MXK6X.=B'VJ)2Y[H-5I>VE(BWNYO[UJ8^25__Y' LTO8'X:|\ JLZ)^\78G[;-MT;(H;X?UQ%Q.9^J9]##42<6OI;%M:C[5H@.IG.IU(N)"GMP_UCNK-69^X,;- MAR_HX_TN9/_U4FEKPE9C*,Z^8XXL'^3(OH,LU-P)&2%Z\2].WS"FIL@2\[\L-M^=^?!A- ';'XR4*XDM>,MWF$@=4KI%RTJ#O-JLUB5$CE;7[1FG3LK6^U^EGK_ M9%)&*!)950VNW,ZA)!\;1NQLJ<>UAAP++MYP/!ID902L[$]F9=?MZOT83I99 M;3;M;K\R9>5FH_)@K$>AV?!:'!7M1FV6JLUFN9R,'D+E95%9*,T4,+#8:086-M*^_?_TY_.L#5;&WN&L_AH$- I>IL('42_=OGS#SFS))FCQ1T%?+J7Q<-^'WZUJ]#*IUV=5Y$S*RM7"BOBLEN-MKQ+A!L*\%5O>B]>2E)K3YJM- A]4>Q2C6Z"W(2-M.UWEUJ^*.QWHS!?A3JUFH7V/,HEL3S#92(CC]4A&NQ8E.-S@YT6CWE+94"H_M1+7T0&? 3A#M!VNC-Y2K$-OX4*>KW/IU*?3WLG+#.U.)V)KI;3HLUL31>,K-M(9LRDM<2+S$?$G"G@#M=W];OBCM] MA/;$S5,E?=[(EN>5S5U?--@--Z]?BVW'#@JFD4RK-S:SR?!"Q-:RXUP+N!.X-M$/D;_F(!W>^6?/D?2\!D=-$JF=FF)8^W?M *__9H-"1\ Y! >6<$2F"YF9.88&8S'G$Y!(J4;L@*PB'Q16/#/P.(<-M;IP"2-E6D0\>#A^LVPN\4?&/I/2G5T8OA,^_H+V-+- *-82&F49$;@L/\A7D]-M,N#3T<_T7A+]?.F>#@_D/Y*\^OU?_(^[*%'!IPS":/KW/N1XV(&K*F&\NH1V M(Y)6)2[(PA%7Y'CR!DI:=7?5Y-__\2]^)QU#HJ9HQB]70_/MRJ&-,!&7$Q0:-M&4B8AX0Q? O$O05D+6]/993QYR[O1YE^>D@=@8+"NR$?_S?@^-SB.8+D0-B$? MQ!SI'%+0&&B3W.9^9S@$2[_43!D.^)>!%'S2*P1/WWLN.1B@[#!W&P,DPW\Z-M&XMPM_'HA8[J0!7@=P?S7X&9&J N_F^WD7D:SU50V13ZV#5=K_/5C]]=4-88-M;[:DC]R)B\FADV((!2A@7OV&L-M*<(TL\"TLF6F@LF,$%(9DO[!6!HC,** [*4^$F\ZF=J((-LYYB-6&T-M/5XG>;L$:P3J,>21;2'F7Y-#!D>7%(XWPL[O%VT5 MK(B/8:D_WL[E>+N]S0Z%SD39]^I%7VHW9]PSP?ON:FL,\R:&-7X9F,6F9Q?' MJ%U<%PQCF%N7&Q69X*D0D?!Z_V=OCM!H&4XL"YTLX-$4#G;X-MGQ]^-VB3^"!51-&-X!- @$&9$E/'(Z@IA>ID(EF:$,%0L1V.U;&E[RWR@.DZ)-MLB%:&CX#4'[9CZ=)N%:0;,5R@6A2B"E(Q\H;4C'-$'[;!(-\I @F_DZX89",-M5&F[P)\9?/L"X?L5[^>GR;RZ_\RS5/_)1-]Y7>"G8H'JH6#(^>M[D7UY6Y#X MZ>:QTQ.T@340N/0B/G\CV7LOW2W-SPF:R'#8P$D.4$OH@BDN5KG>\J',S:VH-MMM6%UC, <0,=4XY+^DT3_$IK/VP:^V-BGOAW"C6VP;75,,AN\;0LIVP#QK@?Q-M4BK6RY6: ((/R#Y.W\@@UA2T8!2=1K8RJ^K)L6G>]1FTS3P^ZAA09K@'5CML>-M>:.@FD)?@@\-M[Y&]7C%YSI)@?CK"J7-" #D"!@@_Q:\D)7T";$88:%3:VM)8O,2C9L$S9J"/K6N2OQ-MURW3M-W3%O-V'/S#N]B':[-KO]\-LT;X65@-^X-? KS>H;K".&,8-#?X/B(-M6V0\B-ZKQ4$E/E_6DNM-;"F*ZN/DU4S"86#GXSDO#.,X^<@VG1ZKRTQYE(NM M8[J2[[/F(CX!/L(_S4=A+)X<-#"BBQZI$[T+DR/EG/!=^(U'VAKR&%([TRO0_^0+YP"K!HF;C*[D9L,G;G[]*R^O*? E[$9/.U_*-MMK*EXPKY&\:*T$$+M!H%Z,96QHB_,[]V3;[BI7Q#TK--6GM&1/ MP[&HIVXG2'V6'EESIKN3J&"7&JI*QCP+WB'[&!8Q.IDF7@-BN/^$CUY@^3;)-MH)6@@.,5-" [\.E,8([Q@$)YH/,9WB5M7VSH$FZP>&++7@,M!-_&3\?@.-@90U-M8\ND0R)2% 93=ZBH29,YOD_9+O0I1@Z3<.A3EH6[W[-&@ZW#QXLQY_B0]UQ3-MWN=O/JFVEML4BTVV%V*7DU0R7M-SLQ'_>JV-F XU6<'XKJG(=-R&'OBP?0L]-M*25B>G^T23\\ZFQFNHZ%BO$/R4X%WIC_&4NJA\@5((H?:)-!PA M,L9^K(/BA8CX0LDV7!H8:V"P,DL;GR^F>?Q8./DC9<+5DQU,?9U&\5'V+N=7-M&5W]XCE[]\MC<>IA8W*- =ASE"L+C:/.P9,4Y]WI%B!K-WOF]#9^3U9K=BR?#-M\UYHWIFMNYEVIS? %6@]W>UQNXFH]+GHZ.&0&"'+%"/(&CWRX.5MO5EF+FW>2-MTW@I).0VN3KQQSV- $YYQ8QE(L%PWR%A>H0,Q+$X-#6_=$;(BL7859,_10A8(-M$RL+JA.F<@VBM_&PRR&EWRARS-SP=T?)@G2? 6!2RZ40OMJB7-HE(/;(:1#Z'-M9TU6A?5#9A#+SP6>U85VA*LUUZD?O\/GG'@863!FFJX4M:"Z%Z/FE]+J2-'%-MUQ'3? IWN"=>RAY*J1GPQ:"."ZO?'XAP\H@V'1NZ#OVH"UA_LQ4799&L\C:]"-MZ7HNQC9ZR=88:? SZD^1HK13NQX1"I)@K1&*S=4).K[=]S#.39QQ"'^8]N)+D-MC^XNZ>^3\S]>E3[QC- ^BPSENB\B+,D^6F/ZLT"N;E61[XT$&LGHTR-MP_$<1YH|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

M0=6HA$86*2A51;R.6R=GYZSV<,*.V5T${>`MH92ZGG[S=E].MV?VXGA/8KR)3N1VY,
<$/T>0]&58QZ2LCXLE[;XOZ@W(YO:G^_%I=#=K93F0WZ&W8[`MK17KL5R+V_)[_)5]5R7(C[2F,>
[%Q^98SQ6DW$ROQ!_O,P6,M%R,OV'98V_2`M:SS:@1W^-GPP:JT5:X1*K=["KH?;
[59[<+|X@P\D@0SCQ$$"V=L0HM.H]@?A`MHK[-=93XN*P];N*%[N3'[T=D:$?
8<&B.O]"QN&^U8Y9#.>$SION78&F!>'ZA`M>+X<2UM&8^G44-8&;/BA;0X+4S4Y?%Q_$DO[IJ;]:_$AP49'6KNVJ,]M,[(9
M#._X7#OU42PM]1AKC1YYJ7]";"\LF3.&:H3N->6\8`M7Q;VWB"7,S>=GB7S$=9HV!-
WWNZ.%L/M8QD]!9JJFL/<].ZNJ_V?+A)`M9Z=%D]]DY%BO$ZYJU5)#EG*KUH_??!2+DL2)V5,[]]:>*\MOXCG)QB=IC_F)
M?_4JS:!\#8KX5-HN@9SL&1SX"UB7#CDI*AG*<|&\D_<[]*\KTO361&HL36W)
M+LWN_6"]U"NS2NM#O6*Q8D$N2KF%Q&YSA;1J&H/4N/*45\QUBHUM1=F&)/I*`M1MN]TW.-
C;UN)EX"N*]^Y,MUFHH$G:;"3E-O[#0E$&&(;%I4Y%^P:%F3?HB.I>S(%R_#!X!*9-,4:UR8^SGZ
M#$,9$TR"RR*1MO7@N1O'!L4(ZN?9[L16`MX\).I=D?:*Q%L\K]`-J"BJCL5U.X4`ML^+)-&V;LDH&@GJ#?
@<8()C$&^/QR6"N*O3B_+92&>0JVY3966T;]P-U?;[1`MY-D47A=EG4<(`M8N$'D?1;I@/6PR[_W%]!0^K]?:N?
WUX&+ZY!VD53[L4E;DX$`MA(B-2+1:P:X$TXO3<-UZ_.?=!.Y_><<^DTZ.-39B63,K-H3`<-'?8
M,=ZY:0%WAE_(0&6=]C4@$Y\%D1:.8_Y"]J559J`9^&=\WPV&JXGUU:F-`8!O
MWDL8W;&/!L[TX3*]=H:=,&47M80M1E@A-U[=;!+71U>PE[B^76$;]QY$:2?JC9!
M7GV(G;N^F36=KQ:=TG\3)K7D51'LH`MX?;I!5K<%1GYL9'<3=?[Y)U4G_!/O?>H'E1J6Q\;^)A`9<+F-=IU"+G@4/AP
MPO,O[/XX[U[HC0R8"8-\LL2QTB%WOE!I+OIL!:W+RF,&-9+9M^=.DUXW2#*A
M@U@'(T=CC+_!P+>V305C',18L4*J/]E&9F0G;&6>;O1R*%);-J1D5#.@C7D;;J`CJ`MSK3WR<\%F0#D%;WM83'<`D<-.W,
(!X3ZCGA(!QG'+CJ-U4_YOY@)V'M_+CH6`M\/:KFFDVU!//(>!X3'Z1FMF]'V,?Y5DF:,WE>R+?39&SZ\9#_2ZM3V1?NKSR
M\!13#GI1S'%/[J*^2CI@YI^?5G)M)Z>*6B_F%IWB;FP@KS@JFT]\)SFRB8C$M[<8-66Z/>.?)A!/IV=#,EKBJ*M067Q?
B".RX*"GYL"!0\8<'6.ZD7`M&Y'^D]I9E,((_^`GC3=!8#>18>=&V#.V]ADOP`$!'*APQ+MPA\`C:1\T>QW7`MM%W3-?
^+1LA:0^-XVNSX1=P88]1B.%S:C58_T5SG9*,[*N:SB<5]W#K%CJ-#
MCG])$L33[/CQ,=+0^ROVGNV4.ZT:>Q=>%5*I5Z?'$79=>Y2I*7DL3*GT]?<._J9UY]Y`MSU`X;BEUP[1L@2A1IWXC,\?
MD:M;$<+-UAK^L"'F3FY?RIL=4BPP;R-ND!NH`M\-$`D]8R1D5)-G6-N*-OO((*&N=QK![=05HZE`7CXTN"6+VT
M[T&HD(\U[`MO:>O03U*L(PD;(_ZA3(DSX%"C;`@'U/$I'E-?;"/(T&?''?CY9P-.?(XC2'9O`M(Q=+`?[TE-]Y),DUZ"'7'CA
/"G&G=M\OY')>06I6L'Q.TW_L__6!^QF7[\L\`MM#>@8\Q\W?IH[:YC1%)69C*P,$SP5-G"2@\,L8292MY:GK)"=E:G(HS\#
(XH`M-[JN$"[]4\2]T"Z[^>1V#WTGM\QADNM>U?$I.)U1`[$XT_SM41'FC(3#'_N6`M3%GW^G"OB==P'_!S#/O"1BKQ'T'
MNTN7YMMRR&V:[`MB2JA)WP8N]X$!!\H,>'C^"D[4\LQPW.]G3I=37!.)\],5ALS%Y[EZW(S;W*1^C--
M1G)1I[VZ5=K0.D+R9L0U6!^%K$^J1._0;/=<%N88X[*G39'_,#^C#NYY22V@`M6KH28U]DT\`A1E<77WVF^(?,D?CFZ-
KQP'D.8]5*#=77RW!G;O='H>)C?E(6`M9RW@.&>ZX@#&NG.Z290('&RR^1+T'16E>&MJ=Z,YU*C>M^J1O,S?
MSX#?:TU`M4HX1F`O_Y9:@[@P@Z/(-W)5LUB\472?G4?3"2?9"*\!F&B'PR$!S(Z@_H:T[`MJ*D;B^0*_D5?`%XW3Y<|>-
V4GF.AJ4=^-[A^14BI#^]O8(VQ7.W'1'2,@D`M<('4T$+#EC,T;,'/7MK8;$4&5B7=SG]X@=^B%B`:U`($M0#O.W7Z;
([=)]H'`MMM>VTVD;@AF-Z37PO&%4Y#F_1DC1UA>*55U:HD:BD7FVU*\8*.HY5_,5)>5KOQKI*3DW=]83X
M2)DW.#$>]Q\(6`CG02GUC3_W1"9`3VN7_&SPN$]YUIC2KA*-OK->
]OAO6DR2[8S>0SA+E(1A.F,6SI7$!A)=B=;!79CF\N'OU2PT'%V$=AE=RH-O&<&VHOF+5]CM]Z'25`MZC2YD!\?
H^W1O!`=U&:A7O6^6X4V^R=]5'68'Z?BI6.9-''&?;[1P.`3RB!2`M;ZX2[+;*3Y?BPS9OB%^.*BWE`QN?
%+OER67>]PR*8]S.^T]3@7M_1-9'6;C`M'Y%*R!0->02QY9&&K7+;:R_Y&E^B,W8*)G4AR^G]2/@HF>?EN1@O7L]W-
7K'`MFRUYK(>T/?"9^=TXKY.:!LIHYD,UDARSX>)=Z&Y2O6\,3:QI\&?[F$(Z]"&#`MLQ\?B)^A{@[.O(3?Y>N?
CN]H3I['7:@=%;3:73B7V;1X:5,2[Q0.,B%OD^?[`M"WO%60'83X#]W&#V<GUP_[?+G$^_5%TUC'6EP2Z]]<$HD1'G$_7M
MW?O?%JG2K(9D-E4=Y4)+-93O)`K3Z3!U/E+%[,<0CSH1N.7&I"Q\5W3\TT2(`M(56#\;]NF6N(P7Z=*>S@(/-K;8I;
[T6TPW.\+XB]7("=]>./MEFU6277:(W+`M\F,]\K@NMX:"X7N?EU;B=H6G,I22K>!_LP)!/Q':\WF5B8'F_S+-'Y/U`M(Z@Z?0
D-?M.(E'U/MLU^?KX86Y"'H?M1?VAA6$$[9_"STYN!C*:#X?1_1?
M_W#Q1>LKEI%VMXV19^0CTY+EQC[UF1QE*L=S65J8U,VW56[,GVG9YQ$]F`ML^^X-
F4%;EZ7GT;I"9_ZQ?.$"IAB#=5A%K9E&V36-;-&QEY1!)'*YR<<$K)7`M+QBF__I81*I)O-Y!(67\4$N8X2L9:BB`MIE/0.
<\,SCTONY2!2FRP-F>1I;@K%]VUN]_TATCU)\^Q&K)7.6.LZ)BI3I3`MHT]42^W8!]`V2;WT$?@+1IC>N/TJ7?5!TA"-
:TP%C!"Z@O4U@&>NNUN(4CYI/ZS=N:/2@J<$ND=8CCPE&.RBP0,EY4EDVBT@A`M+5\2&*[""("IWE6G[&6V'
M62"*!J(A8S*4!:?R3U3PFS$;VC*PX?I[%N`M;HCT%=LI&)O9B-=G++\&Y\;AE1NVJ*6ZH6F.W>93W2+*]][9J?
X*OC!Q>.1#6`M8IUMZAK;F5?K.M+JJ3X+5\8/KYP/XV9(BO?ZO8:VE@IB=C:+)%O#\)`]O#(_
MM*9*R)C*;">Y+4=:66G3J:2@*>WAE8GYHIX:Z16+%2)LLOC0$VO1%%QYM,[H
M@S+29O5))I>9U@2NIO)WM>P$7WFTS@973=VOK+:6R\R3Y7JL6."D4&K('Z_S`M495[N;0^7K/+3+.|'"TCL0/TQ-
\Y=&.`MHGEQ7HSV(^FYG5BEK7ZTO@BM4OC*Z.&51JU03@_"M1Z;B8RLL-AKY>>CUC!Z
M_'9VLD@.)7Y3R*%ILK[=FM)@.4MA=G-T942Y:U:X>2\RWZ[CG7C^?J&T);@R`M<7AEY6Y4MBI\+)(K%!
[$|'TI61U:ZV'\^)D/H55_4&VD.W.Y,Z]S2G>IKQ]2`MP\3QE6I2,'-F.U[/5=AL:Y#<-#`;F^`KCTXSU;N;9N>/[4AO6US-
:^'AW2)K`MM/"5ODZ>E^SF]71AM&Q"R`^K!,<-OLJ3.-^VLM*:K307C0?.:F4Z5NJXP=?I
MZR[:X.N(/3W=>A1\=53#C+EU$[37EPN3&X9`A4C9W,ZU0!K'D!*=$A;LL@'?`M$A;W64=U?$#=[$,HFQ@F:
[V!G$QU2L*6CUNM"X'\N2*IE/7T=#*`I=MZTKF`MVUT`/66\L]"]L]BI04Y)`0T3TH07IY3ZUV?U>]S/*R5MTEXH(2W:I=-
)]B29`MF9#HJ0BZB7ZY'_QK@]Q()R\2,@1%FEGH9K:21$S!MC3W"YJ%2;[92],T=W>C
MUQPGPUJ&NS#GA1S=N25Y_F7H_8[U(@=0=/_.4Z+<+1_YMQ]HSOM<`/K2'GW/`MU_`SQ_@X7:BY?X?
6!B8'FMH*I:;/II0ZAT%>[%XJC$P-FHQ_1"HI>\M&=\FD`MQ]FCY+Z7(XHO0?B__[&D%YS"%.N7(?P`$5)!
'K.KL.WT5AP+M=W+AQ_F^"#`M@[F^@\$$$PW.Y?K.A;N-<<&Y7.&Y<+?)0,)]3,GH/<#QK
M,ET;/*F18)P$M,ST=A6W@D.SPGV:P/#B]%"U!0@'5))]&84B<:_$FQ.N$T#`M+/D(+/E2L'G"?[X/F]N3KXG7BU=_^[D3/-
(?KW$,!.X,*-?^@;ADQI8=QF%5^'KJKR&#$_9962$\Q*`YSZ&NSWNA#J`MW43W]T$N"'\&R/1YR!3]9LC$OX>X]]?
HB")"^S4Z'VYA5T_.N7@W>7YEN_55`MC+V/(/[X[;T2I9_.EW&S2`\K%)],@4EO8<+LWIA:#WM*/N1Q\D?1Y"[.IQ95
MD45],UHW,CH?S9_N90UR_\69.-22!\7AAYO@-5&&Z;P]W#39RF#1>:C8XJ,N
M3H8\29A[#@*^.;_O#0+E3A*KDWY_V8MI:V&9-=G[J+[^8!`$)+';=L._WXG
M$7EE!/^6\LSW""Y<&1C>C^_16./G\CV20.7?+W^XWY=V_'EMQOU'\TI?KCW_
MNDE>IY=5,#1?"Q'>XQ[2Y)&//PI6A+6+F[92G([NY4D+Q`MUK87FE3FE2Z_4-O=:]NAK(?
1P$,9$'C@H7P/C5C1Z^:ZU(T]]`:9T*:XMGO%`MQ/T'4GC&&+
CL=,S>LMTXFX<;=\E(UWH4$(\BO'P<6NKK^Q1K&++X1?D7#C-`M+1A%^R;^Q$_31_^L3?^Y3IL_;,_/5?
=>7A8=08'Y^36T3=JA413MA:U`%="N`MEU`5<]LG)=0)X30N;G.QGJR'>LO[9*H^L\O#ACC!*\;J9_B&BQ_W;/XKH/&
MQM^K\/4JX@O?PE%(]2YAQQ,P3]$-!,T],=4&/L+`1QCX"#_2A?#94:DK`].3`MSL;/AM.WU_^]WL0[<9#U20/\64@(JI18P,?
N1CG]]A>)83/?2D9#2*_?"`MI<+R/M6N)Y`-G4^QXAB]82/'_?[?3W$,N$[`=?Z9!_2SX70-7.=R+M(+LIUL`MT1B5(MUD?
RYT9V)HU&_8926%V4]BQ^_(321^/!3OKZ_L36V>"_R30>>!:S5P`MK09NE]?EP_&8WTN:#1V3KT$P_NM2F9Z?
L,\K"/U]?&R_CDZ)*GLT6%>ZT61A`MWEB%:[7PO&PNH]#"'VO(D?CQ9(^`P,"?V6RZY])X)\0VS]-X>6X'BG-A\5%
MK]&XBXS[\Q+_V(>9'E@9Y6_"D>/@R8$N^A_2MO^X:/E+C1[XF,7Z#0EO1!],`M-
B)37J<&0LP"/W%J,DB%,5E/3(T@&C2=#D'&#G[,;.O(R7/%R/^ZL367.N2M.IN.HAH_F1>:R?M\:S"=31>I\X=\6>3G3B)_?
7Y?L/K+`M3(+=5]3F<%6O"#WM@G#A9_JP6T]7.RR:U]1NXS%=A(L"'88#_COP-HKU6NP]"9'#'+EQY'M]?S>_">NN9(;,.
MY`[2N4]/;#_-(6YVHXT-M,`<#0[F:\.\X?(?`O#]W,N3H`^UD[F'7F_39Q?Z`MFJN+[18;FQ/=\[BZ9Z=['L+W%

(OWIN/NM3PCDQ%||Q}$?#0&>)BF?^^+7A[D MW24&0#S9RR(<<1UDGI.(BQU.=?B?
O>$57O06!AI]QB_7T^7;E3,T(TR<7A,4 MHK,QA#%^\2]!60M;T]EE/'GKM1G^Y3G+ P,A\W@Z+\9WV< QQ$L85BB#V){
MPQ"=V_;G(;I?/C.CPSD82]-__7_VWK1)56W)'W[__Q3&[KY/G!-1VLSH.3=V MA"+.LU(.;PQ$0&12!A4__;,6X&S-
#E1M.V{O4U4BL%;.N3)_B:$).)U1!{^& M"R/0!$U>B51'B4M\1YC_\C'@_0#Q^I].G7D95-N
*/=SJ>5WHSU\VJ""*T^F+4N9E9)\'F3+'),34CW-JRT$ M.WUN>K7863VW1NF)P';)1:] -"JE:DL^-[V:KQ>-A;Z0^ZR7'<=*
*[SWIMT&K M*T^>/LK.%)=//KNJF&V@@I%5ZF;U[$S] C,96\YJU&!=>2!DD^-*H8ZD0^#,_MPZ?*
+Y9Q5BD]5;HX5XHN,UJYQE!P@Q!U-Q&Y7K1I?33=4L8RAK.KFRG/H])QK
M3F+)KKD58[I&M*,G>%X19?/S:2>%R8%H\)K!=:=&:D>+?8%\OGL3.KAPIEI*
*MN>'$XZA*Q6Y0.:5EK9KG)DV/)W)1(&L$PI;;0A'1I952G\ K3]9>JPC%)N[8 M'#>?*W2U0DV:L[4& M?2_@5'S7@TJN-*
R>'2(-9Z3.9]'>7_ M3@,ML>2#+M&C"YH@'H-&(TB75)Y#!J-(%V 'GMU1MV#+G?38X_YKQ&DRT./
M19,N#ST6D7G)GXYD_H01RJ_'#-]I!RXP%@U)$-]JHO0UQ^.^KKSNRAB?/8>X M+*?\O!&Y/Y-;/L(<;QL5'=Q"$^]I5+
[7W."'?3FQ+S]J[.;E9KA>686\)38O M#UB_AN7X43R ?Q<>B(X9>6=L$C&0D/31&>3%+$3$UGF/!E B>I@PEVCY#+)3
M?R9^\S4AD?;/JQG7LLXCC?"I#.+A$FK76DFX,*,5Z^BTA'#V'Q(=)1;=M^MTRSU:9 5-TIP3+U>#7)"_JS.EH"F:9^_::>*
*M<.Q*H P_2::_0YC_'F?,K_UZJ4GQYX7O-_3$_JPUOW6$^&/4]W5 S%NA!*:- M<78G?*
*R]K<+>1S,O+;8GDNEH^WRNKY89MPVEPP"M#GRCDM*7LYP77-W3!_JPU*
*M_S&R?'E7[%/"O!9[VGCIZ:3*TZVB))+%=G((.RHH".:(HLF',/\IN3'?'1-, M'=;B7PZQ_I$?BVI^[%[*_<\,O:\V@*
:+:,GM2_K^CK6R9#]|KJ N,5F?Q]2*
*,7&B%67C4&5+!7^&%3@H++IQ9S^PYN:6[N%C<,2IK8CPD(COZCAN,72@%GA/[_"Y&1!H M/*6NM1G#M56C-*
*G)P9)*K0M $/P>8O!:T]K=-&WS503LQ*TJ^S%$Z*Q(-6J!"CFUY[W\0EK_Q[0Y>"@ :(=IX6YJP1H M#-*
N#!\-6QB$P_+'X[@,PNW6V;4_;RPF7;XYRQD\J,AQR\0H ,T1LWQ8F M[#UH.W8%
](22%PTQF@0:VS0Y].R)8K!@$Y;%&,0#C)&)F)!3UQLOS7N&+CY*
M+F.@8J\@3$1?:E[#V/U^;W^!C=^BNV;6';I7ZK33:KPUG5?C$Z9NI9KG\'^; MC,D3M74RAU]?EQ3,BZ97<$KD\=7ML?
*I%ION)ON<3G28G%:MZ+*P/(?_R]A$ M;U6K9X)C*K6%VPGY3;4YS;>!%>BZ/&E+9+J9+0! MH2.>BC>6XB#)3Y_E*
*M%@;C;KHQD>$]3[=I*;9+N76G8+'S@I86^O*R:CMGT8^3JSQ2*DU$214]E!ET M1UB?*H8END'?,JL*
MMB1OV017GBRIQU:>A:FAVFP[+]94:]B-XYWF6>SE(M,HYCO@6]5:+]2DGK;.
*M3L.*E,,K2[0EZEQ+PQ$E(Z]%ABESJ0Z\\N3I8G60155O97+Y;)=MS55\(NC- MP(';6Q:Y,M1L5APYKX%*
3VI]N\IFD3JG6]6N ME<2>34IJ!KZ)8@#KG79>N2Z$A+\.9/0&8'9?BY^Q"?LNON3_WY&9> ML.I:, M^8-
*RT']]9V.+,GU]0.E77]V/'N"B-R?_1BP]LQ0MAJ)/X1BZ#&\"D/^[<"/*R9O^+^C__X=3!EIN<:2]V)YRUR"WW** MX8\?*
8DQKEHC]%7XUN&;SO:>8":)=<$&7&*_G=\?7^:8<-A,U>\-(C8O"Z>> MP/<"5T.4:'=FPC%G@JB*
%8Z\S<.AVP@SSJ8DA0-HX)^N.?%D-T9N]TLH/4,H M/47#!FP-
'=+T2K&'T,>!B\+/\V%^UOU06Z&2UT:D;)5$!">I]>=I5OMI9S/ MSY]KB6 K_$$P=0G.*
((.$JX!P!OS@*U6SOOKN!&/T_):M[AN25RB\R(B C;] M]1M_=6**9)GZ/D?Y]<268@>(WN*
G0U!FO/8$Z0OH;#O;T5$@,M) ' 73+1+D MA5CXTB$!@Q%2_N0;?_HBG/T"0I&)?
\GQX+OMS3\QY3%W,,\4OMTG1CON[\#V MQ0[PS/V-,0W_#;^#_GWPS&$^(;@%@2>H>R(QG\(P;E(@UX5C M?
#U(NP,N)I+Z,W$Q(T:(/Q>8/&J$0!++D0R2B0 DL@?ZA6,H1(\2?"S8>-4(MW?2'CA6)&"4>?E-$" %TTQ\Z "EJA
"ZZ>'!1H$2#]T4$4(\=%-4"($DB#]T M_,=U/'^,O_W)?MNM^H;3O-X70M'>LE;:&WRL]#:&)5 DY&&UG[K'#1GA@,:*
M=NP[H#ADMIO-5)7=MI&_I8, M>Q\HB@\P[!4KH;>%T)MJ5'Q8S!6%(F]W<[KKM*3-+9>V^7FIQN)C^I5_0[+*
M>=YSF31+SRN#%33DUK9O@;=9!Y[XIQ6#+ M4PSV$\+&GN^0EXB(TKGK@?!M%OE6?FWMI97SJ]'@H W'EET-RZ]*
*4;U'7VZ M1[SRA2*U'\/C-[W?R2//[CT@ESZ>IGB(UAY]R21HTAEWVFO2QL$$.BQGPE? M)IICK^=3M,WJ{V]*
*(:^F%D5Y!O!D_?'EUB-PW/*BJA"@$[$*P2.A\LV/J^X6 M[D0[_?(XW/H9AUMWBY.BS=[?*
^B@LSRN&#-0W,4V&Q@J\$F@+N>,=JS M1FEN< K10^;#N5:.5T:+NKZ=!D:GR,<16;1"SDCMVBVCT&AKD,>!VH.]?
*^[Q MV\&N !THQ)55/-B22PK^?X:=B9O.9BIQA_-:!:;>TAW*T-*OJMF/ON]>!X0! MC:-VT $1_@G((K1;Q)9 1W2*^CF9?*
SCXR&]]SYF)=PT@HSX[6;N]A$.8CM= M&)1,RUXA=6W<;7D+8ZO#G2$ M3M>546D9#$B\TG#$/^9X\=[L?N]-*
*",/JA]#?),;^@-"KW;G!=NELC2TGVWIW MEBV9F44X^? 4-/<'6/KO$SH_5$8$O*4(J(R/X25?7V482*:AVNU9DYMC';TR*
MG608<0H':=^_;YBC?I/Y_>'T.^R"P^AOTFE[P>$7BG$/85QXPJB-)C5$"$;*
MHN<+/3PN_V&'Y<$L)_F/(WOOM8(:+6;I#R.JH+",\43 M+\9FLAEC,:,1C"\WUBFNP!27RV"2[Q6S'7^D\$=^:N\%A?]\]
<#=UQH=X;]I MI^T+PI^C\2BK;(MKJ>'"ZX74S()%2'0_AOU5?\]W7
*M&AWAOVGC\PO"OTQGVT@OKSO_F"ERCZM3G<',JC4+#:;YZWC4>OGK-_!1 MD3,DA(-$_U*4OV-'0-*
JQ2C%3;\7@@^";Q[A$.P'LEZ;Q%EB6#Y1O_QN;6>9" M"0:. BF&MTCO9JOZWUV:KC:.&:83&XDQ3;0AO\ YOK?G$-
*MRABW>D /JPM^] MBJ'HKG[$"!_F(%TT>RWV6475\E2K90FEUNE-[D3]I&KE&]Z2&*IYA*:M+1=! M^5'ZU^]4*
CLCP(G8@=$X8V[\, (L&XWN.' M\GJ SRT ;XY7#$,"5#;'[SK?]>$1R@!_]K^'X'J.O,&X+TL<:8!KR\0B/B(
MAP.&1Z(A3("-4WT[9>]/% ;?T,]P U=QX8L#"?P@BT5K7/W]^=8M^NYS8W] MVSW%;'_4TY%D8@HU5_R#4>
MCN2&XXRO+(O['B ^Q+\ZL+J60KNYLKXP5$S36;-0MUJE]86LY<:/A'L%WA\0 MK@'\'7-
*\7M2T<<[*NTB98KMSZ:\JSS8W'G M/6T&;E]H[/@9-_[31&S:R:[D>]I >I56WU1Z=K*-?W[J^&O^__Z<\$\. MM[D>*
[O;FPN"[XDK07-]-A9$5V'=>"XBB.#[7@RO!ASR@M1^I@#>=NPI8E0<^ M78@&#P5RZ\QN_F0'T9ABA/?F 2_(X36 ?
*KK]#PS2P;UTQ?'!)10#RK@X-D!X M]K2+"('CZP)G$?BEDS49YKIB=!1-25) 4L*UC96 !\YIF4G M8OO8^4?9LF!2V=X -*
*D$3>0OF62Q'_'B-V:=&0D5#Z>,K: M_SN8'K=ERCB@H6G]LTGN[JTJG%J'^7I:%N/!<#I> @_^A]> /K+#5=*IQ+:6*
M\)]M?ACW61LX>1_8GL_P^TXV4N=7\7W=FQC%C11G&+W6 MP]?Q0R/ W*
RT,$!RMH:9_[U']9=X]7"KS^T@8'THQHKA!B;53T6/AI-:WZZR M6:3.Z5:U:R6Q9Y.2FD-X?*
*HKD)C]K_W^[X$(7>*8[=!:M:%L3TP-L)W- @WC M>#43A$# 8FFF#?1D!SPMHX%K?FU6H GF_#DW*WI&UQ*
MG'9>N2Y<:4P$-G &W@.8:?%B'+-/:7]FQAA "Y$ M#\-72=%\FV9/1$T"1F;O_>W-^T.K!,)E/=:.X[&_/,J[\4P(GB]!'!M-NF9
MS9T.7]EW:\/DC@WL>\R=^:D9\ ^L.+U"Y)VVAW5I2 XQ/WF);OW:-G!1@ / M6UX;>(]UR6?7/?=V;S=WS
*#OT,9#1W=D*K75LUAD+N\6V/2''5T? MQVQ_'609D!(\T<^.P]0)T%1B SA=B@-, 1)G*:MM[XOV'GHP_C>'-"^HATD*
S=4A"ZL FE_2'$BN&I#71M(M^R>C%GL"6,L>RH4)CRZ&$X?C6ZF>F#:6:F?U4D)L1U2@J:]!X?Y07M3!3NO MU@EA-*
*JNN(5U61F MN1;Y_/SQ5.*EU=DH7Y,F8Y[DVDL%S]$YK4_K,F#\CVJSM!]B^W0%H7O(=]?-*
ML&QHM7$A+T>KVE);V7V=6*IBQ[7:M87(U_&/YUA\6@$>UN&#P#L$FBB]X!4- M&FD@83G7 5XK5$R|
*(8C/O.:*YQ.79FTY2B:9)-=V:A&@&?[)U7P4_RH@%3&;$@ Q=P93&125#P@HT&?(JI MAKDTX*'6GM(;\2-OHT1=L(-/H?*
*8+=9^?M/"O!ZPQ"BH.]JP%3)O *-!7:K[V M@P)U7AO;^^KXWHGC5WU\WW6!7--P1^ OL8U.NKZ3'JV$]R=>=A>7I,Y9<*
%H M%!&H"VC%1W[^4P)R#-AD%NRZ&>YZD/?F8=H,/-=Q(5,!?@2$/Q]$UX,_M_[@]Y]
[_<$O6#3VW5P&FAH52&QL4EM6\MTCO,TXI<$)34-VGH%.Z^P5626R5 M>5L0#1ZX?
*MOZBH^7H#_.+O4N#7%HV.Q1MVL*U;2X'L60J'YN-Y M)=T;*
*(YAA)*V"FC14/>W/2Z&0)P0Y8]4#,D#:";ZM"C*H3T%N=6:)<\<+]H8INA#5VX(ZZY/,<$WL&&0W;>_:/QMEV7PG>L*
M6RV8?]D1&RPC6.YF$9?CE6F$V#CN!F0>&%]EGV6=LEJD/%4SCBM5/S1B?%T?(S9!_RB4;I)PH_K3U]@7_>
MRR6Q@+]WL0-@.\!W;;!SX;I.'J>[_8^_\IL%BPCC8:?7X[9,D.%:0^7=843 M^TZ7+*
*[%.79C+T6(V0I_D67145Y%YE\\A*5/)BBH\CJ>>DO3GF>V4-<[PV&*/ MQ; W6 S["2R&79S%;*E-4JXT7[&4-*
&@.O05CC90OV+YKL-BLIZ8=LY)5V')E MWLCR.4?(4_+E6 Q[D<7\T\E]+L/?X#)\RV7;4 +>PS%ET3\1W58QG%%]_I5G
M^/5I/V+Y 4R,7YR)D1D^;G!E-H?DE7K1Z+45KU"/F)ZTLGJU61E4"8YG1)+O M3<7\2$Y?CHGQ%Y@X$6-
Y$,KZMSJY$P@@7K/J?NT"S%.U9HE;:)2MEL065,J7>A%Z^1-07A YZ9%$C:!3I)[J> MO%;2;I-

C)@+)*CFK,&;|MA4,/VTT"E2D|S:U7@LS_A2:?:17[$,THRQWK7>G MV8+JL:K98_%.:]23 YI1J1.B!>+U6M(_-N$7L+H_)JY$2U" =@W(^7:QQF7) M$>4|_T>H>78=;+BW/GVW'VZS".A94G.KTKS-9*DNEU^/XD.SNHBO86X?22 (MY(_?L%J6>Y-4Y-SL;-G/-=&NVEE]2W@?, 6D_.N2/D2@KAN'7 M9 1-.;ORKW&86[1W!OTYSG?M5 MTK#)V'_(+KW5.9M-/6#F\/7?,?&GP95ZK=H@W>6Z);N2)X?.I)!NWG[BS]GF M> GL?-P3>>MP#A $,0&?6#9@V:/]/+MU1UN&?7'+TOGF;%0"$]KF)9U%R'Q[M,JQ$9PEXS])?\TC<_M#K!GF@*/2H+?QKZ!,<;@#W[CD;WS2Z&AR|&L0]XV&CJ6,K(O7M#X7>K;H(D M-40'[J0@BN-M#=])E1$($&#G&3"!8UB:!PC@E_)8G#<%79];K_?@. 7?O5R M6O;1//SJ8|EO3!R)FKG|^PG\;@N :(%7HIN0W")@*2VXX&FO1W%+].UC9KP7 MF#8OY@+F)0/NR(W;[:_*,:IL#3*>PH:$0]8\'Y0$^3H"4LP6C M.>?I[!1:UMA7OVX/N[7MLRASW6PY>N<'16|(_C_UCM^6#RSQ(5BNK;F^6%+8%OJ@F/"JF\?NRCT M13;,]|0MS(UVBN2>K(+=)4/27123#;&[JB*N*7:,TFR!EXDFQ(%F)X7&!">(R!78R M^$%S($F;I-)Y-@Y5GJ05N0@8Q2#&2/[&!@E5#J;L&>/(VQW+\/[9D!_SN," MC"> E9SI@=_TBD8HTCYM@7HO9ODW1YI)/I!F'D@SET6:>1U_Y0-H+=@U1.(R M[9%^\ZQOX8(>9#_XONEI/MMJ>923V$6=L<;&84^?S4J)37\X#6 Y1,US8]6^+ CV=^# #3MJ$IC'..= M.+AM'&(,B\X>"H;:?% V9M<;;8WY^L*Z7V7^_1>>J?:34$-TE0G>_O--[@X2! MU^\6$JSCR)&K=.,,CY)&!\F/QP:?PB7/[#6_T!WZ,823_4!B6>U/ZYC<%-AZ MUECPZ3BIN%;ZUV_\"<'(C_6%^F,0@L 2QAOM33'5%2/):Q&([G]]B4[6**X]M9;O]>JWXG),_G8C8[]1]N_*&3%NTR(R*(U:D5\7\/)W.]TM^M11QIAAC"W;X M5D/NQ_IPKY67/"78=4LKWDEOG$@-N7%WU.:8.O]<[A=S]-6-6+=/$5/CZ(PP M%^H\.\/SZ'C,9-$EE%04>5-23==Z75K/U-!MAI=!C M055*;5)85UE$)CY9^L'7S[*"MNZVFPUJK*JZU*1&C:8\5=V7R_4N>1IY\V/%DP*!JTDL/4@E2$7PWC?>3]IOLYW[J'=8\;NLA MH1L8P'B=R<^?UMQ>/IZ^KVIX>S>A,+Z27=D5<@2RCI[#V838Z,;8/QUS;?&D MML='/3HHU[F4/"^^KH<:8ONHRIM?+BN;.2IW++1F<4OE+Y_; M^06;2]Y7^ N>>,DAJ)Q@@E?UQP/.PI<.2N5-2_59D9_!S" 0Y[D+[N*7+?X$ M@7U'B1 /F7B3X9R%&<[9)L-YF-OR)T:(EKZK\SM)K9TI)GHIK;6YXZFE!Z*X ME^QZ(;0^SL5^KPC;?_OMRW_8C&^N.+Y1> .SIG)UH5<9<(H\ ;)>O9"-6 M_\--R\8ST^6Z;'QBU)MRPUZ2.6##J2<4_R Z&HRKC>.>M:OWKWPUS+HN"ZR6 MRP$W*0LV&Y\SW<)JT$!Z]?1'TVE?")\7XVXNNY)6!!L?4?CX>;Y*=]$7-UQ;X'P/1T M!H'I90?@ '!I\|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}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{}VW9F(5F?"&V'9VE9@7BQ#UQHDN#>%6@@F>$6LI4B.1*6'!"Q#IX@G M&J&N5.09/>FZ1V:3N]>RM7+S(-C@V^N8&Z"!/-9%7.3$O+W*YBCJE@_9(3! M(@P3?7?DC.X1:6*5'F1HCNUZ9$;2,$_R?-U#_OJ-H@DR]8KJ^7[!YK._3]_&

MOX^8IKQW$/BF".NHVSA-=U%2T7"' M#E749WRB2KD^FB2K,Q1A^$]F5O8JSJB;#F#S2")!O-9S]_-R/%=%'(A>!'K]
M_,[W:C.\.^3->6UD)C/5W!R55VI9&]LBMY:M9$\ MJ;%QK4NVL,4R0!>CD"<411_YG]OG?^XNIO=+$-U]Z?
*=WH&ZCHZ+A,7TI@;0L M.8-Y :G/U7F_ZY5)?+Y6C0VD60)_#1CQT5G]A;[079OU&>?LM.'ZTPV_)UV% MX*G_>]?*
*V[<*6YS\@+1=OW6;VFO=7D_F922MN2R+U=>M3*%94IE*\]=O)(&? M]FX#YM+_#T\QH-F%24RQ?;()(;U&D'I;2L.B?*
*Y\7K-U$0FP9"GF,#Z3^PVAQVO,>553R0AG*_G^&GBF5R-SSL,!BXT)F M,&;95D^4S]87?"CV&'+PG[.?=V[*!?-*
OS:825R+5D3;&=X3Y+Q^;6%"5_4^GSIPMM7F3<_T.="A]3-"";&_YF-]O7'F) M5P^W^MP.\KZ^&1(C&DO1Z'A(4Y@$?
*I/HX2A%(D!1$P1!$H24E$:_@J?R&R/? MX^OUY,1LKKFYW.5&>%VUSF,HB_&S*ML3;_-FET^#*
*MDWN2^EJO8(865_E4F9^L9'I1{C>'Q! YOK*2F?7Z^G V8N?IE&+;,G"3RO#< MZ^2>6C*;*CV3VK-
*E<7II)EDE8(+ARB-,5_B/$=E&5ZE[=9\":Y,'E^YK":U8:Z5&G'M9[;T MY+1LC2'3@/XG]TP7ZU*U5!@-
*U'H5E^<#D9"\9QE<21Y?:MR>K/>*K3 HDJR?(Y1"8Q-MM?YHJXR"HGLSS:-XIM!)Y*
MPWN>+@GO9(WGRFC25YDEB]EHR^ZTZ>4Y[E]X&:;2FLQ-M9W4S#(YK0XHOGF. MI].%NHX,+
*[&U2=XWLQU)%,MRL%YSN&5C4J*DY$UUV<]L^>E10=GUH5ED#4] MO))>\5)<*^@,|
^Q^F0D+U>"N]YLOAF%FT4YLR40-RV9C>I9'=*C.![;A=_M9-$WN!V:8,Z?<[.BQ]5-H^$VLS:QDN0AO!0/?
*$_P#>"W.6]=35S+>$0 X"7F M(Z#<'N;%?VRKS86>.V%W"ZVZN^ZR=2L]B3-TH:>*Z;O O?#EM*V-R5:2:_>' M]5K:FW3*
*[7O!O3"BY0"?/2:&H8CMXP$#HMBN!B(LQP:!W4($#K]H!% O@*XG
*MT1J,S.S84G$F,0>\31CTA2Y_(H@8/XHKX]\31L$H_>\#7N;GP,ND7L6)?W29 MWZ?]'TN@#UB&"-(%Q1(8^2!,]
CS$)AHTN6!+Q-1NCSP92&+_.Z(_83\67> MTME1Z^Z[-K[,6[[%#^L???#-
GXYOXB9H_J$DMDH,#5'+2#Z&NE,Z<5BMAY_TU8C9&TI3;.0 M&K$,=#-*
*<$['+4,H&92Y!.:HJ_1:A1),8M0J]'/[23Z3HKF'E S'U8U/Z!C MB.(P.8?
*5^RO6I6KM'#9!B:3:#"%GD@DZ>='VZGM'G[G-.+QOX_-'3&G>/#WW M_6%EWEE@&3T'9BLLKR#,D"K19)D^TN%
*<*6DF>X.9.J;"BF0*?Z*3IRV'EX"8 M^2-E[XV*C1^YYK>J(7Z*XW)7A1,--R94-R[8LL\X,ID4VD0[,F^)U"?]VG,A
*MD^P54W+0\0 <&?2RV'D1S-1<#$XOD@'B#?(P40:J>G@]D0'56Y6Z\T&\D$<0 M4>XG4[U,IK4DTP%
*#$H_H:E337,YER=B4AFAM,V]I?=6RNM=*#'14EX/%^K; MH.W9+E8F%-8$&\VB)%W-D45%7 8 ,A@&9.]'I8-
*N!*UW_VCUXM[33*DNCEJ MWK%V&7;)',U,<%8DF3K9&F"+L?%-IR?T*^FII=;=)D)Y/;+>[>%EI@.Q%*!S
*M1#QAZ%6F)]Q?P**!./R#W53G1<&B^=+158H;Y;(8H9]1X9YR? MMR1D5<+20!?!C!"=0!YH>#\-#2_
5SC!3(L40MZ')1&)%% >L@>49[&EON2N M"BY+F<,G@V6*-F2?_TFZ2>@DD^DZW88>9%"3MDC'L3K^V?L6A %
*[V)*U/_G M.=B2(/!#]VB4:9&J5T:+2+?0U\9E7,%J9# MD>JQ"C/59A5;T$S;M380,J^MW'YIZ:>8,?UUJJ$C+;6 >-75
MI&CU3;4 Q?HV$"[.Q!)%'V_FO6 N_L6P ";VEV [YNN#?YB M__T >8D0R M.)8@'RL>_"Q!)9ZT""5Z=$$?\A)-NB")U-
\)X$P1+XJUV/ M#[K<39&].B'M09?[*3+B09CH$>;AD463+D"1/>0EBG1!$LF'1Q9!PCP4633I M
*A390UZB2!>@R!ZN<@0)0SP,S#7I\L%:NC=3R7\"L,_KEO6N.W QP!7RLX K M&)U J9\$N)
*(S0QB2W0G96R=C%P/[>7#::]M#)5(GE6D_AM/>/^#YHYCDA_$(_EW< ME6_$(W G?
*A237$Z1/)ADPR3XC_)>+ZA)KNZ0WH!)/N=Z1JSM.B\:HL5K?I4G M/]850[$=RT^374P51&S%=^FOBA[A+])1%51K?7-
*\P \W;6S+UHE7*_^+AF#J M(KB[XY>>5TPAJ$;?[P,(Q2]MC-,'PL<&==MA/T"FTR[/VWA>8;MN3JVU!U;Q
*MUSOH[(CC7VZRVO9EX+NVITJE5RBG[!Q;KO3%.)^:8N82SBC&?_TF7^O?_F(4 M$C%1N8O&H"*W#9?2&,1#8^#
[&@._@L9P2+VF 5TB^'E5$93C,_;A3Y/<7SGN:L.5+???UY>7V7DV]ALS@UR:R3/.GT-*\N5&2(# ME9'Z]3OU&F;P0V-
*V/X8L(J8L+R:9T1N5/3 M-Y?:$FV1MX2)GZ@:BPM1,V>0?6/?(6,=3>5/WS4W?4.@L3!+%6%8PY/%OQN3 M]0XYJXTH
*NN0W0GBH6FH5K"E./2.#3Y;U5/L*I@'L)KC5&1LAXTXE MY1FFA+15LYMN=J<%=0J'4>"_?E/T*:+
(97!5KWR$'DT]X7,]XMZI%:8+H55OF=R3-F.IS!) M'A8:,;!ZF-!"3L/3R^B1/](?B8!LW4J/)!_^R.726^_1(I)--77-2\J(2,Y3
*MX&K9+66OD]_48^D5QD*T;/JA,O7F:21JV1YF8#^2 KX(\2U_)$_4H]$0+9N
*MID]3(JK&N,%BKEF*9GCG/KCLU%^'DZV>\S-84_*_5'7'EIB[F MY[P[;%1EZ(-!,.2K),DCUC)P_>Q6Q')[/I9F["U@O\=IR-
*6+M.Z.%WV_*]Z[M+STB/NKYG%D[71B43,M>(75MW&UY"W.E$[?,<0GH,U=*SC 2T6VNGAOI'$-2
*MRR'IY]C.3"F[7([KH2U>*M"ZN\CV^4;E'!J2]HBS]:ZSN:,?7>68RVNGH2S#*E?OPGR45UQ^WJLNXO)_0]V
M[K[TB/@3'X,[OYD_,2P8!5YPTQHK(JUYG2EK?'>!+HB]>LW25QK_/)#6[Q6 MBW5WD;E?L=;=EQX-?^)\9]NF]O/.\YQ)
*(EYYW!@N:F6>,V_@3\CF"BM+)IE7 MXS66P+FEA_2Q-- 1?NU5\C21_:B].I>=VLP#^E;S$^XSO*ANQ-(S2]%B*/84
*M.QW[8XEC5Q#',3BN9VE:*F!Y08R-O/.#7-Z2SIEKB<,U1U5*]:0W0N+D>)I: M*:0^?7%$*,S!;HWY[A<-UTB6L;
*(Z.\]95LDE]]UJ>?G9L5C^N!A7<%P+\'C: M&+>"R47^>!U_?
EY=:H3893:K;IBP(^#$2[@7]CXNY7E.+8WTV68Q1NK)=\$ M2ZTBG9G RW4ME?[U.WG:W05GY,
;;6;O6+M:G"6CC\6Q!\Q$@Y=]\?H^'Z& M(@$Q-YR8X;\D_+OI.C;<;#C&Y(6A2[#"+QC;_2$S6OP:S/PBV*Z-J"D8@BN
M9;UCOE/B7A-@N_"G_]1'/ EX=_/R]R-7E]Y^=U__=Z,@HKYLXIB#=<2)F#7 M8PV--P";W/1%3_9YOW,[ZML,1%-6H
*T@,##@5>2)%I[TZS U5=3>Y\-8=ZC]?218N[F MC\&%;U@.UX#M4EV=#H<5 M!.FV!LUEN3/'I-TF)_09[
D'_9=J/A_XC^^S><@+;5?:;E^%_-ETVMSY(H^-:O!#OGRO-OSD>O ';5M-R#<5@4D
*M8D7#!X]#KA#Z=%9E^!=.@$($YC-P@Q9PY)T1 [MAC/VJ>4! 9T-X\#.PJ9:X MT4 [8[WW0N%;PC?RIVB-WNU2?8
*#MMJ%"K0+NJ]=T"''55;3?CS3YABSE$5J MTU%*UI9WY((*S<2JVXF 94#8&<'7(8[KE/ M<3Y\TA.4Q@WY\?
*N1'PY7%4$H!BZ\"2<<1;^-13=>J.0+.1>,RI2!I]$L]MKTE.E59SV*ZK77%4:(RHNH,LE MV%[J51U\MX ATGZKG_I
*D6WBXXV1O%?4!9_U.3_(J5!]%GW+FW5WOF7 ?R]Z MI?991B21N%@A4 WCRG&A1!;37-];58BZ MC_EI5EF,!^#ZO 0>_
*^O+7G/#E=)IQ+XIB#UGVU^'@\42 (G_Q/;^QENQ\E> MPC&K>SMV,$8U_-KA)-7-'|_^0\)XYBS?S T >>Z@O
*Q'BZ,0!,T>252'>E1 M?$>8__*QB05%\'Z=>;E#)(!)4T[$D.__3K=\=G:Z"-&=.?3&MO30._/PS@
*M)5X]W.IS.\C{(CCDDTF$(L;C88KFQ2$!I&XXHH'&0'$$ET1,&B/4Z%?P5'YS M4- Q>KTQRW9KK-
*<:9=KXHJC+;1EHW5KUL%=>+G+? :=CX31Q?F29L?5V:,#2+]5&ST3.>R\8"(E>= MW+-IE0FM-
,G76&RQDC+KN=.SU["T%CN^4G=J4L'2,)92:94O%#%ZM:AV!68)KB2/K\P0="6%-[(%1!F!G5@/AO5Z!UYYLB*M
M,1>'HSZ-((I0%L3HH MELTA??ITIN\@7G*AHJIH3N9S:^3FR%9ZF#R]LM_T
*MUI52I5=$='7LUN5,SEE69'#E9NU'2GHSPEL3S/ES;E;TN+II--QFUB96DCR$ MEQ(7D_#3C.D+>H*V=Z\EL56%'FQ\>?
*I<-BY!Y7=,EA!C-\N83O>_+U#S9]@ MWFP&/ 1H/ A--NH H$'W0)8)T>2BR:!+FH42%#8@S!7(\P'NXG?
*MC%Q^YH2QUW7#=QCG<3V!=>6D_T<$X1)S'1\LKVV>?P[W>")OV7]?PDQ'#-^JO@?4P_LMGUE1\%'PPWIZ=%=/CU],
*M6"*V"9>;U1 :W1\RDO33J!X8/M1F-7M9[% #KLO$5X6ERQ62_:]TF&J\;6_[M6NI6"ZYRCWN/&TH[PG#)&[-
*>OK^HL'QQ.1HQ7%]KNQ#H$OOUFW@BDNA3DKK2 MY.$(,OD]T"[AH4/MNB8)8_0LRSRD(9BSY292CH1D?
*(%.CI=,52=8,D]2&K MJL?04)\0](] X)T5\XWOYGMMVP_M\%,;/2/[^FCYK&$$27)MLKMBD ;J#$L0 M$)O\]1M-X,0?
*(_:7LVVA3Q=QIO] >Z6/-K/'R8S$D5QRZ<79.9'D5SG$:Y?I M] 'SQFU1^&?L6M ?/&B\/,NWFZ1@F [,-
*D(]_A$AV*5=R'O*U,GBW@V1'CVXEU>$ M,[0B6S[]_+>7R(]+5\0Q\$![O$\N[/G9?V<2).J1^1>/)AW2YH_":VO!NDE'[D
*M1-#OZ$&$K/R&_U"FJ8Y>G--EEM*YFH5-S"51EXI7!"I$4 MD BEH^XM2 \]3PD9EAFKGERE#K M7E>>/0_Y6HM(
*PZ'F3$L0?^HS-CIF>P+ ^&:/X.W-BJ>?,D\L2EB_'S^)E4LZ
MZW0]/L51;$6@U<$SCXH0V1'XOA3RE"+1)P2YXIG,'^GHWEL.;G4>^]UWM]_M_;C$W^-
*(MIMCZ'D1:XVY^FKL(L7^8-8I027@>ZG8%;W4GV'>SM7419W=OY\# MNF57JET2LTS=5M1XVW2+F=IPR3I-
*P*Z!RYE*ON%R;F8_WF>S,W, M8+B@P-L33;3MF!BJEST@8/MP(.12T31_4(T8,\"+[,8K'8Y1.MB'_7!.\O\/ M/+QH0+8TQ$
=+Q5GR.35.2H8J^H//PF'$?HS4#0/;JOS7XPM13@OQ1W9XMP%/?!D;M; M_E(VPWFA:8;Z+@?V-M:.H[&_<@IX2LU,Q'
O69A&#$&9XBY;7+&H,FV1X,)0UE0Z/@S".2?,)2YV+Y"[WL.?!
*M;5XPV@W@"0,W$DXRKOQ79#IJ_%%V186DA<0.GAJU6G6WQ6 M%EQ;RJ[BA-%[3GM?F'_UT2R.3W1+7G'/61P1D?
*R$EQA2S>6::?DUK?:"G?*U MC27.8/0XCDF6J0V_E__A60#?[W>H'S;Y7]WL9\Y%[,=]'MGQ58GB"

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

D^FR?5--6 &596X*!HYM=V![>WS;8=)L@ M.5[&M_M,?/7M,-%G[& -'3L>-ZI?2+1SVF7&.JLEDL_#WY?WKA/8#>AMQ>
(S]1+8'G:SG:ZZ&W)!&GI6APOL\ 7C[)O>[6E74O^Z]9M?G_7\Z8_\)|<]O]R[M[-
QHOWHQ#ISU#.V#'K@30W47V\R"%IN,%"\$)=*75T"'A9 7.S_ZV=NST967 MOSP\N3P.@K/],Y9^R>EF O[#?
SI#9TRJ!2!O7V&%3I=O3S_E!KM.R#N_M? MCM7^[(X>#BOGS\^@7-4Y.[O^?#S(?[H+1FZV6FD$A]AX"I1%I9QKI
QJ"YU\ M4\JB;GH:@-I7 $F,Y]<2M^,BM\DD7Q=[W1Q>NJP!/PQ<8LE'6QG5C3K*2^^_)4)6O&7?J_V83VVGFOP//-
[F3!9F=N[43U]?T37BMTU63.*\.!9 >*:XO4=U\^2'U5\ MJ;J&HGI ?A:F1GZ0SSC?
M'MB)#+9,L_S#"-.SL>FRNZ#GVMRA2A[!>_=LQSM MCA-PY_9N_UX]5+|<&.UL\^)SZ:#^HUO5Q^\4
VA]"._PW:V^S[0,3G[E\9?:]2[\;KJ4=1W7A<)ST7M;5."B]EXV\ MEWRN^D;[U[S(Q?
RA/_%1N;+BZLFE8(!_KZF8/9BH6GPS*\;6X$'X)E/ M^V@5\=(44?\#BGA>]K3%0'D::]B
,6@R+'X8JJL8U)EHW]",08%@%E%2F'G!-L8D18/NJJ,Q'_/([QA[W[%S@B1/4(
MBS"#97[:/3#1H_B#8M13J8FCXO=A1ZLY5MT('^3"M^02;VQL[\XIK.VV1F^X'Q%?9S-<9Y'*RSX@Q6IHW/
M/WV_;]Y\NFMUCM3>E[+VD/UZ?ENB.=JU144=;T>KJVZS5K=AQ+^)8%B=89NJ M;FOD=DC+5V-G!I,K 2"'C?
[Q_EWQR]>Q%TP:[4;AG#4DJ.4734M[I?I:+=77 MME1?6S6O2AG3"S&FOFO,JG(KEMN-RL_SR^+=H-C[;?
V^OWWXD>5%M<5J(]6_ MX.+JJ?Z5ZE^I_K4-;.["68YS+X,LNV+BXKOMM5?^>SY9'AW>UENLOJQXC-8
MF>O$YJN^X1IJUS?<5,GZ&QZUOBZ2?P83(GT@'8>ERV4MTS8^!.A%QK\^)K]F M068ZRXM&%M<-
SY1#!D83N0*Q27,T2QG\]2MK3RX;O7J]V!H'OP?'X\OZ"1_J M77H&.W7#](KQU>M5-
=+=;U4U]MT3C;+R?;K[+A6_596\^KER?T/K>96+V_'MMW72\3*-PJ**B^W3\A!0RM U/_"
(,E*M(*I.3=6^5.U+U;XEF.44@)6=5\0M MKVW!$ R]_;#!H\T!_FM6P^1&L]AV#]KE=O$H7_5^&G[Q=*]YVT#66BO
M69NBI5"\8_>_4M%VUB/WF*%R5Z(I^HRN!H']2P(MJB0;,FN=;KFLE\]WA4I'ORT7"OIMHZR"O.JJY4JG"O]CY-
^QM[)?'/G&H'BB MVH MS%L!6GC@>; \",>FK5H3S_2<[@'_T0MQJ463F'#'2C&G1)NFUE:UCYX2 M;5Z!W2MB^PCW
Q,.I)FJA3>@$_SHF0O#"RR?'N'RU[&]<,S3&ICR9HF+1P:2 MCT%]RAX[SAW:(J!/^0R)4OB)G9GS2R;?_?
O#";#_1&#I"O!I7<'![JSK!()3 MCR.S*B$S-K7HA@BMQ1#:C1#:"1$:*S'AL5^!S13AL>GW$ZMXX>W1,K@7XB^&
MKMB.;^ 2V#,#_FE8GC'&L"VK[X0M 28,0%9DSW/*Z;Q%^^K(4#J&8:,?<*BZ ML!#\7-4TD$'PM,'V=)V[S"F?
FLVSG'*U%#10XU--&]MU,&RT.#9*K\:5::N& M,C!4:I\,T+DT"!8\;Z;6Q,_P$?A<]]I:CY^6FB42AEL"0+J.B7?[.!SB%3%
M_,?XX_1AX>,N;3+^AD)[QAO:#UI?M7N&]*KRW%?)#XL794#O14-G$9Z!H:?U MJ:V) YJ #7#7L9\XK-Z94 MI3_$"?,
(3;U)!C=;,(3R3X2\2WW0,RS1&4Q]K MB,7)#PV@B,&,-8R'(4 F^6G/4:WD9R8*RZEU\8K%?2N^D_QZH$Z2'PTMU9[Z
MS$%!;$Z_%/ 3X#.UOZ'K_)JQ;4; R4_'IC6U[A@?%)\A?G@FMC;T(O M@JWK 2"8#C=G.4/\(7[6<]5!^$9: G"MY0R
24Y"F"C01>L4$!Y>_7\1J1/4(,Z]&;@=D@V]YW@YZRPP%^]'4_HL?AT.)- M]!F# \7*<*<_1BAVD*/(;X:G7&
<$%CUB'6U30%2#WY@Z0!K@*%T*P$0S7%O M-$0U#A]7'2+QRU!ZGLYI6E9B]A@R_%
MV]8=+2!"6.U(!0Q%U17@$GCX-9X']ZF@!'"Z;+=C[)@$ M6([_A9_%+H5T-ZFK 6+V[^!IGPZ 2>:6.X"->-)
F(,MH62@KGRFD!O K)-6>81L26P22=226";J2P1AO MWP :<2RGA[W7D!.XC-19C,X/!D *.06/80Z0,:C:?6#"BV?X
MN>=RP4FY)R^#?\C]A^;0P(BP@JI]X+H (2O",X3XV 'T^#TFI>*%<2 M\B3Q9$ O1""'!>ZL'\01'"*P9@2CA4R#@R(
!P\4'1("]D"HT=ESDZA8(O^BN MP1KQ33_P97TNU*Y0MP$EX!!L,^6KT%Q..(FTR$48ZB^MTT/!V6%+XD-IA=_(M4
YP2X>!KX&AXP$YMH@\D@M&3T6_1)BPC8Q!'BFMOFGI /:0? \=;XB61+A(M]+!89)4HN+WL_'.E,"9F#:-U MX ?
@NZR[XG>UQE.0*!^"40?I7-P %VHAI M^P+A,E..T40'CMU!Y4O#"#UH,DB2'IFSR"9UYH=@>A:\3T/*Z8/%:1L&*)X9
M$A1D;X+=;PS]2+,$.@$; '9O663Y@YH$AQ=[,AY U_5BP,*X(SS> 9:9M!MX
M$(B:>*I*S\&M<86<>14"6P6*1,UNIJ="=TB_YNHR::Z]CE36C+*;0TQ3#43GJW')
MQ*%X9.0OLH[>_[XMH]1Q>$AXQ2D\6*$T!,_MW!2JP*3[1,J$XL.+#!)+K?UB7MDYV0_#"'8S^B/'$'-R.-#9V9[MS2E-8
"8&_V#(LJ]!&@GV$S@G/4Q,:N0 MP"?%&P*%.2YSO4H0W&GQYZX8VO6-
]B\.2.RL3"RII8D&:6/#$Q(*7D4X84W!0P4"M@S$X/1!*=4:X99>F?84+%^1,2I,2 MQ
"REPX(,VX]"TDW"85$_(P$A*V'9!=3E+MU2D!P-6=Q9J [!&9*?U;IX>2 MV#\Z+I0N_M__-LJ5CT4N_@M,-
@B;,#//A2+Y'O#%*CJQAW!HST2.^Z",3!=D MDC\9XN6*NSJ_)8MA+<%MIUC37Q06MC#;
/UW9BB9]A];LL:0@\E3&";#6UN M$IED2,-WH4BEG?:!\K(J5X6="N4(3#L78T7"=72UI)1%Z(7*1V$IB0O'KI>J MQ5T
HA>*(SVQYR&]F^)*8NNAF 48="A,@VGX.KW>_G)BLR^8O ,M:*GMD]YF M X-
P/0[%IJ5VU(&*=+=GNAC4ZZN#\+JNFWOA987'KB^G]%0KM4JMN@M[P$) MZ\S30*?NFZZNW > 3N@Z[0*Q%QJ$:
[T0ZW&RU$Y3)A!+Y=5^.!H8(:#N MF';H1>$WAB#FIQ"#]5B4W42K"FP8EWD(X*[HL4;XV!*()E/3_T?^AB%YV=&?
MW'4IY#-1>I;I=,"* RU##0']:>\DEH$@H2P\";;0!!]_27^=LJ$^!C2QF7%2 MJ&=F88JJX*ILB Q+N_"XXDBV) HD%3X@!3?
TKKE^%QBG0U3 MQ3N$4R^TM<4Z/#0?)N+ !T,,5EN6H\7|>:&;#4THD2I#CB6V,SI3^$["2"JS M$9JWY#?D*Q*V
@]O[1>*)3 UZ-\E9>>P?5$4_RS#UY>%W8@(*LK.V66KN2LE M%: &#TLRHABC$R_IP4BZ+V9*&+
<'V;>*A027OC@#IKN M62;2#1$F(1>*K!=\=>SLH:/W[N"VCB>#81^Y#X55^JX#O)Q_J)$T/C:".V-@
MJKOK#$AO^.T=\=P"TP7#-";,BF6BWDC4J[+?O0W6FM/-"FD]8)HJHQHAWUP0 MF:[.3%O)\V^.L',
%_1%!7UCEI$%"SLI\V>*JIN3G'+&?7114IZ7B:1J#^QV M/=H),B^'Y!!X9' M"H)M311T2H'BIPP<'104D33$PP">'^CD+_
=4$9S0"AR.,0&%57 %I^D8*0K MPD$&I@&9#JFIXE9(%=XSF3/.4XZY_U7V7@FAOW<<^<58CE1.V6<*G\@;"^4$
M]QUY)+M0F(EK 'TET(3]9>RXE&"GH8CP--?LH-X'?)H+%!8@D6-9<%#,\B'I
MM31^"76J.@_3^',FN9C*.>4R2OJ),I,PXN[1OEBV(N-P7U1LA+JB"A6)BC.
M1P!%O*,19MYXLON771_")IZNQG]$SZKZB"P()J+AOE X3474)('_>NS&)AJ, MYO*LRK!=4$?$1;(4)]VQ\-]6*#4 (=!
V@.4*MB;JRD#^^*$A]LOQ_F@UE" M6^9OX?DG+#5NH(P)N<4CQ(4PB]C4 DRU#-^^9P3]ETF#'0BKP@H
H.BH#^QT/S6@*(P'/,[&*@=Y':Z\: .#+A& MS[&?6]>CCW!T@>U_*%773ET4)<'X6$A)D1F"F^8@T%@D["G 9EQ_6[(F $4
M#Z,*%P8FL+GD,66I/&C?-9FTT'D$.?(S7IPTKT)YS70A)L^Y8P5UJ)GR<(XC M@$)NS'4+[T?E"4CRX#@39?
1&,LH%4IPY[T!.8%!E0(05(,)4,A@! MXW(43_,4 P!EDM"%/>!!8@=_C8;ESC))S),D\ P9IC5-
,FB8@NPU\!"8V3BX$]FUTCBX$?>*?-RSZHPX'C1F4N&6X7JW[84@;^%U4=&_,KP@,8*.:1 M&HV27@=$_&5P
9.%"8N8O(*SQ/#!.996\I- X.K&6B) M2^@Q$.BA"O00UI5(R(D49P_X(6A=MM$U6?8B*EPZ2QTQIG)^(E>$RC,#2?&7
M],4P>SR6U:W3Q=)W/'RG[$F9FB'Z[D=G(ZGL\3-@BFB86XX)_:AZP3>H:N&^
M*%V21_%0FP_L4'5F;&R_204O8\H&Q2Y!CHCY42:3X'KX"3 RQ^+HVT&-SD:M M&0EF0,6 /(\
X>2:!H&7@X5!*$SH[QNJ!>_F*=[\U[0LB,-N%_V@4M-[&D2NDSX>XM0HT/I5L+?R10+^7N3DJ\HB*NGV7Y<
M+GQ&J3A#9!,ML;('G7'1*,\@H9G]IRB+\3ERFCO@^\Z8M-2I(#6A?!V NHCI@(@O::J5HS?O/MTYGT*[((1!;1
M[!]$C^>44Y9)15P_A$O< FA=P!H#IA"3?!R8K.80;[!4 "&&@V&X=@P W,IL M@&J:#9!F VQT-
@!9'$[/>TU\7&;L,/2V21B5^ M3R8_.3K9)R74B,ML0ZY8)B,^9@X"E#N1L! .@D0"6*I@A(;G)-(O6(T@-SDC M9[*)@462?
U2OC2C$58RY*3*@=#!W)Z*+%,^QY'B.QN,YEA3/L7@\!\. @)=9 MBACE\X5,6"" !
(/=K;CHUD.RQD6WKPIK8F70%N359SO.$QG8,'0;#!4+L5) M0Z(^0]48[$UXYU6,V-AZZ'3/P$:U"'?&M=
P2::8GG$5G($BGSW=NUP*$AC8 M8*"(>?:Z@4MV0V1\QR.S0GF<513E.1;W=L]PUH I:Z%%*\K2>(<(7IO1P?A*
MPA[$TC8L.>6A&S0G%N8&_[NT0/>EH#CW6JAH3.#6 5929M9R;JC93B<\NFFS
M#5%1+5T9CSM(A>=L#72:V3S'A172('R3/FM1?QUWFD6M#W0>>*BD#&FZ)./Q MH'-#V6G-
S)V1"RLFDJ"K@\@1B5S?*)'K2HH\GX0I5WN43N)U&FKPW&=1TA?F-_J'7YA^T9A*1E)%&"+P8O$V51!7
M!IN]V%F@8L/*$%<'#4AW!G P$+1R?(6Q?G$;#99VL2C[B',R:*<(N6(M=Q682B"C-R8"=-
S9'+H<9#218B!A+F&8"K,H.W!1'N"B,THGPJRJ@1 M-7I N"@A'Y3'XV JMF#5L]1?I^^XP,O'K H_>B.Y1:?4.E#
+-04\1,L8F-J M)2<$-58! <*"-$0I_ _<"MZ?;+HAYZS+R6KXHHP4IJ8Z/K]/#E_!D_%V2*W6Q (;RFZD.F6Q+TK?
Y'ME,3*6&*@'Q,&CWX#FWKK:%8Y 5\629Y?' MXN"K;[N)HT:[7A3#CF+0D3B<$8V6;BT KFXQ]QNZ*%FYH3WA\GIFX>

(LX1@\ M=_1C&V3!XQDV,[HM7%$*&M$ UYVP1EEDQNU\PA8 5['.$!"(W/D,':P^\S] M)M>1B3V,%-$H"TZ4Z4D]$28S4@LR(MU4]'1!HBG41$I>$?[<">,_L<8!O))/ M9_+GTL^!1CZK[OM"%.U-%8"+WPC/6I0(6,@O]}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|:UKR[NAA_0!,OY+1Z+<".+]@,.!+X'D.F4B^HAGDJ4PL[G\0&7DBN3 MQ*,>0C<*HFTC")Z;J-7WF4N!=9C=/Y):-4=<[3+6OB)9\BB"5_&8QP9 MO-*!R9T:T8R-J%4N=ONDI8T%K\PI+>;+F$$D,N1"I)[IRA"M1*4A&XDKY3K^ MG'-/R6G^2$NL&Y7\F3112>IVNIAD7T\5^6)-_IMC =O#:_|:1A^I.6C4/A*@ M<^"X!B;EL(1,4 M;C%U$V\(*.@:?D-">.>SJ0*3"F)^/KBT7$8Y]G7R];60[7M&U*\W6;P8%_N. MVU-MWKD\!_+\D+"]GW @M!Z.+HU8\:>H/N5*HS8-@ MX;*#,\S9>S)B1N5/Z&B5+ P+T\!Z?;X/ZCV!2DBT'W1A(M]0I8%O/+-8.&^E MK;+866*ZVE. *,50PQ) V,,HI-9?#DA$*6. >9!A<|V@!\@F?.>EU\/'HE9; M1"PF!2#+E:RN3H3G',LE>$OCR" 3SYAR,CE_E'KC?\7:;.Q<5R@)PTKXXT4G M&I%?'KLCO%S=5469:Y;E_P&^L[N) [BJZ)KRX5E8>ULM*XO7A\ MP%;#@"= B:>GVR(MGHT"P* "3B=B;7]X67L,-Z^'.*-"4 #E&_$C3B.@C'7\ M(? (1_/F9Z86B4&<^L*/:?E/:5M@L$ \SYQWA[7>049D^F.N,JM @HLR M>>X^954MB\',;1/N],#HN %"IU!DT;/7R $0>'])^E*/)>]MDID)O&G"B)@" MZ=&,6I]&&1O #:(-/D;D/HU6>I3,9P/Q)4D\>GV)$T""Q*=_'!(/;SI2%S_< M,S05M9@XE4^,)*4SF"Y#U"Q6P5_/&\=Z?'U1CR2EAT]%>[%",+%- 5YL_X"'7 M'7!KRJ1>!3+FTRQ,;)X0>8ULA_JSH]*E9>1?I MO}B7D1$#NO,?@!R9& T'3UT*"IWMS/]ZV9SM$HP<]+/U;;6#U2? VE/X<]^CX MT3>L3S&&X,*YM/!3IJ7*]M"VA>GK:9@^#=-O6IC^#]G-C"B.2/X)\WB]>*@I M'F>GE%!D3QA+G8Q8DK?,0IB&H3)U0_0# MF%)&^$MC5CF%T4#+H?, (6]GT%'$OY"T7CKNN85C4%H!&B6,UEF7>&9;9Q]XE M-*I,V&E3^5&1U.,SDYE?T:(I8N* :B7EN5JL-(_S;O3^DW/20=\ (YWBQ#D]LJF+?&0A-0CI,J#9)+9G$,BPX M0#FXHN$4:C-L[EP$/DKGY_,)L3A:'(,'F#/Q :" $$/6=9;I4U(@A(5@AIPR M=#%BOE#/*Z!.>:+SQ!QLSR0%-2\OXTW,?#!Z,8&80S6:I^Q)_G?"!GR G'9\ M 8_W:UZT5:1Q/LZ9{[I<66;3R@[P":X8M,..4_NF<'=)TR WK!QMHX*QBYW@ M8?6) M3QX5*O% D^#8T:AOG]4,9UBZ;WCQ\NXD?)B1!*D,8]Y\."D**3DXX\E1ZX< M,.:J=HN/=):#4<'2GG<:.L@;3$RB6&[L1=)}T_= XA) I,M+<,B8>#>ITF0AN MJXKV<$>@PR1K$DLVA^!/!GM#X<$*^K(,9F' M'?/! <2AIYM&?,S'$(_$>&42B^0B/[>]0:UY>Q(8,7C>ZHBD99\>[4@* [*-W M+$R7B8"&L\O@/B;X%R (D!IKO<,+_S*\CZ7OFIV FUZL%R>E;(0"/1ZE=!/B M/DP XEX@*7\BJ@)Z\:MEWA^ M9@5'@CT3UK@)JM4HN,1TZ_FD&WA/H!M@D9.(:GNK%&KCBE=%T4%0HE5FB/P:N M9.H0:?IP(0K MB}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|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

K#N11P1AP]TD-MM-8Z2.">6 -0+QR{(%DG0]4%$\S'?F^L-EQT3>?,B4W"8*T56.&C.HG=DLI:-M*'NB*^4RX?&"J"
YT7.ZM-&"^TMZ>-L6Y}S)?D%P6Q$'{L'H-3H-MF)BW-;"C5FCA+&+N_N&.HNB8Y*$%TA]T-I<[WL725$0?9A_Q##F3>8?
UN0T&-MY;TSE!&]X-4?DO&>,NW#CH>S3N_39=,M$VH@ZX+S$1_#GM3QPM24Y_P;BC5>-MZRGA7M)
{'PE(G/S073Q9;W8$YVA;&>>GXT\PMR=-X=+-MO=D[>5(9ZU*!U*BMN93\R"OZ8P-
ZDE0]6]OT8NJFZ3%9B=.,+HU(Q\115P>]-MYCNN[#Z-*_E"[:3P_WXTRQ,?;-JJ-?%,PJ&#L*MX*YPPC<]<4!(#/2)-O*<5
MX77'YGU@ZIC<2!EF/!0+OP%%6C.\'-_61E#78B/V*L[DBOE"':TP;H$=B?C3
M)2D)J47[J$4;#AF1>F[LY90+L%@FDM&348YL+:?L@/HRH);WX3,'>Q?L2[-+M6RJ.Z-<]7_W,"=-E^,W24UE_DP7*D.
(!9\C-8J6W^/W'>\;3-5I&*J)Y,W_&,EYF(-]()=$RHF]B$5S(6Z7(]U1;N:EM:S5J#(TL8
M#BQRP630.N'3Z^4RZ60R!0OIB1D@K$UE0F$DD11U7JY)4X2*,
M^M"*'F,")#/TROE0$AGZ#"QH0J(T)4M%&C4QW_44J4(S<7>]-^5GK5DR7;;CR-M[M\6LFWLI-D$A3]@D<-SQ\
(V22PT>2DQQ]OX00,SS)A(/+>%/P3>8K-F7*CIV&0*]M)R!J9&S:-8-M:Q_>QH"-(S,DSY@)U>A$->_<=->6MT!Y>IDX)N^
KD8#5<..OF(\#+Q*>&PR-M8H8/+B%-!/-M'!JWX&*S,T,JNJ2!94.&;Z*950N9]\2OG)-K1DESB*DG^#4MF-M4
9A;G#_X3ZITDU!U*2,DM@NY+-:1',SWA%4P1^[Q*#Z*J"<)[J8+7P9#0J6-M:%>("[K^J<[TSY:&-
AW2E47;*TTW**;I!FFZP5K3#9;7+665T@41'?"$.$]) ME<@E/<3,C"GE>3T4;R4<8^$V;":F2<4@C8G]0UT,?0T;Z7-_\OS?
<94D4@[C-M9+5HFUB-8BIF[RG'ER\#Q3G<4H-)[TD3Q7*-4K$O,I"T<(>2W0"6*I0_X(/Z0]XI^
^XS0.M98U9WW$LA)YDP-M%\6T%\AWQ5OY:@5V3%\/F3W(,_2F<:@PAQ)?I5+(%6O_R!#B[Q/0DNQ]:7T'-MUNQ:SEB
1/P[.W;5X0?FTQD#$:![UI7#O%KU8/*IV/,<*?..9?2BS<8$>A"__MR(''_^OK2X"]#_I3%A;0T!V#X.+'+.8*I?0B-N
B"KEJ(IV(3;B(?*Y226]B-M-VZBF*O6TXO8@(LHI!>Q(1U=Y]U2-U'*%JLBL"VL7AP*#2M51,[>,T*LO@3-%@5[#K-%,882
M*&)-08?'4I?"4-JD&F-H/LC^GIR5FH2U\I/Q;4"2-[R5N-:BS*35XH^ZSVM-M5)KT%R)DS3?ZEZ'+G?J5
MT?}B]^V;Q([U"M058$=I6Z3#MF%'+5??>.7A?7KQJY&SV9?]SS9<]LOI
M@%+'!$TSC'C'A.>W?'BBGS3#\\/J3+PUGXW=T/1_5W!-EM^R[@,^;7SS*M))-MUG!PB1HIBV_^5:],QUSW]3XO_F[
=>#O^6W@+^OGO]BG'S=!WQY_&5AZ11]-MMQQ]N9Z>7N,F$^FFQP7#OA)56O_"\-S5U?
J\N_C(L)PAZX>X^>;6)K#6QU+6-MG^&0J_![/)K@_>R,0RG%^IO$;D[>-L[]I8V_^U%H-NS?#
<200OY3+U4W;:8UMHQ="VZH9BZ&.YGB^A>BV%E#O53+E6W;I(-MZT*WZ;/E(V[0K>6W^\K^V6HG=T)-
;F(_1IQ6HIKN2M7CK;5S4B?X:W""/T7)-M*6:JY<:JM?-WB-]O]=R;Z$Q_"AU07[OBRO.EWR!&I&[YK2:$E0N$MTD&F^C>
M?YH39*4^NDU-AK^V9=9FN'QB3?_9E-(=._2S&54C8SNMRK79*YM4>+*Z@#BW
M2=9\N%4SH$P%I[.G88(_MT9>+9:O-YOY.;"\E,E7*EOM(5R;I?$JL9Q;$YN+-MY$M[OH%_%\O;[?Q^@_&*2AJO6*^1;?
5YS8//-MNV+=J9ZIE%>>2/0FR6/VN=>-+L]K1VS>>5=M0)BW*C[F!#;6C2_/
M;H%LWG%7HMYF2I7"RC7<==/$:Z]-6.YN2XU7=[%;%+&--8\=CT\1=:01(MMH-M1:;QB;
<5GUB:QY#)L5(VDT8EMAZW-SLJL;S#ENR%[7;_I<&(-Q6,>(I93";M5B/Y&PQ+/(-
NOUV*_+HMD9=GK)MA@6U0M.*UGWMME15K1_0T[O"FSKVVTHFU
M(_I;Y>AI9<1;.O=;Q?.U10_2^_Z;GT4S])A]/4CW4L?&=&^"T[UX$Z(5.]M3G-N0Z]@$W_CV-M7\<+*Z6;U&Q(UEE3(R-
UAV^-.WS5%8Z%-HZD]_B<*++6^Z\JJ<[DL6@A6W^\JV.R%]-MGI+,,T->C=VR0>[V=5Z:9[&F7G"WM
MDO.D[)]RVL,_[9;S"KOE%#.E\I:W-T^;Y3R#D;"YJ/W$H6#U[1Y/\09C$\^1-MFK5=BOVZ+9/_=F)KC@V\2MBII<.77PU?
P5:9__U/Y_788C',G#KT)H4N2L"3-M=2?H6,9Z!,Y"W'B_(J18-JZQ!F\PN'F0V=!4\Y"_N#K8B<-B[.L39R6B;P-M\6;
(:9FHR*L@IT(U4RQ55D=/]7CZDYC)FZ"G)0,JFT5.2?OISTFKGLF7JJ^+
MKA9ABS"]5G+>38V^/('!EE>HK&P\$OP3/RK9<__Q5:#I%V+T[,$B?+LDFU\Y-MVOP*/-_L3A[=*/[]P?
3A1]K'&9"'\,#Q#=;4^38'>-T:&Y0P'ANTK[7!$W%H/-ML5'@C0%+EX-EYNDI0]>$7\#+%K#-W7{RW94#S[5G-%^3%,R
M,LI0G>#N/&6@ZH;B.XK?-UT=/@9V-'OM.JX"6('+P"I#V*_CPAJN?$B-HP$O-ML
U8VH.5Q.MA,=/.\E_#DJZC!QI\C[_Q#:UO.Y;3FRS<-H$(#JCYT2L=MZ?:
MYF\VY4/9P8LNYC^V+DX]^K/P<9=V#8Q/LTP;>1JJ,?R'YP,L&5A'L&^S1^/;
M%0\X'3MO^*3OFJH%#^(U!9:OV@3N/CLG7[JW0>FBQ=#<%#MH-M;#>B3^"KP-MI6^$RR&45,]S-),-3;]/IRO%P#
<''>B=-&7[1X\::F@EK#/^(_",_:"X=""-M8^16B-I;0F$'<$=X"W[?-0QE-#_N>XIAZP#)SX%M,.%?RF?8\5\L4QP@S]*
MF3CFSB3/L>$:ROMRKHR(;0&2T:/OP1*KBT]HF:&A(>)8DYQR!;O1#;HW__"?P24-M-0N.@J*ZSP$4JJ\(*&%
YO]Y%I4$J!HP6MQ,L2SE1K-K*I6D7=-__T?>?*0[-M9#5@!.X'H6A+I^HS,50D9:)G9#L-G[NLVH47?
U"ML3KQ^"EKC5Q)A$-^A+HZ-M@D&!>RM5_E&DOQ$<4[-6Y&'XJ%'&:-#^"?_&#E0JY6>::K2N2LER3{056-L"_B/>0
CV7/,32'4F'^%Q%[B3ZV'J#G"!0JXDOP>9&8@?S0W@'1W'#CSX-MB8HK699B.S{H!R!-36!Q-1>IN![*7V)"-
GTP=MP[.+IFL-\ZFA:X*-WAZR8P-M*0O?4LXH[XNYAB*#"L12*\>AT]AQ?#)Q(`.9+W3<]7!#,7GL#P
]0UALND#>I)N(;KO]$-MIYFQ?]-:2+ARH82J"UMC^8,45PYEDGKYQ-5S54B>#YV!-W8]-U-.E+*U<+G-M^\-S0%-A^HK\-
#I,X@RE^!E"&0AG9F@IZ95X#I3UA*'*A3$,0*1SX=OT8#-\-M')PXS2JUI+\T362;N4O_MTY="C67KF-
9SABOE*QCI*:124BFD,!U@A#-T78-M11^5=?CD<5VJ^W15[0-!@>U(J-S,1P?J@J4./>.#^$,^-$I8+EU1SFA,/L7E
MN>2YRT>![J)5=>&+.7)*.TO@-K=N$N!*Z(?Y,'YP/3-M?H!IZX]J'5P/I!>+1]6.YUB@:SZSMK'
%;*\)T12&O\^JK8PB2"]B!>Z"%!^-M4XK8B(L-=6YAEX_T)E+>]+8N(N5-FW(1P)M2DECA3?QA%N.C>NO+G;K^!Z=^
M5B[\S)}350,!C"+\|/_>5=X]$2"E0JZ^WF*G^A(-6Q3Z/7!<9E$N;WO."!;_M,=FL&6)_&>7=>
<_\@D[@@0WNK;:#PZNDL.)3*:Q0)HAL,86AJV9U>:\I=B2Q-MH[#MV%%:"4-=*Z-MB8/#Q\A]"'\AP@^'J*&K=P)-
GB*QXG@BSU]9]P#54,3+7S<;E(JY^3%F*OZ\5-M?]=SLT_!WTVWG1.]"$_VLH5|
<6L4LG6CXB,NOV(EU=)UR;\MHS&4^LJ1>4-MM,661=^-=1F%&9_178H(U4N4S53[?
J@E66&U/]Y0*WM2Y7XL)5JK47X,)5LBG-M^F6J7VZYJ50HKK8I?(K,K^.0:S>6GH3,A>)K-)NPT-ZTL1]/H+2:%\I5]CRF
MRN-K,*&6=HB45CPR*<7]-W7NUV(X%>NKDF]K$V9-BP_>6FFJ>"F-73V%$VS2-M\)?UB<37-
29FVK62DD)JSG$)^+I0O3C#=[&%YMY',9!2%%?-:!R5:KVIUOL:-M++ZGD'FY5DIMOY0*WKCM5\CD:]N7N?
A1*AF>V\]]E99@.;4$4_5W\T)S2WLZ-MRS21)+7@4A1^#0&YWTFU7NF:)^BOIORVHJ9AKEZC;;3;&Y;JL,:E72H%::
MWIBF-Y*#,=-(#;F4'-(42$X.I55)S'4K3BP%\K$!FJE^O'K].$X2)2-)W0EP-MR.A:.,,*>P)OXEE7'F-O5=.(6TH;JS
7UW[656=,YC/U>>+Q/S1&>4,&8+_L-MM.L9X[83FUW=!!=FMNXJ1V)*NS=T;,]AL\N9I,]$\^!!Y<3Q[GQKNF&F6*
MTOCV9QY9_H)P$:TVE19-PO0?&PJNE/(9F@"> 8!T+4/S/7H<_@&[]1C@V$H# M8^#@G'O-,$?PZP#
S58VW(%ILS0E@,@(0![-(I?ZB?*Y/J\'U*(R-$)!PB4Z-MN^78O2Q"A@]\S\);$98<" ADU5?&AAO!S]!?
#VC*3\/"\A06PO(>$*O3A8TY-MVEVVHWI$LP-4V6.I<8H>P/H._0Y>US5,/P!&@#^%_P&:UY#:.:14EL$W?"SD-M_Q'L--
!H19,A]MAQ[V-ES<-/FD/7M&B/K^>6*E,(K-X!01_,-<#%FBCO2[FB-M-@>S$"@-QS"IWK2UP&6<-@9"NDN$D7)A#
/@P'!;^,.FYQE(&*XS4((]U_QD-MV$9.63<<-TAPSM\9^RW^O6":),%7.1H,5=-%DW;S]{Q1-#]8FCN-C0CWS1#<
M"B"ZVV.\YCW8.2'-J#[PG4Y-"B'2B!.XB@IWY7GT,WB<,1X-9RBK#![B4Y7N-M%#%X2%E3ID=94_"M90!9]0&*N-47?
HJ+,5$-/W(P91A)$X&==;K9P..+Y92O-MCKSKL4KB'%5S7?"\Q]2$9V9^KP>G_IR(D2FZ(.OP'ILZJ-1PXR[-S5;:8;K<
M6H^Q40"6P:7&P17**4XWH'6!2-/Y3<0%^@3\;3""2=:+99"^018BJ8&IB\[',%E0+Y=X-:P*)RD:\36-L(<.K"0-M,7-
SI@UO]F$?;+@Z'!2L':.'-$E9F3Z)I/3_/$AK-OQE=DZ!V\U-">RB9A-ML#8:G\:OI!#/YS=83B2&7#.)@;!F]E5O"80E@^:]
(5>)1-@\#7I807R-F.0-M#;QC4-%RRA7L1P?<,KBJE=#@"I(T,CV)$(1H8LJ;JKS/2R\-%P2I$-56DG63-MP2?
K,Y_DZ(=6#L,VV(EO:+*2SI$/EBC.?IE,#\ROHINC?_\+_Q$WK('X<]$5-MU>>7$WJ5\))*X(PIUW^?
P'<6'\Q;+4@\BAB*ELK1K^N__R)N/\#FK.9;C?A#^_M+^E47'\ODBNL9V0[-)V[K-J%%W]0K;$Z\?@I:XU<&'7Z$+K0$-Q*
(9\K5?Y1-MI+\1'%.P'*@/60EBW/.6M8PNV@_T,_&9RXT*]J'CF7BM'QCS&1FX>FQ=NABT-M/HJ
@>AKA'_R@Y4+N5KEF:Y*\NJ19T]RZZD*4&WW_]{][]5I:[YXMAUWH%HQ-M\O?O%:EQ0&,M^!95KI-#J?
\N@:MQ4,^"X,MP,>&CRIXR-I3B!Q^76$GPN-U#LHGK;F<0W-0(KW-1R6N,^0)48Q!9R*>"_-M/G

*_DH.X1YLSE['I]YG=;]JJK<&VUR?#7K^>>DJW?&2#2@34X-KE=,U;UTUO M:*F3#Z9-3I".!;J;8#&E(N,XR*
+9)C=6J_T[%8,1H,FN9H=3VRX9>D!FI;A2-ML5/,E787J14A,4ZK%0!0B6;%&QRP7R% M?M5C1X5=#U77-U6+-*
'O!4>9Q*WA7#$"+.)N\+_9XRE&>C:.TP+@"I/&8EQ%O M^-*
)\4$X8\K<7(7^(^YM_S"7OB/F*A+K(PJ:@*EKJT#,^B#_DO:)VQ34KU#$T MIIO$=3DIK,H5N6E=V7?%6X4#F1USN4R?*
2G%1JIND$DF+H].K:SEC 0_Q;XJR M?F!J[Q@@\!*BZR0T >K%X5.UXC@7Z"+ A&^D%[$!%]'(U1?*
6DZ87\6*L*;V'3;@'X$SU]"(VX"* ,Z6R^O]G M[TV;W#:R->'O\RL0&O>$'(&B:U_D[HXHR_:]FFFW/))Z.MY/#I!,5J$% FPL*
M56+_^O=LN6%A425*)*OR1EQWB02!1.;)DV=]GEU8B& T[7M M*Y<8;'H2)D6&'_]EQ=F+QT[(V>CD?*O-KI=K3-*
C8>XB?;OBU*#F#@)F&*OWT M8)KMSS^,-R=*V^X27E>P'IO Z$C:Z6,E[>A\='RTUY+V^C;);]1&Q6>[;ZOW*
MPR/[P?'TV/)R?F&J\N5W7)I2-%623ZN-8BL]S8/F^-';_VAT>KIU>?F2[8\9 MZHUM_F^+BKD/PK%]9?*%PG&R+R?*
#ODG'Y>AJYPV'333W*\KO9?;?\&M2._.X;=^#>E]\LH7$^/;?L%O+[Z^^!E[8)>?:@Z?4?Q!1^JY=Y)J,#+^.A\ MHZC2WV*
*MB^>*TN4=U<\]X_NY_BT%\DRZ,\O*53=40%]J*QSAUAKSN/SB\TR*
MUWQSL=RP^;P/RW9^L=]+]J?]C6RW+&1&!$P=1,#G[M^$R/<3B'P_COOI_/1J MPP;X\Y.&$$'?[UV $W-*
TO/""Z./'P?/LCW. M4?RHJ7B+3@W^DW&^=B@_L6T=^U4=@=U[W4T')D[BBXNCD+?X6GF+;8O+5W4A M=N]U-TU.?*
Q@?'QT_MAK#> MXIZ=/KF%W9<\!=SS;TAS1/2UXKH4^>9R%$_\O;?61;%U.7^6KQW:))[7>S]?=1ZZ()*
[3>S]7.=]:SB"L]Y>\]Z[G M$]]V$K7OIP?X+."+-IPQV&YDXFN ASY]D?O6D$0;CN0_,9%[%FKNFZ,,;3C"*
M'F1N1Y9C%^+A^[\/_G@^4;Z1L_/GUP%]C.*IV\$WO3PR4G OM3@MSR2-TA-IJIZ MTT[)$]]](7#^K5.A^ MO36[O-*
KO)=OC4O8A\U@J2YZ,N[)#0?MM=P]]32M[!U]W(XV FVYO?9;;(<#I*
M[,#K;B2B&1\=;AZ_\#GNB8"ALPNONV'7&+?'V5/;'0%,A\ N#D,D?XO5[P(" M&FK@ ZK.?J+J/*IZZ'+38)Y/7\(#N,[.'Z7'*
<71Y@LCGKQH!VR=_5+>\>'5 MQ5X+^3/,1QP=!6R=;09BQMX]]Q6N(PP5F*7?U=UA*":?_YA_'1<,$\L.R^] M2^F*$U#*
(TZ(99VH[I\U*V?AN0T*Q9BYC"W/Q@'8;GIQ5\)TG5QC4V-!VVK7D MQM9VTSK9CN>RF]9)A3R)W71R'%\=7VYN-*
X7#Z7,2)<]B.ZV91=FM[=1VG3Y_M;QU=Q61]=S7G\@@->W;UQ+3K*B'XD_^JY,O]4">PJ;^1 MIJ>_7Z4US.CDQ\?*
J_HV+TK^:JDYGRR\;_(N_OE.52LK)+1%'_ZSN5%8LYBJO MHU\,M]Q67V*GIM>;K*DS69J(+UJ4*?P"'AY-*
BKQ*JSHJ9M%"E561YRJ+2I4E MM9J:ZV/,X&4-;J^H2C+X)7XV5KF:I37\59<)/"2FYW'&KWN'JBXF'P_&206? M3HHY?*
DP4&W&T2)8XNBJ:)U,5U454WZ;E%#X&%0%CG15E!%*!MX&[+&"\10GW M*-V7A'E4\(!?U.KR6U>9,7-U?*
611WB1Y^A^F"(E>XD(?'_[X^MW;BOX\^O%[&C4HPTF6Y]CGZ(GF'U4-_M<\G3>@?C3F^(3VJ0/OQ^YHKZS)-*
,K@0EZG)ZB2GZ;[E]\1%2R;_;M(2%X;F M(4RFH$LYS=P99: MK<*?R8_,&E?-8I'!:XPV*_J?L\/7H&"4] ZFC2[\[*
M/AU=ZD_H-@LU04G*EJ/H XQEJB:E@AU'@K(Z?^4HA# MO_NZ'QT;FZ6NAHA MJ4%MRJ93F#E:GH/*
M5BYPY]88CYUGP$/UUD[GXZ;$N]2WL/HWMSSMS5CO4]H,-Z52-(5/"3!.^495%>U*#X0#.D ML%2-Z*
J\'RH6FLN@_;#H;.0 M*YZ)=_@M61;1:U*0?8]>YYDQ2HX_6:!]247)3L8#@.^Q_JR=;GQ):6J.'-U! M)PP?*
*"X];PQ/G%4*Y'O9'M;IZ-_JBUR4"H@R'P3N#>3]6K_<9X.UQA5 O?B M;>$25^>X)ZF M=W_],_Q'_VZ2P4&$\WMBMW-*
R$*/ A$N Y//S35_$Z87O!MM-O=7SJ=+SP*YZ< M:.:F__X/=_!V\@\F8->5KW0PQ7FK6_8]CLE?O%$'8Q#ECP?)#!*
[*LGNDV6E M0S=7(U.\\?#IP9DSI7\C/]&?G; MYL,"[$#8**]H3X *P[M[]Z6%J8O%J^.C$?8"@:8ZD!<[/11=G'VEI6IU(ITX*
M,:(DNH5S_B\O_N>'MZ^'W;N*,=)YKEW\M&+OWY [8Q;_#5\BZ:XD=-D'5GU MI[IO!K^-?D"K:U9D67&/FI7/ M-*
3)?;=6[?T0@@J=.[VP.E*NSI)%I5[I/]R1X4:038#B,&$Q\K>=$R:2/==5 M:W6IGRIW.^*76B\G?WXV.EU9.>$(L'/_NXY*
Z'14Z+_3;&T5ZRDP**=2/+?+PP9G[\LY0@+\8T6 LZHL"-V M8B' GUY941Q6(NBFY[4003?MRD* ;@I;8H,K\9FUI*
_:K=_NK2_XZV_JA;^ MR@&.34\".$7XX5]>G+UXY(2<'(TNM]MO=KG&A*U*PO]:E.S\KNLD]R3M/WO3*
M;'F^OC"S_O({3ED4397DTVJCQ?1/H)T=*3C M:-^EXV0C"G7+=5[O_E+P,6K?(U2XS6)S.VK;D^(,0;E=]*
<]YQ8,Y&_'1P='N^-0;9M47P@X/<57O*[S9T ^]"0O5E(WRV+ M9-=D"U+Z!4'>Q>=EL?L@^/XZ/A\0R?*
<=H^SBQ^.#R\V&7P[WG3P[;GOB6]OEV[M M-P'7^OL/'A;0:KWQ#=;6ZI/+WJD^HEX9%?!$@V6Z'/UR$X/3X(_%G;!,_?'*
MSB^ZA!-[Z(UAU'3_3+U!V%^(B^Y=6?I4<*,M9E/SVU" MH(XT1W"D)GI]_2[Z$(S'8#P^!1=J_9**]\UBW ?9?*
U;O_50HPEVB9EG>T?BT^+PN0SN7-@*CSTAG]96.+UZ$N[@CYI* M5'=E]0!C!:LX6,5/P2-\7)GCR?*
G&@YC/4!Z>\3YX$M[A27QQ@Q"/&S3MI=Q1='FZH'V;;UHD^R M'A3\U(/!#W9JL%.?J[]V?M:U4L,N"'+O@>7EKQ_'A^?*
Z503IG7]_2K!&@S6Z M0R[58[;EQ5E(H 5A?B*NU5%\=?(DH#V<8\>EAPOV8[?GZL7=7096LG"+GCN*
M7M193!W%^^M%>?R1FTQSG84T5Z@#"R61%'",3T*76]@.H2Q21QZ/+[I!COWT M"KDP\B';T& A;]Y"]C?*
%"6R*:=$@8^E6=,,&(89W\5TWW2,0'YUW2Z/#W@A[*
MX_,=QJV_Z\8!$>++DP&TR!^(DWFO6*2_VE!=49C1_[5'OSF&&/9DOX_>Y).L*
M01[Q:E'D55&[J3GZXRA+)^1#HPTP@2?@?:*Z3!-;3CHIJKH:/9EYT>"=T6N8 MB;1>S8T>G1S&2(1^&L-TS#*
(UJ2NZ&'YTD]ZI7%7$P%XT=57#%&):=Y$L4=XK*
MFM)D,BD;MR1WVJBH+N@>\Z9N<+)5.4]SKG,2>G>S*#>E4F22X;WT>DR3.H$E*
M2O)JIDKGFONTOHW>UR,8^%0]G?727:I6CDD@:=VR(K\YP F$?V59<1_!4W&J*
MA($)URJ!B5&E,M.LID]G:DXW(Z!E,LRS*BSH: M*Y!O<.(<,89'-Q.27N(#5-%]47Z$D4P4?G"]*-,'OMTIOVL(Y') B3N4SH'*
M\'9T)\FM*(HOPNJM$HKJK2";S,%>^H6YA"'4,)/\69R1E=5@87&N"!QJ@^* MV4%3R&MG("3K[QAGXX\??*
X&1GU8PLF%JW@!A>,= MUKLDFN[H%U-0(9M3*;)^J0F#3Z.;\1)O-9 3#<;6BE@AZ2U*
M&Y*$A\'FG8$N@)O"F\R4=R_8EHL";J1Z!Y?F\,0:QL%<[O"BX/ZH&YP0L%_N MTCKE(UHN7\!]X,GXB)B>(>T)*
<-5!>PZVML>[\M4^P \/=_;,:'%J]\VF!,XUJ M,XYNUA!7,NW!WCJTQP=<_=W9Z%1_@')4+12N,-*
AFH^@#C&8*DJ7$QFJ9;L?V MEU%:.=M 'TMLM271=T?.0\T-X42P_9CDI\3#5XKPH;_"L@8CJ=7$[7C!GQ\Z*
MUJ3[\YY28KKZJ']8[KZ!Q;P#'[,:\>3BKTZZOTHF90'^[1U,0 &> .^Q-58E MAGF=X4$\7OJCA\UEQH-2H?*
[=X.$-6PSG%&2EAK6B/8LOE\M4D%]+3C?X;_D$ MWG=[^VUS9^H/T_3NKW^&_^A;3\!$*3&D>"O/-]%!'(<$%-*
$Y^1HQ0)^S^?C4 M0:#B63@Y=T9__T?[N"MUCF8%%E1OM)Q3.>MQ,$ZII#FC3H8@RQ\/$AF\.!7 M27:?*
+"MYRXNKDQ/D?,W3D=G+N?)IP-GQB2">I"I&3IX M]#/]62E>'W]85"G*W"L^(NX4WMV[+RT,NH?'1R/$YH(-*
H#W'TZ/1Q=E76BHG M.DL16B<\FT2WX,__Y<7__/#V];"TYD4Y3S)/6N6C%W_]0*8VZ,+7\"V:Q49. MDW5DU9_JOAG?*
]^1\P8%RZA_V+V%.OE]UW)MCIWO<
MGSBG99KK)ZX^^$\'3M@452A8F/HICXT=5'/.J/]IXINDSLG!E0U8TR6H+A'!5C+"9FP68$Q M'II?W#\4G2[0#(1O.=A,-*
P!UFSAE0NQM!DLL!IP,F[83,;O'U2E6R=C] NAR5) MYHL,5!KHEM]@%H^=X!XZ^IDB/0>_IF\QE/UV-H.W@;4A_SR7(/?*
1X]M$-S\ M\F5=W"C2='@!2O7QX8_ZVXK^??3C]F (U014- ?DY*I?M:\071OG7GX0)>/B*
M3O'1D"ORNB9*32NMEX#L=>:C; Z,$ #E,GU0Y2?DDPW_,RE+V A5S(YP MZW [LT[=*/JGHH,@I],*
(PYO#3S'SC]L)LSGX]T24'KZ5]@%MO&71P%\F$))$ MZ?0O+_[X[^SCT=GA\=G%U=G)"[8FG[J"?&AD#R@9G/W7L"N2?*
$G:9I)47)Y' M?^"&O(/-B8%K5#BG[OJ^U;FV(Q-XQUW_4Y&44Q:,.X5F@I>NPRMLNJYC'ET> M_8F<9E\?U^4U,JRW@-*
ORCE98:+!\S-W-(.)\?Q M,Y8/?-#E]>F?(CGZ*,5]0W)',X=E "[S%'C/IK!"Z45=]KO;@-ZA!/PVNJ M/(%?*
WJ:3VY4CP8]6CZ;'RC]T-TIGK$E6%>Z :9VQ&"NQBO8WT+MHLH#TO:90 MB9&^4?03A;L+WDTD6)YI*
L=";E+N(MMPX\EMDF/ZRQY>="SQP<@W@:&S*<1) M^*J!N1G4"* \]&%IYG;X// U?ZDF*KVS4FY.P)[1827*
&"=HAI8/OBIL=]SJ M;2,#=K3H ?@"!B1[1LH,3NE$HKNY-AX8;1^CQ&PJNC'/&=LGSHD#=X-3J+I- M%Y5,"&L@V-_?*
6MNU<\H>]^,_? NK3[BZM5%21;!T3%]5($Y;[RUM_J;$'(M66]-?ICQDO?N2.R)9V'Y/S0RUFRD8;H4",&U@
W+N@39/HIB!3HD"=3_'U MJ5I@4 "DJ%G C_1QX4B :W> Z9ZCVF.O',X,;5[.\?R0?UN;WT'&!\U[W#CD*
M^+O>"=9DUBCY8)Y1&EJRS:YCTO->V@O)8,)BTJAH4,5$R MH!2:/ 3(508MT8JZ_AH;E4V0V-)4B]%*
M[HH"_(L6_W!B;YOELY1J/0FX%Q*)I41OKCPB5C2"?@O.GJ*2.>-W^3P/#&A MWHQ^&IU+UH:?]3$O[G/<#HZO-*
D[&2SW<)E-&98)U,V6OCD)4YK95>Y)0B=,_MP>DKTZ*/*
K;=EL:YHE<#^ZPI=2:79/WH^(#V'^;ET@+L35(P.)_K3"!,C4P>_MK4*N#F"ZP*#6]28W-VBSUDI.G0@.X\88#=4M3&2E-*

*2'8DG-Z4#'Y&,&4D+F" M7^1%?I#,<$'@1KS)P5HH2K8%](&KAR%'=+\F[BS,GSK'K=2*[JS+62E)@4J8$P&#>LCD-ABQ?M8J.<;,Z)3%BE]PHGNN!S4*BT.8U10I8R.R=@#<;1ZW=O*

MX;_Z!K"I\V:&4T_1$'!$DCS]CYR&+U__]K;ZW@GRL&@.+X3B<3=V;#!B$_6 MN73X&)U1-BYU-MXM5L&1H=E!VYY5U#@M%J!1YLE$-525ZC;MQ?AU5MS 7@5? M#]2^]QWJ'HP A^<&QPG@ M4#"NEJ-1\,L?"DPEH&(Q*010&4F&YT5P]&AD/_.I@8L#9K[B$V7] @)VXBD5 MDA<1AKVHD4V'VB3@[2ZE]XDY+FU.FAA-8"^UA#^F#AGM+?T?#BQ1:(Q.!@RD MH<-F3Q9C_]^.^?[CM]<](>A6?!2O,*'+)U "MYN#!XL;0ZN_9L6]->/>@PS^*

*MQC+X2[?'P52N;/[MOL4Z<+!,']|=0XT_XI-"6 M"AVL25,7^@,^5>D3[_!U*PKXFJYQ4Y=Z8+H_BV=B/;R-BZ/1Z4K4&><8<^Z/ MG27@\=[K6=/_IG;G5VRJW,,\/6@BB-%&#]:7)N.JR)I:?673H%]B'1R?AX78@86*

'7$<%F(7%N)P='855F('5B+HIAU9B*";=F4A@F[: M[$I\)D[<@W;KMWOK2_CRT3U.7U4M?^6XYX.S\IF3 (X4?OB7%VKC%?J\KH?RU#M>LVQ=B"NN_8!-M>;Z^,!;Q\CO.8A5-E>33:J,,AD]S M>QT_=GL='8\.C[8N+U^ROS*

6Y6^9(!U!.ASI.-F(0MTV9.6JEWROZW@XL5/= M8NG?46@::\VNC>V/0U\0G;_NQ&(3O3#MOV"6X*

*F9;=GMP@>6DL=Y#?([].0 MWSWPB1DHG8Z1ETU%6>#O;=7/>/EJ;RRMGO78V$9['KMJ%[=0$+H@='NBM[=ZM&IOZQ7.Z_UO3G&>1WYZ,7;4-1/]=,+_Y=U=*9%W&KY6WU?0%P0Z"_8!@GQ_&9\<]DOT5"&%WI+7='T8Z7.3K*

MI[^N'7\O_39MPSO5FTTV)[Y4ESAP&8ZGP^W\QNC#@E>OR7")\:U(R=M=W

M)RX3S5IWV!YUVTXMTL,H=^LMHYYS>8.AJ7_X<09"/"%Y&@1YN(5Y>G3B$CHQ M[BF"Q?CRT=(QX\N[Q>

MKCPS"J%+T>=RB!WYOYHJQ =+!3@,1-T.T('[IC>@^^_PF[2ZU6784S6NI:&'_MWM"E"-05$')[UF@(/1K6Q4VS?*

CP#UPGO,,V'<,\M@$@JN'F$3S=)/:BI*)>RVM7=; M'[](V&T/',7N7ICU)+U8R!&F?OH5-JAKO+E@_#T,*/TD-OTL-*

6'3?)E=-BP(M)QXKJ96(M=3>M$36")2TQU"O>38(2E/K72XN.T:U9FAG@>(2W]Y__OO04R^*

*M<&1'*I3,3@\G5S/U1S(Y'/]Q>G%Y]D=RG)S]<3Q+)I?GEU=7TZL)/ #1*OD7 M;\!U._F_'"*1.0+IW"K8R_#.3?*

_V<5A,P79M2?O2M&Q9Q>-')')'2-K&&6-D M!@F#N"8Z@M\8;YR8*YX-_=P:,-*

"$@!Y5<]C/"O$8%T59,S<#LRH1IB.H'#Z$ MWC69BHZ.QP?'6B_\\DE\+CC6#=8P@A.7S/Q!'K^<8ZP,\AE"I]&;P35/]TH*

*M8+#KX:-]0QV^#*C# 76X5U8?1AV6TV-\?#:^.+T\^N/HY!A.C]/QU1^7YY/C M/]3957)X=):HX[-*

IY_0X)0C^(D,$CM_15IRB(O[CXN3]ZO)]F\?&Z2C20R-=

M90>WS2.AZR[MSB%!HGMT;$5WI9/W"])Y&#HC>P@/S_I&'<#/>A/#J()X^XAZ M76F"9&.&DJ$[21<>09.+Z&\!ZXGZ

*PQNO#1#VLE)0X9(@:Q?\!PF#=#?6THB M^5[H/7/D.%!$FJJ\J20N2_"?B*89F1@(;'D5/Y/\:*J0_Y59%S0SD7Z3J5V?*

MB;L^"[,^]!2F.$'S/[6V !CNWLF/AD$5'9TD!T=G+Q73/!R=3?E?#N4;G?7V MW>

*(OG3AF;44B*K_FZ9+N8:4;#1>5T/7$^N8:+:]R,E;ZU M8=03[&MOAMBTJG 22S7!@W(:\[.K"O^LFCEZV__!O[F*!Z]7+*

*(Y"S%&GR,%+ MO#RP+@LU26>II;AY_\MK*D:_^+%B]B"Z#PZZBL4?UZQX[KO @%R&7HWJW2"/*

MA>;Q^7!RCW1@&.V'BQ!='H/_65;L2)8<,MU:2;?KN@F+<>N8AM6 M(J\M4OH;M,:0@$UT781@?

*D**EQ(3GIC6WS)=7#@9D50/<.(.T"Z)M?T-W:<3*

*M0Y@75:WAVC4S(2E*H8_78F+YSS0[I8:51Q(ZVELHX47)&R&I"F8BR=*/N-YU MT;V>MV][^-7@^'?*

=C1#3ZOSL].0J4>".J_'LC].SH_,_+H^N#O](DJNCRXO9 MU>'93'FFU>_7[SZ\>?/VPW__\N[-

WW]]^^ZWZP]OWO[]C_.CT_.CC5I5GNU] M'Z]A<./GKS9A31^"/G!39L>FUH>=!>//H;Z)SL=XYV

M(F/:'V<7%Q>7%]LT88]&$8TJ MGQ^>@AMUXNWG/XZ.ID>GQ[/Q'^=7X[,_3B^OIG]_W%U>7ZE3DX/S\XN

MSSK.U=$UQK"$C_6/TZO3T^/SK0AD/W\CR>CU')98[_9#N^,L;M0O:/>T9R9 MS5 ;)A:'KHB:]1R-26"PH'H&E4+R-*

BSAG7+H6AL&82^V/T4G,?\]DJI)/O MS=5"._D]IE:+[Y-R>@6IA7NBK0L^*02%E@(5@NTV'B8UJRDH@OX)YH(LS*

ME@4V0B?$E3I)&N270[(79I3%4/TRO;Q'A#F9QY\E')<]#2QD(-^-]1]/\5C>9W MG8"/,&MP/,1VIGW(DAB1+?O-

6,&4$!>\IC/591^\7NY,>6_39A/?>!CHW3>5<9JOP31;5BDY7M;H M!5M8WAZO>2?+"Y>\-6:B9CA]Z$5?

*_'5,))^X2)Q@E+P_9:FTGS B*FK-5Q@[MKSLQ0R'>(3,2A["7I7*,0E/.V9FC':;9AFF16>9YO?&EFES8KVB7M23 1,-I MY7-*

*,F>6\%V$[@&!=6]YFOB->NX#1,9LY4\2"X"!+>RFBHS<27:I*82)GQY-B M[?3K"/U^<_^1A5WN+1:Z99BN6=I(UHG4'?<*

*E^'Y5[J\T.^+N25L=0F5A;M< MZP)OTZ,(UFG=U&K%=AU%OS.'?*4X55!)7A!^F2DCB^_1[X4)^SL(*8B4]@I_ME?O^3>*

[WM[7\(Y_HW#-8ZA;W/F?#;DZ>.(W7?I?-^90.GJ"&_/W/]3#BO- MA^GM8"P6A,'"?IPH<8E,ITPBAG)0'>&3+8EJ*

M5"69TJ<,&VR5=EZ+O!J/6ORO&N,CX+X_+-JD36KL6[RY2,T[) M@L"PCHZ/WQ04R2/"6@D=E>H&XXCP@B(+&/4K-'-

Y]VYV&HS8#XLZKOQO23FY MU8'NHS,^[W5!,!VM(%M^%3O5T'HUQ"N[&7K"Z8:O+M;A+CASLR5'5E,U[V'19/

M4&I#HMN:.5UK F_WTXT3S0B/AS^9#)@&UML61V$()/7NM1LR>C/3?.M-KAG7

*MS8ZWU^MAX!#':H*VAAY)9I76V+V+F2/'DM-LT/H[4$A@(9O8X+XE\J]"(C\D M\A^9R-_"\?>3$L^>O82\ 3,*

#Y,AIRFIJ@+;)239Y1YQ+0)W;7'$764"Q]@T MG=0Z3\8$]%$RAWU!6AC4)Z8;X!F&>1R^O[]5Y!"F,ZM[QLA0RS?

*MU8:=,P=5 MTBQK,(91*U=#ZZB%3IC '?6?, NL]9>PFO"%_0>KZI9ZQG/0C)M&J=\'3M\Q M^%"YE&2FLU>?RU'Z9?*

*O"X$$X'^$>):G!01QDR1)T\2LJG.\3)$>"M=[AW>7C M,ZI:F@/<%>HZIPY=.*S<1< M88X;;5+GMVD^*Y.J+G'7E'2#+*

*&M<&ORSWP=O#0'*3I#-V>\(_],%UZY">I; MMIS9HLL+BXTR>R2S7^(U8N&DYY1H0,:U@<1J,:)#!'8.%3<%9*

M[&$K%1(.T3^F*:)OC!LN;Z#*:=QN$LK@S#Z;B,YLV$INZ[=VVK_#EG[N6UH. M/5, (<7ZQ_Y\C3L=K7XL]G&W<@-[1!(

>$:J$L/.,&38'.Q)^^%I"JZC&T9G M%_LAL,)!)H-,#LDD173XF,B7HH"YKV.^R%C14A)"AQAJ!#)]N+Z-#+U=>) MA-*

O[SZH@AD$,5ZE&KC[3&39:=9AAA"T*W[L&LCU,-@4$U(EA32:Y)P[$5L _K);EF MJ:A%\,KNJR;E!"_73#RO%06-

=3&EV%K=8/.D>+)QS8_W993\RK884% !P741HU)9*0@ MU7SFQ8'_S: &]9QV:T7P'Q!=RL'K"'Z,17_)!.LI2"XGV-*

*5#'DCUHP$H'\N72RD^]%LVX=KIT6PMK9A<;?J., M@C%FL R$*UBYZDORQRP%B2V.E^]MZ*5N*;72?*

@<"RC4TN7NR8<-ZQ;7S;-W5 MN C4F/X#=T&Y"+@\S='2P9^B4K<]O;ML@0TK+>K$73J9='5X8 M/;EFGBH?O-*

K.WK9,7Q@M$!R5-EU6659H4I&E M7+?07@R,)Y@+TV0)F^8 _L>I6+,X'W1"PM&G#'1'>\Z,_]@I\J,3U1P,YDBQ

*M)T?/X8.>'9Y\5,,[YAY:L,5L41-;7>#48%0<_!Q86"63;E%43'G@%0 MTC>/:S5MIF;4_ */K=2*

*P>ZF,P.]A%3&>FGRB66UDCV5:",Y:W0;H=@U+2V#5B M4DFWB6NP)]0!CPJ 2]@-WUI*2%1@58&853'/"N@&\C$DY]_-*

*Z7!7CS,SO"ZK M?R1AYUCB)*4)2?8L>.#G-9*YKHIW9XY^7&.&]SG MZ*"ZL9:P5W]#1;=>U0[YR[DJK=-*

U3[JK)H"TI,Q254H"X:>.Y?<:T\+\<]* MTSO4OZ!PQ*7YOY& 0<\4CE:;G/$%32M=RO&F_BB4,T M(;SWFWR6W!6EJRVD*

MSLTJ3FD7-!U4,O^"1J9%P,9 O!6D5G:!,J/NM&K_[.AO8UMX9P/%QJ,,2\HQ6"&E:XAYQH8'?= -D9J

*6%'VU@QI7>\>OP86T*T4<=-C M+U,8&BH;F@_1>_) RZ^"@16X$B[U7XVF0^%/;73$B>PY?7O>-I+0"5D'OOS#*

*M3S"XW.3""/&>5*UH,:Z/,/'H#&@ 1K_%"-HX3ET:/H&FT[?I.XM05[MH"4T/+11]"LO.RYD+/'>)Q%->@9AI$UB*

*+PE(ZHHZV!#.!6C(DXV M0>.D$UPCW$>,I=G2.?YAL"/=\&/%47;4+J2\G'V/T"A>QW=1+@J!*QWJ^G9^ M7W,=C/,*

*<*1RQ_>6X[9<*8[ISUN<"M.H8-5XV2NK75;MR/8Z&*PXH.6&SO8G] M;34A&]AOGZ+/1-URD)KM(7$?:0,2^TYHE!A-*

J&Z3;!:+ >V (_@M3@Y#A-6% M>'?[JE;?MP\$_DNN0+E0]#.6PX&Z+&G2$P+6=TI4I;V$7!$W1,\ HUPO1+FA

MI55>K.NH@=Y(.KL>=BFFJT.C SVBWTS[M.7=,S(H.+_$#_+&.3K$B% @Y@T& M[-

*!$Y/"K2RMF]CEY<"2/",G*_HDT6EB;GK&"N+F6_Y:ZJFYZQ3E[X4 QE&B\ M!>AD[>]-HSLY"^L(D702X:WOW8-3-*

*>?;O4%/V0(8LUIX2FG$AB3PE M9%86_H;FMR<[MV**B59RJ'.YWYVB]BKI5_1A.WV,H^;-#.1:-3P T4XE>O1 M:F^-*

*C0+G-'A@7XB$6DP9<4Q;\M@J+_L,Z:2S\1X#6$G%/K3V!ULQ*M,8PQ%_ M'A9]"(-%W'9RTU;E#,3"^.*

I4(9W%%D6=1M!1,#6UG_644W-2!(45+YIEQ;W@ M4[FE /\T$6?-

>L,T.A480"QS#MK.N.V#2GQLA0YHS>=>)B&/0A(R)"%W-PG9 MMCU2VP"+!H?2LS9?(

M(]'(R.9)R!VT[X]5,VRDO0UDQSHG8(IRL+"[>F0>T)U)@UN:X3YWLG1XESD>:,Z]7/D$ M 72!H;&4KM8A?

G_V,3;U<.@$[#]ALKPW&M.E.G6FZIT8'YYFW(3'\XA!2S6 M:]J;4K->:!_9K?81:@R9@+<4"T1?[!*4F9J"F9]'0QL"+$,:*

MY7/Q8[X";PXMR@.I\P.Z]+4?R4"Y' IZX+=1%0)L-DI_Z5(9LP5;)R#8G MT#PU?0#.>

*MI\QYA#$S&N'/97,372],;CYZ*3PU?__YVM!HP>]_2KD_K(K^)L6Z?3_ZZ6_V M1S-I;>YQ?5TX"MP)'40*T]4EQ!BZ5-*

*P>_>XM=.!*6^!N6*)E7CLU HD=/YO= M/;9"T#M![P2]XY[R,RGJQ6@/L26S%SR3[#1N5(750!/3+IG@EH6-F*1SM^!G*

M=:U_R_>,M=MT(!?2FP3XT-2IFP#G52V%M1 4 -! M#8@:X,-8*"IFEL')"?
OC$9MI%*#^PA.#YZ:!Z]W24XFLMP]O3EV(6<.&AP_1 M+SY&V*YANX;M>FMSUS.-.HGU8Z8;3)>,B2/N(EF&'11V4-
A!IOW9/_$X/MP/ MSX[9Y@,X[N9%JVFI]6NB^AUU"QLN;#EGOV62]=%C71YG>(5H:%VHVN:$:TI
MHX)SQ=I,2>&N>*H:L< +"*E/X&A6NAF)C-?);0+^*VSJ"F$()H2CAE]BWDD* MM>5DI5J:=!(1D!OUBZWYFD@K'I1"4
K/6REPZ)IZM30GX^-+NKS:L*]^YGYQ MCV\0_B#|NAC!,T(Y"$(6)X=D30V>1&7U<>:F.2SX:#=6RXW+#^"ON('>9?_E
M!X8?D"*^#Q!K[&YW?=AYSWSGS9-)67 Y--AN4BAJ8)%,035V1A)J,+9RQ4@2 MS*#1;H4U.HA@A$ZQ,5_U. M44(:K)A?
D=[RZ/#@_[#UPMT/LZQ(N/.&L:EA&KZ[.-.=@+% E)8(KY 5])JK
M[J\9\7KP%M13PUS3##EG&H"YNO="UMS]=>P["^\Q% M%D2H"K"]ZGN5W:F#.3SA5J,A-(QM=*LR;
*Z2:G?"ITC!Y0SK9R^!@*0N;E! MC% N*P(7ZH!Q6[0#Y2@1#?R5(LOE0 C9/Q4@^A 6TSDGJ@ME[$ M,2-
X>2,HY}S'I^N[S/35L(?]KLJ2" YCD\T/\%||^C:(A-<_0%'USRRUX MV03?
4'4F[VM#V@T+TK7QFJ>RROCW\>'QB3UNXNZ)<9\,G!8M5#$Z>6B"+-CI M0P]CF!=!YTYNL+=.VB_]
(6#I1R(]EREBR^@8@'=XP0&K"*\4H;[S3#>2W1+> M6#+1Z$C8JB\(G\V"&NM6";LL]P.;:7 O4M=0QX
M&Y]\]PP<>\$_#D/M 66S6E M[;M,>_5>]ZU%S"4@6ZG>IB+33R!^I* =/-O8 %'TX"+ZS,0.9BG!-",U+
MCC1L&_#M'Z29R-%#B]U1,(3X0>:QH29PNZ1;W 2DD"R; 0NSL@C@*/T.F"R> M2&-I6:=Z>NETUG9
W.IXQGYF:F+F4TYJ;-L\,@3F:K05;*-<\!19N?JI3$(M^5"0?^T@)??#(]/P753GI0#!@.S;K M[B&.RFES22;&O<_,MN4*4
%3TKHK1P/6KV4(!AC[0&N[GV04@T3H]72*Y)C; T*8]4J]#T#0 MAAVP@ 0)V!()"0>UV0L 86P[4T28^H$*>#-9P$/&+/>
[VAV51YB7N",L7G,; MISG6G\4S8Z7:!_ T2_&"; MLGMI6>]_/ M?6"D%9J#V]L*C\>:%NZ)UK%+8#+
[*8;H81C)A'#601(8!WK;%<-WWPO>J9PXS<+7! DLF!)VI MLS!\1!F@,.MIOD_*
<0*V\,';3YE:1M='@<1R\=K[M[G6[#\6#*R"-G M9#&<8(V-:I%A8 W&2W[R+Z_MN>O\3CRZOR?5-
/EW])ZLZU\^36Y1%Q)=0N5= M#G=&;!@$C"R:RL=C@"WJS5GJ5_3SM82@IFND#(H@I;%4KEDCN,X1HDPS[#9
MQ3D9"D22:(%W*9V. SQ@C$,+8UO5B [S*Q(0?DI0@M88&#TBK=LP_1T#]6& MX@KL+ @>T10$!S,3O
3X2X7GL)X\>|.\& M=-$LQ3&3V$F'>WEGP.5_*I)R&ML_Z4!,ZUH)R2@RKE%J&'_"L_=-$8O."]A1&X&XJ2Z%(NX
J'<9:+WB: /0 M"()!8;3+))/:/*SP?3S>@J>'ISH.UYU_K;*=KE%2#1P&[=Z(M19(3_.Z^)A6HAZ
C,5;_R3>Q*=Y):PW=YIZ.=H)8'>&,E#Q?%-_WF+V M#)<';C])%\0/Z%0U$*,0S/]-*31
G[D@=#X@+0#7[3*D$=ZG/1FE?,DGW4! MU-J_)#!1P1R8. V3(&@B(<<:L*ZT4Q:YEXG DY (#(G_4D$)@UH>TN$1KC+
M0@G&(=4N.*.G0$G1&@4:B^$684'(C0F2)XQ9Y0.XF;UT.^@\[)>73&7GT8MJCJ7?I7-J.*_OA?69Q,9T+ _/^Y&Z/(VZ
M.G!'"=LDN[F3_J3\G%B+Z9VX[:B_BW+K/K&9K>')TH:ZX'D3)_N*ZR5E2.=>
MBGB0#C5!*_>H'/A7RU()I@^X?,B/Y!_ZAGEU."MRLB$P@N2&996,D2F=H0H M&7I\=FB N.?
@9S4E4W3:W+,&7\6$LA9WK"6;RM UE0$#D#:&NM[0&N/<.4\$ MC62>..5^6]I6V(_+>)\.Y\NT.S\Z^K*Q*;@XW-
04C*+W*X3?Y;G2B.05QBO8 M>K(^#74XYA4ON=UT3"T*E\T7E@LT2AI0F83'BF87_\:/3?39>P8FV%"(B3W4
MV>D>%Z,#+=GGXS"UF.=HR'M2,KN^=R@XF X#!Z^F_:2KO++UBKM6*B/6+N?W MTZ1.I'R0;N.=)&E.
[!GZI"C3ZJ/A9MDV)Y-^%9WE(&:$6B!'*(W5R%;*7-6 MJ4V7X0/A$VF0(6$S*I85URPU)"^22DLE9]W @J?(B[WY>O=-
M7*>5>8 EO)#(M7(TE(G #--!K#'PO'MK)<'_XK/:!%%X\G1_Q5V!-E&V3X0J M;_VLF"X0@-4]X/!E]/>W?
W,12IQOZN0333IAE"@9S9#8&DP$FOG(N'?G0B] M"RB-*.?
ZW%9>M0=.*7GF'IAS:C#D)3U9CCQ7+ED;F0DTA<@0/=).:TL7A1, MGL%^ JFGYZ]8.?U*\=)1*F.O:>T
M*HK@X*]@!W+P#\:."O4G;>6]-W0"\%#G@P. MEPY(U]+DR^&[:/=ND",*]X='Q\>NC"6BFF[!E/S _)S"Q'2GK30\'KSX-
1F6 M-@V@@^I^ZLV$8K3^(\S#RE8WKL7JR@+?6F,Q6L:G6HU^?3=,0!Z1"=
M$<7MUELNSG)HQB5]XO3"RVU8%3/OP3)BU@,W94ZOI"O4G=/#X[3Z'")4 M/$Q)"VN"0O(%2)=Q&;(WG_D[CHK ^:?L-
(PVK\1BL4DI;Z^OC>/$KV_@ O5L589["\8]<>?P"
M$D&7K3S'*LZH0#)7]N\Z6G2*:*@=51H[5YK"S{RPP1JRGKD(7O!A_!MIAP> M@,.:INN'6ON*B8C04:,+Y3Y;|
[4^#*Z&"YC>6I)8KXFG%_3E0]56.$NT0*T8 M=U-U1-UD8#TZ4JW@G+#+EM@[W(]"0^\.-/0Z/,R>7"Z1(JM&65J!!
[%O2<[3 MD.0,21S4#XYM-.'7/]W@\&B M>DW0=6I5.T!!7[9PUU%,E:I,,1OI5>T>\>9RR_8T57/R\NLH2\,;O]6A)G ?
MT'<(HAU$>_C(]SC$=*./5]6V(98.^/O;(E,8=\$MT;Q?1HBDG MMTG%3;(V$46I:"NSH*^Q7:,(+5US$-,@IH-
B*D13%J'&]G^2H-KN*6L;W*:, MUDC8;^)7+:)BJ25=:*ET=$I#JI22^\!^KMHIX!$M.|QE:3ISI'1\^CL=M M1FHCN7V
Y91?G!>#_'P#D.8KX(L#O.(SWT.N9A>H4I"K6M IG+Y!'WY[N8HA M.6"-ALVPEYNA[*+UF-)=C;Z!NX+.5ZV1$D
YU\>BH^70G?5^.GELYG1?5)=^)>;LVDD4L94%# M54%;R_+K%UI=Q=5I.;,BZI8%.*UG6.6JKY&N-#=KX%B@?
7$V*9[Y%UQ=816^ MP!OH1CB%N=O<":X1%8B.K-G-Y3^4@9+C:-RD&6,V#=%5LUGLUGA9,UJ7=XW5 M#$OB82RF.
2%W*\.T3-*=G=OS,\4[%'/ :%CBC;2R#*EL<)7%]S)G!& M)#P M\F9P9]$9]JK:/-,R\^O/UU*F@N1[N$WQYS
QWL^D5W%).$4+[F/.EAXD Q?! MZ&=2P=% E=+JU^P4S)X?GEY=7%Q]K8+9K]:3@&^,>X\!0-8K_\,2L2:G*%QN
M9G=:D.Q\!!O(-*OH]KJ>HB-'$U?"$:>W !6NZT/[L]]JV^6:,X=KU$ EX:]N M.E5)A(AN$'$(I@.F&#Y#,>690Q>740'=WZ)
(.W%_1'1W)YE.+2_2=)?*[126 M#W(-.8)[U=%M U.!SE!J3[$)EMDZZ.S3M"($T5'T-E>VM2FI-(LU-^!AL;R_MH@8HQ4
%&V$SM4U@]UW]]V!E^?'&]V!F]QNKZ_?11]P71,NX71VGLPS+<3< M !\BL#^MA7L"6.*GS>P0;P+/#D^WJ<)T43$)?
B[5M?/&6@8&?JY=J6S0UO*(MI]FU%75G6;?.%0%U5A2GMZL_810?H@E:<>E\WN2%W46I!N7,S-/:X]"(+SWG
MI2W8'44_*08]=:1%5\=DRR'!<8?## ^I(E&DNZC@/[4*) 9TO?2.5A@F*\F8^ M1N4P$F-P)PM
M^ZKY!2]3^7E#;YOC;JG%/9\74V[WEKUO=SWQ/]-&>T*UFV>A=C/4;H;:S:#-
MO[3,G6TTG65$!R>M:MU$@X#NKV2YE(FX(1D>;*"^\2[8R8_F)6P(@E"![% M72'\5#-F'J$F9_FY4=95A J+_2 *SO
=0WX]B/#*_#JI-DD.NO[PK9H;,YL1 M[?\E/3]\P13$^H[%5W4CFE[HS:"DZI9 ZMX2_"KJ(6<0JQ4E54&,@Q@/5S.!
ML$C1AB+<4 FBIOUB7*0PB"%GVD/^"<]@Q;/,)L#
MIK7E$S))K5[V9%/0A%R#!YB&%O"U@V;!07MPT*S.OBU,J#_(;I#=SY1=RHF2 M[>ID$ >[C#BOESKBK2%Q,62FMQ0R
MN:KOB_*CIK;;"*K"35%,-98*ZM)*TI\NTENIX.8YQL>Y+F$>O*@@GVL7T_?5 M*2,](F7_* >*P4&G8H)+&+KA8-"A1-
BHFYFX),WP+C@WF*I_-\RPP40(6!.0 MSL?(CV.0/!!D$"\FG";D[(B=%U_,3*P3^P<>8'2CU#0>4SEWU'-_O)@GJY
MX!8ISAI@]O2A/<4#\ M)*6J:K*HW0EC<@%T@TV!MZZ5D I7K Y$3J!>+C/[4R?' MI$E4R%'F/8\
<(/#_'.1A/-34A7#,TH\J2V_AO"6006RH!*PDF[&%!IK+NV+$W"S%05F5H#H,R^3C_$6C_\Y5F M:ZF^'/[S38XJE<@
HY^QB_WGUIN_;K_YM\7\7'VB?=,.A4T>Q#^CFC6%O21= M8+U82$9J1S1<03[MB<\[F'Q2G?H9
MA6DQWPP7(]2H!8>.4\(DC]*LX4E@W(8.[VM($-[K$# +,K8>ZEFI)F63FGYY MW;8?
H9/#KH$60DN95P1DJ2!@J]I\,8VO)8IZ"\J[%K))3Y>O@3/3#556](P/ MZ8.:;$Z.U^_>.IP<),5<8T"I7 ;MQ@=8'@4^RAV"
IA\,:AR P*X\ M\1NV3-HG5$M^'FK)0RUY]"4/FO4+->N;'":Z;J3I_YVZ2^%93#2OK8TW[WXR
MQ@:&CVLP*2I+0^^ED'4XH>W+4?C"LW7P^ ^G?Y#1=?L=0,#P>$\MBRCQ@28W
M>0'+,&$+FVQ2Q'U!.!2*N&FXG2!J0=0&18V?3BW 1FV1>Q(5Q%$D.NPVP;*" MFR9$FX(PK8AH,E>@Y'0699HCYK0?
3K(YS(^*8OJS&1%:54KIUH&^\Q.)VO)P M<@8)?'R\4^6:.?M34\F-&T$"CD^"VK; UTM6M
MJ"_H+RJ@'/9G5@U0Q*T/N/!-;A#E8H^G47CF.=5.15LTXYE*.$VH+]:-A1J/>&VP;J9+JWNDVTZBEX/;3BG/J25
MK$_F8U"]6%H'M\O5#<-YIL3],Y?K6%Q35->X<[EH;XVHOY8:I^EK2G;+9 +'_M>F*0:)S=
[@%Y4OE,.UPPBGYM2GSMN+OFIBB9\6IB&:I5@7+=#R;;TIQ.M?$R M:@AS/7KS[B?ZWTZXC,IH"/<5FS21J*.
0[$H);*AKUKE#<0]Y4FTZ/JU*:A[K4S0D/]^BWS]B^_A1O;H#X M\@6(4L@F!S%]);((>KY%#C
M6)M6\EG#'74>145'\O8O!O>:-"F;O>13H[-)/1\M>'T&.DGF MV+/;C6.R!-O4OS>S#3JJ,;NS!ML:=> *'Z]|K4J.(]M&:Q.T(V
,(ZP.!,-TO)!$4.RM^_M=RJ9K1(90[(:#8+3O2&N 9-D.?-1F.&X["5C<3N>@AUD_'2WX<;IZDG=*($
MWG^@K6H%K\:W#EGBV]PFH%8GJJG;="T4JM1];WPR4\>;ECM#146\!G-P? @8 MWG3@(JO.
>ICC&:JMM*I!L1:&O9TD[&&Q)DE=P7SBXQ5KF9I?4#(C!H+SRG: M!7%+3=.QVP.("FCZ+U&I\\CE919M[]O6L#@<8'G

*M*LG=1O6A1D"KKZA7J1^"GFYQP'U[?1)EF27L"CB13S'4N&^;TEIP9;5 =_0V MN1-0HAM!M] KQVFVK!/NAU,*
*]GC10ZRCPF/+I M@A"%*C'MT764MJ]ND6D66:J8SU#2-RT4D16)!LX5[>3_1,)YJN=)A*37&4 M6ZQ!/?9X*$9(-A?*
G.KFWNQ=!PGCGTNS=W_R4_=,)T1MY#H)TP)>R9D5#,2F MJF,S[7H(4JXV(;P:3-3E?#CM^/PSV>X37'Q
MB;FH0H&%358?.(!E;;G$]W GI]=X)K,B2\8J8S$SQS=GJ)10)HU5QL](TGEE M4E5+SI17J>$\:]/3=+$^!E/:W%K?
*VYYL[&KM;YE!:6<71>4^*3'C61%;%;6D MFG6+)?$^21H70 <7N.4K>,,T<@){U+7W*S@HD6I2PT=XCEK7Z^!E=P *=-*
F(MX-X4Y:!8;H_Q\/,]@NMA\LI>Q>7API0#C94B#XZ'+&V8L@G$)28\B:J9DZ,K M $:YH_.U9^O47S
W&"C+16VIPL26MZ:P1U"&\$>KP,ZVLU\;1R\I'[62;%> M8Q^-,S:;.XZ0\U6@"#&'>/!1J05'#J841JOH'TRS2*
*N"Z9@2;JT^\?_Z+.H> MMN=P%,"")O>?"#$"CSP@&VY221,\YJ2\W]?L3>545N 0-$JHU3U*X)>:MI'?*
*MA*NO.G>+-2'K$!EEGZIM0!BS@=/),$C\]#=*BOT=7Z,R)3S.V[&2-+B\,Q=2 MTK""5A:<);:@+Z*
#P4:!+0VRJFD_EYP((?"7V#"IE2W7BM-X5&58BN2$4 GMR3"VJ^#'X-)T**S?:-Q0X M@MWL'R!>=0U.*
M&)P#^2K2!]/A^^#%_9"Z JO,8D]GI$Z]2#P.^X#!GYOU)_-(5ADI+$U[:X M5?!#@X2*F(&YB3D39!>ANUDK,*
]K6T[\H,G3 Z8YVLPK'(54;;@.WP%#+2XE M,&B02:GH\XIO7*57"^_;R6$L 97:;HU>T#+63_)V0W"SRB&*
*M.]K(3/>62(6RJ) $\X,6GTV^K%U&4"T$+&*KVCE;@=X,_!)S'7BXX8[U]'#' MR[(*!X0:C $*P';*JZ.Y@N=/!61:_H:KJ(0Q@4-*
G6:6A\BI(^HKVRMSG(S8 MYFZ<6\2):,?PA]K2\A(3A9";@$$_2[Q:+MQ)'*/NT=!HA1,A"AYX)C$A4/S6
MUPY"'(3X075MHF94^N+822B_W)BDX3DU2N1X24)VETZ;-JP80V!C+":'GV'(M@:"MN18?Q!5Q&
C4G/&N#2PO4BL;8"5IATI,,,!S^8)4!ZE>=6.SS@4F9\K MQ5&G#+T!*M5 VZ*JI=U$.\,3)Q#EQ#5(TXH5'<0QB.-*
*:2K9KYE+ST *[3?7) M;Y4N1LA-^U,-5]WJJ>(.NC (WYK"UPU'#82A* 5B@TR41RHJZ>*SS#=.,*T4*
MY$?."=PKW<\B;5L41#38]V@CV%0P9XA]S]LF@,ZGAM5+3H 8=.!!7B M7\LI8)=/F?S7#TZB_O=Z_UU30[<\&H?
0!+H%,:KLKT5K$L.J\!ER M96%!;4QY \D3N@646NF8A)O+QDL98():Q/IU'5QUX(%&II)])P <*N6&PG0*
*MIM$4"5LH39S"3KSH&VFC=&TA<.*WT+U.L?,"/LWLL"Y43 MVMXZULGU "UH>S*4-P.Z:A]?D-0_7H8\;A8"QIL]\.D5D7-*
QH-_>J&)BL?I6 MYY^]5>=9M9']%.L@0%/2F,:J+[C?D@C>[H^5B4[Y1WW;#X1D@E\S CVY9]5L
M2R;Q(\QN6#NX[,QGDMOJ&?W"7@5A7WFL]$/IRAXF&7BP+XE[/BL>,9?QM4?C MEWRVJE=
*<)CE=/P2K4*DL\WZH\5/@.0W6(6OZHG%3I70(R/<"\X6U<73G+=8, M_/,6/8'%[;*",S@QA1\%BC."8<&Y,"E3;-*
Z"%38;H=4G,96+W"YMG!!3-&6J M4ZE4Q;L'A_=U;)\>:PHT.I$NLAY:)5<#0JY1G8O9[(#K4/&9&N"YL\1<,J?<
*MT5>]&K+#\4AUD;+Q*6'14Q-&>_/QN_(]EJ3Y+T*/Q>.0"#?* H5+37FR<#) MXPSIXQU/?<*_5F;?@=5%N4:CQF'!=N-*
*:L*N:*_S*H2[@88@I-TG+2S"OB3(:Q MO1NT6NA%1N]'@H)%N9Q""N#I-SC3F-WDDFD:?LHEN/C3L<*^GX) >1SY-(U3*
*M(*3R2_,*P\.9%G%T6]QCI0[6\6#5(YZL,']-;ONNENWBI8GI0BB,8'-E)14; MN"M"]DF4 5^"Q4^H-7@$AJ;3"3QQJ;*
*(7+RBI218WBQ0Q=IE*Z XI5YJ7D<(T MLD#&<:K8JWCX)U=<1W]3-7BC\!4+)9YE@]8V,:Y9,)M9@93N9+EFR;VM@\)'*
ML9CHWEX>-I^0TN9L)XSVKJU2=7A,35Z[$/FS?:L:(%$_IWMD&(Q$5LRQKONG M?@W'@_+\IRAN#Q ?;3(%E+=
*IW!E",L3S M/2G*4@YDKQ WS?_5Y!.+M5)B9[#4G:M)P],M?:IB4@F#9SGW3HX],FG?S/0; M#55/ELHNHW1^:Z@C'*_-*
W&G7 MT:9&#Z9Z4?9N65QU;OQPMZWCS>#X6IVJ:!MY<7%+1)ST=71W^QP&RZXMB&#,
M83ZLJ9=A4#)3S!4PP9);_5L(3;MLX_^.6XK/J]R31GLRQ=Y?FK
*MU":T\K#@VYTE5WEZ8OVS+01].'FHJNF(O#0AB)5=DL7*GGLP3VV&VZT%S< M0XJ"C5=LZB^Y=*2C1MG^-*
*SDQJGES\M&ZJ]\ZFD]<> %@.?&KXA$:&XB:WNP MJNC39IFI?1R8%X2#:*NQ">8@Q'R MU<8%,IBJGA0VE!W U,MTT(*
*FO[KM]J] MH JS1R?B9?JU\7M=%3=G'F:#5K9@WG#:'4GI5UB X>%7U)GR=@*0Q/-'AREP M3]*G$0(K:VFH8O=X$#&*
&UE+ A:V>6C,:, "NXE-D?"RLL_IS#.70=\KCGV M:U$3!;LS)..RKRVX?CN0-*
X<'&C7KALZ,Q7[UH!A.X>&"GLZ<\V=RL#H.H7N M'&9UC!H\$[EYJ-(%]/BW__/2QOR,"V^Z0?4GE4K_0QJC%*
(LL=BT[KC?Q_IH, M S&;]@<@&IHVK0+1!R=;NBQ9"4UP ML= ZH99A(R VI"4FR-3OHJ+^$=^0I%9:TH3N.;67P*
)7(4\6\F3[DR?#D "WN-_(+YV6\(4'O@_2VXS.!E.CR4%ND8]JM8[^QAE[9KR^/@/T!YQ5V M7\5TI%72ZY7*@6@/>L>@=*
(&PV\X9DL382S/=D$0R3(W]I&#IT^,C_;#C&;%+
*M9(*_W5@T>Z9RET%_:8_<P'3I0/1*=,N%#+Q["9'3QH3$X,+PY:LMR)ZJ=P/B5D9TP0) MV%;W'+K&6'@S7A0+8[LB-*
2%O\C\\8?KWQ7SG>UWP-?(4-W#_/'24:./_V[MP@"P71-*
*-]BF,F%"MPX$42Q%9BCAX%"'%]4OS*7J)2\&7(Y^BP49EFCO!HT*H M&HPV3P5*1EDL+L;'TAV]["*
<0]A:9E3.\%]G[%!AM;UA940'GH']11HO@_+NL M%,H,SS3):UP%J?5L"P;>$\/6T2VHCJY^P-G3K>1Z:CD$WUXS\IYT?
P@J4 IA M]W()^/W%G]4ER+8=NV?D9XNU\WL3YUAQ^!3YP!W7Q0&ML#SD.F
*M/"=ATB*T"X7F==R:LF2VO(8J_RB";;O%X(S#&<1#FZR61)KBIVJ2DE\&TY64 M9.S.P &@M2G"V1P*
MX;DNA]PESOEYS>5>9-1=.1)%^%/GGM%C]C<)">^ XJ#=Q5[^1B3 653K^7$- M 5B=VM-
VRRV]J?,\5)LKY9:IU8"4GX'4OH:8:OP6LGEB#7(:/UB&0_D?IKKA MS ZGR%ES$-XKU4VPS60S-@A7N
*ILJ+NB_BKRK-,_>BEJ)"CJ! R8L ;ULDLG MHVE];(LQAWA\3]Y:?SMG\U^;O9DM*6R[&;$6G+*J#*
*[;#R=N@T%5RBFE*OG7V M7GV;&BS)V.-@<=O_W+ ")H==Q?3MOH1Q'+^*
/A,I]9NT;1!APLQT013\F6AS<8$^STN/CF?:?L(#CZ=,W:PSL@$^J'0X7M'(X=&KB#9
MCY'LGA(\=A<*\I+D8L(ZCV1UE)T6*HYQ45:A19!,H-D#DJFK5MRL;>E'B>Q M,M>Z0!JB4,CNDZ77TX11/VDLP,Q,O*
*Z6^*ATJ^'O(T3 6>#VFH M(P52VM NR+",&X+N9AQ83<_!-^WPNNI7='Q6U\VP)*TR;ON!/@3A("6P_?V)*
M__^B,9W7<@V-Z]<3=(C1-M#)'PXYF RY'X1$>(/ /LAX;B.+F!U0SS._2OP MW&$MEEO@EE@[5J\+!ZF&CI-*
:)"03,9JJ5L54)ZO4945Q)J;(;XHVE:.G6 3 M7:N';%6XAV)YE?)OI0&C]['\X.PPE!^$\H/]*3^PF,U@^'Q,;GSXYB&X9A_6*
M62I!Q_.TTD%DI]-.5^%F/>BRJPVI&8+=(1TY,HW6=H'VMLMYG-+^5N@U/]N M$HY]PWB?*
*B/]WD4T@7'Z@)"=YP#E;@ MJ0FS#"$5%"T2=L-N&0 V?B@7$%NX?J)K;1T3C*321V PC#@DHEK>*3C6:'DI*
M\TN,WVZ#=5%Z_=4>@'\7OW:@2]A- 6)E1F9Z.NF(5CQL$^GP,<^]%A[N:L/ MTKQ"TY3_C2MJ.KZ+'&ZO"ZS->=*
[NC^VA=99WNZ.?7U_KUC]/ MIW5ZNJ3AD6O061K(UA.. MJ*(T_5%S+Z1\;Q=5M/DPI4F&^3>$!$-UY;R$E*
*MU[QUJ.K:52FS,FDX19J,<5&X]RJIB*X,_Y=_PJ0*:(/74DF-E^X&DPQGA71% M[5)F^_ZK&C),$GW,D7*
*GZ23ZC%L!6V#NU/W;%EV_KJT8Q*TRG3P]E=0#7)6L M'I>IRA#FG4LP!#PPY)="<*@3A?<5K\L?*
4<4.V_KZ,AMBZT'>UI8W/[9=.M:. MB^,?1"J(U-HBI4T[W]DBU(8@1T&.5LB1XT4Z?
**MK>Y%!NH)T#2>5!17N#8ZO3RI-/$9N%Z*(F#BFCGMIL481G,7RFR"W#TD=UZGJ@<0 M%&IB@ABM?*
*SC.FBK)W!I\+-&2]MK,!.6H.V8AQ$:5<_G4OTZG(BD_$$0OB-XJ MT6,@)--G'PZ\("[#XC)C\#'T"A$TRV*S>)!8A"*
*(>)"E(T@I)\K%"?$/*B5.5 M?65&0;*"9*TG65)]*,53(:00I.@1-CF3A'/7)H<.L%3A$__EU0,&D0HB-2Q2*
*M+=2K0"L4I&6%M#@_L3%WM1+KPJ14R@8MM4ZJ3(,BEYUXB+(;WVW_6A*D_,F MA1MVI38'O=/JXKQ%YF)*
*Y!+TJFR:*V M[5*$CZ_^]11TF@;X:6$P-1$PH7V-GG!FZ^@%V-?]'SZ3B$8Q'*CO(L1=J9_1 ME9-8>(J1K#$LH-*
M'FQ45%^@MW7(JO2)NV3W-)@/^:]S\?2ME/PJE[&4?7]* MV3^_V>B?TMZB0:.$GX.*7!TMB[L=F0B*RJDG'9>HZ_-*
D[F',20&?T=MM0"RJ MNG(J?I<.R0:!XC-^D7X]1,TG8%:BERG/T@O_*CW^-@ M;OF/l[]_>&M+K.OE0E@ZI#:A(IX
F@6.::X01F=V$-@UR1H#T,Y%YRXP)$+0 M,O0/%Z^Z?7)\0SLJ4XU?F+,SZ1D"GLTIRD:6JCNI=.?/P+@U(XC
MTT1O+!LE/TFZ&]S6S17OW]_53=8%L8ID.R$;:]$0X-3 M@;@&P$G@@6DMF)2=E62#AMZ)VF8$,<>K_+?OPJ7?J!??2
$8%_PSF9HP^U+V5 MH>*-$+%:L[^,/9@[L,.6Y2Q%3"R4-,&LR&36_5\V=$ F9D79*
*MJ8/0*42F>!567V0>II2VOGWN';>S5^T_I]OOS1B^004P 6EN]2_I-IB93YG5*
M[E3NG:=AEJN800P>#S[F%!:J_B26=?)1Z=842Q) 0BP\!DB5X4(Q8&OV MM@_9-SG,(R+#XT&"
[#1@;=#:$#.#:7ZG96JM#_'D.OR/+7XS3>O$TSY7"%QE M&E/HH ;S[Z:D,Q4_^B_KKEY/Z.C6R_H6FZ%
Q6E5[362&61$85"2X?-1&26 M,G[-96D/(1JRO ZA\YF>8'ESOHL#O4>X&UZ.IO7:>%!6NBF.OC-R0[*@<1=9 M>AO-*
#JY:LJ[?RF<"P'9 G'40@T2RC,((H$];/3!WU*SS[5#,PIR? T_F+)'*
MBXT_<+/CP\,+IP'H^OK:DG_!7?'%G5(0N"4NLMJZ2A+6!^FX-+X O 2*?+R M(>;GG)J\'MC?8S4CQ-%<@\H[E'8Y*^P)*

*[.J2Y075*U(>R%C^(X<]DR3%0N3*_M^Q$T/B%,Z5WKM[ZYQ&FMQ_BU(S!\H<01NHN*F"VS#$T2')$6IDZ7J?#UX>HY*
*M9A&=K*ENEHJ86^-&0Q&Z.\O'Y]8\8X8-WM2_"-+C&R$*]-FT>0%YHG1GE0T3_MF>B2/PO::ES*FU"3#P%;J"1-*
J4#YEG73!ELY,A3/BU^BH21%C1%+J\QDJKX"(I->=]\YR_M1\FT[P&O'44_FZ_;S:G\;_J\P=Y7U)2FX29B9_?*
9QC!#KZQ)=5D2&-SBH^4L_M>PAUD]Y2,,AKRVWI$2BK#L]AMS+:,]X-]U'CE5E_]DTMDBQO,1V!6Q4_[35)_M?%
Q"^O8_W=!)HZ:KGH?&LI4]4([,8J+^2=+:!'4:0W<#C"L>)FZA^95XU#W_MOH2#[Z%M9TT0R;'6TL9!V\"_QJQ+3)_%M&
,T3JAF&UK2)]:-(_.^)]:H5_M\]@BL>BC$.I%T98IX4H+_"_5'J&9U&0NM21CN9IJ))>ILGW0,7X3;/[%S3%P_M]&V2LC?
Z[P!6BZ@ZR$';YR\6ITUB1-IM8]QQ#:0$6CAO5&>SKTW-Y>0_K&>8_M%1/M+O/,DY>
*(RT*XNQ:\%4R'FY3<7@=CEU5LNJ!-E,MQH$#JLBE>G(TZQ*

1GVCOC,->2VQ,UU6I_JOS,'&@N@+QYSS01+&=J]@>BRMG#$0F_MV<(-
*H/5XK1OV>KCD*T.V>I'9JN#Z@RJ$_O<2EWTE%8?=5Z*_M,GAMJF['V>9#FC1K.)R#A*T^G&WD!!P&/*0I:LHI2=\;"?*
*T!0;0^2WD99J&9_M*BD)1S"0F/PG>GH-.AD$*0C22D&R(;)VD_;A4:NB=,,>-@]D7_R,.VEAM.2)*
*M0>R"V*T4.R=;H_%83>PQF:I_-UPS)@2O-D%-$4\\-'_$#W=(RH*0[9Z0@?7^_M"2.PG$=/.(QL:/=:.7?P$Y6)MFN&52.4^]?*
*\I9X89U]MCI!8G;?4&3_OL4_MZ):I2$[,)2ATJ[4,;:*3Y^D@-6=U<4-EM:/H%VL:6[+-H6R#'9'-^KL4J\S'_ML:+\%Y%8!RA*
*?.Y)X;_E!I*L,:FH!,U\N%K.22(C2VH^03CA_MO4J*MG-8,N5603O2LRE+A$M;JX[.G>=MI72RE&:<(X'R;%UEQ(QS+?H^*
*<$]3/9=?Y8.I_MNJF!J4=2$G,G+@"G"B\J^07W6-KI;"9-MI@]9Q4;*9#JT+K%NPZ_Y#8UPW/B_M_8X.*
['QA%,"X71":4M!%H%][Q1+)3JC.DM70J88"P5A:#69%,=5P71R!+7*HF$SHK.*(6Z]T+:EN6R0*K1)=->I-*
*%A\'FYF=;>VYUXY.)4HOI3[RR<+Z_MU>U&P(I'TV7*LL/(^%,X>R=*
<_">5^84FBC\0@B#]5,$@#K^>655238F%&T7VE:L1'LC1--%Q4:L\A4XS<_MJ<'PB;ZD)B^D[H-*
'@1[%!)1/[,;9A"!'D)9!:7'/2R,Q[J&Z@$.]R'/%E_A2%:1J6_?Y,0M;EA]D)DC-"D_I4ZD:)"9(S!H20V)28]%O2L0+V.&NN\K1
*MF<^P_:KASD"\D?[JF6&Z1.,)1<(_MV4RWV*J=S?&%WIBV]MV+LMT@M$[,8!2]['9D!JMO7-Q8^1!P_D2"V(K;8#!=C*
M8R\"_U#D'7$ZA"N2)@2>K_5J:6*^#IH_7=10FL$GO_*%T)_X4?1^CAQZ!"N@_ML$T/9#^Y44Z6W+P)(ZMSP-E-
G#BOW>KXJV_+HKFYC4@A@O;AD$A2EA@SY7_7_M-05F&#OG!AC=N$S]UR:;J%%O:!P83/5BJ1J2A/(:+DH#PG?
*I&W;;4CA;%D3\R8]3O@5""WJ3L-MTHR_M+QP\CX@458Z[.1Q8-VDNV$,I/EP.NU01*J/[PZ2=<)W1:_-*
SX1!3LA.]CUCDWY22S[F_<]^&>E168QP&',%XWX!_@Q
MI1@;W1++],/JE6)$JH5]PYV,W3F7EHUMYUR_P7>!:=T8#$T7$0O3"M,QM*(*
MZTU"QNQ7FGG,L.%6$M.S5.E\##:VH>$8&#XU4H.5>8!6YE>XBI))^NNO[0G_M!Q?AD!V+B7/3+S_S'*
*\MK)S1G*J:4BG+[.#.A4_QM+G#=:G35!'8&CJE3IV4_M\=M"ZV\(>SRF(P1>;K*4._?)$AED,J5*
MJ"T&0W/(O:R4RAE%D/Q>95J:(HSS+N+H93I2(W_7J$FF#69WB4YYI](]JEUM+8EP^,VP209_8H3_KX.8U&N+4AC
*MD,:UI9'$35HV6Y$@DE"0*I2WWM@/7>&V6E@@O2"#00:'ZR_MR91''.)02(&_M]0O6BE[_('-!YE;J/9VBQ0ZU.Y4S(BQY%*
GCRB<^_/P@C)!7(&&P.X+\!?E[_MJ.=!,EEQC_AEAQN7P^AUO:@U1(T8(NXR><3(D(B9%1)-1NDQHV.N?XI]5?*
*QA@(S"7^6X$SF\!X5W&N<'F*\\P^&H"=MOM8MGZ@K\T$-/34&G_H#IN*0(%2D%_MTN0F+V#))II,-HA?*
*$+\'+!TD[3'VM8N9+7P2$?6#:*ET-MQPN"=N]]N8HOXN@:/-D-,)T4!S\52)<-F8Z/#5,$_IV+0A!.VE91'*
M4EE5(DS<\GL#GDM7D;O0N9QRQ$R8U37AM+-_U!=<>G,B=1GQCRHS@MZY8>=_M0C!8U987M(H5*=:,2*
9I19BE_5D8HN[8>DSM_M91?&:>C""%T8^].%X1G25#;?K]E=TB^L/S4:5"LM)+_169D,U3^93H/E%19]
*MDVI^NT6Z+:UA:JE-^;6TDCEJ^MZ@_7FX.@*21FT-NGTA;E.-X37",=@M/QX8_M)*I0AX=Y55<_0T4Q2*';D.=*
=4BOX(0K,].<0VK$#-=D"%XG!F>T)"]556L_MP?E1?_C0B^F^PQQ-6)X-74V_1WT"*
*[SP'KTLSU^2)H6G""E;ARY2CLU(W%A-P_MB(#*C;]0Q"2M+*
*<<:_9+A).E0=6Y"G'@SHK5>;KM^G['=4I_%M0';.X$M!>6FP*1Q2M/72DUH%?U&NPN[7?J;*
MKF(T'>YP+\H=TKQJ2B7)6[:HBO(&//W_<_".6K((\F_*RZ4^VOYE!/QEF1BB_M>M1_M]%MO\(+_Q7,[+YU?NMUT
*M**]UK>:+6GA[,9N_6L'I-&%XUK$T3%"A_$ZU-QLX;^8(ZT:;"+J06L0)!C*Q*
M[?:MGABZJ:1,A,M3)A^&;VXWI)X<3T.C#\I;X_V1\9IV')V_*WJIJ.Z&6]:Y_M!,?4(F(/FNYNXUH%;#\]$H:Z&5DX-*
*O6C6$TXCWJLAY0X43V]1ROR>I&6HYB2*4_MZ.Z)2BJ\I_-1CX%^[WJ,!3><.8JU35D\/+MDY?:VD/G)F@JGT+4S-'Y@P2*
*50NK,%5W0L%Z)#DB[QZ?!>>5"=?\[FX3)F*TDR*\MOLJG:RHC&1\;J_M'L8>^4U]?*
*>\&6(4M3Q>L&I6C!X@T218\+4*63D#^-8/UP%1B=ZN#!N-CN%A;_MV\0B!WTO9YT<8!STY!Q('QUY')_U,K9<;/9M>V/_-*
/'G_Y^];^URVTBR_"L_M/3.[TCE0M21;?K1WYQRU;+?=VVYK+??Z8Q^02!9A@0_-$%7F_/K-N!&1&8D'
MJTI^E&H:\V%:9I%XY",R'C?NI;YU[DT'^4)N^<$U_V^#F'_XAN]EIDJ0S!#T_MEA+2ZGB?*
*DWL2M0),!)/GTH*V[RVGQ!.G]1.J.K[LBI&CY/29VD(!XJ>Z*C7_M3?T$!*.*
<11FL.$4DC<>K)^#:Q$*L*57T@VA:I]=,P64K+LF,%>_!5QZ)_1[_M_[V.;8K$^!H+>$&&_?+M?/1Q:.61Z*
*(^2,T!=U1YM._WL;9L)2,W1--XAO0_ME1*W(T""8F!97S45S1_V7D*7I$0;=]O@%ZLOB5[CYWQ_J\S1S6_:O@P_0Q8**
*M_Y$\>FEA_/C>E(_)'>T5$5*9?&*5]_5FAT-EH'O_?\$$S,_711G#Z6,.'BNA_MI+(_&;O\RL[JV8<<)C/":WA+T22M[;*
EL(6]_[('^0A2L):S%BA(9<)WA;6HO?CP83\,,,_LM,T\FQ9_M,=#^/DQ.JQ=+-66IICR<:LJ7S-
;!#CEM\K+>E6NA,#35A@%OX6W<:=GC9.0E_MVM.?(9)/:6_M=;JLT[/KM/.I7(K5DAX$/&7Z3>13!$S[#8@"42E:*
*["FM@L]%('?EQ<0D4APUYQD@@#?G&)GF/_#,@$P_D/F*_[Y*"%:B+W*VG6+C.FR*
*M^,\M_KZF##^8);A2BK!:@E=2CFN\A3UJ"H(*K\=1^F'@'=@TU_N/;OWE&5B1*
*M%S14"7$'ZNGG1[3IP*V*TGZ2IY*.'O+KU^#D)D7_G!0_(2TF63!D'"S0R5S]_M]OII*&3,Y;8&_8C<6,3/\-,-UPNUZH\\B;='S-*
*K.]+*C5,A]YVB_-Q7(6XT1_M*(5'/H05XYP=F#&U7L_7_"S<)&B[+DUSB2\T47_"ZM$R+6:VS#A<:+*
M:9#GBXG4KF>9O&G,GP%R$['NI2/&?XC24B[RQYZ/Q)>NZ]5WS2"K"E+6_*)_M(KK:<3!*
(RG.=G7LZ]#5H:&>&P6R/7@#"P_5!9;8\BL6]7V[#L>;6D>_M9_KE!G"F:E!SZ91*69*/_VK>K>/4I?*
_E%>T5>2))@^*Y.9%.*5YFX47_\Y/_M4%M44JS<4_\-V)\IET^\1=X?\-*
*:$<"Q3$QUTF9>4Q^+*D"M#'DK1YM='V*H(C%7"W+Z,PRVA_RLK5PP#7%%.2ZM^[0'[&@EA6TK*!YQAUD%]%?*
MP0U%_5>+NMF63,Q>[!O:H?"C_RVH++?H&/6VLU2!$L8=ZRK,XNJZKI_MQ!IQ=_&R6);%,KM8I*$\-*
F^K$\1HZ+UT*!WZMNM=ZAVQZ,[E::G#+DOL]F"9_MVR$&;\"IVW[2]['X,RW545_VD#J:8QG&U!_WAZ_$,/7^:/4'MKJIT?
_8'/XQC_M=>'N8O55Q;0],.?FB/DXHI$/^L:_2>Z&_M?NS:B]4W3>L:/,C$0Y3$>"1OD'0]!SR^5M_F]3L'O95[(@B@D9VX$T
JC(/'_MUS]?(R+A_M1_DOU"&GN=80#4]!+&!:WN^@'K[_CFJ@%OA!&W4SUFUX3;>)_X_X\6G/^"\W\X.'\$*
*MG*J=F'N_CCFI_:Z)\LQ#%S5WF"A"9)@+LAA!.[I(&"4O5B\M"F@&U,!5>LA6_MH_Z$\O<$'H_;L(#5X-:@8[-*
*Y*YQLWEQM<_#$,=@B&A'W\X:Z_Z8-;?C4Y9),HF"_^^3N+T/J'_V]83GY$0D=T:6F!O>C'M6!#(G0[91_M_^*:,7-*
**680.P2WIGY\.SNB,90$K))V"=!SPIMPOP4!?Y-X#,)9T..[I"_QRV]-C8=&LK5R^_6WUOH@]6?-*
IL=1)M,N=$DKN@G:'L%J/6Z7-4:_=M95Z/!D>6<5EOJYX0>L#N6RK]_MP8Y,)TGGIY[G)V#V"Z9=
*AD"\Z;Q3D@TTT'2E8B$_T4H*ZF=TT.G0)$24_6_M0E_MD@+)]##6D?BJII>G:6[.XY><+(AZ-/G;TCLO"+1H>7#;L4)_N=6;*
(D14_M!O'4PX;[<5?TV34Z#83H!F@'[S8)/3=P@HC8X)BD$7X\Q&G@^^I8[OU]F#_,_MK?
*$AD)NQO7H6,\P076\839"HY'T7FLA4:IL^82$)LY*YI?&-K]JF'IFM'4S_M8TG-3L,0![XZ0=:B,QOV*
CS^""AN7X17C#>X04\BD;%B5H9FDC.+MT81V[3T_MQOX;?P2B-?B&B)N3^9M1L;R@L,#;?W^U=>./1U=?
E6VC8]8=6AK4_4$+==4X_M85:FUZ8;!>:.?*
*2\0'>_*NA!"GYO6GKBHB43,AQ^_>/I")&)^XY!83IYU_FZE]A_/RJNQ*/FG^M"N+PM5(_MPG[R_.D'G]ES(IF*%T_^?*
*CI;S45OU$3"#%%9*%_1DG)_$*M.2/&?P=-XX_$_MQ9Z^)&VDIJP[]D4I'0DC^\8&BC9N>CT];)19Q=_FE?0*
D>.;0.Y"G+AW/MXH_M_-9#TU@@I^%VN$3D7=H:F_G]4)WH_N@-\L;!CPTLW(QDWJP4S4V#>]_^A$RN
MGI'<^(&V_SAWX/8-F9Z#NUWAGTB\][42JWJF5R_T.7H4UIRP%???2MW]UZV_MK5@EG*KV5?*

9(_F[E^*.T<<$!P[EWHVA3SLOCS#N"]&]^;XRV1A8H9)-1S_!* MV?GW,12%X!*<_Y[Z6A0XE4<6%4MW7$3-
X>YWG'13CAB-!_4FC2FVW'A/HQ-$ MPD[5U6P3BQH#42M(KJX-'TH$9>F_C,JOT#B)SJ]AD117
*MT*S=Q!$D;Y4;/G[',XKD$UIS7DX-ZA:$.IW+VPVGM*8?6^C$>1$*.>$*1*]\ M4?/-A">=;D\L='VH%A-9)7$0SK*
*Q7>MNBU^L>*H=Y>9@J6G4M8?H#J<%12>R M9CF)Z0.0IBTBCR8M"F97<80$]3*
M#2H;;VO)TJ+375KSI)>"5CSLZ[3=%8:RT':A5BNEJ,9A1W9O.-'&.Z$)$^V8 MY(A0Q8%B)J34)$)!YIK2JC P.O!&!
(:).7/9O:!/G5:$250"^H0/[PSYYYK(MLY4#43,22=&S4JE"G+C2R"<+ZM3TDG3R VZF@HZ&?%+%4X[A28%/H2/GDTE6
*MJR74&SPZ9B3P%OB)L*F+";V&!UG:_'@I;2ZES8=3VAQ9.?\+T261,QJ;U0B/ M,!@.2='5YB_?##8QN5[&\[1&6*
*^'F*T<&T!_Q#ER+8?AKK3)&X^3S] QIZ<0 MGZ;T+$(_28>& M]"2?[=XG%7;VMJ2H@8HTM7(3+,@]$9R7CM7'<*9*
M>,;A_6,S?5QS6I"NR[O,O_VN/,A]N>Q'_H]$FQ+-10J?M12]A;VG:3NE,AU% M$\+^FY2,-SYFHL@H]'S39%YX:
8S8":@HF.Y.Q[3[SSA#L]DXQ9 M2;[!>|\""LF/?/G;O#^!CG /.% 0'1XB95[(3.&
MLWE]YO%P]%RD)N3OLMEI&:/@P"AZNK>[I; B=XF/W'1\BRQGH5FEWLG0>]F M'[J91Q54RED4>AIB#QNFG?*
7JQ>6L48 M>MP[@1$Q*DR%1F;MMF7 K@Q15J8"OJ,*NLX6TS"@EX2EN-B]7 *Z3\P%B1R MJ'/.!M7(5]}^E:V^I-?*
*\JO>+AG.<_WCY9TE^V;X@1-6QQ#.;U%'+H?&:@X3% MD*1FODIYWWGHE^_TUCL(I[HZFEJ,>4T\/1\#S@U[QGB8G-*
*':^2IZ./'&FLF< M/I%'F4Y-9$GY4;.1R6XQ*BUBZVFO[EQ^50*314)8CA?,P%F[<17X[WS>7C!H MZLW1'6B/?*
TF>/H\4T78?7;XG;#0&!=_OY =_]F]4K[XO!6/U3?Y?I[Q=O=GE MA?Z>CWR]PG!$[ZAM1#VN/H]O[X8UC$_M1#
(4^OM8EN/3@+]:Y"]6CW^$D=*@G0*(-2T4QG/ M:BR[^Y$F?%?#I,
*I:E/!%%&]0*JESF/)MD_IO:8+61:6TX+'R>9K*#@BOYA2303O#,O/M /\1-9 9![.@H_.D:E! MI,4O37,QY)*
4(Z/=".DAB4.4,'$B_!!P'P\QLT^-81CZ>W?;27R7/RV-XP9 MIC_]VQ;_ES[#Y]J@P7; *)(R?LW_A;I-*
*X5A!,ANY0K@SJ@I1KUX>6A]C/G_Z M_$/+4ABQPJ/5)JZLV37,4I:*5%8A]S^[T:P(=W^@_,* W6]F%_(2XI#.WH;^*
*M=*9_)*B5K:=5=M!Y-*64,_O"QF4VZUR\9$6)BJ[/Q/UN>Z_LEG- X)NR2CQJ M*)"8>F(6P*SGB.?O;5&;C76'7DJ^)64G)3-*
),;H-Y_;27.C3V$'YO_D.?@DQ?0,>BQG MW^?3YQ $X;C",F3/Q^#N MX&97^?5@3RO#.?
ES'2RPU.BBEQ=Y0_NV]C_B2XF[%1[ULSCT2:?G;[JEEVW M[+I?O.L ?VXZACM$BM3TV,=Q'.++$8QE6?
*3+HG]0BSY=V0KU9I=[WD]+91ZU M.<,?)01NYPJ M%^+6[S9T3>*LFO[@^#=+M$\0"U#.%%*+N0+L;3QIE/A U:V*
MG@WQ(@FTUD$2U&F$-6P4#Z/Z].3RZG8W&]P=KREEU7?+QEXV]D/:V,EIMB^[MB$U+FQ .A-TD+JN2D%-
[S>T$^"8,04O:-QWU6$C6^FW=7#_9-==")W,/.^.A MH7$^6= X"QKG'=$XRRFPG
*_PBF0D(A#+;EUM1.>^H'?,PILF)H')6QM@6<5 M6:;G\4OLRM5(QU.&HA=PSV]U*MQN8'>*

*H720LV!J+^PL:'%VN[S: M/K[=LX5&X#94 /+0*9,3X5474#/.+HXF%*?R: EB(#;.<+CXT>^VIH(<5:29 M,*W2:?*
*U15'A^<*G0?7T:5Z(%@3DJ1;-.D@I8*XYNM)KB*Z]/YY>HB)Y@T#T M&X1-8&BH]$S':'9"8SS39GM[?^1UFUKZ%ORD-*
*]M,.IK]\KF$[+P=TS'(0>)O M%.2=XDT/%0F$Y;,O$J _-3$$4>N =MBG'9C#*1TC +/PHK:P/-E?/FHCG]B8 M7P>>R[2*
):6IF(L(!O/&.87C//D< :C"9D8(T>;VY:R>_,R6"'PC1A">]W7X
M2[!J=DT+7480W]'J29''ILILS)VC@0VV2CKJ*QULX"B]Z1H=F_/0)A@O[2D M)8X-]?H4T1?*
*C4UK7K1WS]_^9B6UY__]E)M@;\=](M%OU=ZT#)[LJL MS0+*L93:T'2Y*/@-H]$-;(=BX/6>X/:(N* T==D<:.E++Y<*
A5J7(+-TKT[. MZ%8[R V11O ="Y8#J%2;=P D$[MZ&@8M4 P/-1OH+R=!U_W1W#!T>__47/D9S']$^&
*(TGZ*YH8$<7:F[A!('"%ND$62&HQ%C8LIZI*4 M#%OJ1.3^!+]&O/,$A!FGP G1;?674DVO "C/@OBBM[C-*
*1)GG2O_JV\Y(>T/ M26\A.BN2.*VHD^D*1H'6/'G2.^&_W;E-+V\HV&T+2#(^2'6:)L@3YW (EEH. M@3_\Y[=C]J4Y-*
IJ4#0C_YO8,9YLZ9AH-$N'-#]>6K1X&MT4F S.)G0]']@3 MF.Z.BEVY0=MQDQ\TC35X#*
[GX>%^83I8]46B/RDMP*ZHMS/92)$L!=^HBV M83\VOZ9PN1GXDYX) :K-[K]M(?"&A!U=QDH4?*
@SH<&4_*OB2:MQGS@/I5@T% MHXZS(X55,4V;N?B> !$.@H,?K'1N7A1 S:K(<:17XA[H[4F]98 Y]#]/>@>,
*M3WJ#__X;=QZ+_B6O+SWG_0R@H5@$1^\&D+4"9\# 3K'5103IMJ2)H ?CF1QQ MV=DVH(1*C+*
*<>>@XWCNJ@$US1:.5#-X5VR4?I]G7>E::Q,'*93/*7 .97=LPW*
MYD#E&0\!#6U&69X[[/=P\>:=]_;Y6;F116O,4>D_'G3U"'"\X[[E#6Z)GG5DQ MQLQED](#+('}S
[&L''ZA8$5^$T_]O_V]UY:@\KJ^N[']J3_"]G.9WNNRTE
MG@[$%"1^/_KQ8O_B[.M>#]I_WH5"2_H<._W)=&-6.J.;G]_[:^W):5)_8 X M+WZ>+/DC,PF*%W*
M;=/MJD;&J=AKBLU4=,6:;;57WDN9IKPM29!32$Y17WWQM[I1A0&B+Q3 WO$6Y(R5[V9M.?H M;>_F*
5,+9^SKOPVS'RTFL$(;C :*[N8B?:G<',]^6OR=0(IH/9ZCL@$>FFI M.R&L>2>ZOUEVOTF:9S.5FT'5Y=Z5M2VM+N
+NOHS.H\2.BRAFN>+2K ME3_U3B+L@#D4']EOGDND-]/W$[>FKXRG6S.3RUA8FV5-_MYWW M+X\2ZU$]+&-
B!2+7@Z=&"1MY7724DX_PI#^@8W144<^DZCC]PM-K)M?3H7X9 M/;0J ML$RHU,5Z-*
3:5'W/VF63+0P:=;>"17Q"V!E"2F)C?FBCN88;J?4?,X<(=8 6 MGU$H3*QMY#PU* G,B# I^,VD_(N4O0T,@?*
*<=H;_LDKR1BE+"NK ,<\K>3\V? M\ XZY\]["K$D4-U57!X63]ZHG?-S[H]Y;L[PN.P;VZ\H3J^(=)FR#==E@0[7**
M=DGN0,P'A?EQ9'ORS4G(.B1RL@\;^+[0XA[>S;:I(@3N.$,YGOE&J.5O-?]D
M@.XZ^ZLO^Y;N(4R\VM/K%L0DXKM%Y,V(\";TNI3/+< 0W@W@Z-*
*$5TFQB\PR90+^>+1ER5D)AG/JEEB;O!/W^=MDY*D#KKH7ISV^@D7JP-/(O$UPOW*N&,$53 VM/:I*Y*
M@%FM^XZ;FNGG-F/P$'OHL8"X&]CFJ XM6X"DD7[1G<)4_#^*G$IU3Y+'&Y
*MDB5QO6M82"N9[E$'8<#G*:!TD*1_*&[2]\"-44X3)PY#V"@] MR$L%\K0))B*RC*A(%KDAALPJC"6H9W"7NC&*
<0GY)13FBUOECH;[O[?R%8K8X M[PRWH]P89A%FJ^MB_,0I9/\$U!GBCRE6>>5"WJ:7/ 6SK49'"$JT]/8HUNI<93:U*
*MA8Z%J5-$LX*3W'R1ORQ941&&0<5< @O'[;A?2RZE(\UB/SVLGGN@_9EO7']4 M=2V_?H)G)S2AY-*
A($G^EPN]&,R^,EO@FR: EW"U)#!@!?D0BF YHIJ#99?Q M67P5/-,(:@Z:H3<2' MQLAW!V@L'5U5^9:\1G85J^8:-*
:Q]&C% MHBZO..HDH34S$%;T<6N0>V5=*(MZ=/P3/R49!+@M0LN%<$(.L62FXT$!I!-) MD>4BX4AOCY1,
[4+2;GN3B_XK6KX;6K3>0<_I@16P/GJZ%+"6 M;[4L#Z)6IQ MPJ[P-
V(YKV(]Y+M0OE^]9.E8T2'Y<]D,#D;Z^K>P8E_714]9W?L5F;NEQ7D0 MSK7T 'C?]T=!JY!#4,7)2CPF\I":3GO!F&^8?
*&T*_VJ_#K$"S0&5\.\QUE%Y MZR-9U4UBL%)>2Z,LB9_2$Q>IH)QH/S;Y@=[Y8E;1[_DG'SW]]/[2(5_78ZP]*
*MQ\62WE"EE@2*$5U0 O]Y'S2D,16?Q U$8U+=C-H$@]<8IO?*2?HL$HGMR"J MU)G?.>^S[##!W+^+R5Y')#$W*?*
*A"#KN>0\G5R?1Q4 M3ORT\JNHLA#+:<+%\]R*U 'TFJ6H5Z]9:$AMUDM*N16PWJ]H2%YNCAEP-'L"*
MF85>G]\P:/P5^MD7_E'8TGWG/_GGUP,WP81RO.GSYZN'M$OI8?D]>N7KUY**
M$PE[THA1_'01WLQ\,7[M<6;C5Z0)>$BY,?B:LCMQ+JD2@Y"('YH.EE0LELOY MY17-20DP5AND7P<-(B\1T8AF.06?
XG'[9S-2M,# >1NQ[_=^^?D7H1?_!EIW M)2W -1[UD)\PNNL12>5VM6[IH6H_U])"CXS)LQ<7S_Z#5L'S#_P_/HLY%ATS
M#B?T!E'#_D#W]?<)SY!8LX3B_;/0@))3M_R3@CE(66JIILAQZ^!P#\ZM49LB
*MI\CH/R@!A<6J^UTF%"^),,5UF[;DWEP\L"X'JN8%>8ZM*Z"19L27_3*^;/,] M/W2%$(@?*
*W!NRO8\%FH*38MP1P!M"1\='/L5X[/N@8AO&"CUFW^%7M$?HALR< MGE>;G@.M.-(Q0UCO?*
%1'N+MZ2XUU&8L<5OS9GH D$-!%7/XCL"N?D67C(4'
MY\VKP@3]\""9A3N%)XNOOP&GE+ZZ[.@GK^#)^(^_[8_^''+DI$B"_6M17.0B M
*,XD;Z84C:_<5(R8R329SU:&%;9@3VVEB/@I_UMV#<\B?+Z=4WWWP=E>FX%?_5-V\R1FIT M%,3S;R@@S4\A.^M/N*MR*
Y2$_Y_%O:-_R=.!0Z/IY^*K),SF]{DWF>+BJ MPR_N+1WYIB0WI#P2Z:Q?\30"HU/6KT$T6UWYY?"C?Q-.)-&;>P?
^TK]3)ZH/ M?GE73H]/W=D&:"UF\,B-@UQL9R3QZB\@O>FGZM O:N M3D GN8T\.'K^:0K>O{(LPCLR[OQ$&"N\]?*
S_N'AS86P-GY4O]WX6B(#=;Z2- M]S=>$U8UG&S/GR%+A@P6K9[\F@S,.S]HV%C>VR^HP[HFLGF_9Y]F.%'6F^@ M-X\]
*) ';5B5#C I!R.;'GGV7_,!H%[9F6&"I*3OD\!C"@EW[UZQKAA^L_NJ_ M2I4#8I"^6/V@"%R]G6%)X#O0_;*)_LQ!IA\-&W4'] *
C[>>"^H$Q@[P=_J>^0 ME+P&FCM?.XH2Z_%S^)UMM7/>D4O&&S MHVAMZ0IE.:Y1X[7?')1$S<.-_7"+V?,Q,AR-

+37'X^GT]$1[KVQ,?_X*/A+' M%+ EU&/CM*&8HAC_C.^[X_\&+%DTR,A*T)M: J;K,?.C#Z#^B+L]O!)&VPK
MZ:EWJS]C@#YG-<::*TX\XI8D'SCPXR''QUL-W?*!!,V(8 :*"93NI[6(1Z6;
M^KOAP2BM:00^M#L6<@MK)WEV.>N348KX]61=&22AK(H;UBI;F)L7-"T4F&M, MCD0)6\Z7Z^K%F $B0(^OJP<#5.
[7O3_M&6SG0C?6.;J'I'4 !GQ]BO>37R$L M@;>B_D)XT#QR?*ABFCYWG98LX&64&HH'/9'8Z,[7OFR;:];%X_.&ARZ.Q4V#
MJ&PT6K60WI^A3UMR!@;(EZ#0RPK#)Q^D$R'@_4&P7EKCB6,K"R<9.K$Q]+)M
M_#P18";'"JX&V2GK.]M&$Y(ZPFDFG4#4\S(8(5TMLNB3RCFV+0P-QY?ITJ,Z
MP;'U9H$2'&%3CCO8U7CHG:1SF%,R&M!"@HHN4C7HI<%\$CC16V!7;[Q+Y\> M!B637I@4!FI?U'_=+PW0D'"-
'\/$8!Z$?7C05J'5Z[YZJP0L]^G:&75W1"#1 MKY*P*>.5DHD8%R=<3)3,QV 8*..A-
8=C;)MASVNR#1\]VO@2G_9BJ35LX[8E M6JS1J9+;Z$%O'B>@KXR'WJ4Z)+$T%V5Y_(7S24O'GW!%L7!
[&81AG@U9NF#I M1"=-I;B#77=0_U=-=6_YRZS)@[,W%)P6QJ\J2ZK(.'5N$H0C]L=CR6K"T)PNHJJ3Y_
RV3%IP$]V3=!ZQ$8/3$.C/ M3$X@743L2:9OG!N*$',C\6] .*L^W4UZ,Y8EQ2C0FO6-$N"N+I>35(!VM&Q%;2V/(&
<+U/RMLWVUH>+R+>=,CD>!XBGF+]/,UW=IO7> M;NAFH=<5>LYN)'R-*P\0X:@6L0S=%3H,'VWT0)"RNQ3A=
DCW7)Q?G8 MZ]>EPYG=[*958";\ M;:F%(^9 ;""6L+3_;:N>X)KBPS/8DKF'3OY ZJPNZ,":F<'0$0C*(E/[A6.U
MOK:.LH,F#'.LE)U%46!8&N+MVD13J,NXI V\<\(RXE^H9$QA7_L]1,5^:=*Z MGP7Z>91GT?
%/;4L8H(!P[*0CF(G!4[@^+6$I!#:<&Z?Y910EJ?):)LSXRXGY M2*E/)U$CM[8!B%T&Y0P@>[M=?
T0TYZW6%8)T7HBETAV1]*<%:ECFV/"@C+;L M=.PR7KD[!DEO^[9J^DM"E-.S"7Z7AMCY8*HY.:>$)LUAY?UI?W)9-
A5T0J$H M0H5$/V[F#>CI\? 0\B9+H%B-] 6LWF<-45B?8U%"B3*?4(C:5K:4R-]NRRG
M3E!L[PH$S=:G&%E&1I8DUI&0[=S4G0VN9-C%=0$HF?A$X]Z 86 NP:($!'Y# M>N>"<+(14HQ$G'9:H N#G\%PDYI7?
SC>Q[>&+X_/$;B5$RT9&W_W9N]:S2/' MGCU.'DQB2;CH777NVO9TBU'-
(@Z[83@T_Q=JV::!CXH53]Z6F[<4CF;>Y^=X;&*2##SU'#B"I;O?>(!6$K4'3!WCA>A\V M2\-A4>X-
>^V5%9>GCI_JE'Y\]Z=HJ^2#!55I9+I(=P>NLBYCT3^)$D3] B#9MY$E,.&E'&GDRKO@5 G[MAE9_LF#6;9,7U-
:JW+BI2KV"A M!VK#7SAQB=-X/31$@>5!"REA@+6JHS8C#K@B \\G_E$\.24?S2%!8Y?A=: $
M'QRHB#/,6DEJ'G,ECZG%$M/GT_A+Y9@5Q ;3=M/%;E)GOH.>T2_+F6D6U7Y$
M^3N8*7J()Y.^"WPIVWYLRNF+)?);FE.DL_05!I)OO;)2/#H%[W$4%V('@\2 M0SL_G$\Z*OK_J6ZNVUQ5A_
J=#0__BW3S_Z^-//AL)% S6B62VDNS[R;;.. M-YD9M2+*WT)AY03>E"-423!0#9J+NX!9^7.
>]XZ"CA+YHGB0@S[AUO7"DFQ M-\0,?]GWVHLV[W80^CSO=OSQZFU)1500]ZMH3^NH(B0)/VD2I3V7K5R)IW_T
M[+$<141"(YSB-6[B3T Z\T%$PR_'OQ3J?.4")@)))\+L+7B]:. W)O5<<6\08
M7Y*'(1=_QQ:&\+B/GO.#J8H&5='Q/UCZPF=N3\\C:Y/HH7G9-$6FQ-6G+#P>
MC00]\3L]IGW*V&/YLR=$;8MX)W[:T'$P2PF\W'J]#,3%N9 MN#%90Z8^2D$AM3KD1KJ:[0PE-W,ZDB\E^R%_=(5&
(N0$D1O75X" \"-OV1C% M\JYU'DR\#_Z"MV*]<)N)6Z)6B;_377.Y+^W@%ME7. 1")R[!.NS.[/.=V7W3 M=3)R]&.-[G8[-
)3^SFV(VRL,OLOZ_E7K=N?,Q=@V_$JZA._1^]BC7H"?7]=* MI_":4$7B4:++19@-(D7XD.+5GGW[Z48"V?_7UZY>A^47#;
('\4UY(]Q7C;/8H MQ)W5G:ZX9SI05]UFY_;,F^@;Q#$MG6MQULVY!,T)-0#N68FQV'$/Q?] .6XD!N;N/O M(85Y#
(]H_EVX;CMPJ%MSG$0+$P6ZHYQR3,77^4U9 MP2"9"S>*7BKW]%:4>^9UX%^2*
ZXPVYNQ*19QI_3L4=AV.\]_^-6M)8&FE\T M9BCZV]JAMV=Y*Y2)9AS/C&"">KOEX&3)L%-35HF6+;\":L*(^XL3>
(">"$6U MT*#,?T4SN5_G'600R>2@LYS_F-?^-CMWY+_JS)EO/-F7Q35Q?BR6AT-
I+24,9,Q9_Q#AAYZ7OX@QS\OD;WGAA3172@U M80?;=LE(_A.2=V&GA=S[.3 !2!Z&X*"&2!-+=,!)&AS)_JV_*!-"RI^57SJ!
M1DJQ$8ES_"LMT]$0)&:E\[9I78&],7_"-LPM3)OPK7.'U;IIWF]MCE)Y2K0@ MS,,2NU
++)\WE;2:L_W)M9V,HR5_@8.RPL%&@6.[E)HR*2!Q+WL=!8&%#P8> M%6CM*HAZ]/51.\];R#"E#1X,7<:D"N9DG#T
M'FCZ/S-=(8L178PH7N@--[+FU]"K]P:,LP;,H#?& #X""FNZDZL9%G\X#]\8 M0S8B+@% *0X
!!*0RH%./@GL%O6^#X6_<'\[RQACVYRY?TR"CDHK@38Y:+)IC?.3"Q1G#N(TU4,X-19!W]> +NF[6\I9!U&
U96/D7*+]PH: M)KBHM&D.(>+H\9O"QY"R,).3SP"'+&,PZI%9+%#@)5,@GX$"W@#8"NA E4#? M^TW:-7($NI]%=$
:.6FM;YWM%HSV9IV))ZR?=>\E5%J:1-MCKQI; MS7 ^?C%>.,[7(#H:";I;6PK!5,8&KK!##1J6$^T
M_,.:&JE6QM7,UKD\3]P,70:* D6G=;(8#% T/E68V>X=I],. 5Q0@UR>0-9/
M*4L\>_K!/5(IWAW&S()CI*@4U.7$;+GZJFP;V>,A;XY3,=^ZXVD.Y*OJ'VN"
MQ233BNV(A'Q@3T'$L0F$F(90,2#%=;1_'6V)X6R]^.3WFZUIBM%^[]!:_X[C
M;6F)""#+:QP=3;H[3PSG+]!XKO9IY_]1P80""M[Y[WFC22APEQ\#)T)1=NCW MAGN3_U?
>%O2HNBWX;M=YA];\;],31@]?NAE.*WL%A&-5OM]+7DFN9U^'ZL\2 MCA 65!)XH!*4;X]NB3W+8%=G;H8'-
/SD/S@36P>M^PG_(I!+F5'@$W%Z!&(+ M;>#E8E ;"2<@.^GG-A)H@=JO;T]6[*\W,N*CK9+P%K7(A1\#*18O";,Q((A
M0R;5S)T<-\/'MCM=>&+J(J?(.01P&D)VLWC^&U[7A\"H*3!OSQW>7!AAA5%U M?MRX P7E1%53&JTTL[;,:>)4JB@?*0-
%O%SP(!XD-<$'"UQA@2L\!+@"#PO7 M7$[8C4)G*BU"&]*[NOEJB!C14AB;X*:C4VDH CD7==LV$>/([!U(\,$08[
M(XC@@S>R3<4EK8UDT:RIX.K>"+[,\1"2DM<-=/NTI2_P+;(#K! SO!O)EXB2 MA8Q97; \$$BO)&3C 2Z8.QMF5Q*P-
"VQ1W-@B2?/?&.)CSNT_>KS:-2L)'PA MKQH9FRZ)I?%H-%YTM92R*$0>.HQ$O#I+U!OGRJPTJ&G^7&[_V\#XC2A2.K\
M5($Z5YZ@[Z9@)RS="!<*%.#&88B>2V8&@T+"O"@;$1F)A]_82_WPXQ?//[A7 M>O91!]!8)
(J7D*T'G$^!O).WBPI!YR8N-Y\"VA^(^-*J!V9#<9XHF!KR:-RP M-FT*YETB#1HMFY0=),E').$/Q^*A8?(YJ]$
M=T8E4)K>X!Q>;SS7#%@U6S_!;&F9DP"T>TXJS%*%)K/KK--(EH>Q=YX4PO MD!E55JXP4JDCVD
B[^B^T*6'BT*^\0Z*929#6DEMWK*4F56*%VZF]"JA32<+.EX* MIAT^F3;X^(@8 MP^KCGY[P DZ7 [G]?I?\J;PK[^D]65?
-YBW2#K+D/KKXZ(5>6JZ#A-%XC9K% MB-$:',&9 $>481<%HU3S1KGTH[HK6/4Y]+ 6,A-7870]],K9T#K"[C]M[2BE
M7%1J9/8\$J?/5%(XK_RS%$)9I1KN65B!(=QBAF#E!-PR3!BK1_I4^&R==EN6;+M]C M0F)CEM20(GB(-
(M86P%6"=5+4G]>-X4LC,@Q'U.E'M%Z1UVGTEAL53%?CR!6T_J X:ZQ&XGL' MXE?\LD
58D.BW"]LGOD#X9_[6GQJ[L+,DF!)>%JB^0R5J:GL>&PT"I?^7O0]:8_\?>;UC"31/^Y:IY2__8 ME.VFWU]I.
[A:IO2U(RS5QM&D#;"DH\1A?4K?W]MW@NJ7A+X1.4C+0<.AD_[Q&7
M5T%'TOT<*EH^]BWGX\L__"=,'\YKTOHL_U,HX#)F=KUL6<0=K'#V*1G1ZSE M"H T=3J"* =O#515
DO@X$.AA)1@+JA6*M337%P+:\8+T=:F,=(*R6,#$ L* MW"(L=F(H+2T'I%CUXGT=#6YFDLY@2;T!+H/-K*>!3
H(Y*#%$@THU MN^US:0Y)-29$M+Q-C**W2%M'2)6V30J&J[%JYW1Y/U!6F#2TAHQ9Y\.-]=)E
MO24<%*,6+/F7>=$A_3*#FZ@261QWS-7@1_#RN!,I=3W>0P<.A1QA]
(KUH;1C9<-6NZ\7Y@/F+QGXT#K>3./@^F5GH&&S] MP]'H'T@]74O6FMTS?NI$5F_*&Y8=&",Y*?L(\R1Y-
Y@/2H!WPBG8-GYO!O0M/>"%A]F>U9A%;C'. MI,=8HPA%U0[.95:TSVU!@%NL>3#H=6%V0WX\-&"+';7=F1)H3<_-G0"
#Q*< M\.$"3EC "0\'G# A/295OPGUL<&193T.!"#@?P3'=XHU->+1',&JZLNVK.:R M$$WP"[1JW01;9]ZHI4>.@(Q3!;
([!6=XOXURB:T3A&P.;"0A5!IM6LJYB,U MS9F2-Z'KP7$!SUEP;J(4S4P*\CY%L;1VQ&+<.L$_DRF ME[UA5F3;T?;S:?
LN..3787BHS>7K-@ T! M.PAMEER],'^:E1T64>K$(G%XE)X/BL.1%*(R$0E=TP*2]}{$H?4+8._/&D MJDF]U4XB%
(DQ@AZ9Q"WF?IAN.D$V.V'7#Z_!S@VI0Y)&J&D6TZ4\P]7MX6@H\ M;EALFGZ;A71*T568FR,KJ,W6#?L3%JOU@_"7@H\
MM 3]7]#!X3_FJG=/S>W$1GO,^#P1*CS4.6,-O$EW5"@!.8UN;(?).PU-7%-4 M9[[#J-BZ!^I1&KC'G
U"KCBW@X14^36N&A0Y+YY6TSOI8G'4D#;Z04?4>]57(\)U_CICH&0QF
M:!B,EH@.O=@G%'OXST3_37JB#1(#\D0U#G;(6UPP+,GTN6Z,:1S N^O@%I MP)1K8;96Y017*J,TZ^J,,E?:VR 9+,
<]A=:9-XA#DQ]3BUI:J3+UAL;B+>:7 M0ZU'\;$V.S2$)(*/]C#K=G@:ZN9#^AA.H3(-A P6+&G(AZ=2[7#:I)+2N%(
MA;',+_YNVO],?8O)IX(AS'B%N#JT.DM@H"))H6B@T0"#!YED0/VUF,&;A$&L
MXRU92T=O4FAFF&P<7JGLL$Q#W\O:=99$1HS7[ZY',CA(Y)03^/ 0KI9J+,?T M9&QJ\E9IYYV%ZA1M7Z9U">G]
<3^OX/$),P;GK7[J21Q.#1YI $W*2L'DP%Y) M <4_YQX^9#X'GAS=6-'?U0433*[6XUHD>CF.1R\,YF]9%QTB=

C^Z757O(B-M+O*XY1"-FT'V0]Q+0Y'U*>E;=&A?.=&^#2/(O^9>Z*VI FI!TA2C0C@G^3\I M%2&.
=#FJ(P$>CF]=^(0J+DE-(7Q[L>FEE9Y19UQ/\(DDVWQ&^E+ K[_G--D M9ZLO>LI)YK5)2 0MULZ<-T8#B8]G?
KS0%:B4DOV>0'A-<>)10OT4@T<7+AH* M.5ZC!*[YBBW+>!,U9-20Z@!*)30 K1VRP37O1{OY%WE.8X,A5[V7J; MP
MU2?L8'BA=%T*.&D2>1XF'"*;6)_)J*,&$3,\B29 &.9IC0*5'/U47+Q,J3B MG)G"@&9*#
J(SZG!XD.J7)*UH+4U,$Q<9V29C1=BK MVM5QGU7F1[KNTP'!,,*M,-^5:/KQKU>:3I:X.@ 7JY=1P9'QP0I+R#A8R&93
MKH-:FK#K!?$_6^8G4SCT%[@%1K<(YEF\|%OA4:>PJ%%8()R/:18BMAQ TH<4
MJMB\"F1=E3)X]%CU-.3.F>U,2K2Q@FA*>L@@)+EPZ^)?K(R@K#"CF3!,.5!2 MO>)!K(8O31\^J9^@2F2:-
!_.#&Y5YVTK6I(A,#239^.UY*@_&GIYR: 9#\.F MH+&F(6O,G,[^L5:,(^'O/\@*XXNEPKA4&!].A5%VL_-?+Z/OK1DKC;
86!K9 MAVKRE+D<022'J/O4O7];(J#>E 1G^ ELC%")*JE5)OET9:EGC:/O RPQFAJP
M!/KI0']%!SUY*C'VL/0<':R0,%#DE[4_S4'>6 =RGKP%<65H%;:7$ZS%\+45 MEEZL2.B5]"<2"L.5\HX%
M[0=YH8R+'^J/\)^Q0BFO)V$-U# %,=I+N9+2C'L?'ON1)S!WG+-L'D,4 P)% M@27@U*E;S(!3OQUT6 [2E1$Q
)02[XP 42^K%4/8S4C]@ZY0R M]9%VX,Y'5$Y*\V, B5_-G.H]3<^2_87[^4 ,OS88E]4%UPS-23%NL:KLECSNG$#[)(W<
M\Z?W2/EP]XYG(N# %&I(&S-&R%<%SN20FI?'\U11H,NC'!&K\.;CDNW=H4_H$
M@9#TWVKU/PLU#A"DL*TQ'73'P=M1*[(0LA6-$?'"=M-SS3=!J2;F=>WG<=Z
MUJ1%.XL@NN=V\O.3:]RHI)0FN06=3*GW3>?H).=]RPG)]Q1+(TT9=.T'DP0O
M0.9#Z3+=+J^VH1\VY(#PU4.5$W%YG4S8,$LRJ %/YE0Y#3G7=W++%P3-I0L9 M"C\Q/4.2
KEW*"/&VEKL=3//.ZC&F2_=\-C?)M/,B<:I'*,R?K MK-46ETIL M(BZ*BW@FQH3[(T2>)RZHV&8O;Y#11*_A;ANHL?
N;V;VAJHM0W=Y909A8 AH;H2'CW(E5#31IG2W=N^ MB %[M'?N-EHB@+M5-5VH=
(H$&Q%,5"AFHGR$IVQ"O3NTP40+@I7 *6[*U*X= ME9+J+K;HI)LVAX-%(2W:V,@#ZPU@KW32F,
3)+OV"C[IC#!]=PQX7K$N)XU5 M(M0.N+L0NC2D@<#T89C80L)DO60TW':U)!Y#Q#^-\0#3FV%'-:EK]B^XD? (
MO0@I_05(U,F@J4!4SJ[)1-/5M9Z!FK/B0% MHA\L:R,$ID+8IO4-\NZ/S?MA"@VR%H0G+)++#R]U=PH)']
QG:LAH25R5_!$O M/NP0,\19XZ'DRIA6Y>8/VU8/,KZ/GKV%VS*62.M/G&/))M"9MAJE?:1$D5>; M^3GZ([MI!:WG]Z(?
>&3[E*J:_U*(4%,(Q\+[A;+!\$A6+IEF71'D0O .]/!(M#;#TD:9[]*64Q,X,J>20!IBFNSC(9_VQ^+L)[WG*0SOOH-GY@1-
PBU>YKSWQ M9T?BT^'XB<1 A#.C_5H/J%OBM)L.TB@%,%[KV62-WL2^*>L1+P]$5F:DID*P M=
(/*KD6U.ND4N#MI_4S?S'> E4"Q+0P<=$BB .2F=?@4ST,E1Q% 7";#<&> M0HL,PF=!#?
A9S^TZ>6C5KH^6:M=2[7HXU:Z[IVI>C](C0]_)=J$(ZJ&#@)F! MTJTM16(0I"&/UY31[SG/\CW<#VI L P@)XG6KHGAL
@/==R\## D\H:G<9? M4-Q4SCES;6UV0A0EW4.FN]E@&<6/X2Y%PB<+$AQ";,-^C9!1@-NL>%#N"F%D
M!LU4P.6OHJFFD(:J9>2X)_B&A1=OX<4CZ]A,9*AH]<(/"0CE\YC)V'VA*F)- M?QXTB91#DI\Y0VBW+-)ED=YID0)+.
[7L1(FDL\MW67C+PIM?>%SD9++VB6;+ MVX(#BIY7H9NI3=W8HF4ON*S89<7.KM@I!'<=*TIG3^6T
L$%CXA%7L[K91'> M5P#%RXL;B@G&_D1.(S@PWUY3#G.V@F4 MA:GG3TY!6F@<5_A6:84O;<5D>4'_863^#A14]:"V&
B7!MK#]UT9>#7H#=#R M])2+>GXH+U;?-PPJ<$.D!6 [K'K_7ZY@>85I;A"DJ6P+KP)K3!OX)$$*Z_:, M"9'B!!
(A05U9FB2CFA^)V M8,4"9DC&5LI#$C6*)R\W:=*;L/>C&@;:S4VW*(^$6WHG?F^#UC ZA*'1A8<4
M]#_,TPK56*>OPCVRS,K7NFW/-&B= MMZ6,(F"0$+,96P:T5*5,.X5D!KEB;O#>NK<$9K@)T!=S$?_42I_")QY.8B$
M=3S5\#&VR'"*RQKOCU/M^_$.%]F)I.O:99+V* H2F/0:-LMAIZTRF&A3IQC-T&D7-?9]Q IPYP01&K&XC31>[(MR!G>)
(2$A*9F1H)CO6$J2HS;..99:W/+"<7*PJ-_^U)_OK)MH?A/%^L_JX" M=X$80"F$IO#>\\E.M?P@AD5YR4' DA>DJNR/7-
TVM(H M:IN;IAUX,511T"D=R;X&@EKQT^9(S44[:S*%O!HR_0V2,;-QJ?7=+E9ON 13 MG09//;B9-ZCN2F#X<_?
=1(ALY&XS)NKH#<4Q"L\JTZ,DI:=UCZ76=&'ZB\:$3TS&Q MIKXFDDDI"0: M00L&HG9J;:J3Y90V"6=@\LZ M
FPBD[UD^:^:,FTKM6NX<'MD=V%\"@BN*3/N6R 90/;;H #R1V9)5GD>X;-1%4@>.?P6 ,QX+%UM'#D
MRYP7]O/;UNX4W+JMT[Y;JL,C41W52E?^NEWS:GO.+8DM:NFE&6-MZT?@>HN'0W'_)^)C]|CQ;>LN[>KW4G M_
@F=*0(K0 7,W$N">0Q9!.2,HA4Y]JD55V*<)EQ&U3R.91U4RM?4E) LK"1 M!H7[+[45/;HC_PH(H]\G]J1B#:7A;CIM
.33&)"$@=.F_REGZ_U$4KM*LLX MRVLB\C!)8?&^D3Y*>JOT3D_3N@[)L-
5]YP1:#+URY;FQZL^#2K*1[E')F%0S7(2QX]C"8T"&9+ ""[S3H*>RBVADR?0"2K34%I*V)BV MRLVG=!({EY.?
0E#E)DBDQB106^Z3,8)X6E EZY1+BIG[6'G;A\2G3DERKUR' M](Q_KXU#1Q1RC_H K'-7NTL8$2,C+D7X)(TBYK-6Z%$
M3J=^G/,T=R %(*9U%UU*9MKP"Z)J-$RQFO1F[X0P?YL.$ /"I?:>P,V[O'*=
M5L^%_PE+I%PSYUS\9:#F"2V0AGXKVL(P;X;4#TQ2./"[\X,1F]?]N$DUVW:E M3]#K=GY7YI(+#*GE&VX# (I5(8
#I<30_]]X,*[A+Y\.T5[=;'Z1^'%848N M328''EA_.OE9#6WZ0JD5] >42GK"-(Q7"0V#OVXI*^,FA3+0[CPXJ([J)D'H
MZA1Y6H4K"<:!J;A9SF3Z^-E$PV=3O)0Y)*@;7/)-7#:E0<88K J^Z0P]))(MH(ZFAO^^
$M_8"Q(Q$FH'BR)Y(FJWE#9]]6W7V6K+ZF.\Y5W?G;9ZN\8TFN5 M:/W&^[:K5Y5?M9M05F9;8?"D0"X-;S4Y8MN83TD-
4E+V"!3,=UT!8[Q0>&]H MGLADAS%035+ 2:V\(&?<=R[*M')1*P^\=?8B 8W#!?=K9YK#C6F:0BJM8M<. MJ*-
B*,_D_9)/9/P8O1A[Z/C^]%*L?J /P;43<;8A9,9D9VU_&0 II^3X M^5YF)"JWC$8!QZ):44=,*?'[A@4EC$EZ@31E2-_?
L1RGGTOO'#1'4$76I+!" MMX).)!5@SV&\")"_22Q3N]KO+6@.WWVF88JTU&2+NZQ:1/86'V>A\F.]S6 M1@GZKT3D.
[BXQ%OJPJU:$WUMJA(GQCV[.B\]/@,16,7*_XQ #!/WBN)$,G[) MX'&#B0';)DK7VXDL)8[R$R,VO7\/W!XI$Q
WK[];8/C.CZ%_EF6MXW? &T-! M6.*Y<6,N=PO4&D/X<;LJ.8#*9#K&[QP49(='A8V9R MK:)^5\@OY0XCIQ*<; M+T/#,:R
2J6R\9NS+/R9(ZO0'[7D+!SYA1(QE1X0R+@F:6@2I<+1PIQBB+7R MSF=7;O*7)GJ)NI97?QNQ3B9,PI)H-
!T\@4GV8O5%%#E/]492CLZ4?G:4#HMN MALTMKA&:TDCL;PL(9]-JH;)23-E=.'Z:O3_G>@.R,,'DZSB]K M-
I&#$1JY4O:Q+E:?N^Y0AF!?8*69$4PP/,,X,UJ0#J9Q=2#B[&N0US,RBT]# M:A,352HY!T=TH,FF20_SP=HQW*B#G$/
A7$BE53D7$$/O=4F"'YR&N@O@II- MSB=5[/T$C72%XH1YXLF3.T\>+N%SS2:ZA9\,^N(L732(4$4MC_=O4EK@CA#6
M1"TA[B>]%$8!/M'IHFV.8#Q1-]#_L!O4#J\5;2B33K6! 4#7!DH'57[-<\O#
MSP,U2=W&&9S<.&&PQ:;GKVYB$DI5KW@#X\1ON$D6_B?(U2O]D">= MLH08251ZK1-
E\L:B@<>@V%N\;",2CY".#U%940$5T_TTRGA-RIN9 MTD*@;AFD;'G#2?.0 .G>,^TK:C>12#3
D)HZI[O+1_"P*FUJY[+!#T?(35 MW.PH\> U#1 MP=R.G!#-R(:OJ'1T8NZC\(^89>3YV2J7?G87IV)9C^><"DV62S]P&W.
5#_9 M<]\..[7"]3H%>EZ2*,OJ>Y?5!^''V(XN\.ZR"^MQR[$;FBG=I39+(B+#[_N6 M&,$11P8PF55P-
KS.DI>93A9JK]M4F*?6LP&/83$7] /@?Q 6Z=4S.MG1ZU0+B;/$6(1*BV"1 M#7"IQ,E4A+VQ+/%EB<^S?
RA\)WBE6LU@VF@M61,' %P!HDWJF"D\) ^Q:5='_M3IW[]HJ=5$?JR\;<0HD4EA6ZK-!W$Z":8 ;XT:\P(DARH>]?:
>F+_0H5L5* MH@&X"A@^+FZ'HO/DSQ]KY5O9QREDJUTL0QO*>5)AZD9?!$/3>[3^E^7_?BW_MA(PZ85X.A>
<$$?'PR)&&/#?6:V*?*N@XQ,Z^\WC1I$M[OS+;8+$@^!^YNR, MP0Y?\?G&760),"2VE78;=SB6TARP)Q/D+S5 T00"
6JSJ*@3/UQQ=9U+OL8? MOAV9!?\G\2D)(VYEQ$S3NHR#,_J\1<_[X%E(4/2XXS14[!*((%WT;*1Z2=R$
M8Q).$=N@1HHIQL&_U.O:8Y%3:4T9X(?_2(C =XSXH*Y4X\UE;@T>^U"(Q+# MX!,<9]J?S[D$?^XQ>2+[(40_TS?
#EQ28Z:=<0XCN;F=&%?R+[8)W=G=M(8R M\PS$ZR,;PK Y"661(K'(*R.%GV%G19AL*'*=R15>.W[$<,1I7P0-V?Z0E^T0
MM)[VFTG_9UPNEOYEQ(E,?5.'HZ5NB$)ZL1DQ-G[&AH>A MN]U$H,B:K\KB?__AGU]5;S_ZZ.F"'[_XX,,_< 7V-
R[VBQU?)W=)>RJ^*[NW MW>H[0X5&HE?)J4KVEY?5=Q^)"+U>O6[=UR'6\H0=?
[5Q5V%63A7]1MH+2B;_>$'*/=ZM&SBV>/ MT2!'D[&5MN]P.8<>RVBW0_5D3Y\]>OF8'PV?
T2,KO26UE@NM0)Q'W/K1G\UO M6+TQ_C+Y-CHP^;;SUT_&1W_.W]2$TMD98C^GAGN\%E@M4S+4#5A\)MX^#O,M
MGFEPPXO5R\VF0=1/$EYV.:B%E\V!.FTD500]W[;J&1M65:*7UHG&JLB4>>B)LK05I;\C&^8O@<]8W(Y:+NIF"QWDI*
<_(;: M$CLH8L5KHOC(4^Z?F&D7>+J[,LQD.W%?ZT)X5Q FC$Z7-M1_Q) =FFO7"H&\ MCP@SZS- LH8:$W?
D!9!+&^9Z2ZXJ?9&@I\$+EB^JQ)OPCS#BVPP3+8=TD(1T MT_G Z,J-%@-[I_Z4)BJGOA;?Q2\"
<%02NY;;EWZ+;P.I1;J-._B]S,1%3(XZ M;*_ "7)2-3F2G]6N828J,V1>-"PY9]"$EVR>R_(ALDA]_'2!$2XPPO_.+%+!
M'"%.1)^$PC);$L@)SG\G@U!R:EKKN$0Q))$\:MY&S1@#2(<(^@2O//PV3\PF|

M!TB5P9O"G;,!T{82V7KK!F+!^_8R_Q$BZ,2_?.,HQEJ]W%.7>P%;^IT3 L O M&X3=W>IER"4\HM]0,/#\Z6?C/^,/SSY{K&-!G+-{0TF[^FM?B43J\^?9ZOG3 M9Q\9'T5F0^?V-O,9/,_C=1,\SUU>;?DFX$6FIWY^\>(_'NLK7Q)WOQ'MHB.%

*MG!Q.711N''7A_(?T>I(A$$_6L_Y6QQO:&OI(-WJB6Y;<"PY3#TZ[^FON/6AF4 M9^2D'_(3]G]9SWNNN!B_P)V' -D6"N^?8*V\{G6H\P-MR7@4RZ %KZP@[/^> MV#= :,RY4;K_\$TTM14E<2_B7,=$HG>@.I.%-T\17_R\L_L]"$PXFE%Q.J2I*

MPHU8H_HD+A<[#===E^>-1V=@!"+53Q)V(.^3<(A:?X4,&#FE?N%=(\-)?A$M*

*M*0Q@T&W'2,;1RB31:$G](Q&HF*MP/SPF#QO[QQ.;%W*IV/[TBV3GX4N5LF6%EW?IW!S?*

2KBWZA1>Y57X.)/#*)G$CJC]D)_/5J^"4 M:KKC44YZ15L 1N1UQ@_]^&$Q9K ?BH27['LB_X#R-)M=IC&IO:?JG5.FB$L2*

MXZ#LCE;Z.EQ'E]Z0 $B'^K[/E^_3PH'F-N'', MRU:CQO'BN%C]L"-%89M1'AQP Q

(0$JJ#99+BH.+8763%:CS(S,GWBKI9RN7B&9GW[D]*OF\L+6(ST+ M7(3A7]*22;/#$RG>%\^>?

*_+TMTKQ_A9V@J;=&";]O%71L8EI$F([$*UEC>^ M:N;R#])M)!SZ8/,'*Y$4NZ3BC@9N=.&Q,T+9'*

7^K7>5RL_341@1&>N9'4, MY5%\)+4M=W[5^[9/ZAW)(M,\3)$%K/7092A[%+QE$W-:S,=1-92O4 8V;"*

*M2;LD*F<3Y[+NTO-F$#15@:\;QZR=*]U7?AM3'+CJ(*Y&1V\T5%*=U/J/WG=; M>I-14KJJZ/D:6[Y&H-\3(??*

64;.^]@5EZ4O[.QY[,7ZQVA@+=Z%H$RYOK%VH M49Y=QQ?LL?S@>#&KUO,Z-(TB/'0U^ 4Y5:

<$[>'A*!4:A&RFQQ#\;)&W,3,O M<7:*LM3MI/1@L/U\]FS]-T& 1BE_9S)DI4M78>A$ +5NL@9!^! F[Q3HF&1K

M(]WO_]OO"\KY!?>.>:WE]8>GG%M3T$ MT/C7RT$OWK?75,G?E0<3'E 0@9#C/NM]MS#D#[0D6,%= ?

R($$1/GEX\QW6^ M'?+GFH+RM0@7;;WOE!^/^>8M MJR)0:$. M"-1_MFW>'=M^PZHJX!?

*(CSG]@AA>ESIR*L.":A4=/D2!R4C!" 6X9KY6?VIG M%&WKA>&S[]%G%1E49XA&F;0N):S+DM<'?*

KH79"4@7B(.\]=CB&IHEFC^X2 MZVWU9=_2T^T;D<-AY'M_9#FH@JIY0>';.'>A(-:LK!"1WR@%Z(?(AQ6(?L+9

MR]F3N4F3.JC A3KQBP-EL/BZL0[+/]WZL>ZUH\T\GM_IPAR=W&5AT;WM *56+YHB.[9S8:;.H(M,@1W-*

PO_E%4HJ5[U%9VSJD$$J6$.0<.MK\JV5W4L'W;W_O:M']%"EM\%P#8S M+S<@()0M;-[76CJM=$?G9^L]KVOOK?

D_8]O1%H#U8W>"-(Q$5S!;5?D:^>8# M^XS"V5R[P(@?ZM2U(]!&KHIX?O7#.E=KJ!48JB9RW T\O1M?V F=1H>">J3*

MO]!C\@FVSZMM7V_DPSKWKXH,=>??'&]!/_+#V.TSHAX3\TOE_<#/JQIPJ/FW ML%

*[Q7#0]"F$A*E4S/]^#K+X^6ZJO2_7U_;V^HFTCZ):H71#B]@!FD5C,D.8K MGK@9\=N'@T,AR9E&;A-*

*D]_!_V39;MYANN"=/G31C!@? HQ0_Y)U/S5&2C*H/ M!)&MHHU!1P^Y?\V>_^U/8N]'/&FV3]32!2\<*

5BUBO_525N2$3..Z0DE ISL21RJ(7Q0<52Y4J\8];!YG*X67)^FF5/M2K/+@ MZ&E(4#@$ M:^1_%>VG_*G,FB_NJ2L"C-

=1\3&+9Q/#=!:W[@]MMM'QM>3 @K/V9G\++-]]'A"YO;WB'F8>(M C([M8X7GS(1J7$'TGE@N9@;I&V2K+E;+

[$\UVM!&9GVC-DY7-G+K:#MNH%U*@2%/ M,.W(X/U6J)Y$M=#TR]UH&@$=#,NJ=9?

$,]&0+J4",T4IA(E3!BA1(^+,RDX, MR4$=&PJ27(-BIY4>E)2IWCJ2S$H4S 9L]$+SGXB;J-XYJP*T/"OL-E1FGDP M%L(%*

(_44;,)4FYPA.S:,=$N#R1J,W=K:L"%U(;; 2>FP],J0;:JGY\//6:Q MYK)4!M)"_IAJ^LO=X,2EQ44?D$'QP=% @F5]BL'3SG\?*

Q[J?".\1U:M+FM!: M&FQ@#' AC0?H4P(47'+ZTZR,8I5;(#.?D51B/,G@-X>=_[V&#O2F1Z(#ANJ M/+-*

U\WK59EPUU)6CM2W2P2%!V&$ "09@@#C'? @ZLT@V-B[;VTCQ#'1B M?

IB4X"'2Z4UY0'7&!W1!@"^,QRELS(^(56AL&5ZHY!_B#@QU:@#\ACEF\%-*

*MM';N1[G\J7<=*T32>L:L;UIHY)+I8]C)MF7\"F&XS'.1V?+&[;_'G$L*Q^;*

*M^V!X1[4M/HLIQBXO63"9%^$*FM)7M&C8QQ/-]%3:B*5[* 8\=$&ABJ@G)"7# MKB;+(V+7R:S3NO7/[DSA**

(;@QW1MX#8>0M,I<:)70L[>K,I'GCD*J-I?;G!''^DI8!/$UULK4]=1E]@,1MB%;B?\Z3/DQ$N@TT&GX\OSZH?*

42Q5O5Z4O\>MT+])3B$$UI+<5" MS]_-2.LH5U5S_:0_A%R$]<$8OX>[=VJ]#S7%RM7C$PT5R/UO^G:L/VHW5GQ?

MUI%3"5/YFDW':N-0YP9Y\C#!$]\G[S3G307T)+I373&T/3AIJ4F<543DPNTJ+<"J2&;PLY)R\S2MK:^&0E(9;E[37TXAK

M;&/%$I;7'?U7'V/#R,])YS(P-647R&<"UL=D/THVQU/P&XNE"BE\6B M'[,L:E)RW1/>1?IV9{(H'-*

QKXWR2A"D[+F@7+,XV5 M"L"D4"SJ3/%+N]D+B#MB7A7[1?L6_G6H_F:#=*;<6!/GKA >,#,HQYZGP)V*

*M_"FX*WT46C!0?5TYL5\G]J\$%Q#TI$G9@M0=V:NI!%M$)6L_9O2'L)IH4582*

M3964VZHX^2W1[4LDOE:SV'70BJD&;:I8Z=5N[5J1I:C@F9<;LAQHO.1?(% MB6$);P*TR!$Q"8

0.L21'R32I\0(2T%P(!M)DC6 N2$V@D#ZVF M^GRJ2XUU?>ZIGIW_'N"- QGV3!>XM05D(;X;UC1G] M+)L2%-/Q/?

#+8OCM/5W(^-7D"_A(]?0D/S[9D1G!UVEL1.LF^_/QE7"RV MX,2)2SR@,,'%5S79FT-%8-

*(B5@2#;*IWL4OIAM88P_!TI9F$7!>*4(R,AE5: MSC76T#*BWW_]>7F+3U39Q,,G/'-#),4IQ)Q:'; MK;95KAA[[-*

*B]D@9J@PT*J7+/(8;4REP[#_:M<&1+),.."?\8M5Z3=P M 9//X-^-#ZH;^@GCIGCD.>#$Z4:YRQ+=LU?*

*2&HLV1;"MUPT=*Y*7P%$G[SAG M@$8/S"<+[6]_GG:N%F078^S#WY 9+$4>\30HZ9M#UB2W#*:]\Z]1<.DY[.(9*

*MVD([4NK/!E]C2/'##9B8B67)ATDUE;2[77\LF*C*U ?MH8%V M/'%5_E&C2>+-,: I)%VL+!@7JI\D:PAF-*

,GE7N=M6B'B3LH!QB_^0=LJO^O] M.LIQSW^\I6PN5Q^^[MIYQQ.V=P&V1.U.F]K@ M3,V$1[/S0;"3O ZH#@A9"0K*

*:^*> ML+.2;'HZ]FZ[JR[F6Y"_-4489-#D< M(T=H?F3262Z@X&A]ZT[10[IOXSB#7Y"G!D0)#TW,*25ULB:IQ(3KU*\T9.6@*

M<(H_:=$U^H.IBU_TSF+XZR[6,P')][>/]S5.)1KFUV5CJ7,/5"7--Z[GG18= MV^C=S[DO$W-4PTY383;>EHT,54S+;C?

(8N-)&LF+:HVD48T0%4 MS+]V(5RQ4>]U"I%H[S6P@?X>E N-U2!EJ-&B@OEN6N4;Z+*7P]HLWX[PF5' M*/:@0J&*

;)XA+G=!\K%3"%PPQ2#8/SAKV1(XF/3)Z4(IP?.M/7/^3S6O%!S# M,@FL !W3]X66LY&,W+ H82*(*(@DN*-JJUO>")-*

,OT(BW+V\.:!8[G,%S19=^0 VX(UX^S,3"*NFZ1TIE>Y\#'I4)!Y> MCW&.Y0;MOC2.1(V&_TB'A5HM&BFM@B"'3OI2@A?*

*U VGI"S0Q1;3%CDPV2N*ROB(U"@? MY@@ZOEA:#U!:]>XB.S_#^+6,CI5078E-\J/0'N7CH-/'O;AZR^1$.>%I*

*M1KY5[TSX@S32HLX@>=D&1B06E+3YXIEHOT+52ZR9M(/T(<[P](J)3^@HZ0*E>#'I2!;%PV*

*MP@$%WX0L8>+%&1(+K1LDZ&@*O5*_D4M%\=I\/-8DB F85/ 6AQ<+G4"UNP0I MU@:X-XK/T4-KXH27>A+-*

*/*N>$P/L,ST%V,(! X43F7](Y@$KG_,.IBSU!# MK=OR%-7-D9&9>752JH:]VSG1 $3RAT^:42FI)PLU"D&S5+CR9?*

*ABK)@ 24NZ0@RHW-0(TKD^! 2-)'\P3,%&_M.^%'-Y+4L/VSC,*4/NN]TL0GRX!UL_R[$B-5KJG4QPZ/7B8\/07RA\@(-*

*:!I#=9(J .SJ4Z=*8:D,:,6G.(K"F.KLMM_ MYK_Q'JW+95F^7\LR,CKPRFD),O4 E<,'483VFDOHD)!;#>*^$:E.Q&]QA0OZ*

*MC4:"0Y4+&%@CF$+)IL56;^Z"*X]:I49_]TDR74D(E-%6YN;RB:Y0;F[/02=Z M Q?*

*7'7FXB*UH"GD/<23__#D%NI8>:EC>F^1^&C(^;55):* U#FBWRC5SH/\> MT$-]SX@ !*_'2-*

*QO1V\\1;JZ[,#+B%F*NX3+#KFEPZ%2'T+4R6/NS_WQ3-KV MEEP7"<[1,NL\%CYK@5?*

*T[2IE&AQ5W*90XF&W4*KI=X2"_SJR)]P)JCLW]UOL M2#R'1-*

RT":RSXRR;Z:I8NU.#))#B@8%0XID,HXO$.&$2,>OC5BEA"NFI+P!3 MN>$U>Y\M4@+[F>0YEFR.&H0K

."B'9B@[0V<0WE[W/W4YV_!D-"T=5XT#&(A MQYJ9)(F\.--^L^F&"OI6U32%;GF;(DKP 5PA%\LJC?

*K,AA_8*D,1/,SWQ$%A M4'U3[/'.'!N"'7I">$1+ 0/X,183(:9-N-<-J8_B2XZ(*4.]);H(K%\ &]AU MF(%QIY9-OT[>/I;["RAXH*

='I#LVNSQ%09I'U2=BT $_ED&A:K\1PT>" @A^ MDU/_"\Y&RP;#EV S',1%^/NT+)FY9H;/0:H@@RD9-

,3,=;_XV0)5BBB2J"@6 M.19[]K7IJ"O;3;^G$W_ND6%.N_,FJXO[0WKVTLU.:&'#QX_DX$Q"H?!JDF-

*M1]G7!J6>\/%:C1*2L QY4PTM_V!/&&<;ZV.DOD>]=2>AZO]LM2O#8(XPKUL_*

*MT+@T#Y<;^AU4B\VOFC;2.D16!WYF[PQ<7A*UE>)I:B%8$ 5//[@>OC1^1-. MQ#N)Y0%N#T_S4&ZN19GJ&-*

*%N1J'N,AH(&01ARZ(+A6]#>7Y=@8R VZL8&VR] M(BHUE!4IQ-1,#J\M7#1\6^\N$6CL\[*C6E"G'#T)GSQMB <)(?EP@9*

L$))[MA9#HC&E.Z_DMG!?8:7:L(_LUSIE;F)L,2["NQM?,)69M @/2F%(P*K>3.P=*

*M=2.5W1[12P6)07V0N3,W:I5I)ZK0N2"6[%BZEYNBG^ 0V/_V1"9QF__IW[;X MOU]*1/]J'4)"PN@+*+UL90M$;JNJ1-*

+6O7BF @G&+R;46\Y'#)6FXZ=Q1_MNE$H:$N:OXM#?:=QN^]FUIL>]F7-X%B723%!8#(GI]$XKIV_&5##*

*M@RYS=X"0&X0,6Z:\Y'4Q);,=&/9*Q6&%M; .?=9AR;!@L"+) =+6%<,%\C?2 MO(?*

*5(91*ADUPNB&=91SE&5L3]=MK!RH&_9J^FW^X?C_]@TE).0SH0-GR7IV6O-..!^\8]\FS> .8% M!MG3WW: !IG;85*X.=S?*

4\[GC=^<]M[P_D]^DT\&O$RW?*%//[KXZ)/?^8TX M8-SO*5QB>2)7$_A^K_5;"P)'[^Q(V(GP_YJ-[(X^-

%.LW!01NP9H[F_IY+YP[) MD%+ AC<<.@#"8$.J9BA]]D(]7CTMAW!87AH#J&!BSP4:J(!/S9Y$LP7P$E!*

*M+32P'0C/UKJKTK^@@/"6O;SLY64OC]XH(9[*E-B"&TG]0;I&#Y{N,7+*=\17-MZ[?>LI^6_;3LI]$;#9<-N6S(94..WJAREV7'=2;#: #Y&X{FEGVS[)MEWXS>Z$=_*C')8]O4-M32])52E!'EHFIIFBO5GVT[*?EOTT>B/-':9$I@JA7C;-LFF633-Z(^HCCT>/ M#WU,?@(=3P)81)>=%50SRE6,,O('TZX\4.DN\K88I*NT?:Q/A*^.N-2MX2W; M<]F>R_:<2..C;&T8S!7$,F;_3?B!I=*][*ME7RW[:OQ&0UR80N,B!E+4;A*(M&$N:2\M&@)@L6VS98LL6.Q>.$8L\<^[2WJHWY:%:MLVR;99M,Y5-+Y5W&)BI M?*

*EVQ@LW&M7XCK:F'#81T^=8=S]2J+%G74LE:]MZR]V{Q1DS[[O<4T]VNJX;D MZB?Z FQ5F7^D#*_NTW/E3#2;$:W=5&V+DI#)W+IU+:P:RK2=$13YK(MEVVY M;,OA&PU;_M^L>8TF-==ODA0:]M3)XJ@A_:>"7]>TS:H*CM8.BXA)3<A!.B4I;8T7&*@1;ARD4-MJ"\U-M^'_T^LW6&U)NNYQ0@6"-VI")H-$L.W.)C+A<9]0CAL0^EBF)N7E-B../+]}#*

*M,BQ%40\MO%A^/"IY.FM!^.^1=LN_A!3I+VJ^O>63/C2B@A<+4<%"5#"Y5M\+ MK8MWV*A!.5(($28"71TM[#EIH49!O5XLQF]=[KX>[6J-SW9T&_HF-/IO+N0-ML-R? MOYX0,]Z3AFT^H>%&L8!2VE0ND%X4?EVPVE&B<2H*E2*!ZE?/W_.NR'_*ILDY MB.S4T77\Y6#.^-LTL>_[*+Y72^#;$9E'MY)A%?8W'MC5*Q$-_H9-&%.2((W#!:JLZ;AFY[FE@R<878E>>?HVSU.Q>K M;VNZCS<%SS[(5L^?/O\P,R1K"-?1=_@;/I*7>"RG MI?_SW^09_B^K3VL[S.>..-.0/K%7>7/TAB=<)*QGHI7QLR"JBD&0Q E-X,0V MPL%1UN6^W_,<23)42?2@$W6RFPG'Q'CL;C&A\C=]T^]ZOV]?O'CQ]-'Z\;-G MCR]N^'ND-(%?K$X?V*O_OUY]N+IT\S'0X-!'__Z"_[UM=W%\=%;\2O'+_V5=4^KE.Y;Y]0_ZI??B?2CTY/\$WV5;=G24TNFW8G68S_UB MV]_]B'WP#$OL]7)I6/U["O\^S/_9?_;/Q18-0%+W*H0XLE,/@:I1 M6,%%66"1!#5FC!XI=\EQBZ$VO@S=[H,7Q/I5(='A7Z=&]@CGMC @ZS*QQ(C^M=SJ\ZKH0"2:[M7)\";;H6&*QN-UH]Q$58[\2^MN]?N.29OS2KK5_$O^1,IU M8$^XUR6DRKA9K6]JAP*R,L121C:UO=:LO(H?O_8_B/;C!R>7@HWS[SWX)@T:GF$5M;Z^L/3@@5I>M7^'R8QH(U['Y5BDJ32H^^^1I^I9!I?"-.QS9%MDW'+]0F(?; M&$M.JMA, D<+[(-G8.354FP@=\3:\FL4MI-2YY+ZSFYR46<<@?_SH^6,-S3I*01#Q?>K5Q+?Y94X,'ZG)\-K@X)S)PVFE

*MMY@B*M#A/':"*I.OO8GSYX^VCQ^],'C1R\?QX'+B?$?PG*TEY_8O4Q&@"B@-M45PQUNOOS15O[&?/;[>S)P?RPAHE''^N#C9L9@PLJR3NRHEP9S+%LZ%_) HM>*

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

M*W+PJ7]Q:%N_O;GH__6AYZ;}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{ML2Z>^&;%7*Y#)U5*]3R1 MP3AO/0V++0&R^^')R90(?L>$/^-=:5]]]!;]'-YEQP[1.D]YB&;O],P-HKJ(M QB6RJ!.0E9LI-)S%FL+8,C1B!O#V!>"[D "3\;ZF(-|M=I #@"[$.(TQ%+XQ-Y_9&_N[X""^M:TBB^QY\.'^K.QGB&F[&=)V[K0,[Y!@ MZLG!O/% &(^6(\[&#W]G)]:31B]0S[I4C_+*&W2:F_XS>Z6;&7B_H#)'<>O MB1LTAHZ:S -=L4NQH?KM?>5?HZ0LC?N M'2:L.W>N9S>I':WJKFL-S!?3.COTH M'1BDM#DK2"X]"UH.':6+=\EG.S2[#M!NP@%X^;M@ COPU>=+2QYEWI0.M!2% M82NK? ;'?%8,SP >| 6?5]ONL5K_N6SB7]K#=NWXZ)?=Q<\9T^:V](V[?O2J MUNSLM_WIMMUZXKTW^8XT;^]O=@+X>W_S(_W-T_B6Y^$'0 Q(LUTE^"Z16\33 M6>GWX;KGTW!;P3W0/8? UL&OF|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|*Z]W^K77\](3"><*#X1? H%U<1"D]*JF"3DAFYXKE4!LHL.94J MA3KL_49D!'NI#NJ2$"BW:5>>V^;.RW:>\Q}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|.Y-0\5_90S14TOE9E W]G M'8*\5^#M[T2[ZQVZI>Z:MM4V>6\Z>SW#L@?T?*,_:;OVF\]'HQABPM#F,)*[(/GG&SARTS3;#Y134$@X<9 M)U+5B.X"]! ^KN/9T&WC[#UWO&B6-9EQ6MN921519862%[_ZW/$./9WB+ESWGH_= M"']#.YRL+]\S$GZ<*YF+R#PZD,JORU7C1=GF1'75, \K.!/4JK[7!:[Y@F[C M.<+&T/K-7TKFU"HO)2365/GD6K*HVO=NUV[OK86+PO+-XK%*\K#OP%0 M2P,$% @ +(-65F?XT: !0 R!H !< !T;6(M,C R-# V,S!X97@S M,F0R+FAT;>U9>T_;2!#_*G.IVH(4OY*0!B>-%$*XIBH))49W]^?:7L=[M;WN M>DW(?? J;]2,8VKO2"BA(12C!NS.S_C-8_'H-TV;)2%)/.K#. ^?T_CMSH%N:MIXA+*F%1-/;!@8 M5M? HF)T>F!W[X(UM#>#L%/8NG.E^07V\G#I_G!V[=HKK0-\V5H6Z;Y[6>&F:+6A$)+ND2G9#JA=1(FR7RW!X^X"O<:8U7\ 3J04D9M'6 M?NVPF&:PH!LXYS%)7K?+%?S.J&#!ZV%!G;%_*(I&\R2]DAJ)V!J%*UV'I?UV M9;I[XY -+>3CYNPJ9"Z3T.WHG9'AHI_21])*4=?G7+(,M8B8W-HA\WV: M(,&K%X..V1V.#$7X0'IYF#M4?(>[3B]6SF3Q.QS-EVV8+Z;ZP_GLNW6;SLZ=_M^)-13):=L"S*D\#$G MT?;>&+*&^]@LX(2+&+N)]A$"+@JQGW=B4]26^T 3'QO+ M^SRAT#7;H:I+&T@& 8OJ+J7X5M3+!59%-)TD/LRNL. GV*OPT)AEF5(=?Q6E MCYT*0BHH*MQ4KS2CU@[U;\-[HEQYFHLTW"J#4#$6PS1D-(3EF#[9"2"91 P MCPK8.Q,,5U)<^F(3Y:DCW2W@@_)Q&]) <9#G:H$O>3*O2S]=I51A+?)ZJ_MKD MN4&I((WV%)X@PB4)S;3E542W,/&*T"A(MW&?R+9BCK?P*>$;=.&:VK]@C@?O M6?NE*YN?#OJS@G>01PA*#S$<*9#M@"?HYYP)JF:G3#GZ5@#W")=@'6PY^_O M(G2-U1U.JS!9A]W>4"'X'BV_,8]T3/WPZ]XHEAAF6R)MK2)[+K'K_$?L6()U M)29%Y<(B)@E+,(M860CJP!)6E!M!,Q7#MMHF..PB&RJ#*8P;*08U:Q=,>!J@"T.>-M2>%.#-G$C6@MUN?"IT#P>123-J%W_T52TCZ>%9>-6 M@Z^*&^IZ$\9-7)=#M5HS,CJ8%&?6DFS2B.EOP.QJL4>B2J7X)!?B>@=ZOW# METWG5(?5CFK,Z0WA' 4&$=_4'JJ?M8T@J>WB)>F3MD$/?'/VW^T3-^-1+NE0 M74"'^-/%^4'%G#+3&DWR-"=@,>'D;JCZE?R?W=O7^,W#NCUC6Z^MOGJ-IAA0J M8>XG.1ZGZ)=0!*M;#H4E&.\'@(]CP-'6;O:K[S*@Q%E535TN)8]M2T>Y@'%G

M/KPPBY^?;J.1&3>FZ&LCGR'B?B!.3P)H/XROGZWX+^0\/[V?!G*^<5?_!:;G MH??3 -/__F/G%I2,XKI3SU8//9_?\5+6'/?"W:W()=ZGM>!YXJO[&!=V/30T MWCS-Q^E9*2-=7*X98$F*XVN>3,KR(_
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end XML 75 tmb-20240630x10q_htm.xml IDEA: XBRL DOCUMENT 0001680048 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001680048 mbio:June2024RegisteredDirectOfferingMember 2024-06-19 2024-06-19 0001680048 mbio:AtMarketOfferingMember 2024-01-01 2024-06-30 0001680048 mbio:AtMarketOfferingMember 2023-01-01 2023-06-30 0001680048 mbio:RegistrationStatements2021S3Member 2021-05-24 2021-05-24 0001680048 mbio:FortressBiotechInc Member 2024-01-02 2024-01-02 0001680048 us-gaap:RetainedEarningsMember 2024-06-30 0001680048 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001680048 us-gaap:RetainedEarningsMember 2024-03-31 0001680048 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001680048 2024-03-31 0001680048 us-gaap:RetainedEarningsMember 2023-12-31 0001680048 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001680048 mbio:CommonStockIssuableMember 2023-12-31 0001680048 us-gaap:RetainedEarningsMember 2023-06-30 0001680048 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001680048 us-gaap:RetainedEarningsMember 2023-03-31 0001680048 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001680048 2023-03-31 0001680048 us-gaap:RetainedEarningsMember 2022-12-31 0001680048 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001680048 mbio:CommonStockIssuableMember 2022-12-31 0001680048 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2024-06-30 0001680048 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-06-30 0001680048 mbio:CommonUnspecifiedClassMember us-gaap:CommonStockMember 2024-06-30 0001680048 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2024-03-31 0001680048 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-31 0001680048 mbio:CommonUnspecifiedClassMember us-gaap:CommonStockMember 2024-03-31 0001680048 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2023-12-31 0001680048 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001680048 mbio:CommonUnspecifiedClassMember us-gaap:CommonStockMember 2023-12-31 0001680048 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2023-06-30 0001680048 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-06-30 0001680048 mbio:CommonUnspecifiedClassMember us-gaap:CommonStockMember 2023-06-30 0001680048 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2023-03-31 0001680048 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-03-31 0001680048 mbio:CommonUnspecifiedClassMember us-gaap:CommonStockMember 2023-03-31 0001680048 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2022-12-31 0001680048 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001680048 mbio:CommonUnspecifiedClassMember us-gaap:CommonStockMember 2022-12-31 0001680048 mbio:June2024RegisteredDirectOfferingMember 2024-06-19 0001680048 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001680048 us-gaap:EmployeeStockOptionMember 2023-12-31 0001680048 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001680048 us-gaap:EmployeeStockOptionMember 2022-06-30 0001680048 us-gaap:EmployeeStockOptionMember 2021-06-30 0001680048 us-gaap:EmployeeStockOptionMember 2018-06-30 0001680048 2019-12-31 0001680048 us-gaap:EmployeeStockOptionMember 2016-12-31 0001680048 2023-06-01 2023-06-30 0001680048 us-gaap:EmployeeStockOptionMember 2022-06-01 2022-06-30 0001680048 us-gaap:EmployeeStockOptionMember 2021-06-01 2021-06-30 0001680048 2021-06-01 2021-06-30 0001680048 us-gaap:EmployeeStockOptionMember 2018-06-01 2018-06-30 0001680048 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0001680048 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001680048 us-gaap:RestrictedStockMember 2023-12-31 0001680048 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001680048 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001680048 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001680048 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001680048 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001680048 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001680048 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001680048 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001680048 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001680048 us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0001680048 mbio:May2024PublicOfferingMember 2024-04-29 0001680048 srt:ScenarioForecastMember mbio:May2024PublicOfferingMember 2029-04-29 2029-04-29 0001680048 mbio:May2024PublicOfferingMember 2024-04-29 2024-04-29 0001680048 2024-04-12 2024-04-12 0001680048 mbio:Il13ra2CarAndC134Member 2022-11-01 2022-11-30 0001680048 mbio:Il13ra2CarAndC134Member 2020-10-01 2020-10-31 0001680048 mbio:FortressBiotechInc Member us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMember mbio:SecondAmendedAndRestatedFoundersAgreementMember 2023-01-01 2023-12-31 0001680048 mbio:RunwayDebtFacilityMember 2023-04-11 2023-04-11 0001680048 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001680048 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001680048 us-gaap:ConstructionInProgressMember 2023-12-31 0001680048 mbio:AssetPurchaseAgreementWithUbrigeneBiosciencesMember 2024-01-01 2024-06-30 0001680048 mbio:FortressBiotechInc Member us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMember mbio:SecondAmendedAndRestatedFoundersAgreementMember 2024-04-01 2024-06-30 0001680048 mbio:FortressBiotechInc Member us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMember mbio:SecondAmendedAndRestatedFoundersAgreementMember 2024-01-01 2024-06-30 0001680048 mbio:FortressBiotechInc Member us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMember mbio:ManagementServicesAgreementMember 2024-01-01 2024-06-30 0001680048 mbio:FortressBiotechInc Member us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMember

mbio:SecondAmendedAndRestatedFoundersAgreementMember 2023-04-01 2023-06-30 0001680048 mbio:FortressBiotechInc Member us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMember mbio:ManagementServicesAgreementMember 2023-04-01 2023-06-30 0001680048 mbio:FortressBiotechInc Member us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMember mbio:SecondAmendedAndRestatedFoundersAgreementMember 2023-01-01 2023-06-30 0001680048 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001680048 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001680048 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001680048 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001680048 mbio:RunwayDebtFacilityMember 2023-04-01 2023-06-30 0001680048 us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0001680048 us-gaap:NonrelatedPartyMember 2024-01-01 2024-06-30 0001680048 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001680048 us-gaap:NonrelatedPartyMember 2023-01-01 2023-06-30 0001680048 2024-06-28 2024-06-28 0001680048 mbio:UbrigeneBiosciencesMember 2023-07-28 2023-07-28 0001680048 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001680048 us-gaap:RestrictedStockMember 2024-06-30 0001680048 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2024-06-30 0001680048 mbio:RunwayDebtFacilityMember 2023-01-01 2023-03-31 0001680048 srt:MinimumMember mbio:RunwayDebtFacilityMember 2022-03-04 2022-03-04 0001680048 mbio:RunwayDebtFacilityMember us-gaap:BaseRateMember 2022-03-04 2022-03-04 0001680048 mbio:RunwayDebtFacilityMember mbio:LiborLondonInterbankOfferedRateMember 2022-03-04 2022-03-04 0001680048 us-gaap:CommonClassAMember 2024-06-30 0001680048 mbio:CommonUnspecifiedClassMember 2024-06-30 0001680048 us-gaap:CommonClassAMember 2023-12-31 0001680048 mbio:CommonUnspecifiedClassMember 2023-12-31 0001680048 us-gaap:EmployeeStockOptionMember 2024-06-30 0001680048 mbio:UnregisteredWarrantsMember 2024-06-30 0001680048 mbio:PrefundedWarrantsMember 2024-06-30 0001680048 mbio:PlacementAgentsWarrantsMember 2024-06-30 0001680048 mbio:PrefundedWarrantsMember 2024-05-31 0001680048 mbio:PlacementAgentsWarrantsMember 2024-05-31 0001680048 mbio:May2024PublicOfferingMember 2024-05-31 0001680048 mbio:UnregisteredWarrantsMember 2023-10-26 0001680048 mbio:PrefundedWarrantsMember 2023-10-26 0001680048 mbio:PlacementAgentsWarrantsMember 2023-10-26 0001680048 mbio:PrefundedWarrantsMember mbio:OctoberRegisteredDirectOfferingMember 2024-06-30 0001680048 mbio:PrefundedWarrantsMember mbio:MayAndJuneRegisteredDirectOfferingMember 2024-06-30 0001680048 mbio:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2024-06-19 0001680048 mbio:PrefundedWarrantsMember mbio:June2024RegisteredDirectOfferingMember 2024-06-19 0001680048 mbio:WainwrightWarrantsMember us-gaap:PrivatePlacementMember 2024-06-18 0001680048 mbio:UnregisteredWarrantsMember 2024-05-31 0001680048 srt:MinimumMember mbio:ExistingWarrantsMember mbio:May2024PublicOfferingMember 2024-04-29 0001680048 mbio:PrefundedWarrantsMember mbio:May2024PublicOfferingMember 2024-04-29 0001680048 mbio:ExistingWarrantsMember mbio:May2024PublicOfferingMember 2024-04-29 0001680048 2022-12-31 0001680048 2023-06-30 0001680048 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001680048 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001680048 us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0001680048 us-gaap:PreferredClassAMember 2024-01-01 2024-06-30 0001680048 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001680048 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001680048 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001680048 us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001680048 us-gaap:PreferredClassAMember 2023-01-01 2023-06-30 0001680048 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001680048 mbio:RunwayDebtFacilityMember 2023-01-01 2023-06-30 0001680048 mbio:CommonStockIssuableMember 2023-01-01 2023-06-30 0001680048 mbio:CommonStockIssuableMember 2024-01-01 2024-06-30 0001680048 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001680048 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001680048 mbio:CommonUnspecifiedClassMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001680048 mbio:CommonUnspecifiedClassMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001680048 mbio:June2024RegisteredDirectOfferingMember 2024-06-21 2024-06-21 0001680048 mbio:RegistrationStatements2024S3Member 2024-06-12 0001680048 mbio:RegistrationStatements2021S3Member 2021-05-24 0001680048 mbio:UbrigeneBiosciencesMember 2023-07-28 0001680048 mbio:St.JudeChildrensResearchHospitalMember mbio:StJudeXscidMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-04-01 2024-06-30 0001680048 mbio:LeidenUniversityMedicalCentreMember mbio:Rag1ScidMb110Member mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-04-01 2024-06-30 0001680048 mbio:FredHutchinsonCancerResearchCenterMember mbio:Cd20TechnologyProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-04-01 2024-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:PscaProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-04-01 2024-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:Il13r2ProductMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-04-01 2024-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:Cs1ProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-04-01 2024-06-30 0001680048 mbio:MayoClinicMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-04-01 2024-06-30 0001680048 mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-04-01 2024-06-30 0001680048 mbio:St.JudeChildrensResearchHospitalMember mbio:StJudeXscidMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-01-01 2024-06-30 0001680048 mbio:LeidenUniversityMedicalCentreMember mbio:Rag1ScidMb110Member mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-01-01 2024-06-30 0001680048 mbio:FredHutchinsonCancerResearchCenterMember mbio:Cd20TechnologyProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-01-01 2024-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:PscaProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-01-01 2024-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:Il13r2ProductMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-01-01 2024-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:Cs1ProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-01-01 2024-06-30 0001680048 mbio:MayoClinicMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-01-01 2024-06-30 0001680048 mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-01-01 2024-06-30 0001680048

mbio:St.JudeChildrensResearchHospitalMember mbio:StJudeXscidMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-04-01 2023-06-30 0001680048 mbio:LeidenUniversityMedicalCentreMember mbio:Rag1ScidMb110Member mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-04-01 2023-06-30 0001680048 mbio:FredHutchinsonCancerResearchCenterMember mbio:Cd20TechnologyProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-04-01 2023-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:PscaProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-04-01 2023-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:Il13r2ProductMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-04-01 2023-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:Cs1ProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-04-01 2023-06-30 0001680048 mbio:MayoClinicMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-04-01 2023-06-30 0001680048 mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-04-01 2023-06-30 0001680048 mbio:St.JudeChildrensResearchHospitalMember mbio:StJudeXscidMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-01-01 2023-06-30 0001680048 mbio:LeidenUniversityMedicalCentreMember mbio:Rag1ScidMb110Member mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-01-01 2023-06-30 0001680048 mbio:FredHutchinsonCancerResearchCenterMember mbio:Cd20TechnologyProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-01-01 2023-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:PscaProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-01-01 2023-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:Il13r2ProductMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-01-01 2023-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:Cs1ProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-01-01 2023-06-30 0001680048 mbio:MayoClinicMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-01-01 2023-06-30 0001680048 mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2023-01-01 2023-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:Cs1ProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2024-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:PscaProductOrProcessMember 2024-06-30 0001680048 mbio:FortressBiotechIncMember us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMember mbio:ManagementServicesAgreementMember 2024-04-01 2024-06-30 0001680048 mbio:FortressBiotechIncMember us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMember mbio:ManagementServicesAgreementMember 2023-01-01 2023-06-30 0001680048 mbio:UbrigeneBiosciencesMember 2024-05-13 0001680048 mbio:MayoClinicMember mbio:CarTTechnologyProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2022-10-01 2022-10-31 0001680048 mbio:MayoClinicMember mbio:CarTTechnologyProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2021-06-01 2021-06-30 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:PscaProductOrProcessMember srt:MaximumMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2020-10-01 2020-10-31 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:Cs1ProductOrProcessMember srt:MaximumMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2020-06-01 2020-06-30 0001680048 mbio:FredHutchinsonCancerResearchCenterMember mbio:Cd20TechnologyProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2017-07-03 2017-07-03 0001680048 2023-04-01 2023-06-30 0001680048 2023-01-01 2023-06-30 0001680048 mbio:CommonUnspecifiedClassMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001680048 mbio:UbrigeneBiosciencesMember 2024-05-13 2024-05-13 0001680048 mbio:FortressBiotechIncMember us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMember mbio:SecondAmendedAndRestatedFoundersAgreementMember 2024-01-02 2024-01-02 0001680048 mbio:FortressBiotechIncMember us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMember mbio:SecondAmendedAndRestatedFoundersAgreementMember 2016-07-22 2016-07-22 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:Il13r2ProductMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2017-02-01 2017-02-28 0001680048 mbio:RegistrationStatements2024S3Member 2024-06-30 0001680048 mbio:AtMarketOfferingMember 2024-05-31 0001680048 mbio:AtMarketOfferingMember 2018-07-31 0001680048 2023-01-01 2023-12-31 0001680048 mbio:UnregisteredWarrantsMember 2024-05-01 2024-05-31 0001680048 mbio:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2024-06-19 2024-06-19 0001680048 mbio:PrefundedWarrantsMember mbio:June2024RegisteredDirectOfferingMember 2024-06-19 2024-06-19 0001680048 mbio:PrefundedWarrantsMember mbio:May2024PublicOfferingMember 2024-04-29 2024-04-29 0001680048 mbio:WainwrightWarrantsMember us-gaap:PrivatePlacementMember 2024-06-18 2024-06-18 0001680048 mbio:SeriesA3WarrantMember mbio:May2024PublicOfferingMember 2024-04-29 0001680048 mbio:SeriesA2WarrantMember mbio:May2024PublicOfferingMember 2024-04-29 0001680048 mbio:SeriesA1WarrantMember mbio:May2024PublicOfferingMember 2024-04-29 0001680048 mbio:AssetPurchaseAgreementWithUbrigeneBiosciencesMember 2024-06-27 0001680048 mbio:AssetPurchaseAgreementWithUbrigeneBiosciencesMember 2024-06-27 2024-06-27 0001680048 mbio:LeidenUniversityMedicalCentreMember mbio:Rag1ScidMb110Member mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2021-09-08 2021-09-08 0001680048 mbio:CityOfHopeNationalMedicalCenterCohMember mbio:Il13r2ProductMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2020-10-01 2020-10-31 0001680048 mbio:CommonUnspecifiedClassMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001680048 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001680048 mbio:FredHutchinsonCancerResearchCenterMember mbio:Cd20TechnologyProductOrProcessMember srt:MaximumMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2022-01-01 2022-01-31 0001680048 mbio:FredHutchinsonCancerResearchCenterMember mbio:Cd20TechnologyProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2022-01-01 2022-01-31 0001680048 mbio:FredHutchinsonCancerResearchCenterMember mbio:Cd20TechnologyProductOrProcessMember mbio:SponsoredResearchAndClinicalTrialAgreementsMember 2020-11-01 2020-11-30 0001680048 2024-06-30 0001680048 2023-12-31 0001680048 2024-04-01 2024-06-30 0001680048 us-gaap:CommonClassAMember 2024-08-09 0001680048 mbio:CommonUnspecifiedClassMember 2024-08-09 0001680048 2024-01-01 2024-06-30 shares

iso4217:USD pure iso4217:USD shares mbio:item http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember 0001680048 --12-31 2024 Q2 false 34098059 8374869 845385 845385 250000 250000 -2796000 P1Y7M6D P5Y P24M P9M P5Y P5D P12M P6M P12M P12M 10-Q true 2024-06-30 false 001-38191 MUSTANG BIO, INC. DE 47-3828760 377 Plantation Street Worcester MA 01605 781 652-4500 Common Stock, par value $0.0001 per share MBIO NASDAQ Yes Yes Non-accelerated Filer true false false 845385 36387236 4268000 6234000 728000 3879000 114000 1233000 2209000 0 7319000 11346000 472000 3247000 375000 750000 250000 833000 103000 1566000 8519000 17742000 13190000 14017000 2304000 834000 429000 520000 15923000 15371000 270000 270000 656000 1978000 16849000 17619000 0.0001 0.0001 2000000 2000000 250000 250000 0 0 0.0001 0.0001 200000000 200000000 845385 845385 0 0 34098059 8374869 3000 1000 0 419089 0 591000 386028000 380502000 -394361000 -380971000 -8330000 123000 8519000 17742000 4360000 10836000 8164000 24836000 2649000 0 2649000 0 1531000 3055000 2958000 5376000 8540000 13891000 13771000 30212000 -8540000 -13891000 -13771000 -30212000 314000 429000 314000 780000 29000 159000 70000 612000 2000 2932000 3000 4108000 341000 -2344000 381000 -2716000 -8199000 -16235000 -13390000 -32928000 -0.35 -0.35 -2.00 -2.00 -0.78 -0.78 -4.06 -4.06 23123178 23123178 8127473 8127473 17090705 17090705 8110661 8110661 250000 845385 9545541 1000 381218000 -386162000 -4943000 575191 163000 163000 4185000 5265000 5265000 5689 -619000 -619000 19786638 2000 1000 3000 -8199000 -8199000 250000 845385 34098059 3000 386028000 -394361000 -8330000 250000 845385 8374869 1000 591000 380502000 -380971000 123000 928277 -477000 640000 163000 4251003 -114000 5379000 5265000 47463 48000 48000 5573 -542000 -542000 20490874 2000 1000 3000 -13390000 -13390000 250000 845385 34098059 3000 386028000 -394361000 -8330000 250000 845385 7293242 1000 375876000 -346062000 29815000 12642 88000 88000 16193 45000 45000 1633 -16235000 -16235000 250000 845385 7320444 1000 376009000 -362297000 13713000 250000 845385 7100111 11000 1109000 374522000 -329369000 46273000 187134 -1109000 1109000 12642 88000 88000 22097 280000 280000 93 -10000 10000 1633 -32928000 -32928000 250000 845385 7320444 1000 376009000 -362297000 13713000 -13390000 -32928000 163000 0 -542000 280000 569000 1291000 0 118000 128000 204000 -29000 0 2649000 0 0 -2796000 314000 220000 -672000 -325000 -167000 0 0 -36000 981000 -2022000 1470000 5000 238000 85000 -7656000 -30200000 0 34000 0 -34000 0 30375000 5944000 0 680000 0 3000 0 48000 88000 5315000 -30287000 -2341000 -60521000 6984000 76656000 4643000 16135000 0 1340000 591000 1109000 0 4348000 2209000 0 2509000 0 6967000 0 3644000 0 1395000 0 Note 1 – Organization, Description of Business and Liquidity and Capital Resources Mustang Bio, Inc. (the “Company” or “Mustang”) was incorporated in Delaware on March 13, 2015. Mustang is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers and solid tumors. The Company may acquire rights to these technologies by licensing the rights or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is a majority-controlled subsidiary of Fortress Biotech, Inc. (“Fortress” or “Parent”). Liquidity and Capital Resources The Company has incurred substantial operating losses and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of June 30, 2024, the Company had an accumulated deficit of $394.4 million. The Company has funded its operations to date primarily through the sale of equity and via debt raises. The Company expects to continue to use the proceeds from its previous financing transactions and asset sale primarily for working capital and general corporate purposes. The Company will require substantial additional financings through equity and debt offerings, collaborations and licensing arrangements or other sources to fully develop, prepare regulatory filings, obtain regulatory approvals and commercialize its existing product candidates. The continuation of our business as a going concern is dependent upon raising additional capital and eventually attaining and maintaining profitable operations. In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these unaudited consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that these unaudited financial statements are issued. In performing its evaluation, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipt of potential funding from future equity or debt issuances cannot be considered probable at this time because these plans are not entirely within the Company’s control nor have been approved by the Board of Directors as of the date of these financial statements. The Company's expectation to generate operating losses and negative operating cash flows in the future, and the need for additional funding to support its planned operations raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that these unaudited financial statements are issued. The Company made strategic decisions, including a significant reduction in the workforce by approximately 81% in April 2024, and also in April 2024, terminated certain license agreements with St. Jude and Leiden University Medical Centre, and with Mayo Clinic in June 2024, to preserve capital and prioritize the allocation of resources. The Company continues to pursue additional cash resources through public or private equity or debt financings. The Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least 12

months from the date of issuance of these unaudited financial statements. The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary if the Company is unable to continue as a going concern. -394400000 0.81 Note 2 - Significant Accounting Policies Basis of Presentation The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the interim unaudited financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. They do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company's audited financial statements and notes thereto for the year ended December 31, 2023, which were included in the Company's Annual Report on Form 10-K and filed with the Securities and Exchange Commission ("SEC") on March 11, 2024 (the "2023 Form 10-K"). The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. Use of Estimates The Company's unaudited financial statements include certain amounts that are based on management's best estimates and judgments. The Company's significant estimates include, but are not limited to, assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Due to the uncertainty inherent in such estimates, actual results could differ from those estimates. Cash, Cash Equivalents and Restricted Cash The Company records cash held in an escrow account as a security deposit for the manufacturing facility in Worcester, Massachusetts, as restricted cash. The following table provides a reconciliation of cash, cash equivalents, and restricted cash from the Unaudited Balance Sheets to the Unaudited Statements of Cash Flows for the six months ended June 30, 2024, and 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:48.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;background:#cceeff;margin:0pt;padding:0pt;"> $ 4,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;background:#cceeff;margin:0pt;padding:0pt;"> $ 15,385 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 375 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 750 </td></tr><tr><td style="vertical-align:bottom;width:51.28%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash, cash equivalents and restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ 4,643 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ 16,135 </td></tr></table> - Assets Held for Sale - Assets held for sale represent assets that have met the criteria of “held for sale” accounting, as specified by Accounting Standards Codification (“ASC”) 360, “Long-lived Assets.” As of June 30, 2024, there were $2.2 million of lab and cell processing equipment, furniture and fixtures and computer equipment that are recorded as assets held for sale. The effect of suspending depreciation on the assets held for sale is immaterial to the results of operations. The assets held for sale are part of the repurchase of assets from uBriGene (see Note 6). - - Impairment of Long-Lived Assets - The Company reviews long-lived assets, including tangible assets and other intangible assets with definitive lives, for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. The Company conducts its long-lived asset impairment analyses in accordance with ASC 360-10, "Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires the Company to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset group is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. - Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies previously disclosed in the 2023 Form 10-K. Recently Issued Accounting Standards As of June 30, 2024, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2023 Form 10-K that affect the Company’s present or future results of operations, overall financial condition, liquidity, or disclosures upon adoption. Basis of Presentation The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the interim unaudited financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. They do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial

statements should be read in conjunction with the Company's audited financial statements and notes thereto for the year ended December 31, 2023, which were included in the Company's Annual Report on Form 10-K and filed with the Securities and Exchange Commission ("SEC") on March 11, 2024 (the "2023 Form 10-K"). The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. Use of Estimates The Company's unaudited financial statements include certain amounts that are based on management's best estimates and judgments. The Company's significant estimates include, but are not limited to, assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Due to the uncertainty inherent in such estimates, actual results could differ from those estimates. Cash, Cash Equivalents and Restricted Cash . The Company records cash held in an escrow account as a security deposit for the manufacturing facility in Worcester, Massachusetts, as restricted cash. . The following table provides a reconciliation of cash, cash equivalents, and restricted cash from the Unaudited Balance Sheets to the Unaudited Statements of Cash Flows for the six months ended June 30, 2024, and 2023: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:48.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;background:#cceeff;margin:0pt;padding:0pt;"> $ 4,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;background:#cceeff;margin:0pt;padding:0pt;"> $ 15,385 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 375 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 750 </td></tr><tr><td style="vertical-align:bottom;width:51.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash, cash equivalents and restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ 4,643 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ 16,135 </td></tr></table> - The following table provides a reconciliation of cash, cash equivalents, and restricted cash from the Unaudited Balance Sheets to the Unaudited Statements of Cash Flows for the six months ended June 30, 2024, and 2023: - <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;margin:0pt;padding:0pt;"> - </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:48.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;background:#cceeff;margin:0pt;padding:0pt;"> $ 4,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;background:#cceeff;margin:0pt;padding:0pt;"> $ 15,385 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.28%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 375 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 750 </td></tr><tr><td style="vertical-align:bottom;width:51.28%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash, cash equivalents and restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:23.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ 4,643 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:23.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 16,135 </td></tr></table> 4268000 15385000 375000 750000 4643000 16135000 Assets Held for Sale Assets held for sale represent assets that have met the criteria of “held for sale” accounting, as specified by Accounting Standards Codification (“ASC”) 360, “Long-lived Assets.” As of June 30, 2024, there were $2.2 million of lab and cell processing equipment, furniture and fixtures and computer equipment that are recorded as assets held for sale. The effect of suspending depreciation on the assets held for sale is immaterial to the results of operations. The assets held for sale are part of the repurchase of assets from uBriGene (see Note 6). 2200000 Impairment of Long-Lived Assets The Company reviews long-lived assets, including tangible assets and other intangible assets with definitive lives, for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. The Company conducts its long-lived asset impairment analyses in accordance with ASC 360-10, "Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires the Company to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset group is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies previously disclosed in the 2023 Form 10-K. Recently Issued Accounting Standards As of June 30, 2024, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2023 Form 10-K that affect the Company’s present or future results of operations, overall financial condition, liquidity, or disclosures upon adoption. Note 3 - Clinical Trial and Sponsored Research Agreements Research and Development Expenses - Sponsored Research and Clinical Trial Agreements For the three and six months ended June 30, 2024 and 2023, the Company recorded the following expenses in research and development for sponsored research and clinical trial agreements in the Unaudited Statements of Operations pursuant to the terms of these agreements: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the three months ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the six months ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.47%;background:#cceeff;margin:0pt;padding:0pt;"> City of Hope National Medical Center </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> IL13Rα2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 111 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 326 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 391 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 636 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.47%;background:#cceeff;margin:0pt;padding:0pt;"> CS1⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 139 </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.33%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> 188 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ccceff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> PSCA⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 22 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 44 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:38.47%;background:#ccceff;margin:0pt;padding:0pt;"> Fred Hutchinson Cancer Center - CD20 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> 312 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> 544 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> 312 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">| </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> 1,098 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ccceff;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> St. Jude Children's Research Hospital - XSCID⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 216 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> (434) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 634 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;width:38.47%;background:#ccceff;margin:0pt;padding:0pt;"> Leiden University Medical Center - RAG1 SCID </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#ccceff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> 121 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccceff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> 112 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccceff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> 241 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccceff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> 224 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">. </td></tr><tr><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> Mayo Clinic⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (275) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 275 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (275) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 551 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:38.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,634 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,375 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> . <sup style="font-

size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> Licenses and associated sponsored research agreements were terminated in May 2023. ⁽²⁾ License and associated Data Transfer Agreement were terminated in April 2024. ⁽³⁾ License and associated sponsored research agreement were terminated in June 2024. Ongoing Clinical Trial and Sponsored Research Agreements IL13Rα2 (MB-101) Clinical Research Support Agreements Since February 2017, the Company has been party to a clinical research support agreement for the IL13Rα2-directed CAR T program (the "IL13Rα2 CRA") with COH, whereby, the Company has agreed to contribute $0.1 million related to patient costs in connection with the on-going investigator-initiated study. Since October 2020, the Company has been party to a clinical research support agreement for the IL13Rα2-directed CAR T program for adult patients with leptomeningeal glioblastoma, ependymoma or medulloblastoma (the "IL13Rα2 Leptomeningeal CRA") with COH, whereby the Company has agreed to contribute $0.1 million per patient in connection with the ongoing investigator-initiated study. Further, the Company agreed to fund approximately $0.2 million annually pertaining to the clinical development of the IL13Rα2-directed CAR T program for this patient population. Since October 2020, the Company has been party to a Sponsored Research Agreement ("SRA") with COH to conduct combination studies of a potential IL13Rα2 CAR (MB-101) and herpes simplex-1 oncolytic virus therapy (MB-108). Pursuant to the SRA, the Company funded research in the amount of $0.3 million for the program. In November 2022, the SRA was amended to include additional funding of $0.6 million. CD20 (MB-106) Clinical Trial Agreement with Fred Hutchinson Cancer Center Since July 3, 2017, in conjunction with the CD20 Technology License from Fred Hutchinson Cancer Center ("Fred Hutch"), the Company has been party to an investigator-initiated clinical trial agreement (the "CD20 CTA") to provide partial funding for a Phase 1/2 clinical trial at Fred Hutch evaluating the safety and efficacy of the CD20 Technology in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. In connection with the CD20 CTA, the Company agreed to fund up to $5.3 million of costs associated with the clinical trial, which commenced during the fourth quarter of 2017. In November 2020, the CD20 CTA was amended to include additional funding of approximately $1.8 million, which includes $0.8 million for the treatment of five patients with chronic lymphocytic leukemia. In January 2022, the CD20 CTA was amended to include additional funding of $2.2 million increasing the total payment obligation of the Company in connection with the CD20 CTA not to exceed $9.3 million. Terminated Clinical Trial and Sponsored Research Agreements CS1 (MB-104) Clinical Research Support Agreement Beginning in June 2020, the Company was party to a clinical research and support agreement with COH in connection with an investigator-sponsored study conducted under an Institutional Review Board-approved for MB-104, whereby the Company has agreed to reimburse COH for costs associated with this trial, when incurred, not to exceed $2.4 million. The agreement will expire upon the delivery of a final study report or earlier. Since inception, the Company has reimbursed COH $2.2 million. In May 2023, the Company determined to discontinue development of its MB-104 program and terminated the associated CRA and license. PSCA (MB-105) Clinical Research Support Agreement Beginning in October 2020, the Company was party to a clinical research support agreement with COH in connection with an investigator-sponsored study conducted under an Institutional Review Board-approved, investigator-initiated protocol entitled: "A Phase 1 Study to Evaluate PSCA-Specific Chimeric Antigen Receptor (CAR)-T Cells for Patients with Metastatic Castration Resistant Prostate Cancer" for MB-105. The Company has agreed to reimburse COH for costs associated with this trial not to exceed $2.3 million. The agreement will expire upon the delivery of a final study report or earlier. Since inception, the Company has reimbursed COH $0.5 million. In May 2023, the Company determined to discontinue development of its MB-105 program and terminated the associated CRA and license. XSCID (MB-107) Data Transfer Agreement with St. Jude Children's Research Hospital Since June 2020, the Company has been party to a Data Transfer Agreement with St. Jude Children's Research Hospital ("St. Jude") under which Mustang will reimburse St. Jude for costs associated with St. Jude's clinical trial for the treatment of infants with X-linked severe combined immunodeficiency ("XSCID"), whereby

the Company will continue to reimburse St. Jude for costs incurred in connection with this trial. In April 2024, the Company terminated its license agreement and the associated Data Transfer Agreement with St. Jude, in exchange for a mutual release of liability and forgiveness by St. Jude of all amounts previously owed by the Company. - RAG1-SCID (MB-110) Sponsored Research Support Agreement ("SRA") with Leiden University Medical Centre - Since September 8, 2021, in connection with the Leiden License, the Company has been party to a Sponsored Research Support Agreement ("SRA") with Leiden University Medical Centre ("LUMC") under which the Company will fund research in the amount of approximately $0.5 million annually over a period of 5 years. The research performed pursuant to this agreement will support technology the Company has licensed from Leiden for the use of a gene therapy under development for the treatment of severe immunodeficiency caused by mutations in the RAG1 gene. In April 2024, the Company delivered a termination notice to LUMC, pursuant to which it terminated the license agreement underpinning the MB-110 product candidate; the Company is currently in discussions with LUMC regarding the terms that will govern such termination. - Sponsored Research Support Agreement with Mayo Clinic From June 2021 until June 2024, the Company was party to an SRA with the Mayo Clinic under which the Company would fund research in the amount of $2.1 million over a period of two years. In October 2022, the SRA was amended to include additional funding of approximately $0.1 million. The research performed pursuant to this agreement supported technology the Company licensed from Mayo Clinic for a novel technology that may be able to transform the administration of CAR T therapies and has the potential to be used as an off-the-shelf therapy. In June 2024, the Company terminated its license agreement and associated SRA with the Mayo Clinic, in exchange for a mutual release of liability and forgiveness by Mayo Clinic of all amounts previously owed by the Company. - <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the three months ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the six months ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.47%;background:#cceeff;margin:0pt;padding:0pt;"> City of Hope National Medical Center </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> IL13Rα2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 111 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 326 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 391 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 636 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.47%;background:#ccceff;margin:0pt;padding:0pt;"> CS1⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> 139 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 188 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> PSCA⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 22 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 44 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:38.47%;background:#cceeff;margin:0pt;padding:0pt;"> Fred Hutchinson Cancer Center - CD20 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 312 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 544 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 312 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 1,098 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> St. Jude Children's Research Hospital - XSCID⁽²⁾ </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 216 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> (434) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 634 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;width:38.47%;background:#cceeff;margin:0pt;padding:0pt;"> Leiden University Medical Center - RAG1 SCID </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 121 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 112 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 241 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 224 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;width:38.47%;margin:0pt;padding:0pt;"> Mayo Clinic⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (275) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">. </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 275 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (275) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 551 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:38.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,634 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,375 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> . ⁽¹⁾ Licenses and associated sponsored research agreements were terminated in May 2023. ⁽²⁾ License and associated Data Transfer Agreement were terminated in April 2024. ⁽³⁾ License and associated sponsored research agreement were terminated in June 2024. 111000 326000 391000 636000 0 139000 0 188000 0 22000 0 44000 312000 544000 312000 1098000 0 216000 -434000 634000 121000 112000 241000 224000 -275000 275000 -275000 551000 268000 1634000 235000 3375000 100000 100000 200000 300000 600000 5300000 1800000 800000 2200000 9300000 2400000 2200000 2300000 500000 500000 P5Y 2100000 P2Y 100000 Note 4 - Related Party Agreements Founders Agreement and

Management Services Agreement with Fortress With respect to the Company's Management Services Agreement (the "Management Services Agreement") with Fortress for the three and six months ended June 30, 2024 and 2023, expenses related to the MSA are recorded 50% in research and development expenses and 50% in general and administrative expenses in the Unaudited Statements of Operations. For the three months ended June 30, 2024 and 2023, the Company recorded expense of $0.1 million and $0.1 million, respectively, related to the MSA. For the six months ended June 30, 2024 and 2023, the Company recorded expense of $0.3 million and $0.3 million, respectively. Under the terms of the Second Amended and Restated Founders Agreement (the "Founders Agreement"), which became effective July 22, 2016, Fortress will receive a grant of shares of the Company's common stock equal to two and one-half percent (2.5%) of the gross amount of any equity or debt financing. For the six months ended June 30, 2024, the Company issued 575,191 shares to Fortress in connection with the equity financings. For the three months ended June 30, 2024 and 2023, the Company recorded expense of approximately $163,000 and zero, respectively, in general and administrative expenses related to these shares. For the six months ended June 30, 2024 and 2023, the Company recorded expense of approximately $163,000 and zero, respectively, in general and administrative expenses related to these shares. Annual Stock Dividend Pursuant to the Company's Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), the Company issued 353,086 shares of common stock to Fortress as the Annual Stock Dividend (as such term is defined in the Certificate of Incorporation), representing 2.5% of the fully-diluted outstanding equity of Mustang on January 2, 2024. This was recorded in the Statement of Stockholders' Equity at December 31, 2023, as Common stock issuable – Founders Agreement. The Company recorded an expense of approximately $0.5 million in research and development – licenses acquired related to these issuable shares during the year ended December 31, 2023. Payables and Accrued Expenses Related Party In the normal course of business Fortress pays for certain expenses on behalf of the Company. Such expenses are recorded as payables and accrued expenses - related party and are typically reimbursed to Fortress in the normal course of business. 0.50 0.50 0.50 0.50 100000 100000 300000 300000 0.025 575191 163000 0 163000 0 353086 0.025 500000 Note 5 – Assets Purchase Agreements Agreements with uBriGene On May 18, 2023, the Company entered into an Asset Purchase Agreement (the "Original Asset Purchase Agreement") with uBriGene (Boston) Biosciences, Inc., a Delaware corporation ("uBriGene"), pursuant to which the Company agreed to sell its leasehold interest in its cell processing facility located in Worcester, Massachusetts (the "Facility"), and associated assets relating to the manufacturing and production of cell and gene therapies at the Facility to uBriGene (the "Transaction"). The Company and uBriGene subsequently entered into Amendment No. 1 to the Original Asset Purchase Agreement, dated as of June 29, 2023 ("Amendment No. 1"), and Amendment No. 2 to the Original Asset Purchase Agreement, dated as of July 28, 2023 ("Amendment No. 2," and together with the Original Asset Purchase Agreement and Amendment No. 1, the "Prior Asset Purchase Agreement"). On July 28, 2023, pursuant to the Prior Asset Purchase Agreement, the Company completed the sale of all of its assets that primarily relate to the manufacturing and production of cell and gene therapies at the Facility (such operations, the "Transferred Operations" and such assets, the "Transferred Assets") to uBriGene for upfront consideration of $6 million cash (the "Base Amount"). The Transferred Assets included all of the Company's assets, except for the Company's lease and related leasehold improvements of the Facility and contracts that are primarily used in the Transferred Operations. The Company recorded a gain of $1.4 million in connection with the sale of the Transferred Assets, and recorded approximately $0.3 million of the base consideration as deferred income, that was to be recognized upon the transfer of the lease. In connection with the Prior Asset Purchase Agreement, the Company and uBriGene submitted a voluntary joint notice to the U.S. Committee on Foreign Investment in the United States ("CFIUS"). Following CFIUS's review and subsequent investigation of the transactions related to the Prior Asset Purchase Agreement, on May 13, 2024, the Company, together with uBriGene and CFIUS, executed a National Security Agreement (the "NSA"), pursuant to which the Company and uBriGene agreed to abandon the transactions related to the Prior Asset Purchase Agreement and the agreements entered into in connection therewith. The NSA obligated uBriGene and the Company to terminate agreements between the two parties, including the Manufacturing Services Agreement, Quality Services Agreement, and Subcontracting CDMO Agreement. In addition, uBriGene must sell, or otherwise dispose of, the equipment assets purchased within 180 days after the execution of the NSA. June 2024 Repurchase of Assets On June 27, 2024 (the "Effective Date"), the Company entered into an Asset Purchase Agreement (the "Repurchase Agreement") with uBriGene, pursuant to which the Company agreed, subject to the terms and conditions set forth therein, to

repurchase the Transferred Assets, primarily lab equipment and supplies, (collectively, the “Repurchased Assets”). Pursuant to the terms of the Repurchase Agreement, the Company and uBriGene also terminated existing manufacturing and services agreements.   As consideration for the Repurchase Agreement, the Company agreed to pay to uBriGene a total purchase price (the “Purchase Price”) of $1.4 million, consisting of (i) an upfront payment of $0.1 million due within five (5) business days of the Effective Date and a (ii) subsequent amount of $1.3 million due on the date that is twelve (12) months after the closing date (the “Deferred Amount”). In the event that as of the original (or any extended) date on which the Deferred Amount is payable, the Company has, as of the date of the public reporting of its then-most recent quarterly audited or unaudited financial statements, net assets below $20 million, then the Company may, upon written notice to uBriGene, elect to delay its payment obligation of the Deferred Amount by an additional six (6) months, with no limit on the number of such extensions available to the Company. Notwithstanding the foregoing, if the Company has not paid the Deferred Amount in full as of the date that is twelve (12) months after closing of the Repurchase Agreement, any amounts that remain outstanding will accrue interest at a rate of 5% per annum beginning on the date that is twelve (12) months after closing and until the Deferred Amount is paid in full. Additionally, in connection with the termination of the agreements described above under the Repurchase Agreement, the Company agreed to forgive a net receivable from uBriGene of approximately $3.3 million, comprised of outstanding receivables of $6.9 million and payables of $3.6 million, resulting in total purchase consideration in the Repurchase Transactions of approximately $4.7 million. As of June 30, 2024, the $1.4 million Purchase Price was recorded in Accrued Other Expenses (see Note 7). The Company allocated the total purchase consideration of $4.7 million to the Repurchased Assets on a relative fair value basis. The Company used a third-party to perform a valuation of the repurchased equipment, which resulted in a fair value less costs to sell of approximately $2.2 million. The remaining purchase consideration of $2.5 million was allocated to the supplies repurchased. The supplies repurchased with no alternative future use were recognized as research and development expense in an amount of $2.2 million. Repurchased supplies with an alternative future use of $0.3 million were also recognized in research and development expense, as the Company does not have plans to resume operations in the facility, and it intends to dispose of the supplies in a single transaction with the equipment. The Company concluded that the disposal group, which includes the repurchased equipment assets and associated supplies, with an aggregate value of approximately $2.2 million met the criteria to be classified as held for sale at the date of acquisition. 6000000 1400000 300000 2 P180D 1400000 100000 1300000 20000000 0.05 3300000 6900000 3600000 4700000 1400000 4700000 2200000 2500000 2200000 300000 2200000 Note 6 – Property, Plant and Equipment, and Asset Impairment At June 30, 2024, and December 31, 2023, property, plant and equipment consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"> Estimated Useful </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"> Leasehold improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"> 9 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 7,694 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 7,694 </td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"> Construction in process </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"> N/A </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29 </td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"> Total property, plant and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 7,694 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 7,723 </td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"> Less: impairment loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> (2,177) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"> Less: accumulated depreciation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,045) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> (4,476) </td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"> Property, plant and equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,247 </td></tr></table> - Depreciation expense for the three months ended June 30, 2024 and 2023, was approximately $0.3 million and $0.6 million, respectively, and was recorded in research and development expense in the Unaudited Statements of Operations. Depreciation expense for the six months ended June 30, 2024 and 2023, was approximately $0.6 million and $1.3 million, respectively, and was recorded in research and development expense in the Unaudited Statements of Operations. - Impairment of Long-Lived Assets - During the three months ended June 30, 2024, The Company concluded it had a triggering event requiring assessment of impairment for certain leasehold improvements and the related right-of-use asset. The Company assessed the carrying value of the asset group consisting of the leasehold improvements and right-of-use asset in accordance with ASC 360, given the significant changes to the Company’s operations, operating cash and the repurchase of equipment. The assessment of the recoverability of the asset group concluded that there was impairment on the carrying value of the asset group of approximately $2.6 million, which was allocated on a pro rata basis using the relative carrying amounts of the assets. Approximately $2.2 million of the impairment loss was allocated to the leasehold improvements, with the remaining $0.4 million allocated to the right-of-use asset. At June 30, 2024, and December 31, 2023, property, plant and equipment consisted of the following: - <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"> Estimated Useful </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"> Leasehold improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"> 9 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 7,694 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 7,694 </td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"> Construction in process </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"> N/A </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29 </td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"> Total property, plant and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 7,694 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 7,723 </td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"> Less: impairment loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> (2,177) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"> Less: accumulated depreciation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,045) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,476) </td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"> Property, plant and equipment, net </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,247 </td></tr></table> P9Y P9Y 7694000 7694000 29000 7694000 7723000 2177000 5045000 4476000 472000 3247000 300000 600000 600000 1300000 2600000 2200000 400000

Note 7 - Accounts Payable and Accrued Expenses

* | *At June 30, 2024, and December 31, 2023, accounts payable and accrued expenses consisted of the following:* | <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.23%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.23%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> | </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> | </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:72.23%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-*

space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"> Accounts payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"> 6,322 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:72.23%;margin:0pt;padding:0pt;"> Accrued research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> 1,606 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> 4,118 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"> 778 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"> 2,838 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.23%;margin:0pt;padding:0pt;"> Other ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,872 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 739 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"> Total accounts payable and accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14,017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> ⁽¹⁾ Other includes approximately $1.4 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 5. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td

colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:72.23%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"> Accounts payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"> 6,322 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:72.23%;margin:0pt;padding:0pt;"> Accrued research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> 1,606 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> 4,118 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"> 778 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"> 2,838 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.23%;margin:0pt;padding:0pt;"> Other ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,872 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 739 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"> Total accounts payable and accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14,017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> . ⁽¹⁾ Other includes approximately $1.4 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 5. 8934000 6322000 1606000 4118000 778000 2838000 1872000 739000 13190000 14017000 1400000 Note 8 – Notes Payable On April 11, 2023, the Company’s long-term debt facility (the “Term Loan”) with Runway Growth Finance Corp. (“Runway”), originally entered into on March 4, 2023, was terminated upon receipt by Runway of a payoff amount of $30.4 million from the Company comprised of principal, interest and the applicable final payment amount. The loss on extinguishment was recorded in interest expense in the Unaudited Statements of Operations. For the three and six months ended June 30, 2024 and 2023, the Company recorded the following components in interest expense: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the three months ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the six months ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:top;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"> Interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 133 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"> 1,188 </td></tr><tr><td style="vertical-align:top;width:43.65%;margin:0pt;padding:0pt;"> Amortization of Debt Discount </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"> 118 </td></tr><tr><td style="vertical-align:top;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"> Loss on Extinguishment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 2,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"> 2,794 </td></tr><tr><td style="vertical-align:top;width:43.65%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8 </td></tr><tr><td style="vertical-align:top;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"> Total Interest Expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,932 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,108 </td></tr></table> The Term Loan accrued interest at a variable annual rate equal to 8.75% plus the greater of (i) 0.50% and (ii) the three month LIBOR Rate for U.S. dollar deposits; provided that the Applicable Rate would not be less than 9.25%. On December 7, 2022, the Company entered into the First Amendment (the “First Amendment”) to the Loan Agreement by and between the Company and Runway. The First Amendment amended

certain definitions and other provisions of the Loan Agreement to replace LIBOR-based benchmark rates applicable to loans outstanding under the Loan Agreement with SOFR-based rates, subject to adjustments as specified in the First Amendment. The Applicable Rate at March 31, 2023 was 13.77%. For the three and six months ended June 30, 2023, the Company made interest payments of $0.3 million and $1.3 million, respectively, recorded in interest expense in the Unaudited Statements of Operations. . Amortization of the debt discount associated with the Term Loan was approximately $0.1 million for the three and six months ended June 30, 2023, and was recorded in interest expense in the Unaudited Statements of Operations. In addition, the Term Loan was secured by a lien on substantially all of the Company's assets other than certain intellectual property assets and certain other excluded collateral, and it contained a minimum liquidity covenant and other covenants that included among other items: (i) limits on indebtedness, and (ii) repurchase of stock from employees, officers and directors.   30400000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the three months ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> <span style="font-

family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the six months ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:43.65%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:top;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"> Interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 133 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"> 1,188 </td></tr><tr><td style="vertical-align:top;width:43.65%;margin:0pt;padding:0pt;"> Amortization of Debt Discount </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"> $ 118 </td></tr><tr><td style="vertical-align:top;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"> Loss on Extinguishment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> $ 2,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"> $ 2,794 </td></tr><tr><td style="vertical-align:top;width:43.65%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ 4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ 8 </td></tr><tr><td style="vertical-align:top;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"> Total Interest Expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$ 2

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,108 </td></tr></table> 133000 1188000 118000 -2795000 2000 4000 3000 8000 2000 2932000 3000 4108000 0.0875 0.0050 0.0925 0.1377 300000 1300000 100000 Note 9 - Stockholders' Equity Registration Statements On April 23, 2021, the Company filed a shelf registration statement on Form S-3 (File No. 333-255476) (the "2021 S-3"), which was declared effective on May 24, 2021. Under the 2021 S-3, the Company was able to sell up to a total of $200.0 million of its securities. The 2021 S-3 expired on May 24, 2024. The Company sold approximately $4.4 million of securities under the 2021 S-3. On May 31, 2024, the Company filed a shelf registration statement on Form S-3 (File No. 333-279891) (the "2024 S-3"), which was declared effective on June 12, 2024. Under the 2024 S-3, the Company may sell up to a total of $40.0 million of its securities. As of June 30, 2024, approximately $37.5 million of the 2024 S-3 remains available for sales of securities. The 2024 S-3 expires on June 12, 2027. As of the filing of this Form 10-Q, the Company is subject to the General Instruction I.B.6 to Form S-3, known as the "baby shelf rules," which limit the number of securities it can sell under its registration statements on Form S-3. May 2024 Public Offering On April 29, 2024, the Company commenced a best efforts public offering with an institutional investor (the "Investor") (the "May 2024 Offering") of an aggregate of (i) 1,160,000 shares of common stock, (ii) pre-funded warrants (the "May 2024 Pre-Funded Warrants") to purchase up to an aggregate of 15,717,638 shares of common stock (the "May 2024 Pre-Funded Warrant Shares"), (iii) Series A-1 warrants (the "Series A-1 Warrants") to purchase up to an aggregate of 16,877,638 shares of common stock (the "Series A-1 Warrant Shares"), (iv) Series A-2 warrants (the "Series A-2 Warrants") to purchase up to an aggregate of 16,877,638 shares of common stock (the "Series A-2 Warrant Shares"), and (v) Series A-3 warrants (the "Series A-3 Warrants," and together with the Series A-1 Warrants and Series A-2 Warrants, the "Warrants") to purchase up to an aggregate of 16,877,638 shares of common stock (the "Series A-3 Warrant Shares"). Each share of common stock or May 2024 Pre-Funded Warrant was sold together with one Series A-1 Warrant to purchase one share of common stock, one Series A-2 Warrant to purchase one share of common stock, and one Series A-3 Warrant to purchase one share of common stock. The public offering price for each share of common stock and accompanying Warrants was $0.237, and the public offering price for each May 2024 Pre-Funded Warrant and accompanying Warrants was $0.2369. The May 2024 Pre-Funded Warrants have an exercise price of $0.0001 per share, were exercisable immediately and will expire when exercised in full. Each Warrant has an exercise price of $0.237 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Warrants (the "Warrant Stockholder Approval"). The Series A-1 Warrant will expire on the five-year anniversary of the Warrant Stockholder Approval. The Series A-2 Warrant will expire on the twenty-four-month anniversary of the Warrant Stockholder Approval. The Series A-3 Warrant will expire on the nine-month anniversary of the Warrant Stockholder Approval. The Warrants contain customary anti-dilution adjustments to the exercise price, including for share splits, share dividends, rights offering and pro rata distributions. The net proceeds of the May 2024 Offering, after deducting the fees and expenses of the Placement Agent (as defined below), described in more detail below, and other offering expenses payable by us, but excluding the net proceeds, if any, from the exercise of the Warrants, was approximately

$3.2 million. The May 2024 Offering closed on May 2, 2024. In connection with the May 2024 Offering, the Company also entered into a warrant amendment agreement (the "Warrant Amendment Agreement") with the Investor. Under the Warrant Amendment Agreement, the Company agreed to amend certain existing warrants to purchase up to 2,588,236 shares of common stock that were previously issued in October 2023 to the Investor, with an exercise price of $1.58 per share (the "Existing Warrants"), in consideration for their purchase of the securities in the May 2024 Offering, as follows: (i) lower the exercise price of the Existing Warrants to $0.237 per share, (ii) provide that the Existing Warrants, as amended, will not be exercisable until the receipt of Warrant Stockholder Approval for the exercisability of the Warrants in the May 2024 Offering, and (iii) extend the original expiration date of the Existing Warrants by five years following the receipt of such Warrant Stockholder Approval. The Warrant Amendment Agreement became effective on May 2, 2024. June 2024 Registered Direct Offering and Concurrent Private Placement of Warrants (the "June 2024 Offering") On June 19, 2024, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with an institutional investor (the "June 2024 Investor"), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of Nasdaq (the "Registered Direct Offering"), (i) 3,025,000 shares of common stock, at a price per Share of $0.41 and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 3,105,000 shares of our common stock, at a price per Pre-Funded Warrant equal to $0.4099, the price per share of common stock, less $0.0001. The Pre-Funded Warrants were sold, in lieu of shares of common stock to the June 2024 Investor. The Pre-Funded Warrants have an exercise price of $0.0001 per share, became exercisable upon issuance and remain exercisable until exercised in full. The Registered Direct Offering closed on June 21, 2024. The Company intends to use the net proceeds of approximately $2.1 million from the Registered Direct Offering for general corporate purposes and working capital requirements. In a concurrent private placement, pursuant to the terms of the Purchase Agreement, the Company also agreed to issue and sell to the June 2024 Investor unregistered warrants (the "Private Placement Warrants") to purchase up to 6,130,000 shares of common stock, at an offering price of $0.41 per Private Placement Warrant to purchase one share of common stock (the "Private Placement" and, together with the Registered Direct Offering, the "Offerings") (which offering price was included in the purchase price per share of common stock or Pre-Funded Warrant). The Private Placement Warrants have an exercise price of $0.41 per share (subject to customary adjustments as set forth in the Private Placement Warrants), were exercisable upon issuance and will expire five years from the date of issuance. The Private Placement Warrants contain customary anti-dilution adjustments to the exercise price, including for share splits, share dividends, rights offering and pro rata distributions. The Private Placement Warrants were subsequently registered in July 2024 on Form S-1 (File No. 333-280927). H.C. Wainwright & Co., LLC ("Wainwright" and together with the June 2024 Investor, the "Selling Stockholders") acted as the exclusive placement agent in connection with the Offerings under an Engagement Letter, dated as of June 18, 2024, between us and Wainwright (the "Engagement Letter"). Pursuant to the Engagement Letter, we issued to Wainwright (or its designees) warrants to purchase up to 367,800 shares of common stock (the "Wainwright Warrants" and, together with the Private Placement Warrants, the "2024 Warrants"). The Wainwright Warrants have substantially the same terms as the Private Placement Warrants, except that the Wainwright Warrants will expire five years from the commencement of the sales of the Offerings and have an exercise price of $0.5125 per share (subject to customary adjustment as set forth in the Wainwright Warrants), representing 125% of the purchase price per share of common stock in the Registered Direct Offering. At-the-Market Offering In July 2018, the Company entered into an At-the-Market Issuance Sales Agreement (the "Mustang ATM") with B. Riley Securities, Inc. (formerly B. Riley FBR, Inc.), Cantor Fitzgerald & Co., National Securities Corporation (now B. Riley FBR, Inc.), and Oppenheimer & Co. Inc. (each an "Agent" and collectively, the "Agents"), relating to the sale of shares of common stock pursuant to the 2020 S-3. Under the Mustang ATM, the Company pays the Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock. On December 31, 2020, the Mustang ATM was amended to add H.C. Wainwright & Co., LLC as an Agent. On April 14, 2023, the Mustang ATM was amended to add the limitations imposed by General Instruction I.B.6 to Form S-3 and remove Oppenheimer & Co., Inc. as an Agent. On May 31, 2024, the Company delivered notice to the Agents to terminate the Mustang ATM, which was effective June 5, 2024. On May 31, 2024, the Company entered into an At-the-Market Offering Agreement (the "Offering Agreement") with H.C. Wainwright (the "Manager") under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock through or to the Manager pursuant to the 2024 S-3. Under the Offering Agreement, the Company

pays the Manager a commission of 3.0% of the gross proceeds from the sales of any shares of common stock. The Company will also reimburse the Manager for certain expenses incurred in connection with the Offering Agreement. The Company and the Manager may each terminate the Sales Agreement at any time upon specified prior written notice. During the six months ended June 30, 2024 and 2023, no shares of common stock were issued under the Mustang ATM Agreement or the Offering Agreement. Equity Incentive Plan The Company has in effect the 2016 Incentive Plan (the “Incentive Plan”). The Incentive Plan was adopted in 2016 by the Company’s stockholders and the compensation committee of the Company’s board of directors and is authorized to grant stock-based awards to directors, officers, employees and consultants. The plan initially authorized grants to issue up to 133,333 shares of authorized but unissued common stock, expires 10 years from adoption, and limits the term of each option to no more than 10 years from the date of grant. In June 2018, the Company’s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 200,000 shares, for a total of 333,333 shares. In June 2021, the Company’s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 200,000 shares, for a total of 533,333 shares. In June 2022, the Company’s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 200,000 shares, for a total of 733,333 shares. As of June 30, 2024, 394,393 shares were available for future issuance under the Incentive Plan. Stock Options The following table summarizes stock option activities for the six months ended June 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> Contractual Life (in </td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> years) </td></tr><tr><td style="vertical-align:bottom;width:56.39%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"> 76,112 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.31</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 85.95 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2.81 </td></tr><tr><td style="vertical-align:bottom;width:56.39%;background:#cceeff;margin:0pt;padding:0pt;"> Options vested and exercisable at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 47,570 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 85.95 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.81 </td></tr></table> - As of June 30, 2024, the Company had no unrecognized stock-based compensation expense related to options. The Company accounts for forfeited awards as they occur as permitted. - Restricted Stock The following table summarizes restricted stock award activities for the six months ended June 30, 2024: - <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"> Grant Date Fair </td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"> Nonvested at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> 64,706 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"> 11.59 </td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,595) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 54.45 </td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"> Nonvested at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 60,111 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8.32 </td></tr></table> As of June 30, 2024, the Company had unrecognized stock-based compensation expense related to restricted stock of $0.3 million, which is expected to be recognized over the remaining weighted average vesting period of approximately 1.6 years. Restricted Stock Units Certain employees and consultants have been awarded restricted stock units with time-based vesting. The following table summarizes restricted stock units' activities for the six months ended June 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;width:69.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"> Grant Date Fair </td></tr><tr><td style="vertical-align:bottom;width:69.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of Units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:69.97%;background:#cceeff;margin:0pt;padding:0pt;"> Nonvested at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"> 95,197 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">18.78</p></td></tr><tr><td style="vertical-align:bottom;width:69.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(63,782)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">18.19</p></td></tr><tr><td style="vertical-align:bottom;width:69.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(17,199)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22.41</p></td></tr><tr><td style="vertical-align:bottom;width:69.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">14,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 17.02 </td></tr></table> As of June 30, 2024, the Company had unrecognized stock-based compensation expense related to restricted stock units of approximately $57,000, which is expected to be recognized over the remaining weighted average vesting period of approximately 1.9 years. The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.47%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the three months ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the six months ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.47%;background:#cceeff;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"> 153 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"> 262 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:36.47%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (670) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (108) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (640) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> 18 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:36.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(619)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 45 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(542)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 280 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr></table> - On April 12, 2024, the Company reduced its workforce by approximately 81 percent, which resulted in the forfeiture of a significant number of outstanding restricted stock units and the reversal of previously incurred stock-based compensation expense. - Employee Stock Purchase Plan - Eligible employees can purchase the Company’s common stock at the end of a predetermined offering period at 85% of the lower of the fair market value at the beginning or end of the offering period. The Employee Stock Purchase Plan (“ESPP”) is compensatory and results in stock-based compensation expense. The ESPP was initially authorized in 2019 to sell up to 26,667 shares of authorized but unissued common stock. In June 2021, the Company’s stockholders approved an amendment to the ESPP to increase the number of authorized shares issuable by 40,000 shares. In addition, in June 2023, the Company’s stockholders approved an amendment to the ESPP to increase the number of authorized shares issuable thereunder by 400,000 for a total of 466,667 shares. - As of June 30, 2024, 128,352 shares have been purchased and 338,315 shares are available for future sale under the Company’s ESPP. Warrants A summary of warrant activities for the six months ended June 30, 2024, is presented below: - <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> Contractual Life (in </td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> years) </td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 4,481,868 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 1.34 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"> 5.34 </td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> (20,490,874) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 76,966,010 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0.19 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2.74 </td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 60,957,004 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.29 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.98 </td></tr></table> Upon the cashless exercise of warrants, the Company will issue new shares of common stock. In connection with the Company's Registered Direct Offering on October 26, 2023, the Company issued pre-funded warrants to purchase up to 1,668,236 shares of common stock, and in a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,588,236 shares of common stock, and the resale of the underlying shares of common stock were subsequently registered in April 2024 on Form S-1 (File No. 333-275997). In connection with these offerings, H.C. Wainwright received Placement Agent Warrants to purchase up to 155,294 shares of common stock. In connection with the Public Offering the Company completed in May 2024, the 2,588,236 unregistered warrants were repriced from the original exercise price of $1.58 to $0.237. In connection with the May 2024 Offering, the Company issued pre-funded warrants to purchase up to 15,717,638 shares of common stock and issued three series of warrants to purchase up to 50,632,914 shares of common stock. In connection with these offerings, H.C. Wainwright received Placement Agent Warrants to purchase up to 1,012,658 shares of common stock. In connection with the Registered Direct Offering, the Company issued pre-funded warrants to purchase up to 3,105,000 shares of common stock, and in the concurrent Private Placement, the Company issued unregistered warrants to purchase up to 6,130,000 shares of common stock, the resale of the underlying shares of common stock were subsequently registered in July 2024 on Form S-1 (File No. 333-280927). In connection with these offerings, H.C. Wainwright received Placement Agent Warrants to purchase up to 367,800 shares of common stock. During the six months ended June 30, 2024, all of the 1,668,236 pre-funded warrants issued in the October Registered Direct Offering were exercised at an exercise price of $0.001, and all of the 18,822,638 pre-funded warrants issued in the May 2024 Offering and the June Registered Direct Offering were exercised at an exercise price of $0.0001. 200000000.0 4400000 40000000.0 37500000 1160000 15717638 16877638 16877638 16877638 1 1 1 1 1 1 0.237 0.2369 0.0001 0.237 3200000 2588236 1.58 0.237 P5Y 3025000 0.41 3105000 0.4099 0.0001 0.0001 2100000 6130000 0.41 1 0.41 367800 P5Y 0.5125 1.25 0.030 0.030 0 0 133333 P10Y P10Y 200000 333333 200000 533333 200000 733333 394393 The following table summarizes stock option activities for the six months ended June 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-

word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"> Weighted Average

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> Contractual Life (in </td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> years) </td></tr><tr><td style="vertical-align:bottom;width:56.39%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"> 76,112 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">85.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.31</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">76,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 85.95 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2.81 </td></tr><tr><td style="vertical-align:bottom;width:56.39%;background:#cceeff;margin:0pt;padding:0pt;"> Options vested and exercisable at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 47,570 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 85.95 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.7%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.81 </td></tr></table> 76112 85.95 P3Y3M21D 76112 85.95 P2Y9M21D 47570 85.95 P2Y9M21D 0 The following table summarizes restricted stock award activities for the six months ended June 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"> Grant Date Fair </td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#ccceff;margin:0pt;padding:0pt;"> Nonvested at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> 64,706 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11.59</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(4,595)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">54.45</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">60,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8.32 </td></tr></table> 64706 11.59 4595 54.45 60111 8.32 300000 Certain employees and consultants have been awarded restricted stock units with time-based vesting. The following table summarizes restricted stock units' activities for the six months ended June 30, 2024: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:69.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;width:69.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"> Grant Date Fair </td></tr><tr><td style="vertical-align:bottom;width:69.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of Units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:69.97%;background:#cceeff;margin:0pt;padding:0pt;"> Nonvested at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"> 95,197 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"> 18.78 </td></tr><tr><td style="vertical-align:bottom;width:69.97%;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> (63,782) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"> 18.19 </td></tr><tr><td style="vertical-align:bottom;width:69.97%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (17,199) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22.41 </td></tr><tr><td style="vertical-align:bottom;width:69.97%;margin:0pt;padding:0pt;"> Nonvested at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">

14,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 17.02 </td></tr></table> 95197 18.78 63782 18.19 17199 22.41 14216 17.02 57000 P1Y10M24D The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.47%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:36.47%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the three months ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the six months ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.47%;background:#cceeff;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"> 153 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"> 262 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.47%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (670) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (108) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (640) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:36.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(619)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 45 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(542)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 280 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> . 51000 153000 98000 262000 -670000 -108000 -640000 18000 -619000 45000 -542000 280000 0.81 0.85 26667 40000 400000 466667 128352 338315 A summary of warrant activities for the six months ended June 30, 2024, is presented below: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> <b style="font-

weight:bold;">Contractual Life (in </td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> years) </td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 4,481,868 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"> 1.34 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"> 5.34 </td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> (20,490,874) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 76,966,010 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0.19 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2.74 </td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:13.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 60,957,004 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.29 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.98 </td></tr></table> 4481868 1.34 P5Y4M2D 20490874 76966010 0.19 P2Y8M26D 60957004 0.29 P2Y11M23D 1668236 2588236 155294 2588236 1.58 0.237 15717638 50632914 1012658 3105000 6130000 367800 1668236 0.001 18822638 0.0001 Note 10 – Net Loss per Share Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period less unvested restricted stock. Since dividends are declared, paid and set aside among the holders of shares of common stock and Class A common shares pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect of shares of common stock to be issued upon the exercise of warrants or outstanding Class A preferred shares, as their inclusion would be anti-dilutive. The two-class method is an earnings allocation formula that treats participating securities as having rights that would otherwise have been available to common stockholders. In addition, as our non-pre-funded warrants are participating securities, we are required to calculate diluted earnings per share under the if-converted method and utilize the most dilutive result. In periods where there is a net loss, no allocation of undistributed net loss to non-pre-funded warrants is performed as the holders of our non-pre-funded warrants are not contractually obligated to participate in our losses. - The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive. - <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.58%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:58.58%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> - </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:39.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the six months ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:58.58%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:58.58%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"> 60,957,004 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;background:#cceeff;margin:0pt;padding:0pt;"> 70,102 </td></tr><tr><td style="vertical-align:bottom;width:58.58%;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"> 76,112 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;margin:0pt;padding:0pt;"> 76,112 </td></tr><tr><td style="vertical-align:bottom;width:58.58%;background:#cceeff;margin:0pt;padding:0pt;"> Class A Preferred Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"> 250,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;background:#cceeff;margin:0pt;padding:0pt;"> 250,000 </td></tr><tr><td style="vertical-align:bottom;width:58.58%;margin:0pt;padding:0pt;"> Unvested restricted stock awards </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"> 60,111 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;margin:0pt;padding:0pt;"> 34,016 </td></tr><tr><td style="vertical-align:bottom;width:58.58%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 129,476 </td></tr><tr><td style="vertical-align:bottom;width:58.58%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 61,357,443 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 559,706 </td></tr></table> - - <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.58%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> - </td><td

style="vertical-align:bottom;white-space:nowrap;width:18.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:39.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the six months ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:58.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:58.58%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"> 60,957,004 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;background:#cceeff;margin:0pt;padding:0pt;"> 70,102 </td></tr><tr><td style="vertical-align:bottom;width:58.58%;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"> 76,112 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;margin:0pt;padding:0pt;"> 76,112 </td></tr><tr><td style="vertical-align:bottom;width:58.58%;background:#cceeff;margin:0pt;padding:0pt;"> Class A Preferred Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"> 250,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;background:#cceeff;margin:0pt;padding:0pt;"> 250,000 </td></tr><tr><td style="vertical-align:bottom;width:58.58%;margin:0pt;padding:0pt;"> Unvested restricted stock awards </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"> 60,111 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;margin:0pt;padding:0pt;"> 34,016 </td></tr><tr><td style="vertical-align:bottom;width:58.58%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 129,476 </td></tr><tr><td style="vertical-align:bottom;width:58.58%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 61,357,443 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 559,706 </td></tr></table> 60957004 70102 76112 76112 250000 250000 60111 34016 14216 129476 61357443 559706 Note 11 – Income Taxes The Company incurred net operating losses and recorded a full valuation allowance against net deferred tax assets for all periods presented. Accordingly, the Company has not recorded a provision for federal or state income taxes. The Company is subject to US federal and state income taxes. Income tax expense is the total of the current year income tax due or refundable and the change in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of Management, it is more likely than not that some portion, or all, of the deferred tax asset will not be realized. Note 12 – Commitments and Contingencies Indemnification In accordance with its Certificate of Incorporation, amended and restated bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company's request in such capacity. The Company has director and officer insurance to address such claims. The Company also provides indemnification of contractual counterparties in certain situations, including without limitation to clinical sites, service providers and licensors. Leases The Company leases office space under an agreement classified as operating leases that expires in October 2026. On June 28, 2024, the Company terminated the lease of its Mercantile Center Facility for a termination fee of $40,000. The Company's lease liabilities result from the lease of its Plantation Street Facility, which expires in 2026. Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Certain of the Company's leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right of use assets as the Company is not reasonably certain to exercise the options. The Company does not act as a lessor or have any leases classified as financing leases. At June 30, 2024, the Company identified triggering events that required an impairment of the asset group consisting of the right-of-use asset and associated leasehold improvements. The assessment concluded that impairment existed as of June 30, 2024, and the impairment loss was allocated to the leasehold improvements and right-of-use assets based on the relative carrying amounts of the assets (see Note 6). As of June 30, 2024, the Company had operating lease liabilities of $1.1 million and right of use assets of $0.1 million, which were included in the Unaudited Balance Sheet. At December 31, 2023, the Company had operating lease liabilities of $2.5 million and right of use assets of $1.6 million, which were included in the Unaudited Balance Sheet. The following summarizes quantitative information about the Company's operating leases: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.61%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.06%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.06%;background:#cceeff;margin:0pt;padding:0pt;"> Lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.06%;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"> 395 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.06%;background:#cceeff;margin:0pt;padding:0pt;"> Variable lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (25) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 380 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.06%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 775 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> <div

*style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"> Operating cash flows from operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> 132 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> *

</td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"> Gain on lease modification </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(314)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> (220) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average remaining lease term – operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> 2.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> 4.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"> Weighted-average discount rate – operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> 9.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> 9.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> % </td></tr></table> - - Maturities of our operating leases, excluding short-term leases, are as follows: - <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> - </td>

<td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Year ended December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 588 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Year ended December 31, 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 774 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Year ended December 31, 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 703 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Year ended December 31, 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 269 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Year ended December 31, 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 274 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 303 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,911 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Less present value discount </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,826) </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,085 </td></tr></table> . 40000 1100000 100000 2500000 1600000 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.61%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.06%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.06%;background:#cceeff;margin:0pt;padding:0pt;"> Lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.06%;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"> 395 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.06%;background:#cceeff;margin:0pt;padding:0pt;"> Variable lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (25) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 380 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

***Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.06%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 775 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> For the Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> ***

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"> Operating cash flows from operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> 132 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"> Gain on lease modification </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> 220 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average remaining lease term - operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> 2.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

***Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"> 4.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"> Weighted-average discount rate – operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> 9.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"> 9.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> % </td></tr></table> 78000 395000 -25000 380000 53000 775000 281000 132000 314000 220000 P2Y3M18D P4Y10M24D 0.090 0.091 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Year ended December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 588 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Year ended December 31, 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 774 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Year ended December 31, 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> ***

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 703 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Year ended December 31, 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 269 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Year ended December 31, 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 274 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 303 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 2,911 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Less present value discount </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,826) </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,085 </td></tr></table> . 588000 774000 703000 269000 274000 303000 2911000 1826000 1085000 false false false false

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

^1])6II0:RE+* M3'%2.)"5=#AA%=%A(V AE V[5>^*9?0D(37 JSA;(5*Z?UFE1\,*H?31!LN5
MZMD0+C13*$V8JYBTE@OU0E F0H:]MP$5,,UI.UD0_E6RZ#;3T!&XUDLT1Y2S M('^CM#$F(B<'. (:3TSEZ(!I3=+UFT-
:S>4 ^D)C/6K !*;0 MIFKPC2'799 M!8)3!\NC"],5SV6(@PL<,V-"L2]7C[($E'AD%W4I 0)3GW',#%243!+/[**\
M(XJ6W9/M(,QY5N54"2FAK,[,]".$ DPQA=.XRDRW&AF4F:&YOROC@*N/_'3T M8_:
<^"3D/*F&*54A*+._UKH2H@*FN6D0A'GS]UY(%QL7WCI,O:B 0A9+UB@(
M96IHID$=9,"T^(!2*@T47'DDIE.A9.K[V2KC,36ZC@S]4)[PT5P0RHS13(LZ MR(!IL0Y0>XH(9VK8=3((3BM-
<]V66]_NGRQHI[%F7&!/7=][+-ZR1&GH']X(MU3J"_;WV$>S)-Z56QB/9XY%LH=L;CV2;.[7Q2/9X)-M, >.1()V8QR/9XY'L
MGN*B=,(S(QQ9P*-3]XCPR(=6J%1>&$J_TM.L+BI@BYLRVWG :IJE2\KC[X?9 ML%*#]4)P G?FFJNC.0*-W21)9J2M70$X
;JVFMHA.0(MR>].U2X%)Q375E]# M79O:<1?#<$S3*@DG0J>C/"U(6XJ2O:>Z71-
Y2!LI6IW0$:\+A74C6#7JD=&3&4'4MMM(-0GJR7$7_I)8@]3V#F>9OJ.J[\Q98@CT/MN=%*8;0:[]5GJ!]NBKDL1QV <7"
=S3ED/6-@#Q8GJ%MHV%1U7?FP;A,>A[6V6FP5U MJVLZ!B^@EH*V"QC&("13.]:V!-
XLOOJ"B!\F:#;_U2/$BVMO8+2LXSARJ5N" M4 O=-&?SQH> MUU$HUG#7&H\CF=X*U"$4?,WNN:%UP%P^L(M?T[:'
7YKN$H"*M\PFL?#X!H)D047BFADY D[\S)^:;XBR+CU*2"8SLB8H+- MO6,K\J1,1!41 LI"-3=)F<[@Y*,6N6K(.:H3NIX.-
!N83 %P$HWN<$QT=2"A MA9+&HJ<&"0CWFAA3OHXCY8O.(MELZI[@EY!.Q\XWGQ+VN3I[P Z+.PP\C5.+Y"=OI
MKOTT!:5#VS&6?F0T1+B*GYN(?437X?EABGQWF.>Y7B,TBYNS;(RK@.(H^NQ$ M^W"8L72 >1JS+5R^B!:6^Z MPB0-
?^?,S>:7Z#F]#!/^,O@]0:LP6\D&].9R4-+-A]*SADB *;_\Y.9#N%BF
MLSG%/DT2E!;A7'UA_D<6<3:O!DI&\U"F82XA8);R,Y4ID\8LIC:]QDF8&SGG M/SF3V$53(2AYLD-
909,\@.F<\W6S6GLAX9G(0GI(148,)?5QL$% (@=@ MNF6FF##0>%R9*QG]=BB[=4 Y*?
MR0O;I!)$.LP1D;LYB/+Q]Q$,Y# M7S0C5Y-"29D:9$TME0*PKDHQ$\;D)(CBWM/N@ M\(7M&^IKOUX02OC-MJ;K2
<)F=?XF/H\5I#<>QO&!S4U^@W)]K:77'WQHXS= M5T 7C(SP,D/,->ZWXT-Q8FA?+4$)X[6SAUY%]XM-
)N.85DHL3[;SF$]>KZ M!SY3+3PJJ]?7ZZ6@Q-ZL]MLZ3&!]4'^+N'/""QS7;"V)0AOY<6C])GY!B8UT
M)V5%4*R@4[J3BP;5/>?82"Y)K"?_0B-)O3;ZB5IAMV)CZEDPFV8[\6')MJ M50.4I5=[(R]?-6L '9KBOO=H (HZS!+:C=
#DSK^@+H[-3A M.',[6C=!?AQ:OPYC+_8M#.G*BJ LLSH-Z4J$P+3]@-9;!Z7<%JN3 1^<-62'6I+)E0+3?.>M8 >LROP!.
<:&>C!A*,-*^ M_HHH@6E.'VSGJ2N<)#\[&C9!#DSKC&_V?[:@?O$B-F8\T-46"?T4!>P'NM@N M?
U&@S"^9JL;=]YMA],/2BQ?H@2X+KN9S)%WT#,T$%/^B^2#OP-)Y31;:A\'! M\5X#V \X[WN8GGF*QXHEY#>$6[-)0,9:
(IQD M!#7TO^[50DDDU_>]W? "LXO"M;^R SYE$BA]U99!2^Y MGY01YP Q"^IFB.R M.Q_$WQ'F+PI/DU]0Q-
\\\6J7P)D5A1+:M*DQ,PFXN\;P@.*"%@I]+WHBH1=1 MR(]K'">8(#950U2>R_WS.,E3*8FWX6K##^]/Z?\F)Y-
#4_2/76L3WMS$BX/) MOL')KL7)HH(ZHA6.6\/."IBPRMLC9H_)B5B/YN7C3 MF_+.Q!X:\\J?UNY1250)E\M3?
9PO;TY=/?]U()S MJJTM:B^9VVS"[8V'?8BK-%GO8=0XTOL6[8OBB>(]C^09%;VV"&;!7-
TP84BY0*#=3%B27UEN:S9>3NYSCM,1Z@Q %+B+CS5DAYE7P_30%:U0A-
MO_GJOZX2<&]$A\U'[JL;+JT7TD)9Z/39'\]IMT(Q@-/E)ZJ'Y.'QDXE.JV6@ M3.\ $9\1' MR25*O3#2CK5^=WIV>E:-
M19Y^..DP 5[,'/'!\\NV7/"_]KR,MDS,_EFR\Y7 M]Z!F0M("C_2O W_TCW\^,',6Q$8KOP&+B4J?OZRPW=/PJR-3882B]BN
<*'0 M"DJR[#E2T"#-CU0FJVPEE6?E=]>1.XD![1:X=;]_'!\T_ X(A8/;/R*47#E MD3B,%W3YX6>KC%\9>$D%[X?
R6R.:"X*).&AI5 <1L%487T!F?IJ1/.%X>]DC M.S]_ES')S.;WVZ<:DJLH7(4QOPN2'[:C__KR2YVLU QFO:^I?PN0@1E((?7_
MDN/*VL5QC,HEK3<>NA@J9)SE_.]ST)?439YM^I-BG$] MPGKZD@,!IB)^4&._#)\1_E32SG4\(I]:&UN57]
Y"#M]OZ5+MH32Y,FNM1[9 M,>"N<(_!*'87HW![WO^X!R$[LM:RKN,Z)-P2)#"U[SAD\PC.XBQ+65B,W6;P
MA(CL9<+F8L=UL+09#X28Y&.XB/D;.BQXRN_09],"'-$Y/_,TM7L):C<1& @.39GM8:YQXT<\$
M9^O=*="&Q=F^L0KK$Q2Q5M@MJ]^L=0\'&$@K=W+%7G M.ND%G<-MZ%3D[UZ4R49SS;+'%1#6!
5LY5&>F;)C5ADA#8%>(?D11F^%.(#I M9[PHKF,]W5=%%
<:V&_B[86'PC%=^KK$A;*'6VWAN&+'5J%#B%087+=C+^^12\%-,M26%P9IRTTBC*LTT *(I329847Z(A0]Y3E?T*%C-
O^%CC+R MNW/J-*Z#%EK6L4]%KO,_R'.CT=E[\F[+I5RX0C+7\E6:QN'-4!'K0XCV(CG; M]R;^0$"BN/E)0>QZX:\G9@6
GN1[G_B>OH!5U*Y7ZWH25B$8Q)Z#=Z=/R%_& M.,*+C8%I:Y5S;>6&SEH+TR!'@-*_90'Z1^*'@>)>N3J1:YLWD[<
P!#"?? 6 M9X^LS>>SLU.Y>(5DK@-#9@(60G SH;Y@V_>(K#V2;M@U"I*5D)C,T4I(%BOO M?
24DEH*C0S9HG1%_Z25H'WBHLB==&1F4!;)24IGI_JR./JK>5TYW7E[W1Q2P M$-$%8FQF5A# E:Z\@ M791#S-L^>AN?
J"[LY"=VA=/|"[-3_=Q82]ISQ-G[-CFT+XYP=:W2] NW;LJP(MZ\/9-NB^RI=]VSIQC/[+HJQC4[/6:>3+4',"96.4^L^BI6
M/N,[:>/*9USYC"L?0"N?5YC0ZFP;=TQH[<-)PDUH/>:T2[/$$B&$,>/29BZ: M',@0>VVO)PW33.QC.B:
<[#4]3&.2H'"_TW62H&*$]-Y=>(1-<,_>?]UF*D%,'HRX%XY*F5]JY_KB-,'HH5IS(<%O5$_YL..^;"-3F_,A[68
M#SO$//=5I9M938D=)MWLJTI9MIH1ZSQE>4R#=3=K>P#]BH_L$J'>YV<%Z.-+ M0'H3JYHE07H)R/NB?
@FH_#N(>9'B): RM^[WM\>,P3%C<,",P8]AA)(4QRBY M]S:,O4\Q%7>!?
^$$HKF0ZVGV('E_&G(88KDT#8)PNVAKHTVCXJZGYX/HU4@B M@VS\4-] PN>,U?N$V?
NF]Q09GR$GM5LNM4JXGO$/HLT2V/ DWD/0+N]Y6&C;1NED>CG0K>*Q$3>IZP\J5WC2?,QG\,FAY(K_1X0DK M-
;K>4!MJDMU)2(/,L.(XHY,!*K$4Q2RH=XW0=D(@G%&IR*&\2-3O#$HE@6%< M<[AZSDC">9[-
:?/)$TZ]:/M&O'#.U%QF<-U]<.*LF\0 X;S2]KG1>Q8;MG'* MZ+OZ'NXCU%=3@9I'?X4QWQ,*H!Z]J>%
MPLLCKKX(($S+#CPI'[2$0((Z;>W7)G.X+Q6]='[%Q\+9I]C%#QFSTD8A![9 M?**#4)S@* P8S\JS6$8UN-
Y.:#;)HLJ,H+G7Y?&>E6P\Q=/17X['(FCJF-0IQ>5^_B?I^K7HGEX(Y!9*6H\N+'&JCI$_A)2-$T.;7$B#G.56
MX3&#\S.*$>&7ATV#%55HDN9!\M8V9[MY*,E+=HW.MI2 [EQX=D_/OZ0"]0RS;W3"L!$IZ5*MQT!#K$%
[F,HPRBF.6I6Q/ MC^WFLP=CT\W!L$7.0:<4E+PGXSZM PY85]R^_ALO>/X<>_57[-DUZ*&D/;7I M8 I8P!2F=
5WZ#/_J97/+!2&DJ5DW5<6, +3ZZ\\-L=M[R%<+-.DX4&8CZ MQ: D)[7193,Z8%H43_^G28+27:[;+%TB\K3TXJ9XE5
0L]8V.(3$_ MJOTK192B>#:?&Z4@=FD&2AI4&RNQ+PT(V5"<_^2^&N R?ZK^^WH:5%[W9%=Y M*1'*8?
+3064)%YXJN4E".^XYF"8@*84^[BF,>PHZB\%/SR1;1?T:IDLCG]6J&M?
>3,_4#B<\VF"$UY%J:X6&OG0+98>T$8BJ&SG= M^NRL0W[\"P7)-17(H\11]=R<< BJ6O!>?=6-4#9JC32N!%"
M8'&1GZE,;G&2S&(!YTVJU2T,92_02*NZX(;8TFFPJDLT1X2?UO3Q2KB[8U@! ME"TY+86U
0BL%^Z.^SWA;5QL>T4N.U+((T(RW]I<#LJ>G9E';<8UR%'D"L\7 MF,Z[[XA1<=U%@3-K>K3FF*-TRW7TEEJBYJ@;-
WI=\2V2.'J\S)#^4X5&]^O MYG/$[?#22\7GT:VW 67/KV\;4,D DG6PLV7HWQFRTN$%E4'9%[2O;P%82(K=
M31)$]GA!%V)AQ.C;Z[6;@++M9]\(M$4PA&G%KI$SZS!=J%T.JP](!^%+RQDGUQ3D=$%",M&TM&MHO#P*NP< M3S-
YT)3!5YT=%,B'UX;74)BS7AQ5.[QRK8>'6N%VH7+./P=!=-$>=I8QRSZ:'7XY(K.@:8AQ +$J%R8U-$9E/58
MEGVA0)P:)K^@B!]$]B)TAU-VB&"L_5%1B= TD0?TTJ&-PP; M>5RF* ?9H,@8SMF<\4'-
=!M+9P,DBZJR$U*%$TC";0FS"H;77.=HDR'"(;2V MSSLJGQ4+9%L+:OKA==(Y?*0&!.$4GS15C-W6P9B^6:V]D/
;/O:7'2GRRPS/ M_OVI?O9O5_D?)[SZB1<'DWT#?^1_Q-JR3X_JK4OA9$8)$A*<_$UQ+>= M!.6HEV4U;M$-$BKV
M_6R5\GCNUCA!7 [OQ M'Y,T_#U/KC4\AFNO>B@GRMIU<7MR &8_4D[OD.)HMJ((E+-GEETYQP8A GF' MT_U3Y^W?
4ORA'DCD%4^V-<-Y0)$]4=(8Z*L0.>A'E^@YO>&++QX-ED?O1(3 M@G5"D1=
[B0B#>U=6YDIZ;U@S.:!8F]RLY/H8X'ZPARS^[&U8L]>>S_/MY5?M MR&FAQ.::#.?P[JX4BGOK_[M'0M9?V9$(A?
NID\&Z!ZS9^=01P!*^TNF(" &Y M&YD1R>0/)VQ_[B6<(V7LMTH$Q0')S:9S1% @%;!)02@A.[7031 YNC>5/?
TGN:BV\!NP%_&D[KW"MD.9"BV\]BL MKRVT@I(LW5KH1RJ35;:2RK/RNVMO+#& G4 KW+H?\O9]J1;1D"V/;Z%LELE9
M+S_]4'861[H%]H#6VXNI9G,ZF/"7#AAN^N<%'4E"69Q-HQR4L51/GQJ @$5' MRRM#.@$+D\(E!\6T9+F_+"4#;$
MVNA2C@J8)G>,;@]0,!02M0DIH>Q&Z>E(" &80HK;7[,Y8Y'M+K"#E_<$K<), M]N*11CDH6TIZRM(
!$QUK^>M*LFQ;SW%67B=:H#]/_X>&LO(1"3)GR-\0(OM M&Z$XWB-
E**;I1X_\AE(>LF!7I)CN$GZH[Q(6FY_D[4^^*7(P.;"0'SY(3](E

M.LDYF>Q8@7*N@#\CQP)KP05>,>>:'RAFAI"_TYJ<;PXTNYMH/GLDT#MXT+E^ M%^O*[#D)@]
CF_QZ9*YRQ9:"@A[8QJ9MM9<6JW(IN/?P!9;8]M9L7GB+3;E? MH5,00"1,VW1+&M/
UE>V7L4S*QXJD5"Z#I:96]8AZTX"J:^]:N'PJ-BO5M*# MB;B8RUT-;(@D53$'E.
[L\;VI0LJE7'<';4MKT$89U=!J^*Z5&KYSJ(9WO:GA M.XMJZ#Y^-\U79-.5VH*G.KY;J-
CQ5H(UT8C/Y72>*KK9M5"]")//BA8+@MB- M![MA^)Z$/KM4>\7>S0W.-_O;#T3.H&5%KOU#/T;312+
0D&O\SEZV69'/Z[# MR8/UXOY.<:W8N$8YRMN?OGAAQ/S2-2;Y-46,'2_V\YOR1%W=O XP&R#V>[FY M,(92AW"-^^
M4X5O_["+WYY,:'L3UN D;W$?IH42I65\UO,//YML]TQGA.Z8*UZ:@!W8
Q;7J*.>O=@5Y26E/7:75"!W8#)**+Y+PX@.%SA*L/3U MP#%UBG0)]G[;G%S&$D(HX2@3$4N@]"OA=[H2KA)""?6TD'
52K\2/M.5<)40 M2K"EA82K4'J2\#W]+6-KY&9?+"6%$ALQD;(4S'A>3?^\FMYL<#R\-AY>&P^O M-8ETO[_^Z*/8(R&6>
,)G2//(-M$#;1 M/(C2I/;RE\-PJX-K3)#O)>))GXH0@K=I-*2J^*L@P,1'> >^;JRT&5;>/>>1[LOGF^TU<"+)JA/";JP
6+M#0NA$\:*DH!^9W M^3.<^6955LB!Q2",U%:! DU%KS);2!W@T%"?DP2@?C8+]FX#^10*>RCI@@Y+ M+
(=M%U38$AKM^YC4"BSRTJS^SH@'R1@J,7F!XQ=$4O'3HU)2*,=R&S6CAG'< MW?#*\Y=E6CL=450OE..\?
75%$69@UE&9V[A1(2!@74;(\=471/PP09SE_8_[05AVH4_+NH8/ MUTB>4.[F.9N! E/]Z[G8XJQK ,C"Y1;.EO^EQ]X?
D(_"%Q3,S,([.G4,KU6+ M 1X=@#"3W?^6Q8BI/S^*R2Y7O0P)\KM<6_)>,^^=-9TGOA\:G^2MCSGP8P[\ MF ,_YL
[R8%O7$4/9 M=3+35!,J]\H93S",)QC&$PRO+&W6PAF&_M)F97(N>T@=<:M+0!DQS*2NQM23
M\'^EO'PFA1BF0NQR6F 9!EH"EZ,9T\/']'#GP^28'O[ZTL/'S$Q1E.$U9F:^ MRKRPSL'ZX\P+.^:4@\Z9F$.E'(S9>T"2-
X\P>^^(4U':YEJZ2441*Z-TR>,A M*X):B)]%^=5E*_[ZQ]9U/.%S]$"'?!\%UQ1UJ;A(;W;K/ZZD3;O8G77-4N+, M?
4;\I;?/HBG<*-AP<9^EFH\FB],JZF,8KE]Y4EK7_$\0.6F-]RHWY^%<8_*8 MGYCTJ>VNZ5JM.OVR5.=Q999VQWL,??
PKS>3O)R'UJ%/YQ^34HW]Y+?_W)F:S M#.JB[B/JGRB&J]4ZPAN4%]A/3^B/+3(9O]-Z@&W[WSTG$\X*?W]MQTQ>
<+)C MAU.,K[#!?84M;YXVH$A)J=" S8^T_JI:!;E[;]X>XP%*'+!.R9*KU#F7O30% M8,]/:?JUL*QU";@WHM+ ,>.<*%,&%?
2N-QR'Z!=%DU"(PKU>Q^>;QN>;CL7D MRA?%3+-T22?>O]>N!NBQ'2@;NSV9IGV! 5O8<@:?FQ$^5Q%>?5F'>?>O-
04D% &J24KD-L=LDC2_>$Q2@E+TS&:-@O_G-7?@M_HS(M1>2_.UM
M_CB=>K^YCU:@9!_T\,1<'^*"YMQ4"8Q2_*WR/%6U04E@%4-W43\,7OH';8HOL M>ZTMLGS[*V]N8!R/Z-<-
?.T0RBG3IS3S:Y$^(K M,\?MF0LV./1JCH)VCMX=#FZ. B&^,G,LR/)7Q-+'43!]0<1;H-+A(";G^5!C MN#8C7T$&PL
2_3JMVZU)O\IY@J$S<6#WK\[8"X.5 V/7;OT5SD(<&KNVV"$: M>YOTND;I/R!F!/3["QRGQ//3S(O8.;AW*L,?
FI.O(&EM:)&^,@.7=VR9#&17 M'#CAY"M(@1M:I, ,?+]C@L@+'6'$@KYC3P4F#!Y#GSSAU(N*OU_@)+W#Z?^@ M]
'Y>!$KDHA[;.]U9M8-(#B8N3$/% B=]% P^6X>.7SQB;;6Y!!;),O\22M9 MYM#:]M@X)I/"=YR%2<[#F$ S)M","31C LV80
,C@:8R])5-.WY]Q:67(G8= ;^(,04WHS+H^\YKN?X9N(>.TU-/H![RE>U M=&CCW:#UM:^H@VUGGQE!";PN9L;
<5[18@=O)S%3VU72S\JP77D\SYN_H)WRO MH;,9:PU8?QNS (\D)]ME%N"1# '\']8A]Q?'*5.JK37Q%>1*6Y,5,%OC&1*9
MG_++!MD+3"BB[CK@_61[V^D]3L(\Z3L*5V',?L[1;"^K5*6B=*WY=2A#*#,70W;T] 5
MG(3[3@/KOD#I\C[W1MW5(RF1.S;)0 KM:AEE4GB8^]TIDE^M2 MD2PIIY?
H!45XS0#JJ%"K))2@H;$"M="Y5]\!45/2K(#0<1*LE/7RK>'E,>U5 M9:8:K6#A="9-
S4E0P)S4_[I[J3>_0'O38A[_@VH>_X?]1'[7TNZN[HW;F;OP M_6G5+%Y5 ,ICY(KYO((>UFR^63&-SXA#F=<+F5/.ZI4E
,WI&ZVO44?6YO/B M)W7NZ6\9\UD[MR.G8=[J E!V7(V,7 W)O>-_S)Z3, @]LGGT^,$T-B-2 M#,X*>D>#LTGGD [."E@
='1@B9TXGRRY @/VU6 M@F9!*$-["W5H(NRO3TSCX&]9C,QUHU\6RA2@76_1!.E^P!&.G4WQRZ9";F.9 M>I
:UX+'',40BI<%VFBV5(Q*&[3DI9+V(9X5E?(Q6ZQL+N*MO0HI\B/MJD% MBD?5UUQKJ,X5R1-2.ZI16
>4W$N;2A0"!9:_)@10NCEZ_V.R_361)46VK M* M]J,ES]L,V%TO5EP0SHTU:=>Q#:N%DI1HI:\;8@>I^X[#LWG-
4!XA[]L"P WC MS7=-WX;SZJ:LA?J@/"K>@\+EH*&K.?=/DIL[K-<^N E\<&X"51$%*'@?%.=R9C, DUJ'3Z>?-KKA-
$.X2\I3N4WN(DH4;+LZON M<8KB-*0L;R[#*&,)I@G9]4,)MK>A#4X62,RX4U.OBDT.MFU.CDT
M"^7:]"GE,:@)Y>J+'V44_S6U)I:6EJ4*VTVO_((\Q)[T>K=G6ZG$1<7J'=C M_'PCKD!U'7N?+
<+*W.K'"$LWO/CGYB[QKO?FXL!VHX>H)>_OMCZ/QE%LZ)4A<*>BA;-FWTHH#E7DH+W:D3':5$M
M!&!W%7(+)>'MIC[TC86;X<:3I+1_#3%^.O_Q]02P,$% @ +(-62&[,BU#:0 - 0& !0 !T;6(M,C R M-#
V,S!?;&%B+GAM;.V];7/D.(XP^'TC[C_P^BZ>J8Y(=[>K9V:W^W;F"9?M
MZO$\KDH_MFMZ]SHN)F2):6M'*>5(2KODR@+MVN:EB3,:5#2B+S$Y1.YSS:;("4?:)['24+>Y7'T2 DY M_>Z;?
WFNV].R(1)F!8?B[B/WWU5):; M'[_]N7EY9N7[[_)\D>&_MWIM__QX?HN?*+KX"1.BS)(0_H58? _%OP?K[,P M*/GT=-
/^1)3>#[;YNQE!#PMY,:[3^Z>3T[DC?'N8E!]@4D[")/R?U7_?!T\ MT.0K I"?;J^4DOS0HU4A?
7M03N^9%=%1['8Q.SPG\"_7[$\]KNGGDJ81C6J^ M@9#F _-QN$(X89T%O:()J#C63Z)F$Z!OLJSM92):KA,\N/?
DX=$QF6/Q9P6V38/J=/'Z'*FFA\Q.K-)!@&N MF*8GG^Z^^O-%[7Z#-"*7:1F7K^0J767YFKNH?
^V)3KWYZY9Z0Q'SRT]M21 M3 V*HP0FUFM]4,$=7#7TC*BUI -/?N$8_]]T*K(*B@?._[8X>0R"C= 3FI1%
M_2^MPE3_\/>[DOD[8.T\"8IBN;HKL_?9Y_C8D=H"_C#JXZU$* _1N"#*I$E M-P--XF
D6Q$.2'X!4&05ZG)^D:V#.%7(*@/$4QHUVUUM&4*AJ(F*#:-^"&!L M#QSG+]P"WNNS]^_QVW MNO5#G%4,?
4J+#0WY!IT/+#4^"_C#VZ"U$&"*1N#9+++.OO"(SG5>=2K"8$62 M WQYK>O*=TPSAE8\;I(\E>4F993_&&Q"FS,5J4[
*\D8!CY)LLY@6_F-0Z9 M3QHM>=P. M,Y8[6L B'&W"B-->=^X918UXXF=BRN*L+\!O:MV\'5W]K@,'XKO][&^3,
M3R>OMY2M:K)4IA(2]VLK&-_]\#M@:#H@Y4.M#@TX$? 8JG%#\SB++M/H(BAU MMK\#AZL64J9WE:('A*82$B[4"B&
"8,F (ZR!.1!6L2P&AE]Q1 4>6E0L#Y8 M)G;@\)8,*2.:Y:.!1W 8XFSF?9S0CUO))E@.@J,0*E9K1=C]_> *(&=@\.'O M:+C-V?
=F>[FSL"0 3P3"X3_\+7V,X2 O+3\&:]E"(0?#5 YRWTEZ,,@*8*, MB8$R5&>C+2P!X,,KPE7:R8WPTY?
S;)N6^>MY%JGUPH"%J296 O6U1HN"I$06 M/*ETJH>Z(!R99#FI"!"@<'A%NP\^7T60IJLS>89U1PF/J5P&(?
IJI0!&4B@M M-RI58DBDCX6V8IU%$9N4HOH/9%9.E;)*83'U1L-\7V4, M##XV!R,<#F'_4>7M7D_?/MS'I?0"^1
$YX.K6*T_^.[O!__@<@8&'YS_!E=] M3M^^>?B:U%B'_.KW>0"/S.Y>UP^93)*=WW&^MY3)^F/W?CSXEY:,/OS, H8(M(
R;OOP4[34AS# M@=:RG<96=L]*#XX9VNM%Z ?W"X)R8Z$7:/2F2P:& C?@"">P^_PH%(&#DIJV,.KP-
TZ2))WVR).::%>;7:@,%5 MRG!?!7H@2"H@X4&E AR4U+"'5X'+-DQ M !+OXXL7*?PYJWB5LMR64!,&-
M+J&%N+A+IML1!G9_.BP<#:PAA94FYDJO=% M@+JH7WIUL!'TBP7#>9!QT48)/])@US]K$ -
BG2R96"].>52P!W^Q$O+R/#TJ\I_"'@" M"*C/#%J^W[-_T3U0'$#B/C)0,+[[QF '#.V)@90/]0N#KGIP!#S=$&]A[+2C
M!^N#?DB8EVM(!Q!91P:<&+6D>]UT<#TY8TQ$G/$DD$6P.[_CZ(.4R5H'>C|> M_+M+1A]\ZP:&)
G);:6J_=Q&J1AS+0U$P^A%-7YW%]*+QE(9JT!I<&#[<< MEY&Q@W_F@LU5VP$IU![#8 M&JQ@?JC(.X"
(^BSE1*'6B^;NBG?Z;2=&S;[^1&YDF90/)VE$?SG\I_;^#E(M&&O%67D>Y/EKG#[^+4BVJAC/$A>QWJ:+<+T2G#:
(.%4Y[3D;*AY#XF7%^1\Z MZ L2E*2F0#@)[.J=4X@9PA]HBX[N)0XKU4'\QJ)\HODM#2ECAVU)5%N (1B> M5U"QW'4
NS HMBYG8J 9'(QTX-#UW(GQW(+Q@ZCR34XW01Q=?M[0M*#,3CE_ MO95=(:\5)I[".PC6M0$+-!2SL.9KH'
5)JE0N3L52K@36J);T/XR4H%:<"$S M+F18!9X!)^/#/NLO-(G>9_D=6\D^9N5-D)?+U45<;+(B2'[*L^U&;W>N1+!W
M9J[B#K=LMA00]W)N+,HW>0L"5$Y667X"=!:$42) "EZTU<0(IW8@FS5&K),(M?Y-
G&YJ7KPNR28*J!Q"$>AO(["W($Z-.V*001FW"6PI[YTEL-L7XUF[4%G8#]L76U=DZ2(:(O SL)9/4Z:>SRV2R],/*=!
W<$N+,H_#DO)D MS$=F:-J53 V.9_XF$;JFKX)%,7L],P-5:L%YWA)BP1H#?9LV7A3(XGF0N1.+ MN%'_%:#(.3P5\X-
$WBX@7C9/SHDB,U;'>QXIO+L0/@1]2[86!?#(_9H&!;V- M'Y_8MNQ30;D@*DGU.(BJ;R-,SP1T"#BF8.9HJ$TU#N%
("\+13K+5"4,4IH(< M^NTG50)()*^%VD)Z4J1"T(,E8>_:;2#^[EZ]K4?])]M/?@SOZG;V[NKZZO[J]
(V7UQ>7OW.W+YOS]= MW?^G-]9G=R=.A^'"%A5G% F)PY2YH+P*S1|<)TUSY&|9R%052D> K546$
MR"P1.^S;6V(1&P:UW)N.W$$E=WWY -W53/A]1\EYN$R>M>-10B-G|^PS;XY>>2L1XSD2[3[9KFLL;K4Q#TQ+I&38/2
)VHX=OH"'8-9OS:&/&"5%3Y M/26V2VV)D@Y5Y"=Y_1SE[KQ8)3:'2+[DPE7BJ)/ANQ@>9,/E+)G3X4.-Q%Y6 M]A-
+Y,.33@KHA!1/65Z>L)'7OF5%K'>Z?F5![+(?GF0]'+(=R'LLQZU4?3^N MH^RX^GU!5Y2Q%$$?

S#4UW@Y0@^/INDF$KL:K8%'T7L_,L 91!4X$O%>7!<:* M$G-
X+P,E\TT9,YYWX9+A!HT)R:>@R7PI11,W'78:G6D5/E"#XY0[,/$S/"ML,42M@R[.-^@QT<0"D3$<[^7X M>1/'[>Z-
9[=MG*^?"* %.2O+/'[8EOQX]\P@@>G9C0%GT;H(OZLN#F$_/*NV M-YPU75D=*21J]0 5XSO5 G;!L*H#R/F0O92O-IQ5|P
.O"!71;&E$?H[,G";R!\TW=]DB'Y(51:<11F)@$]O@E"S9F5\/ MT1\K=);J7; @K%V07VF><=OZ_>D/B^_^[8?
&&H_1!,^BB%<0#Y*;((ZNTO-@ M$Y=!TIDOQ8S:(")>-K46JW?'U(B%<[74DJWAC<,&D0 FB5-2X2YZW:[0=V53 M2
BUJDZ8A*' Q:X*4 9Q2J/+($]97%N"%VO>6W>B[H*@YC=7T ,R)FI0!; ML?HU TQ82-4#[-B2/+X7B*3&)&|ZN*1"5N?
1#F55HP7L2A,)2-^2@M;I';^2 M@';)/T^2?J.2??-J_88W1KI,([<#YK@SR|HBX-I[$6?,K#N3\ MRZ.:GER:3R 5:%X<-
&M%G"TH6?-?-K!\$F6$T%!9'^@ M@Z%HH>S5Z<=H244.J$G'DC=LHQEE21+D!6'KNT@!(9^<]T45::ZS)D-L-3]#
M)%\,3R6.VN!V,3PP-#E+9@.K>I&WB%X9E;-4A9!J<(CAG_F($R2'6:@1_#*; MOA@FDQ'0WIA+EQUK4_'BZ&\/:?
HF$NNE03./97MR[S %/2R_#$4BD,E:.BC> MF,R)VN[Z6!Z:#PNZ.]93R&7='@Y-^X)=)B>&%@-ILA#3BV05EN&/J&Y-
L>:+0\?NY^!N)HMSY* M:(_,0[WI48#Z81;:#8+,)/R[YV@OB'_;G($8YCV.'L4CBS#L;G3P?MB&.?Z7
M&X@_NYKQ(OF_G^E=K'R@T;MM^2F-G981!;)'-J05S^9J;Q_3#[O2L&87E;4$
MR,.V)#4)WXQMA)S#%0JNN^#:G*B"P7=K:W,=924TGE49!.B:D0(4Q6ZTO$@> M#E9P_%IX55
A2PORYE,:;*.8;;61M|9-D8>J.6QAT"0-O >52%1"2"N0[+C M5AZ1SM+H@C[3).,MYBII+C^'R1;"
MK;/PG]N8ER*ZR;.0%L5Y5FB:O8VGB-H/;M^)V&D9-Y8<5E>Y_?B5=6OC%*OG M0 W-IGWXFX8LJ>G"8XV*,@'2,U|G-
P93,\]*U-)$]V2'$[5V?1YT9;I:;X(X M!Z;.6:S[J*Q.HP)&[MJD9'_0Q6D B=?52<&*O,L3::%)!>Y#HW(W&>(&VL>U MGO-
8VS4OSWS_%*3W3WFV?7QZMRWBE)OY^B%.>2S_L3E*XE#LP()J1$^CEL/-
MRHG#G!S$Q_|4Q.EU5A3+]"Y(Z'+5:S[>=!Y7S*8M,IX_=A.OZV7M,%%\IPMK M]4$9/(&T+|FS)-
=Q,4F*V+AU5:D)D4X+=(0F\EP?Q#"IO01+M7H#'=_F9F MS+))P=!!TDTM*9@HG5E.6Z<]B90C)3R,NZ$IS8,$&D-
%ZSB-(?D%%3Z]?:-J M6DQ8B [&3J">9]&CX+@4&YZ&&B>P1 ^V'EZ=M$%?\/<7+.CA>78889MF]NKP
MP>K0P8_#!NM#!N3GL[:,B_>RV>!4P1.U%H>'L *:Y.Q">J#:0|:ERMV"X:KW
M+A|:!1>@5<3HBY8;^8>?"'RK6M=UU=4.HN,?LS3KLU^9JN$\V0(/3_^MA>I: M@Q$)Q38LN1IH6A>O,98*]6N?
CI['"BAR87$E6;5@['- M9/T09W__*6>;',9C@C#GP^O\BH60;-W?YM-@:,LW,(F3M8U4\[$,)@>^!@
M#3UV88_X"/#5QUV08@LIJ\IQ/F9,J5(^&@N$ZP+X;(N9TWC]L&4[69[18D1" M@.RT)872C6'VF/*:J]$V!\N K;>H\3-
S4P"9C5M.S4^=R4!*!%ARVK5)[&MV M3!9:5.QROI07PR20F-?KE(SWK]8-P)"NU2GX&.A&#=FT*./ R(FM$>S[I-W5
M2GE!']072"60^-HM85RFW1TP5.T>|*%6CPIT00 8/3T]0@#3K9;#;*GL&1>I M@]WY1P]K9YAYW/V@:_CNY?
[/:=_GUWYOS#X/V8A=9:FR@--O[/:W"EH:0S:&ZDU+ C^C^W-;9A,=LP?1U;IB=%T&XEU0Q*%"
M*@4LGNYJF>_JL!00Q6-K.!F67ZZ+CC=E1!:$PR/O@UQDJ+6<5PD)JY=V@-1]
MV+H@#UJQ4"SA(DZVI?)!JQ+:'VO8$4!G#Q6H%Q;1X\7*)BH,SZQ"+X>E740& MT0YB&3_3^/&)
<7'&5K[@D7[<0H^;Y6KPK%VW=CC2P+.B4<)V;!P MH+\U#5(1(8(*9-
*'!>;\6+8F%3NHQ$X;L;M&7'BWNBF$KYR4;0$49RK>V;%) M8 M+5I'PR9;U/.YKS7XLN!.+
[F317JS+3=T!YL3<>VE;X6)VU'$0KM]DQP(1 MJ>^.-6>&&A.RWA#^5)MH2K/REL!G'WA/1,6<*&]*!8L8UY:
(K@+B%L8>,B) MIFQNW:_Y%P$_\]T>^RK %D+4K'=J&W,?[8D[%O9XGJTW60H6>_8Y5J6!#3@> MN%^=,%*W*T/
=;=JCA0=ST@+2WX!:+5Q'"8UU1?@(EL'\>[-*0,L8EI*QWPO M*24#Q$E)J3DQ:@SY18 CJTR_J+K=$MP#]6
%EK"NKM'OP_H[8,14C=^[Q==9 M F[J4FI57 +G1:5)M7(/@+#K1^H#LDZIR /IM,4IK"OW^|>0|COA'3ZNJK*2 M4FTU
2/=%S>RW]P>5T(>5'EM6-%K<(V!K|K3R8)<>$K>]EWKM TXB&6H;(3I M5:/2(> 4I3)S-*SKU.
00#J)4U*AX=O)')A5Z[J-W77&HL*&+.*E([]?BTH M&2121254$\KKM,M<\4;+E_%["_AK3@S:K$(=[,=YP%^W=ED)
<'%V#\ M]J0)+&ETP=|YWG Q>'/(MX#VOW8=?Z4MLN6U5=XD2S!7ADF\1TRP_2@^*)U](K:/X<@T:S3U/F\0.<
MH9,RXP]KV1AQ^?I-2XT7NNI3A(*\X)"@]41/$1>P#G1)*!>]VTF*2WU6:K#S:8XX1MS^P:(+!:231G<6'6QYM_\;
M=Z4U->23@VE$[W:%ZR\4!XO=+#95D\CJYJL00[^S\F;[D,3A+[&=()^=RH)?
R("XH1=$33H']*DCX&#M9BFF*F!:UR((:JB!&>T,P%S'(QI'>H>_D=%P"\'I!?3Y('DV-ZY M(!V;PT=1S=7K7I_8X_!"3I)JW%
5#!V1(W*2?)/-%E0--=FCGOFR_4FR5XI MY3 W[$,\!06%&MANT:6)EG=;.SOA+79X>D(^;?1L.'7:[U6A2$VR.LJOB?*Z
M]G[N^T;-A'I+Q+=#Y/+NYL9+.Q>.3RGNJ.R-CIIWMFX[=;Y'#4IG^S=CM=1
M&1Z=R7N=ZW&>#1NK/Y[TC[/X@UAW4R%%OGL][N/KPA\T@IOO-"UD&X-]"'GG MZRS$M@UJY%1\|G!&-
F4Y7$&JB6#XOYYP&N0F>!5=R_*<(?+T)MODK)C;@?.I M%8VA"9FO5CYB0H#0R0,7/>R >]*N0.O-IK!N/27OS-M&
<.LPQG\#-_-ILO Z M8OEB3'S,E)AL?.[S&Z"L<%;+]/(SS<.XH,O5SP%\D')W0S*2!E8:=:,2P;2;5 MD0!B,G44I]++.<_-
N4XOI3*@YSCL/S.(NL MJC\3W.XLNAPW:!Y$ M@E+<3N9O3!ER+KBIKMX4G!\L?SC++)ZU\W;;F;?[C.P\OB-7S>.
[!:G(5ZEP M,0"FKYQE:AHA 8B\.?W#CZ=?,VWZKVU1[GU96>XWWT.9,<8Q]_%GS4@RB96@ M2)
[.P'KCPA1P>+Y)RY#F+IZ(G(0Z\#YDW%^L*FK,:"J(!PHN1D186)[#3<8: MNJIZ;*'Q^W%O;H-S$"$F-]LK\0_2>,:
(XI<9[XIB,N<:WCNS[C-F/OH[:OLV M'"*LTD0.<[>YG\Y:"U1_)5;1#EX@]#XJG]TGV4MA7AI6@>%"14",*H@[L !Z[M_*N"
(4/55\ B',V?6J^WE-<-N GR|O6>[?H+813%N]?N+YH*F"X$,(M9N(K9 M+W!ABXU4],*-/1A2/@/>U'[,TK_X*:-
!NUX<2FEU)M/4S98!^Z)VZ@9BW2>8UAU#+NB,810FWJ.%'NG\ZN)UKF6XCZ[I6 2 M<4)[;5?OLVDL?
YZA,*N7SC=U_:*GTX^#5"MU+D$DYZ3-4) ';@8CX)KJ?MTP M(#]S]M57&0,*O!G-FQE-ZP:<[%_AS[Q&V5;,'VF;I
<3>3SYF4[]!FJYJFH\ MB[=$O*7$>TJ7J;D$@C,)I#.?D:(V9T".^'AG0J,8';Z.*YGU;Q@BU]Q8\E:. M7XJ
6DE4="!940IWZSPIDC#1+'3D[E7IKWN>O1=">U0C87K!=ZM$7>J^-_=G M[[.\9+
%>1=G)0V?/*CF;_V8R+_W0O9/@CQZ]>/\L$?W@H=MZOGR>"E>M6_M0W:1[3Z#*WB%X9T.^M[M2WI9>
'K5ACKK+P/@F?;,E:[%MW]'<6.APP,M*$+ M@J['COP:[>\PR80U6R_C7SE'R]4%?2@OXB*$.[\W.5W'V[5J&V/&0]SFVPK5
MV[.;D' VX'9<#?=^'3P(I "3U*CD386,7UAB*ODBD"^J4'%-JMFH7U.V3-U" MB^WEBNWASXJ"EEV^JY!",3/N9/,;JS(7?
MSI8%BCN.8'&AOFZ+B=!:$4SK) M5B>,%N'$%M4+*K;_::[W[F#R:'"RK?.67C2!5ML'O 0#"%<"L>&()5K^- MBR=Q-
Q36?\VD&/!P#9X<0'&%RF/'3XP *;51PJ#Q*4H$@G. ;6FY,:!1S>B8R6(5E@ M5KWV?>3FG-3FO.
[@PL\B3GN@JRRGD,B(\YV?2IJOL?$?-EF3SH)M;1-\4,0-^/B^I# DO@SX.V6AC1^AE(L]@8]1/3)>%5B
M&9;;'2Q/C%+.EO7RRK6O@^ZAQ5E**$3)+439XS[B@+FSD)\F%3?!*PS*_#[MEWS;.(;B\C,T984KF7S?
5%QL*=SI;)Z+Q/+2%'.-A'6[<=:):R]!SC(,XEW) M&>61EO**&S<1-6ZB4Y^++6!P*L/^5E7J8BZD;"J
%60CN(([=G5/8;B!^9AE MD5CMFKZ5PDZK-ZYEKXA8]I#CXHA\63TO5RR9C;PIK+VQM#;^-J-:T$9F0R
MB"$&Q+0+GX?\E#)O?Y62>D12#4G8F*0:M([!"M(,2ZIQ"1L8:I'= M]M\AH]XB/>1L-M-6]S=H95!-
FQ]WRH;S85YG''%]BN ,:X$3HB=QW'[&S?SP MA:B-=% CM;@.L(^D-QI[(R<3OJ.UC?9XIO6Z3/:%7>$@7 L?P
M9%ZV$MMC>_Y$?KJG\3.'S_"N0[&&X'%5MW"?A]WJ%C+!D8\CF9 AI5'QGO%W%R1TN;JI;C%" M1\F2[?
TOZXN,BMERHH!GR2,$[9]P SJ*[3KS)SE2$Q2$]@(-B.IK*@O>%A9: MK+$-
Y*7Q;NMAK@U,+30D3XM*8]_@QG'1Z<\MO'"7L'&L<1 ^\7 M^WH>\TX7Z_]Y7743F6]7^:(9-
Q)ZOE=]'Z=![&DZP5]42\LY.+<2VL%<-%9_L MULBF]_TV!(]KK^H^#[M[59G@R'O56[JI @GMT[4A&&:);#G+_0+9?
1BD\M@R M)B3EI6LP;]Z867)>5QLRO2$[>-9E4,4+2NY8;'@5>'YD6+1"J?(J4B3T;(J&
M*T,Z0592#I#1%XUIQ)-5"JP+Q^V6BQ,C;[)<<>EJD<^S0OFR0H^"GQO1B2++ MALC@4?,?:H;4&0^F:*)!9V-9'
U]"1HA4UV4D5D. ^)7.R'[>$0VU?$A53;1K1G%S>W=P<2ZIN M[_S'<:3F]DO)>9Z*FRX%YV<*W4UDGD+?
=$1>-8+ZDDD'(>%_<#[W'"00X][2 MHLSCD7\,-9&O7_H0,I"NKMWDUMWHZP/_!'^[>2'\,FW'XM\@;
[\!_'[$;GF.SW&T3G-R'WA\+FUF M#S6OEQ%OIR]3;7INONFQ<14+0J$VR8KG]P2_AYB3NS+(2Y]GY8$^QFD*B],!
MYV;>54G;&.18%I>[[6:3\&XL00+RP9V JW25Y6O^>M!P9<8:&['+CIN O;8[M=]@X?
7A<>!LV>NE@D^8N".D0\.G6RX2R0A.#)"NVN%4Q)0,HS"(#4H;[Y01Z($B% R0\2-[_"B@"8-TM5568,/Z5PNY+ M
"T0GB=:%0ZPD91;/:\# Z>1<86#O],!XZ[:@K5W5--(DFR[:&S9L$KM3Q9W

MOS/%E.QN>?:AB;;KV9]I]47(MAE=>XD;HC7IE="6O$_KY$Q3I%E TVK*IFIF MNW\X6]_(H)&J/.>7]WKRKJIJB=AJ@SE TYSX/TF)%\[H7R7D2%$6\BFET5OR%)A$;&EX] M[@COAHI4/L=1M*:&CB4>7B$=)P8'VOBW(-ER5:Q*5Y<5-:C4QT_T;V[^1[#> M_#^7H'E/C!P/U>#)*E9=G?WDK;$[(H<- ?8O?1F1KRJ(E6V90Z&MZB_|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|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

*Y8|3L(A&!12HTGDW%JI,_D42R M[S/GN5SKB[ILW-"|8ER;,S8C8Y^VV8HW/%@S87IPAF;'XDA' 0T8:BWT*I;8 M5_SF<*)#8$%Z1@C-P2HB7IS-C)2T)U/G>Q[>CZ1NA!_?$5N_TA='!>^0%- MTP2P>FB2 #8/EMP>OGEITAI)9 :,V.E0|PB]#N_]6PB/M]$U.F_3W')^N6 %E1ZND&WUE6@4$Z M*(3AU#MZU/W[6%D47VJ6Y39>/VR9$/#-ERO&8'&? E4%R4^4(Y![*A(.V -L) MTUF)]0B82[(-9[K"2"6 -[F>ZA*;(,]MOKK=5I#LN;+^)%[1,E[3>F%O;L[@ MK>8C)Z&#!D^3 7%!."JY,26_#K+$CY)+")#WI&N^[SJ(D+O=WH5/--HF=+FZ MI4E0TN@&7E?>M_<1BW>OO5\D,<2>M!"[8.|C? *]#]AA".-VSQW,J,5D.1S@@ MZ= @OW TY"Y%'X+_RG)X(_^2TNAN^U#$41SDKY_2$&X@)G$$S&L[$SE1P%/C M$8)VE=K@B1FI)'#@55:-3B#),(/A1NCGI1 M65ZR"2C>Q5E)PZ>K5%.:00V+50_*P'Q;_TD!>-" VX(3B0X(<%+!|^YZ7NCX M%(+@;F 5._3K.*57)5VK>HJ;T?"VJK8B=?>G)AR43:D=4RXI$T E">6+B.4 M" <_6_T>Z7(GS"DA@5@\]BXJM^TP3B-ZR-2./X 6H]M&H]/#AD*-C=4$Y^ 2W M754.-C1BEY8#RSC,IS0,= YG5XR'IN) 7MEVF1']OBRO.-$^FJ]/>K ZQ?@U MW]41*_!0/["'BF#'-^'ZF,6S6?= RV=:|=RF\B>:TCQ(V$R>1>LXC8L2VBH_ MT]%+WM3#^[CFS3/%=HO>M&-[NNK-(>2A',*CX(;[@Z#'C]<+WW]/.<[2]UN= M]_&KWT6<;!FKRVU9E&SD.'V_.) [=EC?M M9;$G"O?Z.TH;":HD:|D2RNF*5QU!4?|5+BAFN:C=Q=0Y#))P"|I-BC(+_T'B MHMCRBXSL-WZOD? V/D<@1JWB-GK$*D70PB4!=D!89T_>-%JWOLE;;)'EM=$!\ M:-P,YI*I)S.!])$_@&,.61$Q6\#CY2R-0G23E4I@E"RE@9N!/C7PXBTE7[,N M<8.#L:(T60)>Q+!>N47OB$ZY15S[.(-2C+RT7L%??.MN5RI@|>Q"RWS7)J2 M*/:@X61XJY^7R>P 3W*K41ZM?7K(8X@3W\59$<:43;VF$)L&&"DV,[+?A&1* M2+Q(S,#20"]J>-)!0+_),*D0F*&0JR#;=WD,^SV__+BDFZ<>U!|OOMO54P?G MA0_7=/>4N/"YNGONH2S2MIXF8'\49MBX4P_IA=)H6W-*U&:^UIQ\L)O=5J(_MQ^634U PB@S6T]IQ(K=/?MUI(#X%'LNL+OL3*VLD"_VMQ^ND)7F/O'K%)&_> M95!:ZNMN#,!O/:&](IYLFO0SX&WP,]T$_'7+Q -G0]H^Q?P|&O]NS;< M9]/ ^[,*#H30+837J%?7#-S8+(?7L]Y5NPO@?>)-GH%;>[UAS)20[V'C\TL# M%W1%<]Z*(,S6TF,,1P)8;PO&B-F^+'#!1GQ7X,ZFH2Y&P2C"?S<5S079 %6> MJZ0U7:AK5<01A3X3434&6S%A$+3'!A/,Q%TE^TTC^TTC>T-I06I:1!!#?6DP ME=3U!Q4!C_KSXJYM=3& ^ZQJF%)5MH^?J5AZ%3[9 @]OK;,6JKOF&9%0UCY+ MKB2O::N*#1!>"TS2HIK"JL.B?@..^:,K|#+RSXTX;I M75I6ZHP7O[W6=R2!O=T?RJ^GNMA7@.RL!7+5Y3.-?*;_= .=[M55G+#DS9CLG[QK<-T 2#J!O>R29J-TSG52T[L] AN" 5R;JR#OJN=ZI9J.7: M&.0ZM#>[V-(;FL=9])ZYA|O5BG*_?!&4|H)|DX]Q5![0/%E[^D;U ,?F-4V2 MF.Z/15M^AXP1X,7&MGWS$9O1.U'G>]G*O;$O&YOFFFN?AG!Z? M^W6>OQW'O.AIGL.,S.^XH=P._>>63A*)2HAY[HJ5XCO[W $E_YVK@F5-5%HT M&+_!P-1ZNIR<9TOUF,)3V[GH2(,ZCB*4NB^^R")L%K3^!*NN5#$C\J#74T*20/O*?HC:<= M20?/H^[%L"8F3<'Q<<*$#9:],$\:@SNM!EF 9TVY>ZW*@Y)U\+I@FW_F)E[R MN"S9KVE6QN+]5WUA:$%HPMPL_%,$3)*X+!H_G#7P53=(2Q738F$K=U>==;95H*JAD M7Q^%+OH3D%_6^JYJIS0-W>,*O:63LF^|W2-Z=$&VA'M39-VX4M$72D37W*VG MK:VL!A'WD471-A.S;^CAFK&2;J4J4M?-? QQFUS:#'9>#M9^^?;VN>:2C<|6V(NG|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|>PR4'I4_VH=FAVJ[8 MH-K.AU:8'NK?4# K_6O1_-*_7;Y<]&^*KHE[:^ U98$"5 BZ6L-%&;$%D#92 MM,+ TS@+0;J:I@%'T3 C/T/-JC%(%P6[4]\4\L0=%%SK@+L29; [EE2"N4N8% MV"ZYT)N''@7//FQ$Z1J(#A[%0LP,#52JBP*7EVJD QG),\T?,KV93" 4LY50 M]YX2-Y"Y-K2OM$'T, (P9B&45Q5RC=K:T9[R,(O.WA+V1?/4I#X5 M=+5-KN.5*FEBA>FA40T%L[*J%LTOL]KER|VN%D3@$R#@JUT91;PLRGC-3QNV M0II$)PVN7?V49X.:'+9('EI33QPK0^(8? ME0AR57|^&HOAJ.3][J?9RN@>|< ME]7"<+O>)F"K;,L6Q#E?-QF72AFD]S)&4,&Z4#9:X/:*F#,)Q$M?(WG57..* M&SHD8830;EM-)EE+B+24")!:-$VE9R7<#=E3 .1"FQ34+Y^Y4T8OJ8E_&OHFZZI:^:GCSB@_J)IZCWX'XB MVC@/\B=E7NLMNO2A7%\U O<2W3$6N[WI%YXXD@/-F? P06?FHLXHN*ZF]9W+ M59.+5DR3 A;"6B9[UJT%!#%/#6<#&OIMFL2BSL::.3H?KP$B8=G':*'Q$C46; W/ MA(,\?P7?+TK>!$5]7?LA8' A)<43I:6H.43-]$CY;>;)"|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|S6&V.&F^Z9SN0)KO8B+M4-45V0$9*0'C+%Z3A+'&Q$O$.+*HN5?$=Q-1!0V[C(807 5.MI'H^1GOZ"-6 MRF5?P8>.H4N"+%?B;*^F@E8<<*JOW(J6V8IVN#O"'[,TJ]\$RON9F<&1;P!K M1!A<^)7 XMWO53*CN,[;A4?N_K2/',B=$+8/11S%0?YZ%T!-_;LR"_^A.;77 MP"/V.C)T6MNH +&Z6:@YV;8ZXM!@>/D<%Z<['?XAMM8R]5]'J1%P"O!:D_Z M;1 1=L M*1CB0P -/P[7Z^*BV,+S/7ZH47 ER:KS0EYHB)R5!)HUB<'(^0YT:[]NXC, M^"Y;OFL4+|X_)Y!CEL?ZCW%1BJB|U%<#8S[4-W$E M.:UL44B+ED_E3@'LUX&=WKWO:L-][&|LF290 9[[J+X9M5# MWFQ5:$$E]R=?.^GE1^19&.LWD*\6HI#&OOO1QG[[_TU]H% 9F/_OZ/"3,(/;.L_6:W"B;-B[IX!-TMES$"=PY>U]EK_?EMN<7E6YI[]!12G9 M1+C30')68X5M_)0K 3P7-8Y32;LY(%.II2!$&DJ$D2*"%JF)$4X-R2U]R4+K M?=%$DE?"!HVP4'MD)82M4] S.2%&GJDR7 J\$1=J@T>ELY'#(CH5'?,]YR$# MQ'42:HZ&[Q$: %BJP@997,UD_WV$OD:DJ-:R4)@1/ZW "E0<)6S!Q2W:%@'; MN!V$.'N$BB^=S^/3/?6[\(E&VR9P>O=Z#A6K[L'9],Y4=1B(Y]9F07H'UFIP MG)-J$S_#M0'@H&L!T]7?|:8EY:O:K,|ZN*+EZN<@SX.T7.:WT/A!ZGIMAU 3P$/%5 M&(1M&CB.%_?FI-)H+|QI,3S3*/45.0VX/UJEO12GT:OY+LA=,HV%&|75F)J; M-2I(I*!#SW@3;\C!\$(-'3^Z* -N6ZDC#5I1)2\56:P0PTF\&KA6>#\NU.PG MPAQ';2Q&H<79]]40:@M5 &(=E>G8;H_"9%"(1UUJ=L9;9\&)DK.3[]'MTT6^ MNXKM[YL%R0?S'"/!22/"?.;YUM8\=P%QS5/.]JYYOO7+/&7L3&">;WTQ3ROY M:N5^ZZ-Y.DEP|G9^\SRU-<]=0%SSE+.]:YZG?IFGC)T)S//4%_.TDJ]6[E,? MS=-)@I/3&@2E D$S6PWABI @[/3+4,C3?434T6W4[=!&R@ M_=J'[BO$#&G((B\[*4CVMS;]R/[R]^9NZEU(TR"/,TD26P-W>#,V,@TVK 0Z M:%K1P,70>5<@\^6D3JT6ZK(^RRG85#(8W,=(*YRR-G>U8P^%)I:R-@8Z$0-9%[_#GF4Q6]B7,SW HN@N+?GPE9UYR<-4'Q#RRDG&B/JRJ2C@ /.$(,P=-FE)28^207?/Q MI_#)%JR0_87?4X4;K32Z2CM%-A03X$;"CV(HMJ*JRJ*8\-$+I-@QJ'\JL2"" M#/\'<7E94(+*=1U:R/6J)A"]E;-[KU:\A(GJ$B&BU6Y!D\0;DZU?PG!YS=.S M_^Z%*4I%4)A=#Q;;Q"3,F,R)H\"]9V%._MB-C2PW]4LQ4FB9W^.E0N\2RWF6 MLM6WI+MUM?6@6.\4]*RWSQ3D<(BO%'0,:?QDG76#:T,YOS:T#E[) X7VNH($ MVJL$)XD&UZ :!-1'"2._2OU1V(H5&N7 NR#8+-,TW.:\"_QYD"3PE/,R")_Z ML/JH>Q^ZZ+NU_2?%>"71A:@_%Q?*

=N;:_WM@+:AOZ1 P SY]AB $6\E(]URS) MX]X%H3 'M3-YI.5$WL1FV:\8KO[&@PZSAY0B>1$:,11! 42#%_" R5KD@8:*
M:592<8;7E!BH-&(TQ]?_E1EM!X. 1@[UL-[L?QYN]+8MZBCBBHA#- M+0UI_$RCI5L^RH:&%[M@>V$56V,S
>S]LBV'IDUTCPZI"<$+:2]34J/%_LB6
MW4V>A91&W/ED\Y4]_>LVI?"OHO03%+Z]B',:6M0QML5$6HO=!&L69#LTO%79
*MA3_3#9LUA]5F>TU$*UB+3@2^7T]/9Y<2=\UG(<@S ME%Y(@I#?-]$V3UO:[R[4<$F5=UK$BBQ&?><&.&AK;*J:18I;*
*[I7V& M;*Z9ZC'0;IO:"-*Y=*H#Q[Q[:N9K7+6%3:5-F\8F*^ACI!U:-J>W4J=5*89 M+/YGIA(O>6>SK;%U-*
2R2E9N8;^Q;!8AGV7J.QMGT2T,3W9@=Q6O!'>QWO-+W M"G$V22=(/X?;A,^L:(18GRC?
*9^_H+8VV(8W>,^WKHW)*YK# M.,!4-GOBFUKHQM=TAN&=/V&.FVLNU1S?=N>X3PLSQ#C Q)TY*]VA3MDN/],| MC*
*LJ[O^PB7T*JK\L5YVJIX:BH1-1]NF\;O3$Z _UG,EZ=O(WDG])(1-!9^@_ MH1$RDZ=@=A$4=5G-JBCJIAJPQ?*
*B"NJ<$Z4Y>FSFD)-=D'J4UCUW2RTO?"FW M.N=L33 %D_2H,)_YO,_R._%P*F1,;[*"[CXUF8@F?*
*N>*O29#UL1B%$$O^EGL MP?G0,P3%$PLAVM-/<66];&F18,5LD4009M2MRNLZX\QS%M!Y!H+;1YHREA+V M3VQ*
7FUZ4PW-+[R_9/D_(#)@TU<,K"<_G,;YZ(KC)E'"GDWB1-.A71' M(IVAX#IK%ZX:CO#Q)^[VD&Q[||<!;B*
MQIG6)TU#']D733E) Q\T!7$\WS,=]W/XG'8D(H;RP=/,.&4=>3=Z>8|C^CF+ MHAA0@N10<9!NQ"..B,P3.6ELI!
[N.,DDSSSQDOMZ%]>Z.0\LYW)*#R,IR8(M(SOMWGZ"M.7,4>MPN"/V^'@+DL"(9,6&)&L^)GF&03LGP6C-1@X^?*
Z+867NHR>>O-UKG'DTU M?WQ$ D,2,:9HG^O)Z>_!YO!F7RU#KIK1'GJ?BQ,4L13=TH+FSS0:]!U6K)D(I4';[5Q'C4LM-
*4&[N>Q43RZUIJ0Z?D M(]U^+C< 6"RW95$&:<0\UVV6)&Q2X,>I0V/#8$>X];2:ODDVGMJ1CFO;:2'**
*M')O.:ECVAW9@\@L,3:JQL1\9'G1&*QS"6$M6 O*+\6%B#S[_+-?C?!&>]S]I*
M,SDM,2E#Q,CMNOZZ7E''^,TM9FAH_#NU<5M"+UG]>Z2<8[7NRLG;4KO/ACD+V[M0HI9O7MGS,-X]]DC4-*
M9K(//9UJ4\/XFC0AM48_;4W6||<|4WIS0Z.R9YL$C M[3T^N6WC[OE7$VM&CM?7C9_VF4)=2RZ.TEN.%?-PP7+-
%JGXVGG$1GXY>RC* M/ C++VC3O]^G,,S8;|(IXWZCWX#[1?2Y7[*C]$L !9CWZ\"Y#C!,^4 ?GB%B GV0Z7+4%=@
Z91IG#I6:^ M9U_&O)(RKD:W="T\)UG*=_Y;8/DGN;KMU._U]J'DR-\[+C_Q$_R+'(\&|?U M@')?.1$W"0UGI,,: =Y\|-=>?*
S+.;N.5[29=I)U+K2\B5/R2H.\^/JX_;AZ M"51-Z>E,'W<4)\?KQ_>8^"G]^ @VCM/CY83,=;^8OWX=![CE!^7Q^/>N/3F*
M207-G]D^0K[)^0CM^T ,/J_%?58&2??W\ZPH/V;E?]+REH;98ZIYSS_C>'CN M>?9)[#KAV09#<;4S2Z-
UJ(VC;'W)@C1CU?X3B+-_+9FYEJ2E7Q@(CW^B?<\4(MU8:>!U'JF$3-Y3^W;W3T%:.?-F
M'F=\3S&2B2/,|>XUW9.D>D=Q<%P9WSU$G*5^$V>'=/@AG'"%2,H[:4+5A2E)6 MX,MXW3'E=[EE<'D
9B/TWS7"!V'_^+=L0S7#AV'?Q+ M=;]S7U >ZWF/^=K'1+,_F),OZYW?+/TI3Q7, MI_*"?*
1HHA<:+H'F1PW;C\DMTPWM]L -G8%Q8_,<^AYSX$CS^)Y0'_91VL_K?BXW"'_FWOJSXNI;\9A>0XULU?*
*AMG!&,_7&I%& .G\?_0ZK1/.K8/._$-0X[J!SV%8O*T&'C>PD*0KO%KP%%LV?:,I\;G*61F?1.DYC.,PNXV=Z^1E\/?U -*
*:^$+"Q],])N*X>6B&B MZ*,#9P.]K'#Y<[<^-JG0R2^" /9EAJFD#'K8N)8&S?:8[CXQH2[H,TVR#;@(*
M&SNSPL2S,@?!NC9F@89B8=9\R=Z5AUY?6L2%,5R]7, MFY)RF=_"=N(>RL8H)D"'@-B0U2A&K_.J$AJGQ:J!G6$O54"
E"(5E..!+Y MA:/M%Q?)>[Y#,8Y'MAS0G$;5L(74\QJAD7JPFP5H>JFK0?%ZHIMXDOB;#6.$
MYW[+)TKB=)7E:Y%4V="\K(I)E1G9=BB3EXHT5NMR9S&["+4]%-BKQ82BS&# M-*
TD0\CW6V2.HA]F:#0A(!FTE1F/36F@\L[9@:[QE;VKB).#4T:U[C+0-#A%(M?AGYI!+-8.O+L,P8)[>-8[F(PC=BU5BTP$-
*JG1O? 2\XHX@]OX$+RR M'>Y?MREU]QSVN$C.PU6XQG_8(N*Y$#<.W;T(H_S%S""AZYD3_%!NK-:.L]=*
MR@2B!F91/4Q.7<8J&HP_$E6[;#DDK "5,)QL5.[MHR3CG=2?LB1BU']7W;OST&@Z#2968X$I&,IM/!
*<=X!DS9FT^O88H' M+ ^-&RM?LZ+-N^Q?J3XO#2>5ZF*0AH3QNES):LU&W\8HNMGESL4P66XRA@A3+*
MCQ>XB>K=2>#%]V-Y';CF/0OOTZ;<\4NCJ#G)@611-Y" V)Y3XQL"82Y8T?UD MP@M_NFS]Z;+QIXW)-
O2(($A@QI"K&DT["XVHS:<^M$/B-^KW=$=2&CXZ(XVP M=JY(0L!31Z3DU-T-/0I21^*$[57NJ#6 U7$#N9_K-
*(.$XG?"%E]WX-Y'DTW M5,Y],"\?$I3DY2D.GRH3 MH 4)@Y0$X3^W,0,J1 ,*YA3#;+W.TJK;PL-*
*KLUKW'&;Y!.0H0SP2ASG%'.O" M.%,+8S'(,?C62;2QFJ!&=S9B%A[%+ QTA3\;BK(D"?*BU=S]GA!-Y*7WW,2Z*
M4SX67[W/9M>5[!%Y;<=$9;3/IK-]D03K8E^]8X;85L^C^L>L5$?>&^-UOCE MP&7-3Z%SZ=B95-*
/SV%F;)L')1:N(^>V8]5Q+DP,ONRXY;_K@AIT^N FC0E99
MWDDAM"EWGUVHXY0X.$YUPV#?':7CG,A/6=1ZXID3%$&\HOW$Y-2/T$')V@2 M=]DG?9S.4R;#M**
[T%,*>TW7)&ZV23).-_1D.EW&=/B\G.8;",:O6?^"PJW;(7A+E>700[B%&P> M>-*
*T6W3O)J0=!K(\TRW3U*B1-.@).C:091!B86)W)'S(FW MB;BS.\5KT+VM;<_Y>/(")[!KEC,.A6.CL\EB9:PQ=Q3VH*
ME207YF.PIMIR268TW^QC))9R5LQ)!14'EO=[$(L=N5P;'JI,1]XWGSM^BB8,0*Y1G\E, MR[QU:-%L!>*
*SD[YS3$8VQD_GYWG8]2TC];,^I,SH8T) MPL=H8%W.Y[*N!1&C("^X<\[435921CY(DE?2S%C1#(+K4JYI45!Z38."7M B*
MS&->Y%V7M--BX)F_A2!=H]: HYBJD9^!6@F,!>$X"]+!\B.G)9?(%/ 9L7S3 M,&UX9D#Q2--
,P91.VVSBH\.X\7&R,=>^CDO1 @3>^\/)#O/N- W1W?-/09Q> M9T6Q3.]IOH[3:OWA$BKF0(^"6"S90I1>C60-/$YI9"-
#PUK!#(6\ :2O";.4 M#AY$0QP3NQ*RNU!=*584^9QRN:%0?#E]Y!Q?Q\%#G,3EJT):)32>61@$Z%J$ M
*A3%&+2\#.LSU=#U^M$@(*O_6#$2 "?)8:1XIOE#=@@YT)<[SOUY5I1UUWOE M.C^ PXP+%4SW(\$=(*383\J%)-*
KC5@J0Y)<:=N;@SD++G=@G(0/T:7$"QJW.
*M5P#ZLB1UV5:O1@#EP4+4LF%>@|YU^H'CN*W83Z;1;ODMW;\%>0S)@X:=CW17*
*M:35P2#=G=4PW=V!E0'BW6=7<##.MXED5VS |5T@=%5B0E);PS*6;==V)3N"6 M89@]IO&O4+S\B;+-*
QT,2/U81?):33=4E+BY(G(;;'(K<=T#/\36?QTX9EI??8B'-.&8;CAESGLFEE%LS)(MK"(M50X "/@47%6=
*(55I916P+T'6+OOJ0*N&]"#8ZK-B#KAJ>,^"+FLQPJ!X M(JLD>RG$,KN(),X0CK7IN0]9%*_B4), MD% "M"LQ&@B-*
2TT7LAFP98F=GOD MJ>"D3@6O.R3@9['$/U 6=L%3]TV<[_S$HHHU5LPU1O=U/>''7DQ<]_[R<3X*
M%U^D^PE]6@I5#Y;XCY"\5S4K=R?CR_)I+[)Z8373\&#)M672O!AK'NF)]!E0 M\VRE'BU]C7@R?-
;9>E=R,NV/J]97\1%"&O+;5#2&\IF7GFSSYV,IV:M$=G: MK"4T_#-*
K)9,CS+JF18#8@E3D_#9L>_D'AAW5XC+JU#N+%O=3%(=U]3Y$N+6(MYLO5>R9-D/PG#53O0/8AB'V3:I]I&%ZR&D,-
\?[5>':55[/4A^P+:'3W0-D& M/(X6I$-<;B@3H"\%W>W)IP7^ D*Y$,=+!KRIS3D^],% :L\ C=PL:4?Z>?R*
M_H4FS_1#EI9/^CN38\AY[@(T4^#L "2T_#5_);-[&S\WBF6?>ULXEG0F/H? MCL/408+[EVS/Z6]H^&_8.P*/L>>*A-*
=FW.-Q&NMEY-##]VG$UYCM'X_(;-F8 M^L8X M3+@K\E@+!AK>&W#+Y#3V"_2.RGPU$Z"QWG
[#NL]6['=!I/CS_P]02P,$% @ +(-6:TK'KUV2@ #W<% !0 !T;6(M,C R-# V M,S!?<')E+GAM;.U]6W/C.);F^T3L?]#F/G1-
*1&>EK[)=,=T;2E^]W>NTO+:S M:F9?,F@2DC%%D6I>G.GZ]0N I"22 B0('"CHFI=MH B',^#\ !<,[!?_SO M'RM_\@*B&*
(;!WS[L_[SW80("-_1@L/S:AS19?#S]\+___C_^[3_^Y\>/__GY M_F;BA6ZZ D$R<2/@),";?(?)\^0Q7^=8/(%1!'T_*
MS_N3CQ__3IKXJ,2H2AA,2%L'/^\7?SC/6PN#7R:GG_8//QWL'1Q-#GXY/OGE M>'[R]Z4H]P7U; &;"OHP^.,7_)\G]+T)DC"
(?_D1P[!]>$Z2]2^?/GW__OWG M[X<_A]$25=_;__2?7VX>W&>P!=!@E,7]^#11BMB-(_3'#S7^^O
M2WU:I;@7RR<8_NR&JT^XR">QUCXIZ/=#@KB/_'9\;$N'IX!2,*O@9-Z$)%8 MO,N-#0W0VSLG0G]*
*[!@ET'5]9URNM*I5C\T,\7\S7("+(=E)_8XN]]?\A"=T_ MGD/?0S/PY;]2Q%95Q&$:N2"6F)L5?E.M#A[@,D 6A>N@!<-*
*UPQ2M&,'R+O2A"]L) MV-"@VMZ?HV*8&8\1='RDK8]D M_$^4YF+J%AM\Y-*
M)]'Z]7:@1'^31LQI)I7C$8V\N([Y]5Y\@'^H.M&*? N?ZQ!$+<;V0*-JI7B M-DQ*
*\;4V'2[75SQOULR+5I,EI17%.@3)31C'=R!Z>$9K:2LU5IM0V\-KM-U> M@4?G1SM6EJHK7EW"U0HF9.K!*W%*
*(EC(0M%T9N5J\1%MZVI[*5M\9. UMKULPDWWM]ZV[SRME;[7W@Z3_+.M7M?A M#NJE-*
*S38RM=A7FINU*S]_05('.AKV>9O/CW@2HJ/8/#_XV'PXO@Y3JA+201= MM(/$?^N@$G7?*
UK8FU_^$D"M5WQ3MH*B>.Z1->^>(ZO/%/]"R+='M6R?"Q]$O
*M8!B%*NKC$&=!*C0CVO(P9T4=!&EL4IN%BR]6O=0'\P6S4@>Y>^J(-FVI('6G MSPV\1]B"TEBTR^CHHQO][3U4D(#?*
7G]]OPX2$"&S)5>7(@E8K?:]K[H'2XA, M,&+&;F_N,"F2+T[T!TCFBP6(D!W7Q2Y4\-6^]?#%><5E[](G9[V(C/_"WW+*

*M]\|T +APIGE$->|"1L#M!U[AC_4M=?;?Z\!%]$*S UXO,,LN4;/A*\@J%"8% M_J-2+;3^>-]:*
(;^9D^WJ]D)>]>C\+_0_IQ6;RJP?T?877P.(YIGO3N2I%5CR MDX,@3%P1S\,57E#(3-M]Q6K[I;[E_1VO_W@%R(>, S1N.
M[[]>0#_%,\@#<-.HZV!M]9G!SAZ5' ;(-#^89%L#//>_"Y8WP.EF]7?ZW&"2 M;YS ^I&TWOQ@DGUQDGRD#(2JR
=;2(^[%J.^$4?H&+@_+\.73\#UB.LY_H'H MANCE.H@AFAH?(P<[T,_PS+AD^0'5FB."\E]@])VFOUV'[;.LU0 L\3G7C?,$
M_]" E?;\J.HU!1V83_#+NS[4R)Y^0L[/5VC?1OJ/EGX;M O\B_AMA2Y=. ^ M WZ@"=O#3J+Y;V&"OW-V=HSZNW>V-*
*_DX*1K;_=$)O$G6\F2W:2Q%(8FNGPV1=01#-%F]D@8[(KMPXB?RE33^N'2<=3XS^4E<_&:+ M<_Z+;YN#A7/?*
*B0M_\=D/&%? ;BQO'.)2H&[YT$Y0)BDT0+K;X8MPY<" @66] MH%$@MD.BCJ2@F$9!B*R;,"*
=GWT!JR<0L2"L%3020D$(*-B)R:=H3D[0=A;L MVBY2J-?,XQ6R8G()O@;Q&K@D9I$(0P6UL;P=V+83,X?
X0"O$W0TI9/N":S2= M5=?7IN)EG1PCG9R- ZQ\;.C0,F53:ST/!N7_ M39T(31W^ZSU8AQ%MD\8H:2O (F)RAFVQZ3D8$,,
[@#[K70;>!;(G.0B6RMF M7[.0.7J'YNUS)6;@R EBB#O>.&ZK16T%7DC.'/LCS2,W.XN[@CZX32GV,JV(M;;)R9?*
#=6P$7(7;"G8K6]'F65HQ.V$3D#&';CK&6;8XA'?#",TD6S^E<^PZ M%[V>AQX;?FXM.]D@+W).CA,CQO6C\^/:P]?
@.'@!=Z1A3F:4MQ-;&6%S5$\Y MJ!X.ANK,\R(BQ_![]=2?4])J M%!O$+ XD]DP"D:P.\^@N"E]@EH:.BV2E>%G.Z?1X:A&
<(K(6F-).F;1A>A?& MB>/_/[CFVD6TPE;CV2QI@2;O'&F(!1-/)+,(. S\=O]L&V-LA48T4Z+AAQQ M.$FG?*
_<%6+V(:7D'P%7KJ/ M>''Q(?7U5/H4\ J_=TVI)J%*V :Y7%.0<3+'^XS=C=E'-_1BMF&M+",!>!F M'-&*
*N5>:FU*V8E@LXB%#P'M>,9$ MAY%,KH>5X_M%CB,FP*52=@+<+&(!\%@\@C*Y+E<@6J)EY-?3FAGX'O-*
^&]6\A.F!LE+-#5?2"46W_$VYBX*). WGB> M)CC.#&_GV.8QIY*=J$I+7!,.T8R=PR?(SU%CG\=>.#'_P'L85PI9RGF D(6*
M,--.GXP_ULBW!5D 1_J,G[T/@NWBX\W)0/ M^WLXY<.F/?1SWN0D:W/RTZ;5?^^8[J%3$/Y
<04#U"^(1FJ8>>DS\D@CGR3 MJ?[MH&JR#"P:+8,$O9!1P[25GK?#5$)"HR+C#$HEH9D $@AR8!<2T:@,!*J2*
M2)PAV?8,@D\(B3J2@F(:!:&J)!&0"@(04[,?G>9!*)L6+;3DSSDDAT6F@W MFX6F%9:QJS $_&Y+*U\VHU)'M*
$[>]!L0N@%S(;9#Y>=: %9%,T<[^ Z"G4 M.; S4?/362'(*V6-1%X 0!;J(N+9 CYY^COPJL_)>=.%+W"8/F;XZ>L#;10*
M78/)(8(SQ:YK+74/IM[V;.Q("WWFR3.([H$+D!ZR5^2H3*D6LXX40@(JL@JT MSQEW$5@[L'B4!HT%(GU)?
0P>"-2TCAIM95:4"4<[6S))_P%\[RJ,'M!L>1LF M^,VS^>("QNLP=OQ?HS!=\XDCUXAU'%(@/B>Y3O?
%1T\689$9Q^ZY17@6Z>I# MDX2)XQL"._.)N5O 7G?854IJ.]Z;'D\-./=OM7N1EK'@RG=Y"B_6GL;!BYW M>F*
5MX<44A+:8G/LF%B-%"6M0=_EMN1-A/L-=UP=K21%O MP70>B0!/68,Z*L 6*A'K6Y@VC-)V4D1&6*
*L/*DKB;Q.%^/@A0WRT^XH?L[C$ M[N4Q1"/H,DA7("H].L@CCU2#997O(PNB>IFH@5\R]&@@5W=EV/7Z7GD76-62*
*MT ZY6LE("G6?HN1E5G2"IGF_++QB-0U06Y@@**>J2S:]^^N+O*\X=?P*-!Z@ MLHJ;S@05.R0IV7O916OW*
+/D7%Y"V1H$M>.Q05' M3\"$/"J/O2C# -,?!"Z;!IP:;X$6LN(KNK'1?G0B?:XQJFD[:2(IO:;(.TL*
MN2NZ2^3G>:M32I8U$8&NY+U!!&5N8>MA^XY8^9Y,)/BSH%H(W_NK"&R MD'>4P[KD:ZQH)VU:RFV+>]D]2!P8
._2B0)DB<_PXZ M:EHPW0R00) #NY"(1B4P4Y2#SCCXA)"@G!(B6D4A(IRT)D"H2 $K!.>1OG>*
*M8@ZZT6+;3LSW"'0F@M]M:>7+-OH<=.5[++19F4=$=(_<9MR!B!Q:"]WVL2J; M30H^ODT7?U(R]WH7J.<:J*R-*
[)CEB;/J%-_;K?/7-I4]E,%R%9+;PMI&GA M.HY3*8ID%>RG!T?.7F\&S:$&^PDWP5IEY1V9&H!G2],W*'O"7B?T^1K*
*5F$&IERTDC+G-.GZYOW/'I,XP/ MPN:'>+[((]+"H-6+=P>U%^^V;4_"Q63;NN:W[]XS4WG&B)+F*5UQEOF";6;*
M'NE@EC=R)#?@0HV=%!+,EH0R]P@2I$[\ L$%> %^2!\YBJX_.'Z*5[P9NZ_ M4DC"DN^BT 5Q?!*
*[&G!2H;5LTDD)RO*CS2K4^+'SU@608O%ZM'1@1QP*T="Z9 MX9OTPE921T)4"S,:T0<.T4DQ6DA:GL=G)WA\CL)T^?*
*PYC9'%A@?/Z@D&!.K? MD0C(PI@O%E+S5?O/E.$YGJ(?QL_$09342[9HW2S^U8'!31C'\P"_LS!?E)*J M;S*J,*
*[@I5ME*QG4OO>N%P%G&HP L\5&R*3P" 5*HCS,?>BN(=I()5N\+R-7+ M(A"_EIW,:2&S+<%!-=V)*
*[N*L9(*8E'8$!FUDS;:|>.ILPGY;TDCTV^S=&T12 M927KA?HV#,*RP,5C8/RCF\9Z8Z=!.P$->:2$[J_|:X3,G4P6FGORSI^-*
!|= M(EMDA83L]41$C[5W':#>@#B7FFRMF&?)M9)6,D%67@L/1 K1<\5=@"?V!4.M*
*MY)L@19.\7:=Z(W>&3"7*F@%64T1.:CMR(]Z"I'$W4"IC) -D#,!&8>P MDA] M4G@X?G9BZ#(II8MZV:*=%-*
U03(;:'&A['APK"KO!?33A.EZPRAM&^@\L7IP MX-0 ^^\ /ZD'O!G:7#I+<)OB>,SYHN:0QAO_4FV,G2+=A>W!S],/ =-
*GCP[7[E+Y/L.YI]^7:RTPCGC&9DM^%D ML*H/CI'D$=(\KEMJNC[:!61\3R1$S^UBR-0N@" '=B$13-3Q%)?*
*4B*PTYN0BL@1_03$->7%XZ*1$)V:\3=$6Y';2&G*A:T[FN)&S*
M0%),YA&O3@,LLTD1E==A@/<^(D88K8[9P+8RQ(3%Y,SA)B7V$#/,=HJ:C:DP M/!S;K$E8FTRS9@[4REE+
#%)1V";$1%P=@ \P3499I3"UB'<0EQ;S#+&>R7<
M(<^M8QTYVDMMZZ,N7'+0"UO+"@EQ;0G+J&B+NYFCEK66#.+2,F_TQYPWV#0D M6VW@^+(I6O9U7](H>G#)-
+#YN-$ %Y)/T69N#="N'NT11HA,>[(ITBRR.S75V%T%:8!9OAL&0% MB,TNW"A:2XD>>Z;8] M0>@-&,40-
4"+$4="'1:&I/*4?+E:^^$K %D:[C1RGYT8X$PM*=F M,Z5$!;UF,M>3$(X[ )G::65(L5LSE&^J:"-I4TGJJ=<)\-
D4A+5%T%HP,-' MF2"("2=:S'[TA@RE8@]3GX3\BD\S$H7QQV#*EC&:\E0FBEAB^1T)_#OO:1 M*O<)6"B&*N?!Y0\0N3*
&\\7O3H13KE37TU9ME%5V9@JG6NTG58C>ZSL2K=S? MI+B2GP1W(PN[$:/8H@YT,2))JL6\/2:=28472'P/O-0E/SV&#-
*>0>_""NY.] MH+#V(9U6W5HTBF/=9J0>%-'K,R8*676%8_M0U\B@F7G_G<8)Z[*&4=0B'LA(*
*MV/6AD3YR($E!?)W]@CHS-%0Q"G)IY,1 Y\K:=_7N:KQR*K@/GY7DW(F?K_SP M>ZOGQ(X:DI'@QB>D=7-*
2D&P$;DCNS\RPD0CTZD9C_B(8"&85Z00B6.%Z0UD MO <^MNONG"AY?*
*8R<(,XLS/CSZ^Y?.+&KX@V8C34;NSK@'64>?9*972FYD0WU M@D:2H".>?()PY+:*" T!3]6"QA.!@QL?<(Y\=D0]WX9!)*
H\M:Q=V(N+V$.& M^A&'0ID"?"L30% V)N)Z#LVP.7L7A2\0[9<^OWZ-\>NCFY=T9FC1>X$);'P0 M6+XALW'G0T@]?
E,AOXE>!)I/9DVAAB$94YN>V6%EIP)Q?5$_!C> S<,7.B# MDOR/H9KYJ(]/O2U:#J9!\]*
[HH5]$DN0F@0OFBSSC2>812P[;KP"8!\T1%I)- M&$FXP7A1N>A4H3OSG&747(,(>X,V^S.^89JUT%(O2:MT4^H"H-
Z[D$>DW2)E MQ>"+JKTW39]&W5CYPOEL%48)_)-(/5_@M]++-O#.RS$@E^NLE MR9=N@O[JP !K?
*AZ@,;H.8Y@-6J*8>)]!1WZE=_*5R=="6UU#QHQT?R0"7Z_6 M#HQ(%N0+R!=^*5IZJ.FK,Q J&N$K0-*
1R:#=Y%+5#Q4'GCS MY!E$F6$JS$R1QHQD:4>JB'"OM6ZLC'^B!RK 4T0 +Y@+Q9QTE4KEI5XBI18*
M%=%.@@GIH>L5P'"&6%W F4L.#N,[YQ4+B(8.^DV4;L92?/G#]5,<53);D8(7 M,HC.A61'=0.=*
M)^A#\7FM6LMNAG110M<#?B.-+G'OJ\Y^LT8RJT^GR"YZ4;6XA6ALF$VUZ^ % MQ"I*LMZ/$-
ZK,;NV\2OCGKIP3HSAUU7,' "5X%!QFG(2+:I-LADY;?2K?8> MK/.YG.MT42UF)$$4X5PGD)#T5E[Z[!J5M0
*9G!),P$JGUGM:!&JG#CMW@)N1 MM'W1&VGC/(R9M]:*F^,1[*:Z+IF&3\IY;FKBV363 IQJKPQ"LEJPKSGR=2>*
M0I&79CCO^M +OUW2-.B@UW>B]+RS:[6SANPDDI/]LP(E>V-5AWUHNAI'LW; M?*P!_/_XR.S%\?'R?*
@^0&J&+5ES\AUG@E7^Q4S)[TJ%Z8[IQV4_/#O!$MRC MU?MRL0#,(X)A.V$DRUL?+QB@.U5K-/4Z4D^2T$Y:
*[8/E[Z3E]T+1PE]_EWW+ MQ.D[$QG]-^"RR1@J[BNS#*K9R'4S\2%=KWVB8\33-K2MIY(I65LV*W*
M2%DQ^T@QI_IIT@O:E.6L20^&3%%TIWB2YQ[UHDB?<>X[<0P7$'BS^!_]Z[" M"'NNT3SC!:N^16YTUH^B>T:?
-9MH?+\'J9SL(#;:W3RXP8)=+&HNS1H M>-WG6/1UGX\3]/F/Y!?;#NR^^3/Y]=0+"]X ^J;)=ST;6?,(!P_E_R">B5FZ
MGNP9W7QDY!Z+7I/35(7[N=&.I05ZR^T7K218^O@G7]7 <90P0;CW M\8FWQLS!=#B6#.8-NBA"S;
<9#WY'74"VUGRQ:$%/7G/O5%2@+Q.=QSH1+\]Q MH(1UM;;**CPPX]E70R@GIBSS/,U:L>TN1;.Z$X/S,
(BA1^*)B29P4HT6A.,U M]\XY!?H:'% KZ<@VT.C>;1T@CP?\@6(W0BNLXRUG],8!B".D;UQ Y&V/-0[M]'.>H %9(R%2W-*
:%K?$H9'\/_=_DXV3[:?2/W:__=;+S?7PT4O1@X@3>9-,' M\J^\%Y-M-S1D^]IJ.R9/Z$,O(T_@W>U@,U_DIW:.OSWZ:3A-4-
*2VCASH77J^_MY<8C8M)GGQTPHOHS1LZ,2AE6RI_^A/;Z>DATH(GQ 2X#DLTT2'*S! ;+.Z0I M%TK->@?*
U66^GZT%'/IC/425\9?(8H:D,37(/:SSKH5YO3E66$7$U+ MJ@%ZI\3'MT0+AHYO,33+N0>ZR3SRA3X[)BK.=%J-
*\./Z",]:G13-ZAWCV3-6 M.X>F#98ZL[BN5X%V.M,T@IGER]P]-"/'?!,RM<=\A"4;Y!)ZH"'*S/V%K1F^:-F>4E9H,3RAJ>-*
S_)V_&?_:%R>836A+ZX=MK[RR1O45.L6$DL/!\T1BSP^F*>:MU27Q\"M >BAV>D6_&!O+]'63_1!AFW-D';DTG6*
MWO#TOW2B ;+C4@- YA=7,/0K7:F::@RRQLY-)N0V1V4OV7^;)@2QRN4A<#P]/JOF&3;>$[2#H'U9 L/2Y&L,YHO+.
($K)V'F M82X7L@!V 8%ZB!W6E+&,!"OQTT16D^L2^K.,A0Y-6D =Y>+W\-ZWJH#-S-UK M)PT2?_40JC-

B"K27KX<(71WG!QOWH'F$#+EU&#O^?'$3!LL;G*(A=SD4,C#: M-#5BYB@7NX?7(E1-&LW[!OX$(E-
Q)10(ZNJIQST3BRWX/N.^%$8H!=S*]8 M9MBQQ2'>P=[A]+'%-DW1GY(@9AQLG=X>K9_ MBI_A;K*I&Z_ZY5L:V8Q
Q8SB Z!($:/WK)6(M?I6=-P[K\X9L"*S.B<266-@MU5D1GOAL'R>_8?QY-U3L<=?IDCFYJ/I0>+W;DF?V K'-5:EDC>3
0JG4ZB:O(6$;4 ME>30]?(%K)Y Q++9F%ZA:C[A)$4U;:H]:[97A,?ZUE%U8,E?GZ@ M_(M&#H?
>63G$9H&OXE[]LXZ'/Y@QK1]FM,@AH/,\XXTD$VB=0L#L MF4AMXH!!I@2#TP7(COZ3^N@7RAF@=;R//GG
=BD4B7Z7-&#DFS1S7I!+(Z!< M_I$'?^SF$I"=%$[KDT(IH8#.P:\@L\"W5IL:QB'0AG;%V[CY#,D=M#)5R^0| MF1Z?
5M_5-B:; %9L]1BG@Y!6!5C40K-E!^49Q5F!DFY Y]B4RCN NO!-K.*W M_;WJ&|=#+],DS$P/O/%QA_N:#;;MU_?
RZ+8.F26+ ?GL6/[1LT1 MLL#RUO(^]*+P8]#[=1'I*OH Y^*P5,8HI(?!BW(]U*@1DS!NKY.MG(&'=[JW
MS@IDLG=\T7&=W;]A,D@YL M:/6D1B9]#=SCD2$Y)SV,9VX"7XJMN_B!;-N&S:1@/Y20WP2VU%^OATJZO26(
MIIZJFJJL+VB9HJTX7*[?>BURT+9E/U7[5?*X)Q. MC\|,R+0T&.V'4&8/R1?J#D$J[I32U+WXD7;9(/YJ:;8*FZ;Y-MW54T
MR//K>C+F2EY([>]1;HEK:7-U7D>-.7_NCCM#D$ /^BEVAGP
;AH1JE[^+&GQ=K%LXEWU'S)R:I')V#N02D;N8,+)H"@[DU#B\+DI1G5.*H/G M&M4R_=P
M,2>AW$BM!MDE#9R(FB%W^[L(".L'>%'-R". 9BC-=W!RB(**'SI M7K\X"9X6Q8X-
6K1D*XG4***OQ(4#K2'S:.D$\$_2R@6(W0BNLY7T*4YVJ-DFM_MPU\G.[V8A(M) MT0^R!FUZDJU(65\FF\Y,?LJ[HV-
9VI7B'$=.^M#+1D3@W>U@-5]ZFR4>B M5M H<%M-E)*R<7GSS]),&&7>IBS>/P9)
<#!,]X+.*VQ1/>//%71A#XC%QZ<,5,@_1 MG^| ZC;^KPL"3O*WKBW;1KM^%-+K9;R>1XN(4\)U'*=H1!)U95H@!^3Q+?
A. M_L1>HT0JV\6M#C+W>L.MB3Y$[$P==Q%T0?6!3YKG)ZV\9221$E/1K35KN=/T M&IKOQ/'F%G\>W .M:J:"'%Q-
TB6U\2P%_Z*\3 M_-_)3E^R!&/;[I "_Z[U=DWQTPO3H^G^R>G1Z>G>V?Y![3Y['%=BIWMHU!C@
MF"^I::DKKT)&DP)ZBY>D?HW"=$U62C+$B,;9.00::AF)K P=33;"#KZ(W^. MT-QT 8WUC.1%&XBEB,*1W2ZJX(<-
%V&$_HG3A>&UFW@RI<#+/9.:\M2W;&UL MM.(0HH%8'75BA_^@JAM)4YC2:F$2E,VDT&CZLU&SY!SMKEZ1P?6;XZ*
(E)2]9/G0?7Y%.7RH M/517_L5.2UD]VY5^[I/R9!%&4&]K6T'O>V\,+F?@T M\OCX\.1@__3X\.AL[^A$=T[;<3^:>;IOQDS8
G7*YG 87>GV-$ZR3QZ M -$+=%F!&[1B1F(_$&Q;ODAI1R!01Z'Y)08]UD?>[YAZ-,TM:Q0)I+"@0B@H
M8.\/69XC+LP7_T#6%ON=RFH94Z$0U.D6#W'I>L?AVM_C YR0=A04(H9A8:X M1BLHB K6_X"(]S'Q-A^8N=AUQ;-
BE[0!'4C[F M48ZR@>,=[#T"]SD(_7#Y*C&&!.H9A5CW%:>MQ+V/L(?DGZD'_C-VH<=YMKI: MR"YTQ,3K?
3C=.\O]!]R'I_W]/388E&)VP2$JH*+#OV&#X,^Q^QJ(D/J25YPZ MGK$IIA4S"F6MFV)A[0A$_Z8O0*LT\A]=F*P.?BL"L+<)
O7+:OA8'H\U1RQ M+XQ5&>)N @^XB;YULK;_|?;9|#W,?S\%ED<|VO:QR4W3!A;L);:,$(3RDZ
M,Z[0Q_^1)DB%01P&YT[@@J@X-/:W2$V[6=%!!SW$2:OBQ!?G-S3@05|O>^F91PY^+8B+*- M&
(FU"KRJAJ,2Q1BQXU20SK[S-'S3$-6C\A-&4E3;HM:[9@VVJNE^=Y<_|+-! M^&6;|)$.G)W-
_5<*44^O@_QR#2=IHUZC=&JQK+_#Z?%I]44H+7GJ>R9(|:)& MO0I[?:_17(?N[6&HQ&IUBY=&C&4+'^^#
[C[>N,\X:3[N-4[_(>_RO1' 3O?O MO:.]@[.SZ=?1GA(\MY,@0B@R^J$AI M1\"[:M0A1YI)((4%%4)! 4<3ZF(.
((*:K4S/H@*.,N1E[.#(B3G2T)>CZ?'9 M.'S#Z2!)RFE1",S8D6LM,?-6PK2XB[$C)"J@(H^;UG$7'!O#.3AW(KSGV3|| M:K
SZD7M0E-&2$6)\Q4CBKK^V&IN%:AG%]:M)5:4!'^D(52:8=>ZR1?6CH"# MW'";? TA5 ;,#<)8E2'N)K"%(50&0-D-
D^JTWT4+1ASRZG6AMXT/;15@<,S4 M\-%TMI&BDQ:LCIPZGA[7LC*.&6DA:8WP\6QG^V%SEV'K;_YF%,):#7R^2C@T
MT) 8 7>5.HHK?S4*W68E4P!I'IG:TG5^<7[5;IBXE#ZNYE(M 1MUU,9;G8,'TZP1 ; ,&PWZ($[" ,1WSBO6V=<
]75'2JK1UE3)2'[U#G/5 MV&NEI5[#*Z]I(@[$F7D>S$\TVE!(HOH[F13HJX<#A(ZGRXPCQS!((OB4XNX]
MAM^=R+M#.B2;KKCVW(Q C7?RM%-1#\<*6[Z<]!!UN%73KK1W(,I%I?H+B%9^ M9U%G;?
7Z#DR_A**\XLXK6A9_BJQ. T*B#2 +4S<]F,=;:NB)ZN/&W4I%0BMH M\:T3LB\5*O+)83T'>*306 ^'"%%F.#@P2$.#[A2L
^B5;]=KBO)P7:]LR6 MU<7/KZ6_""4HD&C+J.E%'K*ZD:)."R;=CXC)PLDR(-Z 48Q0CRK-K.VD&E-I M0O4291Q.>;? ^
]I$\Q]* 3O7Y% M5E80AS[TL$#ITP*N3O/1KABQ,X68^**O-)H_G7]I0R4@L5>!1]49HI0@C5A!& MFB*
5D%OMB)G!$A)]R!.\&QY%:;X0ER$'))-O!6JJ%"+0+>F,7#2%('X:& ME (4N1(,&\&J(8Q1,U^D,"U3H9O
BM88Q:'M5V&4(.7'GV&8 /?Y.N $L;#* M&H=O-Z JRX24U$88$GT=8]XTN&XW53.*)QJ/+/D*Z3W+S!V(7*SD)=Y'D2M>
M?%&7^P?$>9\?0XXE?8\L)]1+[SK@^AI0+U*'^[J1=&M%B&;UM9$5_OY,DRGT^.3JJNRC4P?0(>]NI-KNLI.
M0O>/ZSA.@7>11C!8(AW#T'MX1H#&V>^1Q5,HDG6'+=6(C?14J(E>?="K>3 [MS*<7T$^1QN9I@EU@L
_AY;]2])'M(*5-@\VU;*1'%]%[=2%O%1K5>=*9KP&> M;8,EB<1 Y@4O3+?A._M1J2=I4MID_'32@R,7;)#+]
M3NX'R#BZA\OG)-Z9ABF1+J+5;"90*]E[=?K6LUHQWE:*8Y 441/SY!E$C\]. M\/@GR^7,:(V7C(JT\@<$^]^1"
D(YHN%5*A+^_83,U!=&63)SI137Q7 M/0:/I5W0C^LNZ%G;DZ+QDA.Z1L?S+1MB$D/>\&X>J_@W3:]L5[K#U/4?)%/\
<8;ET7Z;IO7(W%%PV7+)7ZF-&6<.5NF8^2&&JY$K= M$'[0S\F^/D5P"0+P&8:Q"T'@
DZ*>&9AXQ#N!E7E:$Q.;#MNU6MK(=N_FU;4 M*$)T60*DA1R_]W9%4F[,#[WP*- 7F/1;2&GF+$\$J.VO?
H?)L]3\WZ*945!! M?"E0I0$[%XF;!I\K9OE1L*3+2Y$C#@C_@BYR#M[';CABNKH(=6 52Q1)'ZO?D!ZYILB\<]CF-_2
MY"_"X7Q#Y!*!M70UU;.*/]VD[M5=2.$$4]7.>1C$T",N+\@0Q%>#66^_KI%6 M@R17!G//)-
U227EG>TAY!KB#=YIR%.K!/&\BE22Z2$'F"X--P$D M]+2 BK_Q3KQ6&C+/)ZD;)7%B$_"O%"B9VFJ-O5V2B:FB5S\]AA?
=UY+2LDU,'_R MX9+\@L:[EDW9QR^5BLAY=&8ZCUJ.J4OLF1;C(HSD]"K:M8]AO6FE.!/=LY1O MU]B? <3)/9]WY\&.__.-
=)Z@CWJID(3-'WMG9C=5%70UZ Q?C*X5\6>N&Z6@ M4$)K2T^^5?L)]$@G!=../^>ORH^,D7O@ OB"KV+C*]0;M"G'?
O,BA&)6MI\W MU'VR>H 70!AV? M*W=$8AEJ@GY)K.I6$4>)| 69^CGX;O66NH0EX?CP3SQ.?G/\%,Q6V$%Q+
(M[X_"!02?O:O88\3^ 3W*D.3ZX#1.<*6*^N(#Q
M.HP=_]*#\.TU$?)XC%"KE>K1T8D:2RFPSA'.]^R:PZTWI6G:+QOTY(\Q,G M\":;#_R5_)-
T;++MV>2GHF^3<,%O0.^;L&QM-S*VUCWV^$AHG@UU]70#\,R MNRGV%BR_NE&S3SMPZE9+)^%->OJ1V?
W/K_BU,DZ>!X&:1D&O!+HZ$]]J810D MP!)P$SX(U#22!&U1D\"_00,FX7\#D/&$?3G1\AR%+YG]S'V-D5-C7'@WH%3'
M6U9R.U([X//X)$I)_LOK &ESB9\5XE*$5\5RCDB+KBC0^@5$3Z%.FC!5>-.0
M"J2YHI&4&2KINN4I+#>WONA%.AB&8C M:MF*G811J8RNZ4+.,@8%@!S_&S+U[.CF B!!7.AD3OIK'Q"@\8/-893 /[,8
M.\B;J,L74U\T,E!%3N(MJU[02-P$L*#=Y@K)ION)5L5@,]]H;RIN)/""&#:!WR"E;@HPCE?2X+OSB@6Y
ML@B(ZAN7#L/[=^<".(9#Z<.Y\SBU6)&HMY]#A>2 M;/1OK.]*R9V[ZP6-A%H(-3[8!L_6G>'^[,1$1F[X9+F0\3 +S>
2LAE\[7$# MG\+H)@P\'-R)/O#D!'_,%ZA3P&.B*E[1#J0[RFO$Q0A]G,=1LC/&T;^VXQO] MX]N]$RQI2W7I;T9B++4^-
XMCYB/V(NA1!W#EKT8AV P&!;C1FX_7UW"R4SX+0 MQ@#&#T@:QYL'NT;G/H,VHM7M8D\GJ7N-
WC>!1+OO[5VD$0R6V5-H0A1B5;:9 M0%(R]^#@I)L^A?RYDR]6#BM\H5[2+F*("JC(:ZD<"*F:![N) >:+XJX8N^G< M16
%TVKB9>%Z=G&DG;B*');,8LSOV+$$&7&SP+N'RV=DS6U?=Z5DZA:M9A=?
M6DG;@V>3MGS=NVY.M0E6VMFIECBA[.ST<5)\H@A:&;W/DY[TV!6DB)>OF%E MBAHYAMD*;C0%V$(9?
%53D8&]C^@5,U(*[A\/[D]1XL(58,;G>S\2$A M':'\IY>$;#"WLOE>)!9WA_MN\SP^?RZ+7.77?',OCN1)_:23L?
VC9QO6F!,N0GM547CORU/GV+H02=ZS9)0 M$9US'(:9Y+1Z2FV"&O4G"]C)LKFDD3*=@H ML+
<36^%#/HQXVHK)P78PI9FI 8O,T+N$?M1H!'EY"<8SLWJYC,C1?&%YW470!7?X M%?8D =
[GU\T[[+2YK%5#9I*N'Q)4YD%U^K+0@YBHY3J.4^#M.B\2M<>WX#OY M$SMZ0*3RVZ2>
AWUZFM\K&YF0QI<81,#"9J)-7MQH(\7@ZLPNDJ3-)82B=P MP6^.GU)?3Y!MXVV22IVJS'-
$9G,+QC']'/:O1F/'Q9@NF1RBE7WC7!%620]W MSO537&V7DE^<5TRON_3)AVZ'"\B:!^'NI_Y2W$!^G*#O3? ')]D7-Q>-
UMTS M:C)^$|>"%X75&F;.$(UJY][T"'99*3#-/"*A-)QE@EF^K*.SZ?&9"3>$G9<).7E'GS*.*BYW?>#4,)(2E MS>LKHZB-
T,J(:O!#INI3=1H";_O=4K-L;REOIV8XF\&@ ->_L3N:O)VFP,?I M6QG
9EF,V*^TPG'CG_G@@L")8,B86:GEC,)5S2PK+J;H0\2J,@.O$]!T0NZ!Y4$M! M1H=;0$0SL98_:"93X$V#9SFUK%'(*
[]O$)"UE\QWFF^F4TSXW-,^SGQ#KX.= MVSR!.^JF)HSDC3CJ_)OJ5L+;Z+R]U4GAR$YTTLR?4G&;N=
(LJ(49G0=VZK>#_M,^W%5G3H8U9R5NHAZ&;F!2[2$7EEV_%]'#A3G'7F!:7*L1;M8YU?>BC5S=N ME:[])=G/PP -

@&3K=5WR[<7M88.TD+V<&|PL@GGTG&?RV753#GU=JUA6;|: M&23GM(8@|GR#(61@L|J7%;:/%%8-OQL9A>0DS:EQ8@XU1%:DG.SYOXB4S6L3 MI9(UX'<0-V? J3D,Z&>]NOP!(A?&@&AB||>-O<9ZB*E56];P2KT67.[,N;D-ZZC47?J" M5_T>.VL+JOYG&@#,NRS7%'Z;^@)&P.V2X/E0,+X:?SH+L-Y^?))]W=Y8:TVY M4/N*M39FDFA6.V5RD)1Q])?9O<1:G^T=3(_/C@R@@"2<%$)(R3M^.@P3:VT. M0:3@Y=]@2XBMFR?*

*THY*FA9|="2!6TTP&M$.PVDQXM9#8BEL_,|'QS>-'9LI"3]ST|GQ6R90PEY 5),3HC BU M|8-F@RMN'|B(:H1!P*

*WO(B)8,RK82?4TA(;L>#3$?|=2?T]VKD/Y&#-*FLC MRE*RCC>"5"88V!AHV]MFS;*-%TK98&#M<#:#00&N_W5U),'

YL#'Z5L9P&99 MC#"-3 L@.YP>GYAPW:)J1RP@JYD!PB9'HTLJALWRY>]:X9|^+0)":ADFOY71JYS|[&SWSG

MD:6&1X>4M&P7[7K4B8519H8%DHR8?.JUH"AR36D@2>/SHLVNZE=A])#E;7+1

M2%RCKE4M>25M6D.L_K3Q5@+CS OD/C+C FK ;:6@1A0%SYE$R4%"YRP@5"N!

*MAPF=TQ;BE/WW.L!6*9KF[WPTQR/]7*[6?O@*L@H;/HI*

*M_]]-3R:D*Q.$SJ3H3%9Q4G2'E/CW|01!H2Y|$XS(F>Y7A]K@H5!-#[C&K!=< M!0.GNK5OU-*

PD"RSEH+Y7O9AYW2]!RTP^] &.TW2IC%'T& ;D.JF:-<(DAJY; MO%8ZV'A)P-$)_ BM'CYE)..:&

<"X,QQ".2:1KV3NS$E/N&$[S/)&TF P M2.MLDE.4'4Y-C>IF:?NFP0.J>|-FTG/@=;$G-1KANJZ/O.6TU;,T>49;W#]K M"2]

[^XZ9U.Z':@HY+:7.7IW'#O7Q_:E9<4]5Q5W^6,/LA#QSON/Q7$7[94". MI],]$Q[M'I3?O:FQ5||WC;SN,B',/

]F:AAJ1F=_|9W[0RJV5]>[D8Z&7'$O M#O2QI7D51K_BJX2>C9OJY]['P6!:[=7[L-7A/N,->-9%S1WJ(D"?7R$M>QM7 M-

*[(&WH3?073EP.B+$_T!DM|F,-Y!^T=?8|=]8P*8RN>|2)Z 5X:-6Y2I,T EB) M3E#S^6[=SMOFI1IU]9K*_UBWK|?.(?S,3>*

*+<9]JX=!Q+.30D3EK9)^;;+]G MI\/&|<'>N|.&^-F|YME)%MC!'#;*TY 15Z,=?2],68=ZQ4O*]Z()X^V"H2D=*

MMDV.&%,S$G WTT&'(|:T(7.W/8X8AM!@,$A;.V(T4>)MW&7?#.R(80H]!UXD M>U+C&W?$R ;W;FS#?>C[:/^+_ZB:T-

*R/F4GR?DBGD-WR.NW5+T/34:\Z[677 M/_TS/_N.7:27YV*O X&C8D5C8)T=9R=.E(S][MK D5"-CWP?"KWH6)$%E(V%*

*MR|"S9"3D.1*PA=KK2*A]YWU-4#T0Q%1L7A(Q[6-@![7? 0Z"!M[L!43.$I0R MB&!$%T-M&00[8M)\#_"=+OK]*

*M>1@0!Z34|7%JJ@/>:!NV)V603Z;')],1C[Q6VS #%/X^JB0F*99J67EF-?3D M?*

529H'#S]@@95JV#Q(YIBX.X1SI"YBK24^8-%VU_|36 29QIKT5@Q%0H M,&+[M3RA91A-=GY'NC#)^F!IL,31>

["$A/^#LLXB<24INI=9S6,M XD+P'!DFK%<&[!"I]5H@N?$P/7@?;?I'FQ@H7:W!LVR|

M!6#I)#N4V?;JO8;@5G;0"M__GV4Z1]E HAT=?YI&&+5?$UC'V+F&XYC=A$? MYR@3PD21.Y*

U<;3B6JUX89$|VQ=HLL$IC$GR8B..0F1Z:=?2:.!926U&[PGB/OFC6Z9SKV/[Q&,[\Z OJ_;K4|'S!O>

MDOU['^$C&.$J,.TU7DW/2Q|FT&0TQOD9HD'5SGH?VMJ'=D/?#Q MC2@9|_FCH7=A3![/C2]]N((!_G.FI/SY19['?

+>6WS:=^U)@KZ'-!8OU/O%6 M@^?R!_X1M(AH/A%_ZNTC2X>:%F;$'#+:N.'(I4)&

MS28MM$Q9\)KE4W1YX&L+2K@.T+ '&TEO|$